data_1uew_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1uew _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.2 p . . . . . 0 CA--C 1.535 0.377 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 13.0 m -140.83 164.74 29.41 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.514 1.126 . . . . 0.0 109.071 171.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 25.6 p-10 -128.71 94.45 3.86 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 127.601 2.36 . . . . 0.0 108.901 -173.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 24.3 t -90.64 106.94 17.93 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 176.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.7 t -85.5 142.72 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 166.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.0 mt -137.53 132.01 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.152 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 174.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 -115.04 141.35 48.11 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.715 1.606 . . . . 0.0 109.343 -175.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 30.9 ptt180 -139.88 -169.47 2.73 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 124.426 1.09 . . . . 0.0 110.474 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.67 169.12 10.38 Favored 'General case' 0 N--CA 1.463 0.222 0 C-N-CA 124.567 1.147 . . . . 0.0 109.439 168.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -69.89 -15.98 63.16 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 113.43 0.9 . . . . 0.0 113.43 -177.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -84.5 -7.07 59.4 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-O 118.477 -0.773 . . . . 0.0 112.896 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -136.32 172.34 13.16 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 119.649 1.113 . . . . 0.0 111.479 -166.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.74 166.45 26.36 Favored Glycine 0 C--N 1.333 0.413 0 C-N-CA 123.669 0.652 . . . . 0.0 111.927 -170.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -87.27 115.71 24.86 Favored 'General case' 0 N--CA 1.444 -0.726 0 N-CA-C 104.52 -2.4 . . . . 0.0 104.52 150.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -92.7 48.62 2.55 Favored Glycine 0 C--O 1.224 -0.482 0 CA-C-O 118.518 -1.157 . . . . 0.0 112.643 -168.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -126.92 160.08 32.06 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 118.76 1.28 . . . . 0.0 109.873 173.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.4 t -138.39 141.36 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 C-N-CA 126.519 1.927 . . . . 0.0 106.972 -179.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.4 mp -105.9 135.85 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.667 0 C-N-CA 125.817 1.647 . . . . 0.0 107.801 178.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.447 HD13 ' HE3' ' A' ' 46' ' ' LYS . 13.5 pt . . . . . 0 N--CA 1.45 -0.467 0 C-N-CA 125.459 1.504 . . . . 0.0 110.314 175.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo . . . . . 0 N--CA 1.453 -0.875 0 CA-C-O 118.399 -0.75 . . . . 0.0 111.696 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -138.48 125.35 21.11 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 119.73 1.15 . . . . 0.0 110.746 -170.441 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.447 ' HE3' HD13 ' A' ' 29' ' ' ILE . 48.2 pttt -146.64 162.94 37.38 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 124.407 1.083 . . . . 0.0 108.783 166.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 46.4 mm -65.31 130.61 30.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 170.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.42 -49.66 0.65 Allowed Glycine 0 C--N 1.336 0.56 0 C-N-CA 125.254 1.407 . . . . 0.0 112.492 175.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -129.24 150.63 50.54 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 119.433 1.617 . . . . 0.0 108.373 176.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 11.5 mt -128.93 133.31 66.35 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 167.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -60.14 126.37 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.605 0 C-N-CA 125.191 1.396 . . . . 0.0 108.018 169.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.29 121.13 9.43 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 124.483 1.113 . . . . 0.0 108.059 164.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.51 21.55 40.28 Favored Glycine 0 CA--C 1.526 0.778 0 CA-C-O 118.875 -0.958 . . . . 0.0 112.649 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 29.0 p -90.85 164.76 24.55 Favored Pre-proline 0 C--O 1.236 0.349 0 CA-C-N 119.651 1.725 . . . . 0.0 112.915 177.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -65.65 -21.77 58.66 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 121.695 1.597 . . . . 0.0 112.911 162.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.4 -56.36 16.9 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 119.199 0.909 . . . . 0.0 109.134 172.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -57.95 -48.48 79.83 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.597 0.759 . . . . 0.0 109.923 -177.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.3 mtt85 -71.9 -6.85 44.8 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 113.91 1.078 . . . . 0.0 113.91 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 36.1 t -62.29 -21.58 65.34 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 119.817 1.19 . . . . 0.0 109.646 167.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.69 26.23 11.04 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 125.736 1.614 . . . . 0.0 112.665 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.6 mtmm -126.96 -52.13 1.43 Allowed 'General case' 0 CA--C 1.521 -0.145 0 C-N-CA 126.583 1.953 . . . . 0.0 109.153 175.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 9.9 tp -92.85 118.77 31.48 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -161.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 71.4 mmtt -129.97 171.89 12.29 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 123.55 1.643 . . . . 0.0 109.332 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 94.8 t -64.89 122.9 16.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 113.807 -1.542 . . . . 0.0 107.626 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 128.31 -18.89 5.75 Favored Glycine 0 C--N 1.337 0.593 0 C-N-CA 125.02 1.295 . . . . 0.0 109.997 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -77.05 98.25 4.94 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 122.243 1.021 . . . . 0.0 109.196 -165.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 17.8 mtm180 -44.63 120.48 2.28 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 128.653 2.781 . . . . 0.0 110.572 164.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 45.5 mt -101.6 153.31 5.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 126.151 1.78 . . . . 0.0 107.432 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 tp -131.75 -44.89 0.97 Allowed 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.821 1.648 . . . . 0.0 110.589 -172.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -147.98 163.11 37.84 Favored 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 123.267 0.627 . . . . 0.0 110.423 176.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 67.2 t -133.0 118.04 31.54 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 -176.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 42.39 57.11 3.5 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.146 1.778 . . . . 0.0 109.529 -170.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 67.46 -4.12 4.1 Favored Glycine 0 CA--C 1.537 1.435 0 CA-C-O 117.679 -1.623 . . . . 0.0 116.026 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -90.17 130.89 36.26 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 121.398 2.599 . . . . 0.0 110.997 -178.471 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' SER . . . . . 0.423 ' C ' ' H ' ' A' ' 77' ' ' ILE . 70.3 m -73.61 94.33 2.16 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 124.013 0.925 . . . . 0.0 110.509 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.5 pp -60.77 10.96 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.632 0 C-N-CA 128.34 2.656 . . . . 0.0 115.133 177.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.423 ' H ' ' C ' ' A' ' 75' ' ' SER . 52.5 mt -63.46 -79.41 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 C-N-CA 126.029 1.732 . . . . 0.0 108.729 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 62.9 m-80 -79.95 -11.87 59.76 Favored 'General case' 0 N--CA 1.467 0.4 0 O-C-N 121.453 -0.779 . . . . 0.0 113.079 -174.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 16.6 mtp -60.0 140.39 90.48 Favored Pre-proline 0 C--O 1.237 0.401 0 CA-C-N 118.238 0.472 . . . . 0.0 110.172 -178.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -65.27 156.05 65.21 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 121.962 1.775 . . . . 0.0 109.355 169.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 55.9 t60 -57.31 -34.99 69.3 Favored 'General case' 0 C--O 1.224 -0.261 0 CA-C-O 119.003 -0.522 . . . . 0.0 110.701 173.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.74 -41.66 77.91 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-O 118.591 -0.718 . . . . 0.0 112.362 175.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.88 -45.45 82.03 Favored 'General case' 0 C--O 1.222 -0.388 0 CA-C-N 118.909 0.777 . . . . 0.0 109.415 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 67.9 mt -65.42 -44.26 94.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.481 0 C-N-CA 125.53 1.532 . . . . 0.0 109.21 -175.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 22.5 t -55.18 -47.98 76.84 Favored 'Isoleucine or valine' 0 C--O 1.24 0.585 0 C-N-CA 125.147 1.379 . . . . 0.0 109.629 170.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 24.9 mtpt -70.33 -28.11 64.89 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-O 117.134 -1.412 . . . . 0.0 113.526 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.85 -40.83 79.17 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.932 1.696 . . . . 0.0 110.481 177.07 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 81.8 mt -68.74 -46.81 78.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 178.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.1 tmtm? -63.34 -38.12 89.93 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-O 118.678 -0.677 . . . . 0.0 111.729 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -61.93 -32.02 72.38 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 124.169 0.988 . . . . 0.0 110.282 175.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -67.95 -12.18 60.23 Favored 'General case' 0 CA--C 1.543 0.689 0 CA-C-O 121.636 0.731 . . . . 0.0 112.3 175.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 66.13 -100.31 0.51 Allowed Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 125.674 1.607 . . . . 0.0 110.411 173.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 25.1 mt -105.34 -24.72 12.63 Favored 'General case' 0 CA--C 1.504 -0.792 0 CA-C-O 117.68 -1.153 . . . . 0.0 112.495 -176.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.28 121.06 40.11 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 118.678 0.672 . . . . 0.0 109.495 178.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.3 p -125.68 148.48 30.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -176.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -116.28 117.29 29.58 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 124.656 1.183 . . . . 0.0 108.068 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 57.4 mt -98.99 112.64 24.7 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 171.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.3 ttm180 -81.47 112.56 18.83 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 166.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.9 pp -116.72 166.51 10.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 C-N-CA 124.951 1.301 . . . . 0.0 108.618 -178.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.5 mt . . . . . 0 N--CA 1.464 0.26 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 174.219 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 36.9 p . . . . . 0 CA--C 1.537 0.446 0 CA-C-O 118.292 -0.861 . . . . 0.0 109.212 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.3 t -115.57 173.91 6.29 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.532 1.133 . . . . 0.0 109.592 163.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -134.85 94.68 3.2 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 126.624 1.97 . . . . 0.0 108.376 168.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.6 t -99.22 108.07 21.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 O-C-N 120.68 -1.262 . . . . 0.0 107.94 -170.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.5 p -105.48 121.04 57.15 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 CA-C-N 118.841 0.746 . . . . 0.0 111.315 -170.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.6 mt -134.13 129.21 53.61 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 126.089 1.756 . . . . 0.0 109.363 -169.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 37.8 m-70 -108.54 144.18 36.56 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.214 1.806 . . . . 0.0 111.443 -177.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 18.4 ptt180 -126.51 175.59 7.79 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 125.511 1.525 . . . . 0.0 111.018 176.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.445 ' HE3' ' OE2' ' A' ' 22' ' ' GLU . 0.0 OUTLIER -81.05 170.06 16.69 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 160.007 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -68.98 -35.7 77.02 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.609 -0.682 . . . . 0.0 111.709 177.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 68.9 m-20 -71.27 -47.32 57.65 Favored 'General case' 0 C--O 1.232 0.15 0 O-C-N 122.196 -0.315 . . . . 0.0 111.354 -171.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.445 ' OE2' ' HE3' ' A' ' 19' ' ' LYS . 5.3 pt-20 -76.84 166.96 22.64 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.518 0.675 . . . . 0.0 110.456 -176.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.61 -178.07 49.4 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 167.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -70.6 145.28 50.81 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 104.255 -2.498 . . . . 0.0 104.255 149.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.4 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -84.81 44.83 3.42 Favored Glycine 0 C--O 1.221 -0.705 0 CA-C-O 117.529 -1.706 . . . . 0.0 112.519 -176.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -131.48 160.64 34.58 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 119.251 1.526 . . . . 0.0 110.519 179.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.9 t -136.88 127.32 40.18 Favored 'Isoleucine or valine' 0 C--O 1.239 0.53 0 C-N-CA 125.004 1.322 . . . . 0.0 108.055 177.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.1 mt -74.39 143.53 13.39 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 170.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.47 HD11 ' HE3' ' A' ' 46' ' ' LYS . 20.4 pt . . . . . 0 C--O 1.243 0.712 0 C-N-CA 124.25 1.02 . . . . 0.0 109.518 162.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_endo . . . . . 0 N--CA 1.454 -0.85 0 CA-C-O 118.27 -0.804 . . . . 0.0 111.292 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.4 m80 -85.42 126.51 33.84 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 120.07 1.305 . . . . 0.0 110.886 -174.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.47 ' HE3' HD11 ' A' ' 29' ' ' ILE . 11.2 pttp -144.32 162.52 36.21 Favored 'General case' 0 N--CA 1.465 0.281 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 166.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 23.0 mm -62.85 120.5 9.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 164.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -98.32 -30.05 7.18 Favored Glycine 0 CA--C 1.524 0.598 0 CA-C-N 118.455 0.571 . . . . 0.0 113.129 170.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 59.3 ttm-85 -151.97 153.98 35.14 Favored 'General case' 0 CA--C 1.514 -0.429 0 CA-C-N 118.635 1.217 . . . . 0.0 108.221 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 13.4 mt -120.15 149.92 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 O-C-N 124.614 1.196 . . . . 0.0 108.184 166.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.2 mp -78.58 127.29 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.825 0 C-N-CA 126.139 1.776 . . . . 0.0 107.25 168.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -59.42 137.51 57.97 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.44 6.1 89.04 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-O 118.461 -1.188 . . . . 0.0 113.331 174.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.4 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 76.6 p -87.3 166.52 25.37 Favored Pre-proline 0 CA--C 1.53 0.208 0 CA-C-N 119.992 1.896 . . . . 0.0 112.705 -175.2 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -58.16 -25.89 73.61 Favored 'Trans proline' 0 N--CA 1.452 -0.931 0 C-N-CA 122.121 1.881 . . . . 0.0 113.394 167.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.95 -60.62 2.85 Favored 'General case' 0 C--N 1.342 0.247 0 CA-C-N 119.283 0.947 . . . . 0.0 108.859 174.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -57.85 -46.38 84.86 Favored 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 122.981 0.512 . . . . 0.0 110.962 -176.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 78.8 mtt-85 -65.78 -18.21 65.17 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 124.885 1.274 . . . . 0.0 112.676 -176.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 9.0 t -63.12 -33.34 75.25 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 119.245 0.93 . . . . 0.0 110.11 175.266 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 58.23 -31.79 0.04 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 129.584 3.154 . . . . 0.0 114.901 -168.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.5 mtpt -61.55 -8.44 4.33 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.999 1.72 . . . . 0.0 112.093 170.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 21.2 tp -134.75 116.32 14.74 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 126.075 1.75 . . . . 0.0 108.981 -176.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 27.4 mmmt -137.4 171.63 14.19 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 123.535 1.636 . . . . 0.0 111.831 176.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 46.5 t -68.64 110.74 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 113.881 -1.509 . . . . 0.0 108.383 -178.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 138.35 -23.5 2.99 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -177.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -64.99 100.14 0.4 Allowed 'General case' 0 C--O 1.233 0.227 0 CA-C-O 122.114 0.959 . . . . 0.0 109.843 -174.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.9 mtm-85 -48.43 137.62 11.19 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 128.048 2.539 . . . . 0.0 109.602 156.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.8 mt -122.86 143.96 33.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.195 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -173.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.7 mt -107.24 -42.34 4.88 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 125.732 1.613 . . . . 0.0 110.379 175.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -154.68 165.99 34.81 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 123.015 0.526 . . . . 0.0 112.04 -170.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 51.4 t -125.71 123.06 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 C-N-CA 128.141 2.577 . . . . 0.0 104.95 174.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 42.78 39.31 1.64 Allowed 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.212 1.805 . . . . 0.0 111.412 -172.511 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 81.26 -9.75 52.74 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-O 117.638 -1.645 . . . . 0.0 115.173 177.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 7.6 mm-40 -75.07 119.59 19.44 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 120.558 2.179 . . . . 0.0 108.557 172.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.9 m -55.21 127.76 30.79 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 171.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 15.3 pt -100.79 -5.38 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 C-N-CA 123.331 0.652 . . . . 0.0 112.265 -178.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.1 mt -59.13 142.48 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 167.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 73.2 -20.06 0.3 Allowed 'General case' 0 CA--C 1.533 0.294 0 C-N-CA 126.497 1.919 . . . . 0.0 115.325 167.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 14.0 mtp -64.25 148.3 95.97 Favored Pre-proline 0 CA--C 1.539 0.522 0 CA-C-N 119.477 1.035 . . . . 0.0 109.68 167.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -72.57 161.17 44.79 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 122.401 2.067 . . . . 0.0 110.064 169.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -55.28 -47.79 75.0 Favored 'General case' 0 C--O 1.225 -0.209 0 C-N-CA 123.661 0.784 . . . . 0.0 111.016 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -53.76 -40.62 66.37 Favored 'General case' 0 CA--C 1.527 0.092 0 C-N-CA 123.236 0.614 . . . . 0.0 112.174 -176.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -72.19 -42.37 65.9 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 119.259 -0.4 . . . . 0.0 110.478 -175.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 46.9 mt -66.59 -37.28 79.24 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 124.87 1.268 . . . . 0.0 108.846 176.238 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 38.2 t -65.16 -45.63 93.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.484 0 O-C-N 120.274 -1.516 . . . . 0.0 109.841 175.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.3 ttpt -62.41 -42.53 99.51 Favored 'General case' 0 C--O 1.22 -0.482 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.344 175.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.12 -48.01 23.16 Favored 'General case' 0 C--O 1.226 -0.162 0 C-N-CA 126.305 1.842 . . . . 0.0 111.62 171.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 74.4 mt -76.22 -31.89 21.76 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 O-C-N 121.592 -0.692 . . . . 0.0 109.607 -174.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.3 tttp -66.42 -46.08 77.75 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.58 1.082 . . . . 0.0 110.125 170.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -60.87 -18.15 54.47 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 128.134 2.574 . . . . 0.0 111.984 175.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -58.68 -25.91 63.3 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.816 0.446 . . . . 0.0 111.336 169.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 66.86 57.97 8.97 Favored Glycine 0 C--N 1.339 0.71 0 O-C-N 121.338 -0.852 . . . . 0.0 111.063 170.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 48.0 mt 75.48 -38.52 0.36 Allowed 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 128.428 2.691 . . . . 0.0 112.193 -174.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.01 121.43 41.77 Favored 'General case' 0 C--N 1.322 -0.61 0 O-C-N 123.604 0.565 . . . . 0.0 111.062 -173.488 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.5 p -124.77 121.75 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 178.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.2 m -89.49 133.68 34.45 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 164.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 27.7 mt -123.76 139.36 54.06 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 -177.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.8 ttm180 -113.72 115.86 28.5 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -112.52 166.9 6.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 C-N-CA 126.682 1.993 . . . . 0.0 108.083 177.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 70.0 mt . . . . . 0 CA--C 1.54 0.586 0 CA-C-O 117.792 -1.099 . . . . 0.0 109.615 177.529 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 38.4 p . . . . . 0 CA--C 1.537 0.451 0 N-CA-C 107.327 -1.361 . . . . 0.0 107.327 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 23.4 m -137.98 162.3 34.45 Favored 'General case' 0 C--N 1.328 -0.34 0 O-C-N 120.865 -1.147 . . . . 0.0 108.333 164.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -131.72 95.72 3.79 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 127.691 2.396 . . . . 0.0 107.1 -167.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 19.6 t -93.72 94.83 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 -176.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.9 p -80.88 129.25 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 172.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 67.0 mt -135.17 147.15 29.29 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 175.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.6 m-70 -113.4 167.31 10.69 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.008 1.323 . . . . 0.0 109.713 173.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 46.2 ptt85 -145.58 -179.88 6.97 Favored 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 125.996 1.718 . . . . 0.0 107.076 172.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.67 159.29 15.6 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 173.1 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -70.13 -14.77 62.8 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 120.791 -1.193 . . . . 0.0 112.243 -178.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -80.08 7.63 8.78 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.95 1.3 . . . . 0.0 112.264 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -164.62 170.14 16.1 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 120.249 -1.532 . . . . 0.0 109.863 -167.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.2 -167.81 29.12 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 125.399 1.476 . . . . 0.0 110.909 175.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -85.98 159.44 19.62 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 164.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.88 39.28 2.86 Favored Glycine 0 C--O 1.222 -0.623 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.922 -178.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -118.58 161.35 20.2 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 119.587 1.694 . . . . 0.0 109.387 169.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.8 t -140.81 129.79 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 -178.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 61.5 mt -97.4 145.47 9.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.2 pt . . . . . 0 N--CA 1.441 -0.879 0 C-N-CA 125.249 1.42 . . . . 0.0 109.746 168.781 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo . . . . . 0 N--CA 1.456 -0.688 0 CA-C-O 119.457 -0.309 . . . . 0.0 111.492 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -140.39 132.59 28.1 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 125.206 1.403 . . . . 0.0 108.142 -173.371 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.0 pttm -156.89 166.93 31.98 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 125.698 1.599 . . . . 0.0 107.734 174.249 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 26.5 mm -72.71 103.69 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 C-N-CA 124.571 1.148 . . . . 0.0 108.87 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -67.91 -42.58 85.47 Favored Glycine 0 N--CA 1.451 -0.33 0 O-C-N 121.284 -0.885 . . . . 0.0 111.366 172.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 23.6 ttm105 -158.1 152.12 24.09 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -165.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 16.1 mt -122.0 150.49 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 168.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 31.9 mm -87.82 136.47 23.08 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.4 t0 -66.66 148.89 51.28 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-O 121.152 0.501 . . . . 0.0 111.185 -176.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.48 7.93 17.12 Favored Glycine 0 CA--C 1.527 0.834 0 C-N-CA 124.519 1.057 . . . . 0.0 114.369 175.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 79.4 p -76.0 167.98 31.88 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 118.234 1.017 . . . . 0.0 111.144 -176.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -57.8 -27.71 79.26 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 122.149 1.899 . . . . 0.0 112.239 165.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -70.83 -51.96 23.38 Favored 'General case' 0 C--N 1.341 0.204 0 CA-C-N 119.996 1.271 . . . . 0.0 110.171 174.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -57.83 -44.68 86.63 Favored 'General case' 0 N--CA 1.465 0.311 0 C-N-CA 123.343 0.657 . . . . 0.0 110.674 -179.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 27.4 mtt-85 -75.86 -5.53 46.46 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 124.634 1.174 . . . . 0.0 112.706 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.9 t -73.21 -35.97 66.43 Favored 'General case' 0 C--O 1.225 -0.2 0 CA-C-O 117.617 -1.182 . . . . 0.0 110.994 178.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 59.49 -24.94 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 127.985 2.514 . . . . 0.0 116.214 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 6.1 mtpt -66.48 -17.29 64.71 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 120.325 1.421 . . . . 0.0 111.975 161.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.78 119.0 34.08 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -178.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.51 171.47 14.21 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-O 122.563 1.173 . . . . 0.0 109.049 -178.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 78.3 t -72.43 108.14 3.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 O-C-N 120.734 -1.229 . . . . 0.0 108.693 -178.399 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 130.39 -3.94 5.87 Favored Glycine 0 CA--C 1.521 0.418 0 C-N-CA 126.261 1.886 . . . . 0.0 111.275 173.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.5 m-20 -71.31 95.86 1.36 Allowed 'General case' 0 C--O 1.234 0.268 0 CA-C-N 118.585 1.192 . . . . 0.0 108.148 172.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 38.5 mtt85 -53.01 143.3 17.61 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 127.382 2.273 . . . . 0.0 109.116 170.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 34.6 mt -116.84 149.53 19.06 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -168.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.86 -46.05 0.87 Allowed 'General case' 0 N--CA 1.463 0.211 0 C-N-CA 126.336 1.854 . . . . 0.0 109.967 -164.211 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -153.52 168.55 25.77 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.046 0.938 . . . . 0.0 110.012 176.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 80.6 t -133.6 120.99 39.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 174.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 23.2 m-20 48.73 41.22 17.6 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.308 1.043 . . . . 0.0 110.398 -172.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.13 -11.39 3.82 Favored Glycine 0 CA--C 1.527 0.792 0 C-N-CA 126.907 2.194 . . . . 0.0 116.467 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.5 tp-100 -77.13 121.53 23.73 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 120.146 1.973 . . . . 0.0 107.257 -177.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 p -63.29 112.33 2.65 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.32 1.048 . . . . 0.0 110.992 -174.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 1.7 pp -73.34 14.25 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 125.758 1.623 . . . . 0.0 113.188 175.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 60.6 mt -76.78 -86.16 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 O-C-N 121.199 -0.938 . . . . 0.0 109.353 -158.414 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -77.53 -8.72 58.24 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.416 1.086 . . . . 0.0 111.226 176.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 17.1 ttt -53.65 142.26 42.82 Favored Pre-proline 0 N--CA 1.433 -1.303 0 C-N-CA 128.22 2.608 . . . . 0.0 110.924 -177.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -60.66 139.58 86.47 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 121.873 1.715 . . . . 0.0 110.639 174.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -59.3 -39.87 84.38 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.541 0.736 . . . . 0.0 111.587 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.39 -23.49 63.73 Favored 'General case' 0 CA--C 1.53 0.177 0 O-C-N 122.034 -0.416 . . . . 0.0 111.986 175.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -73.72 -46.54 45.43 Favored 'General case' 0 C--O 1.223 -0.293 0 CA-C-O 118.635 -0.697 . . . . 0.0 109.713 179.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 49.1 mt -56.08 -40.32 63.34 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 126.432 1.893 . . . . 0.0 110.568 172.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 35.0 t -66.57 -43.89 90.36 Favored 'Isoleucine or valine' 0 C--O 1.238 0.451 0 O-C-N 120.109 -1.619 . . . . 0.0 110.75 176.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 6.6 tttt -54.82 -49.11 71.8 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 172.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -48.89 -39.38 25.75 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 129.23 3.012 . . . . 0.0 113.721 177.084 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.7 mt -75.9 -46.08 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 CA-C-N 118.791 0.723 . . . . 0.0 109.073 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -57.34 -51.21 70.29 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 119.002 0.819 . . . . 0.0 110.137 173.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -57.71 -19.28 26.17 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 128.69 2.796 . . . . 0.0 112.864 177.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -60.41 -26.87 67.01 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 119.253 0.933 . . . . 0.0 112.596 177.231 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.32 -151.36 18.28 Favored Glycine 0 C--N 1.341 0.822 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -173.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 72.9 mt -71.98 -33.04 67.82 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 117.626 0.713 . . . . 0.0 110.906 168.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.91 145.56 24.54 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 -178.739 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.6 p -140.98 143.24 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 168.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 23.7 m -114.57 102.69 10.29 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 174.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 61.3 mt -89.93 115.21 27.06 Favored 'General case' 0 CA--C 1.514 -0.427 0 N-CA-C 106.587 -1.634 . . . . 0.0 106.587 -174.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -86.4 112.14 21.18 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 -178.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -113.51 167.97 6.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 C-N-CA 124.709 1.203 . . . . 0.0 110.356 -174.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.9 mp . . . . . 0 C--O 1.239 0.518 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 172.655 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 74.0 p . . . . . 0 N--CA 1.444 -0.742 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 m -132.18 155.26 48.52 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 144.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -93.21 143.11 26.58 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 105.632 -1.988 . . . . 0.0 105.632 160.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.7 t -129.96 102.06 6.74 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 169.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.6 p -82.95 144.87 9.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 168.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.1 mt -136.81 152.26 28.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 C-N-CA 127.487 2.315 . . . . 0.0 104.933 173.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 83.0 m-70 -129.92 136.56 49.62 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 125.618 1.567 . . . . 0.0 109.122 -168.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.1 ptt180 -131.39 176.6 8.16 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 120.605 1.548 . . . . 0.0 111.195 -178.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.2 161.98 14.04 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.07 0.948 . . . . 0.0 109.289 172.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -70.55 -15.78 62.81 Favored 'General case' 0 CA--C 1.538 0.502 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -89.2 -10.64 46.32 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.149 0.886 . . . . 0.0 112.642 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 25.9 pt-20 -127.57 175.38 8.3 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 120.344 1.429 . . . . 0.0 110.974 -166.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.01 176.79 19.44 Favored Glycine 0 CA--C 1.531 1.036 0 C-N-CA 124.899 1.238 . . . . 0.0 111.716 177.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 57.9 m-85 -89.3 137.96 31.86 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.024 -1.473 . . . . 0.0 107.024 163.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.76 66.9 0.32 Allowed Glycine 0 C--O 1.222 -0.603 0 C-N-CA 124.571 1.081 . . . . 0.0 111.101 -176.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -133.85 146.31 50.5 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 124.814 1.246 . . . . 0.0 108.459 167.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.6 t -121.54 144.87 29.25 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 173.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.6 mp -118.43 110.62 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 -173.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 31.1 pt . . . . . 0 C--O 1.234 0.261 0 C-N-CA 123.861 0.864 . . . . 0.0 111.072 -169.606 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 N--CA 1.461 -0.403 0 CA-C-O 118.212 -0.829 . . . . 0.0 114.026 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -133.55 121.16 21.73 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 119.734 1.152 . . . . 0.0 108.098 -177.324 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.9 pttt -145.72 149.46 34.45 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 106.9 -1.519 . . . . 0.0 106.9 170.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 17.1 mm -63.03 125.84 20.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 174.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -98.41 -37.51 4.27 Favored Glycine 0 C--N 1.333 0.388 0 C-N-CA 123.88 0.753 . . . . 0.0 112.773 178.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 37.6 ttm180 -158.15 149.14 20.85 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 125.198 1.399 . . . . 0.0 107.906 -174.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.2 mt -127.34 124.88 64.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 C-N-CA 126.598 1.959 . . . . 0.0 106.536 172.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.6 mp -55.59 132.91 19.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.339 0 C-N-CA 125.436 1.494 . . . . 0.0 109.828 168.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -57.42 127.5 32.3 Favored 'General case' 0 C--O 1.24 0.572 0 C-N-CA 124.991 1.316 . . . . 0.0 109.309 174.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.04 5.52 89.55 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 124.447 1.023 . . . . 0.0 113.462 174.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.2 p -65.26 162.69 38.08 Favored Pre-proline 0 CA--C 1.532 0.288 0 CA-C-N 119.21 1.505 . . . . 0.0 110.938 173.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -60.5 -28.95 87.62 Favored 'Trans proline' 0 N--CA 1.45 -1.045 0 C-N-CA 121.781 1.654 . . . . 0.0 112.109 168.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.25 -52.84 63.57 Favored 'General case' 0 C--N 1.344 0.33 0 CA-C-N 119.337 0.972 . . . . 0.0 110.282 172.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -61.55 -51.96 66.42 Favored 'General case' 0 N--CA 1.462 0.146 0 O-C-N 123.285 0.366 . . . . 0.0 110.817 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 90.5 mtt-85 -63.93 -28.9 70.15 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 118.409 -0.805 . . . . 0.0 112.059 -173.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 42.3 t -60.94 -19.1 60.26 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.627 1.171 . . . . 0.0 112.573 174.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 55.78 22.4 5.49 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 125.389 1.475 . . . . 0.0 114.197 171.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 44.5 mtmt -130.1 8.24 5.15 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 124.668 1.187 . . . . 0.0 113.273 178.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -141.06 119.27 12.07 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.13 165.11 24.0 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 119.016 0.826 . . . . 0.0 110.606 176.579 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . 0.263 0.2 OUTLIER -56.98 141.15 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 O-C-N 121.201 -0.937 . . . . 0.0 109.846 172.684 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.2 -6.97 78.7 Favored Glycine 0 CA--C 1.524 0.655 0 CA-C-O 118.215 -1.325 . . . . 0.0 111.651 -174.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 41.8 m-20 -74.59 96.97 3.06 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 119.244 1.522 . . . . 0.0 107.287 168.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 42.8 mtm180 -45.05 130.87 7.61 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 126.882 2.073 . . . . 0.0 110.061 160.034 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 7.1 mt -111.76 143.99 20.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -177.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 tp -112.81 -44.98 3.24 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 127.343 2.257 . . . . 0.0 108.47 -171.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -155.71 170.88 21.02 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.546 0.739 . . . . 0.0 111.474 -177.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.9 p -131.22 125.39 57.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 C-N-CA 125.154 1.382 . . . . 0.0 107.992 174.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 64.2 m-20 46.64 45.65 14.41 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 124.487 1.115 . . . . 0.0 108.957 -170.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 68.3 -2.51 7.15 Favored Glycine 0 CA--C 1.538 1.477 0 C-N-CA 125.81 1.672 . . . . 0.0 116.772 -175.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -91.13 135.32 33.85 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 121.465 2.632 . . . . 0.0 110.359 -174.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -72.41 109.24 5.97 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 126.109 1.764 . . . . 0.0 112.316 -171.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 7.4 pt -87.74 -5.05 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 O-C-N 121.348 -0.845 . . . . 0.0 112.51 -172.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.455 HD12 ' H ' ' A' ' 77' ' ' ILE . 3.6 mp -65.56 -48.23 83.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 C-N-CA 124.626 1.17 . . . . 0.0 110.207 173.097 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 63.6 m-80 -93.45 -26.6 17.13 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 118.523 -0.751 . . . . 0.0 112.255 -162.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 3.9 mtp -70.27 160.53 80.62 Favored Pre-proline 0 CA--C 1.534 0.34 0 C-N-CA 124.685 1.194 . . . . 0.0 112.398 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -71.36 146.18 49.95 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 121.822 1.681 . . . . 0.0 109.764 166.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -49.61 -38.6 32.43 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.765 1.226 . . . . 0.0 111.68 178.253 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -65.76 -30.13 70.75 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 124.152 0.981 . . . . 0.0 113.366 -178.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -82.01 -37.91 25.84 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 119.482 1.037 . . . . 0.0 109.908 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.7 mt -60.5 -36.32 68.95 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 C-N-CA 124.047 0.939 . . . . 0.0 109.659 172.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.9 t -63.79 -51.35 70.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 O-C-N 120.542 -1.349 . . . . 0.0 110.24 170.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -51.88 -46.97 64.72 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 118.138 0.426 . . . . 0.0 111.406 178.543 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.45 -36.11 66.2 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 127.686 2.394 . . . . 0.0 113.602 -179.446 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 86.1 mt -76.7 -48.42 26.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.157 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 59.2 tttt -55.7 -44.86 77.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 122.882 0.473 . . . . 0.0 110.879 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -63.68 -26.9 68.87 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 125.251 1.42 . . . . 0.0 112.27 177.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.39 -28.41 69.25 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 118.195 0.452 . . . . 0.0 110.519 176.098 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.16 -106.88 2.93 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 125.385 1.469 . . . . 0.0 109.708 174.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 81.5 mt -100.35 -36.27 9.3 Favored 'General case' 0 CA--C 1.504 -0.812 0 C-N-CA 123.137 0.575 . . . . 0.0 110.758 -170.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -93.73 143.65 26.12 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 170.325 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.2 p -144.21 138.43 24.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 165.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 m -104.79 130.02 52.96 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 179.125 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 26.7 mt -114.4 117.85 32.21 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 124.642 1.177 . . . . 0.0 107.876 177.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -84.93 116.05 23.13 Favored 'General case' 0 C--O 1.232 0.175 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 174.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 pp -114.92 172.71 3.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 C-N-CA 125.867 1.667 . . . . 0.0 109.941 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 6.2 mt . . . . . 0 C--O 1.237 0.447 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 169.627 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 28.9 p . . . . . 0 N--CA 1.447 -0.58 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.5 m -97.7 135.91 38.82 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 103.912 -2.625 . . . . 0.0 103.912 -174.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -112.92 103.99 11.97 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 18.2 t -87.49 139.29 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 105.532 -2.025 . . . . 0.0 105.532 177.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.4 p -129.11 143.24 41.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 168.037 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 4.0 mt -132.11 152.06 36.07 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 127.12 2.168 . . . . 0.0 105.421 173.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -131.32 130.11 42.31 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 126.646 1.978 . . . . 0.0 107.597 -176.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 34.0 ptt180 -126.11 179.89 5.03 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-N 120.311 1.414 . . . . 0.0 110.492 -175.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.1 164.61 12.09 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.281 1.033 . . . . 0.0 109.073 175.324 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -75.21 -12.95 60.4 Favored 'General case' 0 N--CA 1.466 0.367 0 O-C-N 120.795 -1.19 . . . . 0.0 111.764 176.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -74.44 -8.25 55.67 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 177.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 26.1 pt-20 -143.0 -175.71 4.62 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 124.082 0.953 . . . . 0.0 110.95 -162.136 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -116.89 -179.39 17.77 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 175.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -75.31 174.53 9.41 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 159.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.39 46.43 1.08 Allowed Glycine 0 C--O 1.222 -0.602 0 CA-C-O 118.817 -0.99 . . . . 0.0 111.694 -176.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -133.44 143.95 49.19 Favored 'General case' 0 C--O 1.239 0.506 0 CA-C-N 118.246 1.023 . . . . 0.0 108.29 177.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.6 t -119.21 114.35 44.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 106.009 -1.848 . . . . 0.0 106.009 -171.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 14.5 mt -78.88 136.92 22.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.299 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 174.249 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.0 pt . . . . . 0 N--CA 1.441 -0.883 0 C-N-CA 125.557 1.543 . . . . 0.0 108.236 163.638 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo . . . . . 0 N--CA 1.449 -1.119 0 N-CA-C 108.66 -1.323 . . . . 0.0 108.66 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER 91.74 123.93 0.02 OUTLIER 'General case' 0 C--O 1.233 0.208 0 C-N-CA 130.123 3.369 . . . . 0.0 111.004 167.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -145.44 163.68 33.89 Favored 'General case' 0 C--O 1.233 0.209 0 C-N-CA 124.905 1.282 . . . . 0.0 108.4 163.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.8 mm -65.24 129.73 29.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 165.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -101.97 -49.6 1.24 Allowed Glycine 0 CA--C 1.524 0.628 0 C-N-CA 126.857 2.17 . . . . 0.0 111.774 173.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 49.6 ttt180 -144.38 161.81 38.04 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 125.325 1.45 . . . . 0.0 107.544 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.3 mt -133.46 150.74 32.46 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 C-N-CA 126.453 1.901 . . . . 0.0 107.707 174.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.0 mp -87.03 115.76 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.904 0 C-N-CA 126.57 1.948 . . . . 0.0 106.796 171.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 31.6 m-20 -52.57 142.98 16.74 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.183 0.993 . . . . 0.0 109.048 171.482 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.82 -12.99 26.55 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-O 118.218 -1.323 . . . . 0.0 113.471 175.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 74.3 p -65.85 167.03 12.59 Favored Pre-proline 0 C--O 1.238 0.478 0 CA-C-N 119.639 1.72 . . . . 0.0 111.829 -175.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -59.32 -29.1 89.37 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 121.712 1.608 . . . . 0.0 111.996 166.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.56 -56.74 12.03 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.668 0.667 . . . . 0.0 109.946 177.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -65.29 -51.55 59.97 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 123.039 0.535 . . . . 0.0 110.949 -177.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.0 mtp180 -65.46 -9.37 25.13 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.337 0.865 . . . . 0.0 113.337 -177.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -76.7 -9.27 58.55 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 117.149 -1.405 . . . . 0.0 113.16 171.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 52.11 39.17 26.07 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.905 1.682 . . . . 0.0 113.942 170.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 23.6 mtmm -141.11 13.49 2.23 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.784 1.233 . . . . 0.0 113.34 177.197 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.9 mt -144.26 127.41 16.62 Favored 'General case' 0 C--O 1.237 0.437 0 O-C-N 121.09 -1.006 . . . . 0.0 109.743 175.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -116.3 164.83 13.93 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.657 1.218 . . . . 0.0 108.806 175.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 39.3 t -65.75 133.73 30.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 163.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 110.07 -17.32 29.6 Favored Glycine 0 C--N 1.339 0.704 0 C-N-CA 124.918 1.247 . . . . 0.0 110.307 -177.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -71.91 97.12 1.78 Allowed 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 122.667 1.222 . . . . 0.0 109.09 -175.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 49.6 mtt85 -55.17 148.36 14.44 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 126.013 1.725 . . . . 0.0 110.904 166.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 96.3 mt -122.71 148.1 26.62 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 C-N-CA 126.995 2.118 . . . . 0.0 106.788 -166.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 29.1 mt -126.44 -37.29 2.21 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 114.43 1.27 . . . . 0.0 114.43 179.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -148.42 159.54 43.92 Favored 'General case' 0 N--CA 1.465 0.289 0 C-N-CA 124.454 1.101 . . . . 0.0 110.397 178.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 91.8 t -130.9 118.13 40.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 -175.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 63.03 -65.41 0.1 Allowed 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 128.513 2.725 . . . . 0.0 110.002 -165.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.97 -2.09 0.07 OUTLIER Glycine 0 CA--C 1.532 1.109 0 C-N-CA 125.914 1.721 . . . . 0.0 111.922 163.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -74.59 124.54 26.86 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 119.935 1.867 . . . . 0.0 107.142 -175.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.4 p -68.2 103.74 1.64 Allowed 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.8 pp -74.23 9.9 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 C-N-CA 124.079 0.952 . . . . 0.0 112.698 -177.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 83.0 mt -46.61 -55.71 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.275 0 C-N-CA 128.99 2.916 . . . . 0.0 109.697 179.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -108.77 -30.64 8.06 Favored 'General case' 0 N--CA 1.461 0.089 0 C-N-CA 124.802 1.241 . . . . 0.0 110.951 -174.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 15.0 ttt -49.56 132.29 19.32 Favored Pre-proline 0 N--CA 1.443 -0.799 0 C-N-CA 127.252 2.221 . . . . 0.0 110.008 -170.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -73.18 144.03 36.68 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 121.357 1.372 . . . . 0.0 108.754 -175.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 37.3 t60 -55.33 -35.86 65.63 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.768 0.827 . . . . 0.0 112.306 -170.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.56 -39.95 74.35 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 118.526 0.603 . . . . 0.0 112.18 174.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -69.24 -48.12 62.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 118.065 -0.969 . . . . 0.0 109.27 -176.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 3.1 mp -51.86 -49.75 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 C-N-CA 125.554 1.542 . . . . 0.0 110.785 168.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 3.0 t -58.61 -44.87 90.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 O-C-N 121.362 -0.836 . . . . 0.0 109.768 -176.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 26.7 tttt -64.7 -43.35 93.76 Favored 'General case' 0 C--O 1.223 -0.314 0 CA-C-O 117.966 -1.016 . . . . 0.0 111.759 173.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -50.17 -42.71 51.55 Favored 'General case' 0 C--O 1.224 -0.285 0 C-N-CA 126.935 2.094 . . . . 0.0 112.03 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 86.5 mt -75.19 -46.32 39.32 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -177.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -60.18 -35.43 75.35 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 122.483 0.313 . . . . 0.0 111.149 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -83.81 -11.43 57.05 Favored 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 127.499 2.32 . . . . 0.0 112.633 179.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -63.84 -11.17 24.99 Favored 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -170.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.86 61.58 2.12 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 166.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 76.5 mt 69.09 -39.78 0.43 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 128.966 2.906 . . . . 0.0 114.335 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.66 158.16 15.82 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 172.56 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.1 p -156.32 142.45 10.17 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 166.52 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.9 m -111.65 101.25 9.65 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 118.521 0.6 . . . . 0.0 111.119 -175.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 46.6 mt -90.44 108.57 19.87 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 125.039 1.336 . . . . 0.0 108.269 -178.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -76.5 122.76 25.02 Favored 'General case' 0 C--O 1.239 0.538 0 C-N-CA 124.074 0.949 . . . . 0.0 110.869 172.388 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.7 pt -128.59 165.0 29.18 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 124.27 1.028 . . . . 0.0 111.851 -177.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 72.6 mt . . . . . 0 CA--C 1.539 0.548 0 C-N-CA 125.304 1.442 . . . . 0.0 109.678 170.586 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 13.8 p . . . . . 0 N--CA 1.451 -0.414 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 m -114.32 164.86 13.35 Favored 'General case' 0 C--O 1.239 0.527 0 N-CA-C 106.113 -1.81 . . . . 0.0 106.113 157.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -103.2 153.73 20.06 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 143.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 62.8 t -129.09 142.0 45.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 103.025 -2.954 . . . . 0.0 103.025 161.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.1 t -123.85 132.44 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 168.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 65.4 mt -130.72 131.45 64.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 105.722 -1.955 . . . . 0.0 105.722 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 76.4 m-70 -117.35 146.87 43.1 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 125.576 1.55 . . . . 0.0 108.271 -176.222 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 50.0 ptt85 -141.57 177.15 8.34 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 120.178 1.354 . . . . 0.0 112.014 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.63 169.25 11.48 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 167.414 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -73.72 -28.69 61.84 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 119.951 -0.7 . . . . 0.0 111.908 173.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -61.16 -56.91 15.27 Favored 'General case' 0 CA--C 1.521 -0.17 0 C-N-CA 124.348 1.059 . . . . 0.0 110.256 -177.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -75.46 165.43 25.13 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.944 1.297 . . . . 0.0 109.216 178.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.02 176.89 26.17 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 163.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -71.83 167.27 20.34 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 159.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.11 0.11 57.3 Favored Glycine 0 CA--C 1.525 0.715 0 CA-C-O 117.922 -1.488 . . . . 0.0 114.994 -167.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -112.18 130.41 55.92 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 120.029 1.915 . . . . 0.0 111.878 -153.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 74.9 t -100.96 135.06 38.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 171.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 23.6 mt -93.23 139.0 18.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 171.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 35.3 pt . . . . . 0 N--CA 1.446 -0.666 0 C-N-CA 126.372 1.869 . . . . 0.0 108.29 168.368 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo . . . . . 0 N--CA 1.452 -0.915 0 N-CA-C 108.404 -1.422 . . . . 0.0 108.404 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 6.2 m80 80.44 107.38 0.07 Allowed 'General case' 0 C--O 1.234 0.267 0 C-N-CA 128.711 2.804 . . . . 0.0 112.138 172.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 55.5 pttt -133.2 161.15 35.21 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 123.824 0.849 . . . . 0.0 108.731 157.511 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 47.6 mm -66.25 135.43 28.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 168.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -102.9 -63.05 0.71 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 126.55 2.024 . . . . 0.0 111.223 175.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 8.4 ttm180 -131.14 155.11 47.55 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 125.447 1.499 . . . . 0.0 108.504 -175.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 32.5 mt -133.04 132.61 58.89 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 126.217 1.807 . . . . 0.0 107.117 174.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -55.86 114.18 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.776 1.631 . . . . 0.0 107.018 158.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -56.59 132.49 51.8 Favored 'General case' 0 C--O 1.236 0.383 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 174.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.78 -8.02 67.62 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 125.401 1.477 . . . . 0.0 114.977 175.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 36.2 p -59.91 169.6 1.47 Allowed Pre-proline 0 C--O 1.239 0.53 0 CA-C-N 118.407 1.104 . . . . 0.0 111.971 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -54.91 -31.78 75.05 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 121.242 1.295 . . . . 0.0 112.073 166.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.2 -68.83 0.24 Allowed 'General case' 0 C--N 1.345 0.404 0 C-N-CA 123.793 0.837 . . . . 0.0 110.089 169.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -51.39 -55.23 19.69 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 118.608 0.64 . . . . 0.0 112.559 -171.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -70.11 -7.79 44.3 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 123.349 0.659 . . . . 0.0 111.908 -175.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 10.5 t -62.66 -36.96 84.52 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 119.413 1.006 . . . . 0.0 109.202 166.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 57.69 -22.21 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 129.473 3.109 . . . . 0.0 115.789 -177.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 1.5 mmpp? -68.73 -4.6 16.45 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 127.94 2.496 . . . . 0.0 113.389 174.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -147.08 113.13 5.81 Favored 'General case' 0 C--O 1.237 0.421 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 -173.203 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 25.6 mttt -130.66 170.74 13.91 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 122.008 0.908 . . . . 0.0 112.613 -170.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.8 t -60.99 109.85 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.25 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 131.81 -17.16 4.97 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -70.52 106.45 3.46 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-N 118.525 1.163 . . . . 0.0 111.397 -178.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 52.8 mtm-85 -57.5 144.73 35.75 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 127.23 2.212 . . . . 0.0 110.056 161.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 5.4 mt -131.29 149.14 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 C-N-CA 123.295 0.638 . . . . 0.0 109.428 -168.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.48 -41.23 2.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.789 1.636 . . . . 0.0 112.663 -171.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -160.91 168.2 25.1 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.316 0.647 . . . . 0.0 111.743 -178.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.6 p -140.21 127.51 23.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 123.532 0.733 . . . . 0.0 110.09 -176.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 40.01 48.24 2.1 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 125.732 1.613 . . . . 0.0 109.774 -158.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 63.21 11.67 40.61 Favored Glycine 0 CA--C 1.528 0.869 0 CA-C-O 116.843 -2.087 . . . . 0.0 114.714 -178.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.84 153.97 20.65 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-N 120.684 2.242 . . . . 0.0 111.844 178.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.2 p -62.41 147.64 47.93 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -171.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 8.5 pt -131.52 -7.13 2.0 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 O-C-N 123.602 0.564 . . . . 0.0 112.05 167.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.1 mm -79.71 -45.84 22.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 O-C-N 120.569 -1.332 . . . . 0.0 109.628 176.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -88.48 -29.47 20.11 Favored 'General case' 0 N--CA 1.465 0.297 0 O-C-N 121.635 -0.666 . . . . 0.0 112.751 -178.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.6 mtp -70.61 152.33 95.32 Favored Pre-proline 0 CA--C 1.534 0.352 0 CA-C-N 118.906 0.775 . . . . 0.0 110.984 -177.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_endo -73.64 153.23 48.89 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 122.57 2.18 . . . . 0.0 109.55 171.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -62.49 -37.87 87.68 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.516 -0.74 . . . . 0.0 112.724 -167.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.83 -28.2 65.49 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 119.079 0.854 . . . . 0.0 111.611 -176.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -68.47 -45.06 73.44 Favored 'General case' 0 N--CA 1.46 0.072 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 176.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.7 mt -64.4 -38.38 82.42 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 125.299 1.44 . . . . 0.0 109.569 176.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 37.9 t -61.7 -47.6 92.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 O-C-N 120.22 -1.55 . . . . 0.0 109.093 172.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 4.2 tmtt? -63.59 -37.42 87.25 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.016 -177.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.46 -43.93 75.91 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 125.471 1.508 . . . . 0.0 111.446 173.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 60.0 mt -68.56 -43.36 83.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 119.542 1.065 . . . . 0.0 109.287 177.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 21.1 tttm -64.29 -38.64 91.78 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.671 -0.643 . . . . 0.0 110.546 -178.293 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -86.02 -3.44 58.94 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 126.924 2.09 . . . . 0.0 112.051 179.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -54.89 -26.07 33.23 Favored 'General case' 0 C--N 1.345 0.413 0 N-CA-C 113.817 1.043 . . . . 0.0 113.817 -166.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.51 36.02 3.93 Favored Glycine 0 C--N 1.335 0.479 0 N-CA-C 111.266 -0.733 . . . . 0.0 111.266 173.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 44.9 mt 69.29 -30.82 0.2 Allowed 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 128.596 2.759 . . . . 0.0 113.041 -175.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 m -92.66 148.12 22.32 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 167.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.3 p -139.97 124.42 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.002 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 169.224 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 20.9 m -99.04 123.77 43.58 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 177.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 21.9 mt -120.01 122.3 40.85 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.286 1.034 . . . . 0.0 109.835 -172.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 45.9 ttp180 -85.67 111.94 20.55 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 173.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pp -118.78 167.17 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 125.776 1.63 . . . . 0.0 108.76 175.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 7.6 mt . . . . . 0 N--CA 1.468 0.436 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 169.937 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 59.2 p . . . . . 0 C--O 1.237 0.416 0 N-CA-C 108.204 -1.035 . . . . 0.0 108.204 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 13.7 m -120.2 147.17 45.26 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.511 1.125 . . . . 0.0 108.481 163.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -74.37 155.45 38.13 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 125.3 1.44 . . . . 0.0 108.128 152.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 t -137.57 121.16 21.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 105.088 -2.19 . . . . 0.0 105.088 163.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.8 t -120.04 97.29 5.0 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -173.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 43.1 mt -99.28 126.32 52.61 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -174.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -103.9 149.62 24.93 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.653 -1.239 . . . . 0.0 107.653 177.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -143.21 -175.54 4.57 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 120.706 1.594 . . . . 0.0 109.899 175.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.48 ' N ' ' HE3' ' A' ' 19' ' ' LYS . 0.1 OUTLIER -92.64 163.71 13.68 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 169.001 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -68.25 -36.62 79.74 Favored 'General case' 0 N--CA 1.465 0.317 0 O-C-N 121.425 -0.797 . . . . 0.0 110.82 173.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -75.96 -4.52 41.56 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.418 1.087 . . . . 0.0 112.499 -166.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -123.41 179.33 4.77 Favored 'General case' 0 C--O 1.238 0.45 0 C-N-CA 126.872 2.069 . . . . 0.0 108.376 -178.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.93 178.71 20.94 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 162.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -72.95 -175.43 1.76 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 164.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -138.81 60.54 0.58 Allowed Glycine 0 C--O 1.223 -0.583 0 CA-C-O 118.774 -1.015 . . . . 0.0 112.582 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -140.18 158.16 44.47 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 118.694 1.247 . . . . 0.0 110.651 175.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.9 t -143.45 140.54 26.21 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 105.947 -1.872 . . . . 0.0 105.947 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 1.9 mp -130.47 129.26 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 C-N-CA 124.928 1.291 . . . . 0.0 107.566 -169.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.431 HD12 ' HE3' ' A' ' 46' ' ' LYS . 47.7 pt . . . . . 0 C--O 1.239 0.546 0 C-N-CA 124.32 1.048 . . . . 0.0 110.142 -166.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 CA--C 1.531 0.373 0 CA-C-O 120.694 0.206 . . . . 0.0 112.628 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -139.7 115.14 9.91 Favored 'General case' 0 N--CA 1.442 -0.826 0 C-N-CA 125.259 1.423 . . . . 0.0 107.641 -166.654 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.431 ' HE3' HD12 ' A' ' 29' ' ' ILE . 52.1 pttt -127.91 144.09 51.1 Favored 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 167.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.3 mm -55.38 120.98 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 165.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -87.15 -42.59 6.21 Favored Glycine 0 CA--C 1.522 0.494 0 C-N-CA 125.212 1.387 . . . . 0.0 110.85 175.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.6 ttt-85 -148.05 156.36 42.54 Favored 'General case' 0 C--O 1.233 0.225 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 172.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.67 139.6 48.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 164.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 44.1 mm -67.56 118.48 11.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 173.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -53.55 124.4 14.85 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 124.199 1.0 . . . . 0.0 108.448 173.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.94 -0.88 84.68 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 114.535 0.574 . . . . 0.0 114.535 176.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 57.8 p -69.23 169.52 11.58 Favored Pre-proline 0 C--O 1.235 0.336 0 CA-C-N 118.855 1.327 . . . . 0.0 112.019 175.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -57.37 -28.04 78.4 Favored 'Trans proline' 0 N--CA 1.449 -1.128 0 C-N-CA 121.21 1.273 . . . . 0.0 112.809 161.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.04 -54.26 19.64 Favored 'General case' 0 C--N 1.346 0.434 0 CA-C-N 119.967 1.258 . . . . 0.0 110.235 176.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -52.31 -55.07 23.85 Favored 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 124.918 1.287 . . . . 0.0 110.838 178.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 87.9 mtt180 -69.86 -7.35 39.39 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 123.558 0.743 . . . . 0.0 112.622 -175.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 8.9 t -71.24 -31.18 67.23 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 119.586 1.085 . . . . 0.0 110.569 168.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.97 -29.95 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 129.979 3.312 . . . . 0.0 116.364 -174.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.3 mtpt -69.86 -9.06 53.45 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 126.056 1.742 . . . . 0.0 112.32 169.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -106.46 132.31 52.63 Favored 'General case' 0 C--O 1.237 0.424 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 158.158 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 15.6 ptpt -139.56 169.07 18.42 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 124.387 1.075 . . . . 0.0 110.757 169.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 61.7 t -59.21 138.73 19.87 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 174.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 83.35 4.33 89.53 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 115.889 1.116 . . . . 0.0 115.889 174.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -60.89 -6.85 2.0 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 118.528 2.788 . . . . 0.0 118.528 -164.201 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 84.5 mtm180 49.38 105.59 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 128.658 2.783 . . . . 0.0 114.587 -165.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 57.7 mt -96.79 129.39 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 123.653 0.781 . . . . 0.0 109.241 -179.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -104.41 -23.88 13.12 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.366 1.066 . . . . 0.0 113.601 176.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -155.58 164.75 38.22 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 118.505 0.593 . . . . 0.0 111.258 -179.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.38 121.19 45.2 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 C-N-CA 126.405 1.882 . . . . 0.0 107.0 178.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 52.59 26.87 4.63 Favored 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 176.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 90.76 -2.77 80.56 Favored Glycine 0 CA--C 1.535 1.326 0 C-N-CA 125.581 1.562 . . . . 0.0 114.514 -177.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -94.37 128.91 41.19 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.751 1.775 . . . . 0.0 108.638 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.07 116.84 4.84 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 123.267 0.627 . . . . 0.0 109.479 171.339 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.7 pp -80.99 11.64 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.577 0 C-N-CA 124.149 0.979 . . . . 0.0 113.203 178.069 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 79.5 mt -61.04 -70.36 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 C-N-CA 124.961 1.304 . . . . 0.0 109.382 -175.005 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -94.69 -24.66 17.05 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 120.432 -0.507 . . . . 0.0 111.785 -172.325 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.2 mtp -48.6 134.59 13.47 Favored Pre-proline 0 CA--C 1.536 0.442 0 C-N-CA 125.154 1.382 . . . . 0.0 110.512 176.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.25 157.37 61.64 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 122.356 2.038 . . . . 0.0 109.478 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 16.0 m-70 -56.06 -32.96 64.56 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 119.302 -0.38 . . . . 0.0 110.847 174.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.9 -44.1 97.5 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 117.878 -1.058 . . . . 0.0 112.177 178.027 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -64.65 -45.98 84.47 Favored 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 66.3 mt -61.75 -40.46 86.96 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 C-N-CA 123.814 0.846 . . . . 0.0 110.527 -177.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 24.8 t -60.22 -50.25 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.132 0 O-C-N 121.209 -0.932 . . . . 0.0 109.32 171.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -63.2 -34.05 76.8 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 117.479 -1.248 . . . . 0.0 112.746 -177.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -63.78 -41.51 97.94 Favored 'General case' 0 N--CA 1.442 -0.832 0 C-N-CA 128.07 2.548 . . . . 0.0 110.645 174.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 54.4 mt -67.16 -45.61 86.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 O-C-N 120.774 -1.204 . . . . 0.0 108.875 177.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 4.6 tttt -61.77 -38.98 90.03 Favored 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 123.077 0.551 . . . . 0.0 109.597 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -61.65 -43.08 99.53 Favored 'General case' 0 CA--C 1.517 -0.323 0 C-N-CA 125.058 1.343 . . . . 0.0 110.381 175.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -56.01 -34.56 65.92 Favored 'General case' 0 CA--C 1.537 0.473 0 O-C-N 123.339 0.399 . . . . 0.0 110.63 -175.498 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.03 -116.22 5.46 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 124.896 1.236 . . . . 0.0 110.885 157.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 8.2 mt -83.53 -20.12 34.44 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-N 117.126 0.463 . . . . 0.0 109.753 167.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 p -94.53 156.32 16.51 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 173.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.8 p -157.39 124.84 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.258 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 160.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 56.3 m -109.53 101.86 10.77 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.612 1.565 . . . . 0.0 107.514 -172.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 81.8 mt -90.92 165.17 13.73 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 125.014 1.326 . . . . 0.0 110.369 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 26.6 ttm180 -120.57 127.99 52.65 Favored 'General case' 0 CA--C 1.518 -0.282 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 162.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 pp -128.83 178.64 4.77 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 125.318 1.447 . . . . 0.0 109.29 173.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 75.8 mt . . . . . 0 N--CA 1.469 0.512 0 CA-C-N 119.334 0.97 . . . . 0.0 109.349 167.578 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.8 p . . . . . 0 N--CA 1.445 -0.686 0 CA-C-O 121.842 0.83 . . . . 0.0 108.984 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 58.3 m -121.24 146.84 46.39 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 105.406 -2.072 . . . . 0.0 105.406 174.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -120.85 131.75 54.59 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 -175.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 24.0 t -129.29 94.86 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 104.431 -2.433 . . . . 0.0 104.431 -172.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.5 p -94.83 104.22 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 36.6 mt -101.84 133.89 43.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 105.307 -2.109 . . . . 0.0 105.307 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 51.8 m-70 -111.53 149.19 31.74 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.924 1.29 . . . . 0.0 108.415 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -138.86 -177.35 4.84 Favored 'General case' 0 N--CA 1.468 0.469 0 O-C-N 120.84 -1.162 . . . . 0.0 110.485 177.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.26 153.17 18.17 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 168.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -61.55 -32.61 72.69 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.294 0.568 . . . . 0.0 111.217 -171.035 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -89.13 3.41 51.94 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 124.744 1.218 . . . . 0.0 112.979 -163.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 25.4 pt-20 -139.78 177.74 7.74 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 119.534 1.061 . . . . 0.0 111.187 -170.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.04 163.66 31.91 Favored Glycine 0 CA--C 1.525 0.718 0 O-C-N 121.634 -0.666 . . . . 0.0 111.653 177.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -75.67 161.2 29.3 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 154.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.56 58.19 0.73 Allowed Glycine 0 C--O 1.218 -0.852 0 CA-C-O 117.432 -1.76 . . . . 0.0 111.351 178.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -142.91 141.53 31.52 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 120.326 2.063 . . . . 0.0 110.586 169.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.0 t -105.22 135.7 42.17 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 170.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 25.6 mt -96.63 130.74 44.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 162.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.3 pt . . . . . 0 N--CA 1.447 -0.603 0 C-N-CA 126.585 1.954 . . . . 0.0 108.71 175.042 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.409 ' HG2' ' H ' ' A' ' 45' ' ' HIS . 73.1 Cg_endo . . . . . 0 N--CA 1.45 -1.081 0 N-CA-C 109.838 -0.87 . . . . 0.0 109.838 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . 0.409 ' H ' ' HG2' ' A' ' 44' ' ' PRO . 12.5 m80 -77.23 103.18 7.01 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.632 1.573 . . . . 0.0 109.614 -172.063 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.7 ptmt -130.55 153.17 49.14 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 171.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 39.7 mm -68.54 143.82 14.82 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 175.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.89 -59.46 0.53 Allowed Glycine 0 CA--C 1.529 0.926 0 C-N-CA 125.596 1.57 . . . . 0.0 112.508 175.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 37.4 ttm180 -140.05 144.58 36.94 Favored 'General case' 0 C--O 1.235 0.339 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 21.2 mt -122.66 125.43 72.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 105.821 -1.918 . . . . 0.0 105.821 175.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -51.73 131.07 12.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 CA-C-N 119.23 0.923 . . . . 0.0 108.612 172.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.6 123.27 17.43 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 125.553 1.541 . . . . 0.0 108.868 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.28 9.88 84.31 Favored Glycine 0 CA--C 1.535 1.329 0 C-N-CA 123.947 0.784 . . . . 0.0 114.903 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 37.9 p -66.36 171.76 3.8 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 119.662 1.731 . . . . 0.0 112.458 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -56.85 -36.83 99.07 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 121.783 1.655 . . . . 0.0 112.296 166.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.72 -48.95 75.01 Favored 'General case' 0 C--N 1.34 0.177 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -60.34 -52.95 63.09 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 123.44 0.696 . . . . 0.0 111.594 176.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -60.94 -18.59 57.88 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 124.078 0.951 . . . . 0.0 112.31 -176.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 11.5 t -59.36 -26.25 64.91 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-O 117.819 -1.086 . . . . 0.0 111.257 175.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.15 31.49 18.38 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.913 2.085 . . . . 0.0 112.962 -179.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 40.3 mtmt -132.47 -34.11 1.22 Allowed 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.889 0.875 . . . . 0.0 111.977 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -93.85 126.46 39.06 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 177.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 2.6 ptpp? -117.82 171.58 7.96 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 125.2 1.4 . . . . 0.0 109.139 170.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 82.2 t -66.09 141.66 17.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 O-C-N 120.965 -1.084 . . . . 0.0 108.565 174.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 89.47 -5.02 84.17 Favored Glycine 0 CA--C 1.532 1.095 0 CA-C-O 117.022 -1.988 . . . . 0.0 114.904 176.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -62.9 11.68 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 120.229 3.418 . . . . 0.0 120.229 -150.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.1 mtp180 41.82 86.71 0.02 OUTLIER 'General case' 0 C--O 1.235 0.3 0 C-N-CA 127.178 2.191 . . . . 0.0 113.103 -171.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 44.1 mt -65.32 148.85 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 106.341 -1.725 . . . . 0.0 106.341 170.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.8 tp -118.86 -47.15 2.52 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 125.828 1.651 . . . . 0.0 108.764 177.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -148.54 166.95 26.69 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 125.268 1.427 . . . . 0.0 111.352 -177.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.9 p -134.72 124.36 43.89 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.468 0 C-N-CA 125.493 1.517 . . . . 0.0 107.933 175.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 49.71 38.59 15.72 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.138 0.975 . . . . 0.0 110.009 -178.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 79.21 -10.27 35.88 Favored Glycine 0 CA--C 1.532 1.115 0 CA-C-O 117.822 -1.543 . . . . 0.0 115.415 -176.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.9 mm100 -79.66 122.87 27.08 Favored 'General case' 0 CA--C 1.513 -0.479 0 CA-C-N 121.491 2.646 . . . . 0.0 107.747 -178.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 55.7 m -61.36 110.12 1.34 Allowed 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 167.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.5 pp -80.14 11.49 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 124.604 1.162 . . . . 0.0 112.322 -174.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 25.3 mm -63.01 -77.34 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 C-N-CA 125.24 1.416 . . . . 0.0 108.418 175.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 21.8 m-80 -79.7 -26.92 40.76 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.179 -164.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 1.4 mtp -58.29 133.81 84.79 Favored Pre-proline 0 CA--C 1.538 0.488 0 C-N-CA 123.815 0.846 . . . . 0.0 109.513 174.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -70.61 155.11 63.8 Favored 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 121.989 1.793 . . . . 0.0 110.665 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -57.09 -39.21 74.56 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.365 0.666 . . . . 0.0 111.938 -174.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -60.38 -42.43 95.86 Favored 'General case' 0 C--N 1.338 0.097 0 CA-C-O 118.421 -0.8 . . . . 0.0 111.368 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -62.62 -46.27 89.05 Favored 'General case' 0 C--O 1.218 -0.58 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 177.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.421 ' HA ' ' HB2' ' A' ' 87' ' ' LEU . 29.4 mt -67.71 -33.92 64.74 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 O-C-N 121.212 -0.93 . . . . 0.0 109.925 -175.453 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.0 t -61.79 -44.47 98.84 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 O-C-N 120.83 -1.169 . . . . 0.0 108.669 171.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 7.0 mmtt -52.45 -53.19 48.74 Favored 'General case' 0 C--O 1.22 -0.462 0 CA-C-O 116.568 -1.682 . . . . 0.0 109.481 166.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . 0.421 ' HB2' ' HA ' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -57.7 -28.34 63.74 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 122.472 2.396 . . . . 0.0 114.514 -174.761 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 66.7 mt -77.44 -48.71 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 176.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 13.6 ttpt -63.36 -37.27 86.64 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 118.164 0.438 . . . . 0.0 110.847 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.03 -10.65 59.67 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 126.98 2.112 . . . . 0.0 111.472 -178.381 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.74 -28.31 63.79 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 113.301 0.852 . . . . 0.0 113.301 -171.509 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 92.22 66.52 1.12 Allowed Glycine 0 C--N 1.339 0.741 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 171.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 56.9 mt 61.81 -44.37 0.15 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 129.605 3.162 . . . . 0.0 114.346 -171.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 6.6 p -93.6 140.66 29.36 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 125.28 1.432 . . . . 0.0 107.79 177.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.5 p -134.54 124.34 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 169.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.8 m -93.53 100.57 12.83 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 19.6 mt -90.18 122.83 33.48 Favored 'General case' 0 CA--C 1.516 -0.334 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 172.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 32.0 ttm105 -99.25 117.75 34.41 Favored 'General case' 0 C--O 1.236 0.347 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 179.039 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.9 pp -130.6 174.9 12.19 Favored 'Isoleucine or valine' 0 C--O 1.237 0.427 0 C-N-CA 126.669 1.988 . . . . 0.0 110.004 -166.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.4 mp . . . . . 0 CA--C 1.546 0.812 0 C-N-CA 124.483 1.113 . . . . 0.0 108.651 177.158 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.237 0.423 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.5 m -127.38 150.99 49.37 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.239 1.016 . . . . 0.0 108.291 175.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -120.69 93.46 4.04 Favored 'General case' 0 C--O 1.236 0.355 0 N-CA-C 104.442 -2.429 . . . . 0.0 104.442 176.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.5 t -91.43 94.76 5.04 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.332 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 -170.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.0 p -76.2 134.12 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 173.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 82.5 mt -131.12 126.38 59.15 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.197 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 175.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -92.55 154.01 18.7 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 167.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.47 ' HD3' ' CZ ' ' A' ' 24' ' ' PHE . 5.7 ptt180 -138.96 -176.95 4.67 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 167.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.439 ' HE3' ' C ' ' A' ' 18' ' ' ARG . 0.1 OUTLIER -109.67 168.19 9.59 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 172.48 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -75.71 -19.3 59.19 Favored 'General case' 0 N--CA 1.463 0.176 0 O-C-N 121.716 -0.615 . . . . 0.0 112.172 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -69.77 -2.98 13.53 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.014 0.926 . . . . 0.0 112.735 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -150.07 177.2 10.11 Favored 'General case' 0 C--O 1.238 0.474 0 C-N-CA 125.485 1.514 . . . . 0.0 109.441 -164.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.98 -173.69 19.94 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 171.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.47 ' CZ ' ' HD3' ' A' ' 18' ' ' ARG . 62.9 m-85 -76.24 166.85 22.86 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 159.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.29 60.26 0.68 Allowed Glycine 0 C--O 1.226 -0.364 0 O-C-N 121.022 -1.049 . . . . 0.0 113.05 -173.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 5.3 p90 -144.56 162.08 37.5 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 124.936 1.294 . . . . 0.0 109.999 175.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.5 t -132.99 124.59 50.41 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.3 mp -84.5 140.86 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 173.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.414 HD13 ' HE3' ' A' ' 46' ' ' LYS . 19.9 pt . . . . . 0 N--CA 1.447 -0.623 0 C-N-CA 127.849 2.46 . . . . 0.0 107.759 172.073 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo . . . . . 0 N--CA 1.46 -0.442 0 CA-C-O 118.977 -0.509 . . . . 0.0 113.072 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -135.55 118.82 16.65 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 124.467 1.107 . . . . 0.0 108.367 178.372 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.414 ' HE3' HD13 ' A' ' 29' ' ' ILE . 44.1 pttt -139.88 155.0 47.42 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 123.675 0.79 . . . . 0.0 109.144 167.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.1 mm -64.16 131.02 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 105.409 -2.071 . . . . 0.0 105.409 168.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -113.76 -32.92 1.97 Allowed Glycine 0 CA--C 1.523 0.57 0 C-N-CA 124.233 0.92 . . . . 0.0 113.382 176.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 21.2 ttm-85 -146.21 148.5 32.57 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 7.4 mt -127.43 125.97 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 167.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -57.65 126.99 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 C-N-CA 125.416 1.486 . . . . 0.0 107.1 175.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -60.79 123.09 16.48 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 123.522 0.729 . . . . 0.0 109.145 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.15 24.78 74.96 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.726 0.679 . . . . 0.0 113.284 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 22.5 p -76.94 171.69 11.71 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 118.674 1.237 . . . . 0.0 111.576 168.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -58.16 -22.81 58.4 Favored 'Trans proline' 0 CA--C 1.538 0.696 0 C-N-CA 122.197 1.931 . . . . 0.0 113.259 165.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -72.89 -56.97 4.43 Favored 'General case' 0 C--N 1.343 0.308 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 173.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -57.64 -47.07 83.28 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 123.801 0.841 . . . . 0.0 111.273 -175.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 1.6 ptm180 -54.45 -27.48 37.64 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 113.267 0.839 . . . . 0.0 113.267 174.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 2.7 t -73.17 -12.89 61.04 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 118.29 -0.862 . . . . 0.0 112.858 -162.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 47.33 37.88 6.52 Favored 'General case' 0 C--O 1.239 0.532 0 C-N-CA 126.077 1.751 . . . . 0.0 113.536 178.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.8 mtmt -143.33 -17.47 0.64 Allowed 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 113.92 1.082 . . . . 0.0 113.92 173.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -126.54 111.44 14.38 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 124.715 1.206 . . . . 0.0 108.083 -174.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 25.8 mtmt -129.35 172.12 11.82 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 126.011 1.724 . . . . 0.0 110.674 172.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 84.4 t -57.43 118.97 2.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.382 0 C-N-CA 125.108 1.363 . . . . 0.0 109.567 -175.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 124.7 -23.25 6.33 Favored Glycine 0 C--N 1.336 0.57 0 CA-C-O 118.699 -1.056 . . . . 0.0 111.063 175.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -70.06 81.44 0.5 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.62 1.568 . . . . 0.0 112.253 -167.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 87.7 mtt180 -48.42 134.02 15.58 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 126.619 1.968 . . . . 0.0 110.998 -162.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 61.3 mt -102.9 130.1 53.53 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -112.02 -32.85 6.45 Favored 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 125.254 1.422 . . . . 0.0 112.095 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -154.97 167.81 29.1 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.995 0.918 . . . . 0.0 109.038 -177.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.7 p -129.57 114.34 30.61 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.324 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 177.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 63.8 m-80 61.42 -37.54 0.11 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 128.937 2.895 . . . . 0.0 113.638 -169.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 169.2 -4.43 0.04 OUTLIER Glycine 0 CA--C 1.531 1.043 0 C-N-CA 128.103 2.763 . . . . 0.0 112.692 -176.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -90.72 136.0 33.35 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 120.569 2.185 . . . . 0.0 108.91 -177.273 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.6 p -73.3 119.5 17.62 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.457 0.571 . . . . 0.0 109.592 179.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.4 pp -91.31 -24.25 5.63 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.305 0 C-N-CA 122.262 0.225 . . . . 0.0 111.312 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mp -59.73 -32.67 49.98 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 O-C-N 121.389 -0.819 . . . . 0.0 110.903 -179.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -95.2 -7.58 38.68 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 123.801 0.84 . . . . 0.0 112.222 -170.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.7 mtp -105.88 160.0 27.66 Favored Pre-proline 0 N--CA 1.449 -0.487 0 C-N-CA 125.61 1.564 . . . . 0.0 113.348 -169.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -66.96 140.7 55.63 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 123.245 2.63 . . . . 0.0 110.789 169.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -45.93 -52.77 11.02 Favored 'General case' 0 N--CA 1.453 -0.303 0 C-N-CA 126.132 1.773 . . . . 0.0 110.872 173.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.5 -27.23 69.0 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 123.91 0.884 . . . . 0.0 113.261 -177.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.3 t0 -87.29 -34.73 18.79 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-N 118.991 0.814 . . . . 0.0 110.801 -178.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.0 mt -63.93 -39.57 85.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 C-N-CA 124.339 1.056 . . . . 0.0 108.43 169.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.1 t -57.13 -50.7 75.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 121.11 -0.994 . . . . 0.0 109.114 168.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.9 -36.61 81.81 Favored 'General case' 0 C--N 1.338 0.093 0 CA-C-N 118.881 0.764 . . . . 0.0 112.822 -178.614 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -61.75 -42.12 98.56 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 128.067 2.547 . . . . 0.0 110.836 175.076 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 62.4 mt -67.42 -42.75 87.6 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.281 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 174.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 46.1 tttt -57.73 -41.66 82.29 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.559 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.7 t0 -65.88 -14.62 61.84 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 127.462 2.305 . . . . 0.0 112.451 178.018 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -75.48 -12.38 60.23 Favored 'General case' 0 CA--C 1.544 0.731 0 O-C-N 121.042 -1.036 . . . . 0.0 111.86 169.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 60.45 -116.19 8.82 Favored Glycine 0 CA--C 1.528 0.868 0 O-C-N 120.817 -1.177 . . . . 0.0 110.574 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 93.2 mt -87.1 -36.53 18.07 Favored 'General case' 0 CA--C 1.503 -0.862 0 CA-C-N 117.814 0.807 . . . . 0.0 112.342 -177.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -107.86 120.11 41.33 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.159 0.912 . . . . 0.0 108.628 -175.102 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.7 p -126.99 150.52 32.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.3 m -124.55 138.85 54.3 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 19.0 mt -122.61 128.83 51.18 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 124.583 1.153 . . . . 0.0 109.114 178.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -84.77 107.8 17.13 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 175.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.3 pp -113.92 170.97 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 O-C-N 123.875 0.734 . . . . 0.0 110.763 172.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 20.0 mt . . . . . 0 C--O 1.234 0.263 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 170.984 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 39.1 p . . . . . 0 N--CA 1.448 -0.574 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.2 m -96.09 170.53 9.21 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 -161.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -135.1 94.63 3.17 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 123.505 1.622 . . . . 0.0 107.743 171.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 80.1 t -90.3 93.98 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 104.735 -2.321 . . . . 0.0 104.735 179.123 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.7 p -101.93 116.79 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 -175.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 51.1 mt -133.67 136.85 53.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 -172.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 74.4 m-70 -109.27 149.59 29.22 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 125.396 1.478 . . . . 0.0 109.079 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.433 ' HD3' ' CZ ' ' A' ' 24' ' ' PHE . 1.1 ptm180 -138.69 179.29 6.56 Favored 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 124.937 1.295 . . . . 0.0 109.951 -175.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.16 157.33 15.99 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 176.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -69.92 -20.71 63.34 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 117.76 0.255 . . . . 0.0 111.239 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 31.0 t30 -78.45 -1.83 35.55 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.451 0.7 . . . . 0.0 112.682 -176.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -159.89 -175.74 5.29 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.573 1.149 . . . . 0.0 110.362 -170.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.99 -171.54 29.99 Favored Glycine 0 CA--C 1.522 0.521 0 C-N-CA 125.324 1.44 . . . . 0.0 112.365 177.235 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.433 ' CZ ' ' HD3' ' A' ' 18' ' ' ARG . 29.6 m-85 -73.63 159.68 32.72 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 151.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -105.28 57.52 0.49 Allowed Glycine 0 C--O 1.219 -0.817 0 CA-C-O 118.542 -1.144 . . . . 0.0 110.565 177.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 8.8 p90 -124.02 155.35 38.43 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 118.849 1.324 . . . . 0.0 108.969 171.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -129.63 114.36 30.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 177.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 22.1 mt -78.24 147.38 7.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 171.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 44.0 pt . . . . . 0 N--CA 1.444 -0.77 0 C-N-CA 128.691 2.796 . . . . 0.0 107.662 170.965 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo . . . . . 0 N--CA 1.455 -0.759 0 CA-C-O 116.833 -1.403 . . . . 0.0 113.775 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -141.94 130.02 22.04 Favored 'General case' 0 C--N 1.341 0.22 0 C-N-CA 125.687 1.595 . . . . 0.0 108.948 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 6.8 ptmt -149.66 164.57 34.82 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 125.788 1.635 . . . . 0.0 107.225 176.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 13.2 mm -84.52 143.7 11.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.506 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.0 -36.62 0.94 Allowed Glycine 0 CA--C 1.522 0.491 0 C-N-CA 126.023 1.773 . . . . 0.0 112.745 -177.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 36.6 ttm105 -150.05 159.81 44.12 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 119.096 1.448 . . . . 0.0 108.585 176.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 7.2 mt -121.05 143.58 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 125.46 1.504 . . . . 0.0 107.012 160.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.4 mm -75.43 136.42 25.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -72.03 119.81 16.74 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.637 0.256 . . . . 0.0 110.462 -159.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.32 12.81 83.92 Favored Glycine 0 CA--C 1.527 0.799 0 CA-C-O 119.362 -0.688 . . . . 0.0 114.432 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.502 ' HB2' ' CD ' ' A' ' 55' ' ' PRO . 81.3 p -71.49 176.55 2.09 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 118.342 1.071 . . . . 0.0 112.004 176.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.502 ' CD ' ' HB2' ' A' ' 54' ' ' SER . 4.7 Cg_exo -64.28 -32.27 62.07 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 C-N-CA 122.767 2.311 . . . . 0.0 110.164 176.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.86 -24.52 66.89 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 118.201 -0.904 . . . . 0.0 112.894 175.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -83.65 -47.06 11.64 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 119.128 0.876 . . . . 0.0 110.543 173.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 28.5 mtt-85 -69.11 -41.44 77.41 Favored 'General case' 0 C--O 1.234 0.252 0 C-N-CA 123.247 0.619 . . . . 0.0 111.469 -170.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 62.5 m -81.19 81.38 7.41 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 173.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -62.85 89.78 0.03 OUTLIER 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.22 1.008 . . . . 0.0 109.503 178.2 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.4 mmmt -136.85 -33.72 0.76 Allowed 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 126.598 1.959 . . . . 0.0 109.498 -174.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.57 154.49 50.68 Favored 'General case' 0 C--O 1.234 0.264 0 C-N-CA 124.576 1.15 . . . . 0.0 109.388 171.055 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 16.3 ptmt -134.9 172.12 13.44 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 124.887 1.275 . . . . 0.0 110.868 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.6 t -59.42 137.66 21.54 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 O-C-N 120.401 -1.437 . . . . 0.0 109.572 -175.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 103.11 -14.05 55.54 Favored Glycine 0 C--N 1.342 0.893 0 C-N-CA 125.119 1.342 . . . . 0.0 114.642 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -67.06 19.46 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 120.368 3.47 . . . . 0.0 120.368 -148.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 4.3 mtt-85 43.61 72.53 0.18 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 126.818 2.047 . . . . 0.0 112.811 168.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 31.4 mt -65.33 147.11 12.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -170.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.6 mt -102.69 -52.75 3.01 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 124.606 1.162 . . . . 0.0 109.915 174.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -156.62 171.06 20.99 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.654 0.782 . . . . 0.0 110.524 -172.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 13.0 p -124.54 113.96 38.65 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.257 0 C-N-CA 125.321 1.449 . . . . 0.0 108.1 175.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 45.09 41.75 5.92 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 125.825 1.65 . . . . 0.0 110.095 -169.092 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.31 4.27 78.96 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-O 118.334 -1.259 . . . . 0.0 115.763 179.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -85.99 122.12 29.58 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 120.262 2.031 . . . . 0.0 106.689 174.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 7.7 t -67.52 134.84 52.04 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 -179.036 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 21.8 pt -108.99 0.27 9.65 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 125.508 1.523 . . . . 0.0 111.193 -176.127 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 75.4 mt -65.41 -61.77 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 C-N-CA 125.088 1.355 . . . . 0.0 109.072 -178.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -92.42 -24.22 18.92 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 123.939 0.896 . . . . 0.0 112.33 -174.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.8 ttt -60.91 137.83 93.77 Favored Pre-proline 0 N--CA 1.439 -0.996 0 C-N-CA 125.185 1.394 . . . . 0.0 108.525 178.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -76.07 148.95 31.9 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 121.853 1.702 . . . . 0.0 109.668 -177.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 32.2 t60 -60.76 -31.94 71.26 Favored 'General case' 0 CA--C 1.537 0.476 0 N-CA-C 113.812 1.041 . . . . 0.0 113.812 -165.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -71.18 -27.8 63.78 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 119.217 0.917 . . . . 0.0 113.029 176.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -74.93 -42.09 58.4 Favored 'General case' 0 C--O 1.224 -0.24 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 175.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 28.5 mt -57.82 -37.86 62.46 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 C-N-CA 124.714 1.205 . . . . 0.0 110.476 172.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.3 t -61.4 -52.28 63.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 O-C-N 120.578 -1.326 . . . . 0.0 109.684 172.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.7 ttmt -59.57 -40.39 87.22 Favored 'General case' 0 C--O 1.22 -0.491 0 C-N-CA 119.116 -1.034 . . . . 0.0 111.697 179.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.36 -42.98 67.39 Favored 'General case' 0 N--CA 1.443 -0.816 0 C-N-CA 126.633 1.973 . . . . 0.0 112.102 177.006 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.3 mt -69.25 -43.03 81.64 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 50.0 tttm -58.37 -49.83 75.84 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 118.329 0.513 . . . . 0.0 110.575 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -62.69 -18.62 62.76 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 128.773 2.829 . . . . 0.0 111.648 177.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.6 -34.26 76.64 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 119.588 1.085 . . . . 0.0 109.627 171.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.83 -97.88 1.84 Allowed Glycine 0 C--N 1.337 0.596 0 C-N-CA 126.119 1.819 . . . . 0.0 108.924 173.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.6 mt -121.64 -28.91 4.47 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 124.272 1.029 . . . . 0.0 111.819 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 p -93.3 143.61 26.1 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 170.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.3 p -145.51 153.4 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 166.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.98 112.22 15.66 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 -178.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 7.2 mt -90.54 114.7 26.97 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 173.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -71.85 121.14 18.49 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 164.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pt -128.35 -179.96 3.37 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 125.037 1.335 . . . . 0.0 108.359 175.279 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 43.7 mt . . . . . 0 CA--C 1.537 0.464 0 C-N-CA 124.758 1.223 . . . . 0.0 109.202 169.648 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 17.5 p . . . . . 0 C--O 1.238 0.471 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.4 m -122.6 150.71 42.26 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 167.48 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -90.65 147.03 23.56 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 105.734 -1.95 . . . . 0.0 105.734 168.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 39.0 t -131.99 101.41 4.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 104.84 -2.282 . . . . 0.0 104.84 161.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.37 141.04 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 165.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 53.0 mt -134.74 133.19 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 170.383 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 76.7 m-70 -105.84 154.4 20.57 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 125.351 1.46 . . . . 0.0 108.053 173.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.6 ptt180 -136.43 -171.93 3.02 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 170.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.82 170.38 8.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 166.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -80.36 -23.55 40.43 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 113.289 0.848 . . . . 0.0 113.289 -168.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -69.99 -10.05 57.27 Favored 'General case' 0 N--CA 1.472 0.645 0 CA-C-N 119.595 1.089 . . . . 0.0 112.882 176.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -137.15 169.33 17.97 Favored 'General case' 0 C--O 1.241 0.637 0 C-N-CA 124.288 1.035 . . . . 0.0 110.736 -161.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.11 -178.54 45.87 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 179.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -80.1 170.44 16.44 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 142.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.48 52.39 0.83 Allowed Glycine 0 C--O 1.225 -0.437 0 CA-C-O 118.769 -1.017 . . . . 0.0 112.683 -172.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -136.68 142.11 43.16 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 125.764 1.625 . . . . 0.0 110.696 -177.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.4 t -128.08 136.42 60.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 177.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 56.5 mt -108.23 120.1 58.99 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 -171.124 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 27.8 pt . . . . . 0 C--N 1.322 -0.61 0 C-N-CA 126.471 1.909 . . . . 0.0 108.74 -178.099 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo . . . . . 0 N--CA 1.461 -0.403 0 N-CA-C 113.965 0.717 . . . . 0.0 113.965 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -139.73 122.27 16.23 Favored 'General case' 0 CA--C 1.52 -0.199 0 C-N-CA 124.948 1.299 . . . . 0.0 107.801 178.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.3 ptmt -151.55 154.0 35.63 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 124.299 1.04 . . . . 0.0 108.765 168.163 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 31.1 mm -62.57 144.41 14.38 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 CA-C-N 119.17 0.896 . . . . 0.0 109.6 175.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -128.03 -50.62 0.14 Allowed Glycine 0 CA--C 1.526 0.78 0 C-N-CA 126.39 1.948 . . . . 0.0 113.181 179.334 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 2.0 ttm180 -119.99 139.88 51.81 Favored 'General case' 0 CA--C 1.511 -0.531 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 171.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 12.7 mt -120.06 149.76 22.76 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 N-CA-C 105.568 -2.012 . . . . 0.0 105.568 159.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -87.65 129.54 38.83 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 126.648 1.979 . . . . 0.0 108.097 177.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -61.55 124.51 20.86 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 123.636 0.774 . . . . 0.0 109.194 167.406 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.59 17.61 38.32 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-O 117.771 -1.572 . . . . 0.0 112.767 178.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 87.6 p -106.62 163.76 16.32 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-N 119.006 1.403 . . . . 0.0 113.116 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo -63.85 -25.08 67.76 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 122.902 2.401 . . . . 0.0 112.927 169.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.32 -55.88 29.2 Favored 'General case' 0 C--N 1.345 0.404 0 CA-C-N 120.305 1.411 . . . . 0.0 109.883 174.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -63.32 -37.53 87.64 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.316 0.647 . . . . 0.0 112.355 -175.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -65.72 -23.02 66.66 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 121.657 -0.652 . . . . 0.0 112.731 172.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 73.9 m -92.96 50.36 1.54 Allowed 'General case' 0 CA--C 1.533 0.321 0 O-C-N 120.568 -1.332 . . . . 0.0 110.824 174.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -59.2 9.16 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 127.036 2.134 . . . . 0.0 116.359 -177.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -61.92 -16.01 47.56 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 120.906 -1.121 . . . . 0.0 111.505 154.194 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -115.51 137.64 51.85 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 127.393 2.277 . . . . 0.0 107.348 174.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -136.41 166.35 23.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 119.37 0.986 . . . . 0.0 111.146 172.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.4 t -55.94 112.6 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.251 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 168.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 129.95 -21.23 4.99 Favored Glycine 0 N--CA 1.441 -1.0 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 177.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -70.81 106.05 3.44 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 122.982 1.373 . . . . 0.0 110.772 -174.386 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.1 mtm180 -37.38 143.52 0.1 Allowed 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 129.974 3.31 . . . . 0.0 111.297 156.315 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 23.4 mt -132.41 129.89 59.64 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 -174.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.7 mt -94.28 -40.19 10.11 Favored 'General case' 0 CA--C 1.52 -0.186 0 C-N-CA 123.862 0.865 . . . . 0.0 112.051 179.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.42 168.95 25.84 Favored 'General case' 0 C--O 1.236 0.382 0 C-N-CA 124.189 0.996 . . . . 0.0 109.754 -168.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.5 t -129.2 127.12 65.19 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 169.07 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 43.71 34.94 0.93 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 124.631 1.172 . . . . 0.0 112.193 -165.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.93 -3.7 27.02 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-O 118.349 -1.25 . . . . 0.0 113.347 179.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.2 tp60 -74.54 134.69 42.17 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 119.513 1.657 . . . . 0.0 107.057 174.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.1 m -72.53 136.89 45.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 -176.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 17.0 pt -115.76 -8.28 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 C-N-CA 125.755 1.622 . . . . 0.0 112.078 -175.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.7 mm -54.14 -52.75 34.62 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 123.813 0.845 . . . . 0.0 110.344 172.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -89.28 -26.44 21.15 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 111.712 0.264 . . . . 0.0 111.712 -173.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 7.0 ttt -66.5 137.87 95.45 Favored Pre-proline 0 N--CA 1.441 -0.884 0 C-N-CA 126.78 2.032 . . . . 0.0 109.645 -170.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -75.04 148.03 34.56 Favored 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 121.733 1.622 . . . . 0.0 109.051 178.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -54.24 -35.24 62.25 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -174.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -58.66 -43.01 89.71 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 119.937 1.244 . . . . 0.0 112.904 177.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -69.41 -39.68 77.76 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 125.243 1.417 . . . . 0.0 108.957 -178.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 36.5 mt -65.89 -40.0 86.28 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.529 1.131 . . . . 0.0 110.872 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 72.6 t -66.03 -41.23 89.26 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 O-C-N 118.998 -2.314 . . . . 0.0 109.607 173.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -52.5 -52.89 52.28 Favored 'General case' 0 C--O 1.223 -0.299 0 CA-C-O 117.489 -1.243 . . . . 0.0 109.539 171.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.51 -35.77 61.02 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 126.758 2.023 . . . . 0.0 112.303 -178.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 71.8 mt -78.11 -37.0 22.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 O-C-N 120.878 -1.139 . . . . 0.0 109.257 -179.133 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -65.47 -36.15 83.01 Favored 'General case' 0 N--CA 1.46 0.07 0 O-C-N 121.363 -0.835 . . . . 0.0 110.406 172.099 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -67.52 -37.65 83.09 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 126.401 1.88 . . . . 0.0 110.051 179.124 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.27 -41.6 80.03 Favored 'General case' 0 C--O 1.236 0.373 0 O-C-N 123.644 0.59 . . . . 0.0 110.769 -178.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 109.71 -141.36 16.1 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 124.63 1.11 . . . . 0.0 110.911 171.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 85.9 mt -70.4 -40.92 73.62 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 169.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.98 131.75 40.59 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 123.102 0.561 . . . . 0.0 110.083 176.022 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.3 p -133.04 139.85 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 C-N-CA 125.165 1.386 . . . . 0.0 107.559 171.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.73 109.14 19.75 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 177.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 17.9 mt -90.51 145.63 24.74 Favored 'General case' 0 CA--C 1.52 -0.177 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 174.422 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 19.7 ttm180 -114.48 114.17 25.44 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 174.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pp -114.97 160.96 14.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 125.003 1.321 . . . . 0.0 108.913 -179.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 89.4 mt . . . . . 0 C--O 1.238 0.473 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 167.609 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 32.9 p . . . . . 0 CA--C 1.535 0.375 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.1 t -117.3 158.99 23.42 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 148.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -129.3 94.62 3.83 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 174.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 15.2 t -92.58 96.14 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 C-N-CA 125.838 1.655 . . . . 0.0 107.513 -173.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.1 p -80.42 135.36 25.47 Favored 'Isoleucine or valine' 0 C--O 1.238 0.451 0 C-N-CA 123.322 0.649 . . . . 0.0 109.792 174.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 46.2 mt -132.28 126.46 55.79 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 C-N-CA 125.155 1.382 . . . . 0.0 107.74 176.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -88.76 161.77 16.6 Favored 'General case' 0 C--O 1.233 0.219 0 C-N-CA 125.022 1.329 . . . . 0.0 108.877 171.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 49.3 ptt85 -144.22 -171.11 3.51 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 160.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 168.38 9.59 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 161.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -70.9 -33.68 70.8 Favored 'General case' 0 C--N 1.329 -0.295 0 O-C-N 121.162 -0.962 . . . . 0.0 112.473 -178.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -74.1 6.55 3.36 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 124.586 1.154 . . . . 0.0 113.0 -171.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -143.81 171.66 13.9 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 126.539 1.936 . . . . 0.0 109.261 -169.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.83 176.57 23.01 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 124.434 1.016 . . . . 0.0 111.032 178.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -83.44 133.43 34.91 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 163.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -96.89 57.24 1.28 Allowed Glycine 0 CA--C 1.521 0.441 0 C-N-CA 124.599 1.095 . . . . 0.0 112.66 -171.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -137.97 167.24 22.17 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 125.522 1.529 . . . . 0.0 108.213 172.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.489 HG13 ' H ' ' A' ' 49' ' ' ARG . 0.4 OUTLIER -132.39 157.65 43.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 176.236 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 20.3 mt -117.63 135.82 56.8 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 176.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.7 pt . . . . . 0 C--O 1.241 0.634 0 C-N-CA 124.104 0.962 . . . . 0.0 109.686 175.878 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo . . . . . 0 N--CA 1.449 -1.111 0 N-CA-C 106.692 -2.08 . . . . 0.0 106.692 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 19.4 m80 68.76 108.19 0.05 Allowed 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 126.531 1.933 . . . . 0.0 113.302 171.145 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 52.1 pttt -143.83 157.59 44.27 Favored 'General case' 0 N--CA 1.467 0.421 0 O-C-N 120.678 -1.264 . . . . 0.0 109.22 167.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.1 mm -65.06 123.86 18.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 172.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -110.46 -26.49 4.81 Favored Glycine 0 CA--C 1.535 1.285 0 N-CA-C 114.849 0.7 . . . . 0.0 114.849 176.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . 0.489 ' H ' HG13 ' A' ' 27' ' ' VAL . 67.5 ttt180 -149.85 147.37 27.88 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 177.461 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.5 mt -121.84 131.76 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.72 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 166.257 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 23.8 mm -65.32 153.89 7.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 -177.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -68.51 118.34 11.43 Favored 'General case' 0 C--N 1.328 -0.351 0 O-C-N 121.474 -0.766 . . . . 0.0 110.634 -169.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.41 1.87 24.14 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 115.952 1.141 . . . . 0.0 115.952 169.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.418 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 3.5 p -68.77 175.25 2.07 Favored Pre-proline 0 CA--C 1.554 1.108 0 C-N-CA 126.966 2.106 . . . . 0.0 113.067 178.63 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.418 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 3.3 Cg_exo -64.44 -24.43 64.02 Favored 'Trans proline' 0 C--N 1.351 0.704 0 C-N-CA 121.601 1.534 . . . . 0.0 115.154 -168.097 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -69.38 -48.2 61.9 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 118.803 0.729 . . . . 0.0 109.613 172.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -54.13 -49.63 68.75 Favored 'General case' 0 N--CA 1.464 0.262 0 C-N-CA 125.294 1.437 . . . . 0.0 110.168 177.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.4 mmt-85 -68.88 -15.61 63.54 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 123.694 0.797 . . . . 0.0 112.952 177.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 17.5 t -68.89 -28.2 66.47 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 117.724 -1.131 . . . . 0.0 110.357 177.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 59.38 -28.93 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 128.595 2.758 . . . . 0.0 115.475 -174.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 47.9 mtmt -62.73 -33.17 74.58 Favored 'General case' 0 CA--C 1.521 -0.139 0 C-N-CA 125.55 1.54 . . . . 0.0 112.386 178.043 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -105.87 119.49 39.31 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 -165.081 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 3.0 ptpp? -131.99 167.91 18.84 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 119.665 1.12 . . . . 0.0 110.518 -178.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 73.7 t -64.34 137.77 24.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 178.223 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.96 -16.71 57.13 Favored Glycine 0 N--CA 1.447 -0.613 0 CA-C-O 117.475 -1.736 . . . . 0.0 110.725 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -67.45 92.88 0.31 Allowed 'General case' 0 C--N 1.346 0.426 0 CA-C-N 118.909 1.355 . . . . 0.0 108.458 -178.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.3 mtt85 -46.85 128.91 11.41 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 126.543 1.937 . . . . 0.0 110.892 165.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 55.0 mt -96.89 155.76 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 C-N-CA 126.417 1.887 . . . . 0.0 107.086 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.13 -54.52 1.7 Allowed 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 125.976 1.71 . . . . 0.0 107.961 -179.343 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.97 158.87 43.33 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 125.629 1.572 . . . . 0.0 108.764 -176.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.2 t -136.2 132.96 50.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 57.75 10.23 1.03 Allowed 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.052 0.941 . . . . 0.0 112.449 -163.359 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 82.04 -2.28 84.42 Favored Glycine 0 CA--C 1.534 1.222 0 C-N-CA 125.0 1.286 . . . . 0.0 113.22 -170.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -75.64 141.32 42.82 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 120.537 2.168 . . . . 0.0 107.233 169.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 33.1 m -56.58 147.14 23.03 Favored 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 118.71 0.686 . . . . 0.0 109.569 164.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.3 pp -116.56 5.66 7.26 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 C-N-CA 124.361 1.065 . . . . 0.0 111.838 172.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 98.0 mt -63.5 143.44 15.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 124.274 1.03 . . . . 0.0 108.282 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 61.62 -18.77 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 128.822 2.849 . . . . 0.0 117.291 172.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 4.8 mtp -55.87 145.78 51.21 Favored Pre-proline 0 C--O 1.241 0.611 0 CA-C-N 119.273 0.942 . . . . 0.0 110.034 177.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -69.18 155.21 68.51 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 122.629 2.22 . . . . 0.0 108.027 170.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -59.7 -32.16 70.25 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.7 -171.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.29 -39.45 72.71 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 126.214 1.806 . . . . 0.0 112.861 175.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 61.8 m-20 -70.98 -46.65 61.95 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -178.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 8.5 mt -64.66 -33.58 64.16 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 C-N-CA 126.018 1.727 . . . . 0.0 111.133 -179.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.5 t -65.07 -51.51 65.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 124.475 1.11 . . . . 0.0 108.888 170.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.71 -37.34 81.38 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 116.77 -1.586 . . . . 0.0 110.984 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -51.64 -49.17 62.78 Favored 'General case' 0 N--CA 1.445 -0.697 0 C-N-CA 125.88 1.672 . . . . 0.0 111.301 173.395 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 53.2 mt -70.23 -38.65 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.16 0 O-C-N 121.066 -1.021 . . . . 0.0 108.873 -178.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.1 tttp -65.96 -38.49 88.73 Favored 'General case' 0 N--CA 1.453 -0.291 0 O-C-N 121.728 -0.607 . . . . 0.0 110.925 -179.416 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -66.45 -19.04 65.69 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 129.381 3.072 . . . . 0.0 111.588 174.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -64.5 -31.05 72.1 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.722 -0.611 . . . . 0.0 111.938 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 87.65 -149.85 22.03 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -169.19 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.7 mt -83.1 -20.76 34.24 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 118.201 1.001 . . . . 0.0 111.534 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.2 p -94.49 139.52 31.05 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 169.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 p -145.02 148.15 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 169.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.6 m -125.09 118.39 26.03 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 178.227 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 71.4 mt -90.78 124.05 34.83 Favored 'General case' 0 CA--C 1.509 -0.597 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 170.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 24.5 ttm105 -96.13 121.46 37.93 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 168.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -125.56 173.88 10.63 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 C-N-CA 125.559 1.543 . . . . 0.0 109.211 -166.303 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.6 mp . . . . . 0 C--O 1.237 0.408 0 C-N-CA 124.057 0.943 . . . . 0.0 108.581 179.614 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 32.8 p . . . . . 0 C--O 1.238 0.463 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 42.2 m -111.04 153.23 25.91 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 162.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -122.89 115.38 21.85 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 105.108 -2.182 . . . . 0.0 105.108 174.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -112.31 97.14 5.35 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 C-N-CA 123.703 0.801 . . . . 0.0 109.163 -173.107 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.5 p -76.75 141.36 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 170.253 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 59.7 mt -136.58 140.03 44.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 173.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 14.7 m-70 -124.7 113.28 17.78 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.789 2.436 . . . . 0.0 108.117 -170.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.2 ptt180 -106.16 -179.41 3.93 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 119.287 0.948 . . . . 0.0 111.238 -176.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.93 161.08 13.91 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 119.049 0.84 . . . . 0.0 110.257 170.247 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -64.41 -19.79 65.73 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.501 1.12 . . . . 0.0 112.216 177.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -87.68 -16.87 33.13 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 119.537 1.062 . . . . 0.0 113.235 178.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -113.09 -178.53 3.4 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 119.281 0.946 . . . . 0.0 109.877 -171.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -105.72 -176.38 23.93 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 169.414 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -78.31 176.79 8.98 Favored 'General case' 0 CA--C 1.533 0.316 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 153.53 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.406 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -135.13 50.79 0.85 Allowed Glycine 0 C--O 1.224 -0.531 0 CA-C-O 118.234 -1.315 . . . . 0.0 113.195 -172.123 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 11.7 p90 -137.74 135.5 36.44 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 124.756 1.222 . . . . 0.0 110.299 -179.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.2 t -102.91 109.25 26.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 -179.108 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.1 mp -82.26 124.91 39.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 175.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.465 HD13 ' HE2' ' A' ' 46' ' ' LYS . 15.5 pt . . . . . 0 N--CA 1.448 -0.574 0 C-N-CA 123.852 0.861 . . . . 0.0 109.746 177.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo . . . . . 0 N--CA 1.455 -0.766 0 CA-C-O 117.5 -1.125 . . . . 0.0 113.905 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -136.59 140.4 42.83 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 120.815 1.643 . . . . 0.0 108.071 176.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.465 ' HE2' HD13 ' A' ' 29' ' ' ILE . 10.7 pttm -156.5 165.64 35.73 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 170.146 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 6.9 mm -66.59 148.35 12.14 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.809 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 167.488 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -134.85 -8.45 1.89 Allowed Glycine 0 CA--C 1.529 0.959 0 C-N-CA 125.081 1.324 . . . . 0.0 113.765 173.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.0 ttt180 -165.75 160.95 17.7 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 126.283 1.833 . . . . 0.0 107.13 165.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 36.4 mt -132.54 149.95 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 125.654 1.582 . . . . 0.0 107.685 172.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 41.5 mm -81.77 118.38 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 C-N-CA 125.529 1.532 . . . . 0.0 108.841 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -62.77 96.31 0.08 Allowed 'General case' 0 C--O 1.235 0.332 0 C-N-CA 125.502 1.521 . . . . 0.0 107.957 168.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.23 0.22 6.41 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 125.216 1.388 . . . . 0.0 113.698 -179.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.406 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 66.8 p -91.45 166.28 18.7 Favored Pre-proline 0 C--O 1.237 0.415 0 CA-C-N 118.911 1.355 . . . . 0.0 113.333 -179.768 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -62.96 -32.29 76.59 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.55 2.167 . . . . 0.0 111.659 166.079 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.02 -47.24 74.97 Favored 'General case' 0 C--N 1.346 0.414 0 CA-C-N 119.04 0.836 . . . . 0.0 110.806 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -67.97 -52.68 33.1 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.744 0.418 . . . . 0.0 111.043 178.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 15.0 mtp85 -57.7 -34.61 69.63 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 121.589 -0.694 . . . . 0.0 112.285 -173.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 61.1 m -62.81 -16.54 58.62 Favored 'General case' 0 CA--C 1.534 0.345 0 CA-C-O 117.709 -1.138 . . . . 0.0 112.494 -178.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 46.21 34.98 2.36 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.105 1.762 . . . . 0.0 113.623 170.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 18.9 mtmm -129.65 -6.99 4.61 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 126.908 2.083 . . . . 0.0 111.829 173.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.14 101.06 4.06 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 -173.434 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 13.3 pttp -126.75 159.41 33.85 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 126.184 1.794 . . . . 0.0 109.688 -168.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . 0.374 0.4 OUTLIER -65.5 111.69 1.53 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.255 0 O-C-N 121.363 -0.836 . . . . 0.0 109.476 179.814 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 129.95 -18.79 5.3 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 128.285 2.85 . . . . 0.0 111.462 -175.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -71.56 97.26 1.66 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.401 1.08 . . . . 0.0 110.333 171.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.2 mtm180 -54.34 150.59 8.52 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 127.687 2.395 . . . . 0.0 111.75 173.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 87.7 mt -124.86 117.14 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 -165.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 76.5 mt -89.0 -40.19 13.17 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 124.327 1.051 . . . . 0.0 112.179 179.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.49 170.65 21.93 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 124.676 1.19 . . . . 0.0 108.764 -170.049 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.4 p -122.48 122.81 67.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 170.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 54.32 -73.0 0.01 OUTLIER 'General case' 0 C--O 1.232 0.177 0 C-N-CA 128.191 2.597 . . . . 0.0 111.783 -170.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -155.75 18.93 0.5 Allowed Glycine 0 CA--C 1.529 0.957 0 C-N-CA 126.887 2.184 . . . . 0.0 112.034 -178.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 24.2 mm100 -115.18 135.17 54.46 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 119.661 1.73 . . . . 0.0 108.572 -175.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.7 m -72.61 110.23 6.83 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 123.977 0.911 . . . . 0.0 109.759 174.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 11.1 pt -75.99 -15.63 15.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 C-N-CA 125.133 1.373 . . . . 0.0 111.962 174.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.511 HD12 ' H ' ' A' ' 77' ' ' ILE . 4.1 mp -56.03 -47.0 80.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 C-N-CA 125.121 1.368 . . . . 0.0 113.713 -164.644 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -113.83 -0.93 14.03 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 124.365 1.066 . . . . 0.0 112.237 -169.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . 0.252 11.0 ttt -68.81 146.95 97.82 Favored Pre-proline 0 N--CA 1.434 -1.245 0 C-N-CA 130.62 3.568 . . . . 0.0 109.846 -178.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -57.07 141.34 94.17 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.816 2.344 . . . . 0.0 109.792 167.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 41.4 t60 -66.64 -36.34 82.33 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 120.246 1.384 . . . . 0.0 111.055 -178.264 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -57.72 -31.34 66.33 Favored 'General case' 0 CA--C 1.534 0.332 0 O-C-N 121.361 -0.837 . . . . 0.0 112.74 171.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -73.42 -48.52 33.1 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 124.308 1.043 . . . . 0.0 109.144 177.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 66.2 mt -56.67 -35.59 45.89 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 C-N-CA 125.505 1.522 . . . . 0.0 110.698 175.151 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 45.9 t -77.07 -39.81 29.57 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 C-N-CA 124.176 0.991 . . . . 0.0 110.313 177.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 21.0 ttmt -60.4 -38.5 84.19 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 120.9 -1.125 . . . . 0.0 110.124 173.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -57.61 -38.63 75.28 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 127.464 2.306 . . . . 0.0 112.598 174.718 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 59.9 mt -68.08 -45.98 82.4 Favored 'Isoleucine or valine' 0 C--N 1.341 0.206 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 174.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 6.5 tttm -64.16 -40.14 95.49 Favored 'General case' 0 CA--C 1.536 0.416 0 O-C-N 121.739 -0.601 . . . . 0.0 110.263 -176.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -65.69 -11.8 48.22 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 127.099 2.159 . . . . 0.0 112.188 176.323 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -66.67 -13.4 61.18 Favored 'General case' 0 CA--C 1.541 0.633 0 O-C-N 121.34 -0.85 . . . . 0.0 112.155 170.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 72.66 -90.04 0.55 Allowed Glycine 0 C--N 1.34 0.796 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.6 mt -125.74 -34.49 2.62 Favored 'General case' 0 CA--C 1.514 -0.423 0 C-N-CA 125.589 1.556 . . . . 0.0 111.526 175.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.63 121.85 42.31 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 118.377 0.535 . . . . 0.0 110.131 -179.129 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.7 p -123.96 147.69 28.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 173.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.6 m -119.15 135.79 54.49 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 173.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 31.0 mt -125.19 110.57 14.24 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 125.309 1.444 . . . . 0.0 108.317 -176.326 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 33.4 ttm180 -77.74 106.83 9.81 Favored 'General case' 0 C--O 1.238 0.483 0 C-N-CA 123.811 0.844 . . . . 0.0 111.211 177.087 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -111.27 168.73 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 124.161 0.984 . . . . 0.0 110.597 -175.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.1 mp . . . . . 0 CA--C 1.54 0.583 0 CA-C-O 118.061 -0.971 . . . . 0.0 108.627 175.172 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 44.6 p . . . . . 0 C--O 1.236 0.361 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 m -141.74 150.69 42.12 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.706 1.202 . . . . 0.0 108.421 172.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -104.84 97.37 7.26 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 127.722 2.409 . . . . 0.0 105.862 -179.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 36.9 t -91.65 95.1 5.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 173.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.2 p -74.45 137.7 22.59 Favored 'Isoleucine or valine' 0 C--O 1.238 0.493 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 169.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.5 mt -135.61 134.55 51.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 104.835 -2.283 . . . . 0.0 104.835 174.346 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -108.33 160.43 15.87 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.542 1.137 . . . . 0.0 109.526 177.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 43.4 ptt85 -150.95 -179.64 7.46 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 119.424 1.011 . . . . 0.0 109.582 170.347 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.45 162.59 16.39 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 168.14 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.14 -42.52 95.01 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 174.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -71.52 -1.49 13.54 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-O 117.963 -1.018 . . . . 0.0 113.254 -167.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -137.1 179.07 6.6 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 121.278 1.854 . . . . 0.0 110.754 170.136 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.45 165.02 12.08 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 126.002 1.763 . . . . 0.0 110.169 170.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -66.94 148.96 51.27 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 124.637 1.175 . . . . 0.0 108.398 178.16 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.88 49.12 3.31 Favored Glycine 0 C--O 1.222 -0.629 0 CA-C-O 117.94 -1.478 . . . . 0.0 113.698 -174.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -136.22 156.27 48.91 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 120.745 2.273 . . . . 0.0 111.926 174.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.9 t -128.16 106.39 14.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 106.687 -1.597 . . . . 0.0 106.687 -175.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 23.8 mt -73.68 141.67 15.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 168.066 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.419 HD13 ' HE2' ' A' ' 46' ' ' LYS . 35.7 pt . . . . . 0 CA--C 1.537 0.478 0 C-N-CA 125.308 1.443 . . . . 0.0 110.826 174.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo . . . . . 0 N--CA 1.453 -0.91 0 N-CA-C 109.289 -1.081 . . . . 0.0 109.289 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.16 119.79 13.31 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 122.809 1.29 . . . . 0.0 110.973 -167.601 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . 0.419 ' HE2' HD13 ' A' ' 29' ' ' ILE . 15.2 pttm -152.47 160.08 43.29 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 128.523 2.729 . . . . 0.0 106.267 178.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 34.6 mm -64.33 126.76 23.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 164.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -109.22 -21.14 7.49 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 125.717 1.627 . . . . 0.0 113.757 174.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 53.7 ttt180 -161.7 162.34 29.74 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 126.438 1.895 . . . . 0.0 108.06 166.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 6.5 mt -127.98 150.38 33.7 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 126.422 1.889 . . . . 0.0 108.094 170.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 21.3 mm -85.34 128.67 38.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 126.245 1.818 . . . . 0.0 107.226 178.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -62.1 143.02 57.24 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 123.23 0.612 . . . . 0.0 112.047 -172.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.68 -8.11 6.2 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 125.441 1.496 . . . . 0.0 115.47 176.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 84.8 p -67.49 170.25 7.25 Favored Pre-proline 0 C--O 1.239 0.518 0 CA-C-N 118.241 1.02 . . . . 0.0 112.198 -173.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -57.23 -21.61 44.48 Favored 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.028 1.819 . . . . 0.0 112.508 165.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.43 -50.18 13.25 Favored 'General case' 0 C--N 1.342 0.242 0 CA-C-N 119.883 1.22 . . . . 0.0 110.699 174.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -63.58 -45.09 92.01 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 118.533 0.606 . . . . 0.0 110.763 -175.467 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -70.55 -13.78 62.24 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 123.565 0.746 . . . . 0.0 112.197 178.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . 0.426 ' C ' ' H ' ' A' ' 61' ' ' LYS . 35.6 t -63.16 -49.99 72.15 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 119.127 0.876 . . . . 0.0 109.211 179.254 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.93 -21.41 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 128.439 2.695 . . . . 0.0 115.679 -173.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.426 ' H ' ' C ' ' A' ' 59' ' ' CYS . 11.4 mmmm -63.21 -26.56 68.85 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 125.976 1.71 . . . . 0.0 110.565 165.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -99.39 138.43 36.49 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 161.753 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 21.1 pttm -139.74 171.21 14.55 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 123.641 0.777 . . . . 0.0 110.795 164.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 84.6 t -59.85 137.96 21.52 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.714 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 175.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 93.83 -7.31 73.78 Favored Glycine 0 C--N 1.341 0.849 0 O-C-N 121.039 -1.038 . . . . 0.0 110.567 177.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 68.9 m-20 -71.84 98.76 2.05 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 171.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.9 mtt180 -45.78 158.46 0.09 Allowed 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 127.519 2.328 . . . . 0.0 110.841 162.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 19.1 mt -138.47 118.07 14.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -170.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -78.17 -45.25 23.65 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.567 1.147 . . . . 0.0 111.732 172.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -160.3 166.24 29.86 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.181 0.992 . . . . 0.0 112.163 -160.475 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.2 p -128.66 111.83 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 C-N-CA 126.191 1.796 . . . . 0.0 110.138 -178.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.5 m-20 56.0 17.48 2.64 Favored 'General case' 0 N--CA 1.465 0.282 0 C-N-CA 125.285 1.434 . . . . 0.0 111.147 -168.545 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.48 -10.33 61.13 Favored Glycine 0 CA--C 1.529 0.944 0 CA-C-O 117.527 -1.707 . . . . 0.0 114.382 -175.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -75.92 132.15 40.08 Favored 'General case' 0 C--N 1.341 0.235 0 CA-C-N 120.51 2.155 . . . . 0.0 107.478 177.394 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.3 p -61.68 137.02 58.22 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 124.181 0.992 . . . . 0.0 109.949 175.039 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.7 pt -114.55 -4.37 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 C-N-CA 124.908 1.283 . . . . 0.0 111.331 179.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mt -57.9 145.14 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.596 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 162.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 18.7 m-80 67.13 -21.92 0.11 Allowed 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 128.117 2.567 . . . . 0.0 116.036 171.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 6.6 mtp -69.45 150.7 96.95 Favored Pre-proline 0 C--O 1.244 0.767 0 C-N-CA 124.658 1.183 . . . . 0.0 109.86 175.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -74.68 154.46 44.15 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 123.17 2.58 . . . . 0.0 109.856 173.154 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -54.99 -41.82 71.71 Favored 'General case' 0 N--CA 1.462 0.13 0 C-N-CA 123.42 0.688 . . . . 0.0 111.604 -178.418 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -57.15 -44.58 83.56 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-O 118.822 -0.609 . . . . 0.0 111.332 -174.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.52 -42.44 74.69 Favored 'General case' 0 C--O 1.221 -0.413 0 O-C-N 124.36 1.037 . . . . 0.0 110.011 -175.763 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 68.4 mt -63.33 -41.22 91.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 124.797 1.239 . . . . 0.0 109.679 178.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 41.4 t -62.55 -48.04 90.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 O-C-N 121.161 -0.962 . . . . 0.0 109.456 174.027 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 6.1 tptt -58.44 -43.68 88.86 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 118.614 -0.708 . . . . 0.0 111.279 176.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.05 -34.45 73.43 Favored 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 126.154 1.781 . . . . 0.0 111.71 -176.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 58.1 mt -73.15 -47.63 46.56 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 173.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.3 tttt -58.29 -32.92 68.89 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 122.096 -0.378 . . . . 0.0 111.686 -177.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -99.76 2.09 43.81 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 125.173 1.389 . . . . 0.0 112.276 -177.024 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -54.92 -29.57 56.55 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -171.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.456 ' C ' ' H ' ' A' ' 94' ' ' SER . . . 123.13 27.57 1.49 Allowed Glycine 0 CA--C 1.526 0.768 0 C-N-CA 124.349 0.976 . . . . 0.0 113.285 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 7.8 mt 58.02 -23.11 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 129.023 2.929 . . . . 0.0 114.555 -164.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.456 ' H ' ' C ' ' A' ' 92' ' ' GLY . 1.9 m -93.56 148.59 21.95 Favored 'General case' 0 N--CA 1.435 -1.195 0 N-CA-C 105.24 -2.133 . . . . 0.0 105.24 161.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.1 p -143.26 140.48 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 0 N-CA-C 105.009 -2.219 . . . . 0.0 105.009 169.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.9 m -117.97 102.42 9.04 Favored 'General case' 0 N--CA 1.441 -0.911 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 21.6 mt -90.13 122.1 32.78 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 106.476 -1.676 . . . . 0.0 106.476 -172.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.1 ttt180 -83.73 109.77 17.76 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.011 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -111.94 160.97 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 123.429 0.692 . . . . 0.0 110.83 -177.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 28.5 mt . . . . . 0 CA--C 1.537 0.459 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 169.703 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.7 p . . . . . 0 CA--C 1.538 0.504 0 N-CA-C 110.589 -0.152 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -135.23 163.83 29.07 Favored 'General case' 0 CA--C 1.522 -0.12 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 162.397 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -134.42 94.85 3.27 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 127.185 2.194 . . . . 0.0 107.245 -174.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.8 t -96.89 109.73 23.63 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 125.373 1.469 . . . . 0.0 107.86 -165.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 1.5 t -84.16 141.89 14.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 173.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 69.7 mt -138.22 149.79 24.56 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 105.57 -2.011 . . . . 0.0 105.57 173.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 91.3 m-70 -130.82 156.38 45.1 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.928 1.291 . . . . 0.0 109.271 -176.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 35.3 ptt180 -143.08 -176.86 5.08 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 119.779 1.172 . . . . 0.0 110.048 176.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.44 163.31 12.54 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 124.047 0.939 . . . . 0.0 108.89 170.199 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -70.57 -19.33 62.88 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -177.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.8 m-20 -90.31 5.54 46.81 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 119.745 1.157 . . . . 0.0 112.07 177.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -140.92 176.77 8.53 Favored 'General case' 0 N--CA 1.445 -0.697 0 O-C-N 121.253 -0.905 . . . . 0.0 111.493 -172.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.42 170.73 14.61 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 178.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -71.49 171.14 11.86 Favored 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 152.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -127.94 55.43 0.75 Allowed Glycine 0 C--O 1.222 -0.646 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 25.7 p90 -131.4 158.61 40.3 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 170.215 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 9.2 t -136.88 127.79 41.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 -174.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.0 mp -87.07 146.8 5.85 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 175.166 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 31.6 pt . . . . . 0 N--CA 1.442 -0.842 0 C-N-CA 126.326 1.85 . . . . 0.0 108.239 160.174 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo . . . . . 0 N--CA 1.446 -1.275 0 N-CA-C 109.281 -1.084 . . . . 0.0 109.281 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 2.5 m80 -65.37 116.34 6.57 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 124.25 1.02 . . . . 0.0 111.471 -168.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 39.5 pttt -135.44 151.86 50.82 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 168.055 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 30.0 mm -60.12 115.92 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 C-N-CA 124.261 1.024 . . . . 0.0 109.208 169.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -90.42 -39.43 5.98 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 124.013 0.816 . . . . 0.0 112.629 172.097 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 41.0 ttt85 -149.02 161.46 41.88 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 118.266 1.033 . . . . 0.0 109.559 178.752 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 15.4 mt -131.99 136.71 56.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 126.298 1.839 . . . . 0.0 106.171 169.455 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.4 mp -79.81 132.55 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 C-N-CA 126.016 1.726 . . . . 0.0 108.089 179.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -55.89 133.25 51.25 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 125.942 1.697 . . . . 0.0 109.505 177.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.36 -8.92 75.18 Favored Glycine 0 CA--C 1.528 0.892 0 C-N-CA 123.397 0.522 . . . . 0.0 112.46 169.219 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 76.5 p -71.22 167.1 32.39 Favored Pre-proline 0 N--CA 1.451 -0.385 0 CA-C-N 118.087 0.943 . . . . 0.0 112.836 -169.183 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -54.1 -39.76 84.46 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 C-N-CA 122.35 2.033 . . . . 0.0 111.992 166.414 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.11 -55.78 28.46 Favored 'General case' 0 C--N 1.341 0.216 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -57.13 -30.77 64.69 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.126 1.37 . . . . 0.0 112.447 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 46.6 mtt-85 -83.97 -29.29 27.15 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 114.533 1.309 . . . . 0.0 114.533 175.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 77.0 m -69.46 -27.72 65.48 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 120.292 1.405 . . . . 0.0 111.815 179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 51.54 -160.53 0.09 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.914 0.886 . . . . 0.0 110.496 -169.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 60.9 5.33 0.95 Allowed 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 125.544 1.538 . . . . 0.0 113.323 -167.007 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 14.7 tp -146.59 108.58 4.39 Favored 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.613 1.965 . . . . 0.0 107.17 -175.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 33.4 mttm -133.95 171.1 14.65 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 125.495 1.518 . . . . 0.0 110.419 -175.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 58.2 t -76.47 101.3 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -174.057 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 139.63 -12.78 3.19 Favored Glycine 0 CA--C 1.522 0.515 0 C-N-CA 127.0 2.238 . . . . 0.0 108.951 -175.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 57.7 m-20 -74.6 110.75 9.14 Favored 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 123.219 1.485 . . . . 0.0 107.346 -178.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 19.1 mmt-85 -59.9 158.69 10.25 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 113.918 -1.492 . . . . 0.0 110.377 162.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 35.0 mt -131.6 132.18 62.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 -175.496 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.7 mt -84.49 -51.25 7.05 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 124.323 1.049 . . . . 0.0 111.172 176.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -151.68 168.91 23.53 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 124.53 1.132 . . . . 0.0 109.609 -164.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.1 t -130.27 118.14 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 179.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 39.32 63.12 1.02 Allowed 'General case' 0 N--CA 1.464 0.252 0 C-N-CA 125.53 1.532 . . . . 0.0 110.733 -174.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 69.5 2.09 33.01 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-O 117.672 -1.627 . . . . 0.0 114.461 176.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -111.77 154.03 25.65 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 120.203 2.002 . . . . 0.0 111.676 -171.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 26.7 p -65.9 142.27 57.95 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.984 -179.15 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 5.0 pt -129.8 -5.78 2.87 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 123.318 0.647 . . . . 0.0 112.333 168.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 96.5 mt -73.66 -22.56 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.662 0 C-N-CA 125.046 1.338 . . . . 0.0 109.639 173.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 -124.84 -42.78 2.03 Favored 'General case' 0 C--N 1.341 0.215 0 C-N-CA 124.186 0.994 . . . . 0.0 111.734 -162.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.4 mtp -57.28 151.09 38.89 Favored Pre-proline 0 CA--C 1.533 0.294 0 C-N-CA 123.407 0.683 . . . . 0.0 110.489 176.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -69.34 149.06 69.09 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 121.149 1.233 . . . . 0.0 109.066 171.442 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -55.65 -41.53 73.74 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 124.085 0.954 . . . . 0.0 112.445 -170.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.91 -30.01 70.6 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 118.936 -0.554 . . . . 0.0 111.88 -179.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -70.68 -50.97 30.86 Favored 'General case' 0 C--O 1.223 -0.326 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 14.4 mt -60.18 -40.04 82.37 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 C-N-CA 124.45 1.1 . . . . 0.0 110.19 178.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.0 t -60.52 -47.23 93.58 Favored 'Isoleucine or valine' 0 C--O 1.241 0.611 0 O-C-N 120.78 -1.2 . . . . 0.0 109.97 175.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 22.6 ttmt -65.62 -42.13 91.92 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 117.895 -1.05 . . . . 0.0 110.102 178.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -48.53 -44.86 36.69 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 126.22 1.808 . . . . 0.0 111.097 176.483 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 41.4 mt -73.79 -44.24 52.32 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 48.2 tttt -58.87 -39.09 80.32 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 121.774 -0.579 . . . . 0.0 110.826 -178.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.7 -2.18 57.93 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 127.402 2.281 . . . . 0.0 112.436 -179.463 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.57 -13.4 3.77 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 116.058 1.873 . . . . 0.0 116.058 -164.005 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.45 44.3 6.59 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 118.875 0.762 . . . . 0.0 111.761 172.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 34.9 mt 66.49 -34.83 0.22 Allowed 'General case' 0 CA--C 1.511 -0.524 0 C-N-CA 129.245 3.018 . . . . 0.0 113.714 -175.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -93.47 143.25 26.47 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 178.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.5 p -144.88 135.95 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 172.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 35.0 m -116.53 106.26 13.38 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 -177.008 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 11.8 mt -91.04 110.48 21.75 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 125.07 1.348 . . . . 0.0 108.362 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 ttt180 -78.74 119.68 22.31 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 166.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -117.99 172.55 5.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 C-N-CA 124.733 1.213 . . . . 0.0 109.19 177.01 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 62.4 mt . . . . . 0 CA--C 1.542 0.657 0 C-N-CA 124.647 1.179 . . . . 0.0 108.122 174.707 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 51.0 p . . . . . 0 C--O 1.234 0.26 0 N-CA-C 105.769 -1.937 . . . . 0.0 105.769 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 m -123.45 151.99 42.11 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 161.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -108.67 130.39 55.34 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 128.752 2.821 . . . . 0.0 105.332 176.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.8 t -132.99 109.19 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.4 p -100.61 132.32 46.5 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 176.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 46.2 mt -136.05 147.21 28.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.711 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -120.87 159.28 25.84 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 124.36 1.064 . . . . 0.0 109.564 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.1 ptt180 -140.6 -161.95 1.28 Allowed 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 169.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.23 169.24 10.75 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 169.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 17.7 mm-40 -64.73 -27.37 68.86 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -80.43 -6.92 58.84 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 114.541 1.311 . . . . 0.0 114.541 -173.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -141.25 176.26 8.99 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 119.547 1.067 . . . . 0.0 110.596 -170.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.6 171.77 16.79 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 123.982 0.801 . . . . 0.0 111.353 -172.071 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -85.04 137.9 32.77 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 163.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -97.71 75.3 0.63 Allowed Glycine 0 N--CA 1.442 -0.918 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 -178.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -157.77 148.88 21.31 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 164.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.2 t -137.59 131.04 43.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -174.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 10.3 mt -71.06 154.47 7.92 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.026 0 C-N-CA 124.788 1.235 . . . . 0.0 109.751 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 49.2 pt . . . . . 0 CA--C 1.54 0.594 0 C-N-CA 127.995 2.518 . . . . 0.0 109.143 149.939 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo . . . . . 0 N--CA 1.457 -0.66 0 CA-C-O 117.542 -1.108 . . . . 0.0 113.906 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -138.9 120.78 15.45 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 121.029 1.74 . . . . 0.0 108.913 177.653 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.9 pttt -140.7 162.94 34.2 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 168.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 11.4 mm -65.24 130.87 30.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 172.455 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.06 -51.75 0.72 Allowed Glycine 0 CA--C 1.522 0.491 0 C-N-CA 124.619 1.104 . . . . 0.0 111.224 169.112 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 40.0 ttt85 -134.68 151.79 51.28 Favored 'General case' 0 C--O 1.24 0.579 0 CA-C-N 119.142 1.471 . . . . 0.0 111.165 -168.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 50.5 mt -137.33 119.24 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 C-N-CA 127.14 2.176 . . . . 0.0 106.134 179.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -46.83 126.75 2.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 127.713 2.405 . . . . 0.0 108.418 156.233 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -63.31 128.31 35.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 165.454 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 105.01 4.99 41.51 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 111.514 -0.634 . . . . 0.0 111.514 173.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.5 p -80.88 159.79 67.85 Favored Pre-proline 0 N--CA 1.449 -0.496 0 O-C-N 121.24 -1.153 . . . . 0.0 113.752 -171.693 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -61.71 -35.01 82.25 Favored 'Trans proline' 0 CA--C 1.539 0.737 0 C-N-CA 122.917 2.412 . . . . 0.0 112.404 168.695 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.62 -46.35 69.51 Favored 'General case' 0 C--N 1.34 0.188 0 CA-C-O 118.111 -0.947 . . . . 0.0 111.686 -178.069 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.6 t0 -61.95 -47.64 83.95 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 118.912 0.778 . . . . 0.0 109.805 -172.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 -59.89 -27.47 66.74 Favored 'General case' 0 C--N 1.341 0.229 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.671 177.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 6.1 t -60.57 -37.58 81.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-O 118.405 -0.807 . . . . 0.0 109.982 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.04 -14.34 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 130.535 3.534 . . . . 0.0 116.111 177.577 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.08 -19.19 51.89 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 125.187 1.395 . . . . 0.0 111.477 161.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -119.83 131.92 55.44 Favored 'General case' 0 C--O 1.235 0.292 0 C-N-CA 125.672 1.589 . . . . 0.0 107.688 176.301 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.09 171.32 14.48 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 124.194 0.998 . . . . 0.0 110.041 172.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.4 t -55.89 141.21 12.88 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 O-C-N 121.321 -0.862 . . . . 0.0 109.112 174.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.9 -12.92 65.59 Favored Glycine 0 CA--C 1.534 1.231 0 C-N-CA 125.147 1.356 . . . . 0.0 115.688 172.331 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -68.0 7.31 0.56 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 118.262 2.69 . . . . 0.0 118.262 -151.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 30.8 mtm180 51.87 89.56 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 126.438 1.895 . . . . 0.0 113.122 -178.307 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 61.3 mt -71.95 139.71 19.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -113.52 -53.05 2.72 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 125.632 1.573 . . . . 0.0 108.768 177.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -138.25 154.09 49.08 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.589 0.709 . . . . 0.0 112.319 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 55.6 t -112.15 116.55 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 169.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 57.73 5.12 0.31 Allowed 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 126.763 2.025 . . . . 0.0 115.525 177.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.91 12.28 26.34 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-O 118.81 -0.994 . . . . 0.0 112.863 -175.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 6.0 tp-100 -103.19 140.29 37.56 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 126.405 1.882 . . . . 0.0 108.401 171.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 62.9 m -78.68 100.76 7.18 Favored 'General case' 0 C--O 1.233 0.194 0 C-N-CA 124.666 1.186 . . . . 0.0 111.996 -177.062 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.7 pp -77.6 -5.29 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 179.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.495 HD13 ' H ' ' A' ' 77' ' ' ILE . 0.6 OUTLIER -70.28 -9.92 13.11 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 124.764 1.226 . . . . 0.0 112.381 -178.811 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -138.61 -24.51 0.94 Allowed 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 114.785 1.402 . . . . 0.0 114.785 -174.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.9 mtp -61.06 152.15 72.31 Favored Pre-proline 0 C--O 1.239 0.506 0 CA-C-N 119.856 1.207 . . . . 0.0 110.8 172.205 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -67.12 157.46 61.63 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 121.727 1.618 . . . . 0.0 110.131 171.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -63.21 -37.77 88.53 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.732 -0.605 . . . . 0.0 111.164 -172.057 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.49 -32.47 73.93 Favored 'General case' 0 C--N 1.338 0.068 0 CA-C-N 119.352 0.978 . . . . 0.0 111.975 178.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.74 -52.23 65.12 Favored 'General case' 0 C--O 1.224 -0.249 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 176.623 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 54.2 mt -65.88 -41.63 90.42 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.492 0 C-N-CA 125.91 1.684 . . . . 0.0 109.764 -175.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 17.1 t -60.14 -45.71 95.49 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 O-C-N 121.101 -0.999 . . . . 0.0 110.096 173.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? -59.86 -47.61 85.05 Favored 'General case' 0 C--O 1.219 -0.506 0 CA-C-O 118.692 -0.671 . . . . 0.0 109.376 177.267 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -57.32 -33.75 68.03 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 125.757 1.623 . . . . 0.0 112.676 -177.111 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 63.5 mt -75.1 -45.12 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 175.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.6 ttmp? -60.67 -49.1 78.87 Favored 'General case' 0 CA--C 1.537 0.443 0 O-C-N 121.615 -0.678 . . . . 0.0 110.021 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -76.65 5.93 6.75 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 129.948 3.299 . . . . 0.0 111.842 177.524 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -63.51 -24.01 67.64 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 119.28 0.946 . . . . 0.0 112.386 176.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.81 48.16 5.61 Favored Glycine 0 C--N 1.338 0.659 0 CA-C-N 119.201 0.909 . . . . 0.0 111.436 174.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.0 mt 69.73 -30.79 0.2 Allowed 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 129.764 3.226 . . . . 0.0 113.455 -178.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.29 131.06 40.29 Favored 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 124.722 1.209 . . . . 0.0 108.651 174.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.3 p -135.74 130.77 49.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 170.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.34 125.48 39.99 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 105.96 -1.867 . . . . 0.0 105.96 170.106 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 42.3 mt -116.76 106.85 13.94 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 175.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 -88.82 118.9 28.85 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 177.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.3 pp -119.49 176.66 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 127.216 2.206 . . . . 0.0 108.632 -172.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 5.0 mp . . . . . 0 CA--C 1.533 0.327 0 CA-C-N 119.231 0.923 . . . . 0.0 108.903 172.004 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 36.0 p . . . . . 0 C--O 1.238 0.455 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 26.0 m -120.22 148.82 43.2 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 171.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -96.22 155.52 16.73 Favored 'General case' 0 C--O 1.244 0.789 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 167.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 29.3 t -137.54 103.62 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 177.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.3 p -98.64 134.81 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 171.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 47.6 mt -142.48 134.15 25.49 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 N-CA-C 104.213 -2.514 . . . . 0.0 104.213 -179.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 21.1 m-70 -113.93 159.09 20.27 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.762 1.625 . . . . 0.0 110.171 -174.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.428 ' HD3' ' CE2' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -151.86 175.69 12.21 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 120.334 -1.479 . . . . 0.0 110.863 178.708 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -66.09 161.93 20.69 Favored 'General case' 0 C--O 1.231 0.123 0 C-N-CA 123.426 0.69 . . . . 0.0 109.849 161.458 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -58.11 -50.0 75.0 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 125.863 1.665 . . . . 0.0 111.302 178.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 30.5 t30 -76.48 -21.96 55.16 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.247 1.019 . . . . 0.0 112.621 -173.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -66.96 174.23 3.16 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.377 1.071 . . . . 0.0 109.162 173.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -152.69 46.1 0.58 Allowed Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 124.711 1.148 . . . . 0.0 111.489 -178.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . 0.428 ' CE2' ' HD3' ' A' ' 18' ' ' ARG . 22.3 m-85 50.32 -174.02 0.02 OUTLIER 'General case' 0 N--CA 1.432 -1.345 0 C-N-CA 129.767 3.227 . . . . 0.0 110.753 -174.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.406 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -132.38 45.49 1.12 Allowed Glycine 0 C--O 1.224 -0.482 0 O-C-N 121.353 -0.842 . . . . 0.0 111.97 -176.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -137.96 153.48 49.45 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 124.224 1.01 . . . . 0.0 108.698 -178.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.71 123.13 25.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 -176.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.21 151.2 3.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 171.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 46.2 pt . . . . . 0 N--CA 1.45 -0.466 0 C-N-CA 125.238 1.415 . . . . 0.0 108.137 168.704 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo . . . . . 0 N--CA 1.45 -1.037 0 N-CA-C 108.408 -1.42 . . . . 0.0 108.408 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.2 m80 -61.3 114.24 3.07 Favored 'General case' 0 N--CA 1.446 -0.656 0 C-N-CA 125.595 1.558 . . . . 0.0 111.621 -171.287 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -148.85 154.83 40.05 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 165.491 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 36.3 mm -60.96 129.16 23.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 123.134 0.574 . . . . 0.0 109.686 -178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -100.22 -36.22 4.21 Favored Glycine 0 CA--C 1.529 0.963 0 C-N-CA 126.278 1.894 . . . . 0.0 112.693 172.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 6.9 ttm180 -149.04 151.77 35.07 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 118.437 1.118 . . . . 0.0 108.723 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 11.1 mt -126.86 139.56 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 125.787 1.635 . . . . 0.0 106.709 165.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -82.07 121.77 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 C-N-CA 126.653 1.981 . . . . 0.0 107.829 -178.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -51.46 128.29 22.37 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 124.956 1.302 . . . . 0.0 109.655 173.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 95.01 -12.32 68.57 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 125.449 1.5 . . . . 0.0 112.945 174.022 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' SER . . . . . 0.406 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 59.0 p -69.68 163.07 62.97 Favored Pre-proline 0 CA--C 1.53 0.205 0 CA-C-N 118.98 1.39 . . . . 0.0 113.177 -172.445 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -56.96 -34.81 98.18 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.27 1.98 . . . . 0.0 111.811 165.418 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.44 -49.24 78.34 Favored 'General case' 0 C--N 1.344 0.333 0 CA-C-N 119.526 1.057 . . . . 0.0 110.529 175.133 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -62.17 -49.53 75.46 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 124.265 1.026 . . . . 0.0 111.348 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -53.59 -53.04 57.41 Favored 'General case' 0 C--N 1.343 0.303 0 C-N-CA 124.418 1.087 . . . . 0.0 110.318 178.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 62.5 m -64.73 -13.94 56.73 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 117.536 -1.221 . . . . 0.0 113.592 -170.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 51.89 11.71 0.16 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.577 2.351 . . . . 0.0 116.821 171.167 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.4 mtpt -99.37 -6.77 27.22 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 124.864 1.266 . . . . 0.0 112.03 178.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 93.7 mt -104.8 142.74 34.18 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 154.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 9.4 ptmt -140.81 169.57 17.38 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.492 1.517 . . . . 0.0 110.016 159.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.9 t -73.23 109.32 5.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 O-C-N 121.409 -0.807 . . . . 0.0 109.042 -173.297 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 120.04 -7.71 11.73 Favored Glycine 0 C--N 1.337 0.631 0 O-C-N 121.143 -0.973 . . . . 0.0 110.724 -171.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 -74.11 101.67 3.99 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 172.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 39.5 mtm-85 -50.76 121.38 5.81 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 128.04 2.536 . . . . 0.0 108.424 164.227 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 71.5 mt -105.23 106.85 21.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 104.938 -2.245 . . . . 0.0 104.938 174.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.425 HD23 ' H ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -80.42 -26.57 38.38 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 122.94 0.496 . . . . 0.0 112.111 -179.117 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.48 155.47 30.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 125.109 1.363 . . . . 0.0 111.305 -166.191 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 46.8 t -140.24 132.09 32.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 N-CA-C 105.21 -2.145 . . . . 0.0 105.21 176.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 46.05 34.86 2.19 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.593 1.157 . . . . 0.0 112.472 175.211 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 55.94 26.23 47.63 Favored Glycine 0 CA--C 1.535 1.318 0 CA-C-O 118.491 -1.172 . . . . 0.0 114.257 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -121.93 104.7 9.72 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 127.341 2.257 . . . . 0.0 107.056 -175.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 54.5 p -65.08 103.14 0.71 Allowed 'General case' 0 CA--C 1.538 0.505 0 O-C-N 120.581 -1.324 . . . . 0.0 114.377 -154.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 11.3 pt -74.1 -5.07 6.25 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 C-N-CA 124.226 1.01 . . . . 0.0 113.385 -174.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 50.4 mm -71.4 -21.27 21.57 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 C-N-CA 124.871 1.269 . . . . 0.0 111.336 -178.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -118.28 -28.83 5.69 Favored 'General case' 0 N--CA 1.47 0.536 0 C-N-CA 124.888 1.275 . . . . 0.0 112.372 -176.58 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 9.3 mtp -60.02 151.75 64.04 Favored Pre-proline 0 C--O 1.24 0.558 0 CA-C-N 117.925 0.329 . . . . 0.0 111.398 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -67.11 148.69 81.58 Favored 'Trans proline' 0 N--CA 1.448 -1.166 0 C-N-CA 121.992 1.795 . . . . 0.0 110.282 168.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -60.51 -30.53 69.78 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -172.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -70.03 -35.04 74.02 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 123.692 0.797 . . . . 0.0 112.182 175.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -66.88 -45.19 78.86 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 109.225 -0.658 . . . . 0.0 109.225 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 32.5 mt -64.02 -40.75 90.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 125.555 1.542 . . . . 0.0 108.982 179.418 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.2 t -58.63 -51.02 76.87 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 O-C-N 121.169 -0.957 . . . . 0.0 109.611 173.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.99 -44.6 74.62 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 118.383 -0.818 . . . . 0.0 111.934 176.338 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.35 -46.67 69.61 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 127.157 2.183 . . . . 0.0 110.909 176.362 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 59.7 mt -70.1 -39.77 77.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -176.603 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.1 mtpp -63.35 -39.65 95.12 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 123.066 0.547 . . . . 0.0 110.799 178.008 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -85.84 7.61 23.3 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.253 1.821 . . . . 0.0 112.184 177.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -61.4 -20.21 62.79 Favored 'General case' 0 CA--C 1.535 0.401 0 O-C-N 120.885 -1.135 . . . . 0.0 113.41 -177.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 81.02 63.81 1.85 Allowed Glycine 0 C--N 1.334 0.447 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 175.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 31.4 mt 67.87 -46.96 0.51 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 129.052 2.941 . . . . 0.0 112.699 177.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.51 149.18 21.43 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 170.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.1 p -131.77 133.1 61.67 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 165.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.9 m -106.68 105.02 14.85 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -90.41 160.9 15.82 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 175.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 51.7 ttp180 -113.66 133.26 55.42 Favored 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 106.355 -1.721 . . . . 0.0 106.355 166.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.4 pp -128.21 161.07 37.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 123.899 0.879 . . . . 0.0 109.605 176.029 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 51.0 mt . . . . . 0 CA--C 1.544 0.748 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 169.349 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 42.4 p . . . . . 0 N--CA 1.447 -0.616 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 57.8 m -126.55 152.83 46.03 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 124.362 1.065 . . . . 0.0 109.112 173.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -108.38 103.73 12.94 Favored 'General case' 0 C--O 1.233 0.204 0 C-N-CA 126.235 1.814 . . . . 0.0 106.22 -178.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -88.07 95.2 5.04 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.8 p -78.02 138.08 20.98 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 CA-C-O 121.372 0.606 . . . . 0.0 109.423 171.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 41.2 mt -134.38 142.06 41.84 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 N-CA-C 105.796 -1.927 . . . . 0.0 105.796 173.086 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.2 m-70 -115.77 137.16 52.36 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.711 1.204 . . . . 0.0 109.19 177.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 16.8 ptt180 -118.4 175.65 5.61 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.118 0.872 . . . . 0.0 109.519 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.33 163.9 12.88 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 169.542 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -71.77 -38.6 70.31 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -173.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 54.5 t30 -77.01 18.89 0.33 Allowed 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.785 0.834 . . . . 0.0 112.036 -174.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -161.2 -169.84 2.47 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 120.005 -1.684 . . . . 0.0 111.108 -168.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -121.21 -169.71 13.81 Favored Glycine 0 CA--C 1.521 0.429 0 C-N-CA 126.274 1.892 . . . . 0.0 110.867 -174.212 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 84.2 m-85 -85.97 -110.52 0.05 OUTLIER 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 106.117 -1.808 . . . . 0.0 106.117 165.451 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 152.7 59.04 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.392 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 177.058 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -141.69 133.55 27.33 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 178.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.2 t -113.96 113.53 44.13 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 -172.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 26.7 mt -74.06 131.0 35.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 173.364 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 14.8 pt . . . . . 0 N--CA 1.451 -0.386 0 C-N-CA 125.513 1.525 . . . . 0.0 109.822 172.186 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo . . . . . 0 N--CA 1.456 -0.723 0 CA-C-O 117.661 -1.058 . . . . 0.0 113.802 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -139.02 119.31 13.67 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 120.831 1.65 . . . . 0.0 110.157 174.75 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -143.65 163.99 31.67 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 168.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.8 mm -63.1 125.37 19.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 165.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.83 -24.05 5.37 Favored Glycine 0 CA--C 1.527 0.799 0 CA-C-O 118.828 -0.985 . . . . 0.0 113.469 172.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -154.09 147.52 25.0 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 176.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 5.4 mt -128.37 149.49 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 168.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -78.13 117.38 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 C-N-CA 125.714 1.606 . . . . 0.0 107.105 174.078 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -52.72 105.08 0.11 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.123 2.169 . . . . 0.0 109.256 176.582 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 95.02 7.92 59.37 Favored Glycine 0 CA--C 1.526 0.753 0 C-N-CA 124.569 1.081 . . . . 0.0 114.065 177.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 33.9 p -64.38 166.24 11.72 Favored Pre-proline 0 CA--C 1.531 0.242 0 CA-C-N 119.495 1.647 . . . . 0.0 109.802 164.099 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -58.86 -24.3 71.59 Favored 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 121.728 1.618 . . . . 0.0 112.849 170.095 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.03 -60.6 3.52 Favored 'General case' 0 C--N 1.341 0.201 0 CA-C-N 119.277 0.944 . . . . 0.0 108.671 173.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -65.69 -42.5 91.14 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.833 0.349 . . . . 0.0 111.048 -176.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -69.96 -22.85 63.13 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 118.442 -0.79 . . . . 0.0 112.501 -174.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 2.0 p -73.84 -16.7 61.13 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 117.618 -1.182 . . . . 0.0 110.976 173.513 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 40.08 66.23 0.63 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.324 1.849 . . . . 0.0 110.633 -173.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 33.4 mtmm -139.28 -44.89 0.46 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 124.923 1.289 . . . . 0.0 108.883 170.156 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 22.5 tp -94.02 121.62 35.69 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 -177.179 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.7 mmtt -132.85 162.84 30.48 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 123.394 1.569 . . . . 0.0 110.615 -176.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.4 t -62.77 123.77 16.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 172.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 122.11 -24.96 6.86 Favored Glycine 0 N--CA 1.447 -0.585 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -175.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -79.22 99.22 6.93 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-O 123.282 1.515 . . . . 0.0 109.416 -167.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 39.4 mtm180 -46.39 137.02 6.81 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 129.119 2.967 . . . . 0.0 110.106 162.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 16.0 mt -119.01 144.65 26.72 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 -174.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.1 mp -117.54 -47.22 2.64 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 125.246 1.418 . . . . 0.0 111.214 -176.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -150.04 169.61 20.83 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.084 0.954 . . . . 0.0 109.368 -175.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.6 p -138.89 123.39 20.88 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.299 0 C-N-CA 125.14 1.376 . . . . 0.0 108.197 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 51.39 31.05 6.74 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 123.616 0.767 . . . . 0.0 112.417 -173.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.26 6.75 89.07 Favored Glycine 0 CA--C 1.532 1.117 0 CA-C-O 118.37 -1.239 . . . . 0.0 114.204 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -102.46 135.3 44.32 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 119.963 1.882 . . . . 0.0 109.896 177.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -54.43 129.16 34.81 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 123.087 0.555 . . . . 0.0 110.282 168.828 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 25.8 pt -91.16 -17.79 7.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.716 1.206 . . . . 0.0 110.332 164.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 81.2 mt -68.02 136.26 26.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 82.49 -30.9 0.09 Allowed 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 130.572 3.549 . . . . 0.0 112.847 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 6.3 mtp -64.8 154.07 86.52 Favored Pre-proline 0 CA--C 1.541 0.597 0 CA-C-N 119.298 0.954 . . . . 0.0 111.332 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -76.9 152.1 31.84 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.49 2.127 . . . . 0.0 109.951 173.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -51.97 -42.38 62.86 Favored 'General case' 0 C--O 1.222 -0.345 0 C-N-CA 123.742 0.817 . . . . 0.0 111.657 -176.611 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.0 -41.83 75.46 Favored 'General case' 0 C--N 1.338 0.072 0 CA-C-O 118.356 -0.831 . . . . 0.0 112.855 178.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.9 -30.38 40.1 Favored 'General case' 0 C--O 1.225 -0.231 0 CA-C-N 118.898 0.772 . . . . 0.0 110.927 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 13.3 mt -69.03 -42.15 81.93 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 C-N-CA 124.455 1.102 . . . . 0.0 108.835 171.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 2.5 t -54.54 -46.4 71.73 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 O-C-N 120.542 -1.349 . . . . 0.0 108.932 170.511 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 9.7 tptt -62.14 -43.51 98.67 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-O 117.033 -1.461 . . . . 0.0 111.903 175.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.05 -37.78 80.85 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 121.121 1.782 . . . . 0.0 110.567 -177.361 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 43.0 mt -69.7 -49.58 57.04 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 177.298 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.1 tttp -54.22 -49.14 70.13 Favored 'General case' 0 C--N 1.345 0.371 0 C-N-CA 123.56 0.744 . . . . 0.0 110.234 178.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -65.89 -17.42 64.64 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 127.384 2.274 . . . . 0.0 112.362 -177.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -67.29 -9.43 40.75 Favored 'General case' 0 CA--C 1.548 0.895 0 CA-C-N 119.384 0.993 . . . . 0.0 112.891 176.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.23 -89.12 0.72 Allowed Glycine 0 C--N 1.34 0.779 0 C-N-CA 125.134 1.35 . . . . 0.0 112.262 167.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 78.4 mt -132.03 -27.3 1.85 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 126.47 1.908 . . . . 0.0 110.28 173.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.55 152.29 19.7 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 105.632 -1.988 . . . . 0.0 105.632 174.091 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.7 p -150.75 147.07 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 N-CA-C 105.126 -2.175 . . . . 0.0 105.126 161.104 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 20.6 m -126.08 103.09 7.53 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -175.254 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 18.8 mt -90.77 123.05 34.03 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 124.762 1.225 . . . . 0.0 108.444 -176.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 13.7 ttm180 -83.88 131.42 34.87 Favored 'General case' 0 C--O 1.237 0.431 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 176.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -126.97 159.69 36.6 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 C-N-CA 125.661 1.584 . . . . 0.0 110.581 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 9.2 mt . . . . . 0 N--CA 1.478 0.94 0 C-N-CA 124.841 1.256 . . . . 0.0 110.842 175.709 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 33.5 p . . . . . 0 N--CA 1.448 -0.536 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.9 m -111.23 156.62 21.18 Favored 'General case' 0 C--O 1.235 0.325 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 168.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -120.85 103.54 9.16 Favored 'General case' 0 CA--C 1.511 -0.536 0 N-CA-C 104.029 -2.582 . . . . 0.0 104.029 172.401 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.6 t -91.63 95.03 5.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 105.458 -2.053 . . . . 0.0 105.458 -177.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.4 p -85.47 124.84 40.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 169.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 13.3 mt -116.97 143.38 27.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 171.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.0 m-70 -121.68 143.76 49.16 Favored 'General case' 0 CA--C 1.536 0.404 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 175.445 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.0 ptt-85 -130.86 -175.48 3.68 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 119.797 1.18 . . . . 0.0 109.008 176.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.417 ' N ' ' HE3' ' A' ' 19' ' ' LYS . 0.2 OUTLIER -95.38 168.7 10.56 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 118.814 0.734 . . . . 0.0 109.273 169.836 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -65.94 -20.67 66.29 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.078 0.951 . . . . 0.0 112.544 170.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -123.18 65.67 0.99 Allowed 'General case' 0 C--O 1.234 0.265 0 C-N-CA 124.454 1.101 . . . . 0.0 108.133 -177.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -172.6 179.45 2.44 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 128.38 2.672 . . . . 0.0 107.227 163.164 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.67 176.12 23.84 Favored Glycine 0 CA--C 1.526 0.734 0 C-N-CA 124.432 1.015 . . . . 0.0 110.976 173.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -84.7 170.68 13.04 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 150.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.45 55.6 0.65 Allowed Glycine 0 C--O 1.224 -0.529 0 O-C-N 120.727 -1.233 . . . . 0.0 111.537 -175.138 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.4 p90 -130.12 121.89 27.21 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 117.981 0.89 . . . . 0.0 108.924 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.6 t -96.25 101.04 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 -175.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -74.27 118.87 20.57 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 170.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 24.5 pt . . . . . 0 CA--C 1.536 0.438 0 C-N-CA 124.355 1.062 . . . . 0.0 109.281 176.865 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo . . . . . 0 N--CA 1.456 -0.728 0 N-CA-C 109.818 -0.878 . . . . 0.0 109.818 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.2 m80 -63.68 123.71 19.55 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 118.785 0.72 . . . . 0.0 109.869 -177.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 49.8 pttt -143.67 153.29 42.33 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 107.883 -1.155 . . . . 0.0 107.883 171.086 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.7 mm -66.69 124.12 21.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 167.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -101.97 -30.88 5.59 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 124.246 0.927 . . . . 0.0 112.611 175.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 22.7 ttm180 -154.65 158.41 39.63 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 118.847 1.323 . . . . 0.0 107.564 176.014 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 24.5 mt -130.77 135.28 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 170.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.4 mp -68.81 124.96 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 32.2 t0 -51.96 133.55 32.45 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.375 1.07 . . . . 0.0 109.97 178.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.08 1.0 38.41 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 118.98 -0.9 . . . . 0.0 114.412 174.493 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 61.4 p -64.62 162.7 33.05 Favored Pre-proline 0 CA--C 1.53 0.189 0 CA-C-N 119.483 1.641 . . . . 0.0 109.504 171.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -55.76 -18.17 20.42 Favored 'Trans proline' 0 CA--C 1.534 0.488 0 C-N-CA 122.959 2.439 . . . . 0.0 114.028 175.244 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.59 -69.79 0.27 Allowed 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 169.112 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -66.43 -31.88 72.91 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 118.14 0.427 . . . . 0.0 111.655 -173.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.92 -22.92 67.11 Favored 'General case' 0 C--O 1.234 0.247 0 O-C-N 121.351 -0.843 . . . . 0.0 112.508 175.389 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 7.8 t -80.85 -9.51 59.81 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 119.338 0.972 . . . . 0.0 111.475 173.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 55.92 5.13 0.14 Allowed 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 128.841 2.856 . . . . 0.0 115.724 173.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.9 -49.64 6.96 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 119.796 1.18 . . . . 0.0 110.424 177.39 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 14.8 tp -93.85 129.36 40.28 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 123.5 0.72 . . . . 0.0 109.414 -166.044 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.7 mptt -122.99 169.97 10.62 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 125.451 1.5 . . . . 0.0 110.438 170.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -58.4 148.47 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 C-N-CA 124.367 1.067 . . . . 0.0 109.798 165.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.24 -7.73 80.67 Favored Glycine 0 CA--C 1.524 0.635 0 C-N-CA 125.301 1.429 . . . . 0.0 110.682 -175.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -71.17 88.92 0.83 Allowed 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 172.351 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.1 mtm180 -38.21 121.02 0.94 Allowed 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 128.448 2.699 . . . . 0.0 110.314 159.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 14.3 mt -101.22 118.83 48.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 -178.697 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 88.1 mt -72.0 -52.52 16.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 124.684 1.194 . . . . 0.0 109.959 168.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -150.83 166.24 31.13 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 124.059 0.944 . . . . 0.0 111.951 -162.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 37.2 t -126.26 119.84 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 174.45 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 67.7 m-20 54.51 10.01 0.3 Allowed 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 128.918 2.887 . . . . 0.0 114.477 176.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 114.01 -0.26 24.16 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 126.721 2.105 . . . . 0.0 113.909 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 9.8 mm-40 -105.07 145.22 30.8 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 125.422 1.489 . . . . 0.0 109.243 -176.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.8 p -84.09 99.26 10.36 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 124.73 1.212 . . . . 0.0 111.63 -167.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 7.1 pt -79.76 -2.84 5.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 C-N-CA 123.904 0.882 . . . . 0.0 112.106 -177.258 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.508 HD12 ' H ' ' A' ' 77' ' ' ILE . 3.3 mp -61.85 -33.29 57.19 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 125.223 1.409 . . . . 0.0 110.383 174.31 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -107.7 -44.12 4.33 Favored 'General case' 0 C--O 1.233 0.215 0 C-N-CA 123.049 0.539 . . . . 0.0 111.217 -166.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 5.6 mtp -58.77 153.4 42.54 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 124.329 1.052 . . . . 0.0 111.328 -168.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.75 146.27 97.6 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.187 1.258 . . . . 0.0 109.276 167.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -52.09 -41.28 62.29 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 124.346 1.058 . . . . 0.0 110.028 -178.064 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -59.93 -35.57 75.19 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 114.24 1.2 . . . . 0.0 114.24 177.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.01 -44.86 79.23 Favored 'General case' 0 N--CA 1.463 0.189 0 C-N-CA 123.727 0.811 . . . . 0.0 108.887 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 24.0 mt -69.37 -37.99 76.47 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 C-N-CA 125.967 1.707 . . . . 0.0 109.261 -178.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 4.8 t -56.46 -49.06 78.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 O-C-N 121.127 -0.983 . . . . 0.0 109.427 169.263 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 11.4 ttpt -66.88 -36.48 82.41 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-O 118.742 -0.647 . . . . 0.0 111.258 -177.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -57.09 -44.38 83.11 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 125.4 1.48 . . . . 0.0 111.057 174.29 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 91.1 mt -67.86 -40.99 84.54 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-N 119.371 0.987 . . . . 0.0 108.813 178.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.0 tttt -60.08 -48.76 80.38 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 118.819 0.736 . . . . 0.0 109.942 176.146 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -70.31 -12.28 61.48 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 124.642 1.177 . . . . 0.0 111.268 -178.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.9 -14.99 53.25 Favored 'General case' 0 CA--C 1.545 0.757 0 CA-C-N 119.679 1.127 . . . . 0.0 112.347 168.426 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.28 -132.25 11.16 Favored Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 176.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 5.7 mt -90.7 -10.24 43.83 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 118.878 -0.582 . . . . 0.0 110.336 173.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 26.7 p -93.42 162.3 14.04 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 168.476 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.6 p -156.68 136.6 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.888 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 159.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.1 m -117.34 104.75 11.44 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 -177.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 56.9 mt -90.02 164.55 14.48 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 177.33 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 22.6 ttt180 -127.93 118.74 24.16 Favored 'General case' 0 CA--C 1.513 -0.456 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 173.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pp -129.51 169.2 21.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 C-N-CA 123.952 0.901 . . . . 0.0 109.294 -176.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.0 mp . . . . . 0 CA--C 1.54 0.585 0 C-N-CA 124.205 1.002 . . . . 0.0 109.361 -177.251 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.6 p . . . . . 0 CA--C 1.54 0.581 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 37.3 m -126.6 164.41 21.3 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.875 1.67 . . . . 0.0 109.415 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 18.4 p-10 -128.86 95.12 4.0 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 127.15 2.18 . . . . 0.0 108.057 177.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.0 t -89.47 102.9 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 105.798 -1.927 . . . . 0.0 105.798 174.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.2 t -106.68 111.47 35.6 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -177.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 12.1 mt -108.83 136.55 44.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 N-CA-C 106.126 -1.805 . . . . 0.0 106.126 -178.72 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -119.87 114.15 21.66 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 126.465 1.906 . . . . 0.0 105.989 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 28.4 ptt180 -95.0 174.99 6.81 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 119.606 1.094 . . . . 0.0 109.116 176.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -82.97 171.13 14.16 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 166.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -75.57 -9.85 58.93 Favored 'General case' 0 N--CA 1.469 0.489 0 O-C-N 120.355 -1.466 . . . . 0.0 112.805 175.373 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 40.3 t30 -98.98 -27.38 13.89 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 115.119 1.526 . . . . 0.0 115.119 -160.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -114.37 -122.1 0.29 Allowed 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.235 1.414 . . . . 0.0 108.768 -167.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -154.49 -178.34 28.76 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 167.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -72.97 170.82 14.02 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 151.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -135.2 62.07 0.62 Allowed Glycine 0 C--O 1.22 -0.749 0 CA-C-O 118.27 -1.294 . . . . 0.0 111.591 -176.185 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.2 p90 -146.12 139.96 26.35 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 119.281 1.541 . . . . 0.0 109.033 178.491 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.689 HG11 ' H ' ' A' ' 49' ' ' ARG . 0.8 OUTLIER -110.08 154.78 11.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 171.798 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -128.79 118.75 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 -178.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 26.1 pt . . . . . 0 N--CA 1.45 -0.445 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -179.034 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo . . . . . 0 N--CA 1.453 -0.865 0 N-CA-C 108.475 -1.394 . . . . 0.0 108.475 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -72.58 120.9 18.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.138 0.975 . . . . 0.0 110.559 -174.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 45.3 pttt -137.31 154.93 49.97 Favored 'General case' 0 C--O 1.236 0.371 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 168.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 5.0 mm -60.79 127.29 20.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 166.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -88.51 -69.75 1.27 Allowed Glycine 0 CA--C 1.527 0.806 0 O-C-N 124.495 1.122 . . . . 0.0 110.627 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ARG . . . . . 0.689 ' H ' HG11 ' A' ' 27' ' ' VAL . 31.4 ttm180 -127.6 153.28 46.6 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 128.751 2.821 . . . . 0.0 107.407 -178.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 12.5 mt -119.27 142.68 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 166.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 50.4 mm -73.05 122.59 26.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -60.45 137.17 58.19 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 178.443 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.82 -5.23 54.08 Favored Glycine 0 CA--C 1.531 1.058 0 C-N-CA 126.08 1.8 . . . . 0.0 114.495 -178.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 83.7 p -68.62 167.65 18.22 Favored Pre-proline 0 C--O 1.234 0.283 0 CA-C-N 119.332 1.566 . . . . 0.0 112.472 -176.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -58.23 -29.26 87.1 Favored 'Trans proline' 0 N--CA 1.451 -0.994 0 C-N-CA 122.165 1.91 . . . . 0.0 112.458 166.464 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.85 -53.94 46.45 Favored 'General case' 0 C--N 1.345 0.398 0 CA-C-N 119.814 1.188 . . . . 0.0 109.71 177.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -66.21 -45.89 79.14 Favored 'General case' 0 N--CA 1.463 0.187 0 O-C-N 123.135 0.272 . . . . 0.0 110.525 -178.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -72.45 -22.58 61.06 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 113.237 0.829 . . . . 0.0 113.237 -173.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 24.3 m -61.2 -18.09 56.46 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 119.967 1.258 . . . . 0.0 111.519 165.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 65.16 -25.15 0.09 Allowed 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 130.218 3.407 . . . . 0.0 114.951 171.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 1.9 mtpp -73.54 -8.53 56.31 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 124.955 1.302 . . . . 0.0 112.137 174.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -107.93 125.26 51.28 Favored 'General case' 0 C--N 1.343 0.301 0 CA-C-N 119.645 1.112 . . . . 0.0 108.328 173.262 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 40.5 mttp -135.76 166.41 23.35 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 126.188 1.795 . . . . 0.0 109.115 172.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 71.7 t -64.76 152.7 8.52 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 C-N-CA 123.515 0.726 . . . . 0.0 109.118 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 67.43 43.72 86.36 Favored Glycine 0 CA--C 1.528 0.903 0 CA-C-O 122.047 0.804 . . . . 0.0 112.221 174.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.8 p-10 -78.46 -20.99 49.76 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 125.782 1.633 . . . . 0.0 115.135 -173.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 18.4 mtm180 44.84 90.96 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 128.752 2.821 . . . . 0.0 111.516 -160.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 24.2 mt -68.48 150.21 10.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -116.56 -50.98 2.61 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.413 2.285 . . . . 0.0 108.898 177.186 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -151.91 169.97 20.99 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 124.179 0.991 . . . . 0.0 111.603 -176.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.0 p -128.88 118.89 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 124.371 1.068 . . . . 0.0 109.291 175.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 39.05 47.06 1.23 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.413 1.485 . . . . 0.0 110.494 -169.198 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.16 -3.72 51.05 Favored Glycine 0 CA--C 1.53 1.01 0 C-N-CA 125.952 1.739 . . . . 0.0 115.977 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -82.21 141.84 32.66 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 120.829 2.314 . . . . 0.0 108.578 -178.624 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.7 p -90.02 90.66 8.24 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-O 122.675 1.226 . . . . 0.0 110.374 -171.562 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 13.3 pt -65.39 -3.16 1.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.814 0 C-N-CA 126.833 2.053 . . . . 0.0 113.622 -177.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 26.1 mm -57.48 -58.13 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 126.799 2.04 . . . . 0.0 109.591 175.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -113.8 -22.96 9.91 Favored 'General case' 0 C--O 1.231 0.114 0 O-C-N 123.596 0.56 . . . . 0.0 112.029 -161.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.5 ttt -56.18 142.24 67.29 Favored Pre-proline 0 N--CA 1.437 -1.083 0 C-N-CA 126.292 1.837 . . . . 0.0 109.463 166.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -75.35 153.09 39.88 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 121.259 1.306 . . . . 0.0 111.169 -179.134 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 32.9 t60 -58.19 -41.23 83.51 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.255 0.622 . . . . 0.0 112.015 -170.038 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.68 -32.1 73.12 Favored 'General case' 0 C--O 1.227 -0.101 0 CA-C-O 118.879 -0.582 . . . . 0.0 112.41 178.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 53.5 m-20 -75.8 -42.04 51.12 Favored 'General case' 0 C--O 1.225 -0.221 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 32.8 mt -60.54 -40.26 83.85 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 124.643 1.177 . . . . 0.0 109.72 173.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 19.2 t -68.03 -35.88 73.41 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 O-C-N 120.198 -1.564 . . . . 0.0 110.902 175.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -62.38 -48.67 78.7 Favored 'General case' 0 C--O 1.22 -0.459 0 O-C-N 121.506 -0.746 . . . . 0.0 110.498 171.106 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.88 -35.39 66.45 Favored 'General case' 0 N--CA 1.44 -0.928 0 C-N-CA 126.505 1.922 . . . . 0.0 111.981 -176.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 76.0 mt -69.77 -52.58 30.25 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 176.225 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 6.8 tttp -54.51 -44.33 72.63 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 122.924 0.49 . . . . 0.0 111.172 177.613 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -71.95 -19.43 61.9 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.182 1.793 . . . . 0.0 110.984 -178.112 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.97 -35.38 80.44 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 119.525 1.057 . . . . 0.0 109.447 169.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 86.13 -117.03 4.5 Favored Glycine 0 N--CA 1.449 -0.497 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 172.542 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 39.6 mt -76.48 -49.27 17.0 Favored 'General case' 0 CA--C 1.501 -0.912 0 CA-C-N 118.367 1.083 . . . . 0.0 108.838 -173.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.89 145.81 24.36 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 124.229 0.955 . . . . 0.0 108.638 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.9 p -146.39 139.5 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 167.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 47.1 m -106.07 105.5 15.56 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 125.584 1.554 . . . . 0.0 107.197 176.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 40.7 mt -90.81 127.12 36.24 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.517 ' HB2' HH11 ' A' ' 98' ' ' ARG . 6.4 ttm105 -103.53 111.7 24.28 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.2 pp -121.53 174.61 5.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 C-N-CA 126.048 1.739 . . . . 0.0 108.312 -175.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 8.5 mt . . . . . 0 CA--C 1.54 0.586 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -179.107 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.53 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 67.3 m -50.11 134.2 22.39 Favored 'General case' 0 C--O 1.237 0.419 0 C-N-CA 124.553 1.141 . . . . 0.0 113.157 -178.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 p -62.79 148.47 46.8 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 149.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 125.31 -171.78 17.28 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 124.049 0.833 . . . . 0.0 111.626 178.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 83.2 p -144.42 -164.46 1.91 Allowed 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.943 1.297 . . . . 0.0 109.287 177.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.1 m -84.75 -6.06 59.34 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.391 0.677 . . . . 0.0 112.466 -176.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 78.9 79.57 0.79 Allowed Glycine 0 C--N 1.335 0.484 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 -179.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 18.7 m -130.33 167.52 18.38 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.392 1.877 . . . . 0.0 108.038 177.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.5 mp -61.48 146.56 48.13 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.17 164.42 16.24 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 124.32 1.048 . . . . 0.0 108.953 -174.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.2 p -141.75 163.84 31.83 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.787 1.235 . . . . 0.0 109.613 -172.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 13.0 m -140.83 164.74 29.41 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.514 1.126 . . . . 0.0 109.071 171.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 25.6 p-10 -128.71 94.45 3.86 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 127.601 2.36 . . . . 0.0 108.901 -173.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 24.3 t -90.64 106.94 17.93 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 176.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.7 t -85.5 142.72 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 166.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.0 mt -137.53 132.01 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.152 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 174.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 -115.04 141.35 48.11 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.715 1.606 . . . . 0.0 109.343 -175.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 30.9 ptt180 -139.88 -169.47 2.73 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 124.426 1.09 . . . . 0.0 110.474 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.67 169.12 10.38 Favored 'General case' 0 N--CA 1.463 0.222 0 C-N-CA 124.567 1.147 . . . . 0.0 109.439 168.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -69.89 -15.98 63.16 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 113.43 0.9 . . . . 0.0 113.43 -177.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -84.5 -7.07 59.4 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-O 118.477 -0.773 . . . . 0.0 112.896 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -136.32 172.34 13.16 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 119.649 1.113 . . . . 0.0 111.479 -166.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.74 166.45 26.36 Favored Glycine 0 C--N 1.333 0.413 0 C-N-CA 123.669 0.652 . . . . 0.0 111.927 -170.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -87.27 115.71 24.86 Favored 'General case' 0 N--CA 1.444 -0.726 0 N-CA-C 104.52 -2.4 . . . . 0.0 104.52 150.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -92.7 48.62 2.55 Favored Glycine 0 C--O 1.224 -0.482 0 CA-C-O 118.518 -1.157 . . . . 0.0 112.643 -168.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 19.9 p90 -126.92 160.08 32.06 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 118.76 1.28 . . . . 0.0 109.873 173.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.4 t -138.39 141.36 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 C-N-CA 126.519 1.927 . . . . 0.0 106.972 -179.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.4 mp -105.9 135.85 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.667 0 C-N-CA 125.817 1.647 . . . . 0.0 107.801 178.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.447 HD13 ' HE3' ' A' ' 46' ' ' LYS . 13.5 pt -125.96 -178.73 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 125.459 1.504 . . . . 0.0 110.314 175.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 t 67.35 178.71 0.23 Allowed 'General case' 0 C--O 1.239 0.542 0 C-N-CA 126.552 1.941 . . . . 0.0 109.926 -163.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.9 p -174.29 -57.01 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 127.643 2.377 . . . . 0.0 106.239 169.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.8 tp 34.3 62.72 0.46 Allowed 'General case' 0 C--N 1.342 0.254 0 C-N-CA 126.309 1.844 . . . . 0.0 110.304 -172.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -80.73 41.65 0.58 Allowed 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 121.425 0.631 . . . . 0.0 109.59 -175.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 8.2 tpt180 -122.23 104.99 37.28 Favored Pre-proline 0 N--CA 1.455 -0.212 0 C-N-CA 127.548 2.339 . . . . 0.0 105.498 -173.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -58.01 116.31 3.15 Favored 'Trans proline' 0 N--CA 1.449 -1.113 0 C-N-CA 123.344 2.696 . . . . 0.0 110.079 -177.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -93.04 128.69 39.02 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 124.625 1.17 . . . . 0.0 108.808 175.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.0 t -61.56 -41.51 97.48 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.458 1.103 . . . . 0.0 111.498 178.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.86 156.42 19.27 Favored Glycine 0 CA--C 1.525 0.677 0 CA-C-N 119.034 0.834 . . . . 0.0 111.486 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 69.9 m -70.18 102.83 2.18 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 172.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -85.85 162.71 18.51 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 125.308 1.443 . . . . 0.0 107.463 158.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.6 pt -93.51 86.29 2.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 170.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.0 t -133.33 151.79 51.89 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 124.792 1.237 . . . . 0.0 107.702 -174.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.7 p -127.51 142.49 44.23 Favored Pre-proline 0 C--O 1.238 0.465 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 173.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.3 -29.73 9.21 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 C-N-CA 121.275 1.316 . . . . 0.0 111.696 169.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -138.48 125.35 21.11 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 119.73 1.15 . . . . 0.0 110.746 -170.441 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.447 ' HE3' HD13 ' A' ' 29' ' ' ILE . 48.2 pttt -146.64 162.94 37.38 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 124.407 1.083 . . . . 0.0 108.783 166.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 46.4 mm -65.31 130.61 30.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 170.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.42 -49.66 0.65 Allowed Glycine 0 C--N 1.336 0.56 0 C-N-CA 125.254 1.407 . . . . 0.0 112.492 175.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -129.24 150.63 50.54 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 119.433 1.617 . . . . 0.0 108.373 176.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 11.5 mt -128.93 133.31 66.35 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 167.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -60.14 126.37 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.605 0 C-N-CA 125.191 1.396 . . . . 0.0 108.018 169.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.29 121.13 9.43 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 124.483 1.113 . . . . 0.0 108.059 164.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.51 21.55 40.28 Favored Glycine 0 CA--C 1.526 0.778 0 CA-C-O 118.875 -0.958 . . . . 0.0 112.649 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 29.0 p -90.85 164.76 24.55 Favored Pre-proline 0 C--O 1.236 0.349 0 CA-C-N 119.651 1.725 . . . . 0.0 112.915 177.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -65.65 -21.77 58.66 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 121.695 1.597 . . . . 0.0 112.911 162.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.4 -56.36 16.9 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 119.199 0.909 . . . . 0.0 109.134 172.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -57.95 -48.48 79.83 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.597 0.759 . . . . 0.0 109.923 -177.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.3 mtt85 -71.9 -6.85 44.8 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 113.91 1.078 . . . . 0.0 113.91 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 36.1 t -62.29 -21.58 65.34 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 119.817 1.19 . . . . 0.0 109.646 167.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.69 26.23 11.04 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 125.736 1.614 . . . . 0.0 112.665 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.6 mtmm -126.96 -52.13 1.43 Allowed 'General case' 0 CA--C 1.521 -0.145 0 C-N-CA 126.583 1.953 . . . . 0.0 109.153 175.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 9.9 tp -92.85 118.77 31.48 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -161.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 71.4 mmtt -129.97 171.89 12.29 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 123.55 1.643 . . . . 0.0 109.332 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 94.8 t -64.89 122.9 16.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 113.807 -1.542 . . . . 0.0 107.626 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 128.31 -18.89 5.75 Favored Glycine 0 C--N 1.337 0.593 0 C-N-CA 125.02 1.295 . . . . 0.0 109.997 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -77.05 98.25 4.94 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 122.243 1.021 . . . . 0.0 109.196 -165.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 17.8 mtm180 -44.63 120.48 2.28 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 128.653 2.781 . . . . 0.0 110.572 164.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 45.5 mt -101.6 153.31 5.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 126.151 1.78 . . . . 0.0 107.432 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 tp -131.75 -44.89 0.97 Allowed 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.821 1.648 . . . . 0.0 110.589 -172.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -147.98 163.11 37.84 Favored 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 123.267 0.627 . . . . 0.0 110.423 176.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 67.2 t -133.0 118.04 31.54 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 -176.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 42.39 57.11 3.5 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.146 1.778 . . . . 0.0 109.529 -170.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 67.46 -4.12 4.1 Favored Glycine 0 CA--C 1.537 1.435 0 CA-C-O 117.679 -1.623 . . . . 0.0 116.026 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -90.17 130.89 36.26 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 121.398 2.599 . . . . 0.0 110.997 -178.471 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' SER . . . . . 0.423 ' C ' ' H ' ' A' ' 77' ' ' ILE . 70.3 m -73.61 94.33 2.16 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 124.013 0.925 . . . . 0.0 110.509 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.5 pp -60.77 10.96 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.632 0 C-N-CA 128.34 2.656 . . . . 0.0 115.133 177.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.423 ' H ' ' C ' ' A' ' 75' ' ' SER . 52.5 mt -63.46 -79.41 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 C-N-CA 126.029 1.732 . . . . 0.0 108.729 -178.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 62.9 m-80 -79.95 -11.87 59.76 Favored 'General case' 0 N--CA 1.467 0.4 0 O-C-N 121.453 -0.779 . . . . 0.0 113.079 -174.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 16.6 mtp -60.0 140.39 90.48 Favored Pre-proline 0 C--O 1.237 0.401 0 CA-C-N 118.238 0.472 . . . . 0.0 110.172 -178.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -65.27 156.05 65.21 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 121.962 1.775 . . . . 0.0 109.355 169.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 55.9 t60 -57.31 -34.99 69.3 Favored 'General case' 0 C--O 1.224 -0.261 0 CA-C-O 119.003 -0.522 . . . . 0.0 110.701 173.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.74 -41.66 77.91 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-O 118.591 -0.718 . . . . 0.0 112.362 175.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.88 -45.45 82.03 Favored 'General case' 0 C--O 1.222 -0.388 0 CA-C-N 118.909 0.777 . . . . 0.0 109.415 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 67.9 mt -65.42 -44.26 94.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.481 0 C-N-CA 125.53 1.532 . . . . 0.0 109.21 -175.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 22.5 t -55.18 -47.98 76.84 Favored 'Isoleucine or valine' 0 C--O 1.24 0.585 0 C-N-CA 125.147 1.379 . . . . 0.0 109.629 170.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 24.9 mtpt -70.33 -28.11 64.89 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-O 117.134 -1.412 . . . . 0.0 113.526 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.85 -40.83 79.17 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.932 1.696 . . . . 0.0 110.481 177.07 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 81.8 mt -68.74 -46.81 78.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 178.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.1 tmtm? -63.34 -38.12 89.93 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-O 118.678 -0.677 . . . . 0.0 111.729 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -61.93 -32.02 72.38 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 124.169 0.988 . . . . 0.0 110.282 175.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -67.95 -12.18 60.23 Favored 'General case' 0 CA--C 1.543 0.689 0 CA-C-O 121.636 0.731 . . . . 0.0 112.3 175.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 66.13 -100.31 0.51 Allowed Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 125.674 1.607 . . . . 0.0 110.411 173.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 25.1 mt -105.34 -24.72 12.63 Favored 'General case' 0 CA--C 1.504 -0.792 0 CA-C-O 117.68 -1.153 . . . . 0.0 112.495 -176.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.28 121.06 40.11 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 118.678 0.672 . . . . 0.0 109.495 178.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.3 p -125.68 148.48 30.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -176.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -116.28 117.29 29.58 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 124.656 1.183 . . . . 0.0 108.068 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 57.4 mt -98.99 112.64 24.7 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 171.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.3 ttm180 -81.47 112.56 18.83 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 166.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.9 pp -116.72 166.51 10.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 C-N-CA 124.951 1.301 . . . . 0.0 108.618 -178.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.5 mt -105.07 117.15 59.29 Favored Pre-proline 0 N--CA 1.464 0.26 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 174.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.39 -172.85 1.57 Allowed 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.988 3.125 . . . . 0.0 109.22 174.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -154.28 162.28 41.27 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.529 -0.732 . . . . 0.0 109.707 179.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -127.9 -1.18 5.95 Favored 'General case' 0 CA--C 1.537 0.447 0 N-CA-C 112.876 0.695 . . . . 0.0 112.876 165.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -106.89 5.56 28.49 Favored 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 125.949 1.699 . . . . 0.0 111.917 -163.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -75.09 143.48 43.38 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 124.756 1.222 . . . . 0.0 108.131 172.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -149.58 170.95 17.47 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 127.943 2.497 . . . . 0.0 105.567 165.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -50.55 108.16 0.97 Allowed Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 119.817 1.19 . . . . 0.0 113.076 -171.498 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -67.18 -50.74 0.93 Allowed 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 121.77 1.646 . . . . 0.0 110.429 179.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 8.6 m 53.1 176.47 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 125.265 1.426 . . . . 0.0 113.003 -167.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 159.85 173.32 28.18 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 107.936 -2.066 . . . . 0.0 107.936 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -78.39 56.81 5.98 Favored 'Trans proline' 0 CA--C 1.542 0.917 0 C-N-CA 123.223 2.615 . . . . 0.0 110.002 175.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.1 t -156.76 -178.86 7.67 Favored 'General case' 0 C--O 1.238 0.486 0 C-N-CA 123.768 0.827 . . . . 0.0 111.234 -177.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 2.4 p -139.72 31.82 2.04 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 127.028 2.131 . . . . 0.0 111.566 -168.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.185 0 N-CA-C 108.488 -1.845 . . . . 0.0 108.488 165.642 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.886 0 N-CA-C 108.295 -1.922 . . . . 0.0 108.295 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 11.7 t -131.04 158.17 41.06 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 124.846 1.258 . . . . 0.0 107.784 177.194 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.2 t -61.72 -60.02 4.3 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 123.488 0.715 . . . . 0.0 110.494 -177.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.78 -171.34 53.61 Favored Glycine 0 CA--C 1.53 1.016 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -169.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.6 t 55.52 -167.54 0.1 Allowed 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.782 1.633 . . . . 0.0 113.444 175.036 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -165.04 157.0 15.4 Favored 'General case' 0 C--O 1.239 0.52 0 C-N-CA 127.168 2.187 . . . . 0.0 106.226 160.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -176.82 33.64 0.08 OUTLIER Glycine 0 C--N 1.335 0.509 0 O-C-N 120.496 -1.378 . . . . 0.0 113.617 -178.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -76.71 -47.93 20.42 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 118.506 1.153 . . . . 0.0 111.915 -168.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 88.2 mt -100.56 110.59 22.76 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.939 1.296 . . . . 0.0 110.715 -168.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 25.8 mp0 -63.59 147.9 50.25 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.712 1.205 . . . . 0.0 110.602 173.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 36.9 p -145.49 154.0 41.75 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.214 1.406 . . . . 0.0 109.212 171.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.3 t -115.57 173.91 6.29 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.532 1.133 . . . . 0.0 109.592 163.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -134.85 94.68 3.2 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 126.624 1.97 . . . . 0.0 108.376 168.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.6 t -99.22 108.07 21.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 O-C-N 120.68 -1.262 . . . . 0.0 107.94 -170.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.5 p -105.48 121.04 57.15 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 CA-C-N 118.841 0.746 . . . . 0.0 111.315 -170.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.6 mt -134.13 129.21 53.61 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 126.089 1.756 . . . . 0.0 109.363 -169.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 37.8 m-70 -108.54 144.18 36.56 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.214 1.806 . . . . 0.0 111.443 -177.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 18.4 ptt180 -126.51 175.59 7.79 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 125.511 1.525 . . . . 0.0 111.018 176.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.445 ' HE3' ' OE2' ' A' ' 22' ' ' GLU . 0.0 OUTLIER -81.05 170.06 16.69 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 160.007 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -68.98 -35.7 77.02 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.609 -0.682 . . . . 0.0 111.709 177.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 68.9 m-20 -71.27 -47.32 57.65 Favored 'General case' 0 C--O 1.232 0.15 0 O-C-N 122.196 -0.315 . . . . 0.0 111.354 -171.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.445 ' OE2' ' HE3' ' A' ' 19' ' ' LYS . 5.3 pt-20 -76.84 166.96 22.64 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.518 0.675 . . . . 0.0 110.456 -176.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.61 -178.07 49.4 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 167.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 73.9 m-85 -70.6 145.28 50.81 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 104.255 -2.498 . . . . 0.0 104.255 149.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.4 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -84.81 44.83 3.42 Favored Glycine 0 C--O 1.221 -0.705 0 CA-C-O 117.529 -1.706 . . . . 0.0 112.519 -176.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -131.48 160.64 34.58 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 119.251 1.526 . . . . 0.0 110.519 179.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.9 t -136.88 127.32 40.18 Favored 'Isoleucine or valine' 0 C--O 1.239 0.53 0 C-N-CA 125.004 1.322 . . . . 0.0 108.055 177.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.1 mt -74.39 143.53 13.39 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 170.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.47 HD11 ' HE3' ' A' ' 46' ' ' LYS . 20.4 pt -127.32 176.66 6.88 Favored 'Isoleucine or valine' 0 C--O 1.243 0.712 0 C-N-CA 124.25 1.02 . . . . 0.0 109.518 162.539 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -128.14 114.32 16.86 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.376 1.07 . . . . 0.0 108.747 164.092 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -141.92 120.16 12.24 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.2 mp -98.44 -78.82 0.48 Allowed 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 107.221 -1.399 . . . . 0.0 107.221 176.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 43.9 t-20 44.77 92.73 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 127.842 2.457 . . . . 0.0 112.123 -168.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -62.86 135.6 96.07 Favored Pre-proline 0 C--N 1.342 0.266 0 O-C-N 121.796 -0.565 . . . . 0.0 109.688 -163.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -79.44 31.12 0.47 Allowed 'Trans proline' 0 CA--C 1.539 0.759 0 C-N-CA 124.023 3.149 . . . . 0.0 111.542 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 47.9 -157.49 0.05 Allowed 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 123.646 0.778 . . . . 0.0 111.276 -152.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 41.6 t 58.31 165.24 0.04 OUTLIER 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.977 1.711 . . . . 0.0 110.504 -147.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -96.47 -34.0 5.98 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 171.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 70.8 m -77.13 110.07 11.49 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.481 -1.674 . . . . 0.0 106.481 160.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 66.6 p -116.17 101.87 9.09 Favored 'General case' 0 C--O 1.239 0.507 0 CA-C-N 119.229 0.922 . . . . 0.0 110.357 -171.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 12.8 pt -67.99 110.62 2.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 177.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.21 156.53 43.03 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.936 2.095 . . . . 0.0 107.035 177.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 77.9 t -126.42 146.73 57.5 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-O 117.685 -1.15 . . . . 0.0 108.748 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_endo -62.61 -74.87 0.02 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.463 2.109 . . . . 0.0 111.292 168.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.4 m80 -85.42 126.51 33.84 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 120.07 1.305 . . . . 0.0 110.886 -174.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.47 ' HE3' HD11 ' A' ' 29' ' ' ILE . 11.2 pttp -144.32 162.52 36.21 Favored 'General case' 0 N--CA 1.465 0.281 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 166.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 23.0 mm -62.85 120.5 9.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 164.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -98.32 -30.05 7.18 Favored Glycine 0 CA--C 1.524 0.598 0 CA-C-N 118.455 0.571 . . . . 0.0 113.129 170.187 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 59.3 ttm-85 -151.97 153.98 35.14 Favored 'General case' 0 CA--C 1.514 -0.429 0 CA-C-N 118.635 1.217 . . . . 0.0 108.221 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 13.4 mt -120.15 149.92 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 O-C-N 124.614 1.196 . . . . 0.0 108.184 166.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.2 mp -78.58 127.29 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.825 0 C-N-CA 126.139 1.776 . . . . 0.0 107.25 168.516 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -59.42 137.51 57.97 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.44 6.1 89.04 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-O 118.461 -1.188 . . . . 0.0 113.331 174.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.4 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 76.6 p -87.3 166.52 25.37 Favored Pre-proline 0 CA--C 1.53 0.208 0 CA-C-N 119.992 1.896 . . . . 0.0 112.705 -175.2 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -58.16 -25.89 73.61 Favored 'Trans proline' 0 N--CA 1.452 -0.931 0 C-N-CA 122.121 1.881 . . . . 0.0 113.394 167.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.95 -60.62 2.85 Favored 'General case' 0 C--N 1.342 0.247 0 CA-C-N 119.283 0.947 . . . . 0.0 108.859 174.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -57.85 -46.38 84.86 Favored 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 122.981 0.512 . . . . 0.0 110.962 -176.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 78.8 mtt-85 -65.78 -18.21 65.17 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 124.885 1.274 . . . . 0.0 112.676 -176.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 9.0 t -63.12 -33.34 75.25 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 119.245 0.93 . . . . 0.0 110.11 175.266 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 58.23 -31.79 0.04 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 129.584 3.154 . . . . 0.0 114.901 -168.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.5 mtpt -61.55 -8.44 4.33 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.999 1.72 . . . . 0.0 112.093 170.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 21.2 tp -134.75 116.32 14.74 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 126.075 1.75 . . . . 0.0 108.981 -176.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 27.4 mmmt -137.4 171.63 14.19 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 123.535 1.636 . . . . 0.0 111.831 176.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 46.5 t -68.64 110.74 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 113.881 -1.509 . . . . 0.0 108.383 -178.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 138.35 -23.5 2.99 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -177.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -64.99 100.14 0.4 Allowed 'General case' 0 C--O 1.233 0.227 0 CA-C-O 122.114 0.959 . . . . 0.0 109.843 -174.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.9 mtm-85 -48.43 137.62 11.19 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 128.048 2.539 . . . . 0.0 109.602 156.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.8 mt -122.86 143.96 33.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.195 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -173.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.7 mt -107.24 -42.34 4.88 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 125.732 1.613 . . . . 0.0 110.379 175.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -154.68 165.99 34.81 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 123.015 0.526 . . . . 0.0 112.04 -170.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 51.4 t -125.71 123.06 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 C-N-CA 128.141 2.577 . . . . 0.0 104.95 174.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 42.78 39.31 1.64 Allowed 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.212 1.805 . . . . 0.0 111.412 -172.511 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 81.26 -9.75 52.74 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-O 117.638 -1.645 . . . . 0.0 115.173 177.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 7.6 mm-40 -75.07 119.59 19.44 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 120.558 2.179 . . . . 0.0 108.557 172.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.9 m -55.21 127.76 30.79 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 171.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 15.3 pt -100.79 -5.38 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 C-N-CA 123.331 0.652 . . . . 0.0 112.265 -178.138 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.1 mt -59.13 142.48 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 167.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 73.2 -20.06 0.3 Allowed 'General case' 0 CA--C 1.533 0.294 0 C-N-CA 126.497 1.919 . . . . 0.0 115.325 167.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 14.0 mtp -64.25 148.3 95.97 Favored Pre-proline 0 CA--C 1.539 0.522 0 CA-C-N 119.477 1.035 . . . . 0.0 109.68 167.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -72.57 161.17 44.79 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 122.401 2.067 . . . . 0.0 110.064 169.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -55.28 -47.79 75.0 Favored 'General case' 0 C--O 1.225 -0.209 0 C-N-CA 123.661 0.784 . . . . 0.0 111.016 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -53.76 -40.62 66.37 Favored 'General case' 0 CA--C 1.527 0.092 0 C-N-CA 123.236 0.614 . . . . 0.0 112.174 -176.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -72.19 -42.37 65.9 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 119.259 -0.4 . . . . 0.0 110.478 -175.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 46.9 mt -66.59 -37.28 79.24 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 124.87 1.268 . . . . 0.0 108.846 176.238 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 38.2 t -65.16 -45.63 93.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.484 0 O-C-N 120.274 -1.516 . . . . 0.0 109.841 175.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.3 ttpt -62.41 -42.53 99.51 Favored 'General case' 0 C--O 1.22 -0.482 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.344 175.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.12 -48.01 23.16 Favored 'General case' 0 C--O 1.226 -0.162 0 C-N-CA 126.305 1.842 . . . . 0.0 111.62 171.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 74.4 mt -76.22 -31.89 21.76 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 O-C-N 121.592 -0.692 . . . . 0.0 109.607 -174.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.3 tttp -66.42 -46.08 77.75 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.58 1.082 . . . . 0.0 110.125 170.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -60.87 -18.15 54.47 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 128.134 2.574 . . . . 0.0 111.984 175.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -58.68 -25.91 63.3 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.816 0.446 . . . . 0.0 111.336 169.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 66.86 57.97 8.97 Favored Glycine 0 C--N 1.339 0.71 0 O-C-N 121.338 -0.852 . . . . 0.0 111.063 170.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 48.0 mt 75.48 -38.52 0.36 Allowed 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 128.428 2.691 . . . . 0.0 112.193 -174.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.01 121.43 41.77 Favored 'General case' 0 C--N 1.322 -0.61 0 O-C-N 123.604 0.565 . . . . 0.0 111.062 -173.488 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.5 p -124.77 121.75 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 178.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.2 m -89.49 133.68 34.45 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 164.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 27.7 mt -123.76 139.36 54.06 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 -177.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.8 ttm180 -113.72 115.86 28.5 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -112.52 166.9 6.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 C-N-CA 126.682 1.993 . . . . 0.0 108.083 177.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 70.0 mt -72.2 -59.85 2.51 Favored Pre-proline 0 CA--C 1.54 0.586 0 CA-C-O 117.792 -1.099 . . . . 0.0 109.615 177.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -59.79 167.49 6.85 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 121.682 1.588 . . . . 0.0 115.827 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -146.65 126.81 13.8 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 127.146 2.179 . . . . 0.0 105.55 -175.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -86.79 -24.7 24.95 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.91 0.862 . . . . 0.0 111.34 172.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -84.77 -5.34 59.32 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 125.48 1.512 . . . . 0.0 112.791 -161.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.3 mt -123.62 69.4 1.03 Allowed 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 -175.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -64.54 -54.04 38.5 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.77 0.828 . . . . 0.0 110.509 -175.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.6 m -164.28 151.2 9.98 Favored Pre-proline 0 CA--C 1.542 0.673 0 C-N-CA 126.275 1.83 . . . . 0.0 109.141 170.073 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -79.46 72.55 6.46 Favored 'Trans proline' 0 CA--C 1.539 0.75 0 C-N-CA 124.458 3.439 . . . . 0.0 111.21 173.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 6.9 m 61.34 14.77 5.96 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 114.596 1.332 . . . . 0.0 114.596 165.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -68.25 146.13 45.49 Favored Glycine 0 CA--C 1.533 1.186 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 177.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -62.38 159.26 36.5 Favored 'Trans proline' 0 C--O 1.238 0.524 0 C-N-CA 124.038 3.158 . . . . 0.0 113.61 -174.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 7.8 m -141.31 -19.0 0.78 Allowed 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -174.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.1 m -165.41 -177.28 4.39 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 127.187 2.195 . . . . 0.0 106.939 178.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.682 0 N-CA-C 107.401 -2.279 . . . . 0.0 107.401 159.887 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.896 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 49.7 m -94.86 162.57 13.7 Favored 'General case' 0 C--O 1.234 0.25 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 156.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 21.2 p -157.74 -176.91 6.2 Favored 'General case' 0 C--O 1.237 0.447 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 171.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 175.18 -138.98 4.55 Favored Glycine 0 N--CA 1.446 -0.666 0 N-CA-C 106.691 -2.563 . . . . 0.0 106.691 -177.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 77.8 p -152.26 168.43 25.4 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 167.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.3 m -160.85 130.73 5.01 Favored 'General case' 0 CA--C 1.519 -0.217 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 164.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 142.07 105.77 0.57 Allowed Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 58.6 m -150.01 -88.32 0.07 Allowed 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 161.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 14.2 tp -61.19 150.1 35.45 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 124.005 0.922 . . . . 0.0 111.277 -173.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -67.39 151.64 47.08 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 122.403 1.096 . . . . 0.0 110.861 172.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 38.4 p -144.68 170.03 16.87 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 126.491 1.917 . . . . 0.0 107.327 -173.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 23.4 m -137.98 162.3 34.45 Favored 'General case' 0 C--N 1.328 -0.34 0 O-C-N 120.865 -1.147 . . . . 0.0 108.333 164.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -131.72 95.72 3.79 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 127.691 2.396 . . . . 0.0 107.1 -167.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 19.6 t -93.72 94.83 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 -176.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.9 p -80.88 129.25 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 172.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 67.0 mt -135.17 147.15 29.29 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 175.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.6 m-70 -113.4 167.31 10.69 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.008 1.323 . . . . 0.0 109.713 173.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 46.2 ptt85 -145.58 -179.88 6.97 Favored 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 125.996 1.718 . . . . 0.0 107.076 172.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.67 159.29 15.6 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 173.1 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -70.13 -14.77 62.8 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 120.791 -1.193 . . . . 0.0 112.243 -178.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -80.08 7.63 8.78 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.95 1.3 . . . . 0.0 112.264 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -164.62 170.14 16.1 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 120.249 -1.532 . . . . 0.0 109.863 -167.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.2 -167.81 29.12 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 125.399 1.476 . . . . 0.0 110.909 175.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -85.98 159.44 19.62 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 164.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.88 39.28 2.86 Favored Glycine 0 C--O 1.222 -0.623 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.922 -178.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -118.58 161.35 20.2 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 119.587 1.694 . . . . 0.0 109.387 169.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.8 t -140.81 129.79 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 -178.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 61.5 mt -97.4 145.47 9.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.2 pt -136.51 166.54 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 C-N-CA 125.249 1.42 . . . . 0.0 109.746 168.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.0 t -102.23 177.35 4.91 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 126.944 2.098 . . . . 0.0 108.67 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.1 m -134.21 10.47 3.83 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 125.101 1.36 . . . . 0.0 112.274 164.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 25.5 tp -75.69 63.53 1.61 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.039 0.936 . . . . 0.0 109.493 173.63 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -169.89 139.59 1.93 Allowed 'General case' 0 C--O 1.234 0.241 0 C-N-CA 128.344 2.658 . . . . 0.0 106.676 166.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 6.0 mtt-85 179.2 141.22 0.29 Allowed Pre-proline 0 N--CA 1.466 0.356 0 C-N-CA 127.675 2.39 . . . . 0.0 106.57 154.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.68 94.33 0.86 Allowed 'Trans proline' 0 N--CA 1.455 -0.756 0 C-N-CA 122.988 2.458 . . . . 0.0 107.677 176.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 158.34 -60.49 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 128.717 2.807 . . . . 0.0 107.108 -166.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 69.6 m 53.72 71.33 0.51 Allowed 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.078 1.351 . . . . 0.0 112.358 -163.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.55 11.73 0.99 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.223 1.392 . . . . 0.0 113.842 -176.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 67.8 m -66.84 130.46 43.24 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 118.502 1.151 . . . . 0.0 108.335 170.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 12.7 p -85.09 163.07 19.02 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 125.223 1.409 . . . . 0.0 108.398 161.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 13.3 mm 52.09 35.02 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 124.498 1.119 . . . . 0.0 110.173 178.072 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.4 m -63.74 135.14 56.45 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 120.116 -1.615 . . . . 0.0 106.882 169.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 13.9 m -126.98 157.88 70.55 Favored Pre-proline 0 N--CA 1.446 -0.658 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 173.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -75.66 -37.48 1.7 Allowed 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 123.275 2.65 . . . . 0.0 111.492 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -140.39 132.59 28.1 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 125.206 1.403 . . . . 0.0 108.142 -173.371 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.0 pttm -156.89 166.93 31.98 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 125.698 1.599 . . . . 0.0 107.734 174.249 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 26.5 mm -72.71 103.69 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 C-N-CA 124.571 1.148 . . . . 0.0 108.87 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -67.91 -42.58 85.47 Favored Glycine 0 N--CA 1.451 -0.33 0 O-C-N 121.284 -0.885 . . . . 0.0 111.366 172.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 23.6 ttm105 -158.1 152.12 24.09 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -165.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 16.1 mt -122.0 150.49 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 168.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 31.9 mm -87.82 136.47 23.08 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.4 t0 -66.66 148.89 51.28 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-O 121.152 0.501 . . . . 0.0 111.185 -176.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.48 7.93 17.12 Favored Glycine 0 CA--C 1.527 0.834 0 C-N-CA 124.519 1.057 . . . . 0.0 114.369 175.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 79.4 p -76.0 167.98 31.88 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 118.234 1.017 . . . . 0.0 111.144 -176.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -57.8 -27.71 79.26 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 122.149 1.899 . . . . 0.0 112.239 165.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -70.83 -51.96 23.38 Favored 'General case' 0 C--N 1.341 0.204 0 CA-C-N 119.996 1.271 . . . . 0.0 110.171 174.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -57.83 -44.68 86.63 Favored 'General case' 0 N--CA 1.465 0.311 0 C-N-CA 123.343 0.657 . . . . 0.0 110.674 -179.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 27.4 mtt-85 -75.86 -5.53 46.46 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 124.634 1.174 . . . . 0.0 112.706 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.9 t -73.21 -35.97 66.43 Favored 'General case' 0 C--O 1.225 -0.2 0 CA-C-O 117.617 -1.182 . . . . 0.0 110.994 178.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 59.49 -24.94 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 127.985 2.514 . . . . 0.0 116.214 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 6.1 mtpt -66.48 -17.29 64.71 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 120.325 1.421 . . . . 0.0 111.975 161.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.78 119.0 34.08 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -178.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.51 171.47 14.21 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-O 122.563 1.173 . . . . 0.0 109.049 -178.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 78.3 t -72.43 108.14 3.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 O-C-N 120.734 -1.229 . . . . 0.0 108.693 -178.399 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 130.39 -3.94 5.87 Favored Glycine 0 CA--C 1.521 0.418 0 C-N-CA 126.261 1.886 . . . . 0.0 111.275 173.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.5 m-20 -71.31 95.86 1.36 Allowed 'General case' 0 C--O 1.234 0.268 0 CA-C-N 118.585 1.192 . . . . 0.0 108.148 172.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 38.5 mtt85 -53.01 143.3 17.61 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 127.382 2.273 . . . . 0.0 109.116 170.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 34.6 mt -116.84 149.53 19.06 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -168.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.86 -46.05 0.87 Allowed 'General case' 0 N--CA 1.463 0.211 0 C-N-CA 126.336 1.854 . . . . 0.0 109.967 -164.211 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -153.52 168.55 25.77 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.046 0.938 . . . . 0.0 110.012 176.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 80.6 t -133.6 120.99 39.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 174.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 23.2 m-20 48.73 41.22 17.6 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.308 1.043 . . . . 0.0 110.398 -172.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.13 -11.39 3.82 Favored Glycine 0 CA--C 1.527 0.792 0 C-N-CA 126.907 2.194 . . . . 0.0 116.467 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.5 tp-100 -77.13 121.53 23.73 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 120.146 1.973 . . . . 0.0 107.257 -177.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 p -63.29 112.33 2.65 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.32 1.048 . . . . 0.0 110.992 -174.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 1.7 pp -73.34 14.25 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 125.758 1.623 . . . . 0.0 113.188 175.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 60.6 mt -76.78 -86.16 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 O-C-N 121.199 -0.938 . . . . 0.0 109.353 -158.414 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -77.53 -8.72 58.24 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.416 1.086 . . . . 0.0 111.226 176.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 17.1 ttt -53.65 142.26 42.82 Favored Pre-proline 0 N--CA 1.433 -1.303 0 C-N-CA 128.22 2.608 . . . . 0.0 110.924 -177.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -60.66 139.58 86.47 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 121.873 1.715 . . . . 0.0 110.639 174.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -59.3 -39.87 84.38 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.541 0.736 . . . . 0.0 111.587 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.39 -23.49 63.73 Favored 'General case' 0 CA--C 1.53 0.177 0 O-C-N 122.034 -0.416 . . . . 0.0 111.986 175.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -73.72 -46.54 45.43 Favored 'General case' 0 C--O 1.223 -0.293 0 CA-C-O 118.635 -0.697 . . . . 0.0 109.713 179.089 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 49.1 mt -56.08 -40.32 63.34 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 126.432 1.893 . . . . 0.0 110.568 172.059 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 35.0 t -66.57 -43.89 90.36 Favored 'Isoleucine or valine' 0 C--O 1.238 0.451 0 O-C-N 120.109 -1.619 . . . . 0.0 110.75 176.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 6.6 tttt -54.82 -49.11 71.8 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 172.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -48.89 -39.38 25.75 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 129.23 3.012 . . . . 0.0 113.721 177.084 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.7 mt -75.9 -46.08 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 CA-C-N 118.791 0.723 . . . . 0.0 109.073 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -57.34 -51.21 70.29 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 119.002 0.819 . . . . 0.0 110.137 173.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -57.71 -19.28 26.17 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 128.69 2.796 . . . . 0.0 112.864 177.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -60.41 -26.87 67.01 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 119.253 0.933 . . . . 0.0 112.596 177.231 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.32 -151.36 18.28 Favored Glycine 0 C--N 1.341 0.822 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -173.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 72.9 mt -71.98 -33.04 67.82 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 117.626 0.713 . . . . 0.0 110.906 168.385 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.91 145.56 24.54 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 -178.739 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.6 p -140.98 143.24 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 168.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 23.7 m -114.57 102.69 10.29 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 174.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 61.3 mt -89.93 115.21 27.06 Favored 'General case' 0 CA--C 1.514 -0.427 0 N-CA-C 106.587 -1.634 . . . . 0.0 106.587 -174.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -86.4 112.14 21.18 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 -178.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -113.51 167.97 6.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 C-N-CA 124.709 1.203 . . . . 0.0 110.356 -174.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.9 mp -97.4 121.67 57.83 Favored Pre-proline 0 C--O 1.239 0.518 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 172.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -88.98 168.44 5.47 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 124.635 3.556 . . . . 0.0 111.431 169.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -133.8 157.22 46.44 Favored 'General case' 0 N--CA 1.447 -0.613 0 C-N-CA 126.148 1.779 . . . . 0.0 107.904 178.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -136.04 -0.05 2.57 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 126.384 1.874 . . . . 0.0 110.438 -179.55 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.09 50.26 0.52 Allowed 'General case' 0 N--CA 1.453 -0.3 0 CA-C-O 123.877 1.799 . . . . 0.0 106.691 -167.323 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 2.4 tp -122.89 127.08 48.5 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 104.699 -2.334 . . . . 0.0 104.699 177.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 53.35 56.23 7.67 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 127.608 2.363 . . . . 0.0 113.117 -177.184 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -53.27 126.26 44.96 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-O 117.657 -1.163 . . . . 0.0 108.815 170.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -64.24 97.1 0.24 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 123.393 2.729 . . . . 0.0 111.188 -172.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 3.2 p -159.75 170.78 20.79 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.728 1.611 . . . . 0.0 108.006 -176.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 134.45 85.66 0.23 Allowed Glycine 0 CA--C 1.528 0.865 0 CA-C-O 118.583 -1.12 . . . . 0.0 111.511 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.64 -21.99 33.28 Favored 'Trans proline' 0 CA--C 1.534 0.509 0 C-N-CA 122.517 2.145 . . . . 0.0 113.292 -176.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 14.7 m 58.39 -179.8 0.07 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.811 1.645 . . . . 0.0 112.556 -170.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 73.6 m -155.65 -50.24 0.08 Allowed 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 126.149 1.78 . . . . 0.0 106.393 160.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.254 1.372 0 N-CA-C 106.432 -2.667 . . . . 0.0 106.432 139.772 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.506 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.3 p -121.53 175.5 6.17 Favored 'General case' 0 C--O 1.24 0.572 0 C-N-CA 126.64 1.976 . . . . 0.0 107.708 173.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.7 m -65.52 164.74 13.46 Favored 'General case' 0 CA--C 1.535 0.369 0 O-C-N 121.238 -0.914 . . . . 0.0 109.757 166.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.18 -115.51 0.67 Allowed Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -177.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.6 m -65.47 142.95 57.98 Favored 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 123.751 0.82 . . . . 0.0 110.205 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 45.09 68.91 0.49 Allowed 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 125.727 1.611 . . . . 0.0 112.903 -172.319 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.74 -88.53 0.11 Allowed Glycine 0 N--CA 1.452 -0.289 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 165.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 38.4 m 56.35 -178.63 0.05 OUTLIER 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.998 1.319 . . . . 0.0 112.344 -170.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.2 mp 39.1 76.66 0.06 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.743 2.417 . . . . 0.0 111.422 179.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 45.4 mt-30 -51.16 157.09 0.96 Allowed 'General case' 0 C--O 1.239 0.546 0 CA-C-O 122.731 1.253 . . . . 0.0 113.212 -174.092 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 74.0 p -142.59 169.84 16.82 Favored 'General case' 0 N--CA 1.444 -0.742 0 C-N-CA 127.286 2.235 . . . . 0.0 108.558 -175.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 m -132.18 155.26 48.52 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 144.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -93.21 143.11 26.58 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 105.632 -1.988 . . . . 0.0 105.632 160.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.7 t -129.96 102.06 6.74 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 169.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.6 p -82.95 144.87 9.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 168.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.1 mt -136.81 152.26 28.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 C-N-CA 127.487 2.315 . . . . 0.0 104.933 173.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 83.0 m-70 -129.92 136.56 49.62 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 125.618 1.567 . . . . 0.0 109.122 -168.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.1 ptt180 -131.39 176.6 8.16 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 120.605 1.548 . . . . 0.0 111.195 -178.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.2 161.98 14.04 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.07 0.948 . . . . 0.0 109.289 172.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -70.55 -15.78 62.81 Favored 'General case' 0 CA--C 1.538 0.502 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -89.2 -10.64 46.32 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.149 0.886 . . . . 0.0 112.642 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 25.9 pt-20 -127.57 175.38 8.3 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 120.344 1.429 . . . . 0.0 110.974 -166.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.01 176.79 19.44 Favored Glycine 0 CA--C 1.531 1.036 0 C-N-CA 124.899 1.238 . . . . 0.0 111.716 177.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 57.9 m-85 -89.3 137.96 31.86 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.024 -1.473 . . . . 0.0 107.024 163.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.76 66.9 0.32 Allowed Glycine 0 C--O 1.222 -0.603 0 C-N-CA 124.571 1.081 . . . . 0.0 111.101 -176.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -133.85 146.31 50.5 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 124.814 1.246 . . . . 0.0 108.459 167.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.6 t -121.54 144.87 29.25 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 173.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.6 mp -118.43 110.62 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 -173.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 31.1 pt -107.64 169.37 2.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 C-N-CA 123.861 0.864 . . . . 0.0 111.072 -169.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 t 75.85 -177.83 0.14 Allowed 'General case' 0 C--O 1.238 0.464 0 C-N-CA 127.168 2.187 . . . . 0.0 109.452 -167.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.1 p -158.23 177.44 11.28 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 128.858 2.863 . . . . 0.0 106.033 160.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.3 tt -146.85 112.49 5.64 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 120.324 1.42 . . . . 0.0 107.578 161.317 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.36 145.56 43.72 Favored 'General case' 0 C--O 1.233 0.23 0 C-N-CA 123.523 0.729 . . . . 0.0 110.182 -175.624 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 94.5 mtt-85 62.74 162.15 0.12 Allowed Pre-proline 0 CA--C 1.542 0.648 0 C-N-CA 126.978 2.111 . . . . 0.0 111.378 -177.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -69.43 -34.19 16.19 Favored 'Trans proline' 0 N--CA 1.459 -0.511 0 CA-C-O 117.56 -1.1 . . . . 0.0 113.625 -168.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 60.04 108.86 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 126.25 1.82 . . . . 0.0 110.997 -168.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.3 t -79.05 91.55 4.89 Favored 'General case' 0 N--CA 1.45 -0.444 0 O-C-N 121.275 -0.891 . . . . 0.0 109.576 177.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 150.27 -152.39 24.28 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 111.891 -0.483 . . . . 0.0 111.891 177.153 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 66.7 m -75.62 149.95 38.11 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 125.789 1.635 . . . . 0.0 108.394 168.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.4 p -124.05 110.12 14.35 Favored 'General case' 0 C--N 1.332 -0.168 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -176.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.2 mm -62.7 -72.03 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -174.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 20.5 m -80.94 114.77 20.05 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 107.869 -1.159 . . . . 0.0 107.869 -178.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.9 p -65.21 152.25 92.1 Favored Pre-proline 0 CA--C 1.552 1.02 0 C-N-CA 123.716 0.807 . . . . 0.0 109.765 -174.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -78.8 -31.88 2.24 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.614 2.21 . . . . 0.0 114.026 176.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -133.55 121.16 21.73 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 119.734 1.152 . . . . 0.0 108.098 -177.324 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.9 pttt -145.72 149.46 34.45 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 106.9 -1.519 . . . . 0.0 106.9 170.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 17.1 mm -63.03 125.84 20.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 174.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -98.41 -37.51 4.27 Favored Glycine 0 C--N 1.333 0.388 0 C-N-CA 123.88 0.753 . . . . 0.0 112.773 178.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 37.6 ttm180 -158.15 149.14 20.85 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 125.198 1.399 . . . . 0.0 107.906 -174.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.2 mt -127.34 124.88 64.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 C-N-CA 126.598 1.959 . . . . 0.0 106.536 172.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.6 mp -55.59 132.91 19.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.339 0 C-N-CA 125.436 1.494 . . . . 0.0 109.828 168.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -57.42 127.5 32.3 Favored 'General case' 0 C--O 1.24 0.572 0 C-N-CA 124.991 1.316 . . . . 0.0 109.309 174.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.04 5.52 89.55 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 124.447 1.023 . . . . 0.0 113.462 174.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.2 p -65.26 162.69 38.08 Favored Pre-proline 0 CA--C 1.532 0.288 0 CA-C-N 119.21 1.505 . . . . 0.0 110.938 173.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -60.5 -28.95 87.62 Favored 'Trans proline' 0 N--CA 1.45 -1.045 0 C-N-CA 121.781 1.654 . . . . 0.0 112.109 168.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.25 -52.84 63.57 Favored 'General case' 0 C--N 1.344 0.33 0 CA-C-N 119.337 0.972 . . . . 0.0 110.282 172.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -61.55 -51.96 66.42 Favored 'General case' 0 N--CA 1.462 0.146 0 O-C-N 123.285 0.366 . . . . 0.0 110.817 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 90.5 mtt-85 -63.93 -28.9 70.15 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 118.409 -0.805 . . . . 0.0 112.059 -173.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 42.3 t -60.94 -19.1 60.26 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.627 1.171 . . . . 0.0 112.573 174.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 55.78 22.4 5.49 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 125.389 1.475 . . . . 0.0 114.197 171.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 44.5 mtmt -130.1 8.24 5.15 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 124.668 1.187 . . . . 0.0 113.273 178.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -141.06 119.27 12.07 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.13 165.11 24.0 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 119.016 0.826 . . . . 0.0 110.606 176.579 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . 0.263 0.2 OUTLIER -56.98 141.15 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 O-C-N 121.201 -0.937 . . . . 0.0 109.846 172.684 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.2 -6.97 78.7 Favored Glycine 0 CA--C 1.524 0.655 0 CA-C-O 118.215 -1.325 . . . . 0.0 111.651 -174.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 41.8 m-20 -74.59 96.97 3.06 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 119.244 1.522 . . . . 0.0 107.287 168.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 42.8 mtm180 -45.05 130.87 7.61 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 126.882 2.073 . . . . 0.0 110.061 160.034 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 7.1 mt -111.76 143.99 20.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -177.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 tp -112.81 -44.98 3.24 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 127.343 2.257 . . . . 0.0 108.47 -171.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -155.71 170.88 21.02 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.546 0.739 . . . . 0.0 111.474 -177.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.9 p -131.22 125.39 57.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 C-N-CA 125.154 1.382 . . . . 0.0 107.992 174.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 64.2 m-20 46.64 45.65 14.41 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 124.487 1.115 . . . . 0.0 108.957 -170.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 68.3 -2.51 7.15 Favored Glycine 0 CA--C 1.538 1.477 0 C-N-CA 125.81 1.672 . . . . 0.0 116.772 -175.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -91.13 135.32 33.85 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 121.465 2.632 . . . . 0.0 110.359 -174.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -72.41 109.24 5.97 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 126.109 1.764 . . . . 0.0 112.316 -171.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 7.4 pt -87.74 -5.05 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 O-C-N 121.348 -0.845 . . . . 0.0 112.51 -172.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.455 HD12 ' H ' ' A' ' 77' ' ' ILE . 3.6 mp -65.56 -48.23 83.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 C-N-CA 124.626 1.17 . . . . 0.0 110.207 173.097 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 63.6 m-80 -93.45 -26.6 17.13 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 118.523 -0.751 . . . . 0.0 112.255 -162.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 3.9 mtp -70.27 160.53 80.62 Favored Pre-proline 0 CA--C 1.534 0.34 0 C-N-CA 124.685 1.194 . . . . 0.0 112.398 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -71.36 146.18 49.95 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 121.822 1.681 . . . . 0.0 109.764 166.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -49.61 -38.6 32.43 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.765 1.226 . . . . 0.0 111.68 178.253 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -65.76 -30.13 70.75 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 124.152 0.981 . . . . 0.0 113.366 -178.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -82.01 -37.91 25.84 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 119.482 1.037 . . . . 0.0 109.908 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.7 mt -60.5 -36.32 68.95 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 C-N-CA 124.047 0.939 . . . . 0.0 109.659 172.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.9 t -63.79 -51.35 70.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 O-C-N 120.542 -1.349 . . . . 0.0 110.24 170.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -51.88 -46.97 64.72 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 118.138 0.426 . . . . 0.0 111.406 178.543 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.45 -36.11 66.2 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 127.686 2.394 . . . . 0.0 113.602 -179.446 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 86.1 mt -76.7 -48.42 26.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.157 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 59.2 tttt -55.7 -44.86 77.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 122.882 0.473 . . . . 0.0 110.879 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -63.68 -26.9 68.87 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 125.251 1.42 . . . . 0.0 112.27 177.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.39 -28.41 69.25 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 118.195 0.452 . . . . 0.0 110.519 176.098 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.16 -106.88 2.93 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 125.385 1.469 . . . . 0.0 109.708 174.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 81.5 mt -100.35 -36.27 9.3 Favored 'General case' 0 CA--C 1.504 -0.812 0 C-N-CA 123.137 0.575 . . . . 0.0 110.758 -170.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -93.73 143.65 26.12 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 170.325 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.2 p -144.21 138.43 24.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 165.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 m -104.79 130.02 52.96 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 179.125 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 26.7 mt -114.4 117.85 32.21 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 124.642 1.177 . . . . 0.0 107.876 177.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -84.93 116.05 23.13 Favored 'General case' 0 C--O 1.232 0.175 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 174.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 pp -114.92 172.71 3.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 C-N-CA 125.867 1.667 . . . . 0.0 109.941 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 6.2 mt -113.21 123.06 34.17 Favored Pre-proline 0 C--O 1.237 0.447 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 169.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -83.84 -175.5 2.29 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 123.797 2.998 . . . . 0.0 110.446 178.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.83 151.51 47.08 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 122.749 0.419 . . . . 0.0 109.979 177.52 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -137.73 -3.53 1.85 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.449 0.699 . . . . 0.0 112.111 -178.526 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -158.0 12.57 0.2 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 124.075 0.95 . . . . 0.0 109.857 -165.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.6 tp -103.63 109.39 21.05 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 103.994 -2.595 . . . . 0.0 103.994 169.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -153.52 -153.42 0.47 Allowed 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 158.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.6 p -146.09 142.23 17.47 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 156.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -67.71 -55.88 0.25 Allowed 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.964 2.443 . . . . 0.0 110.85 -172.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 16.4 m 59.43 27.48 16.61 Favored 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 166.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -65.63 172.23 24.08 Favored Glycine 0 CA--C 1.534 1.252 0 O-C-N 121.572 -0.705 . . . . 0.0 111.637 167.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -65.99 162.49 35.07 Favored 'Trans proline' 0 N--CA 1.455 -0.753 0 C-N-CA 123.207 2.605 . . . . 0.0 110.792 177.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -156.7 -174.75 5.08 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.08 1.752 . . . . 0.0 107.105 179.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.0 p -66.16 150.3 48.98 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 162.079 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.159 0 N-CA-C 107.428 -2.269 . . . . 0.0 107.428 175.738 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.344 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 68.5 m -141.61 131.28 24.1 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 105.368 -2.086 . . . . 0.0 105.368 169.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.2 t -171.92 160.45 5.46 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 125.492 1.517 . . . . 0.0 107.596 -157.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -91.68 128.49 9.38 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 171.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.9 m -130.1 120.43 24.62 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 178.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.5 m -54.09 121.67 8.59 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 123.526 0.73 . . . . 0.0 110.223 -175.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.94 150.06 14.96 Favored Glycine 0 N--CA 1.449 -0.494 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 176.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.1 p -153.56 0.11 0.23 Allowed 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 124.553 1.141 . . . . 0.0 111.505 -165.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.8 tp -141.69 95.68 2.86 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 -170.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -103.37 -164.38 1.07 Allowed 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 125.311 1.445 . . . . 0.0 108.72 174.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 28.9 p -132.18 140.09 48.61 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 169.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.5 m -97.7 135.91 38.82 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 103.912 -2.625 . . . . 0.0 103.912 -174.217 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -112.92 103.99 11.97 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 18.2 t -87.49 139.29 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 105.532 -2.025 . . . . 0.0 105.532 177.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.4 p -129.11 143.24 41.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 168.037 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 4.0 mt -132.11 152.06 36.07 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 127.12 2.168 . . . . 0.0 105.421 173.528 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -131.32 130.11 42.31 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 126.646 1.978 . . . . 0.0 107.597 -176.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 34.0 ptt180 -126.11 179.89 5.03 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-N 120.311 1.414 . . . . 0.0 110.492 -175.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.1 164.61 12.09 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.281 1.033 . . . . 0.0 109.073 175.324 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -75.21 -12.95 60.4 Favored 'General case' 0 N--CA 1.466 0.367 0 O-C-N 120.795 -1.19 . . . . 0.0 111.764 176.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -74.44 -8.25 55.67 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 177.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 26.1 pt-20 -143.0 -175.71 4.62 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 124.082 0.953 . . . . 0.0 110.95 -162.136 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -116.89 -179.39 17.77 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 175.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -75.31 174.53 9.41 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 159.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.39 46.43 1.08 Allowed Glycine 0 C--O 1.222 -0.602 0 CA-C-O 118.817 -0.99 . . . . 0.0 111.694 -176.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -133.44 143.95 49.19 Favored 'General case' 0 C--O 1.239 0.506 0 CA-C-N 118.246 1.023 . . . . 0.0 108.29 177.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.6 t -119.21 114.35 44.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 106.009 -1.848 . . . . 0.0 106.009 -171.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 14.5 mt -78.88 136.92 22.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.299 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 174.249 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.0 pt -132.21 171.95 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.883 0 C-N-CA 125.557 1.543 . . . . 0.0 108.236 163.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 74.62 119.21 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 126.073 1.749 . . . . 0.0 108.62 178.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.9 p -149.98 162.66 39.93 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 125.177 1.391 . . . . 0.0 107.731 178.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 21.0 tp -123.53 172.1 9.0 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -123.18 93.23 3.89 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 124.697 1.199 . . . . 0.0 108.261 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 66.64 142.99 0.08 OUTLIER Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 128.648 2.779 . . . . 0.0 110.927 -166.359 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -81.16 78.0 3.8 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 122.2 1.933 . . . . 0.0 109.924 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -68.18 98.71 0.82 Allowed 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 170.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 8.3 t -69.29 108.03 3.51 Favored 'General case' 0 CA--C 1.537 0.447 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.03 -82.22 0.05 OUTLIER Glycine 0 C--N 1.336 0.541 0 CA-C-N 119.292 0.951 . . . . 0.0 111.842 -179.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 40.6 m -117.73 143.23 46.41 Favored 'General case' 0 CA--C 1.518 -0.282 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 172.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 36.1 p -123.48 105.97 10.23 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 -175.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.0 mm -92.76 -20.35 6.52 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 C-N-CA 123.546 0.738 . . . . 0.0 109.598 -177.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.4 p -133.7 -170.31 2.47 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 126.42 1.888 . . . . 0.0 109.345 -167.541 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.7 p -127.25 144.29 50.15 Favored Pre-proline 0 CA--C 1.534 0.362 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 163.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.2 89.69 0.79 Allowed 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 122.346 2.03 . . . . 0.0 108.66 160.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER 91.74 123.93 0.02 OUTLIER 'General case' 0 C--O 1.233 0.208 0 C-N-CA 130.123 3.369 . . . . 0.0 111.004 167.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -145.44 163.68 33.89 Favored 'General case' 0 C--O 1.233 0.209 0 C-N-CA 124.905 1.282 . . . . 0.0 108.4 163.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.8 mm -65.24 129.73 29.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 165.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -101.97 -49.6 1.24 Allowed Glycine 0 CA--C 1.524 0.628 0 C-N-CA 126.857 2.17 . . . . 0.0 111.774 173.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 49.6 ttt180 -144.38 161.81 38.04 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 125.325 1.45 . . . . 0.0 107.544 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.3 mt -133.46 150.74 32.46 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 C-N-CA 126.453 1.901 . . . . 0.0 107.707 174.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.0 mp -87.03 115.76 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.904 0 C-N-CA 126.57 1.948 . . . . 0.0 106.796 171.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 31.6 m-20 -52.57 142.98 16.74 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.183 0.993 . . . . 0.0 109.048 171.482 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.82 -12.99 26.55 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-O 118.218 -1.323 . . . . 0.0 113.471 175.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 74.3 p -65.85 167.03 12.59 Favored Pre-proline 0 C--O 1.238 0.478 0 CA-C-N 119.639 1.72 . . . . 0.0 111.829 -175.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -59.32 -29.1 89.37 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 121.712 1.608 . . . . 0.0 111.996 166.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.56 -56.74 12.03 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.668 0.667 . . . . 0.0 109.946 177.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -65.29 -51.55 59.97 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 123.039 0.535 . . . . 0.0 110.949 -177.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.0 mtp180 -65.46 -9.37 25.13 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.337 0.865 . . . . 0.0 113.337 -177.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -76.7 -9.27 58.55 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 117.149 -1.405 . . . . 0.0 113.16 171.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 52.11 39.17 26.07 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.905 1.682 . . . . 0.0 113.942 170.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 23.6 mtmm -141.11 13.49 2.23 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.784 1.233 . . . . 0.0 113.34 177.197 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.9 mt -144.26 127.41 16.62 Favored 'General case' 0 C--O 1.237 0.437 0 O-C-N 121.09 -1.006 . . . . 0.0 109.743 175.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -116.3 164.83 13.93 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.657 1.218 . . . . 0.0 108.806 175.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 39.3 t -65.75 133.73 30.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 163.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 110.07 -17.32 29.6 Favored Glycine 0 C--N 1.339 0.704 0 C-N-CA 124.918 1.247 . . . . 0.0 110.307 -177.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -71.91 97.12 1.78 Allowed 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 122.667 1.222 . . . . 0.0 109.09 -175.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 49.6 mtt85 -55.17 148.36 14.44 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 126.013 1.725 . . . . 0.0 110.904 166.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 96.3 mt -122.71 148.1 26.62 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 C-N-CA 126.995 2.118 . . . . 0.0 106.788 -166.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 29.1 mt -126.44 -37.29 2.21 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 114.43 1.27 . . . . 0.0 114.43 179.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -148.42 159.54 43.92 Favored 'General case' 0 N--CA 1.465 0.289 0 C-N-CA 124.454 1.101 . . . . 0.0 110.397 178.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 91.8 t -130.9 118.13 40.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 -175.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 63.03 -65.41 0.1 Allowed 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 128.513 2.725 . . . . 0.0 110.002 -165.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.97 -2.09 0.07 OUTLIER Glycine 0 CA--C 1.532 1.109 0 C-N-CA 125.914 1.721 . . . . 0.0 111.922 163.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -74.59 124.54 26.86 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 119.935 1.867 . . . . 0.0 107.142 -175.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.4 p -68.2 103.74 1.64 Allowed 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.8 pp -74.23 9.9 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 C-N-CA 124.079 0.952 . . . . 0.0 112.698 -177.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 83.0 mt -46.61 -55.71 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.275 0 C-N-CA 128.99 2.916 . . . . 0.0 109.697 179.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -108.77 -30.64 8.06 Favored 'General case' 0 N--CA 1.461 0.089 0 C-N-CA 124.802 1.241 . . . . 0.0 110.951 -174.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 15.0 ttt -49.56 132.29 19.32 Favored Pre-proline 0 N--CA 1.443 -0.799 0 C-N-CA 127.252 2.221 . . . . 0.0 110.008 -170.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -73.18 144.03 36.68 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 121.357 1.372 . . . . 0.0 108.754 -175.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 37.3 t60 -55.33 -35.86 65.63 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.768 0.827 . . . . 0.0 112.306 -170.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.56 -39.95 74.35 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 118.526 0.603 . . . . 0.0 112.18 174.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -69.24 -48.12 62.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 118.065 -0.969 . . . . 0.0 109.27 -176.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 3.1 mp -51.86 -49.75 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 C-N-CA 125.554 1.542 . . . . 0.0 110.785 168.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 3.0 t -58.61 -44.87 90.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 O-C-N 121.362 -0.836 . . . . 0.0 109.768 -176.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 26.7 tttt -64.7 -43.35 93.76 Favored 'General case' 0 C--O 1.223 -0.314 0 CA-C-O 117.966 -1.016 . . . . 0.0 111.759 173.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -50.17 -42.71 51.55 Favored 'General case' 0 C--O 1.224 -0.285 0 C-N-CA 126.935 2.094 . . . . 0.0 112.03 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 86.5 mt -75.19 -46.32 39.32 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -177.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -60.18 -35.43 75.35 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 122.483 0.313 . . . . 0.0 111.149 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -83.81 -11.43 57.05 Favored 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 127.499 2.32 . . . . 0.0 112.633 179.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -63.84 -11.17 24.99 Favored 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -170.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.86 61.58 2.12 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 166.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 76.5 mt 69.09 -39.78 0.43 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 128.966 2.906 . . . . 0.0 114.335 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.66 158.16 15.82 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 172.56 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.1 p -156.32 142.45 10.17 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 166.52 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.9 m -111.65 101.25 9.65 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 118.521 0.6 . . . . 0.0 111.119 -175.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 46.6 mt -90.44 108.57 19.87 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 125.039 1.336 . . . . 0.0 108.269 -178.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -76.5 122.76 25.02 Favored 'General case' 0 C--O 1.239 0.538 0 C-N-CA 124.074 0.949 . . . . 0.0 110.869 172.388 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.7 pt -128.59 165.0 29.18 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 124.27 1.028 . . . . 0.0 111.851 -177.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 72.6 mt -82.03 -54.21 0.65 Allowed Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 125.304 1.442 . . . . 0.0 109.678 170.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -66.4 -171.49 0.25 Allowed 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.308 2.005 . . . . 0.0 114.799 178.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.07 150.65 18.78 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 131.031 3.732 . . . . 0.0 103.681 172.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -103.8 -3.99 24.19 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 119.943 1.247 . . . . 0.0 111.304 174.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -114.58 -2.64 13.07 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.511 1.525 . . . . 0.0 112.808 -163.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -79.99 176.76 9.45 Favored 'General case' 0 C--O 1.234 0.263 0 C-N-CA 125.306 1.442 . . . . 0.0 112.106 -173.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.8 m-20 -97.3 96.83 8.66 Favored 'General case' 0 C--O 1.232 0.166 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 -171.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.4 m -107.85 113.58 61.02 Favored Pre-proline 0 C--O 1.237 0.421 0 C-N-CA 123.737 0.815 . . . . 0.0 109.28 176.037 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -73.28 163.46 37.85 Favored 'Trans proline' 0 CA--C 1.535 0.571 0 C-N-CA 122.885 2.39 . . . . 0.0 109.896 175.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.8 m -53.68 -51.15 64.12 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.827 0.851 . . . . 0.0 112.746 -169.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 69.41 162.96 3.37 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 123.267 0.461 . . . . 0.0 112.401 -173.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -78.08 -19.65 12.04 Favored 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 123.334 2.689 . . . . 0.0 113.948 -179.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.2 t 34.61 64.99 0.37 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 127.989 2.516 . . . . 0.0 114.76 174.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . 0.266 87.0 p 69.59 59.9 0.3 Allowed 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 127.555 2.342 . . . . 0.0 114.077 170.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.052 0 N-CA-C 108.786 -1.725 . . . . 0.0 108.786 166.262 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.561 0 N-CA-C 108.041 -2.024 . . . . 0.0 108.041 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.6 t -145.43 -157.11 0.76 Allowed 'General case' 0 C--O 1.237 0.418 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 162.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.3 t -99.3 160.38 14.32 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.627 0.771 . . . . 0.0 110.548 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -82.32 122.4 5.72 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -175.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 p -56.31 146.33 24.26 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 126.094 1.757 . . . . 0.0 110.569 172.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.2 t -165.34 159.75 17.49 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 124.913 1.285 . . . . 0.0 108.277 175.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.3 9.06 0.08 OUTLIER Glycine 0 CA--C 1.53 0.982 0 CA-C-O 118.011 -1.438 . . . . 0.0 115.145 -177.499 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 46.3 m -83.76 -78.46 0.23 Allowed 'General case' 0 C--O 1.232 0.156 0 CA-C-N 120.453 2.127 . . . . 0.0 110.699 176.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 84.5 mt -71.15 148.77 47.05 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 118.023 0.374 . . . . 0.0 111.16 -161.154 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.1 mm-40 -55.86 147.51 19.07 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 124.216 1.006 . . . . 0.0 110.098 171.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 13.8 p -145.08 169.41 18.19 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 127.172 2.189 . . . . 0.0 107.264 177.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 m -114.32 164.86 13.35 Favored 'General case' 0 C--O 1.239 0.527 0 N-CA-C 106.113 -1.81 . . . . 0.0 106.113 157.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -103.2 153.73 20.06 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 143.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 62.8 t -129.09 142.0 45.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 103.025 -2.954 . . . . 0.0 103.025 161.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.1 t -123.85 132.44 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 168.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 65.4 mt -130.72 131.45 64.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 105.722 -1.955 . . . . 0.0 105.722 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 76.4 m-70 -117.35 146.87 43.1 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 125.576 1.55 . . . . 0.0 108.271 -176.222 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 50.0 ptt85 -141.57 177.15 8.34 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 120.178 1.354 . . . . 0.0 112.014 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.63 169.25 11.48 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 167.414 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -73.72 -28.69 61.84 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 119.951 -0.7 . . . . 0.0 111.908 173.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -61.16 -56.91 15.27 Favored 'General case' 0 CA--C 1.521 -0.17 0 C-N-CA 124.348 1.059 . . . . 0.0 110.256 -177.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -75.46 165.43 25.13 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.944 1.297 . . . . 0.0 109.216 178.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.02 176.89 26.17 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 163.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -71.83 167.27 20.34 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 159.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.11 0.11 57.3 Favored Glycine 0 CA--C 1.525 0.715 0 CA-C-O 117.922 -1.488 . . . . 0.0 114.994 -167.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -112.18 130.41 55.92 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 120.029 1.915 . . . . 0.0 111.878 -153.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 74.9 t -100.96 135.06 38.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 171.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 23.6 mt -93.23 139.0 18.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 171.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 35.3 pt -132.3 179.32 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 C-N-CA 126.372 1.869 . . . . 0.0 108.29 168.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 66.04 101.46 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 125.731 1.612 . . . . 0.0 108.935 -172.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.8 t -166.2 -72.13 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 107.081 -1.451 . . . . 0.0 107.081 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.6 tt -122.07 108.05 12.92 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 -176.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -133.81 97.41 3.89 Favored 'General case' 0 CA--C 1.522 -0.115 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 176.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 29.5 mtm105 81.46 145.3 0.09 OUTLIER Pre-proline 0 N--CA 1.468 0.455 1 C-N-CA 131.873 4.069 . . . . 0.0 111.427 -170.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -77.18 25.28 0.47 Allowed 'Trans proline' 0 CA--C 1.54 0.815 0 C-N-CA 124.613 3.542 . . . . 0.0 111.349 171.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -130.49 105.74 8.06 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 105.469 -2.048 . . . . 0.0 105.469 -163.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.1 p -61.23 118.74 7.25 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 -177.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 126.46 73.45 0.2 Allowed Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 107.622 -2.191 . . . . 0.0 107.622 -172.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 19.8 m -125.68 147.19 49.43 Favored 'General case' 0 C--O 1.237 0.414 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 165.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.4 m -124.25 162.94 22.66 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 123.677 0.791 . . . . 0.0 109.555 -175.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp 53.17 57.54 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 -172.127 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 15.1 t -142.59 151.19 41.26 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 175.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 7.5 p -127.97 155.35 77.84 Favored Pre-proline 0 C--N 1.324 -0.5 0 C-N-CA 127.637 2.375 . . . . 0.0 105.856 169.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -72.97 106.13 2.09 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 CA-C-N 121.757 1.663 . . . . 0.0 108.404 156.021 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 6.2 m80 80.44 107.38 0.07 Allowed 'General case' 0 C--O 1.234 0.267 0 C-N-CA 128.711 2.804 . . . . 0.0 112.138 172.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 55.5 pttt -133.2 161.15 35.21 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 123.824 0.849 . . . . 0.0 108.731 157.511 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 47.6 mm -66.25 135.43 28.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 168.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -102.9 -63.05 0.71 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 126.55 2.024 . . . . 0.0 111.223 175.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 8.4 ttm180 -131.14 155.11 47.55 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 125.447 1.499 . . . . 0.0 108.504 -175.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 32.5 mt -133.04 132.61 58.89 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 126.217 1.807 . . . . 0.0 107.117 174.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -55.86 114.18 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.776 1.631 . . . . 0.0 107.018 158.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -56.59 132.49 51.8 Favored 'General case' 0 C--O 1.236 0.383 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 174.216 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.78 -8.02 67.62 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 125.401 1.477 . . . . 0.0 114.977 175.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 36.2 p -59.91 169.6 1.47 Allowed Pre-proline 0 C--O 1.239 0.53 0 CA-C-N 118.407 1.104 . . . . 0.0 111.971 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -54.91 -31.78 75.05 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 121.242 1.295 . . . . 0.0 112.073 166.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.2 -68.83 0.24 Allowed 'General case' 0 C--N 1.345 0.404 0 C-N-CA 123.793 0.837 . . . . 0.0 110.089 169.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -51.39 -55.23 19.69 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 118.608 0.64 . . . . 0.0 112.559 -171.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -70.11 -7.79 44.3 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 123.349 0.659 . . . . 0.0 111.908 -175.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 10.5 t -62.66 -36.96 84.52 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 119.413 1.006 . . . . 0.0 109.202 166.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 57.69 -22.21 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 129.473 3.109 . . . . 0.0 115.789 -177.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 1.5 mmpp? -68.73 -4.6 16.45 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 127.94 2.496 . . . . 0.0 113.389 174.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -147.08 113.13 5.81 Favored 'General case' 0 C--O 1.237 0.421 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 -173.203 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 25.6 mttt -130.66 170.74 13.91 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 122.008 0.908 . . . . 0.0 112.613 -170.527 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.8 t -60.99 109.85 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.25 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 131.81 -17.16 4.97 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -70.52 106.45 3.46 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-N 118.525 1.163 . . . . 0.0 111.397 -178.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 52.8 mtm-85 -57.5 144.73 35.75 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 127.23 2.212 . . . . 0.0 110.056 161.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 5.4 mt -131.29 149.14 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 C-N-CA 123.295 0.638 . . . . 0.0 109.428 -168.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.48 -41.23 2.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.789 1.636 . . . . 0.0 112.663 -171.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -160.91 168.2 25.1 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.316 0.647 . . . . 0.0 111.743 -178.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.6 p -140.21 127.51 23.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 123.532 0.733 . . . . 0.0 110.09 -176.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 40.01 48.24 2.1 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 125.732 1.613 . . . . 0.0 109.774 -158.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 63.21 11.67 40.61 Favored Glycine 0 CA--C 1.528 0.869 0 CA-C-O 116.843 -2.087 . . . . 0.0 114.714 -178.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.84 153.97 20.65 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-N 120.684 2.242 . . . . 0.0 111.844 178.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.2 p -62.41 147.64 47.93 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -171.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 8.5 pt -131.52 -7.13 2.0 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 O-C-N 123.602 0.564 . . . . 0.0 112.05 167.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.1 mm -79.71 -45.84 22.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 O-C-N 120.569 -1.332 . . . . 0.0 109.628 176.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -88.48 -29.47 20.11 Favored 'General case' 0 N--CA 1.465 0.297 0 O-C-N 121.635 -0.666 . . . . 0.0 112.751 -178.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.6 mtp -70.61 152.33 95.32 Favored Pre-proline 0 CA--C 1.534 0.352 0 CA-C-N 118.906 0.775 . . . . 0.0 110.984 -177.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_endo -73.64 153.23 48.89 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 122.57 2.18 . . . . 0.0 109.55 171.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -62.49 -37.87 87.68 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.516 -0.74 . . . . 0.0 112.724 -167.652 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.83 -28.2 65.49 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 119.079 0.854 . . . . 0.0 111.611 -176.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -68.47 -45.06 73.44 Favored 'General case' 0 N--CA 1.46 0.072 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 176.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.7 mt -64.4 -38.38 82.42 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 125.299 1.44 . . . . 0.0 109.569 176.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 37.9 t -61.7 -47.6 92.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 O-C-N 120.22 -1.55 . . . . 0.0 109.093 172.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 4.2 tmtt? -63.59 -37.42 87.25 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.016 -177.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.46 -43.93 75.91 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 125.471 1.508 . . . . 0.0 111.446 173.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 60.0 mt -68.56 -43.36 83.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 119.542 1.065 . . . . 0.0 109.287 177.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 21.1 tttm -64.29 -38.64 91.78 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.671 -0.643 . . . . 0.0 110.546 -178.293 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -86.02 -3.44 58.94 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 126.924 2.09 . . . . 0.0 112.051 179.489 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -54.89 -26.07 33.23 Favored 'General case' 0 C--N 1.345 0.413 0 N-CA-C 113.817 1.043 . . . . 0.0 113.817 -166.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.51 36.02 3.93 Favored Glycine 0 C--N 1.335 0.479 0 N-CA-C 111.266 -0.733 . . . . 0.0 111.266 173.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 44.9 mt 69.29 -30.82 0.2 Allowed 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 128.596 2.759 . . . . 0.0 113.041 -175.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 m -92.66 148.12 22.32 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 167.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.3 p -139.97 124.42 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.002 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 169.224 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 20.9 m -99.04 123.77 43.58 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 177.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 21.9 mt -120.01 122.3 40.85 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.286 1.034 . . . . 0.0 109.835 -172.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 45.9 ttp180 -85.67 111.94 20.55 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 173.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pp -118.78 167.17 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 125.776 1.63 . . . . 0.0 108.76 175.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 7.6 mt -100.8 119.96 56.96 Favored Pre-proline 0 N--CA 1.468 0.436 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 169.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -86.2 -175.58 1.83 Allowed 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 124.266 3.311 . . . . 0.0 110.137 174.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -144.29 171.98 13.56 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 123.83 0.852 . . . . 0.0 109.43 177.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -130.02 -2.8 4.58 Favored 'General case' 0 N--CA 1.463 0.221 0 C-N-CA 123.895 0.878 . . . . 0.0 112.885 170.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -108.62 -6.65 15.91 Favored 'General case' 0 N--CA 1.464 0.252 0 C-N-CA 123.895 0.878 . . . . 0.0 113.125 -164.293 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -70.8 102.48 2.35 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 125.531 1.532 . . . . 0.0 112.007 -163.719 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -156.54 102.5 2.07 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 3.3 m -156.89 159.42 31.29 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 118.804 0.729 . . . . 0.0 110.473 178.7 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -71.78 178.94 5.21 Favored 'Trans proline' 0 N--CA 1.458 -0.56 0 C-N-CA 123.904 3.069 . . . . 0.0 111.385 173.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 14.4 m -126.68 41.36 3.54 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 124.691 1.196 . . . . 0.0 111.26 -164.151 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -73.49 -141.84 0.56 Allowed Glycine 0 CA--C 1.536 1.406 0 C-N-CA 125.392 1.472 . . . . 0.0 112.712 -177.806 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.06 143.05 94.06 Favored 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 122.956 2.437 . . . . 0.0 112.446 -163.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.76 148.34 17.48 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 114.654 -1.157 . . . . 0.0 110.344 -156.357 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.3 m -145.61 -115.39 0.09 Allowed 'General case' 0 C--O 1.236 0.349 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 171.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.929 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 176.855 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.899 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.8 m 47.95 65.67 1.24 Allowed 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 126.143 1.777 . . . . 0.0 113.644 168.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.5 p -79.55 -31.39 41.99 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.976 0.91 . . . . 0.0 112.212 174.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 50.33 -114.49 2.6 Favored Glycine 0 C--N 1.338 0.666 0 C-N-CA 126.116 1.817 . . . . 0.0 111.812 177.206 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 40.0 m -115.09 83.9 1.99 Allowed 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.977 1.311 . . . . 0.0 109.079 -175.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.3 m 47.47 49.2 16.15 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 126.688 1.995 . . . . 0.0 115.512 157.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.62 48.39 0.15 Allowed Glycine 0 C--N 1.336 0.546 0 N-CA-C 108.651 -1.78 . . . . 0.0 108.651 -172.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.9 m -54.77 -34.23 62.32 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 124.846 1.258 . . . . 0.0 114.191 -154.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.3 tp -147.16 85.58 1.61 Allowed 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 174.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 35.0 mm-40 53.75 -169.38 0.06 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.996 1.319 . . . . 0.0 112.624 -175.146 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 59.2 p -130.59 169.65 15.31 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 125.255 1.422 . . . . 0.0 108.204 164.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 13.7 m -120.2 147.17 45.26 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.511 1.125 . . . . 0.0 108.481 163.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -74.37 155.45 38.13 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 125.3 1.44 . . . . 0.0 108.128 152.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 t -137.57 121.16 21.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 105.088 -2.19 . . . . 0.0 105.088 163.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 13.8 t -120.04 97.29 5.0 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -173.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 43.1 mt -99.28 126.32 52.61 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -174.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -103.9 149.62 24.93 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.653 -1.239 . . . . 0.0 107.653 177.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -143.21 -175.54 4.57 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 120.706 1.594 . . . . 0.0 109.899 175.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.48 ' N ' ' HE3' ' A' ' 19' ' ' LYS . 0.1 OUTLIER -92.64 163.71 13.68 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 169.001 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -68.25 -36.62 79.74 Favored 'General case' 0 N--CA 1.465 0.317 0 O-C-N 121.425 -0.797 . . . . 0.0 110.82 173.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -75.96 -4.52 41.56 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.418 1.087 . . . . 0.0 112.499 -166.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -123.41 179.33 4.77 Favored 'General case' 0 C--O 1.238 0.45 0 C-N-CA 126.872 2.069 . . . . 0.0 108.376 -178.731 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.93 178.71 20.94 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 162.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -72.95 -175.43 1.76 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 164.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -138.81 60.54 0.58 Allowed Glycine 0 C--O 1.223 -0.583 0 CA-C-O 118.774 -1.015 . . . . 0.0 112.582 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -140.18 158.16 44.47 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 118.694 1.247 . . . . 0.0 110.651 175.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.9 t -143.45 140.54 26.21 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 105.947 -1.872 . . . . 0.0 105.947 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 1.9 mp -130.47 129.26 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 C-N-CA 124.928 1.291 . . . . 0.0 107.566 -169.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.431 HD12 ' HE3' ' A' ' 46' ' ' LYS . 47.7 pt -126.44 159.61 35.32 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 C-N-CA 124.32 1.048 . . . . 0.0 110.142 -166.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.2 t -128.08 118.17 22.98 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 126.16 1.784 . . . . 0.0 109.275 -173.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 57.7 m -126.79 68.05 1.25 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.825 1.65 . . . . 0.0 107.016 170.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -154.11 117.04 4.46 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 166.383 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -151.01 168.01 25.9 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 162.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 69.2 mtt180 56.32 161.09 0.07 OUTLIER Pre-proline 0 CA--C 1.533 0.301 0 C-N-CA 128.699 2.8 . . . . 0.0 113.472 -166.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -81.56 107.11 1.76 Allowed 'Trans proline' 0 N--CA 1.448 -1.193 0 C-N-CA 123.075 2.517 . . . . 0.0 109.713 172.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -78.88 105.1 9.97 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 156.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 67.7 m 16.33 77.01 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 128.95 2.9 . . . . 0.0 115.06 179.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.14 -150.6 18.16 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 124.663 1.125 . . . . 0.0 111.052 177.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.8 113.68 25.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 104.979 -2.23 . . . . 0.0 104.979 166.156 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 25.5 p -79.81 143.68 34.18 Favored 'General case' 0 N--CA 1.452 -0.367 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 -179.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.462 HD11 ' H ' ' A' ' 41' ' ' ILE . 0.9 OUTLIER -77.85 20.91 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 C-N-CA 126.082 1.753 . . . . 0.0 111.167 -177.168 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.6 p -59.19 171.25 0.77 Allowed 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 127.354 2.262 . . . . 0.0 111.105 173.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 48.1 t -118.13 138.34 25.44 Favored Pre-proline 0 CA--C 1.532 0.283 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 -178.196 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -79.82 -16.44 11.48 Favored 'Trans proline' 0 CA--C 1.531 0.373 0 C-N-CA 122.767 2.311 . . . . 0.0 112.628 -175.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -139.7 115.14 9.91 Favored 'General case' 0 N--CA 1.442 -0.826 0 C-N-CA 125.259 1.423 . . . . 0.0 107.641 -166.654 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.431 ' HE3' HD12 ' A' ' 29' ' ' ILE . 52.1 pttt -127.91 144.09 51.1 Favored 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 167.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.3 mm -55.38 120.98 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 165.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -87.15 -42.59 6.21 Favored Glycine 0 CA--C 1.522 0.494 0 C-N-CA 125.212 1.387 . . . . 0.0 110.85 175.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.6 ttt-85 -148.05 156.36 42.54 Favored 'General case' 0 C--O 1.233 0.225 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 172.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.67 139.6 48.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 164.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 44.1 mm -67.56 118.48 11.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 173.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -53.55 124.4 14.85 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 124.199 1.0 . . . . 0.0 108.448 173.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.94 -0.88 84.68 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 114.535 0.574 . . . . 0.0 114.535 176.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 57.8 p -69.23 169.52 11.58 Favored Pre-proline 0 C--O 1.235 0.336 0 CA-C-N 118.855 1.327 . . . . 0.0 112.019 175.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -57.37 -28.04 78.4 Favored 'Trans proline' 0 N--CA 1.449 -1.128 0 C-N-CA 121.21 1.273 . . . . 0.0 112.809 161.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.04 -54.26 19.64 Favored 'General case' 0 C--N 1.346 0.434 0 CA-C-N 119.967 1.258 . . . . 0.0 110.235 176.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -52.31 -55.07 23.85 Favored 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 124.918 1.287 . . . . 0.0 110.838 178.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 87.9 mtt180 -69.86 -7.35 39.39 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 123.558 0.743 . . . . 0.0 112.622 -175.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 8.9 t -71.24 -31.18 67.23 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 119.586 1.085 . . . . 0.0 110.569 168.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.97 -29.95 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 129.979 3.312 . . . . 0.0 116.364 -174.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.3 mtpt -69.86 -9.06 53.45 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 126.056 1.742 . . . . 0.0 112.32 169.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -106.46 132.31 52.63 Favored 'General case' 0 C--O 1.237 0.424 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 158.158 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 15.6 ptpt -139.56 169.07 18.42 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 124.387 1.075 . . . . 0.0 110.757 169.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 61.7 t -59.21 138.73 19.87 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 174.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 83.35 4.33 89.53 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 115.889 1.116 . . . . 0.0 115.889 174.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -60.89 -6.85 2.0 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 118.528 2.788 . . . . 0.0 118.528 -164.201 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 84.5 mtm180 49.38 105.59 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 128.658 2.783 . . . . 0.0 114.587 -165.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 57.7 mt -96.79 129.39 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 123.653 0.781 . . . . 0.0 109.241 -179.198 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -104.41 -23.88 13.12 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.366 1.066 . . . . 0.0 113.601 176.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -155.58 164.75 38.22 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 118.505 0.593 . . . . 0.0 111.258 -179.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.38 121.19 45.2 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 C-N-CA 126.405 1.882 . . . . 0.0 107.0 178.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 52.59 26.87 4.63 Favored 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 176.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 90.76 -2.77 80.56 Favored Glycine 0 CA--C 1.535 1.326 0 C-N-CA 125.581 1.562 . . . . 0.0 114.514 -177.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -94.37 128.91 41.19 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.751 1.775 . . . . 0.0 108.638 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.07 116.84 4.84 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 123.267 0.627 . . . . 0.0 109.479 171.339 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.7 pp -80.99 11.64 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.577 0 C-N-CA 124.149 0.979 . . . . 0.0 113.203 178.069 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 79.5 mt -61.04 -70.36 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 C-N-CA 124.961 1.304 . . . . 0.0 109.382 -175.005 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -94.69 -24.66 17.05 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 120.432 -0.507 . . . . 0.0 111.785 -172.325 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.2 mtp -48.6 134.59 13.47 Favored Pre-proline 0 CA--C 1.536 0.442 0 C-N-CA 125.154 1.382 . . . . 0.0 110.512 176.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.25 157.37 61.64 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 122.356 2.038 . . . . 0.0 109.478 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 16.0 m-70 -56.06 -32.96 64.56 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 119.302 -0.38 . . . . 0.0 110.847 174.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.9 -44.1 97.5 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 117.878 -1.058 . . . . 0.0 112.177 178.027 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -64.65 -45.98 84.47 Favored 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 66.3 mt -61.75 -40.46 86.96 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 C-N-CA 123.814 0.846 . . . . 0.0 110.527 -177.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 24.8 t -60.22 -50.25 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.132 0 O-C-N 121.209 -0.932 . . . . 0.0 109.32 171.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -63.2 -34.05 76.8 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 117.479 -1.248 . . . . 0.0 112.746 -177.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -63.78 -41.51 97.94 Favored 'General case' 0 N--CA 1.442 -0.832 0 C-N-CA 128.07 2.548 . . . . 0.0 110.645 174.226 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 54.4 mt -67.16 -45.61 86.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 O-C-N 120.774 -1.204 . . . . 0.0 108.875 177.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 4.6 tttt -61.77 -38.98 90.03 Favored 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 123.077 0.551 . . . . 0.0 109.597 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -61.65 -43.08 99.53 Favored 'General case' 0 CA--C 1.517 -0.323 0 C-N-CA 125.058 1.343 . . . . 0.0 110.381 175.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -56.01 -34.56 65.92 Favored 'General case' 0 CA--C 1.537 0.473 0 O-C-N 123.339 0.399 . . . . 0.0 110.63 -175.498 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.03 -116.22 5.46 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 124.896 1.236 . . . . 0.0 110.885 157.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 8.2 mt -83.53 -20.12 34.44 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-N 117.126 0.463 . . . . 0.0 109.753 167.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 p -94.53 156.32 16.51 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 173.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.8 p -157.39 124.84 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.258 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 160.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 56.3 m -109.53 101.86 10.77 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.612 1.565 . . . . 0.0 107.514 -172.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 81.8 mt -90.92 165.17 13.73 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 125.014 1.326 . . . . 0.0 110.369 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 26.6 ttm180 -120.57 127.99 52.65 Favored 'General case' 0 CA--C 1.518 -0.282 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 162.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 pp -128.83 178.64 4.77 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 125.318 1.447 . . . . 0.0 109.29 173.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 75.8 mt -115.68 125.32 28.85 Favored Pre-proline 0 N--CA 1.469 0.512 0 CA-C-N 119.334 0.97 . . . . 0.0 109.349 167.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -78.64 167.38 22.64 Favored 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 122.3 2.0 . . . . 0.0 111.252 176.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 4.2 pt20 -149.52 151.36 33.78 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 -177.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -146.62 1.6 0.81 Allowed 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 123.763 0.825 . . . . 0.0 112.24 177.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 16.9 tt0 -126.07 1.29 7.22 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 126.398 1.879 . . . . 0.0 110.649 -178.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 12.7 mt -104.63 102.05 11.67 Favored 'General case' 0 CA--C 1.515 -0.382 0 C-N-CA 125.782 1.633 . . . . 0.0 106.99 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -139.13 167.57 21.76 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 126.522 1.929 . . . . 0.0 107.42 174.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 3.3 p -147.35 78.53 10.14 Favored Pre-proline 0 CA--C 1.536 0.415 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -163.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -66.95 -57.89 0.17 Allowed 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 123.486 2.791 . . . . 0.0 109.818 -176.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 13.7 m -147.93 -100.78 0.08 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 125.403 1.481 . . . . 0.0 108.25 167.766 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 161.77 -178.38 37.66 Favored Glycine 0 CA--C 1.529 0.931 0 CA-C-N 119.683 1.129 . . . . 0.0 111.14 -174.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 67.2 Cg_endo -72.83 102.02 1.38 Allowed 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 124.438 3.426 . . . . 0.0 109.822 174.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -68.23 91.74 0.38 Allowed 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 125.224 1.41 . . . . 0.0 111.279 -178.233 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 22.3 t -72.72 136.82 45.62 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 164.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.989 0 CA-C-O 117.66 -1.633 . . . . 0.0 109.814 -178.864 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.325 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.2 m 65.83 97.29 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 125.796 1.638 . . . . 0.0 112.361 169.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 66.4 m -76.43 169.03 19.0 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.883 0.873 . . . . 0.0 111.206 178.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 67.14 -179.82 13.59 Favored Glycine 0 CA--C 1.53 1.0 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -172.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.5 m 58.05 171.21 0.05 Allowed 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.991 1.316 . . . . 0.0 113.995 -175.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.9 t -162.05 173.15 14.79 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.883 2.073 . . . . 0.0 106.725 159.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.12 -39.49 1.49 Allowed Glycine 0 CA--C 1.523 0.566 0 C-N-CA 126.134 1.826 . . . . 0.0 109.832 172.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 17.3 m -75.4 85.86 2.54 Favored 'General case' 0 N--CA 1.448 -0.573 0 O-C-N 122.127 -0.631 . . . . 0.0 110.015 164.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 39.8 mt -130.18 80.9 1.98 Allowed 'General case' 0 CA--C 1.52 -0.187 0 C-N-CA 125.126 1.37 . . . . 0.0 108.695 173.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 60.93 172.17 0.1 Allowed 'General case' 0 C--O 1.236 0.352 0 C-N-CA 126.591 1.956 . . . . 0.0 112.714 178.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.8 p -116.07 161.84 18.3 Favored 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 123.884 0.874 . . . . 0.0 108.984 -169.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 58.3 m -121.24 146.84 46.39 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 105.406 -2.072 . . . . 0.0 105.406 174.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -120.85 131.75 54.59 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 -175.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 24.0 t -129.29 94.86 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 104.431 -2.433 . . . . 0.0 104.431 -172.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.5 p -94.83 104.22 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 36.6 mt -101.84 133.89 43.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 105.307 -2.109 . . . . 0.0 105.307 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 51.8 m-70 -111.53 149.19 31.74 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.924 1.29 . . . . 0.0 108.415 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -138.86 -177.35 4.84 Favored 'General case' 0 N--CA 1.468 0.469 0 O-C-N 120.84 -1.162 . . . . 0.0 110.485 177.272 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.26 153.17 18.17 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 168.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -61.55 -32.61 72.69 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.294 0.568 . . . . 0.0 111.217 -171.035 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -89.13 3.41 51.94 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 124.744 1.218 . . . . 0.0 112.979 -163.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 25.4 pt-20 -139.78 177.74 7.74 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 119.534 1.061 . . . . 0.0 111.187 -170.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.04 163.66 31.91 Favored Glycine 0 CA--C 1.525 0.718 0 O-C-N 121.634 -0.666 . . . . 0.0 111.653 177.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -75.67 161.2 29.3 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 154.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.56 58.19 0.73 Allowed Glycine 0 C--O 1.218 -0.852 0 CA-C-O 117.432 -1.76 . . . . 0.0 111.351 178.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -142.91 141.53 31.52 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 120.326 2.063 . . . . 0.0 110.586 169.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.0 t -105.22 135.7 42.17 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 170.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 25.6 mt -96.63 130.74 44.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 162.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.3 pt -122.53 178.69 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.603 0 C-N-CA 126.585 1.954 . . . . 0.0 108.71 175.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.5 p -121.12 170.02 9.96 Favored 'General case' 0 C--O 1.237 0.41 0 C-N-CA 126.197 1.799 . . . . 0.0 109.434 170.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 66.4 m -121.19 -173.08 2.53 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 126.172 1.789 . . . . 0.0 107.597 160.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.9 mp -63.71 128.36 35.46 Favored 'General case' 0 C--O 1.236 0.384 0 O-C-N 121.541 -0.724 . . . . 0.0 109.555 177.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -66.52 171.37 5.08 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 125.366 1.466 . . . . 0.0 110.296 170.028 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -133.22 148.11 67.81 Favored Pre-proline 0 C--O 1.238 0.449 0 C-N-CA 124.606 1.162 . . . . 0.0 108.038 173.137 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -81.03 80.95 2.86 Favored 'Trans proline' 0 N--CA 1.45 -1.03 0 C-N-CA 123.928 3.086 . . . . 0.0 108.298 175.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 34.3 mm-40 -136.16 160.58 38.24 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 126.768 2.027 . . . . 0.0 106.796 176.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 12.0 p -144.04 170.04 16.69 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 123.356 0.662 . . . . 0.0 110.674 -175.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.19 -80.47 0.85 Allowed Glycine 0 C--N 1.335 0.491 0 C-N-CA 124.21 0.91 . . . . 0.0 110.96 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.5 m -65.88 164.18 15.46 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 122.117 0.96 . . . . 0.0 110.544 170.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 12.8 p -123.37 102.34 7.85 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 106.546 -1.649 . . . . 0.0 106.546 -176.537 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.5 mm -108.73 -63.3 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 C-N-CA 124.933 1.293 . . . . 0.0 107.917 -169.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.7 t -75.03 96.21 3.16 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -177.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.6 p -65.6 123.66 85.18 Favored Pre-proline 0 CA--C 1.539 0.528 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.409 ' HG2' ' H ' ' A' ' 45' ' ' HIS . 73.1 Cg_endo -74.72 -65.72 0.03 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 121.851 1.701 . . . . 0.0 109.838 179.259 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.409 ' H ' ' HG2' ' A' ' 44' ' ' PRO . 12.5 m80 -77.23 103.18 7.01 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.632 1.573 . . . . 0.0 109.614 -172.063 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.7 ptmt -130.55 153.17 49.14 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 171.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 39.7 mm -68.54 143.82 14.82 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 175.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.89 -59.46 0.53 Allowed Glycine 0 CA--C 1.529 0.926 0 C-N-CA 125.596 1.57 . . . . 0.0 112.508 175.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 37.4 ttm180 -140.05 144.58 36.94 Favored 'General case' 0 C--O 1.235 0.339 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 21.2 mt -122.66 125.43 72.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 105.821 -1.918 . . . . 0.0 105.821 175.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -51.73 131.07 12.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 CA-C-N 119.23 0.923 . . . . 0.0 108.612 172.506 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.6 123.27 17.43 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 125.553 1.541 . . . . 0.0 108.868 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.28 9.88 84.31 Favored Glycine 0 CA--C 1.535 1.329 0 C-N-CA 123.947 0.784 . . . . 0.0 114.903 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 37.9 p -66.36 171.76 3.8 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 119.662 1.731 . . . . 0.0 112.458 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -56.85 -36.83 99.07 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 121.783 1.655 . . . . 0.0 112.296 166.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.72 -48.95 75.01 Favored 'General case' 0 C--N 1.34 0.177 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -60.34 -52.95 63.09 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 123.44 0.696 . . . . 0.0 111.594 176.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -60.94 -18.59 57.88 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 124.078 0.951 . . . . 0.0 112.31 -176.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 11.5 t -59.36 -26.25 64.91 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-O 117.819 -1.086 . . . . 0.0 111.257 175.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.15 31.49 18.38 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.913 2.085 . . . . 0.0 112.962 -179.208 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 40.3 mtmt -132.47 -34.11 1.22 Allowed 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.889 0.875 . . . . 0.0 111.977 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -93.85 126.46 39.06 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 177.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 2.6 ptpp? -117.82 171.58 7.96 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 125.2 1.4 . . . . 0.0 109.139 170.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 82.2 t -66.09 141.66 17.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 O-C-N 120.965 -1.084 . . . . 0.0 108.565 174.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 89.47 -5.02 84.17 Favored Glycine 0 CA--C 1.532 1.095 0 CA-C-O 117.022 -1.988 . . . . 0.0 114.904 176.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -62.9 11.68 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 120.229 3.418 . . . . 0.0 120.229 -150.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.1 mtp180 41.82 86.71 0.02 OUTLIER 'General case' 0 C--O 1.235 0.3 0 C-N-CA 127.178 2.191 . . . . 0.0 113.103 -171.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 44.1 mt -65.32 148.85 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 106.341 -1.725 . . . . 0.0 106.341 170.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.8 tp -118.86 -47.15 2.52 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 125.828 1.651 . . . . 0.0 108.764 177.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -148.54 166.95 26.69 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 125.268 1.427 . . . . 0.0 111.352 -177.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.9 p -134.72 124.36 43.89 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.468 0 C-N-CA 125.493 1.517 . . . . 0.0 107.933 175.012 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 49.71 38.59 15.72 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.138 0.975 . . . . 0.0 110.009 -178.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 79.21 -10.27 35.88 Favored Glycine 0 CA--C 1.532 1.115 0 CA-C-O 117.822 -1.543 . . . . 0.0 115.415 -176.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.9 mm100 -79.66 122.87 27.08 Favored 'General case' 0 CA--C 1.513 -0.479 0 CA-C-N 121.491 2.646 . . . . 0.0 107.747 -178.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 55.7 m -61.36 110.12 1.34 Allowed 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 167.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.5 pp -80.14 11.49 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 124.604 1.162 . . . . 0.0 112.322 -174.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 25.3 mm -63.01 -77.34 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 C-N-CA 125.24 1.416 . . . . 0.0 108.418 175.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 21.8 m-80 -79.7 -26.92 40.76 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.179 -164.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 1.4 mtp -58.29 133.81 84.79 Favored Pre-proline 0 CA--C 1.538 0.488 0 C-N-CA 123.815 0.846 . . . . 0.0 109.513 174.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -70.61 155.11 63.8 Favored 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 121.989 1.793 . . . . 0.0 110.665 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -57.09 -39.21 74.56 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.365 0.666 . . . . 0.0 111.938 -174.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -60.38 -42.43 95.86 Favored 'General case' 0 C--N 1.338 0.097 0 CA-C-O 118.421 -0.8 . . . . 0.0 111.368 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -62.62 -46.27 89.05 Favored 'General case' 0 C--O 1.218 -0.58 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 177.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.421 ' HA ' ' HB2' ' A' ' 87' ' ' LEU . 29.4 mt -67.71 -33.92 64.74 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 O-C-N 121.212 -0.93 . . . . 0.0 109.925 -175.453 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.0 t -61.79 -44.47 98.84 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 O-C-N 120.83 -1.169 . . . . 0.0 108.669 171.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 7.0 mmtt -52.45 -53.19 48.74 Favored 'General case' 0 C--O 1.22 -0.462 0 CA-C-O 116.568 -1.682 . . . . 0.0 109.481 166.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . 0.421 ' HB2' ' HA ' ' A' ' 84' ' ' ILE . 0.9 OUTLIER -57.7 -28.34 63.74 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 122.472 2.396 . . . . 0.0 114.514 -174.761 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 66.7 mt -77.44 -48.71 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 176.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 13.6 ttpt -63.36 -37.27 86.64 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 118.164 0.438 . . . . 0.0 110.847 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.03 -10.65 59.67 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 126.98 2.112 . . . . 0.0 111.472 -178.381 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.74 -28.31 63.79 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 113.301 0.852 . . . . 0.0 113.301 -171.509 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 92.22 66.52 1.12 Allowed Glycine 0 C--N 1.339 0.741 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 171.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 56.9 mt 61.81 -44.37 0.15 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 129.605 3.162 . . . . 0.0 114.346 -171.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 6.6 p -93.6 140.66 29.36 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 125.28 1.432 . . . . 0.0 107.79 177.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.5 p -134.54 124.34 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 169.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.8 m -93.53 100.57 12.83 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 19.6 mt -90.18 122.83 33.48 Favored 'General case' 0 CA--C 1.516 -0.334 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 172.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 32.0 ttm105 -99.25 117.75 34.41 Favored 'General case' 0 C--O 1.236 0.347 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 179.039 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.9 pp -130.6 174.9 12.19 Favored 'Isoleucine or valine' 0 C--O 1.237 0.427 0 C-N-CA 126.669 1.988 . . . . 0.0 110.004 -166.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.4 mp -129.88 115.21 17.84 Favored Pre-proline 0 CA--C 1.546 0.812 0 C-N-CA 124.483 1.113 . . . . 0.0 108.651 177.158 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -79.76 -179.07 5.01 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 125.294 3.996 . . . . 0.0 109.169 169.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.64 163.78 36.59 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 121.224 -0.923 . . . . 0.0 108.568 177.581 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -102.94 7.05 39.28 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 125.478 1.511 . . . . 0.0 111.957 -171.163 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -130.77 10.03 5.05 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 125.204 1.402 . . . . 0.0 111.223 -173.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 11.2 mt -121.66 64.55 0.9 Allowed 'General case' 0 C--O 1.235 0.321 0 C-N-CA 125.729 1.612 . . . . 0.0 108.789 -169.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 37.0 t30 -148.39 89.49 1.72 Allowed 'General case' 0 C--O 1.234 0.273 0 C-N-CA 125.757 1.623 . . . . 0.0 107.767 172.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.1 m -67.02 149.29 98.6 Favored Pre-proline 0 CA--C 1.543 0.692 0 CA-C-O 119.013 -0.518 . . . . 0.0 111.319 -171.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -79.5 179.55 6.26 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.699 2.932 . . . . 0.0 112.145 -172.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 14.4 t -128.6 -171.98 2.6 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.66 1.584 . . . . 0.0 107.413 163.393 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 67.38 62.24 4.53 Favored Glycine 0 CA--C 1.534 1.265 0 C-N-CA 124.944 1.259 . . . . 0.0 112.949 178.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -67.05 -26.3 43.28 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.636 2.224 . . . . 0.0 113.649 -177.432 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 42.9 t -155.33 98.28 1.97 Allowed 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 175.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 73.4 m -152.06 73.62 1.06 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 174.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.975 0 N-CA-C 103.662 -3.775 . . . . 0.0 103.662 -146.307 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.648 0 N-CA-C 111.589 -0.605 . . . . 0.0 111.589 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.2 p -70.44 93.95 0.92 Allowed 'General case' 0 C--O 1.232 0.148 0 C-N-CA 123.834 0.854 . . . . 0.0 109.238 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.5 m -146.55 162.76 37.68 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 106.188 -1.782 . . . . 0.0 106.188 169.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 159.8 107.08 0.23 Allowed Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -174.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.5 t -123.82 -71.79 0.7 Allowed 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 106.293 -1.743 . . . . 0.0 106.293 174.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m -68.79 -57.57 5.41 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 124.641 1.176 . . . . 0.0 112.888 -174.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 130.84 51.18 0.1 Allowed Glycine 0 C--N 1.342 0.902 0 CA-C-N 119.672 1.124 . . . . 0.0 113.979 174.033 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 27.8 m -70.44 33.77 0.04 OUTLIER 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.094 1.758 . . . . 0.0 113.184 173.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.2 tp -155.94 119.44 4.36 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 161.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -112.13 114.62 27.56 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.2 p -132.51 167.58 19.74 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 123.842 0.857 . . . . 0.0 109.74 -174.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.5 m -127.38 150.99 49.37 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.239 1.016 . . . . 0.0 108.291 175.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -120.69 93.46 4.04 Favored 'General case' 0 C--O 1.236 0.355 0 N-CA-C 104.442 -2.429 . . . . 0.0 104.442 176.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.5 t -91.43 94.76 5.04 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.332 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 -170.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.0 p -76.2 134.12 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 173.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 82.5 mt -131.12 126.38 59.15 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.197 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 175.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -92.55 154.01 18.7 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 167.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.47 ' HD3' ' CZ ' ' A' ' 24' ' ' PHE . 5.7 ptt180 -138.96 -176.95 4.67 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 167.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.439 ' HE3' ' C ' ' A' ' 18' ' ' ARG . 0.1 OUTLIER -109.67 168.19 9.59 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 172.48 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -75.71 -19.3 59.19 Favored 'General case' 0 N--CA 1.463 0.176 0 O-C-N 121.716 -0.615 . . . . 0.0 112.172 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -69.77 -2.98 13.53 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.014 0.926 . . . . 0.0 112.735 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -150.07 177.2 10.11 Favored 'General case' 0 C--O 1.238 0.474 0 C-N-CA 125.485 1.514 . . . . 0.0 109.441 -164.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.98 -173.69 19.94 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 171.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.47 ' CZ ' ' HD3' ' A' ' 18' ' ' ARG . 62.9 m-85 -76.24 166.85 22.86 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 159.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.29 60.26 0.68 Allowed Glycine 0 C--O 1.226 -0.364 0 O-C-N 121.022 -1.049 . . . . 0.0 113.05 -173.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 5.3 p90 -144.56 162.08 37.5 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 124.936 1.294 . . . . 0.0 109.999 175.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.5 t -132.99 124.59 50.41 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.3 mp -84.5 140.86 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 173.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.414 HD13 ' HE3' ' A' ' 46' ' ' LYS . 19.9 pt -131.73 -176.15 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 C-N-CA 127.849 2.46 . . . . 0.0 107.759 172.073 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.6 p -116.39 -58.55 2.08 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 165.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 60.16 88.35 0.08 Allowed 'General case' 0 C--O 1.235 0.301 0 C-N-CA 125.69 1.596 . . . . 0.0 108.743 -159.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 1.4 mt -140.46 159.34 42.41 Favored 'General case' 0 C--O 1.239 0.552 0 C-N-CA 126.017 1.727 . . . . 0.0 107.467 178.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -174.35 137.4 0.51 Allowed 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.249 1.42 . . . . 0.0 108.417 -175.445 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 63.5 mtt85 60.99 156.55 0.11 Allowed Pre-proline 0 CA--C 1.543 0.678 0 C-N-CA 127.464 2.306 . . . . 0.0 112.355 -175.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.08 -22.06 11.64 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.093 1.862 . . . . 0.0 111.667 -178.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 58.95 177.99 0.07 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 126.213 1.805 . . . . 0.0 113.848 -175.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.0 m -130.73 119.67 22.69 Favored 'General case' 0 C--O 1.238 0.451 0 C-N-CA 126.928 2.091 . . . . 0.0 106.618 175.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 128.75 -174.28 19.07 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 125.507 1.527 . . . . 0.0 111.768 169.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 12.6 t -70.22 103.35 2.33 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 160.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 19.6 p -67.57 152.63 45.32 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 124.071 0.948 . . . . 0.0 109.564 179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 5.0 mp -127.21 80.83 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.52 -0.183 0 N-CA-C 104.601 -2.37 . . . . 0.0 104.601 169.353 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.61 164.52 29.69 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 128.212 2.605 . . . . 0.0 105.459 171.393 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.2 p -127.85 138.02 32.01 Favored Pre-proline 0 CA--C 1.541 0.604 0 CA-C-N 120.259 1.39 . . . . 0.0 111.015 -178.151 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.32 -20.01 19.02 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.593 2.196 . . . . 0.0 113.072 178.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -135.55 118.82 16.65 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 124.467 1.107 . . . . 0.0 108.367 178.372 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.414 ' HE3' HD13 ' A' ' 29' ' ' ILE . 44.1 pttt -139.88 155.0 47.42 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 123.675 0.79 . . . . 0.0 109.144 167.573 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.1 mm -64.16 131.02 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 105.409 -2.071 . . . . 0.0 105.409 168.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -113.76 -32.92 1.97 Allowed Glycine 0 CA--C 1.523 0.57 0 C-N-CA 124.233 0.92 . . . . 0.0 113.382 176.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 21.2 ttm-85 -146.21 148.5 32.57 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 7.4 mt -127.43 125.97 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 167.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -57.65 126.99 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 C-N-CA 125.416 1.486 . . . . 0.0 107.1 175.609 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -60.79 123.09 16.48 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 123.522 0.729 . . . . 0.0 109.145 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.15 24.78 74.96 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.726 0.679 . . . . 0.0 113.284 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 22.5 p -76.94 171.69 11.71 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 118.674 1.237 . . . . 0.0 111.576 168.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -58.16 -22.81 58.4 Favored 'Trans proline' 0 CA--C 1.538 0.696 0 C-N-CA 122.197 1.931 . . . . 0.0 113.259 165.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -72.89 -56.97 4.43 Favored 'General case' 0 C--N 1.343 0.308 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 173.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -57.64 -47.07 83.28 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 123.801 0.841 . . . . 0.0 111.273 -175.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 1.6 ptm180 -54.45 -27.48 37.64 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 113.267 0.839 . . . . 0.0 113.267 174.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 2.7 t -73.17 -12.89 61.04 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 118.29 -0.862 . . . . 0.0 112.858 -162.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 47.33 37.88 6.52 Favored 'General case' 0 C--O 1.239 0.532 0 C-N-CA 126.077 1.751 . . . . 0.0 113.536 178.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.8 mtmt -143.33 -17.47 0.64 Allowed 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 113.92 1.082 . . . . 0.0 113.92 173.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -126.54 111.44 14.38 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 124.715 1.206 . . . . 0.0 108.083 -174.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 25.8 mtmt -129.35 172.12 11.82 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 126.011 1.724 . . . . 0.0 110.674 172.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 84.4 t -57.43 118.97 2.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.382 0 C-N-CA 125.108 1.363 . . . . 0.0 109.567 -175.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 124.7 -23.25 6.33 Favored Glycine 0 C--N 1.336 0.57 0 CA-C-O 118.699 -1.056 . . . . 0.0 111.063 175.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -70.06 81.44 0.5 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.62 1.568 . . . . 0.0 112.253 -167.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 87.7 mtt180 -48.42 134.02 15.58 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 126.619 1.968 . . . . 0.0 110.998 -162.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 61.3 mt -102.9 130.1 53.53 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -112.02 -32.85 6.45 Favored 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 125.254 1.422 . . . . 0.0 112.095 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -154.97 167.81 29.1 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.995 0.918 . . . . 0.0 109.038 -177.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.7 p -129.57 114.34 30.61 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.324 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 177.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 63.8 m-80 61.42 -37.54 0.11 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 128.937 2.895 . . . . 0.0 113.638 -169.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 169.2 -4.43 0.04 OUTLIER Glycine 0 CA--C 1.531 1.043 0 C-N-CA 128.103 2.763 . . . . 0.0 112.692 -176.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -90.72 136.0 33.35 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 120.569 2.185 . . . . 0.0 108.91 -177.273 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.6 p -73.3 119.5 17.62 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.457 0.571 . . . . 0.0 109.592 179.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.4 pp -91.31 -24.25 5.63 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.305 0 C-N-CA 122.262 0.225 . . . . 0.0 111.312 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mp -59.73 -32.67 49.98 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 O-C-N 121.389 -0.819 . . . . 0.0 110.903 -179.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -95.2 -7.58 38.68 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 123.801 0.84 . . . . 0.0 112.222 -170.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.7 mtp -105.88 160.0 27.66 Favored Pre-proline 0 N--CA 1.449 -0.487 0 C-N-CA 125.61 1.564 . . . . 0.0 113.348 -169.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -66.96 140.7 55.63 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 123.245 2.63 . . . . 0.0 110.789 169.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -45.93 -52.77 11.02 Favored 'General case' 0 N--CA 1.453 -0.303 0 C-N-CA 126.132 1.773 . . . . 0.0 110.872 173.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.5 -27.23 69.0 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 123.91 0.884 . . . . 0.0 113.261 -177.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.3 t0 -87.29 -34.73 18.79 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-N 118.991 0.814 . . . . 0.0 110.801 -178.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.0 mt -63.93 -39.57 85.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 C-N-CA 124.339 1.056 . . . . 0.0 108.43 169.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.1 t -57.13 -50.7 75.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 121.11 -0.994 . . . . 0.0 109.114 168.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.9 -36.61 81.81 Favored 'General case' 0 C--N 1.338 0.093 0 CA-C-N 118.881 0.764 . . . . 0.0 112.822 -178.614 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -61.75 -42.12 98.56 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 128.067 2.547 . . . . 0.0 110.836 175.076 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 62.4 mt -67.42 -42.75 87.6 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.281 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 174.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 46.1 tttt -57.73 -41.66 82.29 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.559 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.7 t0 -65.88 -14.62 61.84 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 127.462 2.305 . . . . 0.0 112.451 178.018 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -75.48 -12.38 60.23 Favored 'General case' 0 CA--C 1.544 0.731 0 O-C-N 121.042 -1.036 . . . . 0.0 111.86 169.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 60.45 -116.19 8.82 Favored Glycine 0 CA--C 1.528 0.868 0 O-C-N 120.817 -1.177 . . . . 0.0 110.574 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 93.2 mt -87.1 -36.53 18.07 Favored 'General case' 0 CA--C 1.503 -0.862 0 CA-C-N 117.814 0.807 . . . . 0.0 112.342 -177.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -107.86 120.11 41.33 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.159 0.912 . . . . 0.0 108.628 -175.102 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.7 p -126.99 150.52 32.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.3 m -124.55 138.85 54.3 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 19.0 mt -122.61 128.83 51.18 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 124.583 1.153 . . . . 0.0 109.114 178.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -84.77 107.8 17.13 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 175.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.3 pp -113.92 170.97 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 O-C-N 123.875 0.734 . . . . 0.0 110.763 172.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 20.0 mt -121.29 125.74 26.8 Favored Pre-proline 0 C--O 1.234 0.263 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 170.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -85.1 178.84 4.46 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 124.867 3.711 . . . . 0.0 110.715 172.51 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 20.1 mp0 -146.86 135.49 22.07 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 125.9 1.68 . . . . 0.0 107.202 -176.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -123.94 -6.22 7.9 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 123.764 0.826 . . . . 0.0 111.702 170.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -143.42 0.04 1.12 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.758 1.223 . . . . 0.0 113.881 -170.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 18.4 mt -119.95 90.03 3.25 Favored 'General case' 0 C--N 1.339 0.137 0 C-N-CA 124.005 0.922 . . . . 0.0 108.954 -168.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -140.43 -96.75 0.15 Allowed 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 164.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.4 t -163.56 136.31 4.11 Favored Pre-proline 0 C--O 1.241 0.612 0 C-N-CA 126.339 1.856 . . . . 0.0 107.044 179.018 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -77.19 -24.16 9.73 Favored 'Trans proline' 0 N--CA 1.458 -0.589 0 C-N-CA 122.325 2.016 . . . . 0.0 112.658 -174.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 5.3 m -145.09 99.09 3.27 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.12 1.368 . . . . 0.0 108.267 -169.095 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -116.37 87.33 0.43 Allowed Glycine 0 CA--C 1.526 0.735 0 N-CA-C 108.516 -1.834 . . . . 0.0 108.516 176.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -73.43 136.5 24.02 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.294 1.996 . . . . 0.0 109.558 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 16.3 t -127.89 157.04 41.58 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.26 1.424 . . . . 0.0 107.772 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -160.01 176.66 11.58 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.629 0.771 . . . . 0.0 110.304 -178.071 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.329 0 C-N-CA 129.086 3.231 . . . . 0.0 106.109 174.389 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.158 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 p -66.71 144.91 56.08 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 117.882 0.841 . . . . 0.0 109.017 167.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.4 t -179.99 142.43 0.15 Allowed 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 128.811 2.844 . . . . 0.0 104.898 165.156 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.42 67.19 0.23 Allowed Glycine 0 N--CA 1.453 -0.232 0 O-C-N 121.683 -0.636 . . . . 0.0 111.519 -170.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.4 m -70.37 156.23 39.59 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 117.36 0.58 . . . . 0.0 111.652 171.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 16.9 t -151.8 174.71 13.22 Favored 'General case' 0 C--O 1.24 0.564 0 C-N-CA 126.776 2.03 . . . . 0.0 108.226 175.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 147.81 157.38 7.44 Favored Glycine 0 C--O 1.236 0.252 0 C-N-CA 125.206 1.384 . . . . 0.0 110.883 173.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 40.0 t -152.29 51.35 0.78 Allowed 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 124.252 1.021 . . . . 0.0 109.176 176.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.5 tp -139.33 170.72 15.43 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 118.392 0.542 . . . . 0.0 110.536 173.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -177.21 148.54 0.62 Allowed 'General case' 0 C--O 1.239 0.515 0 C-N-CA 127.919 2.488 . . . . 0.0 104.714 167.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 39.1 p -145.11 153.05 41.0 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 172.237 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.2 m -96.09 170.53 9.21 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 -161.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -135.1 94.63 3.17 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 123.505 1.622 . . . . 0.0 107.743 171.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 80.1 t -90.3 93.98 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 104.735 -2.321 . . . . 0.0 104.735 179.123 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.7 p -101.93 116.79 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 -175.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 51.1 mt -133.67 136.85 53.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 -172.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 74.4 m-70 -109.27 149.59 29.22 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 125.396 1.478 . . . . 0.0 109.079 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.433 ' HD3' ' CZ ' ' A' ' 24' ' ' PHE . 1.1 ptm180 -138.69 179.29 6.56 Favored 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 124.937 1.295 . . . . 0.0 109.951 -175.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.16 157.33 15.99 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 176.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -69.92 -20.71 63.34 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 117.76 0.255 . . . . 0.0 111.239 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 31.0 t30 -78.45 -1.83 35.55 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.451 0.7 . . . . 0.0 112.682 -176.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -159.89 -175.74 5.29 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.573 1.149 . . . . 0.0 110.362 -170.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.99 -171.54 29.99 Favored Glycine 0 CA--C 1.522 0.521 0 C-N-CA 125.324 1.44 . . . . 0.0 112.365 177.235 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.433 ' CZ ' ' HD3' ' A' ' 18' ' ' ARG . 29.6 m-85 -73.63 159.68 32.72 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 151.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -105.28 57.52 0.49 Allowed Glycine 0 C--O 1.219 -0.817 0 CA-C-O 118.542 -1.144 . . . . 0.0 110.565 177.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 8.8 p90 -124.02 155.35 38.43 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 118.849 1.324 . . . . 0.0 108.969 171.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -129.63 114.36 30.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 177.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 22.1 mt -78.24 147.38 7.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 171.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 44.0 pt -141.2 174.67 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 C-N-CA 128.691 2.796 . . . . 0.0 107.662 170.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 35.9 p -113.09 177.22 4.7 Favored 'General case' 0 C--O 1.237 0.42 0 C-N-CA 124.182 0.993 . . . . 0.0 108.926 164.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.1 t -144.58 139.62 28.26 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 169.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 14.7 tp -148.04 76.65 1.38 Allowed 'General case' 0 C--O 1.236 0.351 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 6.0 t30 -131.72 -78.86 0.51 Allowed 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 117.903 -1.046 . . . . 0.0 108.825 174.242 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -137.52 157.83 73.11 Favored Pre-proline 0 N--CA 1.472 0.647 0 CA-C-N 120.682 1.583 . . . . 0.0 112.214 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.48 ' HB3' ' H ' ' A' ' 41' ' ' ILE . 97.7 Cg_endo -75.23 160.23 39.64 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.072 2.514 . . . . 0.0 110.197 165.269 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -94.72 73.88 3.65 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 175.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 49.2 m 57.3 171.3 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 128.441 2.696 . . . . 0.0 115.11 178.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.36 -142.93 39.97 Favored Glycine 0 CA--C 1.525 0.711 0 O-C-N 121.302 -0.874 . . . . 0.0 111.435 -175.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 78.9 p -65.5 163.81 15.23 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-O 122.407 1.099 . . . . 0.0 111.171 -178.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 12.5 p -84.61 109.77 18.22 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -172.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.48 ' H ' ' HB3' ' A' ' 35' ' ' PRO . 37.5 mt -126.53 137.12 58.8 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 C-N-CA 127.916 2.487 . . . . 0.0 106.788 -166.437 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.6 t -160.48 123.56 3.39 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 -178.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.0 p -103.59 139.81 20.46 Favored Pre-proline 0 N--CA 1.469 0.514 0 C-N-CA 124.258 1.023 . . . . 0.0 110.335 -173.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -72.96 -27.64 14.01 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 121.75 1.633 . . . . 0.0 113.775 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -141.94 130.02 22.04 Favored 'General case' 0 C--N 1.341 0.22 0 C-N-CA 125.687 1.595 . . . . 0.0 108.948 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 6.8 ptmt -149.66 164.57 34.82 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 125.788 1.635 . . . . 0.0 107.225 176.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 13.2 mm -84.52 143.7 11.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.506 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.0 -36.62 0.94 Allowed Glycine 0 CA--C 1.522 0.491 0 C-N-CA 126.023 1.773 . . . . 0.0 112.745 -177.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 36.6 ttm105 -150.05 159.81 44.12 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 119.096 1.448 . . . . 0.0 108.585 176.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 7.2 mt -121.05 143.58 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 125.46 1.504 . . . . 0.0 107.012 160.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.4 mm -75.43 136.42 25.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -72.03 119.81 16.74 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.637 0.256 . . . . 0.0 110.462 -159.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.32 12.81 83.92 Favored Glycine 0 CA--C 1.527 0.799 0 CA-C-O 119.362 -0.688 . . . . 0.0 114.432 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.502 ' HB2' ' CD ' ' A' ' 55' ' ' PRO . 81.3 p -71.49 176.55 2.09 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 118.342 1.071 . . . . 0.0 112.004 176.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.502 ' CD ' ' HB2' ' A' ' 54' ' ' SER . 4.7 Cg_exo -64.28 -32.27 62.07 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 C-N-CA 122.767 2.311 . . . . 0.0 110.164 176.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.86 -24.52 66.89 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 118.201 -0.904 . . . . 0.0 112.894 175.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -83.65 -47.06 11.64 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 119.128 0.876 . . . . 0.0 110.543 173.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 28.5 mtt-85 -69.11 -41.44 77.41 Favored 'General case' 0 C--O 1.234 0.252 0 C-N-CA 123.247 0.619 . . . . 0.0 111.469 -170.627 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 62.5 m -81.19 81.38 7.41 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 173.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -62.85 89.78 0.03 OUTLIER 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.22 1.008 . . . . 0.0 109.503 178.2 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.4 mmmt -136.85 -33.72 0.76 Allowed 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 126.598 1.959 . . . . 0.0 109.498 -174.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -136.57 154.49 50.68 Favored 'General case' 0 C--O 1.234 0.264 0 C-N-CA 124.576 1.15 . . . . 0.0 109.388 171.055 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 16.3 ptmt -134.9 172.12 13.44 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 124.887 1.275 . . . . 0.0 110.868 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.6 t -59.42 137.66 21.54 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 O-C-N 120.401 -1.437 . . . . 0.0 109.572 -175.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 103.11 -14.05 55.54 Favored Glycine 0 C--N 1.342 0.893 0 C-N-CA 125.119 1.342 . . . . 0.0 114.642 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -67.06 19.46 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 120.368 3.47 . . . . 0.0 120.368 -148.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 4.3 mtt-85 43.61 72.53 0.18 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 126.818 2.047 . . . . 0.0 112.811 168.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 31.4 mt -65.33 147.11 12.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -170.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.6 mt -102.69 -52.75 3.01 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 124.606 1.162 . . . . 0.0 109.915 174.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -156.62 171.06 20.99 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.654 0.782 . . . . 0.0 110.524 -172.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 13.0 p -124.54 113.96 38.65 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.257 0 C-N-CA 125.321 1.449 . . . . 0.0 108.1 175.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 45.09 41.75 5.92 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 125.825 1.65 . . . . 0.0 110.095 -169.092 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.31 4.27 78.96 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-O 118.334 -1.259 . . . . 0.0 115.763 179.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -85.99 122.12 29.58 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 120.262 2.031 . . . . 0.0 106.689 174.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 7.7 t -67.52 134.84 52.04 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 -179.036 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 21.8 pt -108.99 0.27 9.65 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 125.508 1.523 . . . . 0.0 111.193 -176.127 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 75.4 mt -65.41 -61.77 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 C-N-CA 125.088 1.355 . . . . 0.0 109.072 -178.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -92.42 -24.22 18.92 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 123.939 0.896 . . . . 0.0 112.33 -174.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.8 ttt -60.91 137.83 93.77 Favored Pre-proline 0 N--CA 1.439 -0.996 0 C-N-CA 125.185 1.394 . . . . 0.0 108.525 178.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -76.07 148.95 31.9 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 121.853 1.702 . . . . 0.0 109.668 -177.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 32.2 t60 -60.76 -31.94 71.26 Favored 'General case' 0 CA--C 1.537 0.476 0 N-CA-C 113.812 1.041 . . . . 0.0 113.812 -165.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -71.18 -27.8 63.78 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 119.217 0.917 . . . . 0.0 113.029 176.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -74.93 -42.09 58.4 Favored 'General case' 0 C--O 1.224 -0.24 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 175.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 28.5 mt -57.82 -37.86 62.46 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 C-N-CA 124.714 1.205 . . . . 0.0 110.476 172.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.3 t -61.4 -52.28 63.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 O-C-N 120.578 -1.326 . . . . 0.0 109.684 172.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.7 ttmt -59.57 -40.39 87.22 Favored 'General case' 0 C--O 1.22 -0.491 0 C-N-CA 119.116 -1.034 . . . . 0.0 111.697 179.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.36 -42.98 67.39 Favored 'General case' 0 N--CA 1.443 -0.816 0 C-N-CA 126.633 1.973 . . . . 0.0 112.102 177.006 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.3 mt -69.25 -43.03 81.64 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 50.0 tttm -58.37 -49.83 75.84 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 118.329 0.513 . . . . 0.0 110.575 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -62.69 -18.62 62.76 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 128.773 2.829 . . . . 0.0 111.648 177.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.6 -34.26 76.64 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 119.588 1.085 . . . . 0.0 109.627 171.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.83 -97.88 1.84 Allowed Glycine 0 C--N 1.337 0.596 0 C-N-CA 126.119 1.819 . . . . 0.0 108.924 173.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.6 mt -121.64 -28.91 4.47 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 124.272 1.029 . . . . 0.0 111.819 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 p -93.3 143.61 26.1 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 170.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.3 p -145.51 153.4 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 166.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.98 112.22 15.66 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 -178.755 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 7.2 mt -90.54 114.7 26.97 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 173.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -71.85 121.14 18.49 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 164.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pt -128.35 -179.96 3.37 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 125.037 1.335 . . . . 0.0 108.359 175.279 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.469 ' H ' ' HD2' ' A' ' 101' ' ' PRO . 43.7 mt -99.86 -55.05 0.16 Allowed Pre-proline 0 CA--C 1.537 0.464 0 C-N-CA 124.758 1.223 . . . . 0.0 109.202 169.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.469 ' HD2' ' H ' ' A' ' 100' ' ' ILE 0.257 10.7 Cg_endo -61.29 -178.11 0.24 Allowed 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 121.708 1.605 . . . . 0.0 114.39 175.331 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -166.94 175.8 7.42 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 128.736 2.814 . . . . 0.0 105.573 171.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -136.75 5.98 2.91 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.455 1.102 . . . . 0.0 111.914 174.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -124.68 -17.83 5.82 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 121.642 0.735 . . . . 0.0 111.708 -172.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.64 -18.21 60.58 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 124.37 1.068 . . . . 0.0 111.936 -170.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.9 m-80 -136.28 111.84 9.3 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 104.344 -2.465 . . . . 0.0 104.344 162.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.3 m -52.81 -51.69 71.69 Favored Pre-proline 0 CA--C 1.538 0.494 0 C-N-CA 125.506 1.523 . . . . 0.0 110.996 172.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -69.55 149.03 67.74 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 CA-C-N 121.223 1.473 . . . . 0.0 109.385 171.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 96.7 p -132.05 178.81 6.5 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 124.06 0.944 . . . . 0.0 109.495 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -86.74 164.31 35.75 Favored Glycine 0 CA--C 1.531 1.086 0 O-C-N 121.328 -0.857 . . . . 0.0 111.856 -174.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -66.9 177.43 3.56 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.519 2.812 . . . . 0.0 110.506 166.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.9 t -147.37 161.56 40.77 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 122.134 0.968 . . . . 0.0 109.681 160.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -165.2 -167.68 1.23 Allowed 'General case' 0 C--O 1.239 0.529 0 C-N-CA 127.166 2.187 . . . . 0.0 106.782 171.202 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.14 0 N-CA-C 107.79 -2.124 . . . . 0.0 107.79 -165.51 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.991 0 N-CA-C 112.165 -0.374 . . . . 0.0 112.165 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.4 m -73.09 136.68 44.95 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 123.602 0.761 . . . . 0.0 111.279 174.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.6 t -137.26 -170.65 2.78 Favored 'General case' 0 C--O 1.239 0.51 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 150.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.55 -97.97 0.91 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -174.018 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.2 m 59.52 103.8 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 126.603 1.961 . . . . 0.0 110.882 -170.439 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.9 t -122.65 113.7 19.59 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.41 1.084 . . . . 0.0 108.816 177.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.72 143.71 8.84 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 104.513 -3.435 . . . . 0.0 104.513 167.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 37.3 m 69.78 -67.79 0.22 Allowed 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 126.77 2.028 . . . . 0.0 112.759 -175.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 tp -86.31 70.2 10.5 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-O 122.186 0.993 . . . . 0.0 110.527 -165.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.489 ' HG2' ' H ' ' A' ' 11' ' ' THR . 22.9 tt0 -103.88 -172.44 2.11 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 125.534 1.533 . . . . 0.0 108.716 175.456 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' THR . . . . . 0.489 ' H ' ' HG2' ' A' ' 10' ' ' GLN . 17.5 p -136.49 168.46 19.42 Favored 'General case' 0 C--O 1.238 0.471 0 C-N-CA 125.937 1.695 . . . . 0.0 108.486 167.113 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.4 m -122.6 150.71 42.26 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 167.48 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -90.65 147.03 23.56 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 105.734 -1.95 . . . . 0.0 105.734 168.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 39.0 t -131.99 101.41 4.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 104.84 -2.282 . . . . 0.0 104.84 161.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.37 141.04 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 165.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 53.0 mt -134.74 133.19 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 170.383 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 76.7 m-70 -105.84 154.4 20.57 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 125.351 1.46 . . . . 0.0 108.053 173.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.6 ptt180 -136.43 -171.93 3.02 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 170.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.82 170.38 8.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 166.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -80.36 -23.55 40.43 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 113.289 0.848 . . . . 0.0 113.289 -168.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -69.99 -10.05 57.27 Favored 'General case' 0 N--CA 1.472 0.645 0 CA-C-N 119.595 1.089 . . . . 0.0 112.882 176.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -137.15 169.33 17.97 Favored 'General case' 0 C--O 1.241 0.637 0 C-N-CA 124.288 1.035 . . . . 0.0 110.736 -161.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.11 -178.54 45.87 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 179.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -80.1 170.44 16.44 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 142.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.48 52.39 0.83 Allowed Glycine 0 C--O 1.225 -0.437 0 CA-C-O 118.769 -1.017 . . . . 0.0 112.683 -172.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -136.68 142.11 43.16 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 125.764 1.625 . . . . 0.0 110.696 -177.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.4 t -128.08 136.42 60.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 177.642 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 56.5 mt -108.23 120.1 58.99 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 -171.124 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 27.8 pt -110.89 -169.6 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 C-N-CA 126.471 1.909 . . . . 0.0 108.74 -178.099 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 67.83 -177.92 0.21 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.868 1.267 . . . . 0.0 108.319 -159.813 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -161.61 165.64 28.04 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 125.839 1.656 . . . . 0.0 107.164 170.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -57.22 145.35 31.98 Favored 'General case' 0 CA--C 1.536 0.432 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 160.309 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -163.81 157.25 18.69 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 125.001 1.32 . . . . 0.0 109.723 176.256 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 16.4 ptt-85 -51.66 130.76 36.56 Favored Pre-proline 0 CA--C 1.539 0.55 0 C-N-CA 124.34 1.056 . . . . 0.0 109.511 170.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -80.82 -26.36 3.73 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 121.97 1.78 . . . . 0.0 112.5 -171.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 63.43 -54.1 0.2 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 127.769 2.428 . . . . 0.0 113.645 -172.658 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.4 t -79.23 174.84 11.15 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 119.441 1.019 . . . . 0.0 109.549 171.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.99 -54.49 27.52 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 177.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 3.7 p -125.4 146.76 49.46 Favored 'General case' 0 C--O 1.243 0.714 0 C-N-CA 124.386 1.075 . . . . 0.0 108.753 171.086 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 40.8 p -124.05 151.79 43.4 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 171.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 42.0 pt -82.27 5.12 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 C-N-CA 123.776 0.83 . . . . 0.0 110.96 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.5 m -62.21 146.98 49.27 Favored 'General case' 0 N--CA 1.446 -0.64 0 C-N-CA 126.122 1.769 . . . . 0.0 109.105 174.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.5 t -125.15 136.47 28.21 Favored Pre-proline 0 CA--C 1.533 0.306 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 165.697 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -75.15 -9.43 20.56 Favored 'Trans proline' 0 N--CA 1.461 -0.403 0 C-N-CA 122.904 2.403 . . . . 0.0 113.965 -178.293 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -139.73 122.27 16.23 Favored 'General case' 0 CA--C 1.52 -0.199 0 C-N-CA 124.948 1.299 . . . . 0.0 107.801 178.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.3 ptmt -151.55 154.0 35.63 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 124.299 1.04 . . . . 0.0 108.765 168.163 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 31.1 mm -62.57 144.41 14.38 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 CA-C-N 119.17 0.896 . . . . 0.0 109.6 175.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -128.03 -50.62 0.14 Allowed Glycine 0 CA--C 1.526 0.78 0 C-N-CA 126.39 1.948 . . . . 0.0 113.181 179.334 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 2.0 ttm180 -119.99 139.88 51.81 Favored 'General case' 0 CA--C 1.511 -0.531 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 171.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 12.7 mt -120.06 149.76 22.76 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 N-CA-C 105.568 -2.012 . . . . 0.0 105.568 159.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -87.65 129.54 38.83 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 126.648 1.979 . . . . 0.0 108.097 177.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -61.55 124.51 20.86 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 123.636 0.774 . . . . 0.0 109.194 167.406 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.59 17.61 38.32 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-O 117.771 -1.572 . . . . 0.0 112.767 178.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 87.6 p -106.62 163.76 16.32 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-N 119.006 1.403 . . . . 0.0 113.116 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo -63.85 -25.08 67.76 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 122.902 2.401 . . . . 0.0 112.927 169.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.32 -55.88 29.2 Favored 'General case' 0 C--N 1.345 0.404 0 CA-C-N 120.305 1.411 . . . . 0.0 109.883 174.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -63.32 -37.53 87.64 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.316 0.647 . . . . 0.0 112.355 -175.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -65.72 -23.02 66.66 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 121.657 -0.652 . . . . 0.0 112.731 172.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 73.9 m -92.96 50.36 1.54 Allowed 'General case' 0 CA--C 1.533 0.321 0 O-C-N 120.568 -1.332 . . . . 0.0 110.824 174.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -59.2 9.16 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 127.036 2.134 . . . . 0.0 116.359 -177.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -61.92 -16.01 47.56 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 120.906 -1.121 . . . . 0.0 111.505 154.194 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -115.51 137.64 51.85 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 127.393 2.277 . . . . 0.0 107.348 174.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -136.41 166.35 23.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 119.37 0.986 . . . . 0.0 111.146 172.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.4 t -55.94 112.6 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.251 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 168.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 129.95 -21.23 4.99 Favored Glycine 0 N--CA 1.441 -1.0 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 177.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -70.81 106.05 3.44 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 122.982 1.373 . . . . 0.0 110.772 -174.386 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.1 mtm180 -37.38 143.52 0.1 Allowed 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 129.974 3.31 . . . . 0.0 111.297 156.315 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 23.4 mt -132.41 129.89 59.64 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 -174.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.7 mt -94.28 -40.19 10.11 Favored 'General case' 0 CA--C 1.52 -0.186 0 C-N-CA 123.862 0.865 . . . . 0.0 112.051 179.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.42 168.95 25.84 Favored 'General case' 0 C--O 1.236 0.382 0 C-N-CA 124.189 0.996 . . . . 0.0 109.754 -168.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.5 t -129.2 127.12 65.19 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 169.07 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 43.71 34.94 0.93 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 124.631 1.172 . . . . 0.0 112.193 -165.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.93 -3.7 27.02 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-O 118.349 -1.25 . . . . 0.0 113.347 179.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.2 tp60 -74.54 134.69 42.17 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 119.513 1.657 . . . . 0.0 107.057 174.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.1 m -72.53 136.89 45.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 -176.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 17.0 pt -115.76 -8.28 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 C-N-CA 125.755 1.622 . . . . 0.0 112.078 -175.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.7 mm -54.14 -52.75 34.62 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 123.813 0.845 . . . . 0.0 110.344 172.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -89.28 -26.44 21.15 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 111.712 0.264 . . . . 0.0 111.712 -173.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 7.0 ttt -66.5 137.87 95.45 Favored Pre-proline 0 N--CA 1.441 -0.884 0 C-N-CA 126.78 2.032 . . . . 0.0 109.645 -170.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -75.04 148.03 34.56 Favored 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 121.733 1.622 . . . . 0.0 109.051 178.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -54.24 -35.24 62.25 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -174.647 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -58.66 -43.01 89.71 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 119.937 1.244 . . . . 0.0 112.904 177.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -69.41 -39.68 77.76 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 125.243 1.417 . . . . 0.0 108.957 -178.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 36.5 mt -65.89 -40.0 86.28 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.529 1.131 . . . . 0.0 110.872 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 72.6 t -66.03 -41.23 89.26 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 O-C-N 118.998 -2.314 . . . . 0.0 109.607 173.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -52.5 -52.89 52.28 Favored 'General case' 0 C--O 1.223 -0.299 0 CA-C-O 117.489 -1.243 . . . . 0.0 109.539 171.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.51 -35.77 61.02 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 126.758 2.023 . . . . 0.0 112.303 -178.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 71.8 mt -78.11 -37.0 22.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 O-C-N 120.878 -1.139 . . . . 0.0 109.257 -179.133 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -65.47 -36.15 83.01 Favored 'General case' 0 N--CA 1.46 0.07 0 O-C-N 121.363 -0.835 . . . . 0.0 110.406 172.099 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -67.52 -37.65 83.09 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 126.401 1.88 . . . . 0.0 110.051 179.124 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.27 -41.6 80.03 Favored 'General case' 0 C--O 1.236 0.373 0 O-C-N 123.644 0.59 . . . . 0.0 110.769 -178.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 109.71 -141.36 16.1 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 124.63 1.11 . . . . 0.0 110.911 171.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 85.9 mt -70.4 -40.92 73.62 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 169.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.98 131.75 40.59 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 123.102 0.561 . . . . 0.0 110.083 176.022 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.3 p -133.04 139.85 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 C-N-CA 125.165 1.386 . . . . 0.0 107.559 171.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.73 109.14 19.75 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 177.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 17.9 mt -90.51 145.63 24.74 Favored 'General case' 0 CA--C 1.52 -0.177 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 174.422 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 19.7 ttm180 -114.48 114.17 25.44 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 174.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pp -114.97 160.96 14.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 125.003 1.321 . . . . 0.0 108.913 -179.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 89.4 mt -94.62 117.3 66.97 Favored Pre-proline 0 C--O 1.238 0.473 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 167.609 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -87.87 -170.24 0.54 Allowed 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 124.987 3.791 . . . . 0.0 109.472 178.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 4.5 pm0 -145.43 164.54 31.24 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 124.263 1.025 . . . . 0.0 110.049 -173.516 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -139.12 -1.45 1.75 Allowed 'General case' 0 CA--C 1.526 0.056 0 CA-C-N 118.215 0.461 . . . . 0.0 112.132 170.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -121.75 -13.73 8.25 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 114.71 1.374 . . . . 0.0 114.71 -165.379 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 8.5 mt -70.51 154.02 42.32 Favored 'General case' 0 C--O 1.24 0.596 0 C-N-CA 123.73 0.812 . . . . 0.0 109.217 166.098 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -161.29 141.01 10.53 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 126.16 1.784 . . . . 0.0 106.727 161.215 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.9 m -133.63 154.32 80.62 Favored Pre-proline 0 CA--C 1.538 0.503 0 CA-C-N 119.42 1.009 . . . . 0.0 110.104 -177.371 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -76.35 161.94 34.22 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 121.967 1.778 . . . . 0.0 111.468 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 77.3 p -72.21 -13.14 61.46 Favored 'General case' 0 N--CA 1.462 0.147 0 C-N-CA 124.427 1.091 . . . . 0.0 113.336 178.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 179.06 -179.03 48.97 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 108.341 -1.904 . . . . 0.0 108.341 -175.295 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -63.3 136.79 57.3 Favored 'Trans proline' 0 N--CA 1.451 -1.008 0 C-N-CA 122.597 2.198 . . . . 0.0 110.684 178.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.8 m -72.55 136.04 45.74 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 158.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -160.26 -166.85 1.77 Allowed 'General case' 0 C--O 1.237 0.403 0 C-N-CA 124.022 0.929 . . . . 0.0 108.671 167.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.002 0 N-CA-C 103.429 -3.869 . . . . 0.0 103.429 142.031 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.512 0 N-CA-C 108.729 -1.749 . . . . 0.0 108.729 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.5 m -137.05 -91.82 0.24 Allowed 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -178.378 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.8 p -66.74 157.11 33.61 Favored 'General case' 0 C--O 1.238 0.478 0 C-N-CA 124.464 1.106 . . . . 0.0 110.656 173.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.53 177.59 21.27 Favored Glycine 0 CA--C 1.526 0.764 0 C-N-CA 126.568 2.033 . . . . 0.0 109.261 -172.395 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.3 t -61.44 143.27 56.14 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 174.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.5 m -122.02 108.72 13.71 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 124.23 1.012 . . . . 0.0 109.294 -175.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.59 163.1 35.01 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 174.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.36 -53.4 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 125.061 1.344 . . . . 0.0 108.15 174.699 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.4 mp -49.32 108.61 0.2 Allowed 'General case' 0 C--O 1.234 0.284 0 C-N-CA 127.773 2.429 . . . . 0.0 110.868 178.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -63.46 155.15 30.03 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 167.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 32.9 p -132.93 169.07 17.32 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.172 0.589 . . . . 0.0 110.14 171.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.1 t -117.3 158.99 23.42 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 148.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -129.3 94.62 3.83 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 174.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 15.2 t -92.58 96.14 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 C-N-CA 125.838 1.655 . . . . 0.0 107.513 -173.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.1 p -80.42 135.36 25.47 Favored 'Isoleucine or valine' 0 C--O 1.238 0.451 0 C-N-CA 123.322 0.649 . . . . 0.0 109.792 174.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 46.2 mt -132.28 126.46 55.79 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 C-N-CA 125.155 1.382 . . . . 0.0 107.74 176.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -88.76 161.77 16.6 Favored 'General case' 0 C--O 1.233 0.219 0 C-N-CA 125.022 1.329 . . . . 0.0 108.877 171.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 49.3 ptt85 -144.22 -171.11 3.51 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 160.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 168.38 9.59 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 161.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -70.9 -33.68 70.8 Favored 'General case' 0 C--N 1.329 -0.295 0 O-C-N 121.162 -0.962 . . . . 0.0 112.473 -178.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -74.1 6.55 3.36 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 124.586 1.154 . . . . 0.0 113.0 -171.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -143.81 171.66 13.9 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 126.539 1.936 . . . . 0.0 109.261 -169.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.83 176.57 23.01 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 124.434 1.016 . . . . 0.0 111.032 178.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -83.44 133.43 34.91 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 163.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -96.89 57.24 1.28 Allowed Glycine 0 CA--C 1.521 0.441 0 C-N-CA 124.599 1.095 . . . . 0.0 112.66 -171.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -137.97 167.24 22.17 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 125.522 1.529 . . . . 0.0 108.213 172.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.489 HG13 ' H ' ' A' ' 49' ' ' ARG . 0.4 OUTLIER -132.39 157.65 43.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 176.236 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 20.3 mt -117.63 135.82 56.8 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 176.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.7 pt -129.8 156.59 42.19 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 124.104 0.962 . . . . 0.0 109.686 175.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 36.3 t -167.67 -58.97 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 125.383 1.473 . . . . 0.0 109.363 -174.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.7 m 63.1 -65.85 0.1 Allowed 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 126.63 1.972 . . . . 0.0 112.582 -170.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 79.37 -0.48 2.26 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 128.564 2.746 . . . . 0.0 114.976 173.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 14.4 m120 -63.58 -178.11 0.26 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 127.829 2.452 . . . . 0.0 112.217 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.95 130.85 15.42 Favored Pre-proline 0 N--CA 1.469 0.509 0 CA-C-O 116.458 -1.734 . . . . 0.0 108.446 173.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_exo -58.48 -41.51 64.33 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 121.797 1.665 . . . . 0.0 112.083 178.669 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -157.81 -77.28 0.08 Allowed 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 126.08 1.752 . . . . 0.0 106.504 -179.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 92.5 p -142.41 -168.96 2.86 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 127.383 2.273 . . . . 0.0 109.223 175.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 65.0 17.46 63.32 Favored Glycine 0 CA--C 1.53 1.018 0 CA-C-O 119.439 -0.645 . . . . 0.0 113.782 168.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.6 m -65.13 147.31 53.68 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 118.33 1.065 . . . . 0.0 110.378 -171.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.2 p -66.84 160.96 24.92 Favored 'General case' 0 C--O 1.24 0.555 0 C-N-CA 124.318 1.047 . . . . 0.0 109.57 166.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.2 mp -71.34 105.47 1.74 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.453 0 N-CA-C 104.863 -2.273 . . . . 0.0 104.863 160.035 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.2 t -67.83 -170.95 0.18 Allowed 'General case' 0 CA--C 1.542 0.641 0 CA-C-O 121.768 0.794 . . . . 0.0 109.368 169.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 89.7 t -108.47 123.27 37.85 Favored Pre-proline 0 C--O 1.238 0.476 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 174.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -66.48 112.51 2.39 Favored 'Trans proline' 0 N--CA 1.449 -1.111 0 N-CA-C 106.692 -2.08 . . . . 0.0 106.692 159.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 19.4 m80 68.76 108.19 0.05 Allowed 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 126.531 1.933 . . . . 0.0 113.302 171.145 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 52.1 pttt -143.83 157.59 44.27 Favored 'General case' 0 N--CA 1.467 0.421 0 O-C-N 120.678 -1.264 . . . . 0.0 109.22 167.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.1 mm -65.06 123.86 18.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 172.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -110.46 -26.49 4.81 Favored Glycine 0 CA--C 1.535 1.285 0 N-CA-C 114.849 0.7 . . . . 0.0 114.849 176.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.489 ' H ' HG13 ' A' ' 27' ' ' VAL . 67.5 ttt180 -149.85 147.37 27.88 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 177.461 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.5 mt -121.84 131.76 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.72 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 166.257 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 23.8 mm -65.32 153.89 7.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 -177.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -68.51 118.34 11.43 Favored 'General case' 0 C--N 1.328 -0.351 0 O-C-N 121.474 -0.766 . . . . 0.0 110.634 -169.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.41 1.87 24.14 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 115.952 1.141 . . . . 0.0 115.952 169.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.418 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 3.5 p -68.77 175.25 2.07 Favored Pre-proline 0 CA--C 1.554 1.108 0 C-N-CA 126.966 2.106 . . . . 0.0 113.067 178.63 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.418 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 3.3 Cg_exo -64.44 -24.43 64.02 Favored 'Trans proline' 0 C--N 1.351 0.704 0 C-N-CA 121.601 1.534 . . . . 0.0 115.154 -168.097 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -69.38 -48.2 61.9 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 118.803 0.729 . . . . 0.0 109.613 172.569 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -54.13 -49.63 68.75 Favored 'General case' 0 N--CA 1.464 0.262 0 C-N-CA 125.294 1.437 . . . . 0.0 110.168 177.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.4 mmt-85 -68.88 -15.61 63.54 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 123.694 0.797 . . . . 0.0 112.952 177.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 17.5 t -68.89 -28.2 66.47 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 117.724 -1.131 . . . . 0.0 110.357 177.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 59.38 -28.93 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 128.595 2.758 . . . . 0.0 115.475 -174.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 47.9 mtmt -62.73 -33.17 74.58 Favored 'General case' 0 CA--C 1.521 -0.139 0 C-N-CA 125.55 1.54 . . . . 0.0 112.386 178.043 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -105.87 119.49 39.31 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 -165.081 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 3.0 ptpp? -131.99 167.91 18.84 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 119.665 1.12 . . . . 0.0 110.518 -178.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 73.7 t -64.34 137.77 24.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 178.223 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.96 -16.71 57.13 Favored Glycine 0 N--CA 1.447 -0.613 0 CA-C-O 117.475 -1.736 . . . . 0.0 110.725 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -67.45 92.88 0.31 Allowed 'General case' 0 C--N 1.346 0.426 0 CA-C-N 118.909 1.355 . . . . 0.0 108.458 -178.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.3 mtt85 -46.85 128.91 11.41 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 126.543 1.937 . . . . 0.0 110.892 165.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 55.0 mt -96.89 155.76 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 C-N-CA 126.417 1.887 . . . . 0.0 107.086 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.13 -54.52 1.7 Allowed 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 125.976 1.71 . . . . 0.0 107.961 -179.343 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.97 158.87 43.33 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 125.629 1.572 . . . . 0.0 108.764 -176.401 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.2 t -136.2 132.96 50.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 57.75 10.23 1.03 Allowed 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.052 0.941 . . . . 0.0 112.449 -163.359 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 82.04 -2.28 84.42 Favored Glycine 0 CA--C 1.534 1.222 0 C-N-CA 125.0 1.286 . . . . 0.0 113.22 -170.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -75.64 141.32 42.82 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 120.537 2.168 . . . . 0.0 107.233 169.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 33.1 m -56.58 147.14 23.03 Favored 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 118.71 0.686 . . . . 0.0 109.569 164.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.3 pp -116.56 5.66 7.26 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 C-N-CA 124.361 1.065 . . . . 0.0 111.838 172.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 98.0 mt -63.5 143.44 15.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 124.274 1.03 . . . . 0.0 108.282 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 61.62 -18.77 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 128.822 2.849 . . . . 0.0 117.291 172.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 4.8 mtp -55.87 145.78 51.21 Favored Pre-proline 0 C--O 1.241 0.611 0 CA-C-N 119.273 0.942 . . . . 0.0 110.034 177.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -69.18 155.21 68.51 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 122.629 2.22 . . . . 0.0 108.027 170.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -59.7 -32.16 70.25 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.7 -171.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.29 -39.45 72.71 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 126.214 1.806 . . . . 0.0 112.861 175.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 61.8 m-20 -70.98 -46.65 61.95 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -178.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 8.5 mt -64.66 -33.58 64.16 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 C-N-CA 126.018 1.727 . . . . 0.0 111.133 -179.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.5 t -65.07 -51.51 65.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 124.475 1.11 . . . . 0.0 108.888 170.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.71 -37.34 81.38 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 116.77 -1.586 . . . . 0.0 110.984 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -51.64 -49.17 62.78 Favored 'General case' 0 N--CA 1.445 -0.697 0 C-N-CA 125.88 1.672 . . . . 0.0 111.301 173.395 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 53.2 mt -70.23 -38.65 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.16 0 O-C-N 121.066 -1.021 . . . . 0.0 108.873 -178.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.1 tttp -65.96 -38.49 88.73 Favored 'General case' 0 N--CA 1.453 -0.291 0 O-C-N 121.728 -0.607 . . . . 0.0 110.925 -179.416 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -66.45 -19.04 65.69 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 129.381 3.072 . . . . 0.0 111.588 174.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -64.5 -31.05 72.1 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.722 -0.611 . . . . 0.0 111.938 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 87.65 -149.85 22.03 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -169.19 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.7 mt -83.1 -20.76 34.24 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 118.201 1.001 . . . . 0.0 111.534 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.2 p -94.49 139.52 31.05 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 169.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 p -145.02 148.15 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 169.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.6 m -125.09 118.39 26.03 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 178.227 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 71.4 mt -90.78 124.05 34.83 Favored 'General case' 0 CA--C 1.509 -0.597 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 170.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 24.5 ttm105 -96.13 121.46 37.93 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 168.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -125.56 173.88 10.63 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 C-N-CA 125.559 1.543 . . . . 0.0 109.211 -166.303 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.6 mp -114.58 104.57 54.34 Favored Pre-proline 0 C--O 1.237 0.408 0 C-N-CA 124.057 0.943 . . . . 0.0 108.581 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.34 178.93 5.52 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.564 2.843 . . . . 0.0 110.335 173.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.53 162.92 40.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 O-C-N 121.751 -0.593 . . . . 0.0 110.714 -171.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -133.64 -13.37 2.59 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 124.294 1.038 . . . . 0.0 113.156 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.69 -8.11 0.74 Allowed 'General case' 0 C--N 1.322 -0.589 0 C-N-CA 124.397 1.079 . . . . 0.0 112.796 -165.723 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 17.9 mt -90.03 100.06 12.95 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.286 1.434 . . . . 0.0 110.493 -175.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 11.0 p-10 -111.46 -157.67 0.62 Allowed 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.08 1.352 . . . . 0.0 110.152 172.402 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.7 p -121.6 143.17 37.36 Favored Pre-proline 0 CA--C 1.533 0.291 0 CA-C-O 117.253 -1.356 . . . . 0.0 107.816 161.502 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.37 -7.85 20.99 Favored 'Trans proline' 0 CA--C 1.533 0.471 0 C-N-CA 122.633 2.222 . . . . 0.0 115.572 -158.379 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.9 m 36.09 85.36 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.658 1.983 . . . . 0.0 115.014 171.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -122.54 84.69 0.37 Allowed Glycine 0 CA--C 1.53 0.993 0 C-N-CA 124.317 0.961 . . . . 0.0 111.633 178.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -63.42 -52.1 2.18 Favored 'Trans proline' 0 N--CA 1.457 -0.648 0 CA-C-N 119.914 1.857 . . . . 0.0 110.679 167.006 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 14.0 t -66.42 135.24 54.01 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 123.139 0.575 . . . . 0.0 109.628 -177.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.0 m 59.77 85.81 0.1 Allowed 'General case' 0 C--O 1.232 0.173 0 C-N-CA 126.964 2.106 . . . . 0.0 109.629 -170.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.084 0 N-CA-C 107.331 -2.308 . . . . 0.0 107.331 173.363 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.771 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.5 m -104.69 149.45 25.56 Favored 'General case' 0 C--O 1.233 0.212 0 C-N-CA 124.481 1.112 . . . . 0.0 110.434 174.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.3 m -52.04 121.74 7.26 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 123.853 0.861 . . . . 0.0 108.809 165.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 150.14 177.73 24.4 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 106.646 -2.582 . . . . 0.0 106.646 -153.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 68.8 m -112.77 175.19 5.54 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -155.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.7 m -132.88 80.31 1.88 Allowed 'General case' 0 C--O 1.234 0.259 0 C-N-CA 125.735 1.614 . . . . 0.0 107.158 -179.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.61 91.09 0.09 OUTLIER Glycine 0 C--N 1.334 0.452 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -171.092 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 51.3 m -162.74 158.63 23.17 Favored 'General case' 0 C--O 1.238 0.481 0 C-N-CA 126.716 2.006 . . . . 0.0 107.284 166.251 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 11.0 mp 48.37 51.97 14.28 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 126.27 1.828 . . . . 0.0 111.333 175.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.1 tt0 -63.86 134.43 55.18 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 174.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 32.8 p -113.92 169.76 8.76 Favored 'General case' 0 C--O 1.238 0.463 0 C-N-CA 124.661 1.184 . . . . 0.0 109.772 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 42.2 m -111.04 153.23 25.91 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 162.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -122.89 115.38 21.85 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 105.108 -2.182 . . . . 0.0 105.108 174.114 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -112.31 97.14 5.35 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 C-N-CA 123.703 0.801 . . . . 0.0 109.163 -173.107 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.5 p -76.75 141.36 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 170.253 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 59.7 mt -136.58 140.03 44.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 173.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 14.7 m-70 -124.7 113.28 17.78 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.789 2.436 . . . . 0.0 108.117 -170.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.2 ptt180 -106.16 -179.41 3.93 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 119.287 0.948 . . . . 0.0 111.238 -176.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.93 161.08 13.91 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 119.049 0.84 . . . . 0.0 110.257 170.247 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -64.41 -19.79 65.73 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.501 1.12 . . . . 0.0 112.216 177.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -87.68 -16.87 33.13 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 119.537 1.062 . . . . 0.0 113.235 178.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -113.09 -178.53 3.4 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 119.281 0.946 . . . . 0.0 109.877 -171.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -105.72 -176.38 23.93 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 169.414 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -78.31 176.79 8.98 Favored 'General case' 0 CA--C 1.533 0.316 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 153.53 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.406 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -135.13 50.79 0.85 Allowed Glycine 0 C--O 1.224 -0.531 0 CA-C-O 118.234 -1.315 . . . . 0.0 113.195 -172.123 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 11.7 p90 -137.74 135.5 36.44 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 124.756 1.222 . . . . 0.0 110.299 -179.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.2 t -102.91 109.25 26.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 -179.108 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.1 mp -82.26 124.91 39.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 175.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.465 HD13 ' HE2' ' A' ' 46' ' ' LYS . 15.5 pt -111.88 153.28 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 C-N-CA 123.852 0.861 . . . . 0.0 109.746 177.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 31.3 t -91.75 -63.27 1.27 Allowed 'General case' 0 N--CA 1.447 -0.607 0 C-N-CA 126.113 1.765 . . . . 0.0 106.737 169.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 30.1 m 46.92 64.89 1.38 Allowed 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 125.392 1.477 . . . . 0.0 111.647 -173.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 75.71 86.58 0.09 Allowed 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 129.998 3.319 . . . . 0.0 109.691 178.401 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 52.3 t-20 -61.96 136.92 58.17 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 125.381 1.472 . . . . 0.0 109.315 175.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 5.1 mtt180 -132.98 151.99 78.96 Favored Pre-proline 0 C--O 1.236 0.387 0 C-N-CA 124.311 1.044 . . . . 0.0 108.976 167.454 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -70.25 95.93 0.61 Allowed 'Trans proline' 0 N--CA 1.451 -1.008 0 C-N-CA 123.999 3.133 . . . . 0.0 108.642 175.092 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -68.03 110.75 4.07 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 171.381 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.1 t -149.56 103.48 3.27 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 -164.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.25 -109.13 2.7 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 108.542 -1.823 . . . . 0.0 108.542 -179.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.3 m -65.07 109.97 2.34 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 124.328 1.051 . . . . 0.0 109.754 177.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 22.0 p -72.14 148.02 46.08 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.375 1.07 . . . . 0.0 111.843 -174.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 84.4 mt -144.39 -51.97 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.399 0 C-N-CA 125.19 1.396 . . . . 0.0 109.1 -174.235 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -146.86 99.34 3.17 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 123.923 0.889 . . . . 0.0 109.623 -159.238 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 15.9 t -65.55 130.95 94.73 Favored Pre-proline 0 CA--C 1.54 0.571 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -174.407 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.97 -19.92 22.66 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 122.456 2.104 . . . . 0.0 113.905 -174.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -136.59 140.4 42.83 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 120.815 1.643 . . . . 0.0 108.071 176.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.465 ' HE2' HD13 ' A' ' 29' ' ' ILE . 10.7 pttm -156.5 165.64 35.73 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 170.146 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 6.9 mm -66.59 148.35 12.14 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.809 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 167.488 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -134.85 -8.45 1.89 Allowed Glycine 0 CA--C 1.529 0.959 0 C-N-CA 125.081 1.324 . . . . 0.0 113.765 173.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.0 ttt180 -165.75 160.95 17.7 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 126.283 1.833 . . . . 0.0 107.13 165.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 36.4 mt -132.54 149.95 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 125.654 1.582 . . . . 0.0 107.685 172.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 41.5 mm -81.77 118.38 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 C-N-CA 125.529 1.532 . . . . 0.0 108.841 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -62.77 96.31 0.08 Allowed 'General case' 0 C--O 1.235 0.332 0 C-N-CA 125.502 1.521 . . . . 0.0 107.957 168.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.23 0.22 6.41 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 125.216 1.388 . . . . 0.0 113.698 -179.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.406 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 66.8 p -91.45 166.28 18.7 Favored Pre-proline 0 C--O 1.237 0.415 0 CA-C-N 118.911 1.355 . . . . 0.0 113.333 -179.768 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -62.96 -32.29 76.59 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.55 2.167 . . . . 0.0 111.659 166.079 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.02 -47.24 74.97 Favored 'General case' 0 C--N 1.346 0.414 0 CA-C-N 119.04 0.836 . . . . 0.0 110.806 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -67.97 -52.68 33.1 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.744 0.418 . . . . 0.0 111.043 178.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 15.0 mtp85 -57.7 -34.61 69.63 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 121.589 -0.694 . . . . 0.0 112.285 -173.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 61.1 m -62.81 -16.54 58.62 Favored 'General case' 0 CA--C 1.534 0.345 0 CA-C-O 117.709 -1.138 . . . . 0.0 112.494 -178.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 46.21 34.98 2.36 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.105 1.762 . . . . 0.0 113.623 170.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 18.9 mtmm -129.65 -6.99 4.61 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 126.908 2.083 . . . . 0.0 111.829 173.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.14 101.06 4.06 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 -173.434 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 13.3 pttp -126.75 159.41 33.85 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 126.184 1.794 . . . . 0.0 109.688 -168.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . 0.374 0.4 OUTLIER -65.5 111.69 1.53 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.255 0 O-C-N 121.363 -0.836 . . . . 0.0 109.476 179.814 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 129.95 -18.79 5.3 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 128.285 2.85 . . . . 0.0 111.462 -175.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -71.56 97.26 1.66 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.401 1.08 . . . . 0.0 110.333 171.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.2 mtm180 -54.34 150.59 8.52 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 127.687 2.395 . . . . 0.0 111.75 173.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 87.7 mt -124.86 117.14 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 -165.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 76.5 mt -89.0 -40.19 13.17 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 124.327 1.051 . . . . 0.0 112.179 179.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.49 170.65 21.93 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 124.676 1.19 . . . . 0.0 108.764 -170.049 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.4 p -122.48 122.81 67.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 170.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 54.32 -73.0 0.01 OUTLIER 'General case' 0 C--O 1.232 0.177 0 C-N-CA 128.191 2.597 . . . . 0.0 111.783 -170.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -155.75 18.93 0.5 Allowed Glycine 0 CA--C 1.529 0.957 0 C-N-CA 126.887 2.184 . . . . 0.0 112.034 -178.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 24.2 mm100 -115.18 135.17 54.46 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 119.661 1.73 . . . . 0.0 108.572 -175.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.7 m -72.61 110.23 6.83 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 123.977 0.911 . . . . 0.0 109.759 174.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 11.1 pt -75.99 -15.63 15.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 C-N-CA 125.133 1.373 . . . . 0.0 111.962 174.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.511 HD12 ' H ' ' A' ' 77' ' ' ILE . 4.1 mp -56.03 -47.0 80.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 C-N-CA 125.121 1.368 . . . . 0.0 113.713 -164.644 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -113.83 -0.93 14.03 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 124.365 1.066 . . . . 0.0 112.237 -169.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . 0.252 11.0 ttt -68.81 146.95 97.82 Favored Pre-proline 0 N--CA 1.434 -1.245 0 C-N-CA 130.62 3.568 . . . . 0.0 109.846 -178.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -57.07 141.34 94.17 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.816 2.344 . . . . 0.0 109.792 167.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 41.4 t60 -66.64 -36.34 82.33 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 120.246 1.384 . . . . 0.0 111.055 -178.264 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -57.72 -31.34 66.33 Favored 'General case' 0 CA--C 1.534 0.332 0 O-C-N 121.361 -0.837 . . . . 0.0 112.74 171.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -73.42 -48.52 33.1 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 124.308 1.043 . . . . 0.0 109.144 177.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 66.2 mt -56.67 -35.59 45.89 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 C-N-CA 125.505 1.522 . . . . 0.0 110.698 175.151 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 45.9 t -77.07 -39.81 29.57 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 C-N-CA 124.176 0.991 . . . . 0.0 110.313 177.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 21.0 ttmt -60.4 -38.5 84.19 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 120.9 -1.125 . . . . 0.0 110.124 173.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -57.61 -38.63 75.28 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 127.464 2.306 . . . . 0.0 112.598 174.718 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 59.9 mt -68.08 -45.98 82.4 Favored 'Isoleucine or valine' 0 C--N 1.341 0.206 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 174.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 6.5 tttm -64.16 -40.14 95.49 Favored 'General case' 0 CA--C 1.536 0.416 0 O-C-N 121.739 -0.601 . . . . 0.0 110.263 -176.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -65.69 -11.8 48.22 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 127.099 2.159 . . . . 0.0 112.188 176.323 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -66.67 -13.4 61.18 Favored 'General case' 0 CA--C 1.541 0.633 0 O-C-N 121.34 -0.85 . . . . 0.0 112.155 170.656 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 72.66 -90.04 0.55 Allowed Glycine 0 C--N 1.34 0.796 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.6 mt -125.74 -34.49 2.62 Favored 'General case' 0 CA--C 1.514 -0.423 0 C-N-CA 125.589 1.556 . . . . 0.0 111.526 175.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.63 121.85 42.31 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 118.377 0.535 . . . . 0.0 110.131 -179.129 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.7 p -123.96 147.69 28.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 173.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.6 m -119.15 135.79 54.49 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 173.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 31.0 mt -125.19 110.57 14.24 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 125.309 1.444 . . . . 0.0 108.317 -176.326 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 33.4 ttm180 -77.74 106.83 9.81 Favored 'General case' 0 C--O 1.238 0.483 0 C-N-CA 123.811 0.844 . . . . 0.0 111.211 177.087 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -111.27 168.73 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 124.161 0.984 . . . . 0.0 110.597 -175.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.1 mp -93.77 118.15 67.35 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-O 118.061 -0.971 . . . . 0.0 108.627 175.172 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -74.65 -169.48 0.62 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 124.095 3.197 . . . . 0.0 112.296 174.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 3.0 pm0 -155.71 153.76 30.45 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.372 1.469 . . . . 0.0 108.782 -174.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -145.0 18.22 1.6 Allowed 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.428 1.091 . . . . 0.0 111.017 -175.207 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -150.44 -32.79 0.18 Allowed 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 124.903 1.281 . . . . 0.0 113.137 -164.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 49.0 mt -67.37 109.97 3.38 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 126.804 2.041 . . . . 0.0 106.06 173.136 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -162.51 155.75 20.15 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 127.007 2.123 . . . . 0.0 106.002 -176.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -148.03 149.88 33.91 Favored Pre-proline 0 CA--C 1.537 0.453 0 CA-C-N 119.976 1.262 . . . . 0.0 110.238 173.039 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -92.9 -1.73 3.62 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 124.362 3.375 . . . . 0.0 113.872 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 12.8 m -2.83 81.19 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 131.093 3.757 . . . . 0.0 116.087 -172.75 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -96.54 -176.92 35.65 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.012 1.767 . . . . 0.0 110.899 172.138 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -68.24 165.94 26.94 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 122.367 2.045 . . . . 0.0 110.244 173.011 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' SER . . . . . 0.402 ' C ' ' HG ' ' A' ' 113' ' ' SER . 19.4 p -160.54 172.64 16.82 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 123.816 0.846 . . . . 0.0 109.168 175.78 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.402 ' HG ' ' C ' ' A' ' 112' ' ' SER 0.261 71.0 p 55.19 -173.05 0.05 Allowed 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 127.402 2.281 . . . . 0.0 112.587 -173.534 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.932 1 N-CA-C 101.773 -4.531 . . . . 0.0 101.773 -96.221 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.984 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.6 m -63.92 128.59 36.5 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 125.585 1.554 . . . . 0.0 107.333 167.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.8 t -69.2 163.09 25.7 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 119.002 0.819 . . . . 0.0 111.192 -166.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.53 103.44 0.34 Allowed Glycine 0 C--N 1.332 0.332 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 -175.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.4 m -66.14 -37.76 86.48 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 124.678 1.191 . . . . 0.0 113.135 -172.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 65.5 m 43.7 85.3 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 125.224 1.409 . . . . 0.0 112.567 -166.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -86.26 -96.53 0.8 Allowed Glycine 0 CA--C 1.523 0.562 0 N-CA-C 108.582 -1.807 . . . . 0.0 108.582 164.303 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.9 t 67.01 -60.63 0.36 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 126.559 1.944 . . . . 0.0 110.815 -172.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 tp -68.93 165.23 20.42 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.263 1.025 . . . . 0.0 110.083 176.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 70.5 mt-30 -123.75 138.56 54.49 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 170.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 44.6 p -131.22 166.09 21.93 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 167.101 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 m -141.74 150.69 42.12 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.706 1.202 . . . . 0.0 108.421 172.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -104.84 97.37 7.26 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 127.722 2.409 . . . . 0.0 105.862 -179.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 36.9 t -91.65 95.1 5.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 173.059 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.2 p -74.45 137.7 22.59 Favored 'Isoleucine or valine' 0 C--O 1.238 0.493 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 169.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.5 mt -135.61 134.55 51.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 104.835 -2.283 . . . . 0.0 104.835 174.346 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -108.33 160.43 15.87 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.542 1.137 . . . . 0.0 109.526 177.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 43.4 ptt85 -150.95 -179.64 7.46 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 119.424 1.011 . . . . 0.0 109.582 170.347 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.45 162.59 16.39 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 168.14 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.14 -42.52 95.01 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 174.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -71.52 -1.49 13.54 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-O 117.963 -1.018 . . . . 0.0 113.254 -167.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -137.1 179.07 6.6 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 121.278 1.854 . . . . 0.0 110.754 170.136 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.45 165.02 12.08 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 126.002 1.763 . . . . 0.0 110.169 170.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -66.94 148.96 51.27 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 124.637 1.175 . . . . 0.0 108.398 178.16 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.88 49.12 3.31 Favored Glycine 0 C--O 1.222 -0.629 0 CA-C-O 117.94 -1.478 . . . . 0.0 113.698 -174.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -136.22 156.27 48.91 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 120.745 2.273 . . . . 0.0 111.926 174.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.9 t -128.16 106.39 14.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 106.687 -1.597 . . . . 0.0 106.687 -175.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 23.8 mt -73.68 141.67 15.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 168.066 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.419 HD13 ' HE2' ' A' ' 46' ' ' LYS . 35.7 pt -127.09 170.9 16.3 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 C-N-CA 125.308 1.443 . . . . 0.0 110.826 174.561 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 13.5 m 62.57 95.42 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 128.088 2.555 . . . . 0.0 114.27 173.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.5 p -92.61 96.44 10.2 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 158.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 57.3 mt -70.68 151.49 44.86 Favored 'General case' 0 C--O 1.244 0.797 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 155.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 24.3 t30 -168.09 93.69 0.37 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 169.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 33.3 mtt85 -117.1 156.4 48.49 Favored Pre-proline 0 N--CA 1.474 0.754 0 O-C-N 120.723 -1.235 . . . . 0.0 111.202 170.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -81.82 77.61 3.81 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 123.621 2.881 . . . . 0.0 108.972 172.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.0 tm-20 170.91 -42.28 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 129.916 3.286 . . . . 0.0 107.452 173.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.3 m 72.4 -70.38 0.16 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 127.699 2.4 . . . . 0.0 111.289 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 59.34 -173.56 4.1 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.153 0.882 . . . . 0.0 113.48 177.612 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 59.1 m -78.6 111.57 14.8 Favored 'General case' 0 C--O 1.233 0.23 0 O-C-N 121.675 -0.897 . . . . 0.0 109.344 172.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -103.64 137.83 41.14 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.655 1.582 . . . . 0.0 108.709 -179.097 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 10.9 mm -67.89 -76.96 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 118.79 0.723 . . . . 0.0 109.702 -177.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.0 m -56.23 131.11 47.02 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 173.218 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -68.45 156.65 90.02 Favored Pre-proline 0 CA--C 1.541 0.63 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 174.297 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -74.16 -108.75 0.01 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.91 0 C-N-CA 122.58 2.187 . . . . 0.0 109.289 163.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.16 119.79 13.31 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 122.809 1.29 . . . . 0.0 110.973 -167.601 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . 0.419 ' HE2' HD13 ' A' ' 29' ' ' ILE . 15.2 pttm -152.47 160.08 43.29 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 128.523 2.729 . . . . 0.0 106.267 178.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 34.6 mm -64.33 126.76 23.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 164.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -109.22 -21.14 7.49 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 125.717 1.627 . . . . 0.0 113.757 174.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 53.7 ttt180 -161.7 162.34 29.74 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 126.438 1.895 . . . . 0.0 108.06 166.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 6.5 mt -127.98 150.38 33.7 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 126.422 1.889 . . . . 0.0 108.094 170.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 21.3 mm -85.34 128.67 38.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 126.245 1.818 . . . . 0.0 107.226 178.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -62.1 143.02 57.24 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 123.23 0.612 . . . . 0.0 112.047 -172.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.68 -8.11 6.2 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 125.441 1.496 . . . . 0.0 115.47 176.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 84.8 p -67.49 170.25 7.25 Favored Pre-proline 0 C--O 1.239 0.518 0 CA-C-N 118.241 1.02 . . . . 0.0 112.198 -173.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -57.23 -21.61 44.48 Favored 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.028 1.819 . . . . 0.0 112.508 165.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.43 -50.18 13.25 Favored 'General case' 0 C--N 1.342 0.242 0 CA-C-N 119.883 1.22 . . . . 0.0 110.699 174.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -63.58 -45.09 92.01 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 118.533 0.606 . . . . 0.0 110.763 -175.467 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -70.55 -13.78 62.24 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 123.565 0.746 . . . . 0.0 112.197 178.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . 0.426 ' C ' ' H ' ' A' ' 61' ' ' LYS . 35.6 t -63.16 -49.99 72.15 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 119.127 0.876 . . . . 0.0 109.211 179.254 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.93 -21.41 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 128.439 2.695 . . . . 0.0 115.679 -173.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.426 ' H ' ' C ' ' A' ' 59' ' ' CYS . 11.4 mmmm -63.21 -26.56 68.85 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 125.976 1.71 . . . . 0.0 110.565 165.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -99.39 138.43 36.49 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 161.753 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 21.1 pttm -139.74 171.21 14.55 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 123.641 0.777 . . . . 0.0 110.795 164.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 84.6 t -59.85 137.96 21.52 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.714 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 175.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 93.83 -7.31 73.78 Favored Glycine 0 C--N 1.341 0.849 0 O-C-N 121.039 -1.038 . . . . 0.0 110.567 177.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 68.9 m-20 -71.84 98.76 2.05 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 171.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.9 mtt180 -45.78 158.46 0.09 Allowed 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 127.519 2.328 . . . . 0.0 110.841 162.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 19.1 mt -138.47 118.07 14.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -170.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -78.17 -45.25 23.65 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.567 1.147 . . . . 0.0 111.732 172.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -160.3 166.24 29.86 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.181 0.992 . . . . 0.0 112.163 -160.475 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.2 p -128.66 111.83 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 C-N-CA 126.191 1.796 . . . . 0.0 110.138 -178.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.5 m-20 56.0 17.48 2.64 Favored 'General case' 0 N--CA 1.465 0.282 0 C-N-CA 125.285 1.434 . . . . 0.0 111.147 -168.545 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.48 -10.33 61.13 Favored Glycine 0 CA--C 1.529 0.944 0 CA-C-O 117.527 -1.707 . . . . 0.0 114.382 -175.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -75.92 132.15 40.08 Favored 'General case' 0 C--N 1.341 0.235 0 CA-C-N 120.51 2.155 . . . . 0.0 107.478 177.394 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.3 p -61.68 137.02 58.22 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 124.181 0.992 . . . . 0.0 109.949 175.039 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.7 pt -114.55 -4.37 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 C-N-CA 124.908 1.283 . . . . 0.0 111.331 179.286 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mt -57.9 145.14 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.596 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 162.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 18.7 m-80 67.13 -21.92 0.11 Allowed 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 128.117 2.567 . . . . 0.0 116.036 171.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 6.6 mtp -69.45 150.7 96.95 Favored Pre-proline 0 C--O 1.244 0.767 0 C-N-CA 124.658 1.183 . . . . 0.0 109.86 175.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -74.68 154.46 44.15 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 123.17 2.58 . . . . 0.0 109.856 173.154 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -54.99 -41.82 71.71 Favored 'General case' 0 N--CA 1.462 0.13 0 C-N-CA 123.42 0.688 . . . . 0.0 111.604 -178.418 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -57.15 -44.58 83.56 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-O 118.822 -0.609 . . . . 0.0 111.332 -174.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.52 -42.44 74.69 Favored 'General case' 0 C--O 1.221 -0.413 0 O-C-N 124.36 1.037 . . . . 0.0 110.011 -175.763 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 68.4 mt -63.33 -41.22 91.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 124.797 1.239 . . . . 0.0 109.679 178.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 41.4 t -62.55 -48.04 90.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 O-C-N 121.161 -0.962 . . . . 0.0 109.456 174.027 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 6.1 tptt -58.44 -43.68 88.86 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 118.614 -0.708 . . . . 0.0 111.279 176.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.05 -34.45 73.43 Favored 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 126.154 1.781 . . . . 0.0 111.71 -176.873 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 58.1 mt -73.15 -47.63 46.56 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 173.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.3 tttt -58.29 -32.92 68.89 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 122.096 -0.378 . . . . 0.0 111.686 -177.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -99.76 2.09 43.81 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 125.173 1.389 . . . . 0.0 112.276 -177.024 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -54.92 -29.57 56.55 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -171.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.456 ' C ' ' H ' ' A' ' 94' ' ' SER . . . 123.13 27.57 1.49 Allowed Glycine 0 CA--C 1.526 0.768 0 C-N-CA 124.349 0.976 . . . . 0.0 113.285 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 7.8 mt 58.02 -23.11 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 129.023 2.929 . . . . 0.0 114.555 -164.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.456 ' H ' ' C ' ' A' ' 92' ' ' GLY . 1.9 m -93.56 148.59 21.95 Favored 'General case' 0 N--CA 1.435 -1.195 0 N-CA-C 105.24 -2.133 . . . . 0.0 105.24 161.316 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.1 p -143.26 140.48 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 0 N-CA-C 105.009 -2.219 . . . . 0.0 105.009 169.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.9 m -117.97 102.42 9.04 Favored 'General case' 0 N--CA 1.441 -0.911 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 21.6 mt -90.13 122.1 32.78 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 106.476 -1.676 . . . . 0.0 106.476 -172.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.1 ttt180 -83.73 109.77 17.76 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.011 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -111.94 160.97 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 123.429 0.692 . . . . 0.0 110.83 -177.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 28.5 mt -90.6 120.35 68.92 Favored Pre-proline 0 CA--C 1.537 0.459 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 169.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -87.19 -170.83 0.65 Allowed 'Trans proline' 0 N--CA 1.45 -1.046 0 C-N-CA 123.915 3.077 . . . . 0.0 110.978 177.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -145.77 170.41 16.58 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 123.642 0.777 . . . . 0.0 109.293 -178.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -146.55 -7.52 0.51 Allowed 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 113.11 0.782 . . . . 0.0 113.11 156.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -102.75 -9.25 20.17 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 123.787 0.835 . . . . 0.0 112.688 -166.52 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 18.1 mt -77.33 163.01 26.84 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 123.416 0.687 . . . . 0.0 109.706 -178.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -147.85 179.29 7.83 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 161.553 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.3 t -72.09 126.51 91.19 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 167.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -73.65 -179.56 4.65 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 C-N-CA 123.211 2.608 . . . . 0.0 109.651 171.403 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 5.7 t -145.33 160.78 41.01 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 160.381 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -138.55 167.18 25.11 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 108.652 -1.779 . . . . 0.0 108.652 170.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -74.52 -175.93 2.51 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 123.348 2.699 . . . . 0.0 111.673 -175.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 10.6 t -129.88 -174.65 3.37 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 127.551 2.34 . . . . 0.0 107.71 165.762 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 24.2 t -67.03 175.84 2.38 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 124.288 1.035 . . . . 0.0 110.316 174.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.42 0 N-CA-C 106.332 -2.707 . . . . 0.0 106.332 144.498 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.391 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.7 t -64.29 112.37 3.03 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 171.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.2 m -81.18 98.52 8.1 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 171.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.21 -143.57 3.79 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 108.338 -1.905 . . . . 0.0 108.338 -177.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.8 m -140.11 -5.59 1.28 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 114.125 1.158 . . . . 0.0 114.125 174.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.3 p -124.84 160.97 27.55 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 120.583 1.538 . . . . 0.0 111.127 -176.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 144.58 71.29 0.02 OUTLIER Glycine 0 C--N 1.332 0.308 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 172.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 19.7 t -62.91 -53.71 49.8 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 117.815 0.808 . . . . 0.0 108.986 173.598 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -102.33 140.7 36.27 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 177.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -156.15 -130.59 0.03 OUTLIER 'General case' 0 C--O 1.232 0.134 0 C-N-CA 125.511 1.525 . . . . 0.0 109.691 173.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.7 p -136.47 169.18 18.11 Favored 'General case' 0 C--N 1.319 -0.746 0 C-N-CA 129.232 3.013 . . . . 0.0 110.589 -177.606 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -135.23 163.83 29.07 Favored 'General case' 0 CA--C 1.522 -0.12 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 162.397 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -134.42 94.85 3.27 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 127.185 2.194 . . . . 0.0 107.245 -174.043 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.8 t -96.89 109.73 23.63 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 125.373 1.469 . . . . 0.0 107.86 -165.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 1.5 t -84.16 141.89 14.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 173.634 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 69.7 mt -138.22 149.79 24.56 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 105.57 -2.011 . . . . 0.0 105.57 173.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 91.3 m-70 -130.82 156.38 45.1 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.928 1.291 . . . . 0.0 109.271 -176.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 35.3 ptt180 -143.08 -176.86 5.08 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 119.779 1.172 . . . . 0.0 110.048 176.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.44 163.31 12.54 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 124.047 0.939 . . . . 0.0 108.89 170.199 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -70.57 -19.33 62.88 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -177.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.8 m-20 -90.31 5.54 46.81 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 119.745 1.157 . . . . 0.0 112.07 177.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -140.92 176.77 8.53 Favored 'General case' 0 N--CA 1.445 -0.697 0 O-C-N 121.253 -0.905 . . . . 0.0 111.493 -172.832 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.42 170.73 14.61 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 178.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -71.49 171.14 11.86 Favored 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 152.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -127.94 55.43 0.75 Allowed Glycine 0 C--O 1.222 -0.646 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 25.7 p90 -131.4 158.61 40.3 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 170.215 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 9.2 t -136.88 127.79 41.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 -174.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.0 mp -87.07 146.8 5.85 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 175.166 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 31.6 pt -133.68 170.79 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 C-N-CA 126.326 1.85 . . . . 0.0 108.239 160.174 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 t -137.38 -177.7 4.89 Favored 'General case' 0 C--O 1.238 0.478 0 C-N-CA 125.508 1.523 . . . . 0.0 108.847 174.143 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -151.39 99.36 2.63 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 103.743 -2.688 . . . . 0.0 103.743 168.173 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 11.7 tp -163.9 103.32 0.9 Allowed 'General case' 0 C--O 1.233 0.195 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 176.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 15.0 m-80 -64.85 -67.47 0.43 Allowed 'General case' 0 C--O 1.234 0.286 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 160.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 29.8 ptt-85 -158.71 157.07 28.2 Favored Pre-proline 0 C--O 1.236 0.393 0 CA-C-N 118.705 0.684 . . . . 0.0 111.803 -177.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -68.35 175.7 6.53 Favored 'Trans proline' 0 CA--C 1.537 0.629 0 C-N-CA 122.681 2.254 . . . . 0.0 110.68 167.387 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -144.37 -77.19 0.22 Allowed 'General case' 0 C--O 1.235 0.308 0 N-CA-C 107.297 -1.372 . . . . 0.0 107.297 168.173 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -88.93 100.03 12.87 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.392 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 45.42 -111.9 0.66 Allowed Glycine 0 C--N 1.338 0.646 0 C-N-CA 127.398 2.428 . . . . 0.0 113.495 173.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.0 m -125.06 102.79 7.67 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 p -73.49 154.56 39.86 Favored 'General case' 0 C--O 1.24 0.603 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 165.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 72.2 mt -68.77 112.12 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 176.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.6 t -157.08 174.86 14.87 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 125.35 1.46 . . . . 0.0 108.035 174.225 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 10.7 p -126.95 140.18 37.06 Favored Pre-proline 0 C--O 1.237 0.437 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 165.566 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -76.56 -80.36 0.01 OUTLIER 'Trans proline' 0 N--CA 1.446 -1.275 0 C-N-CA 121.884 1.722 . . . . 0.0 109.281 163.264 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 2.5 m80 -65.37 116.34 6.57 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 124.25 1.02 . . . . 0.0 111.471 -168.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 39.5 pttt -135.44 151.86 50.82 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 168.055 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 30.0 mm -60.12 115.92 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 C-N-CA 124.261 1.024 . . . . 0.0 109.208 169.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -90.42 -39.43 5.98 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 124.013 0.816 . . . . 0.0 112.629 172.097 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 41.0 ttt85 -149.02 161.46 41.88 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 118.266 1.033 . . . . 0.0 109.559 178.752 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 15.4 mt -131.99 136.71 56.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 126.298 1.839 . . . . 0.0 106.171 169.455 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.4 mp -79.81 132.55 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 C-N-CA 126.016 1.726 . . . . 0.0 108.089 179.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -55.89 133.25 51.25 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 125.942 1.697 . . . . 0.0 109.505 177.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.36 -8.92 75.18 Favored Glycine 0 CA--C 1.528 0.892 0 C-N-CA 123.397 0.522 . . . . 0.0 112.46 169.219 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 76.5 p -71.22 167.1 32.39 Favored Pre-proline 0 N--CA 1.451 -0.385 0 CA-C-N 118.087 0.943 . . . . 0.0 112.836 -169.183 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -54.1 -39.76 84.46 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 C-N-CA 122.35 2.033 . . . . 0.0 111.992 166.414 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.11 -55.78 28.46 Favored 'General case' 0 C--N 1.341 0.216 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -57.13 -30.77 64.69 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.126 1.37 . . . . 0.0 112.447 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 46.6 mtt-85 -83.97 -29.29 27.15 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 114.533 1.309 . . . . 0.0 114.533 175.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 77.0 m -69.46 -27.72 65.48 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 120.292 1.405 . . . . 0.0 111.815 179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 51.54 -160.53 0.09 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.914 0.886 . . . . 0.0 110.496 -169.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 60.9 5.33 0.95 Allowed 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 125.544 1.538 . . . . 0.0 113.323 -167.007 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 14.7 tp -146.59 108.58 4.39 Favored 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.613 1.965 . . . . 0.0 107.17 -175.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 33.4 mttm -133.95 171.1 14.65 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 125.495 1.518 . . . . 0.0 110.419 -175.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 58.2 t -76.47 101.3 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -174.057 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 139.63 -12.78 3.19 Favored Glycine 0 CA--C 1.522 0.515 0 C-N-CA 127.0 2.238 . . . . 0.0 108.951 -175.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 57.7 m-20 -74.6 110.75 9.14 Favored 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 123.219 1.485 . . . . 0.0 107.346 -178.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 19.1 mmt-85 -59.9 158.69 10.25 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 113.918 -1.492 . . . . 0.0 110.377 162.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 35.0 mt -131.6 132.18 62.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 -175.496 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.7 mt -84.49 -51.25 7.05 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 124.323 1.049 . . . . 0.0 111.172 176.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -151.68 168.91 23.53 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 124.53 1.132 . . . . 0.0 109.609 -164.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.1 t -130.27 118.14 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 179.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 39.32 63.12 1.02 Allowed 'General case' 0 N--CA 1.464 0.252 0 C-N-CA 125.53 1.532 . . . . 0.0 110.733 -174.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 69.5 2.09 33.01 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-O 117.672 -1.627 . . . . 0.0 114.461 176.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -111.77 154.03 25.65 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 120.203 2.002 . . . . 0.0 111.676 -171.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 26.7 p -65.9 142.27 57.95 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.984 -179.15 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 5.0 pt -129.8 -5.78 2.87 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 123.318 0.647 . . . . 0.0 112.333 168.213 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 96.5 mt -73.66 -22.56 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.662 0 C-N-CA 125.046 1.338 . . . . 0.0 109.639 173.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 -124.84 -42.78 2.03 Favored 'General case' 0 C--N 1.341 0.215 0 C-N-CA 124.186 0.994 . . . . 0.0 111.734 -162.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.4 mtp -57.28 151.09 38.89 Favored Pre-proline 0 CA--C 1.533 0.294 0 C-N-CA 123.407 0.683 . . . . 0.0 110.489 176.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -69.34 149.06 69.09 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 121.149 1.233 . . . . 0.0 109.066 171.442 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -55.65 -41.53 73.74 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 124.085 0.954 . . . . 0.0 112.445 -170.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.91 -30.01 70.6 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 118.936 -0.554 . . . . 0.0 111.88 -179.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -70.68 -50.97 30.86 Favored 'General case' 0 C--O 1.223 -0.326 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 14.4 mt -60.18 -40.04 82.37 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 C-N-CA 124.45 1.1 . . . . 0.0 110.19 178.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.0 t -60.52 -47.23 93.58 Favored 'Isoleucine or valine' 0 C--O 1.241 0.611 0 O-C-N 120.78 -1.2 . . . . 0.0 109.97 175.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 22.6 ttmt -65.62 -42.13 91.92 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 117.895 -1.05 . . . . 0.0 110.102 178.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -48.53 -44.86 36.69 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 126.22 1.808 . . . . 0.0 111.097 176.483 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 41.4 mt -73.79 -44.24 52.32 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 48.2 tttt -58.87 -39.09 80.32 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 121.774 -0.579 . . . . 0.0 110.826 -178.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.7 -2.18 57.93 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 127.402 2.281 . . . . 0.0 112.436 -179.463 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.57 -13.4 3.77 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 116.058 1.873 . . . . 0.0 116.058 -164.005 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.45 44.3 6.59 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 118.875 0.762 . . . . 0.0 111.761 172.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 34.9 mt 66.49 -34.83 0.22 Allowed 'General case' 0 CA--C 1.511 -0.524 0 C-N-CA 129.245 3.018 . . . . 0.0 113.714 -175.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -93.47 143.25 26.47 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 178.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.5 p -144.88 135.95 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 172.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 35.0 m -116.53 106.26 13.38 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 -177.008 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 11.8 mt -91.04 110.48 21.75 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 125.07 1.348 . . . . 0.0 108.362 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 ttt180 -78.74 119.68 22.31 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 166.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -117.99 172.55 5.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 C-N-CA 124.733 1.213 . . . . 0.0 109.19 177.01 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 62.4 mt -105.26 -70.8 0.03 OUTLIER Pre-proline 0 CA--C 1.542 0.657 0 C-N-CA 124.647 1.179 . . . . 0.0 108.122 174.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -74.64 106.8 2.32 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.311 2.007 . . . . 0.0 114.51 -171.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -80.41 152.79 28.65 Favored 'General case' 0 N--CA 1.444 -0.751 0 C-N-CA 124.054 0.941 . . . . 0.0 110.482 177.655 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -85.84 -1.79 57.6 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 126.129 1.771 . . . . 0.0 112.112 -176.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -133.15 10.28 4.15 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.553 1.941 . . . . 0.0 110.78 -161.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 13.6 mt -135.85 86.14 2.21 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 126.841 2.056 . . . . 0.0 107.921 -178.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 28.2 m120 -62.12 162.8 8.93 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.297 0.639 . . . . 0.0 109.472 176.227 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.5 m -132.05 158.27 75.98 Favored Pre-proline 0 CA--C 1.537 0.447 0 O-C-N 121.766 -0.583 . . . . 0.0 110.961 -173.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -71.39 94.5 0.67 Allowed 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 123.81 3.006 . . . . 0.0 111.008 174.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.6 p -158.53 166.57 31.83 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 124.131 0.972 . . . . 0.0 109.305 168.184 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -154.96 161.02 30.1 Favored Glycine 0 CA--C 1.53 0.988 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 171.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -78.99 175.79 10.56 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.47 2.78 . . . . 0.0 110.995 175.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.9 p -127.0 157.66 38.98 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 156.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -147.53 -60.96 0.27 Allowed 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 125.836 1.654 . . . . 0.0 106.902 173.163 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.006 0 N-CA-C 104.229 -3.548 . . . . 0.0 104.229 124.307 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.083 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.7 m 61.13 177.87 0.11 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.267 1.027 . . . . 0.0 111.667 -171.058 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.0 p -69.8 126.69 30.46 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 124.683 1.193 . . . . 0.0 109.284 174.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.43 -176.9 49.53 Favored Glycine 0 CA--C 1.53 1.013 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 164.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 59.9 m -153.08 126.55 8.7 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 169.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.8 m -153.1 167.18 30.12 Favored 'General case' 0 C--O 1.239 0.549 0 C-N-CA 125.726 1.61 . . . . 0.0 108.518 171.757 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 136.29 88.7 0.25 Allowed Glycine 0 C--N 1.334 0.42 0 N-CA-C 106.514 -2.634 . . . . 0.0 106.514 -168.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.8 m -87.09 -26.23 23.76 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 123.842 0.857 . . . . 0.0 112.989 -177.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 16.1 tp -108.54 97.01 6.74 Favored 'General case' 0 C--O 1.236 0.372 0 C-N-CA 123.161 0.584 . . . . 0.0 110.791 -160.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 6.3 mm-40 -61.89 133.32 55.27 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-O 121.893 0.854 . . . . 0.0 110.126 169.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 51.0 p -140.27 168.88 18.77 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 128.508 2.723 . . . . 0.0 105.769 165.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 m -123.45 151.99 42.11 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 161.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -108.67 130.39 55.34 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 128.752 2.821 . . . . 0.0 105.332 176.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.8 t -132.99 109.19 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.4 p -100.61 132.32 46.5 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 176.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 46.2 mt -136.05 147.21 28.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.711 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -120.87 159.28 25.84 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 124.36 1.064 . . . . 0.0 109.564 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.1 ptt180 -140.6 -161.95 1.28 Allowed 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 169.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.23 169.24 10.75 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 169.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 17.7 mm-40 -64.73 -27.37 68.86 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -80.43 -6.92 58.84 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 114.541 1.311 . . . . 0.0 114.541 -173.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -141.25 176.26 8.99 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 119.547 1.067 . . . . 0.0 110.596 -170.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.6 171.77 16.79 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 123.982 0.801 . . . . 0.0 111.353 -172.071 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -85.04 137.9 32.77 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 163.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -97.71 75.3 0.63 Allowed Glycine 0 N--CA 1.442 -0.918 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 -178.093 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -157.77 148.88 21.31 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 164.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.2 t -137.59 131.04 43.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -174.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 10.3 mt -71.06 154.47 7.92 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.026 0 C-N-CA 124.788 1.235 . . . . 0.0 109.751 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 49.2 pt -134.56 179.12 4.56 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 C-N-CA 127.995 2.518 . . . . 0.0 109.143 149.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.5 t 76.75 173.34 0.22 Allowed 'General case' 0 C--O 1.238 0.468 0 C-N-CA 128.84 2.856 . . . . 0.0 110.033 -171.174 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -165.21 179.82 6.06 Favored 'General case' 0 C--O 1.24 0.554 0 C-N-CA 124.348 1.059 . . . . 0.0 109.175 -178.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 1.8 mp -72.43 106.64 4.62 Favored 'General case' 0 CA--C 1.522 -0.108 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 167.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 15.7 t30 -156.47 119.56 4.17 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 127.399 2.28 . . . . 0.0 104.918 179.086 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -162.82 155.54 16.36 Favored Pre-proline 0 CA--C 1.536 0.409 0 C-N-CA 125.161 1.384 . . . . 0.0 108.39 178.708 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -67.8 179.97 2.39 Favored 'Trans proline' 0 CA--C 1.534 0.513 0 C-N-CA 123.581 2.854 . . . . 0.0 112.377 175.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -74.31 -71.67 0.32 Allowed 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 172.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 80.2 p -78.28 171.08 15.59 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 118.853 0.751 . . . . 0.0 111.249 174.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.93 26.25 60.71 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-O 118.736 -1.036 . . . . 0.0 113.647 167.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -64.29 124.55 22.01 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 119.283 1.542 . . . . 0.0 111.264 -172.508 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 28.2 p -124.14 162.99 22.44 Favored 'General case' 0 C--O 1.238 0.457 0 C-N-CA 125.255 1.422 . . . . 0.0 109.185 169.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 24.2 mm -72.57 84.42 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 CA-C-O 123.259 1.504 . . . . 0.0 109.452 178.091 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.7 t -70.92 170.31 12.95 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.848 1.259 . . . . 0.0 109.209 156.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 17.2 t -121.36 113.33 32.36 Favored Pre-proline 0 CA--C 1.532 0.27 0 C-N-CA 126.103 1.761 . . . . 0.0 106.882 -178.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -75.03 -20.29 16.94 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 122.389 2.06 . . . . 0.0 113.906 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -138.9 120.78 15.45 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 121.029 1.74 . . . . 0.0 108.913 177.653 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.9 pttt -140.7 162.94 34.2 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 168.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 11.4 mm -65.24 130.87 30.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 172.455 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.06 -51.75 0.72 Allowed Glycine 0 CA--C 1.522 0.491 0 C-N-CA 124.619 1.104 . . . . 0.0 111.224 169.112 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 40.0 ttt85 -134.68 151.79 51.28 Favored 'General case' 0 C--O 1.24 0.579 0 CA-C-N 119.142 1.471 . . . . 0.0 111.165 -168.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 50.5 mt -137.33 119.24 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 C-N-CA 127.14 2.176 . . . . 0.0 106.134 179.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -46.83 126.75 2.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 127.713 2.405 . . . . 0.0 108.418 156.233 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -63.31 128.31 35.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 165.454 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 105.01 4.99 41.51 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 111.514 -0.634 . . . . 0.0 111.514 173.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.5 p -80.88 159.79 67.85 Favored Pre-proline 0 N--CA 1.449 -0.496 0 O-C-N 121.24 -1.153 . . . . 0.0 113.752 -171.693 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -61.71 -35.01 82.25 Favored 'Trans proline' 0 CA--C 1.539 0.737 0 C-N-CA 122.917 2.412 . . . . 0.0 112.404 168.695 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.62 -46.35 69.51 Favored 'General case' 0 C--N 1.34 0.188 0 CA-C-O 118.111 -0.947 . . . . 0.0 111.686 -178.069 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.6 t0 -61.95 -47.64 83.95 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 118.912 0.778 . . . . 0.0 109.805 -172.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 -59.89 -27.47 66.74 Favored 'General case' 0 C--N 1.341 0.229 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.671 177.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 6.1 t -60.57 -37.58 81.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-O 118.405 -0.807 . . . . 0.0 109.982 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.04 -14.34 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 130.535 3.534 . . . . 0.0 116.111 177.577 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.08 -19.19 51.89 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 125.187 1.395 . . . . 0.0 111.477 161.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -119.83 131.92 55.44 Favored 'General case' 0 C--O 1.235 0.292 0 C-N-CA 125.672 1.589 . . . . 0.0 107.688 176.301 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.09 171.32 14.48 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 124.194 0.998 . . . . 0.0 110.041 172.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.4 t -55.89 141.21 12.88 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 O-C-N 121.321 -0.862 . . . . 0.0 109.112 174.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.9 -12.92 65.59 Favored Glycine 0 CA--C 1.534 1.231 0 C-N-CA 125.147 1.356 . . . . 0.0 115.688 172.331 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -68.0 7.31 0.56 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 118.262 2.69 . . . . 0.0 118.262 -151.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.405 HH21 ' NE2' ' A' ' 102' ' ' GLN . 30.8 mtm180 51.87 89.56 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 126.438 1.895 . . . . 0.0 113.122 -178.307 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 61.3 mt -71.95 139.71 19.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.694 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -113.52 -53.05 2.72 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 125.632 1.573 . . . . 0.0 108.768 177.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -138.25 154.09 49.08 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.589 0.709 . . . . 0.0 112.319 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 55.6 t -112.15 116.55 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 169.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 57.73 5.12 0.31 Allowed 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 126.763 2.025 . . . . 0.0 115.525 177.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.91 12.28 26.34 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-O 118.81 -0.994 . . . . 0.0 112.863 -175.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 6.0 tp-100 -103.19 140.29 37.56 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 126.405 1.882 . . . . 0.0 108.401 171.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 62.9 m -78.68 100.76 7.18 Favored 'General case' 0 C--O 1.233 0.194 0 C-N-CA 124.666 1.186 . . . . 0.0 111.996 -177.062 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.7 pp -77.6 -5.29 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 179.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.495 HD13 ' H ' ' A' ' 77' ' ' ILE . 0.6 OUTLIER -70.28 -9.92 13.11 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 124.764 1.226 . . . . 0.0 112.381 -178.811 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -138.61 -24.51 0.94 Allowed 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 114.785 1.402 . . . . 0.0 114.785 -174.34 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.9 mtp -61.06 152.15 72.31 Favored Pre-proline 0 C--O 1.239 0.506 0 CA-C-N 119.856 1.207 . . . . 0.0 110.8 172.205 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -67.12 157.46 61.63 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 121.727 1.618 . . . . 0.0 110.131 171.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -63.21 -37.77 88.53 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.732 -0.605 . . . . 0.0 111.164 -172.057 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.49 -32.47 73.93 Favored 'General case' 0 C--N 1.338 0.068 0 CA-C-N 119.352 0.978 . . . . 0.0 111.975 178.019 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.74 -52.23 65.12 Favored 'General case' 0 C--O 1.224 -0.249 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 176.623 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 54.2 mt -65.88 -41.63 90.42 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.492 0 C-N-CA 125.91 1.684 . . . . 0.0 109.764 -175.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 17.1 t -60.14 -45.71 95.49 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 O-C-N 121.101 -0.999 . . . . 0.0 110.096 173.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? -59.86 -47.61 85.05 Favored 'General case' 0 C--O 1.219 -0.506 0 CA-C-O 118.692 -0.671 . . . . 0.0 109.376 177.267 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -57.32 -33.75 68.03 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 125.757 1.623 . . . . 0.0 112.676 -177.111 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 63.5 mt -75.1 -45.12 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 175.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.6 ttmp? -60.67 -49.1 78.87 Favored 'General case' 0 CA--C 1.537 0.443 0 O-C-N 121.615 -0.678 . . . . 0.0 110.021 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -76.65 5.93 6.75 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 129.948 3.299 . . . . 0.0 111.842 177.524 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -63.51 -24.01 67.64 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 119.28 0.946 . . . . 0.0 112.386 176.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.81 48.16 5.61 Favored Glycine 0 C--N 1.338 0.659 0 CA-C-N 119.201 0.909 . . . . 0.0 111.436 174.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.0 mt 69.73 -30.79 0.2 Allowed 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 129.764 3.226 . . . . 0.0 113.455 -178.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.29 131.06 40.29 Favored 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 124.722 1.209 . . . . 0.0 108.651 174.976 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.3 p -135.74 130.77 49.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 170.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.34 125.48 39.99 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 105.96 -1.867 . . . . 0.0 105.96 170.106 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 42.3 mt -116.76 106.85 13.94 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 175.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 -88.82 118.9 28.85 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 177.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.3 pp -119.49 176.66 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 127.216 2.206 . . . . 0.0 108.632 -172.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 5.0 mp -114.48 117.49 42.76 Favored Pre-proline 0 CA--C 1.533 0.327 0 CA-C-N 119.231 0.923 . . . . 0.0 108.903 172.004 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.03 163.2 35.74 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 123.039 2.492 . . . . 0.0 109.712 -178.549 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . 0.405 ' NE2' HH21 ' A' ' 67' ' ' ARG . 0.0 OUTLIER -126.51 132.14 51.45 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.254 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -138.24 -9.32 1.5 Allowed 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 113.502 -1.681 . . . . 0.0 110.588 172.305 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.76 37.62 0.36 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 124.493 1.117 . . . . 0.0 110.263 -169.3 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -133.57 121.2 21.76 Favored 'General case' 0 C--O 1.235 0.33 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 163.566 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -151.44 112.7 4.33 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 126.253 1.821 . . . . 0.0 107.077 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 9.0 p -74.66 167.64 34.48 Favored Pre-proline 0 CA--C 1.544 0.723 0 N-CA-C 114.279 1.214 . . . . 0.0 114.279 -166.277 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -73.85 -179.24 4.41 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 124.27 3.314 . . . . 0.0 111.924 167.363 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 46.3 m -100.09 -176.28 3.19 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.49 1.116 . . . . 0.0 109.636 166.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -104.88 167.92 15.55 Favored Glycine 0 CA--C 1.536 1.403 0 N-CA-C 108.961 -1.655 . . . . 0.0 108.961 149.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -71.96 170.02 19.9 Favored 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 123.353 2.702 . . . . 0.0 112.073 -175.615 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.5 p -116.37 167.34 11.12 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 124.672 1.189 . . . . 0.0 109.618 169.371 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.8 t -66.13 166.66 11.39 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.215 1.006 . . . . 0.0 111.114 -178.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.338 0 N-CA-C 105.951 -2.859 . . . . 0.0 105.951 153.978 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.226 0 N-CA-C 107.835 -2.106 . . . . 0.0 107.835 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.5 m 70.92 89.44 0.1 Allowed 'General case' 0 CA--C 1.534 0.359 0 O-C-N 124.838 0.964 . . . . 0.0 112.548 153.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 58.6 m -58.74 135.27 57.4 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 162.053 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -72.91 -49.96 15.14 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 173.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 71.1 m 41.47 59.51 2.39 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 126.301 1.841 . . . . 0.0 111.932 178.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.8 t -128.14 154.72 45.45 Favored 'General case' 0 C--O 1.24 0.587 0 C-N-CA 123.555 0.742 . . . . 0.0 110.155 -174.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.7 91.83 0.11 Allowed Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 107.762 -2.135 . . . . 0.0 107.762 -173.464 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.7 m -139.56 100.63 4.02 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 171.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 tp -156.66 164.93 37.59 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 165.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -142.53 127.61 18.51 Favored 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 165.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 36.0 p -127.37 167.06 16.71 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 171.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 26.0 m -120.22 148.82 43.2 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 171.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -96.22 155.52 16.73 Favored 'General case' 0 C--O 1.244 0.789 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 167.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 29.3 t -137.54 103.62 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 177.512 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.3 p -98.64 134.81 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 171.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 47.6 mt -142.48 134.15 25.49 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 N-CA-C 104.213 -2.514 . . . . 0.0 104.213 -179.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 21.1 m-70 -113.93 159.09 20.27 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.762 1.625 . . . . 0.0 110.171 -174.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.428 ' HD3' ' CE2' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -151.86 175.69 12.21 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 120.334 -1.479 . . . . 0.0 110.863 178.708 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -66.09 161.93 20.69 Favored 'General case' 0 C--O 1.231 0.123 0 C-N-CA 123.426 0.69 . . . . 0.0 109.849 161.458 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -58.11 -50.0 75.0 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 125.863 1.665 . . . . 0.0 111.302 178.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 30.5 t30 -76.48 -21.96 55.16 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.247 1.019 . . . . 0.0 112.621 -173.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -66.96 174.23 3.16 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.377 1.071 . . . . 0.0 109.162 173.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -152.69 46.1 0.58 Allowed Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 124.711 1.148 . . . . 0.0 111.489 -178.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . 0.428 ' CE2' ' HD3' ' A' ' 18' ' ' ARG . 22.3 m-85 50.32 -174.02 0.02 OUTLIER 'General case' 0 N--CA 1.432 -1.345 0 C-N-CA 129.767 3.227 . . . . 0.0 110.753 -174.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.406 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -132.38 45.49 1.12 Allowed Glycine 0 C--O 1.224 -0.482 0 O-C-N 121.353 -0.842 . . . . 0.0 111.97 -176.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -137.96 153.48 49.45 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 124.224 1.01 . . . . 0.0 108.698 -178.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.71 123.13 25.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 -176.68 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.21 151.2 3.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 171.218 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 46.2 pt -131.44 163.49 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 125.238 1.415 . . . . 0.0 108.137 168.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 75.4 m -78.27 -50.28 12.13 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.103 0.561 . . . . 0.0 110.483 171.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.7 t 47.78 100.9 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 127.394 2.278 . . . . 0.0 112.754 -167.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -47.13 -36.87 8.98 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 118.001 -1.0 . . . . 0.0 112.665 174.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 47.53 82.54 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 127.599 2.359 . . . . 0.0 113.404 174.546 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 4.5 ptm85 -66.54 150.51 97.28 Favored Pre-proline 0 C--O 1.235 0.313 0 CA-C-O 119.114 -0.47 . . . . 0.0 111.258 -175.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -68.62 163.15 38.06 Favored 'Trans proline' 0 N--CA 1.448 -1.18 0 N-CA-C 108.8 -1.269 . . . . 0.0 108.8 164.217 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -148.79 -44.26 0.15 Allowed 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 124.584 1.154 . . . . 0.0 109.08 177.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.5 t -160.6 175.3 12.83 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 128.556 2.742 . . . . 0.0 105.346 -171.698 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 54.95 -161.39 4.99 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 124.259 0.933 . . . . 0.0 111.705 -179.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 49.4 m -125.56 103.12 7.69 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 105.72 -1.956 . . . . 0.0 105.72 155.481 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -105.51 118.97 37.94 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 176.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.5 pp -53.2 145.37 3.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 C-N-CA 124.116 0.967 . . . . 0.0 110.79 -179.465 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.1 m -75.86 142.2 42.22 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 161.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.0 p -126.56 143.98 48.1 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 104.968 -2.234 . . . . 0.0 104.968 160.632 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -76.91 -95.38 0.01 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.037 0 C-N-CA 121.599 1.532 . . . . 0.0 108.408 172.661 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.2 m80 -61.3 114.24 3.07 Favored 'General case' 0 N--CA 1.446 -0.656 0 C-N-CA 125.595 1.558 . . . . 0.0 111.621 -171.287 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -148.85 154.83 40.05 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 165.491 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 36.3 mm -60.96 129.16 23.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 123.134 0.574 . . . . 0.0 109.686 -178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -100.22 -36.22 4.21 Favored Glycine 0 CA--C 1.529 0.963 0 C-N-CA 126.278 1.894 . . . . 0.0 112.693 172.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 6.9 ttm180 -149.04 151.77 35.07 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 118.437 1.118 . . . . 0.0 108.723 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 11.1 mt -126.86 139.56 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 125.787 1.635 . . . . 0.0 106.709 165.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -82.07 121.77 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 C-N-CA 126.653 1.981 . . . . 0.0 107.829 -178.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -51.46 128.29 22.37 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 124.956 1.302 . . . . 0.0 109.655 173.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 95.01 -12.32 68.57 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 125.449 1.5 . . . . 0.0 112.945 174.022 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' SER . . . . . 0.406 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 59.0 p -69.68 163.07 62.97 Favored Pre-proline 0 CA--C 1.53 0.205 0 CA-C-N 118.98 1.39 . . . . 0.0 113.177 -172.445 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -56.96 -34.81 98.18 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.27 1.98 . . . . 0.0 111.811 165.418 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.44 -49.24 78.34 Favored 'General case' 0 C--N 1.344 0.333 0 CA-C-N 119.526 1.057 . . . . 0.0 110.529 175.133 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -62.17 -49.53 75.46 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 124.265 1.026 . . . . 0.0 111.348 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -53.59 -53.04 57.41 Favored 'General case' 0 C--N 1.343 0.303 0 C-N-CA 124.418 1.087 . . . . 0.0 110.318 178.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 62.5 m -64.73 -13.94 56.73 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 117.536 -1.221 . . . . 0.0 113.592 -170.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 51.89 11.71 0.16 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.577 2.351 . . . . 0.0 116.821 171.167 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 12.4 mtpt -99.37 -6.77 27.22 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 124.864 1.266 . . . . 0.0 112.03 178.524 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 93.7 mt -104.8 142.74 34.18 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 154.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 9.4 ptmt -140.81 169.57 17.38 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.492 1.517 . . . . 0.0 110.016 159.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.9 t -73.23 109.32 5.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 O-C-N 121.409 -0.807 . . . . 0.0 109.042 -173.297 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 120.04 -7.71 11.73 Favored Glycine 0 C--N 1.337 0.631 0 O-C-N 121.143 -0.973 . . . . 0.0 110.724 -171.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 -74.11 101.67 3.99 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 172.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 39.5 mtm-85 -50.76 121.38 5.81 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 128.04 2.536 . . . . 0.0 108.424 164.227 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 71.5 mt -105.23 106.85 21.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 104.938 -2.245 . . . . 0.0 104.938 174.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.425 HD23 ' H ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -80.42 -26.57 38.38 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 122.94 0.496 . . . . 0.0 112.111 -179.117 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.48 155.47 30.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 125.109 1.363 . . . . 0.0 111.305 -166.191 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 46.8 t -140.24 132.09 32.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 N-CA-C 105.21 -2.145 . . . . 0.0 105.21 176.408 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 46.05 34.86 2.19 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.593 1.157 . . . . 0.0 112.472 175.211 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 55.94 26.23 47.63 Favored Glycine 0 CA--C 1.535 1.318 0 CA-C-O 118.491 -1.172 . . . . 0.0 114.257 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -121.93 104.7 9.72 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 127.341 2.257 . . . . 0.0 107.056 -175.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 54.5 p -65.08 103.14 0.71 Allowed 'General case' 0 CA--C 1.538 0.505 0 O-C-N 120.581 -1.324 . . . . 0.0 114.377 -154.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 11.3 pt -74.1 -5.07 6.25 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 C-N-CA 124.226 1.01 . . . . 0.0 113.385 -174.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 50.4 mm -71.4 -21.27 21.57 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 C-N-CA 124.871 1.269 . . . . 0.0 111.336 -178.75 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -118.28 -28.83 5.69 Favored 'General case' 0 N--CA 1.47 0.536 0 C-N-CA 124.888 1.275 . . . . 0.0 112.372 -176.58 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 9.3 mtp -60.02 151.75 64.04 Favored Pre-proline 0 C--O 1.24 0.558 0 CA-C-N 117.925 0.329 . . . . 0.0 111.398 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -67.11 148.69 81.58 Favored 'Trans proline' 0 N--CA 1.448 -1.166 0 C-N-CA 121.992 1.795 . . . . 0.0 110.282 168.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -60.51 -30.53 69.78 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -172.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -70.03 -35.04 74.02 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 123.692 0.797 . . . . 0.0 112.182 175.932 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -66.88 -45.19 78.86 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 109.225 -0.658 . . . . 0.0 109.225 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 32.5 mt -64.02 -40.75 90.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 125.555 1.542 . . . . 0.0 108.982 179.418 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.2 t -58.63 -51.02 76.87 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 O-C-N 121.169 -0.957 . . . . 0.0 109.611 173.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.99 -44.6 74.62 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 118.383 -0.818 . . . . 0.0 111.934 176.338 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.35 -46.67 69.61 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 127.157 2.183 . . . . 0.0 110.909 176.362 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 59.7 mt -70.1 -39.77 77.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -176.603 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.1 mtpp -63.35 -39.65 95.12 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 123.066 0.547 . . . . 0.0 110.799 178.008 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -85.84 7.61 23.3 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.253 1.821 . . . . 0.0 112.184 177.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -61.4 -20.21 62.79 Favored 'General case' 0 CA--C 1.535 0.401 0 O-C-N 120.885 -1.135 . . . . 0.0 113.41 -177.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 81.02 63.81 1.85 Allowed Glycine 0 C--N 1.334 0.447 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 175.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 31.4 mt 67.87 -46.96 0.51 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 129.052 2.941 . . . . 0.0 112.699 177.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.51 149.18 21.43 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 170.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.1 p -131.77 133.1 61.67 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 165.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.9 m -106.68 105.02 14.85 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -90.41 160.9 15.82 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 175.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 51.7 ttp180 -113.66 133.26 55.42 Favored 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 106.355 -1.721 . . . . 0.0 106.355 166.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.4 pp -128.21 161.07 37.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 123.899 0.879 . . . . 0.0 109.605 176.029 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 51.0 mt -104.13 122.84 42.8 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 169.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -89.8 -161.35 0.11 Allowed 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 125.028 3.818 . . . . 0.0 110.199 172.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -157.18 168.19 28.16 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.962 1.305 . . . . 0.0 110.801 -171.578 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -143.23 -4.29 0.91 Allowed 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 124.967 1.307 . . . . 0.0 111.886 163.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -136.35 0.86 2.59 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.921 1.689 . . . . 0.0 112.714 -172.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 12.3 mt -97.26 109.03 21.87 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 174.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -146.84 155.08 42.06 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 159.113 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.1 m -81.18 124.92 80.54 Favored Pre-proline 0 C--O 1.239 0.51 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 165.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -77.13 86.82 1.57 Allowed 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 122.697 2.265 . . . . 0.0 109.718 172.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 38.8 t -135.85 116.65 14.07 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 174.371 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -149.65 170.53 29.81 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 108.919 -1.673 . . . . 0.0 108.919 179.504 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -81.12 -2.9 11.97 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 123.195 2.596 . . . . 0.0 114.186 -172.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 32.8 t 147.89 -69.23 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 130.219 3.408 . . . . 0.0 105.854 -171.098 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.0 m -70.66 103.84 2.66 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 170.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.851 0 N-CA-C 104.773 -3.331 . . . . 0.0 104.773 177.252 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.698 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.1 p -158.71 170.91 21.09 Favored 'General case' 0 C--O 1.241 0.619 0 C-N-CA 125.299 1.44 . . . . 0.0 107.914 171.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.1 m -142.07 169.15 18.12 Favored 'General case' 0 C--O 1.235 0.322 0 C-N-CA 124.392 1.077 . . . . 0.0 111.355 176.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 120.24 144.1 7.05 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 126.328 1.918 . . . . 0.0 108.724 -173.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 28.4 p -139.61 162.93 33.89 Favored 'General case' 0 C--O 1.237 0.432 0 C-N-CA 124.894 1.278 . . . . 0.0 108.282 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.8 t -161.04 -155.76 0.43 Allowed 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -169.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 130.22 -77.34 0.4 Allowed Glycine 0 C--O 1.236 0.269 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 174.47 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 77.8 p 48.29 -170.27 0.02 OUTLIER 'General case' 0 C--O 1.238 0.472 0 C-N-CA 127.564 2.345 . . . . 0.0 114.257 177.193 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.7 tp 35.14 81.14 0.02 OUTLIER 'General case' 0 C--O 1.234 0.282 0 C-N-CA 128.844 2.857 . . . . 0.0 112.266 176.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.493 ' NE2' HE22 ' A' ' 102' ' ' GLN . 15.9 pt20 -44.62 136.28 4.43 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 125.607 1.563 . . . . 0.0 112.166 -176.734 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 42.4 p -145.24 164.18 32.16 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 125.263 1.425 . . . . 0.0 107.333 168.022 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 57.8 m -126.55 152.83 46.03 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 124.362 1.065 . . . . 0.0 109.112 173.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -108.38 103.73 12.94 Favored 'General case' 0 C--O 1.233 0.204 0 C-N-CA 126.235 1.814 . . . . 0.0 106.22 -178.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -88.07 95.2 5.04 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.8 p -78.02 138.08 20.98 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 CA-C-O 121.372 0.606 . . . . 0.0 109.423 171.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 41.2 mt -134.38 142.06 41.84 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 N-CA-C 105.796 -1.927 . . . . 0.0 105.796 173.086 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.2 m-70 -115.77 137.16 52.36 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.711 1.204 . . . . 0.0 109.19 177.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 16.8 ptt180 -118.4 175.65 5.61 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.118 0.872 . . . . 0.0 109.519 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.33 163.9 12.88 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 169.542 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -71.77 -38.6 70.31 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -173.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 54.5 t30 -77.01 18.89 0.33 Allowed 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.785 0.834 . . . . 0.0 112.036 -174.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -161.2 -169.84 2.47 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 120.005 -1.684 . . . . 0.0 111.108 -168.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -121.21 -169.71 13.81 Favored Glycine 0 CA--C 1.521 0.429 0 C-N-CA 126.274 1.892 . . . . 0.0 110.867 -174.212 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 84.2 m-85 -85.97 -110.52 0.05 OUTLIER 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 106.117 -1.808 . . . . 0.0 106.117 165.451 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 152.7 59.04 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.392 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 177.058 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -141.69 133.55 27.33 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 178.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.2 t -113.96 113.53 44.13 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 -172.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 26.7 mt -74.06 131.0 35.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 173.364 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 14.8 pt -120.75 170.17 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 C-N-CA 125.513 1.525 . . . . 0.0 109.822 172.186 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -129.94 155.18 46.48 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 125.366 1.467 . . . . 0.0 109.735 -177.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -160.3 94.53 1.09 Allowed 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.864 1.666 . . . . 0.0 106.75 163.512 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 4.0 tt -137.9 84.51 2.04 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-O 122.005 0.907 . . . . 0.0 110.837 177.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -69.81 156.76 38.55 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.311 160.094 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 15.3 tpt180 61.28 128.19 0.02 OUTLIER Pre-proline 0 CA--C 1.541 0.596 0 C-N-CA 130.695 3.598 . . . . 0.0 113.484 176.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -68.0 100.87 0.65 Allowed 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.08 1.853 . . . . 0.0 107.922 168.22 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 74.8 mm-40 -124.82 166.05 16.92 Favored 'General case' 0 C--O 1.238 0.455 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 171.007 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 38.1 m -159.24 -34.06 0.06 Allowed 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.134 0.974 . . . . 0.0 111.782 -178.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -79.76 -25.51 58.15 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-N 119.463 1.029 . . . . 0.0 112.412 -172.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 14.2 t -125.74 133.9 51.94 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 164.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.6 p -123.78 108.04 12.07 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.106 1.363 . . . . 0.0 109.796 -163.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.6 mt -130.35 -58.61 1.0 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.356 0 C-N-CA 125.029 1.331 . . . . 0.0 109.706 -166.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.2 p -65.96 155.06 37.66 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 123.562 0.745 . . . . 0.0 109.202 172.456 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.1 t -126.21 127.37 24.67 Favored Pre-proline 0 CA--C 1.539 0.523 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -78.4 -13.95 14.83 Favored 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 122.825 2.35 . . . . 0.0 113.802 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -139.02 119.31 13.67 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 120.831 1.65 . . . . 0.0 110.157 174.75 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 45.4 pttt -143.65 163.99 31.67 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 168.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.8 mm -63.1 125.37 19.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 165.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.83 -24.05 5.37 Favored Glycine 0 CA--C 1.527 0.799 0 CA-C-O 118.828 -0.985 . . . . 0.0 113.469 172.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -154.09 147.52 25.0 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 176.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 5.4 mt -128.37 149.49 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 168.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -78.13 117.38 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 C-N-CA 125.714 1.606 . . . . 0.0 107.105 174.078 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -52.72 105.08 0.11 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.123 2.169 . . . . 0.0 109.256 176.582 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 95.02 7.92 59.37 Favored Glycine 0 CA--C 1.526 0.753 0 C-N-CA 124.569 1.081 . . . . 0.0 114.065 177.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 33.9 p -64.38 166.24 11.72 Favored Pre-proline 0 CA--C 1.531 0.242 0 CA-C-N 119.495 1.647 . . . . 0.0 109.802 164.099 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -58.86 -24.3 71.59 Favored 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 121.728 1.618 . . . . 0.0 112.849 170.095 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.03 -60.6 3.52 Favored 'General case' 0 C--N 1.341 0.201 0 CA-C-N 119.277 0.944 . . . . 0.0 108.671 173.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -65.69 -42.5 91.14 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.833 0.349 . . . . 0.0 111.048 -176.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -69.96 -22.85 63.13 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 118.442 -0.79 . . . . 0.0 112.501 -174.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 2.0 p -73.84 -16.7 61.13 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 117.618 -1.182 . . . . 0.0 110.976 173.513 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 40.08 66.23 0.63 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.324 1.849 . . . . 0.0 110.633 -173.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 33.4 mtmm -139.28 -44.89 0.46 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 124.923 1.289 . . . . 0.0 108.883 170.156 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 22.5 tp -94.02 121.62 35.69 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 -177.179 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.7 mmtt -132.85 162.84 30.48 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 123.394 1.569 . . . . 0.0 110.615 -176.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.4 t -62.77 123.77 16.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 172.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 122.11 -24.96 6.86 Favored Glycine 0 N--CA 1.447 -0.585 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -175.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -79.22 99.22 6.93 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-O 123.282 1.515 . . . . 0.0 109.416 -167.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 39.4 mtm180 -46.39 137.02 6.81 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 129.119 2.967 . . . . 0.0 110.106 162.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 16.0 mt -119.01 144.65 26.72 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 -174.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.1 mp -117.54 -47.22 2.64 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 125.246 1.418 . . . . 0.0 111.214 -176.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -150.04 169.61 20.83 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.084 0.954 . . . . 0.0 109.368 -175.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.6 p -138.89 123.39 20.88 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.299 0 C-N-CA 125.14 1.376 . . . . 0.0 108.197 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 51.39 31.05 6.74 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 123.616 0.767 . . . . 0.0 112.417 -173.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.26 6.75 89.07 Favored Glycine 0 CA--C 1.532 1.117 0 CA-C-O 118.37 -1.239 . . . . 0.0 114.204 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -102.46 135.3 44.32 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 119.963 1.882 . . . . 0.0 109.896 177.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -54.43 129.16 34.81 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 123.087 0.555 . . . . 0.0 110.282 168.828 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 25.8 pt -91.16 -17.79 7.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.716 1.206 . . . . 0.0 110.332 164.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 81.2 mt -68.02 136.26 26.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 82.49 -30.9 0.09 Allowed 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 130.572 3.549 . . . . 0.0 112.847 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 6.3 mtp -64.8 154.07 86.52 Favored Pre-proline 0 CA--C 1.541 0.597 0 CA-C-N 119.298 0.954 . . . . 0.0 111.332 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -76.9 152.1 31.84 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.49 2.127 . . . . 0.0 109.951 173.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -51.97 -42.38 62.86 Favored 'General case' 0 C--O 1.222 -0.345 0 C-N-CA 123.742 0.817 . . . . 0.0 111.657 -176.611 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.0 -41.83 75.46 Favored 'General case' 0 C--N 1.338 0.072 0 CA-C-O 118.356 -0.831 . . . . 0.0 112.855 178.825 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.9 -30.38 40.1 Favored 'General case' 0 C--O 1.225 -0.231 0 CA-C-N 118.898 0.772 . . . . 0.0 110.927 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 13.3 mt -69.03 -42.15 81.93 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 C-N-CA 124.455 1.102 . . . . 0.0 108.835 171.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 2.5 t -54.54 -46.4 71.73 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 O-C-N 120.542 -1.349 . . . . 0.0 108.932 170.511 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 9.7 tptt -62.14 -43.51 98.67 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-O 117.033 -1.461 . . . . 0.0 111.903 175.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.05 -37.78 80.85 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 121.121 1.782 . . . . 0.0 110.567 -177.361 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 43.0 mt -69.7 -49.58 57.04 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 177.298 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.1 tttp -54.22 -49.14 70.13 Favored 'General case' 0 C--N 1.345 0.371 0 C-N-CA 123.56 0.744 . . . . 0.0 110.234 178.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -65.89 -17.42 64.64 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 127.384 2.274 . . . . 0.0 112.362 -177.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -67.29 -9.43 40.75 Favored 'General case' 0 CA--C 1.548 0.895 0 CA-C-N 119.384 0.993 . . . . 0.0 112.891 176.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.23 -89.12 0.72 Allowed Glycine 0 C--N 1.34 0.779 0 C-N-CA 125.134 1.35 . . . . 0.0 112.262 167.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 78.4 mt -132.03 -27.3 1.85 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 126.47 1.908 . . . . 0.0 110.28 173.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.55 152.29 19.7 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 105.632 -1.988 . . . . 0.0 105.632 174.091 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.7 p -150.75 147.07 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 N-CA-C 105.126 -2.175 . . . . 0.0 105.126 161.104 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 20.6 m -126.08 103.09 7.53 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -175.254 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 18.8 mt -90.77 123.05 34.03 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 124.762 1.225 . . . . 0.0 108.444 -176.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 13.7 ttm180 -83.88 131.42 34.87 Favored 'General case' 0 C--O 1.237 0.431 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 176.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -126.97 159.69 36.6 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 C-N-CA 125.661 1.584 . . . . 0.0 110.581 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 9.2 mt -69.46 -57.03 7.45 Favored Pre-proline 0 N--CA 1.478 0.94 0 C-N-CA 124.841 1.256 . . . . 0.0 110.842 175.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -67.13 -176.33 0.79 Allowed 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 122.397 2.065 . . . . 0.0 114.051 177.255 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . 0.493 HE22 ' NE2' ' A' ' 10' ' ' GLN . 2.1 mp0 -113.31 169.31 9.04 Favored 'General case' 0 N--CA 1.436 -1.144 0 C-N-CA 128.273 2.629 . . . . 0.0 107.088 171.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -121.54 0.95 10.03 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 126.183 1.793 . . . . 0.0 110.8 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -151.17 17.89 0.75 Allowed 'General case' 0 CA--C 1.531 0.242 0 CA-C-O 122.397 1.094 . . . . 0.0 110.31 -165.022 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 12.7 tp -107.53 121.25 44.26 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 126.823 2.049 . . . . 0.0 107.284 -179.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -55.54 105.37 0.17 Allowed 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 166.222 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.6 p -154.5 160.0 31.36 Favored Pre-proline 0 C--O 1.237 0.406 0 CA-C-N 120.773 1.624 . . . . 0.0 110.284 163.292 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -84.04 -6.2 10.38 Favored 'Trans proline' 0 CA--C 1.534 0.493 0 C-N-CA 122.617 2.211 . . . . 0.0 114.341 -176.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 26.6 m 4.51 88.01 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 129.014 2.926 . . . . 0.0 114.45 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -64.55 164.41 34.25 Favored Glycine 0 CA--C 1.535 1.311 0 C-N-CA 124.153 0.882 . . . . 0.0 113.517 -166.215 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -66.76 160.5 46.24 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 124.005 3.137 . . . . 0.0 113.061 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.4 p -99.36 -15.17 18.88 Favored 'General case' 0 C--O 1.235 0.326 0 C-N-CA 125.779 1.632 . . . . 0.0 112.402 179.156 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 21.8 p -122.47 68.33 0.95 Allowed 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 124.127 0.971 . . . . 0.0 108.74 -175.657 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.867 0 N-CA-C 106.714 -2.554 . . . . 0.0 106.714 -169.241 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.156 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 31.0 t -136.59 132.69 35.46 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 105.5 -2.037 . . . . 0.0 105.5 174.21 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 m -144.59 126.53 15.41 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -169.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -161.42 76.36 0.18 Allowed Glycine 0 N--CA 1.449 -0.463 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 -175.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 44.0 m -145.65 155.57 43.1 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 124.995 1.318 . . . . 0.0 109.522 173.188 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.0 t 61.87 111.35 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 128.54 2.736 . . . . 0.0 113.873 168.14 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.24 152.59 17.33 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 106.335 -2.706 . . . . 0.0 106.335 -178.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.9 m -165.0 -74.91 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 124.98 1.312 . . . . 0.0 109.042 -172.342 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.9 tp -83.14 120.7 26.11 Favored 'General case' 0 C--O 1.238 0.456 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 176.337 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 22.5 mt-30 -70.65 138.03 50.38 Favored 'General case' 0 N--CA 1.453 -0.288 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 169.213 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 33.5 p -138.37 160.48 39.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 178.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.9 m -111.23 156.62 21.18 Favored 'General case' 0 C--O 1.235 0.325 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 168.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -120.85 103.54 9.16 Favored 'General case' 0 CA--C 1.511 -0.536 0 N-CA-C 104.029 -2.582 . . . . 0.0 104.029 172.401 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.6 t -91.63 95.03 5.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 105.458 -2.053 . . . . 0.0 105.458 -177.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.4 p -85.47 124.84 40.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 169.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 13.3 mt -116.97 143.38 27.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 171.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.0 m-70 -121.68 143.76 49.16 Favored 'General case' 0 CA--C 1.536 0.404 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 175.445 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 3.0 ptt-85 -130.86 -175.48 3.68 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 119.797 1.18 . . . . 0.0 109.008 176.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.417 ' N ' ' HE3' ' A' ' 19' ' ' LYS . 0.2 OUTLIER -95.38 168.7 10.56 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 118.814 0.734 . . . . 0.0 109.273 169.836 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -65.94 -20.67 66.29 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.078 0.951 . . . . 0.0 112.544 170.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -123.18 65.67 0.99 Allowed 'General case' 0 C--O 1.234 0.265 0 C-N-CA 124.454 1.101 . . . . 0.0 108.133 -177.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -172.6 179.45 2.44 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 128.38 2.672 . . . . 0.0 107.227 163.164 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.67 176.12 23.84 Favored Glycine 0 CA--C 1.526 0.734 0 C-N-CA 124.432 1.015 . . . . 0.0 110.976 173.548 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -84.7 170.68 13.04 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 150.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.45 55.6 0.65 Allowed Glycine 0 C--O 1.224 -0.529 0 O-C-N 120.727 -1.233 . . . . 0.0 111.537 -175.138 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.4 p90 -130.12 121.89 27.21 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 117.981 0.89 . . . . 0.0 108.924 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.6 t -96.25 101.04 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 -175.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -74.27 118.87 20.57 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 170.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 24.5 pt -103.87 -176.76 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 C-N-CA 124.355 1.062 . . . . 0.0 109.281 176.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.0 m 54.86 53.83 9.91 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.155 0.982 . . . . 0.0 112.325 175.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.4 t -60.75 176.05 0.42 Allowed 'General case' 0 CA--C 1.543 0.682 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.726 164.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 58.6 tp -25.75 115.49 0.06 Allowed 'General case' 0 N--CA 1.469 0.48 0 C-N-CA 128.681 2.792 . . . . 0.0 111.832 177.489 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 17.4 t30 -136.45 130.62 32.9 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 118.941 -0.552 . . . . 0.0 111.07 -170.696 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 66.17 162.4 0.13 Allowed Pre-proline 0 N--CA 1.471 0.611 0 C-N-CA 128.315 2.646 . . . . 0.0 113.106 -173.476 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -77.86 65.49 8.24 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 123.916 3.078 . . . . 0.0 109.194 168.14 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -130.88 166.44 20.89 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 126.197 1.799 . . . . 0.0 106.703 173.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.3 t -123.63 -125.49 0.26 Allowed 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 179.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.48 93.52 0.09 OUTLIER Glycine 0 C--N 1.336 0.56 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 173.466 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.4 t -120.74 130.81 54.2 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 -174.489 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 20.4 p -64.86 162.52 16.11 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 124.052 0.941 . . . . 0.0 111.589 177.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 12.2 mt 66.24 162.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 C-N-CA 127.023 2.129 . . . . 0.0 109.802 179.182 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.3 m 57.15 171.66 0.04 OUTLIER 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.213 1.405 . . . . 0.0 111.595 -167.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 21.9 t -126.7 123.24 23.79 Favored Pre-proline 0 C--O 1.235 0.332 0 N-CA-C 103.672 -2.714 . . . . 0.0 103.672 161.378 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -58.54 -78.64 0.02 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 121.878 1.719 . . . . 0.0 109.818 175.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.2 m80 -63.68 123.71 19.55 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 118.785 0.72 . . . . 0.0 109.869 -177.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 49.8 pttt -143.67 153.29 42.33 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 107.883 -1.155 . . . . 0.0 107.883 171.086 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 32.7 mm -66.69 124.12 21.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 167.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -101.97 -30.88 5.59 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 124.246 0.927 . . . . 0.0 112.611 175.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 22.7 ttm180 -154.65 158.41 39.63 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 118.847 1.323 . . . . 0.0 107.564 176.014 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 24.5 mt -130.77 135.28 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 170.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.4 mp -68.81 124.96 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 32.2 t0 -51.96 133.55 32.45 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.375 1.07 . . . . 0.0 109.97 178.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.08 1.0 38.41 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 118.98 -0.9 . . . . 0.0 114.412 174.493 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 61.4 p -64.62 162.7 33.05 Favored Pre-proline 0 CA--C 1.53 0.189 0 CA-C-N 119.483 1.641 . . . . 0.0 109.504 171.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -55.76 -18.17 20.42 Favored 'Trans proline' 0 CA--C 1.534 0.488 0 C-N-CA 122.959 2.439 . . . . 0.0 114.028 175.244 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.59 -69.79 0.27 Allowed 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 169.112 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -66.43 -31.88 72.91 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 118.14 0.427 . . . . 0.0 111.655 -173.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.92 -22.92 67.11 Favored 'General case' 0 C--O 1.234 0.247 0 O-C-N 121.351 -0.843 . . . . 0.0 112.508 175.389 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 7.8 t -80.85 -9.51 59.81 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 119.338 0.972 . . . . 0.0 111.475 173.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 55.92 5.13 0.14 Allowed 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 128.841 2.856 . . . . 0.0 115.724 173.777 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.9 -49.64 6.96 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 119.796 1.18 . . . . 0.0 110.424 177.39 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 14.8 tp -93.85 129.36 40.28 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 123.5 0.72 . . . . 0.0 109.414 -166.044 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.7 mptt -122.99 169.97 10.62 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 125.451 1.5 . . . . 0.0 110.438 170.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -58.4 148.47 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 C-N-CA 124.367 1.067 . . . . 0.0 109.798 165.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.24 -7.73 80.67 Favored Glycine 0 CA--C 1.524 0.635 0 C-N-CA 125.301 1.429 . . . . 0.0 110.682 -175.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -71.17 88.92 0.83 Allowed 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 172.351 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.1 mtm180 -38.21 121.02 0.94 Allowed 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 128.448 2.699 . . . . 0.0 110.314 159.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 14.3 mt -101.22 118.83 48.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 -178.697 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 88.1 mt -72.0 -52.52 16.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 124.684 1.194 . . . . 0.0 109.959 168.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -150.83 166.24 31.13 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 124.059 0.944 . . . . 0.0 111.951 -162.32 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 37.2 t -126.26 119.84 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 174.45 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 67.7 m-20 54.51 10.01 0.3 Allowed 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 128.918 2.887 . . . . 0.0 114.477 176.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 114.01 -0.26 24.16 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 126.721 2.105 . . . . 0.0 113.909 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 9.8 mm-40 -105.07 145.22 30.8 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 125.422 1.489 . . . . 0.0 109.243 -176.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.8 p -84.09 99.26 10.36 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 124.73 1.212 . . . . 0.0 111.63 -167.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 7.1 pt -79.76 -2.84 5.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 C-N-CA 123.904 0.882 . . . . 0.0 112.106 -177.258 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.508 HD12 ' H ' ' A' ' 77' ' ' ILE . 3.3 mp -61.85 -33.29 57.19 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 125.223 1.409 . . . . 0.0 110.383 174.31 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -107.7 -44.12 4.33 Favored 'General case' 0 C--O 1.233 0.215 0 C-N-CA 123.049 0.539 . . . . 0.0 111.217 -166.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 5.6 mtp -58.77 153.4 42.54 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 124.329 1.052 . . . . 0.0 111.328 -168.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.75 146.27 97.6 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.187 1.258 . . . . 0.0 109.276 167.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -52.09 -41.28 62.29 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 124.346 1.058 . . . . 0.0 110.028 -178.064 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -59.93 -35.57 75.19 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 114.24 1.2 . . . . 0.0 114.24 177.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.01 -44.86 79.23 Favored 'General case' 0 N--CA 1.463 0.189 0 C-N-CA 123.727 0.811 . . . . 0.0 108.887 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 24.0 mt -69.37 -37.99 76.47 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 C-N-CA 125.967 1.707 . . . . 0.0 109.261 -178.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 4.8 t -56.46 -49.06 78.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 O-C-N 121.127 -0.983 . . . . 0.0 109.427 169.263 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 11.4 ttpt -66.88 -36.48 82.41 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-O 118.742 -0.647 . . . . 0.0 111.258 -177.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -57.09 -44.38 83.11 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 125.4 1.48 . . . . 0.0 111.057 174.29 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 91.1 mt -67.86 -40.99 84.54 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-N 119.371 0.987 . . . . 0.0 108.813 178.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.0 tttt -60.08 -48.76 80.38 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 118.819 0.736 . . . . 0.0 109.942 176.146 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -70.31 -12.28 61.48 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 124.642 1.177 . . . . 0.0 111.268 -178.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.9 -14.99 53.25 Favored 'General case' 0 CA--C 1.545 0.757 0 CA-C-N 119.679 1.127 . . . . 0.0 112.347 168.426 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.28 -132.25 11.16 Favored Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 176.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 5.7 mt -90.7 -10.24 43.83 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 118.878 -0.582 . . . . 0.0 110.336 173.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 26.7 p -93.42 162.3 14.04 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 168.476 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.6 p -156.68 136.6 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.888 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 159.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.1 m -117.34 104.75 11.44 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 -177.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 56.9 mt -90.02 164.55 14.48 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 177.33 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 22.6 ttt180 -127.93 118.74 24.16 Favored 'General case' 0 CA--C 1.513 -0.456 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 173.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pp -129.51 169.2 21.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 C-N-CA 123.952 0.901 . . . . 0.0 109.294 -176.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.0 mp -98.45 117.99 63.94 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 124.205 1.002 . . . . 0.0 109.361 -177.251 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -82.97 157.33 15.44 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 123.375 2.717 . . . . 0.0 111.766 172.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -146.12 170.5 16.57 Favored 'General case' 0 C--O 1.242 0.662 0 C-N-CA 129.015 2.926 . . . . 0.0 106.521 -178.102 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -136.72 -19.58 1.35 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 119.094 0.861 . . . . 0.0 113.018 -168.289 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 18.9 pm0 -87.47 -2.93 58.95 Favored 'General case' 0 C--N 1.316 -0.88 0 C-N-CA 127.743 2.417 . . . . 0.0 112.162 -173.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 3.1 mt -114.87 108.88 17.33 Favored 'General case' 0 C--O 1.233 0.194 0 C-N-CA 125.578 1.551 . . . . 0.0 109.039 -170.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 19.8 t30 -145.87 104.52 3.86 Favored 'General case' 0 C--O 1.232 0.137 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 164.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 72.9 m -65.49 152.32 92.6 Favored Pre-proline 0 CA--C 1.533 0.314 0 CA-C-O 119.395 -0.336 . . . . 0.0 111.638 173.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -79.54 -174.0 2.1 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 124.328 3.352 . . . . 0.0 111.33 171.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.2 t -67.17 13.91 0.06 Allowed 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.058 1.743 . . . . 0.0 113.395 175.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 39.32 63.41 1.13 Allowed Glycine 0 CA--C 1.534 1.253 0 C-N-CA 126.565 2.031 . . . . 0.0 112.375 -176.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -60.61 118.28 5.13 Favored 'Trans proline' 0 N--CA 1.458 -0.618 0 C-N-CA 123.644 2.896 . . . . 0.0 110.164 -166.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.1 t 30.07 63.92 0.16 Allowed 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 127.956 2.503 . . . . 0.0 110.874 -167.125 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 5.6 t -53.83 118.55 4.06 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 170.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.006 0 N-CA-C 106.344 -2.702 . . . . 0.0 106.344 -165.754 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.148 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.3 m -54.11 129.41 34.53 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 159.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 m -63.8 -45.67 88.61 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.321 0.649 . . . . 0.0 110.383 -173.487 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 140.55 -150.37 21.6 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 -169.543 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 57.4 m -138.07 173.6 11.45 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 107.823 -1.176 . . . . 0.0 107.823 157.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -130.44 -175.97 3.81 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 151.797 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 167.58 -145.77 10.06 Favored Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 106.221 -2.752 . . . . 0.0 106.221 -173.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 12.2 m 72.18 159.76 0.22 Allowed 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 126.773 2.029 . . . . 0.0 110.68 -178.244 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 10.1 mp -123.07 125.08 44.51 Favored 'General case' 0 C--O 1.237 0.418 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -168.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -143.89 -154.24 0.52 Allowed 'General case' 0 C--O 1.234 0.283 0 C-N-CA 122.948 0.499 . . . . 0.0 111.185 179.359 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.6 p -138.28 165.54 26.46 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 128.14 2.576 . . . . 0.0 108.735 -171.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 37.3 m -126.6 164.41 21.3 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.875 1.67 . . . . 0.0 109.415 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 18.4 p-10 -128.86 95.12 4.0 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 127.15 2.18 . . . . 0.0 108.057 177.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.0 t -89.47 102.9 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 105.798 -1.927 . . . . 0.0 105.798 174.321 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.2 t -106.68 111.47 35.6 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -177.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 12.1 mt -108.83 136.55 44.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 N-CA-C 106.126 -1.805 . . . . 0.0 106.126 -178.72 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -119.87 114.15 21.66 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 126.465 1.906 . . . . 0.0 105.989 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 28.4 ptt180 -95.0 174.99 6.81 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 119.606 1.094 . . . . 0.0 109.116 176.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -82.97 171.13 14.16 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 166.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -75.57 -9.85 58.93 Favored 'General case' 0 N--CA 1.469 0.489 0 O-C-N 120.355 -1.466 . . . . 0.0 112.805 175.373 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 40.3 t30 -98.98 -27.38 13.89 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 115.119 1.526 . . . . 0.0 115.119 -160.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -114.37 -122.1 0.29 Allowed 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.235 1.414 . . . . 0.0 108.768 -167.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -154.49 -178.34 28.76 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 167.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -72.97 170.82 14.02 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 151.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -135.2 62.07 0.62 Allowed Glycine 0 C--O 1.22 -0.749 0 CA-C-O 118.27 -1.294 . . . . 0.0 111.591 -176.185 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.2 p90 -146.12 139.96 26.35 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 119.281 1.541 . . . . 0.0 109.033 178.491 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.689 HG11 ' H ' ' A' ' 49' ' ' ARG . 0.8 OUTLIER -110.08 154.78 11.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 171.798 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -128.79 118.75 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 -178.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 26.1 pt -112.45 156.11 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -179.034 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.5 m -128.05 84.72 2.27 Favored 'General case' 0 C--O 1.239 0.544 0 C-N-CA 124.859 1.263 . . . . 0.0 107.968 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.8 m -73.07 150.91 41.92 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 121.42 -0.8 . . . . 0.0 110.365 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 32.6 mt -70.14 -45.46 66.76 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 124.206 1.002 . . . . 0.0 110.396 -174.522 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.9 m120 37.1 73.04 0.1 Allowed 'General case' 0 C--O 1.238 0.489 0 C-N-CA 127.965 2.506 . . . . 0.0 112.005 178.246 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.45 148.84 63.28 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 122.974 0.51 . . . . 0.0 111.123 -174.223 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -76.7 -24.2 10.44 Favored 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 123.066 2.511 . . . . 0.0 113.922 -174.046 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 37.15 69.52 0.22 Allowed 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 126.863 2.065 . . . . 0.0 112.491 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 66.3 m 57.89 2.64 0.18 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 127.548 2.339 . . . . 0.0 116.287 179.663 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -95.2 -178.72 37.26 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 166.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 8.1 t -126.22 102.16 7.07 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 104.351 -2.463 . . . . 0.0 104.351 132.168 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 65.8 p -101.98 158.45 16.13 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 177.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . 0.26 14.0 tt -60.79 124.52 15.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 C-N-CA 123.862 0.865 . . . . 0.0 111.034 -166.193 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.3 m -144.51 154.94 43.42 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.194 1.398 . . . . 0.0 108.898 -173.019 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 8.6 p -127.51 151.07 74.48 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 117.739 -1.124 . . . . 0.0 109.223 169.064 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -72.08 -84.47 0.0 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.274 1.983 . . . . 0.0 108.475 162.389 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -72.58 120.9 18.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.138 0.975 . . . . 0.0 110.559 -174.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 45.3 pttt -137.31 154.93 49.97 Favored 'General case' 0 C--O 1.236 0.371 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 168.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 5.0 mm -60.79 127.29 20.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 166.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -88.51 -69.75 1.27 Allowed Glycine 0 CA--C 1.527 0.806 0 O-C-N 124.495 1.122 . . . . 0.0 110.627 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ARG . . . . . 0.689 ' H ' HG11 ' A' ' 27' ' ' VAL . 31.4 ttm180 -127.6 153.28 46.6 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 128.751 2.821 . . . . 0.0 107.407 -178.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 12.5 mt -119.27 142.68 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 166.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 50.4 mm -73.05 122.59 26.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -60.45 137.17 58.19 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 178.443 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.82 -5.23 54.08 Favored Glycine 0 CA--C 1.531 1.058 0 C-N-CA 126.08 1.8 . . . . 0.0 114.495 -178.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 83.7 p -68.62 167.65 18.22 Favored Pre-proline 0 C--O 1.234 0.283 0 CA-C-N 119.332 1.566 . . . . 0.0 112.472 -176.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -58.23 -29.26 87.1 Favored 'Trans proline' 0 N--CA 1.451 -0.994 0 C-N-CA 122.165 1.91 . . . . 0.0 112.458 166.464 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.85 -53.94 46.45 Favored 'General case' 0 C--N 1.345 0.398 0 CA-C-N 119.814 1.188 . . . . 0.0 109.71 177.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -66.21 -45.89 79.14 Favored 'General case' 0 N--CA 1.463 0.187 0 O-C-N 123.135 0.272 . . . . 0.0 110.525 -178.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -72.45 -22.58 61.06 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 113.237 0.829 . . . . 0.0 113.237 -173.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 24.3 m -61.2 -18.09 56.46 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 119.967 1.258 . . . . 0.0 111.519 165.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 65.16 -25.15 0.09 Allowed 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 130.218 3.407 . . . . 0.0 114.951 171.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 1.9 mtpp -73.54 -8.53 56.31 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 124.955 1.302 . . . . 0.0 112.137 174.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -107.93 125.26 51.28 Favored 'General case' 0 C--N 1.343 0.301 0 CA-C-N 119.645 1.112 . . . . 0.0 108.328 173.262 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 40.5 mttp -135.76 166.41 23.35 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 126.188 1.795 . . . . 0.0 109.115 172.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 71.7 t -64.76 152.7 8.52 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 C-N-CA 123.515 0.726 . . . . 0.0 109.118 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 67.43 43.72 86.36 Favored Glycine 0 CA--C 1.528 0.903 0 CA-C-O 122.047 0.804 . . . . 0.0 112.221 174.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.8 p-10 -78.46 -20.99 49.76 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 125.782 1.633 . . . . 0.0 115.135 -173.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 18.4 mtm180 44.84 90.96 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 128.752 2.821 . . . . 0.0 111.516 -160.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 24.2 mt -68.48 150.21 10.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -116.56 -50.98 2.61 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.413 2.285 . . . . 0.0 108.898 177.186 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -151.91 169.97 20.99 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 124.179 0.991 . . . . 0.0 111.603 -176.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.0 p -128.88 118.89 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 124.371 1.068 . . . . 0.0 109.291 175.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 39.05 47.06 1.23 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.413 1.485 . . . . 0.0 110.494 -169.198 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.16 -3.72 51.05 Favored Glycine 0 CA--C 1.53 1.01 0 C-N-CA 125.952 1.739 . . . . 0.0 115.977 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -82.21 141.84 32.66 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 120.829 2.314 . . . . 0.0 108.578 -178.624 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.7 p -90.02 90.66 8.24 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-O 122.675 1.226 . . . . 0.0 110.374 -171.562 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 13.3 pt -65.39 -3.16 1.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.814 0 C-N-CA 126.833 2.053 . . . . 0.0 113.622 -177.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 26.1 mm -57.48 -58.13 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 126.799 2.04 . . . . 0.0 109.591 175.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -113.8 -22.96 9.91 Favored 'General case' 0 C--O 1.231 0.114 0 O-C-N 123.596 0.56 . . . . 0.0 112.029 -161.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.5 ttt -56.18 142.24 67.29 Favored Pre-proline 0 N--CA 1.437 -1.083 0 C-N-CA 126.292 1.837 . . . . 0.0 109.463 166.47 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -75.35 153.09 39.88 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 121.259 1.306 . . . . 0.0 111.169 -179.134 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 32.9 t60 -58.19 -41.23 83.51 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.255 0.622 . . . . 0.0 112.015 -170.038 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.68 -32.1 73.12 Favored 'General case' 0 C--O 1.227 -0.101 0 CA-C-O 118.879 -0.582 . . . . 0.0 112.41 178.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 53.5 m-20 -75.8 -42.04 51.12 Favored 'General case' 0 C--O 1.225 -0.221 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 32.8 mt -60.54 -40.26 83.85 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 124.643 1.177 . . . . 0.0 109.72 173.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 19.2 t -68.03 -35.88 73.41 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 O-C-N 120.198 -1.564 . . . . 0.0 110.902 175.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -62.38 -48.67 78.7 Favored 'General case' 0 C--O 1.22 -0.459 0 O-C-N 121.506 -0.746 . . . . 0.0 110.498 171.106 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.88 -35.39 66.45 Favored 'General case' 0 N--CA 1.44 -0.928 0 C-N-CA 126.505 1.922 . . . . 0.0 111.981 -176.875 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 76.0 mt -69.77 -52.58 30.25 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 176.225 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 6.8 tttp -54.51 -44.33 72.63 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 122.924 0.49 . . . . 0.0 111.172 177.613 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -71.95 -19.43 61.9 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.182 1.793 . . . . 0.0 110.984 -178.112 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.97 -35.38 80.44 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 119.525 1.057 . . . . 0.0 109.447 169.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 86.13 -117.03 4.5 Favored Glycine 0 N--CA 1.449 -0.497 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 172.542 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 39.6 mt -76.48 -49.27 17.0 Favored 'General case' 0 CA--C 1.501 -0.912 0 CA-C-N 118.367 1.083 . . . . 0.0 108.838 -173.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.89 145.81 24.36 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 124.229 0.955 . . . . 0.0 108.638 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.9 p -146.39 139.5 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 167.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 47.1 m -106.07 105.5 15.56 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 125.584 1.554 . . . . 0.0 107.197 176.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 40.7 mt -90.81 127.12 36.24 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.517 ' HB2' HH11 ' A' ' 98' ' ' ARG . 6.4 ttm105 -103.53 111.7 24.28 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.2 pp -121.53 174.61 5.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 C-N-CA 126.048 1.739 . . . . 0.0 108.312 -175.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 8.5 mt -118.3 121.69 30.94 Favored Pre-proline 0 CA--C 1.54 0.586 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -179.107 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -90.64 134.3 1.89 Allowed 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 123.647 2.898 . . . . 0.0 111.668 -176.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 6.4 mt-30 -129.0 -179.92 5.38 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.379 1.872 . . . . 0.0 107.979 -173.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -132.1 -25.8 1.98 Allowed 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 118.775 0.716 . . . . 0.0 112.779 173.497 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -81.58 -6.37 58.92 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 124.526 1.131 . . . . 0.0 111.411 -171.453 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -81.58 -11.5 59.11 Favored 'General case' 0 C--O 1.235 0.316 0 C-N-CA 129.298 3.039 . . . . 0.0 114.275 -168.061 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -148.58 -165.29 2.23 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 119.219 0.918 . . . . 0.0 109.401 -169.514 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 56.8 m -79.54 105.16 2.93 Favored Pre-proline 0 N--CA 1.448 -0.526 0 CA-C-O 117.903 -1.046 . . . . 0.0 108.238 156.036 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -70.02 153.18 67.98 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 CA-C-N 120.901 1.357 . . . . 0.0 109.457 168.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 14.6 t -162.29 149.65 13.9 Favored 'General case' 0 C--O 1.24 0.603 0 C-N-CA 126.116 1.766 . . . . 0.0 106.646 167.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.24 -165.11 13.1 Favored Glycine 0 CA--C 1.531 1.049 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -67.62 168.96 16.89 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.222 2.615 . . . . 0.0 112.06 -170.124 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.7 t -146.11 -28.56 0.42 Allowed 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 126.458 1.903 . . . . 0.0 110.47 -172.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -77.6 96.07 4.71 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 124.158 0.983 . . . . 0.0 110.86 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 171.703 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.2 p . . . . . 0 CA--C 1.535 0.377 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 13.0 m -140.83 164.74 29.41 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.514 1.126 . . . . 0.0 109.071 171.046 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 25.6 p-10 -128.71 94.45 3.86 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 127.601 2.36 . . . . 0.0 108.901 -173.477 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.452 HG11 ' HB2' ' A' ' 62' ' ' LEU . 24.3 t -90.64 106.94 17.93 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 176.615 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.7 t -85.5 142.72 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 166.343 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.0 mt -137.53 132.01 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.152 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 174.152 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 -115.04 141.35 48.11 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.715 1.606 . . . . 0.0 109.343 -175.053 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 30.9 ptt180 -139.88 -169.47 2.73 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 124.426 1.09 . . . . 0.0 110.474 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.67 169.12 10.38 Favored 'General case' 0 N--CA 1.463 0.222 0 C-N-CA 124.567 1.147 . . . . 0.0 109.439 168.143 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -69.89 -15.98 63.16 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 113.43 0.9 . . . . 0.0 113.43 -177.189 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -84.5 -7.07 59.4 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-O 118.477 -0.773 . . . . 0.0 112.896 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -136.32 172.34 13.16 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 119.649 1.113 . . . . 0.0 111.479 -166.415 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.74 166.45 26.36 Favored Glycine 0 C--N 1.333 0.413 0 C-N-CA 123.669 0.652 . . . . 0.0 111.927 -170.458 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -87.27 115.71 24.86 Favored 'General case' 0 N--CA 1.444 -0.726 0 N-CA-C 104.52 -2.4 . . . . 0.0 104.52 150.067 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -92.7 48.62 2.55 Favored Glycine 0 C--O 1.224 -0.482 0 CA-C-O 118.518 -1.157 . . . . 0.0 112.643 -168.437 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.433 ' CE2' HD11 ' A' ' 28' ' ' ILE . 19.9 p90 -126.92 160.08 32.06 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 118.76 1.28 . . . . 0.0 109.873 173.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.4 t -138.39 141.36 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 C-N-CA 126.519 1.927 . . . . 0.0 106.972 -179.29 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.433 HD11 ' CE2' ' A' ' 26' ' ' PHE . 4.4 mp -105.9 135.85 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.667 0 C-N-CA 125.817 1.647 . . . . 0.0 107.801 178.009 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.473 HD11 ' HE3' ' A' ' 46' ' ' LYS . 13.5 pt . . . . . 0 N--CA 1.45 -0.467 0 C-N-CA 125.459 1.504 . . . . 0.0 110.314 175.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo . . . . . 0 N--CA 1.453 -0.875 0 CA-C-O 118.399 -0.75 . . . . 0.0 111.696 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -138.48 125.35 21.11 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 119.73 1.15 . . . . 0.0 110.746 -170.441 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.473 ' HE3' HD11 ' A' ' 29' ' ' ILE . 48.2 pttt -146.64 162.94 37.38 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 124.407 1.083 . . . . 0.0 108.783 166.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 46.4 mm -65.31 130.61 30.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 170.551 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.42 -49.66 0.65 Allowed Glycine 0 C--N 1.336 0.56 0 C-N-CA 125.254 1.407 . . . . 0.0 112.492 175.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -129.24 150.63 50.54 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 119.433 1.617 . . . . 0.0 108.373 176.478 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 11.5 mt -128.93 133.31 66.35 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 167.61 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -60.14 126.37 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.605 0 C-N-CA 125.191 1.396 . . . . 0.0 108.018 169.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.29 121.13 9.43 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 124.483 1.113 . . . . 0.0 108.059 164.8 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.51 21.55 40.28 Favored Glycine 0 CA--C 1.526 0.778 0 CA-C-O 118.875 -0.958 . . . . 0.0 112.649 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 29.0 p -90.85 164.76 24.55 Favored Pre-proline 0 C--O 1.236 0.349 0 CA-C-N 119.651 1.725 . . . . 0.0 112.915 177.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -65.65 -21.77 58.66 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 121.695 1.597 . . . . 0.0 112.911 162.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.4 -56.36 16.9 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 119.199 0.909 . . . . 0.0 109.134 172.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -57.95 -48.48 79.83 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.597 0.759 . . . . 0.0 109.923 -177.355 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.3 mtt85 -71.9 -6.85 44.8 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 113.91 1.078 . . . . 0.0 113.91 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 36.1 t -62.29 -21.58 65.34 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 119.817 1.19 . . . . 0.0 109.646 167.74 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.69 26.23 11.04 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 125.736 1.614 . . . . 0.0 112.665 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.6 mtmm -126.96 -52.13 1.43 Allowed 'General case' 0 CA--C 1.521 -0.145 0 C-N-CA 126.583 1.953 . . . . 0.0 109.153 175.758 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.452 ' HB2' HG11 ' A' ' 14' ' ' VAL . 9.9 tp -92.85 118.77 31.48 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -161.441 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 71.4 mmtt -129.97 171.89 12.29 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 123.55 1.643 . . . . 0.0 109.332 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 94.8 t -64.89 122.9 16.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 113.807 -1.542 . . . . 0.0 107.626 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 128.31 -18.89 5.75 Favored Glycine 0 C--N 1.337 0.593 0 C-N-CA 125.02 1.295 . . . . 0.0 109.997 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -77.05 98.25 4.94 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 122.243 1.021 . . . . 0.0 109.196 -165.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 17.8 mtm180 -44.63 120.48 2.28 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 128.653 2.781 . . . . 0.0 110.572 164.38 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 45.5 mt -101.6 153.31 5.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 126.151 1.78 . . . . 0.0 107.432 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 tp -131.75 -44.89 0.97 Allowed 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.821 1.648 . . . . 0.0 110.589 -172.255 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -147.98 163.11 37.84 Favored 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 123.267 0.627 . . . . 0.0 110.423 176.644 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 67.2 t -133.0 118.04 31.54 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 -176.19 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 42.39 57.11 3.5 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.146 1.778 . . . . 0.0 109.529 -170.674 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 67.46 -4.12 4.1 Favored Glycine 0 CA--C 1.537 1.435 0 CA-C-O 117.679 -1.623 . . . . 0.0 116.026 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -90.17 130.89 36.26 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 121.398 2.599 . . . . 0.0 110.997 -178.471 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 70.3 m -73.61 94.33 2.16 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 124.013 0.925 . . . . 0.0 110.509 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.5 pp -60.77 10.96 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.632 0 C-N-CA 128.34 2.656 . . . . 0.0 115.133 177.3 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 52.5 mt -63.46 -79.41 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 C-N-CA 126.029 1.732 . . . . 0.0 108.729 -178.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 62.9 m-80 -79.95 -11.87 59.76 Favored 'General case' 0 N--CA 1.467 0.4 0 O-C-N 121.453 -0.779 . . . . 0.0 113.079 -174.794 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 16.6 mtp -60.0 140.39 90.48 Favored Pre-proline 0 C--O 1.237 0.401 0 CA-C-N 118.238 0.472 . . . . 0.0 110.172 -178.41 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -65.27 156.05 65.21 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 121.962 1.775 . . . . 0.0 109.355 169.184 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 55.9 t60 -57.31 -34.99 69.3 Favored 'General case' 0 C--O 1.224 -0.261 0 CA-C-O 119.003 -0.522 . . . . 0.0 110.701 173.8 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.74 -41.66 77.91 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-O 118.591 -0.718 . . . . 0.0 112.362 175.465 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.88 -45.45 82.03 Favored 'General case' 0 C--O 1.222 -0.388 0 CA-C-N 118.909 0.777 . . . . 0.0 109.415 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 67.9 mt -65.42 -44.26 94.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.481 0 C-N-CA 125.53 1.532 . . . . 0.0 109.21 -175.521 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 22.5 t -55.18 -47.98 76.84 Favored 'Isoleucine or valine' 0 C--O 1.24 0.585 0 C-N-CA 125.147 1.379 . . . . 0.0 109.629 170.248 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 24.9 mtpt -70.33 -28.11 64.89 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-O 117.134 -1.412 . . . . 0.0 113.526 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.85 -40.83 79.17 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.932 1.696 . . . . 0.0 110.481 177.07 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 81.8 mt -68.74 -46.81 78.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 178.419 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.1 tmtm? -63.34 -38.12 89.93 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-O 118.678 -0.677 . . . . 0.0 111.729 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -61.93 -32.02 72.38 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 124.169 0.988 . . . . 0.0 110.282 175.277 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -67.95 -12.18 60.23 Favored 'General case' 0 CA--C 1.543 0.689 0 CA-C-O 121.636 0.731 . . . . 0.0 112.3 175.096 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 66.13 -100.31 0.51 Allowed Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 125.674 1.607 . . . . 0.0 110.411 173.519 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 25.1 mt -105.34 -24.72 12.63 Favored 'General case' 0 CA--C 1.504 -0.792 0 CA-C-O 117.68 -1.153 . . . . 0.0 112.495 -176.248 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.28 121.06 40.11 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 118.678 0.672 . . . . 0.0 109.495 178.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.3 p -125.68 148.48 30.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -176.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -116.28 117.29 29.58 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 124.656 1.183 . . . . 0.0 108.068 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 57.4 mt -98.99 112.64 24.7 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 171.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.3 ttm180 -81.47 112.56 18.83 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 166.746 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.9 pp -116.72 166.51 10.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 C-N-CA 124.951 1.301 . . . . 0.0 108.618 -178.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.5 mt . . . . . 0 N--CA 1.464 0.26 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 174.219 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 36.9 p . . . . . 0 CA--C 1.537 0.446 0 CA-C-O 118.292 -0.861 . . . . 0.0 109.212 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.3 t -115.57 173.91 6.29 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.532 1.133 . . . . 0.0 109.592 163.191 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -134.85 94.68 3.2 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 126.624 1.97 . . . . 0.0 108.376 168.449 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.6 t -99.22 108.07 21.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 O-C-N 120.68 -1.262 . . . . 0.0 107.94 -170.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.5 p -105.48 121.04 57.15 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 CA-C-N 118.841 0.746 . . . . 0.0 111.315 -170.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.6 mt -134.13 129.21 53.61 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 126.089 1.756 . . . . 0.0 109.363 -169.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 37.8 m-70 -108.54 144.18 36.56 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.214 1.806 . . . . 0.0 111.443 -177.359 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.414 HH11 ' H ' ' A' ' 24' ' ' PHE . 18.4 ptt180 -126.51 175.59 7.79 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 125.511 1.525 . . . . 0.0 111.018 176.135 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.436 ' HE3' ' OE2' ' A' ' 22' ' ' GLU . 0.0 OUTLIER -81.05 170.06 16.69 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 160.007 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -68.98 -35.7 77.02 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.609 -0.682 . . . . 0.0 111.709 177.67 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 68.9 m-20 -71.27 -47.32 57.65 Favored 'General case' 0 C--O 1.232 0.15 0 O-C-N 122.196 -0.315 . . . . 0.0 111.354 -171.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.436 ' OE2' ' HE3' ' A' ' 19' ' ' LYS . 5.3 pt-20 -76.84 166.96 22.64 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.518 0.675 . . . . 0.0 110.456 -176.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.61 -178.07 49.4 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 167.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.483 ' CE1' HG12 ' A' ' 95' ' ' VAL . 73.9 m-85 -70.6 145.28 50.81 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 104.255 -2.498 . . . . 0.0 104.255 149.443 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.419 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -84.81 44.83 3.42 Favored Glycine 0 C--O 1.221 -0.705 0 CA-C-O 117.529 -1.706 . . . . 0.0 112.519 -176.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -131.48 160.64 34.58 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 119.251 1.526 . . . . 0.0 110.519 179.3 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.9 t -136.88 127.32 40.18 Favored 'Isoleucine or valine' 0 C--O 1.239 0.53 0 C-N-CA 125.004 1.322 . . . . 0.0 108.055 177.865 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.1 mt -74.39 143.53 13.39 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 170.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.542 HD11 ' HE3' ' A' ' 46' ' ' LYS . 20.4 pt . . . . . 0 C--O 1.243 0.712 0 C-N-CA 124.25 1.02 . . . . 0.0 109.518 162.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_endo . . . . . 0 N--CA 1.454 -0.85 0 CA-C-O 118.27 -0.804 . . . . 0.0 111.292 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.9 m170 -85.42 126.51 33.84 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 120.07 1.305 . . . . 0.0 110.886 -174.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.542 ' HE3' HD11 ' A' ' 29' ' ' ILE . 11.2 pttp -144.32 162.52 36.21 Favored 'General case' 0 N--CA 1.465 0.281 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 166.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 23.0 mm -62.85 120.5 9.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 164.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -98.32 -30.05 7.18 Favored Glycine 0 CA--C 1.524 0.598 0 CA-C-N 118.455 0.571 . . . . 0.0 113.129 170.187 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 59.3 ttm-85 -151.97 153.98 35.14 Favored 'General case' 0 CA--C 1.514 -0.429 0 CA-C-N 118.635 1.217 . . . . 0.0 108.221 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 13.4 mt -120.15 149.92 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 O-C-N 124.614 1.196 . . . . 0.0 108.184 166.359 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.2 mp -78.58 127.29 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.825 0 C-N-CA 126.139 1.776 . . . . 0.0 107.25 168.516 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -59.42 137.51 57.97 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.738 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.44 6.1 89.04 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-O 118.461 -1.188 . . . . 0.0 113.331 174.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.419 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 76.6 p -87.3 166.52 25.37 Favored Pre-proline 0 CA--C 1.53 0.208 0 CA-C-N 119.992 1.896 . . . . 0.0 112.705 -175.2 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -58.16 -25.89 73.61 Favored 'Trans proline' 0 N--CA 1.452 -0.931 0 C-N-CA 122.121 1.881 . . . . 0.0 113.394 167.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.95 -60.62 2.85 Favored 'General case' 0 C--N 1.342 0.247 0 CA-C-N 119.283 0.947 . . . . 0.0 108.859 174.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -57.85 -46.38 84.86 Favored 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 122.981 0.512 . . . . 0.0 110.962 -176.227 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 78.8 mtt-85 -65.78 -18.21 65.17 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 124.885 1.274 . . . . 0.0 112.676 -176.492 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 9.0 t -63.12 -33.34 75.25 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 119.245 0.93 . . . . 0.0 110.11 175.266 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 58.23 -31.79 0.04 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 129.584 3.154 . . . . 0.0 114.901 -168.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.5 mtpt -61.55 -8.44 4.33 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.999 1.72 . . . . 0.0 112.093 170.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 21.2 tp -134.75 116.32 14.74 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 126.075 1.75 . . . . 0.0 108.981 -176.334 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 27.4 mmmt -137.4 171.63 14.19 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 123.535 1.636 . . . . 0.0 111.831 176.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 46.5 t -68.64 110.74 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 113.881 -1.509 . . . . 0.0 108.383 -178.071 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 138.35 -23.5 2.99 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -177.034 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -64.99 100.14 0.4 Allowed 'General case' 0 C--O 1.233 0.227 0 CA-C-O 122.114 0.959 . . . . 0.0 109.843 -174.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.9 mtm-85 -48.43 137.62 11.19 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 128.048 2.539 . . . . 0.0 109.602 156.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.8 mt -122.86 143.96 33.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.195 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -173.619 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.7 mt -107.24 -42.34 4.88 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 125.732 1.613 . . . . 0.0 110.379 175.507 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -154.68 165.99 34.81 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 123.015 0.526 . . . . 0.0 112.04 -170.189 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 51.4 t -125.71 123.06 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 C-N-CA 128.141 2.577 . . . . 0.0 104.95 174.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 42.78 39.31 1.64 Allowed 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.212 1.805 . . . . 0.0 111.412 -172.511 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 81.26 -9.75 52.74 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-O 117.638 -1.645 . . . . 0.0 115.173 177.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 7.6 mm-40 -75.07 119.59 19.44 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 120.558 2.179 . . . . 0.0 108.557 172.169 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.9 m -55.21 127.76 30.79 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 171.561 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 15.3 pt -100.79 -5.38 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 C-N-CA 123.331 0.652 . . . . 0.0 112.265 -178.138 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.1 mt -59.13 142.48 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 167.454 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 73.2 -20.06 0.3 Allowed 'General case' 0 CA--C 1.533 0.294 0 C-N-CA 126.497 1.919 . . . . 0.0 115.325 167.315 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 14.0 mtp -64.25 148.3 95.97 Favored Pre-proline 0 CA--C 1.539 0.522 0 CA-C-N 119.477 1.035 . . . . 0.0 109.68 167.361 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -72.57 161.17 44.79 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 122.401 2.067 . . . . 0.0 110.064 169.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -55.28 -47.79 75.0 Favored 'General case' 0 C--O 1.225 -0.209 0 C-N-CA 123.661 0.784 . . . . 0.0 111.016 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -53.76 -40.62 66.37 Favored 'General case' 0 CA--C 1.527 0.092 0 C-N-CA 123.236 0.614 . . . . 0.0 112.174 -176.098 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -72.19 -42.37 65.9 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 119.259 -0.4 . . . . 0.0 110.478 -175.548 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 46.9 mt -66.59 -37.28 79.24 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 124.87 1.268 . . . . 0.0 108.846 176.238 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 38.2 t -65.16 -45.63 93.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.484 0 O-C-N 120.274 -1.516 . . . . 0.0 109.841 175.221 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.3 ttpt -62.41 -42.53 99.51 Favored 'General case' 0 C--O 1.22 -0.482 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.344 175.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.12 -48.01 23.16 Favored 'General case' 0 C--O 1.226 -0.162 0 C-N-CA 126.305 1.842 . . . . 0.0 111.62 171.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 74.4 mt -76.22 -31.89 21.76 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 O-C-N 121.592 -0.692 . . . . 0.0 109.607 -174.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.3 tttp -66.42 -46.08 77.75 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.58 1.082 . . . . 0.0 110.125 170.779 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -60.87 -18.15 54.47 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 128.134 2.574 . . . . 0.0 111.984 175.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -58.68 -25.91 63.3 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.816 0.446 . . . . 0.0 111.336 169.743 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 66.86 57.97 8.97 Favored Glycine 0 C--N 1.339 0.71 0 O-C-N 121.338 -0.852 . . . . 0.0 111.063 170.399 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 48.0 mt 75.48 -38.52 0.36 Allowed 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 128.428 2.691 . . . . 0.0 112.193 -174.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.01 121.43 41.77 Favored 'General case' 0 C--N 1.322 -0.61 0 O-C-N 123.604 0.565 . . . . 0.0 111.062 -173.488 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.483 HG12 ' CE1' ' A' ' 24' ' ' PHE . 8.5 p -124.77 121.75 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 178.215 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.2 m -89.49 133.68 34.45 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 164.325 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 27.7 mt -123.76 139.36 54.06 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 -177.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.8 ttm180 -113.72 115.86 28.5 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -112.52 166.9 6.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 C-N-CA 126.682 1.993 . . . . 0.0 108.083 177.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 70.0 mt . . . . . 0 CA--C 1.54 0.586 0 CA-C-O 117.792 -1.099 . . . . 0.0 109.615 177.529 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 38.4 p . . . . . 0 CA--C 1.537 0.451 0 N-CA-C 107.327 -1.361 . . . . 0.0 107.327 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 23.4 m -137.98 162.3 34.45 Favored 'General case' 0 C--N 1.328 -0.34 0 O-C-N 120.865 -1.147 . . . . 0.0 108.333 164.632 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -131.72 95.72 3.79 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 127.691 2.396 . . . . 0.0 107.1 -167.214 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 19.6 t -93.72 94.83 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 -176.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.9 p -80.88 129.25 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 172.6 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 67.0 mt -135.17 147.15 29.29 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 175.756 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.6 m-70 -113.4 167.31 10.69 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.008 1.323 . . . . 0.0 109.713 173.616 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 46.2 ptt85 -145.58 -179.88 6.97 Favored 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 125.996 1.718 . . . . 0.0 107.076 172.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.67 159.29 15.6 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 173.1 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.556 ' HG2' HD21 ' A' ' 93' ' ' LEU . 8.8 mt-10 -70.13 -14.77 62.8 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 120.791 -1.193 . . . . 0.0 112.243 -178.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -80.08 7.63 8.78 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.95 1.3 . . . . 0.0 112.264 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -164.62 170.14 16.1 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 120.249 -1.532 . . . . 0.0 109.863 -167.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.2 -167.81 29.12 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 125.399 1.476 . . . . 0.0 110.909 175.519 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -85.98 159.44 19.62 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 164.343 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.88 39.28 2.86 Favored Glycine 0 C--O 1.222 -0.623 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.922 -178.305 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -118.58 161.35 20.2 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 119.587 1.694 . . . . 0.0 109.387 169.33 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.8 t -140.81 129.79 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 -178.421 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 61.5 mt -97.4 145.47 9.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.2 pt . . . . . 0 N--CA 1.441 -0.879 0 C-N-CA 125.249 1.42 . . . . 0.0 109.746 168.781 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo . . . . . 0 N--CA 1.456 -0.688 0 CA-C-O 119.457 -0.309 . . . . 0.0 111.492 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -140.39 132.59 28.1 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 125.206 1.403 . . . . 0.0 108.142 -173.371 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.0 pttm -156.89 166.93 31.98 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 125.698 1.599 . . . . 0.0 107.734 174.249 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 26.5 mm -72.71 103.69 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 C-N-CA 124.571 1.148 . . . . 0.0 108.87 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -67.91 -42.58 85.47 Favored Glycine 0 N--CA 1.451 -0.33 0 O-C-N 121.284 -0.885 . . . . 0.0 111.366 172.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 23.6 ttm105 -158.1 152.12 24.09 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -165.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 16.1 mt -122.0 150.49 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 168.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 31.9 mm -87.82 136.47 23.08 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.4 t0 -66.66 148.89 51.28 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-O 121.152 0.501 . . . . 0.0 111.185 -176.064 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.48 7.93 17.12 Favored Glycine 0 CA--C 1.527 0.834 0 C-N-CA 124.519 1.057 . . . . 0.0 114.369 175.603 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.406 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 79.4 p -76.0 167.98 31.88 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 118.234 1.017 . . . . 0.0 111.144 -176.343 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.406 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 12.5 Cg_endo -57.8 -27.71 79.26 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 122.149 1.899 . . . . 0.0 112.239 165.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -70.83 -51.96 23.38 Favored 'General case' 0 C--N 1.341 0.204 0 CA-C-N 119.996 1.271 . . . . 0.0 110.171 174.391 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -57.83 -44.68 86.63 Favored 'General case' 0 N--CA 1.465 0.311 0 C-N-CA 123.343 0.657 . . . . 0.0 110.674 -179.137 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 27.4 mtt-85 -75.86 -5.53 46.46 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 124.634 1.174 . . . . 0.0 112.706 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.9 t -73.21 -35.97 66.43 Favored 'General case' 0 C--O 1.225 -0.2 0 CA-C-O 117.617 -1.182 . . . . 0.0 110.994 178.202 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 59.49 -24.94 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 127.985 2.514 . . . . 0.0 116.214 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 6.1 mtpt -66.48 -17.29 64.71 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 120.325 1.421 . . . . 0.0 111.975 161.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.78 119.0 34.08 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -178.476 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.51 171.47 14.21 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-O 122.563 1.173 . . . . 0.0 109.049 -178.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 78.3 t -72.43 108.14 3.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 O-C-N 120.734 -1.229 . . . . 0.0 108.693 -178.399 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 130.39 -3.94 5.87 Favored Glycine 0 CA--C 1.521 0.418 0 C-N-CA 126.261 1.886 . . . . 0.0 111.275 173.43 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.5 m-20 -71.31 95.86 1.36 Allowed 'General case' 0 C--O 1.234 0.268 0 CA-C-N 118.585 1.192 . . . . 0.0 108.148 172.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 38.5 mtt85 -53.01 143.3 17.61 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 127.382 2.273 . . . . 0.0 109.116 170.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 34.6 mt -116.84 149.53 19.06 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -168.32 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.86 -46.05 0.87 Allowed 'General case' 0 N--CA 1.463 0.211 0 C-N-CA 126.336 1.854 . . . . 0.0 109.967 -164.211 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -153.52 168.55 25.77 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.046 0.938 . . . . 0.0 110.012 176.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.453 HG22 HD23 ' A' ' 97' ' ' LEU . 80.6 t -133.6 120.99 39.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 174.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.554 HD21 ' HB2' ' A' ' 91' ' ' ALA . 23.2 m-20 48.73 41.22 17.6 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.308 1.043 . . . . 0.0 110.398 -172.699 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.13 -11.39 3.82 Favored Glycine 0 CA--C 1.527 0.792 0 C-N-CA 126.907 2.194 . . . . 0.0 116.467 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.5 tp-100 -77.13 121.53 23.73 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 120.146 1.973 . . . . 0.0 107.257 -177.635 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 p -63.29 112.33 2.65 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.32 1.048 . . . . 0.0 110.992 -174.833 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 1.7 pp -73.34 14.25 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 125.758 1.623 . . . . 0.0 113.188 175.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 60.6 mt -76.78 -86.16 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 O-C-N 121.199 -0.938 . . . . 0.0 109.353 -158.414 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -77.53 -8.72 58.24 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.416 1.086 . . . . 0.0 111.226 176.073 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 17.1 ttt -53.65 142.26 42.82 Favored Pre-proline 0 N--CA 1.433 -1.303 0 C-N-CA 128.22 2.608 . . . . 0.0 110.924 -177.511 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -60.66 139.58 86.47 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 121.873 1.715 . . . . 0.0 110.639 174.714 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -59.3 -39.87 84.38 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.541 0.736 . . . . 0.0 111.587 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.39 -23.49 63.73 Favored 'General case' 0 CA--C 1.53 0.177 0 O-C-N 122.034 -0.416 . . . . 0.0 111.986 175.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -73.72 -46.54 45.43 Favored 'General case' 0 C--O 1.223 -0.293 0 CA-C-O 118.635 -0.697 . . . . 0.0 109.713 179.089 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 49.1 mt -56.08 -40.32 63.34 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 126.432 1.893 . . . . 0.0 110.568 172.059 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 35.0 t -66.57 -43.89 90.36 Favored 'Isoleucine or valine' 0 C--O 1.238 0.451 0 O-C-N 120.109 -1.619 . . . . 0.0 110.75 176.264 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 6.6 tttt -54.82 -49.11 71.8 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 172.72 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -48.89 -39.38 25.75 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 129.23 3.012 . . . . 0.0 113.721 177.084 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.7 mt -75.9 -46.08 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 CA-C-N 118.791 0.723 . . . . 0.0 109.073 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -57.34 -51.21 70.29 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 119.002 0.819 . . . . 0.0 110.137 173.108 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -57.71 -19.28 26.17 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 128.69 2.796 . . . . 0.0 112.864 177.258 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.554 ' HB2' HD21 ' A' ' 72' ' ' ASN . . . -60.41 -26.87 67.01 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 119.253 0.933 . . . . 0.0 112.596 177.231 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.32 -151.36 18.28 Favored Glycine 0 C--N 1.341 0.822 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -173.252 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' LEU . . . . . 0.556 HD21 ' HG2' ' A' ' 20' ' ' GLU . 72.9 mt -71.98 -33.04 67.82 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 117.626 0.713 . . . . 0.0 110.906 168.385 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.91 145.56 24.54 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 -178.739 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.6 p -140.98 143.24 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 168.557 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 23.7 m -114.57 102.69 10.29 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 174.428 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.453 HD23 HG22 ' A' ' 71' ' ' VAL . 61.3 mt -89.93 115.21 27.06 Favored 'General case' 0 CA--C 1.514 -0.427 0 N-CA-C 106.587 -1.634 . . . . 0.0 106.587 -174.573 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -86.4 112.14 21.18 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 -178.032 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -113.51 167.97 6.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 C-N-CA 124.709 1.203 . . . . 0.0 110.356 -174.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.9 mp . . . . . 0 C--O 1.239 0.518 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 172.655 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 74.0 p . . . . . 0 N--CA 1.444 -0.742 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 m -132.18 155.26 48.52 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 144.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -93.21 143.11 26.58 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 105.632 -1.988 . . . . 0.0 105.632 160.018 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.7 t -129.96 102.06 6.74 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 169.329 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.6 p -82.95 144.87 9.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 168.108 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.1 mt -136.81 152.26 28.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 C-N-CA 127.487 2.315 . . . . 0.0 104.933 173.349 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 83.0 m-70 -129.92 136.56 49.62 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 125.618 1.567 . . . . 0.0 109.122 -168.712 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.1 ptt180 -131.39 176.6 8.16 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 120.605 1.548 . . . . 0.0 111.195 -178.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.2 161.98 14.04 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.07 0.948 . . . . 0.0 109.289 172.351 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -70.55 -15.78 62.81 Favored 'General case' 0 CA--C 1.538 0.502 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -89.2 -10.64 46.32 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.149 0.886 . . . . 0.0 112.642 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 25.9 pt-20 -127.57 175.38 8.3 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 120.344 1.429 . . . . 0.0 110.974 -166.906 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.01 176.79 19.44 Favored Glycine 0 CA--C 1.531 1.036 0 C-N-CA 124.899 1.238 . . . . 0.0 111.716 177.503 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 57.9 m-85 -89.3 137.96 31.86 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.024 -1.473 . . . . 0.0 107.024 163.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.76 66.9 0.32 Allowed Glycine 0 C--O 1.222 -0.603 0 C-N-CA 124.571 1.081 . . . . 0.0 111.101 -176.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -133.85 146.31 50.5 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 124.814 1.246 . . . . 0.0 108.459 167.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.6 t -121.54 144.87 29.25 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 173.111 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.6 mp -118.43 110.62 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 -173.019 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.451 HD11 ' HE3' ' A' ' 46' ' ' LYS . 31.1 pt . . . . . 0 C--O 1.234 0.261 0 C-N-CA 123.861 0.864 . . . . 0.0 111.072 -169.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 N--CA 1.461 -0.403 0 CA-C-O 118.212 -0.829 . . . . 0.0 114.026 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -133.55 121.16 21.73 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 119.734 1.152 . . . . 0.0 108.098 -177.324 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.451 ' HE3' HD11 ' A' ' 29' ' ' ILE . 1.9 pttt -145.72 149.46 34.45 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 106.9 -1.519 . . . . 0.0 106.9 170.654 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.519 HG13 HD22 ' A' ' 62' ' ' LEU . 17.1 mm -63.03 125.84 20.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 174.754 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -98.41 -37.51 4.27 Favored Glycine 0 C--N 1.333 0.388 0 C-N-CA 123.88 0.753 . . . . 0.0 112.773 178.056 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 37.6 ttm180 -158.15 149.14 20.85 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 125.198 1.399 . . . . 0.0 107.906 -174.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.2 mt -127.34 124.88 64.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 C-N-CA 126.598 1.959 . . . . 0.0 106.536 172.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.6 mp -55.59 132.91 19.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.339 0 C-N-CA 125.436 1.494 . . . . 0.0 109.828 168.476 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -57.42 127.5 32.3 Favored 'General case' 0 C--O 1.24 0.572 0 C-N-CA 124.991 1.316 . . . . 0.0 109.309 174.734 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.04 5.52 89.55 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 124.447 1.023 . . . . 0.0 113.462 174.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.2 p -65.26 162.69 38.08 Favored Pre-proline 0 CA--C 1.532 0.288 0 CA-C-N 119.21 1.505 . . . . 0.0 110.938 173.539 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -60.5 -28.95 87.62 Favored 'Trans proline' 0 N--CA 1.45 -1.045 0 C-N-CA 121.781 1.654 . . . . 0.0 112.109 168.568 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.25 -52.84 63.57 Favored 'General case' 0 C--N 1.344 0.33 0 CA-C-N 119.337 0.972 . . . . 0.0 110.282 172.805 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -61.55 -51.96 66.42 Favored 'General case' 0 N--CA 1.462 0.146 0 O-C-N 123.285 0.366 . . . . 0.0 110.817 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 90.5 mtt-85 -63.93 -28.9 70.15 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 118.409 -0.805 . . . . 0.0 112.059 -173.185 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 42.3 t -60.94 -19.1 60.26 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.627 1.171 . . . . 0.0 112.573 174.662 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 55.78 22.4 5.49 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 125.389 1.475 . . . . 0.0 114.197 171.086 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 44.5 mtmt -130.1 8.24 5.15 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 124.668 1.187 . . . . 0.0 113.273 178.268 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.519 HD22 HG13 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -141.06 119.27 12.07 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 -179.764 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.13 165.11 24.0 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 119.016 0.826 . . . . 0.0 110.606 176.579 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . 0.263 0.2 OUTLIER -56.98 141.15 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 O-C-N 121.201 -0.937 . . . . 0.0 109.846 172.684 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.2 -6.97 78.7 Favored Glycine 0 CA--C 1.524 0.655 0 CA-C-O 118.215 -1.325 . . . . 0.0 111.651 -174.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 41.8 m-20 -74.59 96.97 3.06 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 119.244 1.522 . . . . 0.0 107.287 168.043 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 42.8 mtm180 -45.05 130.87 7.61 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 126.882 2.073 . . . . 0.0 110.061 160.034 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 7.1 mt -111.76 143.99 20.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -177.112 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 tp -112.81 -44.98 3.24 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 127.343 2.257 . . . . 0.0 108.47 -171.685 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -155.71 170.88 21.02 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.546 0.739 . . . . 0.0 111.474 -177.12 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.9 p -131.22 125.39 57.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 C-N-CA 125.154 1.382 . . . . 0.0 107.992 174.285 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 64.2 m-20 46.64 45.65 14.41 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 124.487 1.115 . . . . 0.0 108.957 -170.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 68.3 -2.51 7.15 Favored Glycine 0 CA--C 1.538 1.477 0 C-N-CA 125.81 1.672 . . . . 0.0 116.772 -175.58 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -91.13 135.32 33.85 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 121.465 2.632 . . . . 0.0 110.359 -174.748 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -72.41 109.24 5.97 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 126.109 1.764 . . . . 0.0 112.316 -171.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 7.4 pt -87.74 -5.05 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 O-C-N 121.348 -0.845 . . . . 0.0 112.51 -172.537 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.521 ' H ' HD12 ' A' ' 77' ' ' ILE . 3.6 mp -65.56 -48.23 83.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 C-N-CA 124.626 1.17 . . . . 0.0 110.207 173.097 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 63.6 m-80 -93.45 -26.6 17.13 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 118.523 -0.751 . . . . 0.0 112.255 -162.556 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 3.9 mtp -70.27 160.53 80.62 Favored Pre-proline 0 CA--C 1.534 0.34 0 C-N-CA 124.685 1.194 . . . . 0.0 112.398 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -71.36 146.18 49.95 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 121.822 1.681 . . . . 0.0 109.764 166.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -49.61 -38.6 32.43 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.765 1.226 . . . . 0.0 111.68 178.253 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -65.76 -30.13 70.75 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 124.152 0.981 . . . . 0.0 113.366 -178.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -82.01 -37.91 25.84 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 119.482 1.037 . . . . 0.0 109.908 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.7 mt -60.5 -36.32 68.95 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 C-N-CA 124.047 0.939 . . . . 0.0 109.659 172.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.9 t -63.79 -51.35 70.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 O-C-N 120.542 -1.349 . . . . 0.0 110.24 170.122 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -51.88 -46.97 64.72 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 118.138 0.426 . . . . 0.0 111.406 178.543 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.45 -36.11 66.2 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 127.686 2.394 . . . . 0.0 113.602 -179.446 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 86.1 mt -76.7 -48.42 26.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.157 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.713 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 59.2 tttt -55.7 -44.86 77.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 122.882 0.473 . . . . 0.0 110.879 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -63.68 -26.9 68.87 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 125.251 1.42 . . . . 0.0 112.27 177.115 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.39 -28.41 69.25 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 118.195 0.452 . . . . 0.0 110.519 176.098 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.16 -106.88 2.93 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 125.385 1.469 . . . . 0.0 109.708 174.26 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 81.5 mt -100.35 -36.27 9.3 Favored 'General case' 0 CA--C 1.504 -0.812 0 C-N-CA 123.137 0.575 . . . . 0.0 110.758 -170.402 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -93.73 143.65 26.12 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 170.325 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.2 p -144.21 138.43 24.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 165.721 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 m -104.79 130.02 52.96 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 179.125 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 26.7 mt -114.4 117.85 32.21 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 124.642 1.177 . . . . 0.0 107.876 177.868 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -84.93 116.05 23.13 Favored 'General case' 0 C--O 1.232 0.175 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 174.189 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 pp -114.92 172.71 3.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 C-N-CA 125.867 1.667 . . . . 0.0 109.941 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 6.2 mt . . . . . 0 C--O 1.237 0.447 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 169.627 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 28.9 p . . . . . 0 N--CA 1.447 -0.58 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 12' ' ' SER . . . . . 0.401 ' HB2' HG13 ' A' ' 99' ' ' ILE . 5.5 m -97.7 135.91 38.82 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 103.912 -2.625 . . . . 0.0 103.912 -174.217 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -112.92 103.99 11.97 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 18.2 t -87.49 139.29 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 105.532 -2.025 . . . . 0.0 105.532 177.028 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.4 p -129.11 143.24 41.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 168.037 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 4.0 mt -132.11 152.06 36.07 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 127.12 2.168 . . . . 0.0 105.421 173.528 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -131.32 130.11 42.31 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 126.646 1.978 . . . . 0.0 107.597 -176.189 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 34.0 ptt180 -126.11 179.89 5.03 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-N 120.311 1.414 . . . . 0.0 110.492 -175.154 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.1 164.61 12.09 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.281 1.033 . . . . 0.0 109.073 175.324 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -75.21 -12.95 60.4 Favored 'General case' 0 N--CA 1.466 0.367 0 O-C-N 120.795 -1.19 . . . . 0.0 111.764 176.107 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -74.44 -8.25 55.67 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 177.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 26.1 pt-20 -143.0 -175.71 4.62 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 124.082 0.953 . . . . 0.0 110.95 -162.136 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -116.89 -179.39 17.77 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 175.104 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.404 ' CE1' HG12 ' A' ' 95' ' ' VAL . 69.8 m-85 -75.31 174.53 9.41 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 159.069 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.39 46.43 1.08 Allowed Glycine 0 C--O 1.222 -0.602 0 CA-C-O 118.817 -0.99 . . . . 0.0 111.694 -176.491 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -133.44 143.95 49.19 Favored 'General case' 0 C--O 1.239 0.506 0 CA-C-N 118.246 1.023 . . . . 0.0 108.29 177.381 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.6 t -119.21 114.35 44.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 106.009 -1.848 . . . . 0.0 106.009 -171.076 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 14.5 mt -78.88 136.92 22.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.299 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 174.249 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.0 pt . . . . . 0 N--CA 1.441 -0.883 0 C-N-CA 125.557 1.543 . . . . 0.0 108.236 163.638 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo . . . . . 0 N--CA 1.449 -1.119 0 N-CA-C 108.66 -1.323 . . . . 0.0 108.66 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER 91.74 123.93 0.02 OUTLIER 'General case' 0 C--O 1.233 0.208 0 C-N-CA 130.123 3.369 . . . . 0.0 111.004 167.819 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -145.44 163.68 33.89 Favored 'General case' 0 C--O 1.233 0.209 0 C-N-CA 124.905 1.282 . . . . 0.0 108.4 163.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.8 mm -65.24 129.73 29.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 165.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -101.97 -49.6 1.24 Allowed Glycine 0 CA--C 1.524 0.628 0 C-N-CA 126.857 2.17 . . . . 0.0 111.774 173.586 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 49.6 ttt180 -144.38 161.81 38.04 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 125.325 1.45 . . . . 0.0 107.544 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.3 mt -133.46 150.74 32.46 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 C-N-CA 126.453 1.901 . . . . 0.0 107.707 174.394 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.0 mp -87.03 115.76 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.904 0 C-N-CA 126.57 1.948 . . . . 0.0 106.796 171.446 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 31.6 m-20 -52.57 142.98 16.74 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.183 0.993 . . . . 0.0 109.048 171.482 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.82 -12.99 26.55 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-O 118.218 -1.323 . . . . 0.0 113.471 175.413 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 74.3 p -65.85 167.03 12.59 Favored Pre-proline 0 C--O 1.238 0.478 0 CA-C-N 119.639 1.72 . . . . 0.0 111.829 -175.671 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -59.32 -29.1 89.37 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 121.712 1.608 . . . . 0.0 111.996 166.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.56 -56.74 12.03 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.668 0.667 . . . . 0.0 109.946 177.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -65.29 -51.55 59.97 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 123.039 0.535 . . . . 0.0 110.949 -177.314 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.0 mtp180 -65.46 -9.37 25.13 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.337 0.865 . . . . 0.0 113.337 -177.151 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -76.7 -9.27 58.55 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 117.149 -1.405 . . . . 0.0 113.16 171.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 52.11 39.17 26.07 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.905 1.682 . . . . 0.0 113.942 170.377 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 23.6 mtmm -141.11 13.49 2.23 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.784 1.233 . . . . 0.0 113.34 177.197 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.9 mt -144.26 127.41 16.62 Favored 'General case' 0 C--O 1.237 0.437 0 O-C-N 121.09 -1.006 . . . . 0.0 109.743 175.563 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -116.3 164.83 13.93 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.657 1.218 . . . . 0.0 108.806 175.508 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 39.3 t -65.75 133.73 30.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 163.165 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 110.07 -17.32 29.6 Favored Glycine 0 C--N 1.339 0.704 0 C-N-CA 124.918 1.247 . . . . 0.0 110.307 -177.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -71.91 97.12 1.78 Allowed 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 122.667 1.222 . . . . 0.0 109.09 -175.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 49.6 mtt85 -55.17 148.36 14.44 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 126.013 1.725 . . . . 0.0 110.904 166.599 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 96.3 mt -122.71 148.1 26.62 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 C-N-CA 126.995 2.118 . . . . 0.0 106.788 -166.668 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 29.1 mt -126.44 -37.29 2.21 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 114.43 1.27 . . . . 0.0 114.43 179.326 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -148.42 159.54 43.92 Favored 'General case' 0 N--CA 1.465 0.289 0 C-N-CA 124.454 1.101 . . . . 0.0 110.397 178.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 91.8 t -130.9 118.13 40.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 -175.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 63.03 -65.41 0.1 Allowed 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 128.513 2.725 . . . . 0.0 110.002 -165.639 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.97 -2.09 0.07 OUTLIER Glycine 0 CA--C 1.532 1.109 0 C-N-CA 125.914 1.721 . . . . 0.0 111.922 163.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -74.59 124.54 26.86 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 119.935 1.867 . . . . 0.0 107.142 -175.743 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.4 p -68.2 103.74 1.64 Allowed 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.8 pp -74.23 9.9 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 C-N-CA 124.079 0.952 . . . . 0.0 112.698 -177.235 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 83.0 mt -46.61 -55.71 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.275 0 C-N-CA 128.99 2.916 . . . . 0.0 109.697 179.342 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -108.77 -30.64 8.06 Favored 'General case' 0 N--CA 1.461 0.089 0 C-N-CA 124.802 1.241 . . . . 0.0 110.951 -174.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.462 ' HB3' HD11 ' A' ' 84' ' ' ILE . 15.0 ttt -49.56 132.29 19.32 Favored Pre-proline 0 N--CA 1.443 -0.799 0 C-N-CA 127.252 2.221 . . . . 0.0 110.008 -170.495 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -73.18 144.03 36.68 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 121.357 1.372 . . . . 0.0 108.754 -175.543 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 37.3 t60 -55.33 -35.86 65.63 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.768 0.827 . . . . 0.0 112.306 -170.338 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.56 -39.95 74.35 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 118.526 0.603 . . . . 0.0 112.18 174.345 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -69.24 -48.12 62.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 118.065 -0.969 . . . . 0.0 109.27 -176.424 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.462 HD11 ' HB3' ' A' ' 79' ' ' MET . 3.1 mp -51.86 -49.75 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 C-N-CA 125.554 1.542 . . . . 0.0 110.785 168.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 3.0 t -58.61 -44.87 90.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 O-C-N 121.362 -0.836 . . . . 0.0 109.768 -176.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 26.7 tttt -64.7 -43.35 93.76 Favored 'General case' 0 C--O 1.223 -0.314 0 CA-C-O 117.966 -1.016 . . . . 0.0 111.759 173.516 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -50.17 -42.71 51.55 Favored 'General case' 0 C--O 1.224 -0.285 0 C-N-CA 126.935 2.094 . . . . 0.0 112.03 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 86.5 mt -75.19 -46.32 39.32 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -177.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -60.18 -35.43 75.35 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 122.483 0.313 . . . . 0.0 111.149 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -83.81 -11.43 57.05 Favored 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 127.499 2.32 . . . . 0.0 112.633 179.26 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -63.84 -11.17 24.99 Favored 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -170.372 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.86 61.58 2.12 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 166.881 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 76.5 mt 69.09 -39.78 0.43 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 128.966 2.906 . . . . 0.0 114.335 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.66 158.16 15.82 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 172.56 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.404 HG12 ' CE1' ' A' ' 24' ' ' PHE . 12.1 p -156.32 142.45 10.17 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 166.52 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.9 m -111.65 101.25 9.65 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 118.521 0.6 . . . . 0.0 111.119 -175.673 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 46.6 mt -90.44 108.57 19.87 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 125.039 1.336 . . . . 0.0 108.269 -178.189 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -76.5 122.76 25.02 Favored 'General case' 0 C--O 1.239 0.538 0 C-N-CA 124.074 0.949 . . . . 0.0 110.869 172.388 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.401 HG13 ' HB2' ' A' ' 12' ' ' SER . 2.7 pt -128.59 165.0 29.18 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 124.27 1.028 . . . . 0.0 111.851 -177.061 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 72.6 mt . . . . . 0 CA--C 1.539 0.548 0 C-N-CA 125.304 1.442 . . . . 0.0 109.678 170.586 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 13.8 p . . . . . 0 N--CA 1.451 -0.414 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 m -114.32 164.86 13.35 Favored 'General case' 0 C--O 1.239 0.527 0 N-CA-C 106.113 -1.81 . . . . 0.0 106.113 157.363 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -103.2 153.73 20.06 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 143.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.658 HG11 ' HB2' ' A' ' 62' ' ' LEU . 62.8 t -129.09 142.0 45.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 103.025 -2.954 . . . . 0.0 103.025 161.719 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.1 t -123.85 132.44 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 168.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 65.4 mt -130.72 131.45 64.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 105.722 -1.955 . . . . 0.0 105.722 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 76.4 m-70 -117.35 146.87 43.1 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 125.576 1.55 . . . . 0.0 108.271 -176.222 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 50.0 ptt85 -141.57 177.15 8.34 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 120.178 1.354 . . . . 0.0 112.014 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.63 169.25 11.48 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 167.414 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -73.72 -28.69 61.84 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 119.951 -0.7 . . . . 0.0 111.908 173.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -61.16 -56.91 15.27 Favored 'General case' 0 CA--C 1.521 -0.17 0 C-N-CA 124.348 1.059 . . . . 0.0 110.256 -177.7 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -75.46 165.43 25.13 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.944 1.297 . . . . 0.0 109.216 178.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.02 176.89 26.17 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 163.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -71.83 167.27 20.34 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 159.79 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.11 0.11 57.3 Favored Glycine 0 CA--C 1.525 0.715 0 CA-C-O 117.922 -1.488 . . . . 0.0 114.994 -167.337 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -112.18 130.41 55.92 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 120.029 1.915 . . . . 0.0 111.878 -153.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 74.9 t -100.96 135.06 38.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 171.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 23.6 mt -93.23 139.0 18.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 171.679 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 35.3 pt . . . . . 0 N--CA 1.446 -0.666 0 C-N-CA 126.372 1.869 . . . . 0.0 108.29 168.368 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo . . . . . 0 N--CA 1.452 -0.915 0 N-CA-C 108.404 -1.422 . . . . 0.0 108.404 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 6.2 m80 80.44 107.38 0.07 Allowed 'General case' 0 C--O 1.234 0.267 0 C-N-CA 128.711 2.804 . . . . 0.0 112.138 172.272 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 55.5 pttt -133.2 161.15 35.21 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 123.824 0.849 . . . . 0.0 108.731 157.511 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 47.6 mm -66.25 135.43 28.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 168.087 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -102.9 -63.05 0.71 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 126.55 2.024 . . . . 0.0 111.223 175.071 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 8.4 ttm180 -131.14 155.11 47.55 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 125.447 1.499 . . . . 0.0 108.504 -175.19 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 32.5 mt -133.04 132.61 58.89 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 126.217 1.807 . . . . 0.0 107.117 174.636 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -55.86 114.18 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.776 1.631 . . . . 0.0 107.018 158.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -56.59 132.49 51.8 Favored 'General case' 0 C--O 1.236 0.383 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 174.216 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.78 -8.02 67.62 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 125.401 1.477 . . . . 0.0 114.977 175.651 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 36.2 p -59.91 169.6 1.47 Allowed Pre-proline 0 C--O 1.239 0.53 0 CA-C-N 118.407 1.104 . . . . 0.0 111.971 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -54.91 -31.78 75.05 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 121.242 1.295 . . . . 0.0 112.073 166.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.2 -68.83 0.24 Allowed 'General case' 0 C--N 1.345 0.404 0 C-N-CA 123.793 0.837 . . . . 0.0 110.089 169.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -51.39 -55.23 19.69 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 118.608 0.64 . . . . 0.0 112.559 -171.202 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -70.11 -7.79 44.3 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 123.349 0.659 . . . . 0.0 111.908 -175.079 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 10.5 t -62.66 -36.96 84.52 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 119.413 1.006 . . . . 0.0 109.202 166.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 57.69 -22.21 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 129.473 3.109 . . . . 0.0 115.789 -177.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 1.5 mmpp? -68.73 -4.6 16.45 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 127.94 2.496 . . . . 0.0 113.389 174.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.658 ' HB2' HG11 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -147.08 113.13 5.81 Favored 'General case' 0 C--O 1.237 0.421 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 -173.203 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 25.6 mttt -130.66 170.74 13.91 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 122.008 0.908 . . . . 0.0 112.613 -170.527 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.8 t -60.99 109.85 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.25 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 131.81 -17.16 4.97 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -70.52 106.45 3.46 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-N 118.525 1.163 . . . . 0.0 111.397 -178.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 52.8 mtm-85 -57.5 144.73 35.75 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 127.23 2.212 . . . . 0.0 110.056 161.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 5.4 mt -131.29 149.14 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 C-N-CA 123.295 0.638 . . . . 0.0 109.428 -168.424 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.48 -41.23 2.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.789 1.636 . . . . 0.0 112.663 -171.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -160.91 168.2 25.1 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.316 0.647 . . . . 0.0 111.743 -178.097 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.6 p -140.21 127.51 23.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 123.532 0.733 . . . . 0.0 110.09 -176.57 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 40.01 48.24 2.1 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 125.732 1.613 . . . . 0.0 109.774 -158.311 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 63.21 11.67 40.61 Favored Glycine 0 CA--C 1.528 0.869 0 CA-C-O 116.843 -2.087 . . . . 0.0 114.714 -178.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.84 153.97 20.65 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-N 120.684 2.242 . . . . 0.0 111.844 178.791 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.2 p -62.41 147.64 47.93 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -171.832 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 8.5 pt -131.52 -7.13 2.0 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 O-C-N 123.602 0.564 . . . . 0.0 112.05 167.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.1 mm -79.71 -45.84 22.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 O-C-N 120.569 -1.332 . . . . 0.0 109.628 176.263 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -88.48 -29.47 20.11 Favored 'General case' 0 N--CA 1.465 0.297 0 O-C-N 121.635 -0.666 . . . . 0.0 112.751 -178.252 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.6 mtp -70.61 152.33 95.32 Favored Pre-proline 0 CA--C 1.534 0.352 0 CA-C-N 118.906 0.775 . . . . 0.0 110.984 -177.044 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_endo -73.64 153.23 48.89 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 122.57 2.18 . . . . 0.0 109.55 171.529 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -62.49 -37.87 87.68 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.516 -0.74 . . . . 0.0 112.724 -167.652 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.83 -28.2 65.49 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 119.079 0.854 . . . . 0.0 111.611 -176.706 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -68.47 -45.06 73.44 Favored 'General case' 0 N--CA 1.46 0.072 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 176.45 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.7 mt -64.4 -38.38 82.42 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 125.299 1.44 . . . . 0.0 109.569 176.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 37.9 t -61.7 -47.6 92.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 O-C-N 120.22 -1.55 . . . . 0.0 109.093 172.697 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 4.2 tmtt? -63.59 -37.42 87.25 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.016 -177.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.46 -43.93 75.91 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 125.471 1.508 . . . . 0.0 111.446 173.813 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 60.0 mt -68.56 -43.36 83.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 119.542 1.065 . . . . 0.0 109.287 177.502 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 21.1 tttm -64.29 -38.64 91.78 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.671 -0.643 . . . . 0.0 110.546 -178.293 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -86.02 -3.44 58.94 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 126.924 2.09 . . . . 0.0 112.051 179.489 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -54.89 -26.07 33.23 Favored 'General case' 0 C--N 1.345 0.413 0 N-CA-C 113.817 1.043 . . . . 0.0 113.817 -166.457 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.51 36.02 3.93 Favored Glycine 0 C--N 1.335 0.479 0 N-CA-C 111.266 -0.733 . . . . 0.0 111.266 173.343 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 44.9 mt 69.29 -30.82 0.2 Allowed 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 128.596 2.759 . . . . 0.0 113.041 -175.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 m -92.66 148.12 22.32 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 167.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.3 p -139.97 124.42 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.002 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 169.224 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 20.9 m -99.04 123.77 43.58 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 177.549 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 21.9 mt -120.01 122.3 40.85 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.286 1.034 . . . . 0.0 109.835 -172.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 45.9 ttp180 -85.67 111.94 20.55 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 173.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pp -118.78 167.17 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 125.776 1.63 . . . . 0.0 108.76 175.258 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 7.6 mt . . . . . 0 N--CA 1.468 0.436 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 169.937 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 59.2 p . . . . . 0 C--O 1.237 0.416 0 N-CA-C 108.204 -1.035 . . . . 0.0 108.204 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 13.7 m -120.2 147.17 45.26 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.511 1.125 . . . . 0.0 108.481 163.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -74.37 155.45 38.13 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 125.3 1.44 . . . . 0.0 108.128 152.387 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 t -137.57 121.16 21.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 105.088 -2.19 . . . . 0.0 105.088 163.052 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' VAL . . . . . 0.404 HG22 HG23 ' A' ' 96' ' ' THR . 13.8 t -120.04 97.29 5.0 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -173.443 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 43.1 mt -99.28 126.32 52.61 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -174.803 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -103.9 149.62 24.93 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.653 -1.239 . . . . 0.0 107.653 177.446 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -143.21 -175.54 4.57 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 120.706 1.594 . . . . 0.0 109.899 175.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.525 ' N ' ' HE3' ' A' ' 19' ' ' LYS . 0.1 OUTLIER -92.64 163.71 13.68 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 169.001 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -68.25 -36.62 79.74 Favored 'General case' 0 N--CA 1.465 0.317 0 O-C-N 121.425 -0.797 . . . . 0.0 110.82 173.026 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -75.96 -4.52 41.56 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.418 1.087 . . . . 0.0 112.499 -166.01 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -123.41 179.33 4.77 Favored 'General case' 0 C--O 1.238 0.45 0 C-N-CA 126.872 2.069 . . . . 0.0 108.376 -178.731 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.93 178.71 20.94 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 162.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -72.95 -175.43 1.76 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 164.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -138.81 60.54 0.58 Allowed Glycine 0 C--O 1.223 -0.583 0 CA-C-O 118.774 -1.015 . . . . 0.0 112.582 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.477 ' CE2' HD11 ' A' ' 28' ' ' ILE . 32.8 p90 -140.18 158.16 44.47 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 118.694 1.247 . . . . 0.0 110.651 175.847 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.9 t -143.45 140.54 26.21 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 105.947 -1.872 . . . . 0.0 105.947 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.477 HD11 ' CE2' ' A' ' 26' ' ' PHE . 1.9 mp -130.47 129.26 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 C-N-CA 124.928 1.291 . . . . 0.0 107.566 -169.124 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.424 HD11 ' HE3' ' A' ' 46' ' ' LYS . 47.7 pt . . . . . 0 C--O 1.239 0.546 0 C-N-CA 124.32 1.048 . . . . 0.0 110.142 -166.505 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 CA--C 1.531 0.373 0 CA-C-O 120.694 0.206 . . . . 0.0 112.628 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -139.7 115.14 9.91 Favored 'General case' 0 N--CA 1.442 -0.826 0 C-N-CA 125.259 1.423 . . . . 0.0 107.641 -166.654 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.424 ' HE3' HD11 ' A' ' 29' ' ' ILE . 52.1 pttt -127.91 144.09 51.1 Favored 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 167.725 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.3 mm -55.38 120.98 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 165.189 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -87.15 -42.59 6.21 Favored Glycine 0 CA--C 1.522 0.494 0 C-N-CA 125.212 1.387 . . . . 0.0 110.85 175.757 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.6 ttt-85 -148.05 156.36 42.54 Favored 'General case' 0 C--O 1.233 0.225 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 172.168 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.67 139.6 48.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 164.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 44.1 mm -67.56 118.48 11.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 173.803 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -53.55 124.4 14.85 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 124.199 1.0 . . . . 0.0 108.448 173.655 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.94 -0.88 84.68 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 114.535 0.574 . . . . 0.0 114.535 176.662 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 57.8 p -69.23 169.52 11.58 Favored Pre-proline 0 C--O 1.235 0.336 0 CA-C-N 118.855 1.327 . . . . 0.0 112.019 175.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -57.37 -28.04 78.4 Favored 'Trans proline' 0 N--CA 1.449 -1.128 0 C-N-CA 121.21 1.273 . . . . 0.0 112.809 161.52 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.04 -54.26 19.64 Favored 'General case' 0 C--N 1.346 0.434 0 CA-C-N 119.967 1.258 . . . . 0.0 110.235 176.377 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -52.31 -55.07 23.85 Favored 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 124.918 1.287 . . . . 0.0 110.838 178.422 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 87.9 mtt180 -69.86 -7.35 39.39 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 123.558 0.743 . . . . 0.0 112.622 -175.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 8.9 t -71.24 -31.18 67.23 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 119.586 1.085 . . . . 0.0 110.569 168.435 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.97 -29.95 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 129.979 3.312 . . . . 0.0 116.364 -174.635 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.3 mtpt -69.86 -9.06 53.45 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 126.056 1.742 . . . . 0.0 112.32 169.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -106.46 132.31 52.63 Favored 'General case' 0 C--O 1.237 0.424 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 158.158 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 15.6 ptpt -139.56 169.07 18.42 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 124.387 1.075 . . . . 0.0 110.757 169.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 61.7 t -59.21 138.73 19.87 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 174.059 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 83.35 4.33 89.53 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 115.889 1.116 . . . . 0.0 115.889 174.613 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -60.89 -6.85 2.0 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 118.528 2.788 . . . . 0.0 118.528 -164.201 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 84.5 mtm180 49.38 105.59 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 128.658 2.783 . . . . 0.0 114.587 -165.393 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 57.7 mt -96.79 129.39 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 123.653 0.781 . . . . 0.0 109.241 -179.198 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.451 HD22 ' N ' ' A' ' 69' ' ' LEU . 2.0 mm? -104.41 -23.88 13.12 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.366 1.066 . . . . 0.0 113.601 176.314 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -155.58 164.75 38.22 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 118.505 0.593 . . . . 0.0 111.258 -179.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.38 121.19 45.2 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 C-N-CA 126.405 1.882 . . . . 0.0 107.0 178.81 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 52.59 26.87 4.63 Favored 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 176.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 90.76 -2.77 80.56 Favored Glycine 0 CA--C 1.535 1.326 0 C-N-CA 125.581 1.562 . . . . 0.0 114.514 -177.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -94.37 128.91 41.19 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.751 1.775 . . . . 0.0 108.638 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.07 116.84 4.84 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 123.267 0.627 . . . . 0.0 109.479 171.339 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.7 pp -80.99 11.64 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.577 0 C-N-CA 124.149 0.979 . . . . 0.0 113.203 178.069 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 79.5 mt -61.04 -70.36 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 C-N-CA 124.961 1.304 . . . . 0.0 109.382 -175.005 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -94.69 -24.66 17.05 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 120.432 -0.507 . . . . 0.0 111.785 -172.325 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.2 mtp -48.6 134.59 13.47 Favored Pre-proline 0 CA--C 1.536 0.442 0 C-N-CA 125.154 1.382 . . . . 0.0 110.512 176.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.25 157.37 61.64 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 122.356 2.038 . . . . 0.0 109.478 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 16.0 m-70 -56.06 -32.96 64.56 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 119.302 -0.38 . . . . 0.0 110.847 174.615 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.9 -44.1 97.5 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 117.878 -1.058 . . . . 0.0 112.177 178.027 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -64.65 -45.98 84.47 Favored 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 66.3 mt -61.75 -40.46 86.96 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 C-N-CA 123.814 0.846 . . . . 0.0 110.527 -177.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 24.8 t -60.22 -50.25 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.132 0 O-C-N 121.209 -0.932 . . . . 0.0 109.32 171.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -63.2 -34.05 76.8 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 117.479 -1.248 . . . . 0.0 112.746 -177.281 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -63.78 -41.51 97.94 Favored 'General case' 0 N--CA 1.442 -0.832 0 C-N-CA 128.07 2.548 . . . . 0.0 110.645 174.226 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 54.4 mt -67.16 -45.61 86.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 O-C-N 120.774 -1.204 . . . . 0.0 108.875 177.281 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 4.6 tttt -61.77 -38.98 90.03 Favored 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 123.077 0.551 . . . . 0.0 109.597 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -61.65 -43.08 99.53 Favored 'General case' 0 CA--C 1.517 -0.323 0 C-N-CA 125.058 1.343 . . . . 0.0 110.381 175.2 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -56.01 -34.56 65.92 Favored 'General case' 0 CA--C 1.537 0.473 0 O-C-N 123.339 0.399 . . . . 0.0 110.63 -175.498 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.03 -116.22 5.46 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 124.896 1.236 . . . . 0.0 110.885 157.449 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 8.2 mt -83.53 -20.12 34.44 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-N 117.126 0.463 . . . . 0.0 109.753 167.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 p -94.53 156.32 16.51 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 173.088 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.8 p -157.39 124.84 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.258 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 160.016 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' THR . . . . . 0.404 HG23 HG22 ' A' ' 15' ' ' VAL . 56.3 m -109.53 101.86 10.77 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.612 1.565 . . . . 0.0 107.514 -172.827 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 81.8 mt -90.92 165.17 13.73 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 125.014 1.326 . . . . 0.0 110.369 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 26.6 ttm180 -120.57 127.99 52.65 Favored 'General case' 0 CA--C 1.518 -0.282 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 162.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.408 HD12 ' C ' ' A' ' 100' ' ' ILE . 1.7 pp -128.83 178.64 4.77 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 125.318 1.447 . . . . 0.0 109.29 173.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.408 ' C ' HD12 ' A' ' 99' ' ' ILE . 75.8 mt . . . . . 0 N--CA 1.469 0.512 0 CA-C-N 119.334 0.97 . . . . 0.0 109.349 167.578 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.8 p . . . . . 0 N--CA 1.445 -0.686 0 CA-C-O 121.842 0.83 . . . . 0.0 108.984 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 58.3 m -121.24 146.84 46.39 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 105.406 -2.072 . . . . 0.0 105.406 174.008 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -120.85 131.75 54.59 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 -175.677 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 24.0 t -129.29 94.86 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 104.431 -2.433 . . . . 0.0 104.431 -172.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.5 p -94.83 104.22 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 36.6 mt -101.84 133.89 43.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 105.307 -2.109 . . . . 0.0 105.307 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 51.8 m-70 -111.53 149.19 31.74 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.924 1.29 . . . . 0.0 108.415 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -138.86 -177.35 4.84 Favored 'General case' 0 N--CA 1.468 0.469 0 O-C-N 120.84 -1.162 . . . . 0.0 110.485 177.272 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.26 153.17 18.17 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 168.74 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -61.55 -32.61 72.69 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.294 0.568 . . . . 0.0 111.217 -171.035 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -89.13 3.41 51.94 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 124.744 1.218 . . . . 0.0 112.979 -163.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 25.4 pt-20 -139.78 177.74 7.74 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 119.534 1.061 . . . . 0.0 111.187 -170.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.04 163.66 31.91 Favored Glycine 0 CA--C 1.525 0.718 0 O-C-N 121.634 -0.666 . . . . 0.0 111.653 177.132 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -75.67 161.2 29.3 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 154.413 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.56 58.19 0.73 Allowed Glycine 0 C--O 1.218 -0.852 0 CA-C-O 117.432 -1.76 . . . . 0.0 111.351 178.838 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.421 ' CZ ' HD11 ' A' ' 97' ' ' LEU . 28.7 p90 -142.91 141.53 31.52 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 120.326 2.063 . . . . 0.0 110.586 169.862 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.0 t -105.22 135.7 42.17 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 170.415 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 25.6 mt -96.63 130.74 44.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 162.37 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.3 pt . . . . . 0 N--CA 1.447 -0.603 0 C-N-CA 126.585 1.954 . . . . 0.0 108.71 175.042 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo . . . . . 0 N--CA 1.45 -1.081 0 N-CA-C 109.838 -0.87 . . . . 0.0 109.838 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.5 m80 -77.23 103.18 7.01 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.632 1.573 . . . . 0.0 109.614 -172.063 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.7 ptmt -130.55 153.17 49.14 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 171.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.436 HG13 HD22 ' A' ' 62' ' ' LEU . 39.7 mm -68.54 143.82 14.82 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 175.375 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.89 -59.46 0.53 Allowed Glycine 0 CA--C 1.529 0.926 0 C-N-CA 125.596 1.57 . . . . 0.0 112.508 175.337 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 37.4 ttm180 -140.05 144.58 36.94 Favored 'General case' 0 C--O 1.235 0.339 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 21.2 mt -122.66 125.43 72.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 105.821 -1.918 . . . . 0.0 105.821 175.478 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -51.73 131.07 12.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 CA-C-N 119.23 0.923 . . . . 0.0 108.612 172.506 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.6 123.27 17.43 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 125.553 1.541 . . . . 0.0 108.868 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.28 9.88 84.31 Favored Glycine 0 CA--C 1.535 1.329 0 C-N-CA 123.947 0.784 . . . . 0.0 114.903 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 37.9 p -66.36 171.76 3.8 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 119.662 1.731 . . . . 0.0 112.458 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -56.85 -36.83 99.07 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 121.783 1.655 . . . . 0.0 112.296 166.156 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.72 -48.95 75.01 Favored 'General case' 0 C--N 1.34 0.177 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -60.34 -52.95 63.09 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 123.44 0.696 . . . . 0.0 111.594 176.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -60.94 -18.59 57.88 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 124.078 0.951 . . . . 0.0 112.31 -176.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 11.5 t -59.36 -26.25 64.91 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-O 117.819 -1.086 . . . . 0.0 111.257 175.676 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.15 31.49 18.38 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.913 2.085 . . . . 0.0 112.962 -179.208 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 40.3 mtmt -132.47 -34.11 1.22 Allowed 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.889 0.875 . . . . 0.0 111.977 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.444 HD23 ' HA ' ' A' ' 62' ' ' LEU . 0.3 OUTLIER -93.85 126.46 39.06 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 177.509 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 2.6 ptpp? -117.82 171.58 7.96 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 125.2 1.4 . . . . 0.0 109.139 170.577 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 82.2 t -66.09 141.66 17.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 O-C-N 120.965 -1.084 . . . . 0.0 108.565 174.626 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 89.47 -5.02 84.17 Favored Glycine 0 CA--C 1.532 1.095 0 CA-C-O 117.022 -1.988 . . . . 0.0 114.904 176.546 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -62.9 11.68 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 120.229 3.418 . . . . 0.0 120.229 -150.554 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.1 mtp180 41.82 86.71 0.02 OUTLIER 'General case' 0 C--O 1.235 0.3 0 C-N-CA 127.178 2.191 . . . . 0.0 113.103 -171.683 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 44.1 mt -65.32 148.85 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 106.341 -1.725 . . . . 0.0 106.341 170.172 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.48 HD22 HD11 ' A' ' 100' ' ' ILE . 1.8 tp -118.86 -47.15 2.52 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 125.828 1.651 . . . . 0.0 108.764 177.282 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -148.54 166.95 26.69 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 125.268 1.427 . . . . 0.0 111.352 -177.599 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.9 p -134.72 124.36 43.89 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.468 0 C-N-CA 125.493 1.517 . . . . 0.0 107.933 175.012 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 49.71 38.59 15.72 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.138 0.975 . . . . 0.0 110.009 -178.021 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 79.21 -10.27 35.88 Favored Glycine 0 CA--C 1.532 1.115 0 CA-C-O 117.822 -1.543 . . . . 0.0 115.415 -176.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.9 mm100 -79.66 122.87 27.08 Favored 'General case' 0 CA--C 1.513 -0.479 0 CA-C-N 121.491 2.646 . . . . 0.0 107.747 -178.384 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 55.7 m -61.36 110.12 1.34 Allowed 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 167.421 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.5 pp -80.14 11.49 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 124.604 1.162 . . . . 0.0 112.322 -174.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 25.3 mm -63.01 -77.34 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 C-N-CA 125.24 1.416 . . . . 0.0 108.418 175.268 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 21.8 m-80 -79.7 -26.92 40.76 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.179 -164.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' MET . . . . . 0.512 ' CE ' HD13 ' A' ' 87' ' ' LEU . 1.4 mtp -58.29 133.81 84.79 Favored Pre-proline 0 CA--C 1.538 0.488 0 C-N-CA 123.815 0.846 . . . . 0.0 109.513 174.347 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -70.61 155.11 63.8 Favored 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 121.989 1.793 . . . . 0.0 110.665 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -57.09 -39.21 74.56 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.365 0.666 . . . . 0.0 111.938 -174.248 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -60.38 -42.43 95.86 Favored 'General case' 0 C--N 1.338 0.097 0 CA-C-O 118.421 -0.8 . . . . 0.0 111.368 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ASP . . . . . 0.404 ' O ' HD12 ' A' ' 87' ' ' LEU . 1.4 m-20 -62.62 -46.27 89.05 Favored 'General case' 0 C--O 1.218 -0.58 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 177.135 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.45 ' HA ' ' HB2' ' A' ' 87' ' ' LEU . 29.4 mt -67.71 -33.92 64.74 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 O-C-N 121.212 -0.93 . . . . 0.0 109.925 -175.453 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.0 t -61.79 -44.47 98.84 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 O-C-N 120.83 -1.169 . . . . 0.0 108.669 171.484 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 7.0 mmtt -52.45 -53.19 48.74 Favored 'General case' 0 C--O 1.22 -0.462 0 CA-C-O 116.568 -1.682 . . . . 0.0 109.481 166.16 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.512 HD13 ' CE ' ' A' ' 79' ' ' MET . 0.9 OUTLIER -57.7 -28.34 63.74 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 122.472 2.396 . . . . 0.0 114.514 -174.761 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 66.7 mt -77.44 -48.71 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 176.57 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 13.6 ttpt -63.36 -37.27 86.64 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 118.164 0.438 . . . . 0.0 110.847 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.03 -10.65 59.67 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 126.98 2.112 . . . . 0.0 111.472 -178.381 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.74 -28.31 63.79 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 113.301 0.852 . . . . 0.0 113.301 -171.509 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 92.22 66.52 1.12 Allowed Glycine 0 C--N 1.339 0.741 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 171.678 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 56.9 mt 61.81 -44.37 0.15 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 129.605 3.162 . . . . 0.0 114.346 -171.564 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 6.6 p -93.6 140.66 29.36 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 125.28 1.432 . . . . 0.0 107.79 177.291 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.5 p -134.54 124.34 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 169.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.8 m -93.53 100.57 12.83 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.421 HD11 ' CZ ' ' A' ' 26' ' ' PHE . 19.6 mt -90.18 122.83 33.48 Favored 'General case' 0 CA--C 1.516 -0.334 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 172.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 32.0 ttm105 -99.25 117.75 34.41 Favored 'General case' 0 C--O 1.236 0.347 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 179.039 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.53 ' C ' HD12 ' A' ' 100' ' ' ILE . 1.9 pp -130.6 174.9 12.19 Favored 'Isoleucine or valine' 0 C--O 1.237 0.427 0 C-N-CA 126.669 1.988 . . . . 0.0 110.004 -166.545 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.53 HD12 ' C ' ' A' ' 99' ' ' ILE . 3.4 mp . . . . . 0 CA--C 1.546 0.812 0 C-N-CA 124.483 1.113 . . . . 0.0 108.651 177.158 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.237 0.423 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.5 m -127.38 150.99 49.37 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.239 1.016 . . . . 0.0 108.291 175.067 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -120.69 93.46 4.04 Favored 'General case' 0 C--O 1.236 0.355 0 N-CA-C 104.442 -2.429 . . . . 0.0 104.442 176.714 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.5 t -91.43 94.76 5.04 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.332 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 -170.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.0 p -76.2 134.12 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 173.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 82.5 mt -131.12 126.38 59.15 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.197 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 175.269 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -92.55 154.01 18.7 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 167.749 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.487 ' HD3' ' CZ ' ' A' ' 24' ' ' PHE . 5.7 ptt180 -138.96 -176.95 4.67 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 167.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.461 ' HE3' ' C ' ' A' ' 18' ' ' ARG . 0.1 OUTLIER -109.67 168.19 9.59 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 172.48 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -75.71 -19.3 59.19 Favored 'General case' 0 N--CA 1.463 0.176 0 O-C-N 121.716 -0.615 . . . . 0.0 112.172 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -69.77 -2.98 13.53 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.014 0.926 . . . . 0.0 112.735 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -150.07 177.2 10.11 Favored 'General case' 0 C--O 1.238 0.474 0 C-N-CA 125.485 1.514 . . . . 0.0 109.441 -164.607 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.98 -173.69 19.94 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 171.04 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.487 ' CZ ' ' HD3' ' A' ' 18' ' ' ARG . 62.9 m-85 -76.24 166.85 22.86 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 159.41 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.29 60.26 0.68 Allowed Glycine 0 C--O 1.226 -0.364 0 O-C-N 121.022 -1.049 . . . . 0.0 113.05 -173.508 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 5.3 p90 -144.56 162.08 37.5 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 124.936 1.294 . . . . 0.0 109.999 175.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.5 t -132.99 124.59 50.41 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.3 mp -84.5 140.86 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 173.457 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.474 HD11 ' HE3' ' A' ' 46' ' ' LYS . 19.9 pt . . . . . 0 N--CA 1.447 -0.623 0 C-N-CA 127.849 2.46 . . . . 0.0 107.759 172.073 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo . . . . . 0 N--CA 1.46 -0.442 0 CA-C-O 118.977 -0.509 . . . . 0.0 113.072 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.59 ' CD2' HD13 ' A' ' 76' ' ' ILE . 0.6 OUTLIER -135.55 118.82 16.65 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 124.467 1.107 . . . . 0.0 108.367 178.372 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.474 ' HE3' HD11 ' A' ' 29' ' ' ILE . 44.1 pttt -139.88 155.0 47.42 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 123.675 0.79 . . . . 0.0 109.144 167.573 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.1 mm -64.16 131.02 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 105.409 -2.071 . . . . 0.0 105.409 168.48 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -113.76 -32.92 1.97 Allowed Glycine 0 CA--C 1.523 0.57 0 C-N-CA 124.233 0.92 . . . . 0.0 113.382 176.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 21.2 ttm-85 -146.21 148.5 32.57 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 7.4 mt -127.43 125.97 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 167.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -57.65 126.99 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 C-N-CA 125.416 1.486 . . . . 0.0 107.1 175.609 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -60.79 123.09 16.48 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 123.522 0.729 . . . . 0.0 109.145 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.15 24.78 74.96 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.726 0.679 . . . . 0.0 113.284 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 22.5 p -76.94 171.69 11.71 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 118.674 1.237 . . . . 0.0 111.576 168.742 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -58.16 -22.81 58.4 Favored 'Trans proline' 0 CA--C 1.538 0.696 0 C-N-CA 122.197 1.931 . . . . 0.0 113.259 165.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -72.89 -56.97 4.43 Favored 'General case' 0 C--N 1.343 0.308 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 173.237 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -57.64 -47.07 83.28 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 123.801 0.841 . . . . 0.0 111.273 -175.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 1.6 ptm180 -54.45 -27.48 37.64 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 113.267 0.839 . . . . 0.0 113.267 174.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 2.7 t -73.17 -12.89 61.04 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 118.29 -0.862 . . . . 0.0 112.858 -162.544 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 47.33 37.88 6.52 Favored 'General case' 0 C--O 1.239 0.532 0 C-N-CA 126.077 1.751 . . . . 0.0 113.536 178.159 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.8 mtmt -143.33 -17.47 0.64 Allowed 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 113.92 1.082 . . . . 0.0 113.92 173.343 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.422 HD23 ' HA ' ' A' ' 62' ' ' LEU . 0.1 OUTLIER -126.54 111.44 14.38 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 124.715 1.206 . . . . 0.0 108.083 -174.583 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 25.8 mtmt -129.35 172.12 11.82 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 126.011 1.724 . . . . 0.0 110.674 172.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 84.4 t -57.43 118.97 2.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.382 0 C-N-CA 125.108 1.363 . . . . 0.0 109.567 -175.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 124.7 -23.25 6.33 Favored Glycine 0 C--N 1.336 0.57 0 CA-C-O 118.699 -1.056 . . . . 0.0 111.063 175.627 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -70.06 81.44 0.5 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.62 1.568 . . . . 0.0 112.253 -167.224 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 87.7 mtt180 -48.42 134.02 15.58 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 126.619 1.968 . . . . 0.0 110.998 -162.789 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 61.3 mt -102.9 130.1 53.53 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -112.02 -32.85 6.45 Favored 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 125.254 1.422 . . . . 0.0 112.095 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -154.97 167.81 29.1 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.995 0.918 . . . . 0.0 109.038 -177.562 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.7 p -129.57 114.34 30.61 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.324 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 177.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 63.8 m-80 61.42 -37.54 0.11 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 128.937 2.895 . . . . 0.0 113.638 -169.864 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 169.2 -4.43 0.04 OUTLIER Glycine 0 CA--C 1.531 1.043 0 C-N-CA 128.103 2.763 . . . . 0.0 112.692 -176.613 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -90.72 136.0 33.35 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 120.569 2.185 . . . . 0.0 108.91 -177.273 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.6 p -73.3 119.5 17.62 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.457 0.571 . . . . 0.0 109.592 179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.59 HD13 ' CD2' ' A' ' 45' ' ' HIS . 2.4 pp -91.31 -24.25 5.63 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.305 0 C-N-CA 122.262 0.225 . . . . 0.0 111.312 -174.389 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mp -59.73 -32.67 49.98 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 O-C-N 121.389 -0.819 . . . . 0.0 110.903 -179.222 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -95.2 -7.58 38.68 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 123.801 0.84 . . . . 0.0 112.222 -170.477 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.7 mtp -105.88 160.0 27.66 Favored Pre-proline 0 N--CA 1.449 -0.487 0 C-N-CA 125.61 1.564 . . . . 0.0 113.348 -169.094 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -66.96 140.7 55.63 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 123.245 2.63 . . . . 0.0 110.789 169.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -45.93 -52.77 11.02 Favored 'General case' 0 N--CA 1.453 -0.303 0 C-N-CA 126.132 1.773 . . . . 0.0 110.872 173.276 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.5 -27.23 69.0 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 123.91 0.884 . . . . 0.0 113.261 -177.57 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.3 t0 -87.29 -34.73 18.79 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-N 118.991 0.814 . . . . 0.0 110.801 -178.236 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.0 mt -63.93 -39.57 85.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 C-N-CA 124.339 1.056 . . . . 0.0 108.43 169.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.1 t -57.13 -50.7 75.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 121.11 -0.994 . . . . 0.0 109.114 168.779 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.9 -36.61 81.81 Favored 'General case' 0 C--N 1.338 0.093 0 CA-C-N 118.881 0.764 . . . . 0.0 112.822 -178.614 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -61.75 -42.12 98.56 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 128.067 2.547 . . . . 0.0 110.836 175.076 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 62.4 mt -67.42 -42.75 87.6 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.281 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 174.054 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 46.1 tttt -57.73 -41.66 82.29 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.559 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.7 t0 -65.88 -14.62 61.84 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 127.462 2.305 . . . . 0.0 112.451 178.018 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -75.48 -12.38 60.23 Favored 'General case' 0 CA--C 1.544 0.731 0 O-C-N 121.042 -1.036 . . . . 0.0 111.86 169.18 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 60.45 -116.19 8.82 Favored Glycine 0 CA--C 1.528 0.868 0 O-C-N 120.817 -1.177 . . . . 0.0 110.574 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 93.2 mt -87.1 -36.53 18.07 Favored 'General case' 0 CA--C 1.503 -0.862 0 CA-C-N 117.814 0.807 . . . . 0.0 112.342 -177.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -107.86 120.11 41.33 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.159 0.912 . . . . 0.0 108.628 -175.102 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.7 p -126.99 150.52 32.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.3 m -124.55 138.85 54.3 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 19.0 mt -122.61 128.83 51.18 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 124.583 1.153 . . . . 0.0 109.114 178.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -84.77 107.8 17.13 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 175.046 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.3 pp -113.92 170.97 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 O-C-N 123.875 0.734 . . . . 0.0 110.763 172.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 20.0 mt . . . . . 0 C--O 1.234 0.263 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 170.984 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 39.1 p . . . . . 0 N--CA 1.448 -0.574 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.2 m -96.09 170.53 9.21 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 -161.893 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -135.1 94.63 3.17 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 123.505 1.622 . . . . 0.0 107.743 171.188 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.544 HG11 ' HB3' ' A' ' 62' ' ' LEU . 80.1 t -90.3 93.98 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 104.735 -2.321 . . . . 0.0 104.735 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.7 p -101.93 116.79 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 -175.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 51.1 mt -133.67 136.85 53.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 -172.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 74.4 m-70 -109.27 149.59 29.22 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 125.396 1.478 . . . . 0.0 109.079 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.49 ' HD3' ' CZ ' ' A' ' 24' ' ' PHE . 1.1 ptm180 -138.69 179.29 6.56 Favored 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 124.937 1.295 . . . . 0.0 109.951 -175.353 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.16 157.33 15.99 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 176.016 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -69.92 -20.71 63.34 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 117.76 0.255 . . . . 0.0 111.239 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 31.0 t30 -78.45 -1.83 35.55 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.451 0.7 . . . . 0.0 112.682 -176.372 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -159.89 -175.74 5.29 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.573 1.149 . . . . 0.0 110.362 -170.027 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.99 -171.54 29.99 Favored Glycine 0 CA--C 1.522 0.521 0 C-N-CA 125.324 1.44 . . . . 0.0 112.365 177.235 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.49 ' CZ ' ' HD3' ' A' ' 18' ' ' ARG . 29.6 m-85 -73.63 159.68 32.72 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 151.829 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -105.28 57.52 0.49 Allowed Glycine 0 C--O 1.219 -0.817 0 CA-C-O 118.542 -1.144 . . . . 0.0 110.565 177.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 8.8 p90 -124.02 155.35 38.43 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 118.849 1.324 . . . . 0.0 108.969 171.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -129.63 114.36 30.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 177.019 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 22.1 mt -78.24 147.38 7.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 171.319 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 44.0 pt . . . . . 0 N--CA 1.444 -0.77 0 C-N-CA 128.691 2.796 . . . . 0.0 107.662 170.965 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo . . . . . 0 N--CA 1.455 -0.759 0 CA-C-O 116.833 -1.403 . . . . 0.0 113.775 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -141.94 130.02 22.04 Favored 'General case' 0 C--N 1.341 0.22 0 C-N-CA 125.687 1.595 . . . . 0.0 108.948 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 6.8 ptmt -149.66 164.57 34.82 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 125.788 1.635 . . . . 0.0 107.225 176.015 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.602 HG13 HD23 ' A' ' 62' ' ' LEU . 13.2 mm -84.52 143.7 11.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.506 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -176.612 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.0 -36.62 0.94 Allowed Glycine 0 CA--C 1.522 0.491 0 C-N-CA 126.023 1.773 . . . . 0.0 112.745 -177.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 36.6 ttm105 -150.05 159.81 44.12 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 119.096 1.448 . . . . 0.0 108.585 176.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 7.2 mt -121.05 143.58 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 125.46 1.504 . . . . 0.0 107.012 160.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.4 mm -75.43 136.42 25.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -72.03 119.81 16.74 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.637 0.256 . . . . 0.0 110.462 -159.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.32 12.81 83.92 Favored Glycine 0 CA--C 1.527 0.799 0 CA-C-O 119.362 -0.688 . . . . 0.0 114.432 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.567 ' HB2' ' CD ' ' A' ' 55' ' ' PRO . 81.3 p -71.49 176.55 2.09 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 118.342 1.071 . . . . 0.0 112.004 176.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.567 ' CD ' ' HB2' ' A' ' 54' ' ' SER . 4.7 Cg_exo -64.28 -32.27 62.07 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 C-N-CA 122.767 2.311 . . . . 0.0 110.164 176.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.86 -24.52 66.89 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 118.201 -0.904 . . . . 0.0 112.894 175.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -83.65 -47.06 11.64 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 119.128 0.876 . . . . 0.0 110.543 173.32 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 28.5 mtt-85 -69.11 -41.44 77.41 Favored 'General case' 0 C--O 1.234 0.252 0 C-N-CA 123.247 0.619 . . . . 0.0 111.469 -170.627 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 62.5 m -81.19 81.38 7.41 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 173.054 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -62.85 89.78 0.03 OUTLIER 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.22 1.008 . . . . 0.0 109.503 178.2 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.51 ' CB ' HG13 ' A' ' 14' ' ' VAL . 26.4 mmmt -136.85 -33.72 0.76 Allowed 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 126.598 1.959 . . . . 0.0 109.498 -174.711 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.602 HD23 HG13 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -136.57 154.49 50.68 Favored 'General case' 0 C--O 1.234 0.264 0 C-N-CA 124.576 1.15 . . . . 0.0 109.388 171.055 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 16.3 ptmt -134.9 172.12 13.44 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 124.887 1.275 . . . . 0.0 110.868 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.6 t -59.42 137.66 21.54 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 O-C-N 120.401 -1.437 . . . . 0.0 109.572 -175.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 103.11 -14.05 55.54 Favored Glycine 0 C--N 1.342 0.893 0 C-N-CA 125.119 1.342 . . . . 0.0 114.642 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -67.06 19.46 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 120.368 3.47 . . . . 0.0 120.368 -148.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 4.3 mtt-85 43.61 72.53 0.18 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 126.818 2.047 . . . . 0.0 112.811 168.443 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 31.4 mt -65.33 147.11 12.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -170.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.6 mt -102.69 -52.75 3.01 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 124.606 1.162 . . . . 0.0 109.915 174.788 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -156.62 171.06 20.99 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.654 0.782 . . . . 0.0 110.524 -172.217 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 13.0 p -124.54 113.96 38.65 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.257 0 C-N-CA 125.321 1.449 . . . . 0.0 108.1 175.762 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 45.09 41.75 5.92 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 125.825 1.65 . . . . 0.0 110.095 -169.092 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.31 4.27 78.96 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-O 118.334 -1.259 . . . . 0.0 115.763 179.427 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -85.99 122.12 29.58 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 120.262 2.031 . . . . 0.0 106.689 174.229 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 7.7 t -67.52 134.84 52.04 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 -179.036 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 21.8 pt -108.99 0.27 9.65 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 125.508 1.523 . . . . 0.0 111.193 -176.127 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 75.4 mt -65.41 -61.77 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 C-N-CA 125.088 1.355 . . . . 0.0 109.072 -178.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -92.42 -24.22 18.92 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 123.939 0.896 . . . . 0.0 112.33 -174.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.8 ttt -60.91 137.83 93.77 Favored Pre-proline 0 N--CA 1.439 -0.996 0 C-N-CA 125.185 1.394 . . . . 0.0 108.525 178.706 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -76.07 148.95 31.9 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 121.853 1.702 . . . . 0.0 109.668 -177.709 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.409 ' HA ' HD12 ' A' ' 84' ' ' ILE . 32.2 t60 -60.76 -31.94 71.26 Favored 'General case' 0 CA--C 1.537 0.476 0 N-CA-C 113.812 1.041 . . . . 0.0 113.812 -165.628 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -71.18 -27.8 63.78 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 119.217 0.917 . . . . 0.0 113.029 176.187 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -74.93 -42.09 58.4 Favored 'General case' 0 C--O 1.224 -0.24 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 175.736 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.409 HD12 ' HA ' ' A' ' 81' ' ' HIS . 28.5 mt -57.82 -37.86 62.46 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 C-N-CA 124.714 1.205 . . . . 0.0 110.476 172.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.3 t -61.4 -52.28 63.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 O-C-N 120.578 -1.326 . . . . 0.0 109.684 172.264 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.7 ttmt -59.57 -40.39 87.22 Favored 'General case' 0 C--O 1.22 -0.491 0 C-N-CA 119.116 -1.034 . . . . 0.0 111.697 179.299 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.36 -42.98 67.39 Favored 'General case' 0 N--CA 1.443 -0.816 0 C-N-CA 126.633 1.973 . . . . 0.0 112.102 177.006 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.3 mt -69.25 -43.03 81.64 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.523 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 50.0 tttm -58.37 -49.83 75.84 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 118.329 0.513 . . . . 0.0 110.575 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -62.69 -18.62 62.76 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 128.773 2.829 . . . . 0.0 111.648 177.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.6 -34.26 76.64 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 119.588 1.085 . . . . 0.0 109.627 171.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.83 -97.88 1.84 Allowed Glycine 0 C--N 1.337 0.596 0 C-N-CA 126.119 1.819 . . . . 0.0 108.924 173.07 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.6 mt -121.64 -28.91 4.47 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 124.272 1.029 . . . . 0.0 111.819 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 p -93.3 143.61 26.1 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 170.069 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.3 p -145.51 153.4 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 166.342 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.98 112.22 15.66 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 -178.755 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 7.2 mt -90.54 114.7 26.97 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 173.326 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -71.85 121.14 18.49 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 164.669 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pt -128.35 -179.96 3.37 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 125.037 1.335 . . . . 0.0 108.359 175.279 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 43.7 mt . . . . . 0 CA--C 1.537 0.464 0 C-N-CA 124.758 1.223 . . . . 0.0 109.202 169.648 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 17.5 p . . . . . 0 C--O 1.238 0.471 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.4 m -122.6 150.71 42.26 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 167.48 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -90.65 147.03 23.56 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 105.734 -1.95 . . . . 0.0 105.734 168.26 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 39.0 t -131.99 101.41 4.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 104.84 -2.282 . . . . 0.0 104.84 161.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.37 141.04 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 165.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.46 HD11 HD12 ' A' ' 62' ' ' LEU . 53.0 mt -134.74 133.19 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 170.383 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 76.7 m-70 -105.84 154.4 20.57 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 125.351 1.46 . . . . 0.0 108.053 173.431 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.6 ptt180 -136.43 -171.93 3.02 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 170.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.82 170.38 8.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 166.902 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -80.36 -23.55 40.43 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 113.289 0.848 . . . . 0.0 113.289 -168.405 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -69.99 -10.05 57.27 Favored 'General case' 0 N--CA 1.472 0.645 0 CA-C-N 119.595 1.089 . . . . 0.0 112.882 176.503 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -137.15 169.33 17.97 Favored 'General case' 0 C--O 1.241 0.637 0 C-N-CA 124.288 1.035 . . . . 0.0 110.736 -161.368 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.11 -178.54 45.87 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 179.378 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -80.1 170.44 16.44 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 142.742 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.48 52.39 0.83 Allowed Glycine 0 C--O 1.225 -0.437 0 CA-C-O 118.769 -1.017 . . . . 0.0 112.683 -172.512 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -136.68 142.11 43.16 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 125.764 1.625 . . . . 0.0 110.696 -177.455 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.4 t -128.08 136.42 60.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 177.642 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 56.5 mt -108.23 120.1 58.99 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 -171.124 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 27.8 pt . . . . . 0 C--N 1.322 -0.61 0 C-N-CA 126.471 1.909 . . . . 0.0 108.74 -178.099 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo . . . . . 0 N--CA 1.461 -0.403 0 N-CA-C 113.965 0.717 . . . . 0.0 113.965 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -139.73 122.27 16.23 Favored 'General case' 0 CA--C 1.52 -0.199 0 C-N-CA 124.948 1.299 . . . . 0.0 107.801 178.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.3 ptmt -151.55 154.0 35.63 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 124.299 1.04 . . . . 0.0 108.765 168.163 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.429 HG13 HD22 ' A' ' 62' ' ' LEU . 31.1 mm -62.57 144.41 14.38 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 CA-C-N 119.17 0.896 . . . . 0.0 109.6 175.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -128.03 -50.62 0.14 Allowed Glycine 0 CA--C 1.526 0.78 0 C-N-CA 126.39 1.948 . . . . 0.0 113.181 179.334 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 2.0 ttm180 -119.99 139.88 51.81 Favored 'General case' 0 CA--C 1.511 -0.531 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 171.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 12.7 mt -120.06 149.76 22.76 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 N-CA-C 105.568 -2.012 . . . . 0.0 105.568 159.608 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -87.65 129.54 38.83 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 126.648 1.979 . . . . 0.0 108.097 177.67 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -61.55 124.51 20.86 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 123.636 0.774 . . . . 0.0 109.194 167.406 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.59 17.61 38.32 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-O 117.771 -1.572 . . . . 0.0 112.767 178.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 87.6 p -106.62 163.76 16.32 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-N 119.006 1.403 . . . . 0.0 113.116 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo -63.85 -25.08 67.76 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 122.902 2.401 . . . . 0.0 112.927 169.217 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.32 -55.88 29.2 Favored 'General case' 0 C--N 1.345 0.404 0 CA-C-N 120.305 1.411 . . . . 0.0 109.883 174.006 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -63.32 -37.53 87.64 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.316 0.647 . . . . 0.0 112.355 -175.397 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -65.72 -23.02 66.66 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 121.657 -0.652 . . . . 0.0 112.731 172.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 73.9 m -92.96 50.36 1.54 Allowed 'General case' 0 CA--C 1.533 0.321 0 O-C-N 120.568 -1.332 . . . . 0.0 110.824 174.769 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -59.2 9.16 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 127.036 2.134 . . . . 0.0 116.359 -177.195 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -61.92 -16.01 47.56 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 120.906 -1.121 . . . . 0.0 111.505 154.194 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.464 HD11 HD13 ' A' ' 97' ' ' LEU . 0.6 OUTLIER -115.51 137.64 51.85 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 127.393 2.277 . . . . 0.0 107.348 174.763 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -136.41 166.35 23.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 119.37 0.986 . . . . 0.0 111.146 172.35 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.4 t -55.94 112.6 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.251 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 168.842 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 129.95 -21.23 4.99 Favored Glycine 0 N--CA 1.441 -1.0 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 177.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -70.81 106.05 3.44 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 122.982 1.373 . . . . 0.0 110.772 -174.386 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.4 ' HG3' ' H ' ' A' ' 67' ' ' ARG . 31.1 mtm180 -37.38 143.52 0.1 Allowed 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 129.974 3.31 . . . . 0.0 111.297 156.315 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 23.4 mt -132.41 129.89 59.64 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 -174.636 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.7 mt -94.28 -40.19 10.11 Favored 'General case' 0 CA--C 1.52 -0.186 0 C-N-CA 123.862 0.865 . . . . 0.0 112.051 179.376 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.42 168.95 25.84 Favored 'General case' 0 C--O 1.236 0.382 0 C-N-CA 124.189 0.996 . . . . 0.0 109.754 -168.532 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.5 t -129.2 127.12 65.19 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 169.07 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 43.71 34.94 0.93 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 124.631 1.172 . . . . 0.0 112.193 -165.283 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.93 -3.7 27.02 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-O 118.349 -1.25 . . . . 0.0 113.347 179.11 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.2 tp60 -74.54 134.69 42.17 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 119.513 1.657 . . . . 0.0 107.057 174.458 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.1 m -72.53 136.89 45.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 -176.076 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 17.0 pt -115.76 -8.28 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 C-N-CA 125.755 1.622 . . . . 0.0 112.078 -175.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.7 mm -54.14 -52.75 34.62 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 123.813 0.845 . . . . 0.0 110.344 172.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -89.28 -26.44 21.15 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 111.712 0.264 . . . . 0.0 111.712 -173.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 7.0 ttt -66.5 137.87 95.45 Favored Pre-proline 0 N--CA 1.441 -0.884 0 C-N-CA 126.78 2.032 . . . . 0.0 109.645 -170.484 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -75.04 148.03 34.56 Favored 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 121.733 1.622 . . . . 0.0 109.051 178.361 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -54.24 -35.24 62.25 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -174.647 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -58.66 -43.01 89.71 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 119.937 1.244 . . . . 0.0 112.904 177.496 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -69.41 -39.68 77.76 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 125.243 1.417 . . . . 0.0 108.957 -178.342 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 36.5 mt -65.89 -40.0 86.28 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.529 1.131 . . . . 0.0 110.872 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 72.6 t -66.03 -41.23 89.26 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 O-C-N 118.998 -2.314 . . . . 0.0 109.607 173.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -52.5 -52.89 52.28 Favored 'General case' 0 C--O 1.223 -0.299 0 CA-C-O 117.489 -1.243 . . . . 0.0 109.539 171.652 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.51 -35.77 61.02 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 126.758 2.023 . . . . 0.0 112.303 -178.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 71.8 mt -78.11 -37.0 22.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 O-C-N 120.878 -1.139 . . . . 0.0 109.257 -179.133 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -65.47 -36.15 83.01 Favored 'General case' 0 N--CA 1.46 0.07 0 O-C-N 121.363 -0.835 . . . . 0.0 110.406 172.099 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -67.52 -37.65 83.09 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 126.401 1.88 . . . . 0.0 110.051 179.124 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.27 -41.6 80.03 Favored 'General case' 0 C--O 1.236 0.373 0 O-C-N 123.644 0.59 . . . . 0.0 110.769 -178.741 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 109.71 -141.36 16.1 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 124.63 1.11 . . . . 0.0 110.911 171.092 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 85.9 mt -70.4 -40.92 73.62 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 169.123 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.98 131.75 40.59 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 123.102 0.561 . . . . 0.0 110.083 176.022 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.3 p -133.04 139.85 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 C-N-CA 125.165 1.386 . . . . 0.0 107.559 171.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.73 109.14 19.75 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 177.259 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.464 HD13 HD11 ' A' ' 62' ' ' LEU . 17.9 mt -90.51 145.63 24.74 Favored 'General case' 0 CA--C 1.52 -0.177 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 174.422 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 19.7 ttm180 -114.48 114.17 25.44 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 174.857 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pp -114.97 160.96 14.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 125.003 1.321 . . . . 0.0 108.913 -179.112 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 89.4 mt . . . . . 0 C--O 1.238 0.473 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 167.609 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 32.9 p . . . . . 0 CA--C 1.535 0.375 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.1 t -117.3 158.99 23.42 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 148.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -129.3 94.62 3.83 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 174.073 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 15.2 t -92.58 96.14 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 C-N-CA 125.838 1.655 . . . . 0.0 107.513 -173.181 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.1 p -80.42 135.36 25.47 Favored 'Isoleucine or valine' 0 C--O 1.238 0.451 0 C-N-CA 123.322 0.649 . . . . 0.0 109.792 174.81 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 46.2 mt -132.28 126.46 55.79 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 C-N-CA 125.155 1.382 . . . . 0.0 107.74 176.272 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -88.76 161.77 16.6 Favored 'General case' 0 C--O 1.233 0.219 0 C-N-CA 125.022 1.329 . . . . 0.0 108.877 171.812 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 49.3 ptt85 -144.22 -171.11 3.51 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 160.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 168.38 9.59 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 161.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -70.9 -33.68 70.8 Favored 'General case' 0 C--N 1.329 -0.295 0 O-C-N 121.162 -0.962 . . . . 0.0 112.473 -178.464 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -74.1 6.55 3.36 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 124.586 1.154 . . . . 0.0 113.0 -171.575 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -143.81 171.66 13.9 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 126.539 1.936 . . . . 0.0 109.261 -169.626 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.83 176.57 23.01 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 124.434 1.016 . . . . 0.0 111.032 178.503 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -83.44 133.43 34.91 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 163.628 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -96.89 57.24 1.28 Allowed Glycine 0 CA--C 1.521 0.441 0 C-N-CA 124.599 1.095 . . . . 0.0 112.66 -171.507 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -137.97 167.24 22.17 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 125.522 1.529 . . . . 0.0 108.213 172.098 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.576 HG12 ' H ' ' A' ' 49' ' ' ARG . 0.4 OUTLIER -132.39 157.65 43.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 176.236 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 20.3 mt -117.63 135.82 56.8 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 176.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.7 pt . . . . . 0 C--O 1.241 0.634 0 C-N-CA 124.104 0.962 . . . . 0.0 109.686 175.878 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo . . . . . 0 N--CA 1.449 -1.111 0 N-CA-C 106.692 -2.08 . . . . 0.0 106.692 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.558 ' NE2' HD13 ' A' ' 84' ' ' ILE . 19.4 m80 68.76 108.19 0.05 Allowed 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 126.531 1.933 . . . . 0.0 113.302 171.145 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 52.1 pttt -143.83 157.59 44.27 Favored 'General case' 0 N--CA 1.467 0.421 0 O-C-N 120.678 -1.264 . . . . 0.0 109.22 167.286 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.1 mm -65.06 123.86 18.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 172.051 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -110.46 -26.49 4.81 Favored Glycine 0 CA--C 1.535 1.285 0 N-CA-C 114.849 0.7 . . . . 0.0 114.849 176.654 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.576 ' H ' HG12 ' A' ' 27' ' ' VAL . 67.5 ttt180 -149.85 147.37 27.88 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 177.461 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.5 mt -121.84 131.76 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.72 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 166.257 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 23.8 mm -65.32 153.89 7.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 -177.826 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -68.51 118.34 11.43 Favored 'General case' 0 C--N 1.328 -0.351 0 O-C-N 121.474 -0.766 . . . . 0.0 110.634 -169.212 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.41 1.87 24.14 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 115.952 1.141 . . . . 0.0 115.952 169.712 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.49 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 3.5 p -68.77 175.25 2.07 Favored Pre-proline 0 CA--C 1.554 1.108 0 C-N-CA 126.966 2.106 . . . . 0.0 113.067 178.63 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.49 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 3.3 Cg_exo -64.44 -24.43 64.02 Favored 'Trans proline' 0 C--N 1.351 0.704 0 C-N-CA 121.601 1.534 . . . . 0.0 115.154 -168.097 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -69.38 -48.2 61.9 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 118.803 0.729 . . . . 0.0 109.613 172.569 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -54.13 -49.63 68.75 Favored 'General case' 0 N--CA 1.464 0.262 0 C-N-CA 125.294 1.437 . . . . 0.0 110.168 177.553 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.4 mmt-85 -68.88 -15.61 63.54 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 123.694 0.797 . . . . 0.0 112.952 177.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 17.5 t -68.89 -28.2 66.47 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 117.724 -1.131 . . . . 0.0 110.357 177.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 59.38 -28.93 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 128.595 2.758 . . . . 0.0 115.475 -174.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 47.9 mtmt -62.73 -33.17 74.58 Favored 'General case' 0 CA--C 1.521 -0.139 0 C-N-CA 125.55 1.54 . . . . 0.0 112.386 178.043 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -105.87 119.49 39.31 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 -165.081 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 3.0 ptpp? -131.99 167.91 18.84 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 119.665 1.12 . . . . 0.0 110.518 -178.073 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 73.7 t -64.34 137.77 24.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 178.223 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.96 -16.71 57.13 Favored Glycine 0 N--CA 1.447 -0.613 0 CA-C-O 117.475 -1.736 . . . . 0.0 110.725 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -67.45 92.88 0.31 Allowed 'General case' 0 C--N 1.346 0.426 0 CA-C-N 118.909 1.355 . . . . 0.0 108.458 -178.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.3 mtt85 -46.85 128.91 11.41 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 126.543 1.937 . . . . 0.0 110.892 165.173 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 55.0 mt -96.89 155.76 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 C-N-CA 126.417 1.887 . . . . 0.0 107.086 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.13 -54.52 1.7 Allowed 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 125.976 1.71 . . . . 0.0 107.961 -179.343 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.97 158.87 43.33 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 125.629 1.572 . . . . 0.0 108.764 -176.401 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.577 HG22 HD23 ' A' ' 97' ' ' LEU . 39.2 t -136.2 132.96 50.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.067 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 57.75 10.23 1.03 Allowed 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.052 0.941 . . . . 0.0 112.449 -163.359 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 82.04 -2.28 84.42 Favored Glycine 0 CA--C 1.534 1.222 0 C-N-CA 125.0 1.286 . . . . 0.0 113.22 -170.366 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -75.64 141.32 42.82 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 120.537 2.168 . . . . 0.0 107.233 169.727 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 33.1 m -56.58 147.14 23.03 Favored 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 118.71 0.686 . . . . 0.0 109.569 164.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.3 pp -116.56 5.66 7.26 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 C-N-CA 124.361 1.065 . . . . 0.0 111.838 172.525 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 98.0 mt -63.5 143.44 15.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 124.274 1.03 . . . . 0.0 108.282 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 61.62 -18.77 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 128.822 2.849 . . . . 0.0 117.291 172.829 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 4.8 mtp -55.87 145.78 51.21 Favored Pre-proline 0 C--O 1.241 0.611 0 CA-C-N 119.273 0.942 . . . . 0.0 110.034 177.701 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -69.18 155.21 68.51 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 122.629 2.22 . . . . 0.0 108.027 170.73 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -59.7 -32.16 70.25 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.7 -171.628 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.29 -39.45 72.71 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 126.214 1.806 . . . . 0.0 112.861 175.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 61.8 m-20 -70.98 -46.65 61.95 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -178.797 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.558 HD13 ' NE2' ' A' ' 45' ' ' HIS . 8.5 mt -64.66 -33.58 64.16 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 C-N-CA 126.018 1.727 . . . . 0.0 111.133 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.5 t -65.07 -51.51 65.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 124.475 1.11 . . . . 0.0 108.888 170.052 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.71 -37.34 81.38 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 116.77 -1.586 . . . . 0.0 110.984 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -51.64 -49.17 62.78 Favored 'General case' 0 N--CA 1.445 -0.697 0 C-N-CA 125.88 1.672 . . . . 0.0 111.301 173.395 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 53.2 mt -70.23 -38.65 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.16 0 O-C-N 121.066 -1.021 . . . . 0.0 108.873 -178.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.1 tttp -65.96 -38.49 88.73 Favored 'General case' 0 N--CA 1.453 -0.291 0 O-C-N 121.728 -0.607 . . . . 0.0 110.925 -179.416 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -66.45 -19.04 65.69 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 129.381 3.072 . . . . 0.0 111.588 174.589 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -64.5 -31.05 72.1 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.722 -0.611 . . . . 0.0 111.938 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 87.65 -149.85 22.03 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -169.19 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.7 mt -83.1 -20.76 34.24 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 118.201 1.001 . . . . 0.0 111.534 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.2 p -94.49 139.52 31.05 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 169.548 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 p -145.02 148.15 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 169.305 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.6 m -125.09 118.39 26.03 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 178.227 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.577 HD23 HG22 ' A' ' 71' ' ' VAL . 71.4 mt -90.78 124.05 34.83 Favored 'General case' 0 CA--C 1.509 -0.597 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 170.405 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 24.5 ttm105 -96.13 121.46 37.93 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 168.182 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -125.56 173.88 10.63 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 C-N-CA 125.559 1.543 . . . . 0.0 109.211 -166.303 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.6 mp . . . . . 0 C--O 1.237 0.408 0 C-N-CA 124.057 0.943 . . . . 0.0 108.581 179.614 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 32.8 p . . . . . 0 C--O 1.238 0.463 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 42.2 m -111.04 153.23 25.91 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 162.225 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -122.89 115.38 21.85 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 105.108 -2.182 . . . . 0.0 105.108 174.114 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -112.31 97.14 5.35 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 C-N-CA 123.703 0.801 . . . . 0.0 109.163 -173.107 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.5 p -76.75 141.36 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 170.253 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 59.7 mt -136.58 140.03 44.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 173.123 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 14.7 m-70 -124.7 113.28 17.78 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.789 2.436 . . . . 0.0 108.117 -170.809 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.2 ptt180 -106.16 -179.41 3.93 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 119.287 0.948 . . . . 0.0 111.238 -176.123 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.93 161.08 13.91 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 119.049 0.84 . . . . 0.0 110.257 170.247 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -64.41 -19.79 65.73 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.501 1.12 . . . . 0.0 112.216 177.76 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -87.68 -16.87 33.13 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 119.537 1.062 . . . . 0.0 113.235 178.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -113.09 -178.53 3.4 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 119.281 0.946 . . . . 0.0 109.877 -171.445 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -105.72 -176.38 23.93 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 169.414 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -78.31 176.79 8.98 Favored 'General case' 0 CA--C 1.533 0.316 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 153.53 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.418 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -135.13 50.79 0.85 Allowed Glycine 0 C--O 1.224 -0.531 0 CA-C-O 118.234 -1.315 . . . . 0.0 113.195 -172.123 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PHE . . . . . 0.52 ' CE2' HD11 ' A' ' 28' ' ' ILE . 11.7 p90 -137.74 135.5 36.44 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 124.756 1.222 . . . . 0.0 110.299 -179.405 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.2 t -102.91 109.25 26.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 -179.108 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.552 HD12 ' H ' ' A' ' 28' ' ' ILE . 4.1 mp -82.26 124.91 39.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 175.21 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.533 HD11 ' HE2' ' A' ' 46' ' ' LYS . 15.5 pt . . . . . 0 N--CA 1.448 -0.574 0 C-N-CA 123.852 0.861 . . . . 0.0 109.746 177.743 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo . . . . . 0 N--CA 1.455 -0.766 0 CA-C-O 117.5 -1.125 . . . . 0.0 113.905 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -136.59 140.4 42.83 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 120.815 1.643 . . . . 0.0 108.071 176.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.533 ' HE2' HD11 ' A' ' 29' ' ' ILE . 10.7 pttm -156.5 165.64 35.73 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 170.146 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.438 HD13 HD11 ' A' ' 68' ' ' ILE . 6.9 mm -66.59 148.35 12.14 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.809 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 167.488 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -134.85 -8.45 1.89 Allowed Glycine 0 CA--C 1.529 0.959 0 C-N-CA 125.081 1.324 . . . . 0.0 113.765 173.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.0 ttt180 -165.75 160.95 17.7 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 126.283 1.833 . . . . 0.0 107.13 165.544 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 36.4 mt -132.54 149.95 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 125.654 1.582 . . . . 0.0 107.685 172.698 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 41.5 mm -81.77 118.38 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 C-N-CA 125.529 1.532 . . . . 0.0 108.841 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -62.77 96.31 0.08 Allowed 'General case' 0 C--O 1.235 0.332 0 C-N-CA 125.502 1.521 . . . . 0.0 107.957 168.478 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.23 0.22 6.41 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 125.216 1.388 . . . . 0.0 113.698 -179.166 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.418 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 66.8 p -91.45 166.28 18.7 Favored Pre-proline 0 C--O 1.237 0.415 0 CA-C-N 118.911 1.355 . . . . 0.0 113.333 -179.768 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -62.96 -32.29 76.59 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.55 2.167 . . . . 0.0 111.659 166.079 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.02 -47.24 74.97 Favored 'General case' 0 C--N 1.346 0.414 0 CA-C-N 119.04 0.836 . . . . 0.0 110.806 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -67.97 -52.68 33.1 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.744 0.418 . . . . 0.0 111.043 178.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 15.0 mtp85 -57.7 -34.61 69.63 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 121.589 -0.694 . . . . 0.0 112.285 -173.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 61.1 m -62.81 -16.54 58.62 Favored 'General case' 0 CA--C 1.534 0.345 0 CA-C-O 117.709 -1.138 . . . . 0.0 112.494 -178.754 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 46.21 34.98 2.36 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.105 1.762 . . . . 0.0 113.623 170.686 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 18.9 mtmm -129.65 -6.99 4.61 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 126.908 2.083 . . . . 0.0 111.829 173.623 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.14 101.06 4.06 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 -173.434 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 13.3 pttp -126.75 159.41 33.85 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 126.184 1.794 . . . . 0.0 109.688 -168.775 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . 0.374 0.4 OUTLIER -65.5 111.69 1.53 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.255 0 O-C-N 121.363 -0.836 . . . . 0.0 109.476 179.814 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 129.95 -18.79 5.3 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 128.285 2.85 . . . . 0.0 111.462 -175.193 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -71.56 97.26 1.66 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.401 1.08 . . . . 0.0 110.333 171.64 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.2 mtm180 -54.34 150.59 8.52 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 127.687 2.395 . . . . 0.0 111.75 173.602 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.484 HG22 ' CD1' ' A' ' 76' ' ' ILE . 87.7 mt -124.86 117.14 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 -165.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 76.5 mt -89.0 -40.19 13.17 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 124.327 1.051 . . . . 0.0 112.179 179.115 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.49 170.65 21.93 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 124.676 1.19 . . . . 0.0 108.764 -170.049 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.4 p -122.48 122.81 67.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 170.641 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 54.32 -73.0 0.01 OUTLIER 'General case' 0 C--O 1.232 0.177 0 C-N-CA 128.191 2.597 . . . . 0.0 111.783 -170.723 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -155.75 18.93 0.5 Allowed Glycine 0 CA--C 1.529 0.957 0 C-N-CA 126.887 2.184 . . . . 0.0 112.034 -178.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 24.2 mm100 -115.18 135.17 54.46 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 119.661 1.73 . . . . 0.0 108.572 -175.66 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.7 m -72.61 110.23 6.83 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 123.977 0.911 . . . . 0.0 109.759 174.627 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.484 ' CD1' HG22 ' A' ' 68' ' ' ILE . 11.1 pt -75.99 -15.63 15.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 C-N-CA 125.133 1.373 . . . . 0.0 111.962 174.644 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.522 ' H ' HD12 ' A' ' 77' ' ' ILE . 4.1 mp -56.03 -47.0 80.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 C-N-CA 125.121 1.368 . . . . 0.0 113.713 -164.644 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -113.83 -0.93 14.03 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 124.365 1.066 . . . . 0.0 112.237 -169.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . 0.252 11.0 ttt -68.81 146.95 97.82 Favored Pre-proline 0 N--CA 1.434 -1.245 0 C-N-CA 130.62 3.568 . . . . 0.0 109.846 -178.662 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -57.07 141.34 94.17 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.816 2.344 . . . . 0.0 109.792 167.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.517 ' HA ' HD12 ' A' ' 84' ' ' ILE . 41.4 t60 -66.64 -36.34 82.33 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 120.246 1.384 . . . . 0.0 111.055 -178.264 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -57.72 -31.34 66.33 Favored 'General case' 0 CA--C 1.534 0.332 0 O-C-N 121.361 -0.837 . . . . 0.0 112.74 171.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -73.42 -48.52 33.1 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 124.308 1.043 . . . . 0.0 109.144 177.491 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.517 HD12 ' HA ' ' A' ' 81' ' ' HIS . 66.2 mt -56.67 -35.59 45.89 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 C-N-CA 125.505 1.522 . . . . 0.0 110.698 175.151 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 45.9 t -77.07 -39.81 29.57 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 C-N-CA 124.176 0.991 . . . . 0.0 110.313 177.962 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 21.0 ttmt -60.4 -38.5 84.19 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 120.9 -1.125 . . . . 0.0 110.124 173.786 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -57.61 -38.63 75.28 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 127.464 2.306 . . . . 0.0 112.598 174.718 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 59.9 mt -68.08 -45.98 82.4 Favored 'Isoleucine or valine' 0 C--N 1.341 0.206 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 174.522 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 6.5 tttm -64.16 -40.14 95.49 Favored 'General case' 0 CA--C 1.536 0.416 0 O-C-N 121.739 -0.601 . . . . 0.0 110.263 -176.769 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -65.69 -11.8 48.22 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 127.099 2.159 . . . . 0.0 112.188 176.323 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -66.67 -13.4 61.18 Favored 'General case' 0 CA--C 1.541 0.633 0 O-C-N 121.34 -0.85 . . . . 0.0 112.155 170.656 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 72.66 -90.04 0.55 Allowed Glycine 0 C--N 1.34 0.796 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.6 mt -125.74 -34.49 2.62 Favored 'General case' 0 CA--C 1.514 -0.423 0 C-N-CA 125.589 1.556 . . . . 0.0 111.526 175.6 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.63 121.85 42.31 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 118.377 0.535 . . . . 0.0 110.131 -179.129 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.7 p -123.96 147.69 28.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 173.589 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.6 m -119.15 135.79 54.49 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 173.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 31.0 mt -125.19 110.57 14.24 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 125.309 1.444 . . . . 0.0 108.317 -176.326 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 33.4 ttm180 -77.74 106.83 9.81 Favored 'General case' 0 C--O 1.238 0.483 0 C-N-CA 123.811 0.844 . . . . 0.0 111.211 177.087 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -111.27 168.73 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 124.161 0.984 . . . . 0.0 110.597 -175.85 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.1 mp . . . . . 0 CA--C 1.54 0.583 0 CA-C-O 118.061 -0.971 . . . . 0.0 108.627 175.172 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 44.6 p . . . . . 0 C--O 1.236 0.361 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 m -141.74 150.69 42.12 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.706 1.202 . . . . 0.0 108.421 172.831 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -104.84 97.37 7.26 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 127.722 2.409 . . . . 0.0 105.862 -179.542 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 36.9 t -91.65 95.1 5.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 173.059 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.2 p -74.45 137.7 22.59 Favored 'Isoleucine or valine' 0 C--O 1.238 0.493 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 169.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.5 mt -135.61 134.55 51.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 104.835 -2.283 . . . . 0.0 104.835 174.346 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -108.33 160.43 15.87 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.542 1.137 . . . . 0.0 109.526 177.57 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 43.4 ptt85 -150.95 -179.64 7.46 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 119.424 1.011 . . . . 0.0 109.582 170.347 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.45 162.59 16.39 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 168.14 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.14 -42.52 95.01 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 174.828 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -71.52 -1.49 13.54 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-O 117.963 -1.018 . . . . 0.0 113.254 -167.827 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -137.1 179.07 6.6 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 121.278 1.854 . . . . 0.0 110.754 170.136 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.45 165.02 12.08 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 126.002 1.763 . . . . 0.0 110.169 170.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -66.94 148.96 51.27 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 124.637 1.175 . . . . 0.0 108.398 178.16 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.88 49.12 3.31 Favored Glycine 0 C--O 1.222 -0.629 0 CA-C-O 117.94 -1.478 . . . . 0.0 113.698 -174.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -136.22 156.27 48.91 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 120.745 2.273 . . . . 0.0 111.926 174.839 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.9 t -128.16 106.39 14.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 106.687 -1.597 . . . . 0.0 106.687 -175.11 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 23.8 mt -73.68 141.67 15.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 168.066 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.493 HD11 ' HE2' ' A' ' 46' ' ' LYS . 35.7 pt . . . . . 0 CA--C 1.537 0.478 0 C-N-CA 125.308 1.443 . . . . 0.0 110.826 174.561 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo . . . . . 0 N--CA 1.453 -0.91 0 N-CA-C 109.289 -1.081 . . . . 0.0 109.289 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.16 119.79 13.31 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 122.809 1.29 . . . . 0.0 110.973 -167.601 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.493 ' HE2' HD11 ' A' ' 29' ' ' ILE . 15.2 pttm -152.47 160.08 43.29 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 128.523 2.729 . . . . 0.0 106.267 178.433 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.409 HG13 HD22 ' A' ' 62' ' ' LEU . 34.6 mm -64.33 126.76 23.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 164.835 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -109.22 -21.14 7.49 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 125.717 1.627 . . . . 0.0 113.757 174.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 53.7 ttt180 -161.7 162.34 29.74 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 126.438 1.895 . . . . 0.0 108.06 166.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 6.5 mt -127.98 150.38 33.7 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 126.422 1.889 . . . . 0.0 108.094 170.505 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 21.3 mm -85.34 128.67 38.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 126.245 1.818 . . . . 0.0 107.226 178.584 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -62.1 143.02 57.24 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 123.23 0.612 . . . . 0.0 112.047 -172.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.68 -8.11 6.2 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 125.441 1.496 . . . . 0.0 115.47 176.798 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 84.8 p -67.49 170.25 7.25 Favored Pre-proline 0 C--O 1.239 0.518 0 CA-C-N 118.241 1.02 . . . . 0.0 112.198 -173.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.456 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 6.3 Cg_endo -57.23 -21.61 44.48 Favored 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.028 1.819 . . . . 0.0 112.508 165.843 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.43 -50.18 13.25 Favored 'General case' 0 C--N 1.342 0.242 0 CA-C-N 119.883 1.22 . . . . 0.0 110.699 174.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -63.58 -45.09 92.01 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 118.533 0.606 . . . . 0.0 110.763 -175.467 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -70.55 -13.78 62.24 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 123.565 0.746 . . . . 0.0 112.197 178.578 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 35.6 t -63.16 -49.99 72.15 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 119.127 0.876 . . . . 0.0 109.211 179.254 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.93 -21.41 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 128.439 2.695 . . . . 0.0 115.679 -173.401 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.4 mmmm -63.21 -26.56 68.85 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 125.976 1.71 . . . . 0.0 110.565 165.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.409 HD22 HG13 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -99.39 138.43 36.49 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 161.753 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 21.1 pttm -139.74 171.21 14.55 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 123.641 0.777 . . . . 0.0 110.795 164.383 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 84.6 t -59.85 137.96 21.52 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.714 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 175.389 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 93.83 -7.31 73.78 Favored Glycine 0 C--N 1.341 0.849 0 O-C-N 121.039 -1.038 . . . . 0.0 110.567 177.057 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 68.9 m-20 -71.84 98.76 2.05 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 171.281 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.9 mtt180 -45.78 158.46 0.09 Allowed 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 127.519 2.328 . . . . 0.0 110.841 162.504 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 19.1 mt -138.47 118.07 14.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -170.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.434 HD22 ' H ' ' A' ' 69' ' ' LEU . 1.9 mm? -78.17 -45.25 23.65 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.567 1.147 . . . . 0.0 111.732 172.21 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -160.3 166.24 29.86 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.181 0.992 . . . . 0.0 112.163 -160.475 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.2 p -128.66 111.83 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 C-N-CA 126.191 1.796 . . . . 0.0 110.138 -178.506 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.5 m-20 56.0 17.48 2.64 Favored 'General case' 0 N--CA 1.465 0.282 0 C-N-CA 125.285 1.434 . . . . 0.0 111.147 -168.545 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.48 -10.33 61.13 Favored Glycine 0 CA--C 1.529 0.944 0 CA-C-O 117.527 -1.707 . . . . 0.0 114.382 -175.684 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -75.92 132.15 40.08 Favored 'General case' 0 C--N 1.341 0.235 0 CA-C-N 120.51 2.155 . . . . 0.0 107.478 177.394 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.3 p -61.68 137.02 58.22 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 124.181 0.992 . . . . 0.0 109.949 175.039 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.7 pt -114.55 -4.37 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 C-N-CA 124.908 1.283 . . . . 0.0 111.331 179.286 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mt -57.9 145.14 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.596 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 162.555 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 18.7 m-80 67.13 -21.92 0.11 Allowed 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 128.117 2.567 . . . . 0.0 116.036 171.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 6.6 mtp -69.45 150.7 96.95 Favored Pre-proline 0 C--O 1.244 0.767 0 C-N-CA 124.658 1.183 . . . . 0.0 109.86 175.737 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -74.68 154.46 44.15 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 123.17 2.58 . . . . 0.0 109.856 173.154 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -54.99 -41.82 71.71 Favored 'General case' 0 N--CA 1.462 0.13 0 C-N-CA 123.42 0.688 . . . . 0.0 111.604 -178.418 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -57.15 -44.58 83.56 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-O 118.822 -0.609 . . . . 0.0 111.332 -174.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.52 -42.44 74.69 Favored 'General case' 0 C--O 1.221 -0.413 0 O-C-N 124.36 1.037 . . . . 0.0 110.011 -175.763 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 68.4 mt -63.33 -41.22 91.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 124.797 1.239 . . . . 0.0 109.679 178.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 41.4 t -62.55 -48.04 90.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 O-C-N 121.161 -0.962 . . . . 0.0 109.456 174.027 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 6.1 tptt -58.44 -43.68 88.86 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 118.614 -0.708 . . . . 0.0 111.279 176.623 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.05 -34.45 73.43 Favored 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 126.154 1.781 . . . . 0.0 111.71 -176.873 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 58.1 mt -73.15 -47.63 46.56 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 173.446 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.3 tttt -58.29 -32.92 68.89 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 122.096 -0.378 . . . . 0.0 111.686 -177.682 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -99.76 2.09 43.81 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 125.173 1.389 . . . . 0.0 112.276 -177.024 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -54.92 -29.57 56.55 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -171.572 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 123.13 27.57 1.49 Allowed Glycine 0 CA--C 1.526 0.768 0 C-N-CA 124.349 0.976 . . . . 0.0 113.285 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 7.8 mt 58.02 -23.11 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 129.023 2.929 . . . . 0.0 114.555 -164.442 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -93.56 148.59 21.95 Favored 'General case' 0 N--CA 1.435 -1.195 0 N-CA-C 105.24 -2.133 . . . . 0.0 105.24 161.316 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.1 p -143.26 140.48 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 0 N-CA-C 105.009 -2.219 . . . . 0.0 105.009 169.639 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.9 m -117.97 102.42 9.04 Favored 'General case' 0 N--CA 1.441 -0.911 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 21.6 mt -90.13 122.1 32.78 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 106.476 -1.676 . . . . 0.0 106.476 -172.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.1 ttt180 -83.73 109.77 17.76 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.011 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -111.94 160.97 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 123.429 0.692 . . . . 0.0 110.83 -177.811 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 28.5 mt . . . . . 0 CA--C 1.537 0.459 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 169.703 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.7 p . . . . . 0 CA--C 1.538 0.504 0 N-CA-C 110.589 -0.152 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -135.23 163.83 29.07 Favored 'General case' 0 CA--C 1.522 -0.12 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 162.397 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -134.42 94.85 3.27 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 127.185 2.194 . . . . 0.0 107.245 -174.043 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.8 t -96.89 109.73 23.63 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 125.373 1.469 . . . . 0.0 107.86 -165.167 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 1.5 t -84.16 141.89 14.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 173.634 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 69.7 mt -138.22 149.79 24.56 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 105.57 -2.011 . . . . 0.0 105.57 173.815 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 91.3 m-70 -130.82 156.38 45.1 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.928 1.291 . . . . 0.0 109.271 -176.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 35.3 ptt180 -143.08 -176.86 5.08 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 119.779 1.172 . . . . 0.0 110.048 176.633 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.44 163.31 12.54 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 124.047 0.939 . . . . 0.0 108.89 170.199 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -70.57 -19.33 62.88 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -177.554 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.8 m-20 -90.31 5.54 46.81 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 119.745 1.157 . . . . 0.0 112.07 177.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -140.92 176.77 8.53 Favored 'General case' 0 N--CA 1.445 -0.697 0 O-C-N 121.253 -0.905 . . . . 0.0 111.493 -172.832 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.42 170.73 14.61 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 178.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.443 ' CE1' HG12 ' A' ' 95' ' ' VAL . 40.2 m-85 -71.49 171.14 11.86 Favored 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 152.515 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -127.94 55.43 0.75 Allowed Glycine 0 C--O 1.222 -0.646 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 25.7 p90 -131.4 158.61 40.3 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 170.215 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 9.2 t -136.88 127.79 41.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 -174.474 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.0 mp -87.07 146.8 5.85 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 175.166 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 31.6 pt . . . . . 0 N--CA 1.442 -0.842 0 C-N-CA 126.326 1.85 . . . . 0.0 108.239 160.174 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo . . . . . 0 N--CA 1.446 -1.275 0 N-CA-C 109.281 -1.084 . . . . 0.0 109.281 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.481 ' CE1' HG21 ' A' ' 84' ' ' ILE . 8.2 m-70 -65.37 116.34 6.57 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 124.25 1.02 . . . . 0.0 111.471 -168.505 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 39.5 pttt -135.44 151.86 50.82 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 168.055 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 30.0 mm -60.12 115.92 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 C-N-CA 124.261 1.024 . . . . 0.0 109.208 169.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -90.42 -39.43 5.98 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 124.013 0.816 . . . . 0.0 112.629 172.097 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 41.0 ttt85 -149.02 161.46 41.88 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 118.266 1.033 . . . . 0.0 109.559 178.752 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 15.4 mt -131.99 136.71 56.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 126.298 1.839 . . . . 0.0 106.171 169.455 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.4 mp -79.81 132.55 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 C-N-CA 126.016 1.726 . . . . 0.0 108.089 179.596 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -55.89 133.25 51.25 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 125.942 1.697 . . . . 0.0 109.505 177.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.36 -8.92 75.18 Favored Glycine 0 CA--C 1.528 0.892 0 C-N-CA 123.397 0.522 . . . . 0.0 112.46 169.219 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 76.5 p -71.22 167.1 32.39 Favored Pre-proline 0 N--CA 1.451 -0.385 0 CA-C-N 118.087 0.943 . . . . 0.0 112.836 -169.183 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -54.1 -39.76 84.46 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 C-N-CA 122.35 2.033 . . . . 0.0 111.992 166.414 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.11 -55.78 28.46 Favored 'General case' 0 C--N 1.341 0.216 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.78 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -57.13 -30.77 64.69 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.126 1.37 . . . . 0.0 112.447 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 46.6 mtt-85 -83.97 -29.29 27.15 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 114.533 1.309 . . . . 0.0 114.533 175.305 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 77.0 m -69.46 -27.72 65.48 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 120.292 1.405 . . . . 0.0 111.815 179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 51.54 -160.53 0.09 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.914 0.886 . . . . 0.0 110.496 -169.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 60.9 5.33 0.95 Allowed 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 125.544 1.538 . . . . 0.0 113.323 -167.007 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 14.7 tp -146.59 108.58 4.39 Favored 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.613 1.965 . . . . 0.0 107.17 -175.343 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 33.4 mttm -133.95 171.1 14.65 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 125.495 1.518 . . . . 0.0 110.419 -175.864 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 58.2 t -76.47 101.3 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -174.057 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 139.63 -12.78 3.19 Favored Glycine 0 CA--C 1.522 0.515 0 C-N-CA 127.0 2.238 . . . . 0.0 108.951 -175.433 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 57.7 m-20 -74.6 110.75 9.14 Favored 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 123.219 1.485 . . . . 0.0 107.346 -178.802 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 19.1 mmt-85 -59.9 158.69 10.25 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 113.918 -1.492 . . . . 0.0 110.377 162.687 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 35.0 mt -131.6 132.18 62.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 -175.496 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.7 mt -84.49 -51.25 7.05 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 124.323 1.049 . . . . 0.0 111.172 176.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -151.68 168.91 23.53 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 124.53 1.132 . . . . 0.0 109.609 -164.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.431 HG23 HG21 ' A' ' 76' ' ' ILE . 4.1 t -130.27 118.14 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 179.396 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 39.32 63.12 1.02 Allowed 'General case' 0 N--CA 1.464 0.252 0 C-N-CA 125.53 1.532 . . . . 0.0 110.733 -174.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 69.5 2.09 33.01 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-O 117.672 -1.627 . . . . 0.0 114.461 176.548 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -111.77 154.03 25.65 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 120.203 2.002 . . . . 0.0 111.676 -171.746 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 26.7 p -65.9 142.27 57.95 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.984 -179.15 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.431 HG21 HG23 ' A' ' 71' ' ' VAL . 5.0 pt -129.8 -5.78 2.87 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 123.318 0.647 . . . . 0.0 112.333 168.213 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 96.5 mt -73.66 -22.56 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.662 0 C-N-CA 125.046 1.338 . . . . 0.0 109.639 173.505 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 -124.84 -42.78 2.03 Favored 'General case' 0 C--N 1.341 0.215 0 C-N-CA 124.186 0.994 . . . . 0.0 111.734 -162.103 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.4 mtp -57.28 151.09 38.89 Favored Pre-proline 0 CA--C 1.533 0.294 0 C-N-CA 123.407 0.683 . . . . 0.0 110.489 176.772 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -69.34 149.06 69.09 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 121.149 1.233 . . . . 0.0 109.066 171.442 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -55.65 -41.53 73.74 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 124.085 0.954 . . . . 0.0 112.445 -170.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.91 -30.01 70.6 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 118.936 -0.554 . . . . 0.0 111.88 -179.434 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -70.68 -50.97 30.86 Favored 'General case' 0 C--O 1.223 -0.326 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.265 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.481 HG21 ' CE1' ' A' ' 45' ' ' HIS . 14.4 mt -60.18 -40.04 82.37 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 C-N-CA 124.45 1.1 . . . . 0.0 110.19 178.288 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.0 t -60.52 -47.23 93.58 Favored 'Isoleucine or valine' 0 C--O 1.241 0.611 0 O-C-N 120.78 -1.2 . . . . 0.0 109.97 175.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 22.6 ttmt -65.62 -42.13 91.92 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 117.895 -1.05 . . . . 0.0 110.102 178.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -48.53 -44.86 36.69 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 126.22 1.808 . . . . 0.0 111.097 176.483 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 41.4 mt -73.79 -44.24 52.32 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 48.2 tttt -58.87 -39.09 80.32 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 121.774 -0.579 . . . . 0.0 110.826 -178.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.7 -2.18 57.93 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 127.402 2.281 . . . . 0.0 112.436 -179.463 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.57 -13.4 3.77 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 116.058 1.873 . . . . 0.0 116.058 -164.005 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.45 44.3 6.59 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 118.875 0.762 . . . . 0.0 111.761 172.359 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 34.9 mt 66.49 -34.83 0.22 Allowed 'General case' 0 CA--C 1.511 -0.524 0 C-N-CA 129.245 3.018 . . . . 0.0 113.714 -175.189 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -93.47 143.25 26.47 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 178.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.443 HG12 ' CE1' ' A' ' 24' ' ' PHE . 11.5 p -144.88 135.95 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 172.337 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 35.0 m -116.53 106.26 13.38 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 -177.008 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 11.8 mt -91.04 110.48 21.75 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 125.07 1.348 . . . . 0.0 108.362 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 ttt180 -78.74 119.68 22.31 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 166.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -117.99 172.55 5.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 C-N-CA 124.733 1.213 . . . . 0.0 109.19 177.01 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 62.4 mt . . . . . 0 CA--C 1.542 0.657 0 C-N-CA 124.647 1.179 . . . . 0.0 108.122 174.707 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 51.0 p . . . . . 0 C--O 1.234 0.26 0 N-CA-C 105.769 -1.937 . . . . 0.0 105.769 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 m -123.45 151.99 42.11 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 161.685 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -108.67 130.39 55.34 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 128.752 2.821 . . . . 0.0 105.332 176.659 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.8 t -132.99 109.19 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.4 p -100.61 132.32 46.5 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 176.598 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 46.2 mt -136.05 147.21 28.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.711 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -120.87 159.28 25.84 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 124.36 1.064 . . . . 0.0 109.564 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.1 ptt180 -140.6 -161.95 1.28 Allowed 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 169.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.23 169.24 10.75 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 169.754 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 17.7 mm-40 -64.73 -27.37 68.86 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -80.43 -6.92 58.84 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 114.541 1.311 . . . . 0.0 114.541 -173.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -141.25 176.26 8.99 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 119.547 1.067 . . . . 0.0 110.596 -170.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.6 171.77 16.79 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 123.982 0.801 . . . . 0.0 111.353 -172.071 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -85.04 137.9 32.77 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 163.662 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.447 ' O ' ' HB3' ' A' ' 56' ' ' ALA . . . -97.71 75.3 0.63 Allowed Glycine 0 N--CA 1.442 -0.918 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 -178.093 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -157.77 148.88 21.31 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 164.508 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.2 t -137.59 131.04 43.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -174.196 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 10.3 mt -71.06 154.47 7.92 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.026 0 C-N-CA 124.788 1.235 . . . . 0.0 109.751 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 49.2 pt . . . . . 0 CA--C 1.54 0.594 0 C-N-CA 127.995 2.518 . . . . 0.0 109.143 149.939 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo . . . . . 0 N--CA 1.457 -0.66 0 CA-C-O 117.542 -1.108 . . . . 0.0 113.906 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -138.9 120.78 15.45 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 121.029 1.74 . . . . 0.0 108.913 177.653 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.9 pttt -140.7 162.94 34.2 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 168.572 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 11.4 mm -65.24 130.87 30.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 172.455 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.06 -51.75 0.72 Allowed Glycine 0 CA--C 1.522 0.491 0 C-N-CA 124.619 1.104 . . . . 0.0 111.224 169.112 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 40.0 ttt85 -134.68 151.79 51.28 Favored 'General case' 0 C--O 1.24 0.579 0 CA-C-N 119.142 1.471 . . . . 0.0 111.165 -168.609 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 50.5 mt -137.33 119.24 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 C-N-CA 127.14 2.176 . . . . 0.0 106.134 179.713 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.427 ' H ' HD12 ' A' ' 51' ' ' ILE . 1.9 mp -46.83 126.75 2.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 127.713 2.405 . . . . 0.0 108.418 156.233 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -63.31 128.31 35.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 165.454 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 105.01 4.99 41.51 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 111.514 -0.634 . . . . 0.0 111.514 173.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.5 p -80.88 159.79 67.85 Favored Pre-proline 0 N--CA 1.449 -0.496 0 O-C-N 121.24 -1.153 . . . . 0.0 113.752 -171.693 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -61.71 -35.01 82.25 Favored 'Trans proline' 0 CA--C 1.539 0.737 0 C-N-CA 122.917 2.412 . . . . 0.0 112.404 168.695 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.447 ' HB3' ' O ' ' A' ' 25' ' ' GLY . . . -68.62 -46.35 69.51 Favored 'General case' 0 C--N 1.34 0.188 0 CA-C-O 118.111 -0.947 . . . . 0.0 111.686 -178.069 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.6 t0 -61.95 -47.64 83.95 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 118.912 0.778 . . . . 0.0 109.805 -172.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 -59.89 -27.47 66.74 Favored 'General case' 0 C--N 1.341 0.229 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.671 177.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 6.1 t -60.57 -37.58 81.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-O 118.405 -0.807 . . . . 0.0 109.982 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.04 -14.34 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 130.535 3.534 . . . . 0.0 116.111 177.577 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.08 -19.19 51.89 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 125.187 1.395 . . . . 0.0 111.477 161.892 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -119.83 131.92 55.44 Favored 'General case' 0 C--O 1.235 0.292 0 C-N-CA 125.672 1.589 . . . . 0.0 107.688 176.301 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.09 171.32 14.48 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 124.194 0.998 . . . . 0.0 110.041 172.763 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.4 t -55.89 141.21 12.88 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 O-C-N 121.321 -0.862 . . . . 0.0 109.112 174.333 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.9 -12.92 65.59 Favored Glycine 0 CA--C 1.534 1.231 0 C-N-CA 125.147 1.356 . . . . 0.0 115.688 172.331 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -68.0 7.31 0.56 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 118.262 2.69 . . . . 0.0 118.262 -151.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 30.8 mtm180 51.87 89.56 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 126.438 1.895 . . . . 0.0 113.122 -178.307 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 61.3 mt -71.95 139.71 19.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.694 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -113.52 -53.05 2.72 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 125.632 1.573 . . . . 0.0 108.768 177.737 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -138.25 154.09 49.08 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.589 0.709 . . . . 0.0 112.319 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.446 HG23 HG21 ' A' ' 76' ' ' ILE . 55.6 t -112.15 116.55 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 169.815 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 57.73 5.12 0.31 Allowed 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 126.763 2.025 . . . . 0.0 115.525 177.644 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.91 12.28 26.34 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-O 118.81 -0.994 . . . . 0.0 112.863 -175.125 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 6.0 tp-100 -103.19 140.29 37.56 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 126.405 1.882 . . . . 0.0 108.401 171.034 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 62.9 m -78.68 100.76 7.18 Favored 'General case' 0 C--O 1.233 0.194 0 C-N-CA 124.666 1.186 . . . . 0.0 111.996 -177.062 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.446 HG21 HG23 ' A' ' 71' ' ' VAL . 2.7 pp -77.6 -5.29 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 179.262 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.565 ' H ' HD12 ' A' ' 77' ' ' ILE . 0.6 OUTLIER -70.28 -9.92 13.11 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 124.764 1.226 . . . . 0.0 112.381 -178.811 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -138.61 -24.51 0.94 Allowed 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 114.785 1.402 . . . . 0.0 114.785 -174.34 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.9 mtp -61.06 152.15 72.31 Favored Pre-proline 0 C--O 1.239 0.506 0 CA-C-N 119.856 1.207 . . . . 0.0 110.8 172.205 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -67.12 157.46 61.63 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 121.727 1.618 . . . . 0.0 110.131 171.322 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -63.21 -37.77 88.53 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.732 -0.605 . . . . 0.0 111.164 -172.057 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.49 -32.47 73.93 Favored 'General case' 0 C--N 1.338 0.068 0 CA-C-N 119.352 0.978 . . . . 0.0 111.975 178.019 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.74 -52.23 65.12 Favored 'General case' 0 C--O 1.224 -0.249 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 176.623 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 54.2 mt -65.88 -41.63 90.42 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.492 0 C-N-CA 125.91 1.684 . . . . 0.0 109.764 -175.628 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 17.1 t -60.14 -45.71 95.49 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 O-C-N 121.101 -0.999 . . . . 0.0 110.096 173.706 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? -59.86 -47.61 85.05 Favored 'General case' 0 C--O 1.219 -0.506 0 CA-C-O 118.692 -0.671 . . . . 0.0 109.376 177.267 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -57.32 -33.75 68.03 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 125.757 1.623 . . . . 0.0 112.676 -177.111 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 63.5 mt -75.1 -45.12 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 175.795 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.6 ttmp? -60.67 -49.1 78.87 Favored 'General case' 0 CA--C 1.537 0.443 0 O-C-N 121.615 -0.678 . . . . 0.0 110.021 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -76.65 5.93 6.75 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 129.948 3.299 . . . . 0.0 111.842 177.524 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -63.51 -24.01 67.64 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 119.28 0.946 . . . . 0.0 112.386 176.422 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.81 48.16 5.61 Favored Glycine 0 C--N 1.338 0.659 0 CA-C-N 119.201 0.909 . . . . 0.0 111.436 174.111 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.0 mt 69.73 -30.79 0.2 Allowed 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 129.764 3.226 . . . . 0.0 113.455 -178.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.29 131.06 40.29 Favored 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 124.722 1.209 . . . . 0.0 108.651 174.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.3 p -135.74 130.77 49.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 170.222 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.34 125.48 39.99 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 105.96 -1.867 . . . . 0.0 105.96 170.106 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 42.3 mt -116.76 106.85 13.94 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 175.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 -88.82 118.9 28.85 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 177.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.3 pp -119.49 176.66 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 127.216 2.206 . . . . 0.0 108.632 -172.673 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 5.0 mp . . . . . 0 CA--C 1.533 0.327 0 CA-C-N 119.231 0.923 . . . . 0.0 108.903 172.004 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 36.0 p . . . . . 0 C--O 1.238 0.455 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 26.0 m -120.22 148.82 43.2 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 171.358 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -96.22 155.52 16.73 Favored 'General case' 0 C--O 1.244 0.789 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 167.721 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.441 HG11 ' HG ' ' A' ' 62' ' ' LEU . 29.3 t -137.54 103.62 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 177.512 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.3 p -98.64 134.81 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 171.616 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 47.6 mt -142.48 134.15 25.49 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 N-CA-C 104.213 -2.514 . . . . 0.0 104.213 -179.659 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 21.1 m-70 -113.93 159.09 20.27 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.762 1.625 . . . . 0.0 110.171 -174.65 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.445 ' HG2' ' CE1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -151.86 175.69 12.21 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 120.334 -1.479 . . . . 0.0 110.863 178.708 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -66.09 161.93 20.69 Favored 'General case' 0 C--O 1.231 0.123 0 C-N-CA 123.426 0.69 . . . . 0.0 109.849 161.458 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -58.11 -50.0 75.0 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 125.863 1.665 . . . . 0.0 111.302 178.27 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 30.5 t30 -76.48 -21.96 55.16 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.247 1.019 . . . . 0.0 112.621 -173.339 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -66.96 174.23 3.16 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.377 1.071 . . . . 0.0 109.162 173.513 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -152.69 46.1 0.58 Allowed Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 124.711 1.148 . . . . 0.0 111.489 -178.404 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.445 ' CE1' ' HG2' ' A' ' 18' ' ' ARG . 22.3 m-85 50.32 -174.02 0.02 OUTLIER 'General case' 0 N--CA 1.432 -1.345 0 C-N-CA 129.767 3.227 . . . . 0.0 110.753 -174.845 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.422 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -132.38 45.49 1.12 Allowed Glycine 0 C--O 1.224 -0.482 0 O-C-N 121.353 -0.842 . . . . 0.0 111.97 -176.617 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -137.96 153.48 49.45 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 124.224 1.01 . . . . 0.0 108.698 -178.75 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.71 123.13 25.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 -176.68 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.21 151.2 3.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 171.218 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 46.2 pt . . . . . 0 N--CA 1.45 -0.466 0 C-N-CA 125.238 1.415 . . . . 0.0 108.137 168.704 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo . . . . . 0 N--CA 1.45 -1.037 0 N-CA-C 108.408 -1.42 . . . . 0.0 108.408 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.0 m170 -61.3 114.24 3.07 Favored 'General case' 0 N--CA 1.446 -0.656 0 C-N-CA 125.595 1.558 . . . . 0.0 111.621 -171.287 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -148.85 154.83 40.05 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 165.491 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.501 HD11 HD11 ' A' ' 68' ' ' ILE . 36.3 mm -60.96 129.16 23.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 123.134 0.574 . . . . 0.0 109.686 -178.29 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -100.22 -36.22 4.21 Favored Glycine 0 CA--C 1.529 0.963 0 C-N-CA 126.278 1.894 . . . . 0.0 112.693 172.53 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 6.9 ttm180 -149.04 151.77 35.07 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 118.437 1.118 . . . . 0.0 108.723 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 11.1 mt -126.86 139.56 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 125.787 1.635 . . . . 0.0 106.709 165.537 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -82.07 121.77 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 C-N-CA 126.653 1.981 . . . . 0.0 107.829 -178.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -51.46 128.29 22.37 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 124.956 1.302 . . . . 0.0 109.655 173.474 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 95.01 -12.32 68.57 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 125.449 1.5 . . . . 0.0 112.945 174.022 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.422 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 59.0 p -69.68 163.07 62.97 Favored Pre-proline 0 CA--C 1.53 0.205 0 CA-C-N 118.98 1.39 . . . . 0.0 113.177 -172.445 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -56.96 -34.81 98.18 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.27 1.98 . . . . 0.0 111.811 165.418 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.44 -49.24 78.34 Favored 'General case' 0 C--N 1.344 0.333 0 CA-C-N 119.526 1.057 . . . . 0.0 110.529 175.133 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -62.17 -49.53 75.46 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 124.265 1.026 . . . . 0.0 111.348 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -53.59 -53.04 57.41 Favored 'General case' 0 C--N 1.343 0.303 0 C-N-CA 124.418 1.087 . . . . 0.0 110.318 178.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 62.5 m -64.73 -13.94 56.73 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 117.536 -1.221 . . . . 0.0 113.592 -170.894 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 51.89 11.71 0.16 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.577 2.351 . . . . 0.0 116.821 171.167 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.42 ' HB2' HG13 ' A' ' 14' ' ' VAL . 12.4 mtpt -99.37 -6.77 27.22 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 124.864 1.266 . . . . 0.0 112.03 178.524 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.441 ' HG ' HG11 ' A' ' 14' ' ' VAL . 93.7 mt -104.8 142.74 34.18 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 154.804 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 9.4 ptmt -140.81 169.57 17.38 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.492 1.517 . . . . 0.0 110.016 159.832 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.9 t -73.23 109.32 5.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 O-C-N 121.409 -0.807 . . . . 0.0 109.042 -173.297 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 120.04 -7.71 11.73 Favored Glycine 0 C--N 1.337 0.631 0 O-C-N 121.143 -0.973 . . . . 0.0 110.724 -171.244 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 -74.11 101.67 3.99 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 172.462 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 39.5 mtm-85 -50.76 121.38 5.81 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 128.04 2.536 . . . . 0.0 108.424 164.227 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.501 HD11 HD11 ' A' ' 47' ' ' ILE . 71.5 mt -105.23 106.85 21.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 104.938 -2.245 . . . . 0.0 104.938 174.653 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.658 HD21 HG13 ' A' ' 100' ' ' ILE . 0.3 OUTLIER -80.42 -26.57 38.38 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 122.94 0.496 . . . . 0.0 112.111 -179.117 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.48 155.47 30.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 125.109 1.363 . . . . 0.0 111.305 -166.191 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.6 HG23 HD13 ' A' ' 76' ' ' ILE . 46.8 t -140.24 132.09 32.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 N-CA-C 105.21 -2.145 . . . . 0.0 105.21 176.408 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 46.05 34.86 2.19 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.593 1.157 . . . . 0.0 112.472 175.211 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 55.94 26.23 47.63 Favored Glycine 0 CA--C 1.535 1.318 0 CA-C-O 118.491 -1.172 . . . . 0.0 114.257 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -121.93 104.7 9.72 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 127.341 2.257 . . . . 0.0 107.056 -175.66 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 54.5 p -65.08 103.14 0.71 Allowed 'General case' 0 CA--C 1.538 0.505 0 O-C-N 120.581 -1.324 . . . . 0.0 114.377 -154.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.6 HD13 HG23 ' A' ' 71' ' ' VAL . 11.3 pt -74.1 -5.07 6.25 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 C-N-CA 124.226 1.01 . . . . 0.0 113.385 -174.76 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 50.4 mm -71.4 -21.27 21.57 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 C-N-CA 124.871 1.269 . . . . 0.0 111.336 -178.75 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -118.28 -28.83 5.69 Favored 'General case' 0 N--CA 1.47 0.536 0 C-N-CA 124.888 1.275 . . . . 0.0 112.372 -176.58 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 9.3 mtp -60.02 151.75 64.04 Favored Pre-proline 0 C--O 1.24 0.558 0 CA-C-N 117.925 0.329 . . . . 0.0 111.398 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -67.11 148.69 81.58 Favored 'Trans proline' 0 N--CA 1.448 -1.166 0 C-N-CA 121.992 1.795 . . . . 0.0 110.282 168.403 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -60.51 -30.53 69.78 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -172.394 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -70.03 -35.04 74.02 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 123.692 0.797 . . . . 0.0 112.182 175.932 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -66.88 -45.19 78.86 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 109.225 -0.658 . . . . 0.0 109.225 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 32.5 mt -64.02 -40.75 90.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 125.555 1.542 . . . . 0.0 108.982 179.418 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.2 t -58.63 -51.02 76.87 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 O-C-N 121.169 -0.957 . . . . 0.0 109.611 173.506 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.99 -44.6 74.62 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 118.383 -0.818 . . . . 0.0 111.934 176.338 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.35 -46.67 69.61 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 127.157 2.183 . . . . 0.0 110.909 176.362 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 59.7 mt -70.1 -39.77 77.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -176.603 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.1 mtpp -63.35 -39.65 95.12 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 123.066 0.547 . . . . 0.0 110.799 178.008 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -85.84 7.61 23.3 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.253 1.821 . . . . 0.0 112.184 177.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -61.4 -20.21 62.79 Favored 'General case' 0 CA--C 1.535 0.401 0 O-C-N 120.885 -1.135 . . . . 0.0 113.41 -177.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 81.02 63.81 1.85 Allowed Glycine 0 C--N 1.334 0.447 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 175.468 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 31.4 mt 67.87 -46.96 0.51 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 129.052 2.941 . . . . 0.0 112.699 177.459 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.51 149.18 21.43 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 170.689 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.495 HG22 HD13 ' A' ' 97' ' ' LEU . 14.1 p -131.77 133.1 61.67 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 165.362 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.9 m -106.68 105.02 14.85 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.617 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' LEU . . . . . 0.495 HD13 HG22 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -90.41 160.9 15.82 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 175.856 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 51.7 ttp180 -113.66 133.26 55.42 Favored 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 106.355 -1.721 . . . . 0.0 106.355 166.069 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.4 pp -128.21 161.07 37.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 123.899 0.879 . . . . 0.0 109.605 176.029 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.658 HG13 HD21 ' A' ' 69' ' ' LEU . 51.0 mt . . . . . 0 CA--C 1.544 0.748 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 169.349 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 42.4 p . . . . . 0 N--CA 1.447 -0.616 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 57.8 m -126.55 152.83 46.03 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 124.362 1.065 . . . . 0.0 109.112 173.562 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -108.38 103.73 12.94 Favored 'General case' 0 C--O 1.233 0.204 0 C-N-CA 126.235 1.814 . . . . 0.0 106.22 -178.132 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -88.07 95.2 5.04 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.8 p -78.02 138.08 20.98 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 CA-C-O 121.372 0.606 . . . . 0.0 109.423 171.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 41.2 mt -134.38 142.06 41.84 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 N-CA-C 105.796 -1.927 . . . . 0.0 105.796 173.086 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.2 m-70 -115.77 137.16 52.36 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.711 1.204 . . . . 0.0 109.19 177.487 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 16.8 ptt180 -118.4 175.65 5.61 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.118 0.872 . . . . 0.0 109.519 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.33 163.9 12.88 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 169.542 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -71.77 -38.6 70.31 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -173.584 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 54.5 t30 -77.01 18.89 0.33 Allowed 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.785 0.834 . . . . 0.0 112.036 -174.069 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -161.2 -169.84 2.47 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 120.005 -1.684 . . . . 0.0 111.108 -168.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -121.21 -169.71 13.81 Favored Glycine 0 CA--C 1.521 0.429 0 C-N-CA 126.274 1.892 . . . . 0.0 110.867 -174.212 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 84.2 m-85 -85.97 -110.52 0.05 OUTLIER 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 106.117 -1.808 . . . . 0.0 106.117 165.451 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 152.7 59.04 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.392 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 177.058 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -141.69 133.55 27.33 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 178.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.2 t -113.96 113.53 44.13 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 -172.49 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 26.7 mt -74.06 131.0 35.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 173.364 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.409 HD11 ' HE3' ' A' ' 46' ' ' LYS . 14.8 pt . . . . . 0 N--CA 1.451 -0.386 0 C-N-CA 125.513 1.525 . . . . 0.0 109.822 172.186 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo . . . . . 0 N--CA 1.456 -0.723 0 CA-C-O 117.661 -1.058 . . . . 0.0 113.802 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.485 ' CD2' HD12 ' A' ' 76' ' ' ILE . 0.6 OUTLIER -139.02 119.31 13.67 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 120.831 1.65 . . . . 0.0 110.157 174.75 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.409 ' HE3' HD11 ' A' ' 29' ' ' ILE . 45.4 pttt -143.65 163.99 31.67 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 168.283 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.8 mm -63.1 125.37 19.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 165.548 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.83 -24.05 5.37 Favored Glycine 0 CA--C 1.527 0.799 0 CA-C-O 118.828 -0.985 . . . . 0.0 113.469 172.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -154.09 147.52 25.0 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 176.76 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 5.4 mt -128.37 149.49 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 168.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -78.13 117.38 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 C-N-CA 125.714 1.606 . . . . 0.0 107.105 174.078 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -52.72 105.08 0.11 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.123 2.169 . . . . 0.0 109.256 176.582 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 95.02 7.92 59.37 Favored Glycine 0 CA--C 1.526 0.753 0 C-N-CA 124.569 1.081 . . . . 0.0 114.065 177.361 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 33.9 p -64.38 166.24 11.72 Favored Pre-proline 0 CA--C 1.531 0.242 0 CA-C-N 119.495 1.647 . . . . 0.0 109.802 164.099 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -58.86 -24.3 71.59 Favored 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 121.728 1.618 . . . . 0.0 112.849 170.095 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.03 -60.6 3.52 Favored 'General case' 0 C--N 1.341 0.201 0 CA-C-N 119.277 0.944 . . . . 0.0 108.671 173.103 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -65.69 -42.5 91.14 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.833 0.349 . . . . 0.0 111.048 -176.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -69.96 -22.85 63.13 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 118.442 -0.79 . . . . 0.0 112.501 -174.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 2.0 p -73.84 -16.7 61.13 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 117.618 -1.182 . . . . 0.0 110.976 173.513 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 40.08 66.23 0.63 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.324 1.849 . . . . 0.0 110.633 -173.168 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 33.4 mtmm -139.28 -44.89 0.46 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 124.923 1.289 . . . . 0.0 108.883 170.156 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 22.5 tp -94.02 121.62 35.69 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 -177.179 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.7 mmtt -132.85 162.84 30.48 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 123.394 1.569 . . . . 0.0 110.615 -176.138 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.4 t -62.77 123.77 16.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 172.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 122.11 -24.96 6.86 Favored Glycine 0 N--CA 1.447 -0.585 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -175.277 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -79.22 99.22 6.93 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-O 123.282 1.515 . . . . 0.0 109.416 -167.817 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 39.4 mtm180 -46.39 137.02 6.81 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 129.119 2.967 . . . . 0.0 110.106 162.737 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 16.0 mt -119.01 144.65 26.72 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 -174.256 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.523 HD11 HG13 ' A' ' 100' ' ' ILE . 6.1 mp -117.54 -47.22 2.64 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 125.246 1.418 . . . . 0.0 111.214 -176.416 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -150.04 169.61 20.83 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.084 0.954 . . . . 0.0 109.368 -175.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.6 p -138.89 123.39 20.88 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.299 0 C-N-CA 125.14 1.376 . . . . 0.0 108.197 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 51.39 31.05 6.74 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 123.616 0.767 . . . . 0.0 112.417 -173.737 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.26 6.75 89.07 Favored Glycine 0 CA--C 1.532 1.117 0 CA-C-O 118.37 -1.239 . . . . 0.0 114.204 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -102.46 135.3 44.32 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 119.963 1.882 . . . . 0.0 109.896 177.651 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -54.43 129.16 34.81 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 123.087 0.555 . . . . 0.0 110.282 168.828 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.485 HD12 ' CD2' ' A' ' 45' ' ' HIS . 25.8 pt -91.16 -17.79 7.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.716 1.206 . . . . 0.0 110.332 164.914 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 81.2 mt -68.02 136.26 26.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.712 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 82.49 -30.9 0.09 Allowed 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 130.572 3.549 . . . . 0.0 112.847 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 6.3 mtp -64.8 154.07 86.52 Favored Pre-proline 0 CA--C 1.541 0.597 0 CA-C-N 119.298 0.954 . . . . 0.0 111.332 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -76.9 152.1 31.84 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.49 2.127 . . . . 0.0 109.951 173.58 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -51.97 -42.38 62.86 Favored 'General case' 0 C--O 1.222 -0.345 0 C-N-CA 123.742 0.817 . . . . 0.0 111.657 -176.611 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.0 -41.83 75.46 Favored 'General case' 0 C--N 1.338 0.072 0 CA-C-O 118.356 -0.831 . . . . 0.0 112.855 178.825 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.9 -30.38 40.1 Favored 'General case' 0 C--O 1.225 -0.231 0 CA-C-N 118.898 0.772 . . . . 0.0 110.927 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 13.3 mt -69.03 -42.15 81.93 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 C-N-CA 124.455 1.102 . . . . 0.0 108.835 171.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 2.5 t -54.54 -46.4 71.73 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 O-C-N 120.542 -1.349 . . . . 0.0 108.932 170.511 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 9.7 tptt -62.14 -43.51 98.67 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-O 117.033 -1.461 . . . . 0.0 111.903 175.079 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.05 -37.78 80.85 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 121.121 1.782 . . . . 0.0 110.567 -177.361 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 43.0 mt -69.7 -49.58 57.04 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 177.298 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.1 tttp -54.22 -49.14 70.13 Favored 'General case' 0 C--N 1.345 0.371 0 C-N-CA 123.56 0.744 . . . . 0.0 110.234 178.418 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -65.89 -17.42 64.64 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 127.384 2.274 . . . . 0.0 112.362 -177.626 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -67.29 -9.43 40.75 Favored 'General case' 0 CA--C 1.548 0.895 0 CA-C-N 119.384 0.993 . . . . 0.0 112.891 176.948 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.23 -89.12 0.72 Allowed Glycine 0 C--N 1.34 0.779 0 C-N-CA 125.134 1.35 . . . . 0.0 112.262 167.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 78.4 mt -132.03 -27.3 1.85 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 126.47 1.908 . . . . 0.0 110.28 173.644 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.55 152.29 19.7 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 105.632 -1.988 . . . . 0.0 105.632 174.091 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.7 p -150.75 147.07 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 N-CA-C 105.126 -2.175 . . . . 0.0 105.126 161.104 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 20.6 m -126.08 103.09 7.53 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -175.254 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 18.8 mt -90.77 123.05 34.03 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 124.762 1.225 . . . . 0.0 108.444 -176.329 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 13.7 ttm180 -83.88 131.42 34.87 Favored 'General case' 0 C--O 1.237 0.431 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 176.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -126.97 159.69 36.6 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 C-N-CA 125.661 1.584 . . . . 0.0 110.581 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.523 HG13 HD11 ' A' ' 69' ' ' LEU . 9.2 mt . . . . . 0 N--CA 1.478 0.94 0 C-N-CA 124.841 1.256 . . . . 0.0 110.842 175.709 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 33.5 p . . . . . 0 N--CA 1.448 -0.536 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.9 m -111.23 156.62 21.18 Favored 'General case' 0 C--O 1.235 0.325 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 168.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -120.85 103.54 9.16 Favored 'General case' 0 CA--C 1.511 -0.536 0 N-CA-C 104.029 -2.582 . . . . 0.0 104.029 172.401 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.467 HG11 ' HB2' ' A' ' 62' ' ' LEU . 59.6 t -91.63 95.03 5.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 105.458 -2.053 . . . . 0.0 105.458 -177.713 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.4 p -85.47 124.84 40.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 169.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 13.3 mt -116.97 143.38 27.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 171.269 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.0 m-70 -121.68 143.76 49.16 Favored 'General case' 0 CA--C 1.536 0.404 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 175.445 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.405 ' NH1' ' CE2' ' A' ' 24' ' ' PHE . 3.0 ptt-85 -130.86 -175.48 3.68 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 119.797 1.18 . . . . 0.0 109.008 176.334 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.437 ' N ' ' HE3' ' A' ' 19' ' ' LYS . 0.2 OUTLIER -95.38 168.7 10.56 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 118.814 0.734 . . . . 0.0 109.273 169.836 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -65.94 -20.67 66.29 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.078 0.951 . . . . 0.0 112.544 170.679 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -123.18 65.67 0.99 Allowed 'General case' 0 C--O 1.234 0.265 0 C-N-CA 124.454 1.101 . . . . 0.0 108.133 -177.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -172.6 179.45 2.44 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 128.38 2.672 . . . . 0.0 107.227 163.164 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.67 176.12 23.84 Favored Glycine 0 CA--C 1.526 0.734 0 C-N-CA 124.432 1.015 . . . . 0.0 110.976 173.548 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' PHE . . . . . 0.405 ' CE2' ' NH1' ' A' ' 18' ' ' ARG . 40.5 m-85 -84.7 170.68 13.04 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 150.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.45 55.6 0.65 Allowed Glycine 0 C--O 1.224 -0.529 0 O-C-N 120.727 -1.233 . . . . 0.0 111.537 -175.138 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.4 p90 -130.12 121.89 27.21 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 117.981 0.89 . . . . 0.0 108.924 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.6 t -96.25 101.04 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 -175.38 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.567 HD12 ' H ' ' A' ' 28' ' ' ILE . 3.5 mp -74.27 118.87 20.57 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 170.436 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.457 HD11 ' HE3' ' A' ' 46' ' ' LYS . 24.5 pt . . . . . 0 CA--C 1.536 0.438 0 C-N-CA 124.355 1.062 . . . . 0.0 109.281 176.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo . . . . . 0 N--CA 1.456 -0.728 0 N-CA-C 109.818 -0.878 . . . . 0.0 109.818 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.2 m80 -63.68 123.71 19.55 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 118.785 0.72 . . . . 0.0 109.869 -177.599 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' LYS . . . . . 0.457 ' HE3' HD11 ' A' ' 29' ' ' ILE . 49.8 pttt -143.67 153.29 42.33 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 107.883 -1.155 . . . . 0.0 107.883 171.086 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ILE . . . . . 0.407 HD13 HD11 ' A' ' 68' ' ' ILE . 32.7 mm -66.69 124.12 21.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 167.57 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -101.97 -30.88 5.59 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 124.246 0.927 . . . . 0.0 112.611 175.199 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 22.7 ttm180 -154.65 158.41 39.63 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 118.847 1.323 . . . . 0.0 107.564 176.014 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 24.5 mt -130.77 135.28 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 170.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.4 mp -68.81 124.96 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.396 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 32.2 t0 -51.96 133.55 32.45 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.375 1.07 . . . . 0.0 109.97 178.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.08 1.0 38.41 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 118.98 -0.9 . . . . 0.0 114.412 174.493 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 61.4 p -64.62 162.7 33.05 Favored Pre-proline 0 CA--C 1.53 0.189 0 CA-C-N 119.483 1.641 . . . . 0.0 109.504 171.394 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -55.76 -18.17 20.42 Favored 'Trans proline' 0 CA--C 1.534 0.488 0 C-N-CA 122.959 2.439 . . . . 0.0 114.028 175.244 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.59 -69.79 0.27 Allowed 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 169.112 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -66.43 -31.88 72.91 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 118.14 0.427 . . . . 0.0 111.655 -173.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.92 -22.92 67.11 Favored 'General case' 0 C--O 1.234 0.247 0 O-C-N 121.351 -0.843 . . . . 0.0 112.508 175.389 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 7.8 t -80.85 -9.51 59.81 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 119.338 0.972 . . . . 0.0 111.475 173.803 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 55.92 5.13 0.14 Allowed 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 128.841 2.856 . . . . 0.0 115.724 173.777 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.9 -49.64 6.96 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 119.796 1.18 . . . . 0.0 110.424 177.39 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' LEU . . . . . 0.467 ' HB2' HG11 ' A' ' 14' ' ' VAL . 14.8 tp -93.85 129.36 40.28 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 123.5 0.72 . . . . 0.0 109.414 -166.044 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.7 mptt -122.99 169.97 10.62 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 125.451 1.5 . . . . 0.0 110.438 170.291 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -58.4 148.47 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 C-N-CA 124.367 1.067 . . . . 0.0 109.798 165.696 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.24 -7.73 80.67 Favored Glycine 0 CA--C 1.524 0.635 0 C-N-CA 125.301 1.429 . . . . 0.0 110.682 -175.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -71.17 88.92 0.83 Allowed 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 172.351 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.1 mtm180 -38.21 121.02 0.94 Allowed 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 128.448 2.699 . . . . 0.0 110.314 159.436 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ILE . . . . . 0.407 HD11 HD13 ' A' ' 47' ' ' ILE . 14.3 mt -101.22 118.83 48.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 -178.697 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 88.1 mt -72.0 -52.52 16.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 124.684 1.194 . . . . 0.0 109.959 168.409 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -150.83 166.24 31.13 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 124.059 0.944 . . . . 0.0 111.951 -162.32 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 37.2 t -126.26 119.84 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 174.45 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.561 HD21 ' HB2' ' A' ' 91' ' ' ALA . 67.7 m-20 54.51 10.01 0.3 Allowed 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 128.918 2.887 . . . . 0.0 114.477 176.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 114.01 -0.26 24.16 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 126.721 2.105 . . . . 0.0 113.909 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 9.8 mm-40 -105.07 145.22 30.8 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 125.422 1.489 . . . . 0.0 109.243 -176.047 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.8 p -84.09 99.26 10.36 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 124.73 1.212 . . . . 0.0 111.63 -167.83 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 7.1 pt -79.76 -2.84 5.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 C-N-CA 123.904 0.882 . . . . 0.0 112.106 -177.258 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.731 ' H ' HD12 ' A' ' 77' ' ' ILE . 3.3 mp -61.85 -33.29 57.19 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 125.223 1.409 . . . . 0.0 110.383 174.31 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -107.7 -44.12 4.33 Favored 'General case' 0 C--O 1.233 0.215 0 C-N-CA 123.049 0.539 . . . . 0.0 111.217 -166.483 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 5.6 mtp -58.77 153.4 42.54 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 124.329 1.052 . . . . 0.0 111.328 -168.226 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.75 146.27 97.6 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.187 1.258 . . . . 0.0 109.276 167.649 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -52.09 -41.28 62.29 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 124.346 1.058 . . . . 0.0 110.028 -178.064 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -59.93 -35.57 75.19 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 114.24 1.2 . . . . 0.0 114.24 177.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.01 -44.86 79.23 Favored 'General case' 0 N--CA 1.463 0.189 0 C-N-CA 123.727 0.811 . . . . 0.0 108.887 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 24.0 mt -69.37 -37.99 76.47 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 C-N-CA 125.967 1.707 . . . . 0.0 109.261 -178.863 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 4.8 t -56.46 -49.06 78.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 O-C-N 121.127 -0.983 . . . . 0.0 109.427 169.263 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 11.4 ttpt -66.88 -36.48 82.41 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-O 118.742 -0.647 . . . . 0.0 111.258 -177.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -57.09 -44.38 83.11 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 125.4 1.48 . . . . 0.0 111.057 174.29 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 91.1 mt -67.86 -40.99 84.54 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-N 119.371 0.987 . . . . 0.0 108.813 178.22 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.0 tttt -60.08 -48.76 80.38 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 118.819 0.736 . . . . 0.0 109.942 176.146 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -70.31 -12.28 61.48 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 124.642 1.177 . . . . 0.0 111.268 -178.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.561 ' HB2' HD21 ' A' ' 72' ' ' ASN . . . -62.9 -14.99 53.25 Favored 'General case' 0 CA--C 1.545 0.757 0 CA-C-N 119.679 1.127 . . . . 0.0 112.347 168.426 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.28 -132.25 11.16 Favored Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 176.093 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 5.7 mt -90.7 -10.24 43.83 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 118.878 -0.582 . . . . 0.0 110.336 173.682 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 26.7 p -93.42 162.3 14.04 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 168.476 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.6 p -156.68 136.6 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.888 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 159.018 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.1 m -117.34 104.75 11.44 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 -177.838 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 56.9 mt -90.02 164.55 14.48 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 177.33 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 22.6 ttt180 -127.93 118.74 24.16 Favored 'General case' 0 CA--C 1.513 -0.456 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 173.68 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pp -129.51 169.2 21.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 C-N-CA 123.952 0.901 . . . . 0.0 109.294 -176.051 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.0 mp . . . . . 0 CA--C 1.54 0.585 0 C-N-CA 124.205 1.002 . . . . 0.0 109.361 -177.251 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.6 p . . . . . 0 CA--C 1.54 0.581 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 37.3 m -126.6 164.41 21.3 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.875 1.67 . . . . 0.0 109.415 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 18.4 p-10 -128.86 95.12 4.0 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 127.15 2.18 . . . . 0.0 108.057 177.871 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.0 t -89.47 102.9 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 105.798 -1.927 . . . . 0.0 105.798 174.321 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.2 t -106.68 111.47 35.6 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -177.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 12.1 mt -108.83 136.55 44.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 N-CA-C 106.126 -1.805 . . . . 0.0 106.126 -178.72 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -119.87 114.15 21.66 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 126.465 1.906 . . . . 0.0 105.989 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 28.4 ptt180 -95.0 174.99 6.81 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 119.606 1.094 . . . . 0.0 109.116 176.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -82.97 171.13 14.16 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 166.931 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -75.57 -9.85 58.93 Favored 'General case' 0 N--CA 1.469 0.489 0 O-C-N 120.355 -1.466 . . . . 0.0 112.805 175.373 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 40.3 t30 -98.98 -27.38 13.89 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 115.119 1.526 . . . . 0.0 115.119 -160.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -114.37 -122.1 0.29 Allowed 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.235 1.414 . . . . 0.0 108.768 -167.36 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -154.49 -178.34 28.76 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 167.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -72.97 170.82 14.02 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 151.41 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -135.2 62.07 0.62 Allowed Glycine 0 C--O 1.22 -0.749 0 CA-C-O 118.27 -1.294 . . . . 0.0 111.591 -176.185 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.2 p90 -146.12 139.96 26.35 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 119.281 1.541 . . . . 0.0 109.033 178.491 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.848 HG12 ' H ' ' A' ' 49' ' ' ARG . 0.8 OUTLIER -110.08 154.78 11.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 171.798 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -128.79 118.75 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 -178.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 26.1 pt . . . . . 0 N--CA 1.45 -0.445 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -179.034 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo . . . . . 0 N--CA 1.453 -0.865 0 N-CA-C 108.475 -1.394 . . . . 0.0 108.475 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -72.58 120.9 18.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.138 0.975 . . . . 0.0 110.559 -174.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 45.3 pttt -137.31 154.93 49.97 Favored 'General case' 0 C--O 1.236 0.371 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 168.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 5.0 mm -60.79 127.29 20.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 166.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -88.51 -69.75 1.27 Allowed Glycine 0 CA--C 1.527 0.806 0 O-C-N 124.495 1.122 . . . . 0.0 110.627 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ARG . . . . . 0.848 ' H ' HG12 ' A' ' 27' ' ' VAL . 31.4 ttm180 -127.6 153.28 46.6 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 128.751 2.821 . . . . 0.0 107.407 -178.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 12.5 mt -119.27 142.68 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 166.785 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 50.4 mm -73.05 122.59 26.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.16 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -60.45 137.17 58.19 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 178.443 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.82 -5.23 54.08 Favored Glycine 0 CA--C 1.531 1.058 0 C-N-CA 126.08 1.8 . . . . 0.0 114.495 -178.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' SER . . . . . 0.434 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 83.7 p -68.62 167.65 18.22 Favored Pre-proline 0 C--O 1.234 0.283 0 CA-C-N 119.332 1.566 . . . . 0.0 112.472 -176.224 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 18.0 Cg_endo -58.23 -29.26 87.1 Favored 'Trans proline' 0 N--CA 1.451 -0.994 0 C-N-CA 122.165 1.91 . . . . 0.0 112.458 166.464 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.85 -53.94 46.45 Favored 'General case' 0 C--N 1.345 0.398 0 CA-C-N 119.814 1.188 . . . . 0.0 109.71 177.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -66.21 -45.89 79.14 Favored 'General case' 0 N--CA 1.463 0.187 0 O-C-N 123.135 0.272 . . . . 0.0 110.525 -178.814 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -72.45 -22.58 61.06 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 113.237 0.829 . . . . 0.0 113.237 -173.463 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 24.3 m -61.2 -18.09 56.46 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 119.967 1.258 . . . . 0.0 111.519 165.396 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 65.16 -25.15 0.09 Allowed 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 130.218 3.407 . . . . 0.0 114.951 171.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 1.9 mtpp -73.54 -8.53 56.31 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 124.955 1.302 . . . . 0.0 112.137 174.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -107.93 125.26 51.28 Favored 'General case' 0 C--N 1.343 0.301 0 CA-C-N 119.645 1.112 . . . . 0.0 108.328 173.262 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 40.5 mttp -135.76 166.41 23.35 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 126.188 1.795 . . . . 0.0 109.115 172.773 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 71.7 t -64.76 152.7 8.52 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 C-N-CA 123.515 0.726 . . . . 0.0 109.118 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 67.43 43.72 86.36 Favored Glycine 0 CA--C 1.528 0.903 0 CA-C-O 122.047 0.804 . . . . 0.0 112.221 174.564 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.8 p-10 -78.46 -20.99 49.76 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 125.782 1.633 . . . . 0.0 115.135 -173.272 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 18.4 mtm180 44.84 90.96 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 128.752 2.821 . . . . 0.0 111.516 -160.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 24.2 mt -68.48 150.21 10.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.343 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -116.56 -50.98 2.61 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.413 2.285 . . . . 0.0 108.898 177.186 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -151.91 169.97 20.99 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 124.179 0.991 . . . . 0.0 111.603 -176.831 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.0 p -128.88 118.89 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 124.371 1.068 . . . . 0.0 109.291 175.628 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 39.05 47.06 1.23 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.413 1.485 . . . . 0.0 110.494 -169.198 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.16 -3.72 51.05 Favored Glycine 0 CA--C 1.53 1.01 0 C-N-CA 125.952 1.739 . . . . 0.0 115.977 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -82.21 141.84 32.66 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 120.829 2.314 . . . . 0.0 108.578 -178.624 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.7 p -90.02 90.66 8.24 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-O 122.675 1.226 . . . . 0.0 110.374 -171.562 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 13.3 pt -65.39 -3.16 1.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.814 0 C-N-CA 126.833 2.053 . . . . 0.0 113.622 -177.224 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 26.1 mm -57.48 -58.13 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 126.799 2.04 . . . . 0.0 109.591 175.274 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -113.8 -22.96 9.91 Favored 'General case' 0 C--O 1.231 0.114 0 O-C-N 123.596 0.56 . . . . 0.0 112.029 -161.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.5 ttt -56.18 142.24 67.29 Favored Pre-proline 0 N--CA 1.437 -1.083 0 C-N-CA 126.292 1.837 . . . . 0.0 109.463 166.47 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -75.35 153.09 39.88 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 121.259 1.306 . . . . 0.0 111.169 -179.134 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 32.9 t60 -58.19 -41.23 83.51 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.255 0.622 . . . . 0.0 112.015 -170.038 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.68 -32.1 73.12 Favored 'General case' 0 C--O 1.227 -0.101 0 CA-C-O 118.879 -0.582 . . . . 0.0 112.41 178.716 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 53.5 m-20 -75.8 -42.04 51.12 Favored 'General case' 0 C--O 1.225 -0.221 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 32.8 mt -60.54 -40.26 83.85 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 124.643 1.177 . . . . 0.0 109.72 173.783 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 19.2 t -68.03 -35.88 73.41 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 O-C-N 120.198 -1.564 . . . . 0.0 110.902 175.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -62.38 -48.67 78.7 Favored 'General case' 0 C--O 1.22 -0.459 0 O-C-N 121.506 -0.746 . . . . 0.0 110.498 171.106 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.88 -35.39 66.45 Favored 'General case' 0 N--CA 1.44 -0.928 0 C-N-CA 126.505 1.922 . . . . 0.0 111.981 -176.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 76.0 mt -69.77 -52.58 30.25 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 176.225 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 6.8 tttp -54.51 -44.33 72.63 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 122.924 0.49 . . . . 0.0 111.172 177.613 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -71.95 -19.43 61.9 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.182 1.793 . . . . 0.0 110.984 -178.112 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.97 -35.38 80.44 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 119.525 1.057 . . . . 0.0 109.447 169.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 86.13 -117.03 4.5 Favored Glycine 0 N--CA 1.449 -0.497 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 172.542 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 39.6 mt -76.48 -49.27 17.0 Favored 'General case' 0 CA--C 1.501 -0.912 0 CA-C-N 118.367 1.083 . . . . 0.0 108.838 -173.636 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.89 145.81 24.36 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 124.229 0.955 . . . . 0.0 108.638 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.9 p -146.39 139.5 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 167.623 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 47.1 m -106.07 105.5 15.56 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 125.584 1.554 . . . . 0.0 107.197 176.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 40.7 mt -90.81 127.12 36.24 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.784 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.418 HH11 ' HB2' ' A' ' 98' ' ' ARG . 6.4 ttm105 -103.53 111.7 24.28 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.2 pp -121.53 174.61 5.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 C-N-CA 126.048 1.739 . . . . 0.0 108.312 -175.224 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 8.5 mt . . . . . 0 CA--C 1.54 0.586 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -179.107 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.53 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 67.3 m -50.11 134.2 22.39 Favored 'General case' 0 C--O 1.237 0.419 0 C-N-CA 124.553 1.141 . . . . 0.0 113.157 -178.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 p -62.79 148.47 46.8 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 149.157 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 125.31 -171.78 17.28 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 124.049 0.833 . . . . 0.0 111.626 178.024 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 83.2 p -144.42 -164.46 1.91 Allowed 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.943 1.297 . . . . 0.0 109.287 177.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.1 m -84.75 -6.06 59.34 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.391 0.677 . . . . 0.0 112.466 -176.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 78.9 79.57 0.79 Allowed Glycine 0 C--N 1.335 0.484 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 -179.613 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 18.7 m -130.33 167.52 18.38 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.392 1.877 . . . . 0.0 108.038 177.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.5 mp -61.48 146.56 48.13 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.17 164.42 16.24 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 124.32 1.048 . . . . 0.0 108.953 -174.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.2 p -141.75 163.84 31.83 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.787 1.235 . . . . 0.0 109.613 -172.352 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 13.0 m -140.83 164.74 29.41 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.514 1.126 . . . . 0.0 109.071 171.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 25.6 p-10 -128.71 94.45 3.86 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 127.601 2.36 . . . . 0.0 108.901 -173.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.452 HG11 ' HB2' ' A' ' 62' ' ' LEU . 24.3 t -90.64 106.94 17.93 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 176.615 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.7 t -85.5 142.72 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 166.343 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.0 mt -137.53 132.01 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.152 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 174.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 -115.04 141.35 48.11 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.715 1.606 . . . . 0.0 109.343 -175.053 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 30.9 ptt180 -139.88 -169.47 2.73 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 124.426 1.09 . . . . 0.0 110.474 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.67 169.12 10.38 Favored 'General case' 0 N--CA 1.463 0.222 0 C-N-CA 124.567 1.147 . . . . 0.0 109.439 168.143 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -69.89 -15.98 63.16 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 113.43 0.9 . . . . 0.0 113.43 -177.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -84.5 -7.07 59.4 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-O 118.477 -0.773 . . . . 0.0 112.896 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -136.32 172.34 13.16 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 119.649 1.113 . . . . 0.0 111.479 -166.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.74 166.45 26.36 Favored Glycine 0 C--N 1.333 0.413 0 C-N-CA 123.669 0.652 . . . . 0.0 111.927 -170.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -87.27 115.71 24.86 Favored 'General case' 0 N--CA 1.444 -0.726 0 N-CA-C 104.52 -2.4 . . . . 0.0 104.52 150.067 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -92.7 48.62 2.55 Favored Glycine 0 C--O 1.224 -0.482 0 CA-C-O 118.518 -1.157 . . . . 0.0 112.643 -168.437 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.433 ' CE2' HD11 ' A' ' 28' ' ' ILE . 19.9 p90 -126.92 160.08 32.06 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 118.76 1.28 . . . . 0.0 109.873 173.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.4 t -138.39 141.36 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 C-N-CA 126.519 1.927 . . . . 0.0 106.972 -179.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.433 HD11 ' CE2' ' A' ' 26' ' ' PHE . 4.4 mp -105.9 135.85 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.667 0 C-N-CA 125.817 1.647 . . . . 0.0 107.801 178.009 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.473 HD11 ' HE3' ' A' ' 46' ' ' LYS . 13.5 pt -125.96 -178.73 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 125.459 1.504 . . . . 0.0 110.314 175.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 t 67.35 178.71 0.23 Allowed 'General case' 0 C--O 1.239 0.542 0 C-N-CA 126.552 1.941 . . . . 0.0 109.926 -163.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.9 p -174.29 -57.01 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 127.643 2.377 . . . . 0.0 106.239 169.162 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.8 tp 34.3 62.72 0.46 Allowed 'General case' 0 C--N 1.342 0.254 0 C-N-CA 126.309 1.844 . . . . 0.0 110.304 -172.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -80.73 41.65 0.58 Allowed 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 121.425 0.631 . . . . 0.0 109.59 -175.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 8.2 tpt180 -122.23 104.99 37.28 Favored Pre-proline 0 N--CA 1.455 -0.212 0 C-N-CA 127.548 2.339 . . . . 0.0 105.498 -173.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -58.01 116.31 3.15 Favored 'Trans proline' 0 N--CA 1.449 -1.113 0 C-N-CA 123.344 2.696 . . . . 0.0 110.079 -177.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -93.04 128.69 39.02 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 124.625 1.17 . . . . 0.0 108.808 175.498 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.0 t -61.56 -41.51 97.48 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.458 1.103 . . . . 0.0 111.498 178.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.86 156.42 19.27 Favored Glycine 0 CA--C 1.525 0.677 0 CA-C-N 119.034 0.834 . . . . 0.0 111.486 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 69.9 m -70.18 102.83 2.18 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 172.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -85.85 162.71 18.51 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 125.308 1.443 . . . . 0.0 107.463 158.782 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.6 pt -93.51 86.29 2.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 170.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.0 t -133.33 151.79 51.89 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 124.792 1.237 . . . . 0.0 107.702 -174.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.7 p -127.51 142.49 44.23 Favored Pre-proline 0 C--O 1.238 0.465 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 173.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.3 -29.73 9.21 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 C-N-CA 121.275 1.316 . . . . 0.0 111.696 169.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -138.48 125.35 21.11 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 119.73 1.15 . . . . 0.0 110.746 -170.441 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.473 ' HE3' HD11 ' A' ' 29' ' ' ILE . 48.2 pttt -146.64 162.94 37.38 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 124.407 1.083 . . . . 0.0 108.783 166.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 46.4 mm -65.31 130.61 30.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 170.551 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.42 -49.66 0.65 Allowed Glycine 0 C--N 1.336 0.56 0 C-N-CA 125.254 1.407 . . . . 0.0 112.492 175.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -129.24 150.63 50.54 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 119.433 1.617 . . . . 0.0 108.373 176.478 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 11.5 mt -128.93 133.31 66.35 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 167.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -60.14 126.37 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.605 0 C-N-CA 125.191 1.396 . . . . 0.0 108.018 169.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.29 121.13 9.43 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 124.483 1.113 . . . . 0.0 108.059 164.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.51 21.55 40.28 Favored Glycine 0 CA--C 1.526 0.778 0 CA-C-O 118.875 -0.958 . . . . 0.0 112.649 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 29.0 p -90.85 164.76 24.55 Favored Pre-proline 0 C--O 1.236 0.349 0 CA-C-N 119.651 1.725 . . . . 0.0 112.915 177.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -65.65 -21.77 58.66 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 121.695 1.597 . . . . 0.0 112.911 162.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.4 -56.36 16.9 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 119.199 0.909 . . . . 0.0 109.134 172.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -57.95 -48.48 79.83 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.597 0.759 . . . . 0.0 109.923 -177.355 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.3 mtt85 -71.9 -6.85 44.8 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 113.91 1.078 . . . . 0.0 113.91 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 36.1 t -62.29 -21.58 65.34 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 119.817 1.19 . . . . 0.0 109.646 167.74 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.69 26.23 11.04 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 125.736 1.614 . . . . 0.0 112.665 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.6 mtmm -126.96 -52.13 1.43 Allowed 'General case' 0 CA--C 1.521 -0.145 0 C-N-CA 126.583 1.953 . . . . 0.0 109.153 175.758 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.452 ' HB2' HG11 ' A' ' 14' ' ' VAL . 9.9 tp -92.85 118.77 31.48 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -161.441 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 71.4 mmtt -129.97 171.89 12.29 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 123.55 1.643 . . . . 0.0 109.332 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 94.8 t -64.89 122.9 16.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 113.807 -1.542 . . . . 0.0 107.626 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 128.31 -18.89 5.75 Favored Glycine 0 C--N 1.337 0.593 0 C-N-CA 125.02 1.295 . . . . 0.0 109.997 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -77.05 98.25 4.94 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 122.243 1.021 . . . . 0.0 109.196 -165.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 17.8 mtm180 -44.63 120.48 2.28 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 128.653 2.781 . . . . 0.0 110.572 164.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 45.5 mt -101.6 153.31 5.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 126.151 1.78 . . . . 0.0 107.432 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 tp -131.75 -44.89 0.97 Allowed 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.821 1.648 . . . . 0.0 110.589 -172.255 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -147.98 163.11 37.84 Favored 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 123.267 0.627 . . . . 0.0 110.423 176.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 67.2 t -133.0 118.04 31.54 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 -176.19 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 42.39 57.11 3.5 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.146 1.778 . . . . 0.0 109.529 -170.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 67.46 -4.12 4.1 Favored Glycine 0 CA--C 1.537 1.435 0 CA-C-O 117.679 -1.623 . . . . 0.0 116.026 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -90.17 130.89 36.26 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 121.398 2.599 . . . . 0.0 110.997 -178.471 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 70.3 m -73.61 94.33 2.16 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 124.013 0.925 . . . . 0.0 110.509 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.5 pp -60.77 10.96 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.632 0 C-N-CA 128.34 2.656 . . . . 0.0 115.133 177.3 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 52.5 mt -63.46 -79.41 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 C-N-CA 126.029 1.732 . . . . 0.0 108.729 -178.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 62.9 m-80 -79.95 -11.87 59.76 Favored 'General case' 0 N--CA 1.467 0.4 0 O-C-N 121.453 -0.779 . . . . 0.0 113.079 -174.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 16.6 mtp -60.0 140.39 90.48 Favored Pre-proline 0 C--O 1.237 0.401 0 CA-C-N 118.238 0.472 . . . . 0.0 110.172 -178.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -65.27 156.05 65.21 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 121.962 1.775 . . . . 0.0 109.355 169.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 55.9 t60 -57.31 -34.99 69.3 Favored 'General case' 0 C--O 1.224 -0.261 0 CA-C-O 119.003 -0.522 . . . . 0.0 110.701 173.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.74 -41.66 77.91 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-O 118.591 -0.718 . . . . 0.0 112.362 175.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.88 -45.45 82.03 Favored 'General case' 0 C--O 1.222 -0.388 0 CA-C-N 118.909 0.777 . . . . 0.0 109.415 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 67.9 mt -65.42 -44.26 94.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.481 0 C-N-CA 125.53 1.532 . . . . 0.0 109.21 -175.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 22.5 t -55.18 -47.98 76.84 Favored 'Isoleucine or valine' 0 C--O 1.24 0.585 0 C-N-CA 125.147 1.379 . . . . 0.0 109.629 170.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 24.9 mtpt -70.33 -28.11 64.89 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-O 117.134 -1.412 . . . . 0.0 113.526 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.85 -40.83 79.17 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.932 1.696 . . . . 0.0 110.481 177.07 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 81.8 mt -68.74 -46.81 78.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 178.419 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.1 tmtm? -63.34 -38.12 89.93 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-O 118.678 -0.677 . . . . 0.0 111.729 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -61.93 -32.02 72.38 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 124.169 0.988 . . . . 0.0 110.282 175.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -67.95 -12.18 60.23 Favored 'General case' 0 CA--C 1.543 0.689 0 CA-C-O 121.636 0.731 . . . . 0.0 112.3 175.096 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 66.13 -100.31 0.51 Allowed Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 125.674 1.607 . . . . 0.0 110.411 173.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 25.1 mt -105.34 -24.72 12.63 Favored 'General case' 0 CA--C 1.504 -0.792 0 CA-C-O 117.68 -1.153 . . . . 0.0 112.495 -176.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.28 121.06 40.11 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 118.678 0.672 . . . . 0.0 109.495 178.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.3 p -125.68 148.48 30.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -176.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -116.28 117.29 29.58 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 124.656 1.183 . . . . 0.0 108.068 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 57.4 mt -98.99 112.64 24.7 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 171.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.3 ttm180 -81.47 112.56 18.83 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 166.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.9 pp -116.72 166.51 10.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 C-N-CA 124.951 1.301 . . . . 0.0 108.618 -178.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.5 mt -105.07 117.15 59.29 Favored Pre-proline 0 N--CA 1.464 0.26 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 174.219 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.39 -172.85 1.57 Allowed 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.988 3.125 . . . . 0.0 109.22 174.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -154.28 162.28 41.27 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.529 -0.732 . . . . 0.0 109.707 179.217 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -127.9 -1.18 5.95 Favored 'General case' 0 CA--C 1.537 0.447 0 N-CA-C 112.876 0.695 . . . . 0.0 112.876 165.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -106.89 5.56 28.49 Favored 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 125.949 1.699 . . . . 0.0 111.917 -163.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -75.09 143.48 43.38 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 124.756 1.222 . . . . 0.0 108.131 172.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -149.58 170.95 17.47 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 127.943 2.497 . . . . 0.0 105.567 165.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -50.55 108.16 0.97 Allowed Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 119.817 1.19 . . . . 0.0 113.076 -171.498 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -67.18 -50.74 0.93 Allowed 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 121.77 1.646 . . . . 0.0 110.429 179.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 8.6 m 53.1 176.47 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 125.265 1.426 . . . . 0.0 113.003 -167.407 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 159.85 173.32 28.18 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 107.936 -2.066 . . . . 0.0 107.936 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -78.39 56.81 5.98 Favored 'Trans proline' 0 CA--C 1.542 0.917 0 C-N-CA 123.223 2.615 . . . . 0.0 110.002 175.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.1 t -156.76 -178.86 7.67 Favored 'General case' 0 C--O 1.238 0.486 0 C-N-CA 123.768 0.827 . . . . 0.0 111.234 -177.554 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 2.4 p -139.72 31.82 2.04 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 127.028 2.131 . . . . 0.0 111.566 -168.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.185 0 N-CA-C 108.488 -1.845 . . . . 0.0 108.488 165.642 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.886 0 N-CA-C 108.295 -1.922 . . . . 0.0 108.295 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 11.7 t -131.04 158.17 41.06 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 124.846 1.258 . . . . 0.0 107.784 177.194 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.2 t -61.72 -60.02 4.3 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 123.488 0.715 . . . . 0.0 110.494 -177.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.78 -171.34 53.61 Favored Glycine 0 CA--C 1.53 1.016 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -169.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.6 t 55.52 -167.54 0.1 Allowed 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.782 1.633 . . . . 0.0 113.444 175.036 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -165.04 157.0 15.4 Favored 'General case' 0 C--O 1.239 0.52 0 C-N-CA 127.168 2.187 . . . . 0.0 106.226 160.683 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -176.82 33.64 0.08 OUTLIER Glycine 0 C--N 1.335 0.509 0 O-C-N 120.496 -1.378 . . . . 0.0 113.617 -178.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -76.71 -47.93 20.42 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 118.506 1.153 . . . . 0.0 111.915 -168.706 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 88.2 mt -100.56 110.59 22.76 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.939 1.296 . . . . 0.0 110.715 -168.217 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 25.8 mp0 -63.59 147.9 50.25 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.712 1.205 . . . . 0.0 110.602 173.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 36.9 p -145.49 154.0 41.75 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.214 1.406 . . . . 0.0 109.212 171.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.3 t -115.57 173.91 6.29 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.532 1.133 . . . . 0.0 109.592 163.191 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -134.85 94.68 3.2 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 126.624 1.97 . . . . 0.0 108.376 168.449 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.6 t -99.22 108.07 21.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 O-C-N 120.68 -1.262 . . . . 0.0 107.94 -170.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.5 p -105.48 121.04 57.15 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 CA-C-N 118.841 0.746 . . . . 0.0 111.315 -170.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.6 mt -134.13 129.21 53.61 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 126.089 1.756 . . . . 0.0 109.363 -169.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 37.8 m-70 -108.54 144.18 36.56 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.214 1.806 . . . . 0.0 111.443 -177.359 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.414 HH11 ' H ' ' A' ' 24' ' ' PHE . 18.4 ptt180 -126.51 175.59 7.79 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 125.511 1.525 . . . . 0.0 111.018 176.135 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.436 ' HE3' ' OE2' ' A' ' 22' ' ' GLU . 0.0 OUTLIER -81.05 170.06 16.69 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 160.007 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -68.98 -35.7 77.02 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.609 -0.682 . . . . 0.0 111.709 177.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 68.9 m-20 -71.27 -47.32 57.65 Favored 'General case' 0 C--O 1.232 0.15 0 O-C-N 122.196 -0.315 . . . . 0.0 111.354 -171.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.436 ' OE2' ' HE3' ' A' ' 19' ' ' LYS . 5.3 pt-20 -76.84 166.96 22.64 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.518 0.675 . . . . 0.0 110.456 -176.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.61 -178.07 49.4 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 167.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.483 ' CE1' HG12 ' A' ' 95' ' ' VAL . 73.9 m-85 -70.6 145.28 50.81 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 104.255 -2.498 . . . . 0.0 104.255 149.443 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.419 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -84.81 44.83 3.42 Favored Glycine 0 C--O 1.221 -0.705 0 CA-C-O 117.529 -1.706 . . . . 0.0 112.519 -176.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -131.48 160.64 34.58 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 119.251 1.526 . . . . 0.0 110.519 179.3 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.9 t -136.88 127.32 40.18 Favored 'Isoleucine or valine' 0 C--O 1.239 0.53 0 C-N-CA 125.004 1.322 . . . . 0.0 108.055 177.865 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.1 mt -74.39 143.53 13.39 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 170.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.542 HD11 ' HE3' ' A' ' 46' ' ' LYS . 20.4 pt -127.32 176.66 6.88 Favored 'Isoleucine or valine' 0 C--O 1.243 0.712 0 C-N-CA 124.25 1.02 . . . . 0.0 109.518 162.539 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -128.14 114.32 16.86 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.376 1.07 . . . . 0.0 108.747 164.092 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -141.92 120.16 12.24 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.2 mp -98.44 -78.82 0.48 Allowed 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 107.221 -1.399 . . . . 0.0 107.221 176.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 43.9 t-20 44.77 92.73 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 127.842 2.457 . . . . 0.0 112.123 -168.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -62.86 135.6 96.07 Favored Pre-proline 0 C--N 1.342 0.266 0 O-C-N 121.796 -0.565 . . . . 0.0 109.688 -163.571 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -79.44 31.12 0.47 Allowed 'Trans proline' 0 CA--C 1.539 0.759 0 C-N-CA 124.023 3.149 . . . . 0.0 111.542 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 47.9 -157.49 0.05 Allowed 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 123.646 0.778 . . . . 0.0 111.276 -152.353 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 41.6 t 58.31 165.24 0.04 OUTLIER 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.977 1.711 . . . . 0.0 110.504 -147.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -96.47 -34.0 5.98 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 171.249 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 70.8 m -77.13 110.07 11.49 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.481 -1.674 . . . . 0.0 106.481 160.045 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 66.6 p -116.17 101.87 9.09 Favored 'General case' 0 C--O 1.239 0.507 0 CA-C-N 119.229 0.922 . . . . 0.0 110.357 -171.372 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 12.8 pt -67.99 110.62 2.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 177.095 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.21 156.53 43.03 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.936 2.095 . . . . 0.0 107.035 177.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 77.9 t -126.42 146.73 57.5 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-O 117.685 -1.15 . . . . 0.0 108.748 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_endo -62.61 -74.87 0.02 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.463 2.109 . . . . 0.0 111.292 168.321 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.9 m170 -85.42 126.51 33.84 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 120.07 1.305 . . . . 0.0 110.886 -174.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.542 ' HE3' HD11 ' A' ' 29' ' ' ILE . 11.2 pttp -144.32 162.52 36.21 Favored 'General case' 0 N--CA 1.465 0.281 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 166.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 23.0 mm -62.85 120.5 9.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 164.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -98.32 -30.05 7.18 Favored Glycine 0 CA--C 1.524 0.598 0 CA-C-N 118.455 0.571 . . . . 0.0 113.129 170.187 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 59.3 ttm-85 -151.97 153.98 35.14 Favored 'General case' 0 CA--C 1.514 -0.429 0 CA-C-N 118.635 1.217 . . . . 0.0 108.221 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 13.4 mt -120.15 149.92 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 O-C-N 124.614 1.196 . . . . 0.0 108.184 166.359 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.2 mp -78.58 127.29 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.825 0 C-N-CA 126.139 1.776 . . . . 0.0 107.25 168.516 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -59.42 137.51 57.97 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.44 6.1 89.04 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-O 118.461 -1.188 . . . . 0.0 113.331 174.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.419 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 76.6 p -87.3 166.52 25.37 Favored Pre-proline 0 CA--C 1.53 0.208 0 CA-C-N 119.992 1.896 . . . . 0.0 112.705 -175.2 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -58.16 -25.89 73.61 Favored 'Trans proline' 0 N--CA 1.452 -0.931 0 C-N-CA 122.121 1.881 . . . . 0.0 113.394 167.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.95 -60.62 2.85 Favored 'General case' 0 C--N 1.342 0.247 0 CA-C-N 119.283 0.947 . . . . 0.0 108.859 174.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -57.85 -46.38 84.86 Favored 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 122.981 0.512 . . . . 0.0 110.962 -176.227 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 78.8 mtt-85 -65.78 -18.21 65.17 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 124.885 1.274 . . . . 0.0 112.676 -176.492 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 9.0 t -63.12 -33.34 75.25 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 119.245 0.93 . . . . 0.0 110.11 175.266 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 58.23 -31.79 0.04 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 129.584 3.154 . . . . 0.0 114.901 -168.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.5 mtpt -61.55 -8.44 4.33 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.999 1.72 . . . . 0.0 112.093 170.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 21.2 tp -134.75 116.32 14.74 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 126.075 1.75 . . . . 0.0 108.981 -176.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 27.4 mmmt -137.4 171.63 14.19 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 123.535 1.636 . . . . 0.0 111.831 176.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 46.5 t -68.64 110.74 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 113.881 -1.509 . . . . 0.0 108.383 -178.071 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 138.35 -23.5 2.99 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -177.034 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -64.99 100.14 0.4 Allowed 'General case' 0 C--O 1.233 0.227 0 CA-C-O 122.114 0.959 . . . . 0.0 109.843 -174.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.9 mtm-85 -48.43 137.62 11.19 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 128.048 2.539 . . . . 0.0 109.602 156.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.8 mt -122.86 143.96 33.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.195 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -173.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.7 mt -107.24 -42.34 4.88 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 125.732 1.613 . . . . 0.0 110.379 175.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -154.68 165.99 34.81 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 123.015 0.526 . . . . 0.0 112.04 -170.189 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 51.4 t -125.71 123.06 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 C-N-CA 128.141 2.577 . . . . 0.0 104.95 174.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 42.78 39.31 1.64 Allowed 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.212 1.805 . . . . 0.0 111.412 -172.511 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 81.26 -9.75 52.74 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-O 117.638 -1.645 . . . . 0.0 115.173 177.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 7.6 mm-40 -75.07 119.59 19.44 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 120.558 2.179 . . . . 0.0 108.557 172.169 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.9 m -55.21 127.76 30.79 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 171.561 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 15.3 pt -100.79 -5.38 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 C-N-CA 123.331 0.652 . . . . 0.0 112.265 -178.138 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.1 mt -59.13 142.48 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 167.454 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 73.2 -20.06 0.3 Allowed 'General case' 0 CA--C 1.533 0.294 0 C-N-CA 126.497 1.919 . . . . 0.0 115.325 167.315 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 14.0 mtp -64.25 148.3 95.97 Favored Pre-proline 0 CA--C 1.539 0.522 0 CA-C-N 119.477 1.035 . . . . 0.0 109.68 167.361 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -72.57 161.17 44.79 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 122.401 2.067 . . . . 0.0 110.064 169.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -55.28 -47.79 75.0 Favored 'General case' 0 C--O 1.225 -0.209 0 C-N-CA 123.661 0.784 . . . . 0.0 111.016 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -53.76 -40.62 66.37 Favored 'General case' 0 CA--C 1.527 0.092 0 C-N-CA 123.236 0.614 . . . . 0.0 112.174 -176.098 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -72.19 -42.37 65.9 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 119.259 -0.4 . . . . 0.0 110.478 -175.548 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 46.9 mt -66.59 -37.28 79.24 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 124.87 1.268 . . . . 0.0 108.846 176.238 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 38.2 t -65.16 -45.63 93.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.484 0 O-C-N 120.274 -1.516 . . . . 0.0 109.841 175.221 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.3 ttpt -62.41 -42.53 99.51 Favored 'General case' 0 C--O 1.22 -0.482 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.344 175.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.12 -48.01 23.16 Favored 'General case' 0 C--O 1.226 -0.162 0 C-N-CA 126.305 1.842 . . . . 0.0 111.62 171.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 74.4 mt -76.22 -31.89 21.76 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 O-C-N 121.592 -0.692 . . . . 0.0 109.607 -174.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.3 tttp -66.42 -46.08 77.75 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.58 1.082 . . . . 0.0 110.125 170.779 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -60.87 -18.15 54.47 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 128.134 2.574 . . . . 0.0 111.984 175.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -58.68 -25.91 63.3 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.816 0.446 . . . . 0.0 111.336 169.743 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 66.86 57.97 8.97 Favored Glycine 0 C--N 1.339 0.71 0 O-C-N 121.338 -0.852 . . . . 0.0 111.063 170.399 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 48.0 mt 75.48 -38.52 0.36 Allowed 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 128.428 2.691 . . . . 0.0 112.193 -174.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.01 121.43 41.77 Favored 'General case' 0 C--N 1.322 -0.61 0 O-C-N 123.604 0.565 . . . . 0.0 111.062 -173.488 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.483 HG12 ' CE1' ' A' ' 24' ' ' PHE . 8.5 p -124.77 121.75 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 178.215 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.2 m -89.49 133.68 34.45 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 164.325 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 27.7 mt -123.76 139.36 54.06 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 -177.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.8 ttm180 -113.72 115.86 28.5 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -112.52 166.9 6.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 C-N-CA 126.682 1.993 . . . . 0.0 108.083 177.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 70.0 mt -72.2 -59.85 2.51 Favored Pre-proline 0 CA--C 1.54 0.586 0 CA-C-O 117.792 -1.099 . . . . 0.0 109.615 177.529 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -59.79 167.49 6.85 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 121.682 1.588 . . . . 0.0 115.827 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -146.65 126.81 13.8 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 127.146 2.179 . . . . 0.0 105.55 -175.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -86.79 -24.7 24.95 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.91 0.862 . . . . 0.0 111.34 172.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -84.77 -5.34 59.32 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 125.48 1.512 . . . . 0.0 112.791 -161.573 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.3 mt -123.62 69.4 1.03 Allowed 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 -175.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -64.54 -54.04 38.5 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.77 0.828 . . . . 0.0 110.509 -175.198 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.6 m -164.28 151.2 9.98 Favored Pre-proline 0 CA--C 1.542 0.673 0 C-N-CA 126.275 1.83 . . . . 0.0 109.141 170.073 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -79.46 72.55 6.46 Favored 'Trans proline' 0 CA--C 1.539 0.75 0 C-N-CA 124.458 3.439 . . . . 0.0 111.21 173.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 6.9 m 61.34 14.77 5.96 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 114.596 1.332 . . . . 0.0 114.596 165.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -68.25 146.13 45.49 Favored Glycine 0 CA--C 1.533 1.186 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 177.342 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -62.38 159.26 36.5 Favored 'Trans proline' 0 C--O 1.238 0.524 0 C-N-CA 124.038 3.158 . . . . 0.0 113.61 -174.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 7.8 m -141.31 -19.0 0.78 Allowed 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -174.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.1 m -165.41 -177.28 4.39 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 127.187 2.195 . . . . 0.0 106.939 178.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.682 0 N-CA-C 107.401 -2.279 . . . . 0.0 107.401 159.887 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.896 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 49.7 m -94.86 162.57 13.7 Favored 'General case' 0 C--O 1.234 0.25 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 156.01 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 21.2 p -157.74 -176.91 6.2 Favored 'General case' 0 C--O 1.237 0.447 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 171.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 175.18 -138.98 4.55 Favored Glycine 0 N--CA 1.446 -0.666 0 N-CA-C 106.691 -2.563 . . . . 0.0 106.691 -177.013 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 77.8 p -152.26 168.43 25.4 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 167.202 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.3 m -160.85 130.73 5.01 Favored 'General case' 0 CA--C 1.519 -0.217 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 164.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 142.07 105.77 0.57 Allowed Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 58.6 m -150.01 -88.32 0.07 Allowed 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 161.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 14.2 tp -61.19 150.1 35.45 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 124.005 0.922 . . . . 0.0 111.277 -173.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -67.39 151.64 47.08 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 122.403 1.096 . . . . 0.0 110.861 172.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 38.4 p -144.68 170.03 16.87 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 126.491 1.917 . . . . 0.0 107.327 -173.29 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 23.4 m -137.98 162.3 34.45 Favored 'General case' 0 C--N 1.328 -0.34 0 O-C-N 120.865 -1.147 . . . . 0.0 108.333 164.632 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -131.72 95.72 3.79 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 127.691 2.396 . . . . 0.0 107.1 -167.214 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 19.6 t -93.72 94.83 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 -176.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.9 p -80.88 129.25 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 172.6 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 67.0 mt -135.17 147.15 29.29 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 175.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.6 m-70 -113.4 167.31 10.69 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.008 1.323 . . . . 0.0 109.713 173.616 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 46.2 ptt85 -145.58 -179.88 6.97 Favored 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 125.996 1.718 . . . . 0.0 107.076 172.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.67 159.29 15.6 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 173.1 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.556 ' HG2' HD21 ' A' ' 93' ' ' LEU . 8.8 mt-10 -70.13 -14.77 62.8 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 120.791 -1.193 . . . . 0.0 112.243 -178.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -80.08 7.63 8.78 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.95 1.3 . . . . 0.0 112.264 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -164.62 170.14 16.1 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 120.249 -1.532 . . . . 0.0 109.863 -167.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.2 -167.81 29.12 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 125.399 1.476 . . . . 0.0 110.909 175.519 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -85.98 159.44 19.62 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 164.343 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.88 39.28 2.86 Favored Glycine 0 C--O 1.222 -0.623 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.922 -178.305 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -118.58 161.35 20.2 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 119.587 1.694 . . . . 0.0 109.387 169.33 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.8 t -140.81 129.79 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 -178.421 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 61.5 mt -97.4 145.47 9.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.2 pt -136.51 166.54 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 C-N-CA 125.249 1.42 . . . . 0.0 109.746 168.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.0 t -102.23 177.35 4.91 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 126.944 2.098 . . . . 0.0 108.67 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.1 m -134.21 10.47 3.83 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 125.101 1.36 . . . . 0.0 112.274 164.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 25.5 tp -75.69 63.53 1.61 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.039 0.936 . . . . 0.0 109.493 173.63 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -169.89 139.59 1.93 Allowed 'General case' 0 C--O 1.234 0.241 0 C-N-CA 128.344 2.658 . . . . 0.0 106.676 166.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 6.0 mtt-85 179.2 141.22 0.29 Allowed Pre-proline 0 N--CA 1.466 0.356 0 C-N-CA 127.675 2.39 . . . . 0.0 106.57 154.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.68 94.33 0.86 Allowed 'Trans proline' 0 N--CA 1.455 -0.756 0 C-N-CA 122.988 2.458 . . . . 0.0 107.677 176.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 158.34 -60.49 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 128.717 2.807 . . . . 0.0 107.108 -166.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 69.6 m 53.72 71.33 0.51 Allowed 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.078 1.351 . . . . 0.0 112.358 -163.113 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.55 11.73 0.99 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.223 1.392 . . . . 0.0 113.842 -176.557 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 67.8 m -66.84 130.46 43.24 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 118.502 1.151 . . . . 0.0 108.335 170.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 12.7 p -85.09 163.07 19.02 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 125.223 1.409 . . . . 0.0 108.398 161.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 13.3 mm 52.09 35.02 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 124.498 1.119 . . . . 0.0 110.173 178.072 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.4 m -63.74 135.14 56.45 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 120.116 -1.615 . . . . 0.0 106.882 169.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 13.9 m -126.98 157.88 70.55 Favored Pre-proline 0 N--CA 1.446 -0.658 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 173.195 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -75.66 -37.48 1.7 Allowed 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 123.275 2.65 . . . . 0.0 111.492 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -140.39 132.59 28.1 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 125.206 1.403 . . . . 0.0 108.142 -173.371 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.0 pttm -156.89 166.93 31.98 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 125.698 1.599 . . . . 0.0 107.734 174.249 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 26.5 mm -72.71 103.69 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 C-N-CA 124.571 1.148 . . . . 0.0 108.87 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -67.91 -42.58 85.47 Favored Glycine 0 N--CA 1.451 -0.33 0 O-C-N 121.284 -0.885 . . . . 0.0 111.366 172.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 23.6 ttm105 -158.1 152.12 24.09 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -165.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 16.1 mt -122.0 150.49 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 168.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 31.9 mm -87.82 136.47 23.08 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.4 t0 -66.66 148.89 51.28 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-O 121.152 0.501 . . . . 0.0 111.185 -176.064 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.48 7.93 17.12 Favored Glycine 0 CA--C 1.527 0.834 0 C-N-CA 124.519 1.057 . . . . 0.0 114.369 175.603 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.406 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 79.4 p -76.0 167.98 31.88 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 118.234 1.017 . . . . 0.0 111.144 -176.343 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.406 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 12.5 Cg_endo -57.8 -27.71 79.26 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 122.149 1.899 . . . . 0.0 112.239 165.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -70.83 -51.96 23.38 Favored 'General case' 0 C--N 1.341 0.204 0 CA-C-N 119.996 1.271 . . . . 0.0 110.171 174.391 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -57.83 -44.68 86.63 Favored 'General case' 0 N--CA 1.465 0.311 0 C-N-CA 123.343 0.657 . . . . 0.0 110.674 -179.137 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 27.4 mtt-85 -75.86 -5.53 46.46 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 124.634 1.174 . . . . 0.0 112.706 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.9 t -73.21 -35.97 66.43 Favored 'General case' 0 C--O 1.225 -0.2 0 CA-C-O 117.617 -1.182 . . . . 0.0 110.994 178.202 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 59.49 -24.94 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 127.985 2.514 . . . . 0.0 116.214 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 6.1 mtpt -66.48 -17.29 64.71 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 120.325 1.421 . . . . 0.0 111.975 161.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.78 119.0 34.08 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -178.476 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.51 171.47 14.21 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-O 122.563 1.173 . . . . 0.0 109.049 -178.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 78.3 t -72.43 108.14 3.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 O-C-N 120.734 -1.229 . . . . 0.0 108.693 -178.399 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 130.39 -3.94 5.87 Favored Glycine 0 CA--C 1.521 0.418 0 C-N-CA 126.261 1.886 . . . . 0.0 111.275 173.43 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.5 m-20 -71.31 95.86 1.36 Allowed 'General case' 0 C--O 1.234 0.268 0 CA-C-N 118.585 1.192 . . . . 0.0 108.148 172.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 38.5 mtt85 -53.01 143.3 17.61 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 127.382 2.273 . . . . 0.0 109.116 170.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 34.6 mt -116.84 149.53 19.06 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -168.32 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.86 -46.05 0.87 Allowed 'General case' 0 N--CA 1.463 0.211 0 C-N-CA 126.336 1.854 . . . . 0.0 109.967 -164.211 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -153.52 168.55 25.77 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.046 0.938 . . . . 0.0 110.012 176.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.453 HG22 HD23 ' A' ' 97' ' ' LEU . 80.6 t -133.6 120.99 39.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 174.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.554 HD21 ' HB2' ' A' ' 91' ' ' ALA . 23.2 m-20 48.73 41.22 17.6 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.308 1.043 . . . . 0.0 110.398 -172.699 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.13 -11.39 3.82 Favored Glycine 0 CA--C 1.527 0.792 0 C-N-CA 126.907 2.194 . . . . 0.0 116.467 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.5 tp-100 -77.13 121.53 23.73 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 120.146 1.973 . . . . 0.0 107.257 -177.635 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 p -63.29 112.33 2.65 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.32 1.048 . . . . 0.0 110.992 -174.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 1.7 pp -73.34 14.25 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 125.758 1.623 . . . . 0.0 113.188 175.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 60.6 mt -76.78 -86.16 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 O-C-N 121.199 -0.938 . . . . 0.0 109.353 -158.414 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -77.53 -8.72 58.24 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.416 1.086 . . . . 0.0 111.226 176.073 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 17.1 ttt -53.65 142.26 42.82 Favored Pre-proline 0 N--CA 1.433 -1.303 0 C-N-CA 128.22 2.608 . . . . 0.0 110.924 -177.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -60.66 139.58 86.47 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 121.873 1.715 . . . . 0.0 110.639 174.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -59.3 -39.87 84.38 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.541 0.736 . . . . 0.0 111.587 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.39 -23.49 63.73 Favored 'General case' 0 CA--C 1.53 0.177 0 O-C-N 122.034 -0.416 . . . . 0.0 111.986 175.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -73.72 -46.54 45.43 Favored 'General case' 0 C--O 1.223 -0.293 0 CA-C-O 118.635 -0.697 . . . . 0.0 109.713 179.089 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 49.1 mt -56.08 -40.32 63.34 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 126.432 1.893 . . . . 0.0 110.568 172.059 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 35.0 t -66.57 -43.89 90.36 Favored 'Isoleucine or valine' 0 C--O 1.238 0.451 0 O-C-N 120.109 -1.619 . . . . 0.0 110.75 176.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 6.6 tttt -54.82 -49.11 71.8 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 172.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -48.89 -39.38 25.75 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 129.23 3.012 . . . . 0.0 113.721 177.084 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.7 mt -75.9 -46.08 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 CA-C-N 118.791 0.723 . . . . 0.0 109.073 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -57.34 -51.21 70.29 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 119.002 0.819 . . . . 0.0 110.137 173.108 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -57.71 -19.28 26.17 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 128.69 2.796 . . . . 0.0 112.864 177.258 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.554 ' HB2' HD21 ' A' ' 72' ' ' ASN . . . -60.41 -26.87 67.01 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 119.253 0.933 . . . . 0.0 112.596 177.231 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.32 -151.36 18.28 Favored Glycine 0 C--N 1.341 0.822 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -173.252 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' LEU . . . . . 0.556 HD21 ' HG2' ' A' ' 20' ' ' GLU . 72.9 mt -71.98 -33.04 67.82 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 117.626 0.713 . . . . 0.0 110.906 168.385 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.91 145.56 24.54 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 -178.739 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.6 p -140.98 143.24 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 168.557 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 23.7 m -114.57 102.69 10.29 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 174.428 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.453 HD23 HG22 ' A' ' 71' ' ' VAL . 61.3 mt -89.93 115.21 27.06 Favored 'General case' 0 CA--C 1.514 -0.427 0 N-CA-C 106.587 -1.634 . . . . 0.0 106.587 -174.573 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -86.4 112.14 21.18 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 -178.032 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -113.51 167.97 6.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 C-N-CA 124.709 1.203 . . . . 0.0 110.356 -174.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.9 mp -97.4 121.67 57.83 Favored Pre-proline 0 C--O 1.239 0.518 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 172.655 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -88.98 168.44 5.47 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 124.635 3.556 . . . . 0.0 111.431 169.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 12.7 mp0 -133.8 157.22 46.44 Favored 'General case' 0 N--CA 1.447 -0.613 0 C-N-CA 126.148 1.779 . . . . 0.0 107.904 178.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -136.04 -0.05 2.57 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 126.384 1.874 . . . . 0.0 110.438 -179.55 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.09 50.26 0.52 Allowed 'General case' 0 N--CA 1.453 -0.3 0 CA-C-O 123.877 1.799 . . . . 0.0 106.691 -167.323 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 2.4 tp -122.89 127.08 48.5 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 104.699 -2.334 . . . . 0.0 104.699 177.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 53.35 56.23 7.67 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 127.608 2.363 . . . . 0.0 113.117 -177.184 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -53.27 126.26 44.96 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-O 117.657 -1.163 . . . . 0.0 108.815 170.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -64.24 97.1 0.24 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 123.393 2.729 . . . . 0.0 111.188 -172.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 3.2 p -159.75 170.78 20.79 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.728 1.611 . . . . 0.0 108.006 -176.678 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 134.45 85.66 0.23 Allowed Glycine 0 CA--C 1.528 0.865 0 CA-C-O 118.583 -1.12 . . . . 0.0 111.511 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.64 -21.99 33.28 Favored 'Trans proline' 0 CA--C 1.534 0.509 0 C-N-CA 122.517 2.145 . . . . 0.0 113.292 -176.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 14.7 m 58.39 -179.8 0.07 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.811 1.645 . . . . 0.0 112.556 -170.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 73.6 m -155.65 -50.24 0.08 Allowed 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 126.149 1.78 . . . . 0.0 106.393 160.379 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.254 1.372 0 N-CA-C 106.432 -2.667 . . . . 0.0 106.432 139.772 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.506 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.3 p -121.53 175.5 6.17 Favored 'General case' 0 C--O 1.24 0.572 0 C-N-CA 126.64 1.976 . . . . 0.0 107.708 173.745 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.7 m -65.52 164.74 13.46 Favored 'General case' 0 CA--C 1.535 0.369 0 O-C-N 121.238 -0.914 . . . . 0.0 109.757 166.019 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.18 -115.51 0.67 Allowed Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -177.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.6 m -65.47 142.95 57.98 Favored 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 123.751 0.82 . . . . 0.0 110.205 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 45.09 68.91 0.49 Allowed 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 125.727 1.611 . . . . 0.0 112.903 -172.319 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.74 -88.53 0.11 Allowed Glycine 0 N--CA 1.452 -0.289 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 165.262 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 38.4 m 56.35 -178.63 0.05 OUTLIER 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.998 1.319 . . . . 0.0 112.344 -170.455 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.2 mp 39.1 76.66 0.06 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.743 2.417 . . . . 0.0 111.422 179.311 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 45.4 mt-30 -51.16 157.09 0.96 Allowed 'General case' 0 C--O 1.239 0.546 0 CA-C-O 122.731 1.253 . . . . 0.0 113.212 -174.092 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 74.0 p -142.59 169.84 16.82 Favored 'General case' 0 N--CA 1.444 -0.742 0 C-N-CA 127.286 2.235 . . . . 0.0 108.558 -175.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 m -132.18 155.26 48.52 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 144.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -93.21 143.11 26.58 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 105.632 -1.988 . . . . 0.0 105.632 160.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.7 t -129.96 102.06 6.74 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 169.329 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.6 p -82.95 144.87 9.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 168.108 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.1 mt -136.81 152.26 28.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 C-N-CA 127.487 2.315 . . . . 0.0 104.933 173.349 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 83.0 m-70 -129.92 136.56 49.62 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 125.618 1.567 . . . . 0.0 109.122 -168.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.1 ptt180 -131.39 176.6 8.16 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 120.605 1.548 . . . . 0.0 111.195 -178.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.2 161.98 14.04 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.07 0.948 . . . . 0.0 109.289 172.351 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -70.55 -15.78 62.81 Favored 'General case' 0 CA--C 1.538 0.502 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -89.2 -10.64 46.32 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.149 0.886 . . . . 0.0 112.642 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 25.9 pt-20 -127.57 175.38 8.3 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 120.344 1.429 . . . . 0.0 110.974 -166.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.01 176.79 19.44 Favored Glycine 0 CA--C 1.531 1.036 0 C-N-CA 124.899 1.238 . . . . 0.0 111.716 177.503 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 57.9 m-85 -89.3 137.96 31.86 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.024 -1.473 . . . . 0.0 107.024 163.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.76 66.9 0.32 Allowed Glycine 0 C--O 1.222 -0.603 0 C-N-CA 124.571 1.081 . . . . 0.0 111.101 -176.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -133.85 146.31 50.5 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 124.814 1.246 . . . . 0.0 108.459 167.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.6 t -121.54 144.87 29.25 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 173.111 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.6 mp -118.43 110.62 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 -173.019 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.451 HD11 ' HE3' ' A' ' 46' ' ' LYS . 31.1 pt -107.64 169.37 2.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 C-N-CA 123.861 0.864 . . . . 0.0 111.072 -169.606 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 t 75.85 -177.83 0.14 Allowed 'General case' 0 C--O 1.238 0.464 0 C-N-CA 127.168 2.187 . . . . 0.0 109.452 -167.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.1 p -158.23 177.44 11.28 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 128.858 2.863 . . . . 0.0 106.033 160.258 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.3 tt -146.85 112.49 5.64 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 120.324 1.42 . . . . 0.0 107.578 161.317 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.36 145.56 43.72 Favored 'General case' 0 C--O 1.233 0.23 0 C-N-CA 123.523 0.729 . . . . 0.0 110.182 -175.624 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 94.5 mtt-85 62.74 162.15 0.12 Allowed Pre-proline 0 CA--C 1.542 0.648 0 C-N-CA 126.978 2.111 . . . . 0.0 111.378 -177.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -69.43 -34.19 16.19 Favored 'Trans proline' 0 N--CA 1.459 -0.511 0 CA-C-O 117.56 -1.1 . . . . 0.0 113.625 -168.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 60.04 108.86 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 126.25 1.82 . . . . 0.0 110.997 -168.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.3 t -79.05 91.55 4.89 Favored 'General case' 0 N--CA 1.45 -0.444 0 O-C-N 121.275 -0.891 . . . . 0.0 109.576 177.64 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 150.27 -152.39 24.28 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 111.891 -0.483 . . . . 0.0 111.891 177.153 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 66.7 m -75.62 149.95 38.11 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 125.789 1.635 . . . . 0.0 108.394 168.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.4 p -124.05 110.12 14.35 Favored 'General case' 0 C--N 1.332 -0.168 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -176.241 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.2 mm -62.7 -72.03 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -174.46 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 20.5 m -80.94 114.77 20.05 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 107.869 -1.159 . . . . 0.0 107.869 -178.722 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.9 p -65.21 152.25 92.1 Favored Pre-proline 0 CA--C 1.552 1.02 0 C-N-CA 123.716 0.807 . . . . 0.0 109.765 -174.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -78.8 -31.88 2.24 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.614 2.21 . . . . 0.0 114.026 176.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -133.55 121.16 21.73 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 119.734 1.152 . . . . 0.0 108.098 -177.324 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.451 ' HE3' HD11 ' A' ' 29' ' ' ILE . 1.9 pttt -145.72 149.46 34.45 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 106.9 -1.519 . . . . 0.0 106.9 170.654 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.519 HG13 HD22 ' A' ' 62' ' ' LEU . 17.1 mm -63.03 125.84 20.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 174.754 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -98.41 -37.51 4.27 Favored Glycine 0 C--N 1.333 0.388 0 C-N-CA 123.88 0.753 . . . . 0.0 112.773 178.056 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 37.6 ttm180 -158.15 149.14 20.85 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 125.198 1.399 . . . . 0.0 107.906 -174.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.2 mt -127.34 124.88 64.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 C-N-CA 126.598 1.959 . . . . 0.0 106.536 172.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.6 mp -55.59 132.91 19.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.339 0 C-N-CA 125.436 1.494 . . . . 0.0 109.828 168.476 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -57.42 127.5 32.3 Favored 'General case' 0 C--O 1.24 0.572 0 C-N-CA 124.991 1.316 . . . . 0.0 109.309 174.734 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.04 5.52 89.55 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 124.447 1.023 . . . . 0.0 113.462 174.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.2 p -65.26 162.69 38.08 Favored Pre-proline 0 CA--C 1.532 0.288 0 CA-C-N 119.21 1.505 . . . . 0.0 110.938 173.539 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -60.5 -28.95 87.62 Favored 'Trans proline' 0 N--CA 1.45 -1.045 0 C-N-CA 121.781 1.654 . . . . 0.0 112.109 168.568 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.25 -52.84 63.57 Favored 'General case' 0 C--N 1.344 0.33 0 CA-C-N 119.337 0.972 . . . . 0.0 110.282 172.805 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -61.55 -51.96 66.42 Favored 'General case' 0 N--CA 1.462 0.146 0 O-C-N 123.285 0.366 . . . . 0.0 110.817 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 90.5 mtt-85 -63.93 -28.9 70.15 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 118.409 -0.805 . . . . 0.0 112.059 -173.185 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 42.3 t -60.94 -19.1 60.26 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.627 1.171 . . . . 0.0 112.573 174.662 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 55.78 22.4 5.49 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 125.389 1.475 . . . . 0.0 114.197 171.086 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 44.5 mtmt -130.1 8.24 5.15 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 124.668 1.187 . . . . 0.0 113.273 178.268 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.519 HD22 HG13 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -141.06 119.27 12.07 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 -179.764 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.13 165.11 24.0 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 119.016 0.826 . . . . 0.0 110.606 176.579 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . 0.263 0.2 OUTLIER -56.98 141.15 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 O-C-N 121.201 -0.937 . . . . 0.0 109.846 172.684 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.2 -6.97 78.7 Favored Glycine 0 CA--C 1.524 0.655 0 CA-C-O 118.215 -1.325 . . . . 0.0 111.651 -174.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 41.8 m-20 -74.59 96.97 3.06 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 119.244 1.522 . . . . 0.0 107.287 168.043 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 42.8 mtm180 -45.05 130.87 7.61 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 126.882 2.073 . . . . 0.0 110.061 160.034 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 7.1 mt -111.76 143.99 20.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -177.112 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 tp -112.81 -44.98 3.24 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 127.343 2.257 . . . . 0.0 108.47 -171.685 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -155.71 170.88 21.02 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.546 0.739 . . . . 0.0 111.474 -177.12 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.9 p -131.22 125.39 57.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 C-N-CA 125.154 1.382 . . . . 0.0 107.992 174.285 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 64.2 m-20 46.64 45.65 14.41 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 124.487 1.115 . . . . 0.0 108.957 -170.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 68.3 -2.51 7.15 Favored Glycine 0 CA--C 1.538 1.477 0 C-N-CA 125.81 1.672 . . . . 0.0 116.772 -175.58 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -91.13 135.32 33.85 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 121.465 2.632 . . . . 0.0 110.359 -174.748 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -72.41 109.24 5.97 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 126.109 1.764 . . . . 0.0 112.316 -171.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 7.4 pt -87.74 -5.05 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 O-C-N 121.348 -0.845 . . . . 0.0 112.51 -172.537 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.521 ' H ' HD12 ' A' ' 77' ' ' ILE . 3.6 mp -65.56 -48.23 83.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 C-N-CA 124.626 1.17 . . . . 0.0 110.207 173.097 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 63.6 m-80 -93.45 -26.6 17.13 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 118.523 -0.751 . . . . 0.0 112.255 -162.556 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 3.9 mtp -70.27 160.53 80.62 Favored Pre-proline 0 CA--C 1.534 0.34 0 C-N-CA 124.685 1.194 . . . . 0.0 112.398 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -71.36 146.18 49.95 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 121.822 1.681 . . . . 0.0 109.764 166.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -49.61 -38.6 32.43 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.765 1.226 . . . . 0.0 111.68 178.253 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -65.76 -30.13 70.75 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 124.152 0.981 . . . . 0.0 113.366 -178.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -82.01 -37.91 25.84 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 119.482 1.037 . . . . 0.0 109.908 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.7 mt -60.5 -36.32 68.95 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 C-N-CA 124.047 0.939 . . . . 0.0 109.659 172.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.9 t -63.79 -51.35 70.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 O-C-N 120.542 -1.349 . . . . 0.0 110.24 170.122 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -51.88 -46.97 64.72 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 118.138 0.426 . . . . 0.0 111.406 178.543 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.45 -36.11 66.2 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 127.686 2.394 . . . . 0.0 113.602 -179.446 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 86.1 mt -76.7 -48.42 26.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.157 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.713 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 59.2 tttt -55.7 -44.86 77.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 122.882 0.473 . . . . 0.0 110.879 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -63.68 -26.9 68.87 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 125.251 1.42 . . . . 0.0 112.27 177.115 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.39 -28.41 69.25 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 118.195 0.452 . . . . 0.0 110.519 176.098 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.16 -106.88 2.93 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 125.385 1.469 . . . . 0.0 109.708 174.26 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 81.5 mt -100.35 -36.27 9.3 Favored 'General case' 0 CA--C 1.504 -0.812 0 C-N-CA 123.137 0.575 . . . . 0.0 110.758 -170.402 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -93.73 143.65 26.12 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 170.325 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.2 p -144.21 138.43 24.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 165.721 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 m -104.79 130.02 52.96 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 179.125 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 26.7 mt -114.4 117.85 32.21 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 124.642 1.177 . . . . 0.0 107.876 177.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -84.93 116.05 23.13 Favored 'General case' 0 C--O 1.232 0.175 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 174.189 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 pp -114.92 172.71 3.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 C-N-CA 125.867 1.667 . . . . 0.0 109.941 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 6.2 mt -113.21 123.06 34.17 Favored Pre-proline 0 C--O 1.237 0.447 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 169.627 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -83.84 -175.5 2.29 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 123.797 2.998 . . . . 0.0 110.446 178.541 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.83 151.51 47.08 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 122.749 0.419 . . . . 0.0 109.979 177.52 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -137.73 -3.53 1.85 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.449 0.699 . . . . 0.0 112.111 -178.526 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -158.0 12.57 0.2 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 124.075 0.95 . . . . 0.0 109.857 -165.687 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.6 tp -103.63 109.39 21.05 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 103.994 -2.595 . . . . 0.0 103.994 169.175 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -153.52 -153.42 0.47 Allowed 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 158.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.6 p -146.09 142.23 17.47 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 156.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -67.71 -55.88 0.25 Allowed 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.964 2.443 . . . . 0.0 110.85 -172.28 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 16.4 m 59.43 27.48 16.61 Favored 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 166.346 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -65.63 172.23 24.08 Favored Glycine 0 CA--C 1.534 1.252 0 O-C-N 121.572 -0.705 . . . . 0.0 111.637 167.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -65.99 162.49 35.07 Favored 'Trans proline' 0 N--CA 1.455 -0.753 0 C-N-CA 123.207 2.605 . . . . 0.0 110.792 177.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -156.7 -174.75 5.08 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.08 1.752 . . . . 0.0 107.105 179.777 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.0 p -66.16 150.3 48.98 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 162.079 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.159 0 N-CA-C 107.428 -2.269 . . . . 0.0 107.428 175.738 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.344 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 68.5 m -141.61 131.28 24.1 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 105.368 -2.086 . . . . 0.0 105.368 169.59 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.2 t -171.92 160.45 5.46 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 125.492 1.517 . . . . 0.0 107.596 -157.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -91.68 128.49 9.38 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 171.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.9 m -130.1 120.43 24.62 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 178.443 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.5 m -54.09 121.67 8.59 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 123.526 0.73 . . . . 0.0 110.223 -175.429 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.94 150.06 14.96 Favored Glycine 0 N--CA 1.449 -0.494 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 176.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.1 p -153.56 0.11 0.23 Allowed 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 124.553 1.141 . . . . 0.0 111.505 -165.542 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.8 tp -141.69 95.68 2.86 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 -170.582 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -103.37 -164.38 1.07 Allowed 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 125.311 1.445 . . . . 0.0 108.72 174.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 28.9 p -132.18 140.09 48.61 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 169.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . 0.401 ' HB2' HG13 ' A' ' 99' ' ' ILE . 5.5 m -97.7 135.91 38.82 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 103.912 -2.625 . . . . 0.0 103.912 -174.217 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -112.92 103.99 11.97 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 18.2 t -87.49 139.29 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 105.532 -2.025 . . . . 0.0 105.532 177.028 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.4 p -129.11 143.24 41.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 168.037 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 4.0 mt -132.11 152.06 36.07 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 127.12 2.168 . . . . 0.0 105.421 173.528 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -131.32 130.11 42.31 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 126.646 1.978 . . . . 0.0 107.597 -176.189 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 34.0 ptt180 -126.11 179.89 5.03 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-N 120.311 1.414 . . . . 0.0 110.492 -175.154 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.1 164.61 12.09 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.281 1.033 . . . . 0.0 109.073 175.324 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -75.21 -12.95 60.4 Favored 'General case' 0 N--CA 1.466 0.367 0 O-C-N 120.795 -1.19 . . . . 0.0 111.764 176.107 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -74.44 -8.25 55.67 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 177.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 26.1 pt-20 -143.0 -175.71 4.62 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 124.082 0.953 . . . . 0.0 110.95 -162.136 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -116.89 -179.39 17.77 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 175.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.404 ' CE1' HG12 ' A' ' 95' ' ' VAL . 69.8 m-85 -75.31 174.53 9.41 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 159.069 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.39 46.43 1.08 Allowed Glycine 0 C--O 1.222 -0.602 0 CA-C-O 118.817 -0.99 . . . . 0.0 111.694 -176.491 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -133.44 143.95 49.19 Favored 'General case' 0 C--O 1.239 0.506 0 CA-C-N 118.246 1.023 . . . . 0.0 108.29 177.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.6 t -119.21 114.35 44.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 106.009 -1.848 . . . . 0.0 106.009 -171.076 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 14.5 mt -78.88 136.92 22.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.299 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 174.249 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.0 pt -132.21 171.95 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.883 0 C-N-CA 125.557 1.543 . . . . 0.0 108.236 163.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 74.62 119.21 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 126.073 1.749 . . . . 0.0 108.62 178.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.9 p -149.98 162.66 39.93 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 125.177 1.391 . . . . 0.0 107.731 178.459 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 21.0 tp -123.53 172.1 9.0 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -123.18 93.23 3.89 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 124.697 1.199 . . . . 0.0 108.261 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 66.64 142.99 0.08 OUTLIER Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 128.648 2.779 . . . . 0.0 110.927 -166.359 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -81.16 78.0 3.8 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 122.2 1.933 . . . . 0.0 109.924 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -68.18 98.71 0.82 Allowed 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 170.463 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 8.3 t -69.29 108.03 3.51 Favored 'General case' 0 CA--C 1.537 0.447 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.03 -82.22 0.05 OUTLIER Glycine 0 C--N 1.336 0.541 0 CA-C-N 119.292 0.951 . . . . 0.0 111.842 -179.67 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 40.6 m -117.73 143.23 46.41 Favored 'General case' 0 CA--C 1.518 -0.282 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 172.354 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 36.1 p -123.48 105.97 10.23 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 -175.655 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.0 mm -92.76 -20.35 6.52 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 C-N-CA 123.546 0.738 . . . . 0.0 109.598 -177.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.4 p -133.7 -170.31 2.47 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 126.42 1.888 . . . . 0.0 109.345 -167.541 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.7 p -127.25 144.29 50.15 Favored Pre-proline 0 CA--C 1.534 0.362 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 163.188 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.2 89.69 0.79 Allowed 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 122.346 2.03 . . . . 0.0 108.66 160.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER 91.74 123.93 0.02 OUTLIER 'General case' 0 C--O 1.233 0.208 0 C-N-CA 130.123 3.369 . . . . 0.0 111.004 167.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -145.44 163.68 33.89 Favored 'General case' 0 C--O 1.233 0.209 0 C-N-CA 124.905 1.282 . . . . 0.0 108.4 163.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.8 mm -65.24 129.73 29.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 165.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -101.97 -49.6 1.24 Allowed Glycine 0 CA--C 1.524 0.628 0 C-N-CA 126.857 2.17 . . . . 0.0 111.774 173.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 49.6 ttt180 -144.38 161.81 38.04 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 125.325 1.45 . . . . 0.0 107.544 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.3 mt -133.46 150.74 32.46 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 C-N-CA 126.453 1.901 . . . . 0.0 107.707 174.394 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.0 mp -87.03 115.76 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.904 0 C-N-CA 126.57 1.948 . . . . 0.0 106.796 171.446 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 31.6 m-20 -52.57 142.98 16.74 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.183 0.993 . . . . 0.0 109.048 171.482 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.82 -12.99 26.55 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-O 118.218 -1.323 . . . . 0.0 113.471 175.413 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 74.3 p -65.85 167.03 12.59 Favored Pre-proline 0 C--O 1.238 0.478 0 CA-C-N 119.639 1.72 . . . . 0.0 111.829 -175.671 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -59.32 -29.1 89.37 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 121.712 1.608 . . . . 0.0 111.996 166.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.56 -56.74 12.03 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.668 0.667 . . . . 0.0 109.946 177.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -65.29 -51.55 59.97 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 123.039 0.535 . . . . 0.0 110.949 -177.314 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.0 mtp180 -65.46 -9.37 25.13 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.337 0.865 . . . . 0.0 113.337 -177.151 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -76.7 -9.27 58.55 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 117.149 -1.405 . . . . 0.0 113.16 171.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 52.11 39.17 26.07 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.905 1.682 . . . . 0.0 113.942 170.377 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 23.6 mtmm -141.11 13.49 2.23 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.784 1.233 . . . . 0.0 113.34 177.197 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.9 mt -144.26 127.41 16.62 Favored 'General case' 0 C--O 1.237 0.437 0 O-C-N 121.09 -1.006 . . . . 0.0 109.743 175.563 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -116.3 164.83 13.93 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.657 1.218 . . . . 0.0 108.806 175.508 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 39.3 t -65.75 133.73 30.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 163.165 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 110.07 -17.32 29.6 Favored Glycine 0 C--N 1.339 0.704 0 C-N-CA 124.918 1.247 . . . . 0.0 110.307 -177.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -71.91 97.12 1.78 Allowed 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 122.667 1.222 . . . . 0.0 109.09 -175.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 49.6 mtt85 -55.17 148.36 14.44 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 126.013 1.725 . . . . 0.0 110.904 166.599 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 96.3 mt -122.71 148.1 26.62 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 C-N-CA 126.995 2.118 . . . . 0.0 106.788 -166.668 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 29.1 mt -126.44 -37.29 2.21 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 114.43 1.27 . . . . 0.0 114.43 179.326 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -148.42 159.54 43.92 Favored 'General case' 0 N--CA 1.465 0.289 0 C-N-CA 124.454 1.101 . . . . 0.0 110.397 178.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 91.8 t -130.9 118.13 40.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 -175.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 63.03 -65.41 0.1 Allowed 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 128.513 2.725 . . . . 0.0 110.002 -165.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.97 -2.09 0.07 OUTLIER Glycine 0 CA--C 1.532 1.109 0 C-N-CA 125.914 1.721 . . . . 0.0 111.922 163.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -74.59 124.54 26.86 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 119.935 1.867 . . . . 0.0 107.142 -175.743 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.4 p -68.2 103.74 1.64 Allowed 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.8 pp -74.23 9.9 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 C-N-CA 124.079 0.952 . . . . 0.0 112.698 -177.235 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 83.0 mt -46.61 -55.71 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.275 0 C-N-CA 128.99 2.916 . . . . 0.0 109.697 179.342 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -108.77 -30.64 8.06 Favored 'General case' 0 N--CA 1.461 0.089 0 C-N-CA 124.802 1.241 . . . . 0.0 110.951 -174.857 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.462 ' HB3' HD11 ' A' ' 84' ' ' ILE . 15.0 ttt -49.56 132.29 19.32 Favored Pre-proline 0 N--CA 1.443 -0.799 0 C-N-CA 127.252 2.221 . . . . 0.0 110.008 -170.495 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -73.18 144.03 36.68 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 121.357 1.372 . . . . 0.0 108.754 -175.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 37.3 t60 -55.33 -35.86 65.63 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.768 0.827 . . . . 0.0 112.306 -170.338 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.56 -39.95 74.35 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 118.526 0.603 . . . . 0.0 112.18 174.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -69.24 -48.12 62.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 118.065 -0.969 . . . . 0.0 109.27 -176.424 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.462 HD11 ' HB3' ' A' ' 79' ' ' MET . 3.1 mp -51.86 -49.75 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 C-N-CA 125.554 1.542 . . . . 0.0 110.785 168.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 3.0 t -58.61 -44.87 90.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 O-C-N 121.362 -0.836 . . . . 0.0 109.768 -176.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 26.7 tttt -64.7 -43.35 93.76 Favored 'General case' 0 C--O 1.223 -0.314 0 CA-C-O 117.966 -1.016 . . . . 0.0 111.759 173.516 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -50.17 -42.71 51.55 Favored 'General case' 0 C--O 1.224 -0.285 0 C-N-CA 126.935 2.094 . . . . 0.0 112.03 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 86.5 mt -75.19 -46.32 39.32 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -177.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -60.18 -35.43 75.35 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 122.483 0.313 . . . . 0.0 111.149 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -83.81 -11.43 57.05 Favored 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 127.499 2.32 . . . . 0.0 112.633 179.26 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -63.84 -11.17 24.99 Favored 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -170.372 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.86 61.58 2.12 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 166.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 76.5 mt 69.09 -39.78 0.43 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 128.966 2.906 . . . . 0.0 114.335 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.66 158.16 15.82 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 172.56 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.404 HG12 ' CE1' ' A' ' 24' ' ' PHE . 12.1 p -156.32 142.45 10.17 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 166.52 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.9 m -111.65 101.25 9.65 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 118.521 0.6 . . . . 0.0 111.119 -175.673 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 46.6 mt -90.44 108.57 19.87 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 125.039 1.336 . . . . 0.0 108.269 -178.189 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -76.5 122.76 25.02 Favored 'General case' 0 C--O 1.239 0.538 0 C-N-CA 124.074 0.949 . . . . 0.0 110.869 172.388 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.401 HG13 ' HB2' ' A' ' 12' ' ' SER . 2.7 pt -128.59 165.0 29.18 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 124.27 1.028 . . . . 0.0 111.851 -177.061 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.423 ' HB ' ' HD3' ' A' ' 101' ' ' PRO . 72.6 mt -82.03 -54.21 0.65 Allowed Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 125.304 1.442 . . . . 0.0 109.678 170.586 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.423 ' HD3' ' HB ' ' A' ' 100' ' ' ILE . 20.9 Cg_endo -66.4 -171.49 0.25 Allowed 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.308 2.005 . . . . 0.0 114.799 178.342 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.07 150.65 18.78 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 131.031 3.732 . . . . 0.0 103.681 172.576 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -103.8 -3.99 24.19 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 119.943 1.247 . . . . 0.0 111.304 174.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -114.58 -2.64 13.07 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.511 1.525 . . . . 0.0 112.808 -163.407 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -79.99 176.76 9.45 Favored 'General case' 0 C--O 1.234 0.263 0 C-N-CA 125.306 1.442 . . . . 0.0 112.106 -173.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.8 m-20 -97.3 96.83 8.66 Favored 'General case' 0 C--O 1.232 0.166 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 -171.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.4 m -107.85 113.58 61.02 Favored Pre-proline 0 C--O 1.237 0.421 0 C-N-CA 123.737 0.815 . . . . 0.0 109.28 176.037 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -73.28 163.46 37.85 Favored 'Trans proline' 0 CA--C 1.535 0.571 0 C-N-CA 122.885 2.39 . . . . 0.0 109.896 175.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.8 m -53.68 -51.15 64.12 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.827 0.851 . . . . 0.0 112.746 -169.235 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 69.41 162.96 3.37 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 123.267 0.461 . . . . 0.0 112.401 -173.729 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -78.08 -19.65 12.04 Favored 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 123.334 2.689 . . . . 0.0 113.948 -179.308 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.2 t 34.61 64.99 0.37 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 127.989 2.516 . . . . 0.0 114.76 174.196 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . 0.266 87.0 p 69.59 59.9 0.3 Allowed 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 127.555 2.342 . . . . 0.0 114.077 170.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.052 0 N-CA-C 108.786 -1.725 . . . . 0.0 108.786 166.262 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.561 0 N-CA-C 108.041 -2.024 . . . . 0.0 108.041 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.6 t -145.43 -157.11 0.76 Allowed 'General case' 0 C--O 1.237 0.418 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 162.551 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.3 t -99.3 160.38 14.32 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.627 0.771 . . . . 0.0 110.548 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -82.32 122.4 5.72 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -175.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 p -56.31 146.33 24.26 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 126.094 1.757 . . . . 0.0 110.569 172.709 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.2 t -165.34 159.75 17.49 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 124.913 1.285 . . . . 0.0 108.277 175.317 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.3 9.06 0.08 OUTLIER Glycine 0 CA--C 1.53 0.982 0 CA-C-O 118.011 -1.438 . . . . 0.0 115.145 -177.499 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 46.3 m -83.76 -78.46 0.23 Allowed 'General case' 0 C--O 1.232 0.156 0 CA-C-N 120.453 2.127 . . . . 0.0 110.699 176.479 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 84.5 mt -71.15 148.77 47.05 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 118.023 0.374 . . . . 0.0 111.16 -161.154 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.1 mm-40 -55.86 147.51 19.07 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 124.216 1.006 . . . . 0.0 110.098 171.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 13.8 p -145.08 169.41 18.19 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 127.172 2.189 . . . . 0.0 107.264 177.274 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 m -114.32 164.86 13.35 Favored 'General case' 0 C--O 1.239 0.527 0 N-CA-C 106.113 -1.81 . . . . 0.0 106.113 157.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -103.2 153.73 20.06 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 143.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.658 HG11 ' HB2' ' A' ' 62' ' ' LEU . 62.8 t -129.09 142.0 45.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 103.025 -2.954 . . . . 0.0 103.025 161.719 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.1 t -123.85 132.44 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 168.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 65.4 mt -130.72 131.45 64.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 105.722 -1.955 . . . . 0.0 105.722 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 76.4 m-70 -117.35 146.87 43.1 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 125.576 1.55 . . . . 0.0 108.271 -176.222 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 50.0 ptt85 -141.57 177.15 8.34 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 120.178 1.354 . . . . 0.0 112.014 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.63 169.25 11.48 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 167.414 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -73.72 -28.69 61.84 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 119.951 -0.7 . . . . 0.0 111.908 173.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -61.16 -56.91 15.27 Favored 'General case' 0 CA--C 1.521 -0.17 0 C-N-CA 124.348 1.059 . . . . 0.0 110.256 -177.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -75.46 165.43 25.13 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.944 1.297 . . . . 0.0 109.216 178.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.02 176.89 26.17 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 163.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -71.83 167.27 20.34 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 159.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.11 0.11 57.3 Favored Glycine 0 CA--C 1.525 0.715 0 CA-C-O 117.922 -1.488 . . . . 0.0 114.994 -167.337 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -112.18 130.41 55.92 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 120.029 1.915 . . . . 0.0 111.878 -153.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 74.9 t -100.96 135.06 38.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 171.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 23.6 mt -93.23 139.0 18.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 171.679 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 35.3 pt -132.3 179.32 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 C-N-CA 126.372 1.869 . . . . 0.0 108.29 168.368 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 66.04 101.46 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 125.731 1.612 . . . . 0.0 108.935 -172.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.8 t -166.2 -72.13 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 107.081 -1.451 . . . . 0.0 107.081 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.6 tt -122.07 108.05 12.92 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 -176.398 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -133.81 97.41 3.89 Favored 'General case' 0 CA--C 1.522 -0.115 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 176.277 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 29.5 mtm105 81.46 145.3 0.09 OUTLIER Pre-proline 0 N--CA 1.468 0.455 1 C-N-CA 131.873 4.069 . . . . 0.0 111.427 -170.157 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -77.18 25.28 0.47 Allowed 'Trans proline' 0 CA--C 1.54 0.815 0 C-N-CA 124.613 3.542 . . . . 0.0 111.349 171.458 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -130.49 105.74 8.06 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 105.469 -2.048 . . . . 0.0 105.469 -163.711 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.1 p -61.23 118.74 7.25 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 -177.297 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 126.46 73.45 0.2 Allowed Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 107.622 -2.191 . . . . 0.0 107.622 -172.083 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 19.8 m -125.68 147.19 49.43 Favored 'General case' 0 C--O 1.237 0.414 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 165.358 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.4 m -124.25 162.94 22.66 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 123.677 0.791 . . . . 0.0 109.555 -175.124 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp 53.17 57.54 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 -172.127 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 15.1 t -142.59 151.19 41.26 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 175.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 7.5 p -127.97 155.35 77.84 Favored Pre-proline 0 C--N 1.324 -0.5 0 C-N-CA 127.637 2.375 . . . . 0.0 105.856 169.568 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -72.97 106.13 2.09 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 CA-C-N 121.757 1.663 . . . . 0.0 108.404 156.021 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 6.2 m80 80.44 107.38 0.07 Allowed 'General case' 0 C--O 1.234 0.267 0 C-N-CA 128.711 2.804 . . . . 0.0 112.138 172.272 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 55.5 pttt -133.2 161.15 35.21 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 123.824 0.849 . . . . 0.0 108.731 157.511 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 47.6 mm -66.25 135.43 28.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 168.087 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -102.9 -63.05 0.71 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 126.55 2.024 . . . . 0.0 111.223 175.071 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 8.4 ttm180 -131.14 155.11 47.55 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 125.447 1.499 . . . . 0.0 108.504 -175.19 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 32.5 mt -133.04 132.61 58.89 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 126.217 1.807 . . . . 0.0 107.117 174.636 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -55.86 114.18 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.776 1.631 . . . . 0.0 107.018 158.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -56.59 132.49 51.8 Favored 'General case' 0 C--O 1.236 0.383 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 174.216 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.78 -8.02 67.62 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 125.401 1.477 . . . . 0.0 114.977 175.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 36.2 p -59.91 169.6 1.47 Allowed Pre-proline 0 C--O 1.239 0.53 0 CA-C-N 118.407 1.104 . . . . 0.0 111.971 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -54.91 -31.78 75.05 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 121.242 1.295 . . . . 0.0 112.073 166.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.2 -68.83 0.24 Allowed 'General case' 0 C--N 1.345 0.404 0 C-N-CA 123.793 0.837 . . . . 0.0 110.089 169.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -51.39 -55.23 19.69 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 118.608 0.64 . . . . 0.0 112.559 -171.202 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -70.11 -7.79 44.3 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 123.349 0.659 . . . . 0.0 111.908 -175.079 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 10.5 t -62.66 -36.96 84.52 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 119.413 1.006 . . . . 0.0 109.202 166.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 57.69 -22.21 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 129.473 3.109 . . . . 0.0 115.789 -177.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 1.5 mmpp? -68.73 -4.6 16.45 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 127.94 2.496 . . . . 0.0 113.389 174.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.658 ' HB2' HG11 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -147.08 113.13 5.81 Favored 'General case' 0 C--O 1.237 0.421 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 -173.203 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 25.6 mttt -130.66 170.74 13.91 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 122.008 0.908 . . . . 0.0 112.613 -170.527 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.8 t -60.99 109.85 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.25 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 131.81 -17.16 4.97 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -70.52 106.45 3.46 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-N 118.525 1.163 . . . . 0.0 111.397 -178.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 52.8 mtm-85 -57.5 144.73 35.75 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 127.23 2.212 . . . . 0.0 110.056 161.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 5.4 mt -131.29 149.14 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 C-N-CA 123.295 0.638 . . . . 0.0 109.428 -168.424 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.48 -41.23 2.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.789 1.636 . . . . 0.0 112.663 -171.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -160.91 168.2 25.1 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.316 0.647 . . . . 0.0 111.743 -178.097 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.6 p -140.21 127.51 23.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 123.532 0.733 . . . . 0.0 110.09 -176.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 40.01 48.24 2.1 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 125.732 1.613 . . . . 0.0 109.774 -158.311 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 63.21 11.67 40.61 Favored Glycine 0 CA--C 1.528 0.869 0 CA-C-O 116.843 -2.087 . . . . 0.0 114.714 -178.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.84 153.97 20.65 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-N 120.684 2.242 . . . . 0.0 111.844 178.791 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.2 p -62.41 147.64 47.93 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -171.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 8.5 pt -131.52 -7.13 2.0 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 O-C-N 123.602 0.564 . . . . 0.0 112.05 167.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.1 mm -79.71 -45.84 22.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 O-C-N 120.569 -1.332 . . . . 0.0 109.628 176.263 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -88.48 -29.47 20.11 Favored 'General case' 0 N--CA 1.465 0.297 0 O-C-N 121.635 -0.666 . . . . 0.0 112.751 -178.252 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.6 mtp -70.61 152.33 95.32 Favored Pre-proline 0 CA--C 1.534 0.352 0 CA-C-N 118.906 0.775 . . . . 0.0 110.984 -177.044 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_endo -73.64 153.23 48.89 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 122.57 2.18 . . . . 0.0 109.55 171.529 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -62.49 -37.87 87.68 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.516 -0.74 . . . . 0.0 112.724 -167.652 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.83 -28.2 65.49 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 119.079 0.854 . . . . 0.0 111.611 -176.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -68.47 -45.06 73.44 Favored 'General case' 0 N--CA 1.46 0.072 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 176.45 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.7 mt -64.4 -38.38 82.42 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 125.299 1.44 . . . . 0.0 109.569 176.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 37.9 t -61.7 -47.6 92.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 O-C-N 120.22 -1.55 . . . . 0.0 109.093 172.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 4.2 tmtt? -63.59 -37.42 87.25 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.016 -177.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.46 -43.93 75.91 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 125.471 1.508 . . . . 0.0 111.446 173.813 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 60.0 mt -68.56 -43.36 83.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 119.542 1.065 . . . . 0.0 109.287 177.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 21.1 tttm -64.29 -38.64 91.78 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.671 -0.643 . . . . 0.0 110.546 -178.293 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -86.02 -3.44 58.94 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 126.924 2.09 . . . . 0.0 112.051 179.489 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -54.89 -26.07 33.23 Favored 'General case' 0 C--N 1.345 0.413 0 N-CA-C 113.817 1.043 . . . . 0.0 113.817 -166.457 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.51 36.02 3.93 Favored Glycine 0 C--N 1.335 0.479 0 N-CA-C 111.266 -0.733 . . . . 0.0 111.266 173.343 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 44.9 mt 69.29 -30.82 0.2 Allowed 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 128.596 2.759 . . . . 0.0 113.041 -175.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 m -92.66 148.12 22.32 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 167.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.3 p -139.97 124.42 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.002 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 169.224 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 20.9 m -99.04 123.77 43.58 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 177.549 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 21.9 mt -120.01 122.3 40.85 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.286 1.034 . . . . 0.0 109.835 -172.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 45.9 ttp180 -85.67 111.94 20.55 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 173.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pp -118.78 167.17 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 125.776 1.63 . . . . 0.0 108.76 175.258 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 7.6 mt -100.8 119.96 56.96 Favored Pre-proline 0 N--CA 1.468 0.436 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 169.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -86.2 -175.58 1.83 Allowed 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 124.266 3.311 . . . . 0.0 110.137 174.36 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLN . . . . . 0.437 ' HG3' HD23 ' A' ' 105' ' ' LEU . 0.1 OUTLIER -144.29 171.98 13.56 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 123.83 0.852 . . . . 0.0 109.43 177.634 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -130.02 -2.8 4.58 Favored 'General case' 0 N--CA 1.463 0.221 0 C-N-CA 123.895 0.878 . . . . 0.0 112.885 170.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -108.62 -6.65 15.91 Favored 'General case' 0 N--CA 1.464 0.252 0 C-N-CA 123.895 0.878 . . . . 0.0 113.125 -164.293 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.437 HD23 ' HG3' ' A' ' 102' ' ' GLN . 0.4 OUTLIER -70.8 102.48 2.35 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 125.531 1.532 . . . . 0.0 112.007 -163.719 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -156.54 102.5 2.07 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 3.3 m -156.89 159.42 31.29 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 118.804 0.729 . . . . 0.0 110.473 178.7 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -71.78 178.94 5.21 Favored 'Trans proline' 0 N--CA 1.458 -0.56 0 C-N-CA 123.904 3.069 . . . . 0.0 111.385 173.662 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 14.4 m -126.68 41.36 3.54 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 124.691 1.196 . . . . 0.0 111.26 -164.151 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -73.49 -141.84 0.56 Allowed Glycine 0 CA--C 1.536 1.406 0 C-N-CA 125.392 1.472 . . . . 0.0 112.712 -177.806 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.06 143.05 94.06 Favored 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 122.956 2.437 . . . . 0.0 112.446 -163.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.76 148.34 17.48 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 114.654 -1.157 . . . . 0.0 110.344 -156.357 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.3 m -145.61 -115.39 0.09 Allowed 'General case' 0 C--O 1.236 0.349 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 171.271 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.929 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 176.855 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.899 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.8 m 47.95 65.67 1.24 Allowed 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 126.143 1.777 . . . . 0.0 113.644 168.052 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.5 p -79.55 -31.39 41.99 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.976 0.91 . . . . 0.0 112.212 174.443 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 50.33 -114.49 2.6 Favored Glycine 0 C--N 1.338 0.666 0 C-N-CA 126.116 1.817 . . . . 0.0 111.812 177.206 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 40.0 m -115.09 83.9 1.99 Allowed 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.977 1.311 . . . . 0.0 109.079 -175.319 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.3 m 47.47 49.2 16.15 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 126.688 1.995 . . . . 0.0 115.512 157.307 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.62 48.39 0.15 Allowed Glycine 0 C--N 1.336 0.546 0 N-CA-C 108.651 -1.78 . . . . 0.0 108.651 -172.57 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.9 m -54.77 -34.23 62.32 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 124.846 1.258 . . . . 0.0 114.191 -154.507 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.3 tp -147.16 85.58 1.61 Allowed 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 174.473 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 35.0 mm-40 53.75 -169.38 0.06 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.996 1.319 . . . . 0.0 112.624 -175.146 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 59.2 p -130.59 169.65 15.31 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 125.255 1.422 . . . . 0.0 108.204 164.716 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 13.7 m -120.2 147.17 45.26 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.511 1.125 . . . . 0.0 108.481 163.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -74.37 155.45 38.13 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 125.3 1.44 . . . . 0.0 108.128 152.387 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 t -137.57 121.16 21.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 105.088 -2.19 . . . . 0.0 105.088 163.052 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' VAL . . . . . 0.404 HG22 HG23 ' A' ' 96' ' ' THR . 13.8 t -120.04 97.29 5.0 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -173.443 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 43.1 mt -99.28 126.32 52.61 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -174.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -103.9 149.62 24.93 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.653 -1.239 . . . . 0.0 107.653 177.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -143.21 -175.54 4.57 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 120.706 1.594 . . . . 0.0 109.899 175.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.525 ' N ' ' HE3' ' A' ' 19' ' ' LYS . 0.1 OUTLIER -92.64 163.71 13.68 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 169.001 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -68.25 -36.62 79.74 Favored 'General case' 0 N--CA 1.465 0.317 0 O-C-N 121.425 -0.797 . . . . 0.0 110.82 173.026 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -75.96 -4.52 41.56 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.418 1.087 . . . . 0.0 112.499 -166.01 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -123.41 179.33 4.77 Favored 'General case' 0 C--O 1.238 0.45 0 C-N-CA 126.872 2.069 . . . . 0.0 108.376 -178.731 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.93 178.71 20.94 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 162.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -72.95 -175.43 1.76 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 164.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -138.81 60.54 0.58 Allowed Glycine 0 C--O 1.223 -0.583 0 CA-C-O 118.774 -1.015 . . . . 0.0 112.582 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.477 ' CE2' HD11 ' A' ' 28' ' ' ILE . 32.8 p90 -140.18 158.16 44.47 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 118.694 1.247 . . . . 0.0 110.651 175.847 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.9 t -143.45 140.54 26.21 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 105.947 -1.872 . . . . 0.0 105.947 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.477 HD11 ' CE2' ' A' ' 26' ' ' PHE . 1.9 mp -130.47 129.26 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 C-N-CA 124.928 1.291 . . . . 0.0 107.566 -169.124 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.424 HD11 ' HE3' ' A' ' 46' ' ' LYS . 47.7 pt -126.44 159.61 35.32 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 C-N-CA 124.32 1.048 . . . . 0.0 110.142 -166.505 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.2 t -128.08 118.17 22.98 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 126.16 1.784 . . . . 0.0 109.275 -173.551 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 57.7 m -126.79 68.05 1.25 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.825 1.65 . . . . 0.0 107.016 170.404 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -154.11 117.04 4.46 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 166.383 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -151.01 168.01 25.9 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 162.24 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 69.2 mtt180 56.32 161.09 0.07 OUTLIER Pre-proline 0 CA--C 1.533 0.301 0 C-N-CA 128.699 2.8 . . . . 0.0 113.472 -166.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -81.56 107.11 1.76 Allowed 'Trans proline' 0 N--CA 1.448 -1.193 0 C-N-CA 123.075 2.517 . . . . 0.0 109.713 172.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -78.88 105.1 9.97 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 156.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 67.7 m 16.33 77.01 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 128.95 2.9 . . . . 0.0 115.06 179.257 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.14 -150.6 18.16 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 124.663 1.125 . . . . 0.0 111.052 177.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.8 113.68 25.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 104.979 -2.23 . . . . 0.0 104.979 166.156 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 25.5 p -79.81 143.68 34.18 Favored 'General case' 0 N--CA 1.452 -0.367 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 -179.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.503 ' H ' HD12 ' A' ' 41' ' ' ILE . 0.9 OUTLIER -77.85 20.91 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 C-N-CA 126.082 1.753 . . . . 0.0 111.167 -177.168 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.6 p -59.19 171.25 0.77 Allowed 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 127.354 2.262 . . . . 0.0 111.105 173.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 48.1 t -118.13 138.34 25.44 Favored Pre-proline 0 CA--C 1.532 0.283 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 -178.196 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -79.82 -16.44 11.48 Favored 'Trans proline' 0 CA--C 1.531 0.373 0 C-N-CA 122.767 2.311 . . . . 0.0 112.628 -175.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -139.7 115.14 9.91 Favored 'General case' 0 N--CA 1.442 -0.826 0 C-N-CA 125.259 1.423 . . . . 0.0 107.641 -166.654 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.424 ' HE3' HD11 ' A' ' 29' ' ' ILE . 52.1 pttt -127.91 144.09 51.1 Favored 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 167.725 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.3 mm -55.38 120.98 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 165.189 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -87.15 -42.59 6.21 Favored Glycine 0 CA--C 1.522 0.494 0 C-N-CA 125.212 1.387 . . . . 0.0 110.85 175.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.6 ttt-85 -148.05 156.36 42.54 Favored 'General case' 0 C--O 1.233 0.225 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 172.168 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.67 139.6 48.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 164.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 44.1 mm -67.56 118.48 11.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 173.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -53.55 124.4 14.85 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 124.199 1.0 . . . . 0.0 108.448 173.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.94 -0.88 84.68 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 114.535 0.574 . . . . 0.0 114.535 176.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 57.8 p -69.23 169.52 11.58 Favored Pre-proline 0 C--O 1.235 0.336 0 CA-C-N 118.855 1.327 . . . . 0.0 112.019 175.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -57.37 -28.04 78.4 Favored 'Trans proline' 0 N--CA 1.449 -1.128 0 C-N-CA 121.21 1.273 . . . . 0.0 112.809 161.52 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.04 -54.26 19.64 Favored 'General case' 0 C--N 1.346 0.434 0 CA-C-N 119.967 1.258 . . . . 0.0 110.235 176.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -52.31 -55.07 23.85 Favored 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 124.918 1.287 . . . . 0.0 110.838 178.422 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 87.9 mtt180 -69.86 -7.35 39.39 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 123.558 0.743 . . . . 0.0 112.622 -175.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 8.9 t -71.24 -31.18 67.23 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 119.586 1.085 . . . . 0.0 110.569 168.435 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.97 -29.95 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 129.979 3.312 . . . . 0.0 116.364 -174.635 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.3 mtpt -69.86 -9.06 53.45 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 126.056 1.742 . . . . 0.0 112.32 169.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -106.46 132.31 52.63 Favored 'General case' 0 C--O 1.237 0.424 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 158.158 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 15.6 ptpt -139.56 169.07 18.42 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 124.387 1.075 . . . . 0.0 110.757 169.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 61.7 t -59.21 138.73 19.87 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 174.059 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 83.35 4.33 89.53 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 115.889 1.116 . . . . 0.0 115.889 174.613 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -60.89 -6.85 2.0 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 118.528 2.788 . . . . 0.0 118.528 -164.201 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 84.5 mtm180 49.38 105.59 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 128.658 2.783 . . . . 0.0 114.587 -165.393 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 57.7 mt -96.79 129.39 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 123.653 0.781 . . . . 0.0 109.241 -179.198 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.451 HD22 ' N ' ' A' ' 69' ' ' LEU . 2.0 mm? -104.41 -23.88 13.12 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.366 1.066 . . . . 0.0 113.601 176.314 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -155.58 164.75 38.22 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 118.505 0.593 . . . . 0.0 111.258 -179.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.38 121.19 45.2 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 C-N-CA 126.405 1.882 . . . . 0.0 107.0 178.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 52.59 26.87 4.63 Favored 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 176.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 90.76 -2.77 80.56 Favored Glycine 0 CA--C 1.535 1.326 0 C-N-CA 125.581 1.562 . . . . 0.0 114.514 -177.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -94.37 128.91 41.19 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.751 1.775 . . . . 0.0 108.638 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.07 116.84 4.84 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 123.267 0.627 . . . . 0.0 109.479 171.339 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.7 pp -80.99 11.64 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.577 0 C-N-CA 124.149 0.979 . . . . 0.0 113.203 178.069 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 79.5 mt -61.04 -70.36 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 C-N-CA 124.961 1.304 . . . . 0.0 109.382 -175.005 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -94.69 -24.66 17.05 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 120.432 -0.507 . . . . 0.0 111.785 -172.325 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.2 mtp -48.6 134.59 13.47 Favored Pre-proline 0 CA--C 1.536 0.442 0 C-N-CA 125.154 1.382 . . . . 0.0 110.512 176.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.25 157.37 61.64 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 122.356 2.038 . . . . 0.0 109.478 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 16.0 m-70 -56.06 -32.96 64.56 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 119.302 -0.38 . . . . 0.0 110.847 174.615 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.9 -44.1 97.5 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 117.878 -1.058 . . . . 0.0 112.177 178.027 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -64.65 -45.98 84.47 Favored 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 66.3 mt -61.75 -40.46 86.96 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 C-N-CA 123.814 0.846 . . . . 0.0 110.527 -177.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 24.8 t -60.22 -50.25 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.132 0 O-C-N 121.209 -0.932 . . . . 0.0 109.32 171.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -63.2 -34.05 76.8 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 117.479 -1.248 . . . . 0.0 112.746 -177.281 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -63.78 -41.51 97.94 Favored 'General case' 0 N--CA 1.442 -0.832 0 C-N-CA 128.07 2.548 . . . . 0.0 110.645 174.226 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 54.4 mt -67.16 -45.61 86.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 O-C-N 120.774 -1.204 . . . . 0.0 108.875 177.281 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 4.6 tttt -61.77 -38.98 90.03 Favored 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 123.077 0.551 . . . . 0.0 109.597 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -61.65 -43.08 99.53 Favored 'General case' 0 CA--C 1.517 -0.323 0 C-N-CA 125.058 1.343 . . . . 0.0 110.381 175.2 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -56.01 -34.56 65.92 Favored 'General case' 0 CA--C 1.537 0.473 0 O-C-N 123.339 0.399 . . . . 0.0 110.63 -175.498 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.03 -116.22 5.46 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 124.896 1.236 . . . . 0.0 110.885 157.449 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 8.2 mt -83.53 -20.12 34.44 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-N 117.126 0.463 . . . . 0.0 109.753 167.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 p -94.53 156.32 16.51 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 173.088 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.8 p -157.39 124.84 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.258 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 160.016 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' THR . . . . . 0.404 HG23 HG22 ' A' ' 15' ' ' VAL . 56.3 m -109.53 101.86 10.77 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.612 1.565 . . . . 0.0 107.514 -172.827 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 81.8 mt -90.92 165.17 13.73 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 125.014 1.326 . . . . 0.0 110.369 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 26.6 ttm180 -120.57 127.99 52.65 Favored 'General case' 0 CA--C 1.518 -0.282 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 162.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.408 HD12 ' C ' ' A' ' 100' ' ' ILE . 1.7 pp -128.83 178.64 4.77 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 125.318 1.447 . . . . 0.0 109.29 173.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.408 ' C ' HD12 ' A' ' 99' ' ' ILE . 75.8 mt -115.68 125.32 28.85 Favored Pre-proline 0 N--CA 1.469 0.512 0 CA-C-N 119.334 0.97 . . . . 0.0 109.349 167.578 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -78.64 167.38 22.64 Favored 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 122.3 2.0 . . . . 0.0 111.252 176.508 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 4.2 pt20 -149.52 151.36 33.78 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 -177.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -146.62 1.6 0.81 Allowed 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 123.763 0.825 . . . . 0.0 112.24 177.432 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 16.9 tt0 -126.07 1.29 7.22 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 126.398 1.879 . . . . 0.0 110.649 -178.623 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 12.7 mt -104.63 102.05 11.67 Favored 'General case' 0 CA--C 1.515 -0.382 0 C-N-CA 125.782 1.633 . . . . 0.0 106.99 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -139.13 167.57 21.76 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 126.522 1.929 . . . . 0.0 107.42 174.276 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 3.3 p -147.35 78.53 10.14 Favored Pre-proline 0 CA--C 1.536 0.415 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -163.058 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -66.95 -57.89 0.17 Allowed 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 123.486 2.791 . . . . 0.0 109.818 -176.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 13.7 m -147.93 -100.78 0.08 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 125.403 1.481 . . . . 0.0 108.25 167.766 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 161.77 -178.38 37.66 Favored Glycine 0 CA--C 1.529 0.931 0 CA-C-N 119.683 1.129 . . . . 0.0 111.14 -174.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 67.2 Cg_endo -72.83 102.02 1.38 Allowed 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 124.438 3.426 . . . . 0.0 109.822 174.078 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -68.23 91.74 0.38 Allowed 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 125.224 1.41 . . . . 0.0 111.279 -178.233 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 22.3 t -72.72 136.82 45.62 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 164.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.989 0 CA-C-O 117.66 -1.633 . . . . 0.0 109.814 -178.864 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.325 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.2 m 65.83 97.29 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 125.796 1.638 . . . . 0.0 112.361 169.297 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 66.4 m -76.43 169.03 19.0 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.883 0.873 . . . . 0.0 111.206 178.174 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 67.14 -179.82 13.59 Favored Glycine 0 CA--C 1.53 1.0 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -172.17 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.5 m 58.05 171.21 0.05 Allowed 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.991 1.316 . . . . 0.0 113.995 -175.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.9 t -162.05 173.15 14.79 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.883 2.073 . . . . 0.0 106.725 159.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.12 -39.49 1.49 Allowed Glycine 0 CA--C 1.523 0.566 0 C-N-CA 126.134 1.826 . . . . 0.0 109.832 172.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 17.3 m -75.4 85.86 2.54 Favored 'General case' 0 N--CA 1.448 -0.573 0 O-C-N 122.127 -0.631 . . . . 0.0 110.015 164.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 39.8 mt -130.18 80.9 1.98 Allowed 'General case' 0 CA--C 1.52 -0.187 0 C-N-CA 125.126 1.37 . . . . 0.0 108.695 173.764 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 60.93 172.17 0.1 Allowed 'General case' 0 C--O 1.236 0.352 0 C-N-CA 126.591 1.956 . . . . 0.0 112.714 178.594 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.8 p -116.07 161.84 18.3 Favored 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 123.884 0.874 . . . . 0.0 108.984 -169.334 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 58.3 m -121.24 146.84 46.39 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 105.406 -2.072 . . . . 0.0 105.406 174.008 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -120.85 131.75 54.59 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 -175.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 24.0 t -129.29 94.86 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 104.431 -2.433 . . . . 0.0 104.431 -172.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.5 p -94.83 104.22 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 36.6 mt -101.84 133.89 43.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 105.307 -2.109 . . . . 0.0 105.307 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 51.8 m-70 -111.53 149.19 31.74 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.924 1.29 . . . . 0.0 108.415 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -138.86 -177.35 4.84 Favored 'General case' 0 N--CA 1.468 0.469 0 O-C-N 120.84 -1.162 . . . . 0.0 110.485 177.272 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.26 153.17 18.17 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 168.74 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -61.55 -32.61 72.69 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.294 0.568 . . . . 0.0 111.217 -171.035 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -89.13 3.41 51.94 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 124.744 1.218 . . . . 0.0 112.979 -163.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 25.4 pt-20 -139.78 177.74 7.74 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 119.534 1.061 . . . . 0.0 111.187 -170.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.04 163.66 31.91 Favored Glycine 0 CA--C 1.525 0.718 0 O-C-N 121.634 -0.666 . . . . 0.0 111.653 177.132 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -75.67 161.2 29.3 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 154.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.56 58.19 0.73 Allowed Glycine 0 C--O 1.218 -0.852 0 CA-C-O 117.432 -1.76 . . . . 0.0 111.351 178.838 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.421 ' CZ ' HD11 ' A' ' 97' ' ' LEU . 28.7 p90 -142.91 141.53 31.52 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 120.326 2.063 . . . . 0.0 110.586 169.862 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.0 t -105.22 135.7 42.17 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 170.415 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 25.6 mt -96.63 130.74 44.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 162.37 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.3 pt -122.53 178.69 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.603 0 C-N-CA 126.585 1.954 . . . . 0.0 108.71 175.042 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.5 p -121.12 170.02 9.96 Favored 'General case' 0 C--O 1.237 0.41 0 C-N-CA 126.197 1.799 . . . . 0.0 109.434 170.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 66.4 m -121.19 -173.08 2.53 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 126.172 1.789 . . . . 0.0 107.597 160.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.9 mp -63.71 128.36 35.46 Favored 'General case' 0 C--O 1.236 0.384 0 O-C-N 121.541 -0.724 . . . . 0.0 109.555 177.433 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -66.52 171.37 5.08 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 125.366 1.466 . . . . 0.0 110.296 170.028 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ARG . . . . . 0.537 ' H ' HG21 ' A' ' 42' ' ' THR . 0.6 OUTLIER -133.22 148.11 67.81 Favored Pre-proline 0 C--O 1.238 0.449 0 C-N-CA 124.606 1.162 . . . . 0.0 108.038 173.137 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -81.03 80.95 2.86 Favored 'Trans proline' 0 N--CA 1.45 -1.03 0 C-N-CA 123.928 3.086 . . . . 0.0 108.298 175.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 34.3 mm-40 -136.16 160.58 38.24 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 126.768 2.027 . . . . 0.0 106.796 176.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 12.0 p -144.04 170.04 16.69 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 123.356 0.662 . . . . 0.0 110.674 -175.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.19 -80.47 0.85 Allowed Glycine 0 C--N 1.335 0.491 0 C-N-CA 124.21 0.91 . . . . 0.0 110.96 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.5 m -65.88 164.18 15.46 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 122.117 0.96 . . . . 0.0 110.544 170.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 12.8 p -123.37 102.34 7.85 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 106.546 -1.649 . . . . 0.0 106.546 -176.537 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.5 mm -108.73 -63.3 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 C-N-CA 124.933 1.293 . . . . 0.0 107.917 -169.408 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.537 HG21 ' H ' ' A' ' 34' ' ' ARG . 2.7 t -75.03 96.21 3.16 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -177.167 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.6 p -65.6 123.66 85.18 Favored Pre-proline 0 CA--C 1.539 0.528 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -74.72 -65.72 0.03 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 121.851 1.701 . . . . 0.0 109.838 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.5 m80 -77.23 103.18 7.01 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.632 1.573 . . . . 0.0 109.614 -172.063 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.7 ptmt -130.55 153.17 49.14 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 171.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.436 HG13 HD22 ' A' ' 62' ' ' LEU . 39.7 mm -68.54 143.82 14.82 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 175.375 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.89 -59.46 0.53 Allowed Glycine 0 CA--C 1.529 0.926 0 C-N-CA 125.596 1.57 . . . . 0.0 112.508 175.337 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 37.4 ttm180 -140.05 144.58 36.94 Favored 'General case' 0 C--O 1.235 0.339 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 21.2 mt -122.66 125.43 72.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 105.821 -1.918 . . . . 0.0 105.821 175.478 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -51.73 131.07 12.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 CA-C-N 119.23 0.923 . . . . 0.0 108.612 172.506 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.6 123.27 17.43 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 125.553 1.541 . . . . 0.0 108.868 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.28 9.88 84.31 Favored Glycine 0 CA--C 1.535 1.329 0 C-N-CA 123.947 0.784 . . . . 0.0 114.903 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 37.9 p -66.36 171.76 3.8 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 119.662 1.731 . . . . 0.0 112.458 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -56.85 -36.83 99.07 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 121.783 1.655 . . . . 0.0 112.296 166.156 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.72 -48.95 75.01 Favored 'General case' 0 C--N 1.34 0.177 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -60.34 -52.95 63.09 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 123.44 0.696 . . . . 0.0 111.594 176.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -60.94 -18.59 57.88 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 124.078 0.951 . . . . 0.0 112.31 -176.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 11.5 t -59.36 -26.25 64.91 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-O 117.819 -1.086 . . . . 0.0 111.257 175.676 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.15 31.49 18.38 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.913 2.085 . . . . 0.0 112.962 -179.208 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 40.3 mtmt -132.47 -34.11 1.22 Allowed 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.889 0.875 . . . . 0.0 111.977 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.444 HD23 ' HA ' ' A' ' 62' ' ' LEU . 0.3 OUTLIER -93.85 126.46 39.06 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 177.509 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 2.6 ptpp? -117.82 171.58 7.96 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 125.2 1.4 . . . . 0.0 109.139 170.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 82.2 t -66.09 141.66 17.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 O-C-N 120.965 -1.084 . . . . 0.0 108.565 174.626 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 89.47 -5.02 84.17 Favored Glycine 0 CA--C 1.532 1.095 0 CA-C-O 117.022 -1.988 . . . . 0.0 114.904 176.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -62.9 11.68 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 120.229 3.418 . . . . 0.0 120.229 -150.554 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.1 mtp180 41.82 86.71 0.02 OUTLIER 'General case' 0 C--O 1.235 0.3 0 C-N-CA 127.178 2.191 . . . . 0.0 113.103 -171.683 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 44.1 mt -65.32 148.85 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 106.341 -1.725 . . . . 0.0 106.341 170.172 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.48 HD22 HD11 ' A' ' 100' ' ' ILE . 1.8 tp -118.86 -47.15 2.52 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 125.828 1.651 . . . . 0.0 108.764 177.282 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -148.54 166.95 26.69 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 125.268 1.427 . . . . 0.0 111.352 -177.599 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.9 p -134.72 124.36 43.89 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.468 0 C-N-CA 125.493 1.517 . . . . 0.0 107.933 175.012 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 49.71 38.59 15.72 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.138 0.975 . . . . 0.0 110.009 -178.021 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 79.21 -10.27 35.88 Favored Glycine 0 CA--C 1.532 1.115 0 CA-C-O 117.822 -1.543 . . . . 0.0 115.415 -176.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.9 mm100 -79.66 122.87 27.08 Favored 'General case' 0 CA--C 1.513 -0.479 0 CA-C-N 121.491 2.646 . . . . 0.0 107.747 -178.384 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 55.7 m -61.36 110.12 1.34 Allowed 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 167.421 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.5 pp -80.14 11.49 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 124.604 1.162 . . . . 0.0 112.322 -174.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 25.3 mm -63.01 -77.34 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 C-N-CA 125.24 1.416 . . . . 0.0 108.418 175.268 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 21.8 m-80 -79.7 -26.92 40.76 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.179 -164.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' MET . . . . . 0.512 ' CE ' HD13 ' A' ' 87' ' ' LEU . 1.4 mtp -58.29 133.81 84.79 Favored Pre-proline 0 CA--C 1.538 0.488 0 C-N-CA 123.815 0.846 . . . . 0.0 109.513 174.347 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -70.61 155.11 63.8 Favored 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 121.989 1.793 . . . . 0.0 110.665 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -57.09 -39.21 74.56 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.365 0.666 . . . . 0.0 111.938 -174.248 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -60.38 -42.43 95.86 Favored 'General case' 0 C--N 1.338 0.097 0 CA-C-O 118.421 -0.8 . . . . 0.0 111.368 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.404 ' O ' HD12 ' A' ' 87' ' ' LEU . 1.4 m-20 -62.62 -46.27 89.05 Favored 'General case' 0 C--O 1.218 -0.58 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 177.135 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.45 ' HA ' ' HB2' ' A' ' 87' ' ' LEU . 29.4 mt -67.71 -33.92 64.74 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 O-C-N 121.212 -0.93 . . . . 0.0 109.925 -175.453 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.0 t -61.79 -44.47 98.84 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 O-C-N 120.83 -1.169 . . . . 0.0 108.669 171.484 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 7.0 mmtt -52.45 -53.19 48.74 Favored 'General case' 0 C--O 1.22 -0.462 0 CA-C-O 116.568 -1.682 . . . . 0.0 109.481 166.16 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.512 HD13 ' CE ' ' A' ' 79' ' ' MET . 0.9 OUTLIER -57.7 -28.34 63.74 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 122.472 2.396 . . . . 0.0 114.514 -174.761 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 66.7 mt -77.44 -48.71 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 176.57 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 13.6 ttpt -63.36 -37.27 86.64 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 118.164 0.438 . . . . 0.0 110.847 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.03 -10.65 59.67 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 126.98 2.112 . . . . 0.0 111.472 -178.381 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.74 -28.31 63.79 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 113.301 0.852 . . . . 0.0 113.301 -171.509 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 92.22 66.52 1.12 Allowed Glycine 0 C--N 1.339 0.741 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 171.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 56.9 mt 61.81 -44.37 0.15 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 129.605 3.162 . . . . 0.0 114.346 -171.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 6.6 p -93.6 140.66 29.36 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 125.28 1.432 . . . . 0.0 107.79 177.291 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.5 p -134.54 124.34 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 169.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.8 m -93.53 100.57 12.83 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.421 HD11 ' CZ ' ' A' ' 26' ' ' PHE . 19.6 mt -90.18 122.83 33.48 Favored 'General case' 0 CA--C 1.516 -0.334 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 172.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 32.0 ttm105 -99.25 117.75 34.41 Favored 'General case' 0 C--O 1.236 0.347 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 179.039 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.53 ' C ' HD12 ' A' ' 100' ' ' ILE . 1.9 pp -130.6 174.9 12.19 Favored 'Isoleucine or valine' 0 C--O 1.237 0.427 0 C-N-CA 126.669 1.988 . . . . 0.0 110.004 -166.545 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.53 HD12 ' C ' ' A' ' 99' ' ' ILE . 3.4 mp -129.88 115.21 17.84 Favored Pre-proline 0 CA--C 1.546 0.812 0 C-N-CA 124.483 1.113 . . . . 0.0 108.651 177.158 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -79.76 -179.07 5.01 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 125.294 3.996 . . . . 0.0 109.169 169.714 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -158.64 163.78 36.59 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 121.224 -0.923 . . . . 0.0 108.568 177.581 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -102.94 7.05 39.28 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 125.478 1.511 . . . . 0.0 111.957 -171.163 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -130.77 10.03 5.05 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 125.204 1.402 . . . . 0.0 111.223 -173.58 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 11.2 mt -121.66 64.55 0.9 Allowed 'General case' 0 C--O 1.235 0.321 0 C-N-CA 125.729 1.612 . . . . 0.0 108.789 -169.165 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 37.0 t30 -148.39 89.49 1.72 Allowed 'General case' 0 C--O 1.234 0.273 0 C-N-CA 125.757 1.623 . . . . 0.0 107.767 172.332 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.1 m -67.02 149.29 98.6 Favored Pre-proline 0 CA--C 1.543 0.692 0 CA-C-O 119.013 -0.518 . . . . 0.0 111.319 -171.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -79.5 179.55 6.26 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.699 2.932 . . . . 0.0 112.145 -172.289 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 14.4 t -128.6 -171.98 2.6 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.66 1.584 . . . . 0.0 107.413 163.393 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 67.38 62.24 4.53 Favored Glycine 0 CA--C 1.534 1.265 0 C-N-CA 124.944 1.259 . . . . 0.0 112.949 178.258 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -67.05 -26.3 43.28 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.636 2.224 . . . . 0.0 113.649 -177.432 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 42.9 t -155.33 98.28 1.97 Allowed 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 175.151 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 73.4 m -152.06 73.62 1.06 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 174.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.975 0 N-CA-C 103.662 -3.775 . . . . 0.0 103.662 -146.307 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.648 0 N-CA-C 111.589 -0.605 . . . . 0.0 111.589 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.2 p -70.44 93.95 0.92 Allowed 'General case' 0 C--O 1.232 0.148 0 C-N-CA 123.834 0.854 . . . . 0.0 109.238 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.5 m -146.55 162.76 37.68 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 106.188 -1.782 . . . . 0.0 106.188 169.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 159.8 107.08 0.23 Allowed Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -174.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.5 t -123.82 -71.79 0.7 Allowed 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 106.293 -1.743 . . . . 0.0 106.293 174.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m -68.79 -57.57 5.41 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 124.641 1.176 . . . . 0.0 112.888 -174.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 130.84 51.18 0.1 Allowed Glycine 0 C--N 1.342 0.902 0 CA-C-N 119.672 1.124 . . . . 0.0 113.979 174.033 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 27.8 m -70.44 33.77 0.04 OUTLIER 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.094 1.758 . . . . 0.0 113.184 173.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.2 tp -155.94 119.44 4.36 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 161.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -112.13 114.62 27.56 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.2 p -132.51 167.58 19.74 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 123.842 0.857 . . . . 0.0 109.74 -174.167 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.5 m -127.38 150.99 49.37 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.239 1.016 . . . . 0.0 108.291 175.067 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -120.69 93.46 4.04 Favored 'General case' 0 C--O 1.236 0.355 0 N-CA-C 104.442 -2.429 . . . . 0.0 104.442 176.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.5 t -91.43 94.76 5.04 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.332 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 -170.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.0 p -76.2 134.12 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 173.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 82.5 mt -131.12 126.38 59.15 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.197 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 175.269 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -92.55 154.01 18.7 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 167.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.487 ' HD3' ' CZ ' ' A' ' 24' ' ' PHE . 5.7 ptt180 -138.96 -176.95 4.67 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 167.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.461 ' HE3' ' C ' ' A' ' 18' ' ' ARG . 0.1 OUTLIER -109.67 168.19 9.59 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 172.48 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -75.71 -19.3 59.19 Favored 'General case' 0 N--CA 1.463 0.176 0 O-C-N 121.716 -0.615 . . . . 0.0 112.172 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -69.77 -2.98 13.53 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.014 0.926 . . . . 0.0 112.735 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -150.07 177.2 10.11 Favored 'General case' 0 C--O 1.238 0.474 0 C-N-CA 125.485 1.514 . . . . 0.0 109.441 -164.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.98 -173.69 19.94 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 171.04 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.487 ' CZ ' ' HD3' ' A' ' 18' ' ' ARG . 62.9 m-85 -76.24 166.85 22.86 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 159.41 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.29 60.26 0.68 Allowed Glycine 0 C--O 1.226 -0.364 0 O-C-N 121.022 -1.049 . . . . 0.0 113.05 -173.508 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 5.3 p90 -144.56 162.08 37.5 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 124.936 1.294 . . . . 0.0 109.999 175.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.5 t -132.99 124.59 50.41 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.3 mp -84.5 140.86 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 173.457 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.474 HD11 ' HE3' ' A' ' 46' ' ' LYS . 19.9 pt -131.73 -176.15 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 C-N-CA 127.849 2.46 . . . . 0.0 107.759 172.073 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.6 p -116.39 -58.55 2.08 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 165.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 60.16 88.35 0.08 Allowed 'General case' 0 C--O 1.235 0.301 0 C-N-CA 125.69 1.596 . . . . 0.0 108.743 -159.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 1.4 mt -140.46 159.34 42.41 Favored 'General case' 0 C--O 1.239 0.552 0 C-N-CA 126.017 1.727 . . . . 0.0 107.467 178.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -174.35 137.4 0.51 Allowed 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.249 1.42 . . . . 0.0 108.417 -175.445 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 63.5 mtt85 60.99 156.55 0.11 Allowed Pre-proline 0 CA--C 1.543 0.678 0 C-N-CA 127.464 2.306 . . . . 0.0 112.355 -175.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.08 -22.06 11.64 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.093 1.862 . . . . 0.0 111.667 -178.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 58.95 177.99 0.07 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 126.213 1.805 . . . . 0.0 113.848 -175.385 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.0 m -130.73 119.67 22.69 Favored 'General case' 0 C--O 1.238 0.451 0 C-N-CA 126.928 2.091 . . . . 0.0 106.618 175.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 128.75 -174.28 19.07 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 125.507 1.527 . . . . 0.0 111.768 169.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 12.6 t -70.22 103.35 2.33 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 160.38 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 19.6 p -67.57 152.63 45.32 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 124.071 0.948 . . . . 0.0 109.564 179.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 5.0 mp -127.21 80.83 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.52 -0.183 0 N-CA-C 104.601 -2.37 . . . . 0.0 104.601 169.353 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.61 164.52 29.69 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 128.212 2.605 . . . . 0.0 105.459 171.393 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.2 p -127.85 138.02 32.01 Favored Pre-proline 0 CA--C 1.541 0.604 0 CA-C-N 120.259 1.39 . . . . 0.0 111.015 -178.151 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.32 -20.01 19.02 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.593 2.196 . . . . 0.0 113.072 178.016 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.59 ' CD2' HD13 ' A' ' 76' ' ' ILE . 0.6 OUTLIER -135.55 118.82 16.65 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 124.467 1.107 . . . . 0.0 108.367 178.372 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.474 ' HE3' HD11 ' A' ' 29' ' ' ILE . 44.1 pttt -139.88 155.0 47.42 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 123.675 0.79 . . . . 0.0 109.144 167.573 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.1 mm -64.16 131.02 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 105.409 -2.071 . . . . 0.0 105.409 168.48 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -113.76 -32.92 1.97 Allowed Glycine 0 CA--C 1.523 0.57 0 C-N-CA 124.233 0.92 . . . . 0.0 113.382 176.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 21.2 ttm-85 -146.21 148.5 32.57 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 7.4 mt -127.43 125.97 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 167.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -57.65 126.99 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 C-N-CA 125.416 1.486 . . . . 0.0 107.1 175.609 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -60.79 123.09 16.48 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 123.522 0.729 . . . . 0.0 109.145 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.15 24.78 74.96 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.726 0.679 . . . . 0.0 113.284 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 22.5 p -76.94 171.69 11.71 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 118.674 1.237 . . . . 0.0 111.576 168.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -58.16 -22.81 58.4 Favored 'Trans proline' 0 CA--C 1.538 0.696 0 C-N-CA 122.197 1.931 . . . . 0.0 113.259 165.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -72.89 -56.97 4.43 Favored 'General case' 0 C--N 1.343 0.308 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 173.237 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -57.64 -47.07 83.28 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 123.801 0.841 . . . . 0.0 111.273 -175.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 1.6 ptm180 -54.45 -27.48 37.64 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 113.267 0.839 . . . . 0.0 113.267 174.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 2.7 t -73.17 -12.89 61.04 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 118.29 -0.862 . . . . 0.0 112.858 -162.544 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 47.33 37.88 6.52 Favored 'General case' 0 C--O 1.239 0.532 0 C-N-CA 126.077 1.751 . . . . 0.0 113.536 178.159 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.8 mtmt -143.33 -17.47 0.64 Allowed 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 113.92 1.082 . . . . 0.0 113.92 173.343 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.422 HD23 ' HA ' ' A' ' 62' ' ' LEU . 0.1 OUTLIER -126.54 111.44 14.38 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 124.715 1.206 . . . . 0.0 108.083 -174.583 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 25.8 mtmt -129.35 172.12 11.82 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 126.011 1.724 . . . . 0.0 110.674 172.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 84.4 t -57.43 118.97 2.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.382 0 C-N-CA 125.108 1.363 . . . . 0.0 109.567 -175.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 124.7 -23.25 6.33 Favored Glycine 0 C--N 1.336 0.57 0 CA-C-O 118.699 -1.056 . . . . 0.0 111.063 175.627 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -70.06 81.44 0.5 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.62 1.568 . . . . 0.0 112.253 -167.224 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 87.7 mtt180 -48.42 134.02 15.58 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 126.619 1.968 . . . . 0.0 110.998 -162.789 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 61.3 mt -102.9 130.1 53.53 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -112.02 -32.85 6.45 Favored 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 125.254 1.422 . . . . 0.0 112.095 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -154.97 167.81 29.1 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.995 0.918 . . . . 0.0 109.038 -177.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.7 p -129.57 114.34 30.61 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.324 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 177.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 63.8 m-80 61.42 -37.54 0.11 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 128.937 2.895 . . . . 0.0 113.638 -169.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 169.2 -4.43 0.04 OUTLIER Glycine 0 CA--C 1.531 1.043 0 C-N-CA 128.103 2.763 . . . . 0.0 112.692 -176.613 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -90.72 136.0 33.35 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 120.569 2.185 . . . . 0.0 108.91 -177.273 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.6 p -73.3 119.5 17.62 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.457 0.571 . . . . 0.0 109.592 179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.59 HD13 ' CD2' ' A' ' 45' ' ' HIS . 2.4 pp -91.31 -24.25 5.63 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.305 0 C-N-CA 122.262 0.225 . . . . 0.0 111.312 -174.389 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mp -59.73 -32.67 49.98 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 O-C-N 121.389 -0.819 . . . . 0.0 110.903 -179.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -95.2 -7.58 38.68 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 123.801 0.84 . . . . 0.0 112.222 -170.477 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.7 mtp -105.88 160.0 27.66 Favored Pre-proline 0 N--CA 1.449 -0.487 0 C-N-CA 125.61 1.564 . . . . 0.0 113.348 -169.094 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -66.96 140.7 55.63 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 123.245 2.63 . . . . 0.0 110.789 169.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -45.93 -52.77 11.02 Favored 'General case' 0 N--CA 1.453 -0.303 0 C-N-CA 126.132 1.773 . . . . 0.0 110.872 173.276 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.5 -27.23 69.0 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 123.91 0.884 . . . . 0.0 113.261 -177.57 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.3 t0 -87.29 -34.73 18.79 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-N 118.991 0.814 . . . . 0.0 110.801 -178.236 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.0 mt -63.93 -39.57 85.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 C-N-CA 124.339 1.056 . . . . 0.0 108.43 169.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.1 t -57.13 -50.7 75.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 121.11 -0.994 . . . . 0.0 109.114 168.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.9 -36.61 81.81 Favored 'General case' 0 C--N 1.338 0.093 0 CA-C-N 118.881 0.764 . . . . 0.0 112.822 -178.614 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -61.75 -42.12 98.56 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 128.067 2.547 . . . . 0.0 110.836 175.076 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 62.4 mt -67.42 -42.75 87.6 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.281 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 174.054 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 46.1 tttt -57.73 -41.66 82.29 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.559 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.7 t0 -65.88 -14.62 61.84 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 127.462 2.305 . . . . 0.0 112.451 178.018 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -75.48 -12.38 60.23 Favored 'General case' 0 CA--C 1.544 0.731 0 O-C-N 121.042 -1.036 . . . . 0.0 111.86 169.18 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 60.45 -116.19 8.82 Favored Glycine 0 CA--C 1.528 0.868 0 O-C-N 120.817 -1.177 . . . . 0.0 110.574 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 93.2 mt -87.1 -36.53 18.07 Favored 'General case' 0 CA--C 1.503 -0.862 0 CA-C-N 117.814 0.807 . . . . 0.0 112.342 -177.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -107.86 120.11 41.33 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.159 0.912 . . . . 0.0 108.628 -175.102 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.7 p -126.99 150.52 32.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.3 m -124.55 138.85 54.3 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 19.0 mt -122.61 128.83 51.18 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 124.583 1.153 . . . . 0.0 109.114 178.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -84.77 107.8 17.13 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 175.046 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.3 pp -113.92 170.97 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 O-C-N 123.875 0.734 . . . . 0.0 110.763 172.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 20.0 mt -121.29 125.74 26.8 Favored Pre-proline 0 C--O 1.234 0.263 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 170.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -85.1 178.84 4.46 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 124.867 3.711 . . . . 0.0 110.715 172.51 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 20.1 mp0 -146.86 135.49 22.07 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 125.9 1.68 . . . . 0.0 107.202 -176.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -123.94 -6.22 7.9 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 123.764 0.826 . . . . 0.0 111.702 170.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -143.42 0.04 1.12 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.758 1.223 . . . . 0.0 113.881 -170.56 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 18.4 mt -119.95 90.03 3.25 Favored 'General case' 0 C--N 1.339 0.137 0 C-N-CA 124.005 0.922 . . . . 0.0 108.954 -168.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -140.43 -96.75 0.15 Allowed 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 164.477 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.4 t -163.56 136.31 4.11 Favored Pre-proline 0 C--O 1.241 0.612 0 C-N-CA 126.339 1.856 . . . . 0.0 107.044 179.018 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -77.19 -24.16 9.73 Favored 'Trans proline' 0 N--CA 1.458 -0.589 0 C-N-CA 122.325 2.016 . . . . 0.0 112.658 -174.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 5.3 m -145.09 99.09 3.27 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.12 1.368 . . . . 0.0 108.267 -169.095 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -116.37 87.33 0.43 Allowed Glycine 0 CA--C 1.526 0.735 0 N-CA-C 108.516 -1.834 . . . . 0.0 108.516 176.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -73.43 136.5 24.02 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.294 1.996 . . . . 0.0 109.558 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 16.3 t -127.89 157.04 41.58 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.26 1.424 . . . . 0.0 107.772 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -160.01 176.66 11.58 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.629 0.771 . . . . 0.0 110.304 -178.071 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.329 0 C-N-CA 129.086 3.231 . . . . 0.0 106.109 174.389 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.158 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 p -66.71 144.91 56.08 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 117.882 0.841 . . . . 0.0 109.017 167.308 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.4 t -179.99 142.43 0.15 Allowed 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 128.811 2.844 . . . . 0.0 104.898 165.156 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.42 67.19 0.23 Allowed Glycine 0 N--CA 1.453 -0.232 0 O-C-N 121.683 -0.636 . . . . 0.0 111.519 -170.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.4 m -70.37 156.23 39.59 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 117.36 0.58 . . . . 0.0 111.652 171.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 16.9 t -151.8 174.71 13.22 Favored 'General case' 0 C--O 1.24 0.564 0 C-N-CA 126.776 2.03 . . . . 0.0 108.226 175.409 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 147.81 157.38 7.44 Favored Glycine 0 C--O 1.236 0.252 0 C-N-CA 125.206 1.384 . . . . 0.0 110.883 173.343 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 40.0 t -152.29 51.35 0.78 Allowed 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 124.252 1.021 . . . . 0.0 109.176 176.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.5 tp -139.33 170.72 15.43 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 118.392 0.542 . . . . 0.0 110.536 173.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -177.21 148.54 0.62 Allowed 'General case' 0 C--O 1.239 0.515 0 C-N-CA 127.919 2.488 . . . . 0.0 104.714 167.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 39.1 p -145.11 153.05 41.0 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 172.237 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.2 m -96.09 170.53 9.21 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 -161.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -135.1 94.63 3.17 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 123.505 1.622 . . . . 0.0 107.743 171.188 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.544 HG11 ' HB3' ' A' ' 62' ' ' LEU . 80.1 t -90.3 93.98 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 104.735 -2.321 . . . . 0.0 104.735 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.7 p -101.93 116.79 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 -175.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 51.1 mt -133.67 136.85 53.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 -172.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 74.4 m-70 -109.27 149.59 29.22 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 125.396 1.478 . . . . 0.0 109.079 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.49 ' HD3' ' CZ ' ' A' ' 24' ' ' PHE . 1.1 ptm180 -138.69 179.29 6.56 Favored 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 124.937 1.295 . . . . 0.0 109.951 -175.353 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.16 157.33 15.99 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 176.016 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -69.92 -20.71 63.34 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 117.76 0.255 . . . . 0.0 111.239 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 31.0 t30 -78.45 -1.83 35.55 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.451 0.7 . . . . 0.0 112.682 -176.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -159.89 -175.74 5.29 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.573 1.149 . . . . 0.0 110.362 -170.027 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.99 -171.54 29.99 Favored Glycine 0 CA--C 1.522 0.521 0 C-N-CA 125.324 1.44 . . . . 0.0 112.365 177.235 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.49 ' CZ ' ' HD3' ' A' ' 18' ' ' ARG . 29.6 m-85 -73.63 159.68 32.72 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 151.829 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -105.28 57.52 0.49 Allowed Glycine 0 C--O 1.219 -0.817 0 CA-C-O 118.542 -1.144 . . . . 0.0 110.565 177.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 8.8 p90 -124.02 155.35 38.43 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 118.849 1.324 . . . . 0.0 108.969 171.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -129.63 114.36 30.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 177.019 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 22.1 mt -78.24 147.38 7.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 171.319 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 44.0 pt -141.2 174.67 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 C-N-CA 128.691 2.796 . . . . 0.0 107.662 170.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 35.9 p -113.09 177.22 4.7 Favored 'General case' 0 C--O 1.237 0.42 0 C-N-CA 124.182 0.993 . . . . 0.0 108.926 164.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.1 t -144.58 139.62 28.26 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 169.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 14.7 tp -148.04 76.65 1.38 Allowed 'General case' 0 C--O 1.236 0.351 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 6.0 t30 -131.72 -78.86 0.51 Allowed 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 117.903 -1.046 . . . . 0.0 108.825 174.242 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -137.52 157.83 73.11 Favored Pre-proline 0 N--CA 1.472 0.647 0 CA-C-N 120.682 1.583 . . . . 0.0 112.214 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.568 ' HB3' ' H ' ' A' ' 41' ' ' ILE . 97.7 Cg_endo -75.23 160.23 39.64 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.072 2.514 . . . . 0.0 110.197 165.269 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -94.72 73.88 3.65 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 175.758 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 49.2 m 57.3 171.3 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 128.441 2.696 . . . . 0.0 115.11 178.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.36 -142.93 39.97 Favored Glycine 0 CA--C 1.525 0.711 0 O-C-N 121.302 -0.874 . . . . 0.0 111.435 -175.57 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 78.9 p -65.5 163.81 15.23 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-O 122.407 1.099 . . . . 0.0 111.171 -178.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 12.5 p -84.61 109.77 18.22 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -172.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.568 ' H ' ' HB3' ' A' ' 35' ' ' PRO . 37.5 mt -126.53 137.12 58.8 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 C-N-CA 127.916 2.487 . . . . 0.0 106.788 -166.437 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.6 t -160.48 123.56 3.39 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 -178.512 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.0 p -103.59 139.81 20.46 Favored Pre-proline 0 N--CA 1.469 0.514 0 C-N-CA 124.258 1.023 . . . . 0.0 110.335 -173.417 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -72.96 -27.64 14.01 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 121.75 1.633 . . . . 0.0 113.775 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -141.94 130.02 22.04 Favored 'General case' 0 C--N 1.341 0.22 0 C-N-CA 125.687 1.595 . . . . 0.0 108.948 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 6.8 ptmt -149.66 164.57 34.82 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 125.788 1.635 . . . . 0.0 107.225 176.015 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.602 HG13 HD23 ' A' ' 62' ' ' LEU . 13.2 mm -84.52 143.7 11.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.506 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -176.612 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.0 -36.62 0.94 Allowed Glycine 0 CA--C 1.522 0.491 0 C-N-CA 126.023 1.773 . . . . 0.0 112.745 -177.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 36.6 ttm105 -150.05 159.81 44.12 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 119.096 1.448 . . . . 0.0 108.585 176.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 7.2 mt -121.05 143.58 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 125.46 1.504 . . . . 0.0 107.012 160.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.4 mm -75.43 136.42 25.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -72.03 119.81 16.74 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.637 0.256 . . . . 0.0 110.462 -159.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.32 12.81 83.92 Favored Glycine 0 CA--C 1.527 0.799 0 CA-C-O 119.362 -0.688 . . . . 0.0 114.432 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.567 ' HB2' ' CD ' ' A' ' 55' ' ' PRO . 81.3 p -71.49 176.55 2.09 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 118.342 1.071 . . . . 0.0 112.004 176.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.567 ' CD ' ' HB2' ' A' ' 54' ' ' SER . 4.7 Cg_exo -64.28 -32.27 62.07 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 C-N-CA 122.767 2.311 . . . . 0.0 110.164 176.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.86 -24.52 66.89 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 118.201 -0.904 . . . . 0.0 112.894 175.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -83.65 -47.06 11.64 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 119.128 0.876 . . . . 0.0 110.543 173.32 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 28.5 mtt-85 -69.11 -41.44 77.41 Favored 'General case' 0 C--O 1.234 0.252 0 C-N-CA 123.247 0.619 . . . . 0.0 111.469 -170.627 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 62.5 m -81.19 81.38 7.41 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 173.054 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -62.85 89.78 0.03 OUTLIER 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.22 1.008 . . . . 0.0 109.503 178.2 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.51 ' CB ' HG13 ' A' ' 14' ' ' VAL . 26.4 mmmt -136.85 -33.72 0.76 Allowed 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 126.598 1.959 . . . . 0.0 109.498 -174.711 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.602 HD23 HG13 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -136.57 154.49 50.68 Favored 'General case' 0 C--O 1.234 0.264 0 C-N-CA 124.576 1.15 . . . . 0.0 109.388 171.055 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 16.3 ptmt -134.9 172.12 13.44 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 124.887 1.275 . . . . 0.0 110.868 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.6 t -59.42 137.66 21.54 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 O-C-N 120.401 -1.437 . . . . 0.0 109.572 -175.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 103.11 -14.05 55.54 Favored Glycine 0 C--N 1.342 0.893 0 C-N-CA 125.119 1.342 . . . . 0.0 114.642 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -67.06 19.46 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 120.368 3.47 . . . . 0.0 120.368 -148.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 4.3 mtt-85 43.61 72.53 0.18 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 126.818 2.047 . . . . 0.0 112.811 168.443 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 31.4 mt -65.33 147.11 12.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -170.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.6 mt -102.69 -52.75 3.01 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 124.606 1.162 . . . . 0.0 109.915 174.788 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -156.62 171.06 20.99 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.654 0.782 . . . . 0.0 110.524 -172.217 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 13.0 p -124.54 113.96 38.65 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.257 0 C-N-CA 125.321 1.449 . . . . 0.0 108.1 175.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 45.09 41.75 5.92 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 125.825 1.65 . . . . 0.0 110.095 -169.092 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.31 4.27 78.96 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-O 118.334 -1.259 . . . . 0.0 115.763 179.427 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -85.99 122.12 29.58 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 120.262 2.031 . . . . 0.0 106.689 174.229 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 7.7 t -67.52 134.84 52.04 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 -179.036 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 21.8 pt -108.99 0.27 9.65 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 125.508 1.523 . . . . 0.0 111.193 -176.127 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 75.4 mt -65.41 -61.77 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 C-N-CA 125.088 1.355 . . . . 0.0 109.072 -178.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -92.42 -24.22 18.92 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 123.939 0.896 . . . . 0.0 112.33 -174.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.8 ttt -60.91 137.83 93.77 Favored Pre-proline 0 N--CA 1.439 -0.996 0 C-N-CA 125.185 1.394 . . . . 0.0 108.525 178.706 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -76.07 148.95 31.9 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 121.853 1.702 . . . . 0.0 109.668 -177.709 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.409 ' HA ' HD12 ' A' ' 84' ' ' ILE . 32.2 t60 -60.76 -31.94 71.26 Favored 'General case' 0 CA--C 1.537 0.476 0 N-CA-C 113.812 1.041 . . . . 0.0 113.812 -165.628 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -71.18 -27.8 63.78 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 119.217 0.917 . . . . 0.0 113.029 176.187 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -74.93 -42.09 58.4 Favored 'General case' 0 C--O 1.224 -0.24 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 175.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.409 HD12 ' HA ' ' A' ' 81' ' ' HIS . 28.5 mt -57.82 -37.86 62.46 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 C-N-CA 124.714 1.205 . . . . 0.0 110.476 172.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.3 t -61.4 -52.28 63.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 O-C-N 120.578 -1.326 . . . . 0.0 109.684 172.264 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.7 ttmt -59.57 -40.39 87.22 Favored 'General case' 0 C--O 1.22 -0.491 0 C-N-CA 119.116 -1.034 . . . . 0.0 111.697 179.299 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.36 -42.98 67.39 Favored 'General case' 0 N--CA 1.443 -0.816 0 C-N-CA 126.633 1.973 . . . . 0.0 112.102 177.006 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.3 mt -69.25 -43.03 81.64 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 50.0 tttm -58.37 -49.83 75.84 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 118.329 0.513 . . . . 0.0 110.575 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -62.69 -18.62 62.76 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 128.773 2.829 . . . . 0.0 111.648 177.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.6 -34.26 76.64 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 119.588 1.085 . . . . 0.0 109.627 171.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.83 -97.88 1.84 Allowed Glycine 0 C--N 1.337 0.596 0 C-N-CA 126.119 1.819 . . . . 0.0 108.924 173.07 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.6 mt -121.64 -28.91 4.47 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 124.272 1.029 . . . . 0.0 111.819 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 p -93.3 143.61 26.1 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 170.069 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.3 p -145.51 153.4 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 166.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.98 112.22 15.66 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 -178.755 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 7.2 mt -90.54 114.7 26.97 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 173.326 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -71.85 121.14 18.49 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 164.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pt -128.35 -179.96 3.37 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 125.037 1.335 . . . . 0.0 108.359 175.279 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.435 ' H ' ' HD2' ' A' ' 101' ' ' PRO . 43.7 mt -99.86 -55.05 0.16 Allowed Pre-proline 0 CA--C 1.537 0.464 0 C-N-CA 124.758 1.223 . . . . 0.0 109.202 169.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.435 ' HD2' ' H ' ' A' ' 100' ' ' ILE 0.257 10.7 Cg_endo -61.29 -178.11 0.24 Allowed 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 121.708 1.605 . . . . 0.0 114.39 175.331 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -166.94 175.8 7.42 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 128.736 2.814 . . . . 0.0 105.573 171.223 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -136.75 5.98 2.91 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.455 1.102 . . . . 0.0 111.914 174.171 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -124.68 -17.83 5.82 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 121.642 0.735 . . . . 0.0 111.708 -172.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.64 -18.21 60.58 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 124.37 1.068 . . . . 0.0 111.936 -170.331 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.9 m-80 -136.28 111.84 9.3 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 104.344 -2.465 . . . . 0.0 104.344 162.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.3 m -52.81 -51.69 71.69 Favored Pre-proline 0 CA--C 1.538 0.494 0 C-N-CA 125.506 1.523 . . . . 0.0 110.996 172.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -69.55 149.03 67.74 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 CA-C-N 121.223 1.473 . . . . 0.0 109.385 171.417 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 96.7 p -132.05 178.81 6.5 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 124.06 0.944 . . . . 0.0 109.495 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -86.74 164.31 35.75 Favored Glycine 0 CA--C 1.531 1.086 0 O-C-N 121.328 -0.857 . . . . 0.0 111.856 -174.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -66.9 177.43 3.56 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.519 2.812 . . . . 0.0 110.506 166.787 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.9 t -147.37 161.56 40.77 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 122.134 0.968 . . . . 0.0 109.681 160.299 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -165.2 -167.68 1.23 Allowed 'General case' 0 C--O 1.239 0.529 0 C-N-CA 127.166 2.187 . . . . 0.0 106.782 171.202 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.14 0 N-CA-C 107.79 -2.124 . . . . 0.0 107.79 -165.51 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.991 0 N-CA-C 112.165 -0.374 . . . . 0.0 112.165 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.4 m -73.09 136.68 44.95 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 123.602 0.761 . . . . 0.0 111.279 174.83 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.6 t -137.26 -170.65 2.78 Favored 'General case' 0 C--O 1.239 0.51 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 150.856 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.55 -97.97 0.91 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -174.018 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.2 m 59.52 103.8 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 126.603 1.961 . . . . 0.0 110.882 -170.439 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.9 t -122.65 113.7 19.59 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.41 1.084 . . . . 0.0 108.816 177.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.72 143.71 8.84 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 104.513 -3.435 . . . . 0.0 104.513 167.783 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 37.3 m 69.78 -67.79 0.22 Allowed 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 126.77 2.028 . . . . 0.0 112.759 -175.856 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 tp -86.31 70.2 10.5 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-O 122.186 0.993 . . . . 0.0 110.527 -165.91 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.401 ' HG2' ' H ' ' A' ' 11' ' ' THR . 22.9 tt0 -103.88 -172.44 2.11 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 125.534 1.533 . . . . 0.0 108.716 175.456 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' THR . . . . . 0.401 ' H ' ' HG2' ' A' ' 10' ' ' GLN . 17.5 p -136.49 168.46 19.42 Favored 'General case' 0 C--O 1.238 0.471 0 C-N-CA 125.937 1.695 . . . . 0.0 108.486 167.113 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.4 m -122.6 150.71 42.26 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 167.48 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -90.65 147.03 23.56 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 105.734 -1.95 . . . . 0.0 105.734 168.26 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 39.0 t -131.99 101.41 4.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 104.84 -2.282 . . . . 0.0 104.84 161.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.37 141.04 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 165.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.46 HD11 HD12 ' A' ' 62' ' ' LEU . 53.0 mt -134.74 133.19 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 170.383 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 76.7 m-70 -105.84 154.4 20.57 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 125.351 1.46 . . . . 0.0 108.053 173.431 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.6 ptt180 -136.43 -171.93 3.02 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 170.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.82 170.38 8.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 166.902 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -80.36 -23.55 40.43 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 113.289 0.848 . . . . 0.0 113.289 -168.405 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -69.99 -10.05 57.27 Favored 'General case' 0 N--CA 1.472 0.645 0 CA-C-N 119.595 1.089 . . . . 0.0 112.882 176.503 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -137.15 169.33 17.97 Favored 'General case' 0 C--O 1.241 0.637 0 C-N-CA 124.288 1.035 . . . . 0.0 110.736 -161.368 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.11 -178.54 45.87 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 179.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -80.1 170.44 16.44 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 142.742 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.48 52.39 0.83 Allowed Glycine 0 C--O 1.225 -0.437 0 CA-C-O 118.769 -1.017 . . . . 0.0 112.683 -172.512 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -136.68 142.11 43.16 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 125.764 1.625 . . . . 0.0 110.696 -177.455 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.4 t -128.08 136.42 60.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 177.642 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 56.5 mt -108.23 120.1 58.99 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 -171.124 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 27.8 pt -110.89 -169.6 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 C-N-CA 126.471 1.909 . . . . 0.0 108.74 -178.099 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 67.83 -177.92 0.21 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.868 1.267 . . . . 0.0 108.319 -159.813 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -161.61 165.64 28.04 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 125.839 1.656 . . . . 0.0 107.164 170.771 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.583 HD22 ' C ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -57.22 145.35 31.98 Favored 'General case' 0 CA--C 1.536 0.432 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 160.309 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -163.81 157.25 18.69 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 125.001 1.32 . . . . 0.0 109.723 176.256 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 16.4 ptt-85 -51.66 130.76 36.56 Favored Pre-proline 0 CA--C 1.539 0.55 0 C-N-CA 124.34 1.056 . . . . 0.0 109.511 170.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -80.82 -26.36 3.73 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 121.97 1.78 . . . . 0.0 112.5 -171.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 63.43 -54.1 0.2 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 127.769 2.428 . . . . 0.0 113.645 -172.658 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.4 t -79.23 174.84 11.15 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 119.441 1.019 . . . . 0.0 109.549 171.109 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.99 -54.49 27.52 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 177.721 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 3.7 p -125.4 146.76 49.46 Favored 'General case' 0 C--O 1.243 0.714 0 C-N-CA 124.386 1.075 . . . . 0.0 108.753 171.086 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 40.8 p -124.05 151.79 43.4 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 171.815 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 42.0 pt -82.27 5.12 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 C-N-CA 123.776 0.83 . . . . 0.0 110.96 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.5 m -62.21 146.98 49.27 Favored 'General case' 0 N--CA 1.446 -0.64 0 C-N-CA 126.122 1.769 . . . . 0.0 109.105 174.569 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.5 t -125.15 136.47 28.21 Favored Pre-proline 0 CA--C 1.533 0.306 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 165.697 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -75.15 -9.43 20.56 Favored 'Trans proline' 0 N--CA 1.461 -0.403 0 C-N-CA 122.904 2.403 . . . . 0.0 113.965 -178.293 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -139.73 122.27 16.23 Favored 'General case' 0 CA--C 1.52 -0.199 0 C-N-CA 124.948 1.299 . . . . 0.0 107.801 178.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.3 ptmt -151.55 154.0 35.63 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 124.299 1.04 . . . . 0.0 108.765 168.163 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.429 HG13 HD22 ' A' ' 62' ' ' LEU . 31.1 mm -62.57 144.41 14.38 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 CA-C-N 119.17 0.896 . . . . 0.0 109.6 175.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -128.03 -50.62 0.14 Allowed Glycine 0 CA--C 1.526 0.78 0 C-N-CA 126.39 1.948 . . . . 0.0 113.181 179.334 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 2.0 ttm180 -119.99 139.88 51.81 Favored 'General case' 0 CA--C 1.511 -0.531 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 171.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 12.7 mt -120.06 149.76 22.76 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 N-CA-C 105.568 -2.012 . . . . 0.0 105.568 159.608 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -87.65 129.54 38.83 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 126.648 1.979 . . . . 0.0 108.097 177.67 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -61.55 124.51 20.86 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 123.636 0.774 . . . . 0.0 109.194 167.406 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.59 17.61 38.32 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-O 117.771 -1.572 . . . . 0.0 112.767 178.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 87.6 p -106.62 163.76 16.32 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-N 119.006 1.403 . . . . 0.0 113.116 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo -63.85 -25.08 67.76 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 122.902 2.401 . . . . 0.0 112.927 169.217 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.32 -55.88 29.2 Favored 'General case' 0 C--N 1.345 0.404 0 CA-C-N 120.305 1.411 . . . . 0.0 109.883 174.006 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -63.32 -37.53 87.64 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.316 0.647 . . . . 0.0 112.355 -175.397 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -65.72 -23.02 66.66 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 121.657 -0.652 . . . . 0.0 112.731 172.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 73.9 m -92.96 50.36 1.54 Allowed 'General case' 0 CA--C 1.533 0.321 0 O-C-N 120.568 -1.332 . . . . 0.0 110.824 174.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -59.2 9.16 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 127.036 2.134 . . . . 0.0 116.359 -177.195 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -61.92 -16.01 47.56 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 120.906 -1.121 . . . . 0.0 111.505 154.194 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.464 HD11 HD13 ' A' ' 97' ' ' LEU . 0.6 OUTLIER -115.51 137.64 51.85 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 127.393 2.277 . . . . 0.0 107.348 174.763 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -136.41 166.35 23.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 119.37 0.986 . . . . 0.0 111.146 172.35 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.4 t -55.94 112.6 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.251 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 168.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 129.95 -21.23 4.99 Favored Glycine 0 N--CA 1.441 -1.0 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 177.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -70.81 106.05 3.44 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 122.982 1.373 . . . . 0.0 110.772 -174.386 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.4 ' HG3' ' H ' ' A' ' 67' ' ' ARG . 31.1 mtm180 -37.38 143.52 0.1 Allowed 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 129.974 3.31 . . . . 0.0 111.297 156.315 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 23.4 mt -132.41 129.89 59.64 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 -174.636 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.7 mt -94.28 -40.19 10.11 Favored 'General case' 0 CA--C 1.52 -0.186 0 C-N-CA 123.862 0.865 . . . . 0.0 112.051 179.376 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.42 168.95 25.84 Favored 'General case' 0 C--O 1.236 0.382 0 C-N-CA 124.189 0.996 . . . . 0.0 109.754 -168.532 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.5 t -129.2 127.12 65.19 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 169.07 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 43.71 34.94 0.93 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 124.631 1.172 . . . . 0.0 112.193 -165.283 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.93 -3.7 27.02 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-O 118.349 -1.25 . . . . 0.0 113.347 179.11 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.2 tp60 -74.54 134.69 42.17 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 119.513 1.657 . . . . 0.0 107.057 174.458 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.1 m -72.53 136.89 45.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 -176.076 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 17.0 pt -115.76 -8.28 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 C-N-CA 125.755 1.622 . . . . 0.0 112.078 -175.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.7 mm -54.14 -52.75 34.62 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 123.813 0.845 . . . . 0.0 110.344 172.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -89.28 -26.44 21.15 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 111.712 0.264 . . . . 0.0 111.712 -173.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 7.0 ttt -66.5 137.87 95.45 Favored Pre-proline 0 N--CA 1.441 -0.884 0 C-N-CA 126.78 2.032 . . . . 0.0 109.645 -170.484 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -75.04 148.03 34.56 Favored 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 121.733 1.622 . . . . 0.0 109.051 178.361 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -54.24 -35.24 62.25 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -174.647 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -58.66 -43.01 89.71 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 119.937 1.244 . . . . 0.0 112.904 177.496 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -69.41 -39.68 77.76 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 125.243 1.417 . . . . 0.0 108.957 -178.342 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 36.5 mt -65.89 -40.0 86.28 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.529 1.131 . . . . 0.0 110.872 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 72.6 t -66.03 -41.23 89.26 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 O-C-N 118.998 -2.314 . . . . 0.0 109.607 173.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -52.5 -52.89 52.28 Favored 'General case' 0 C--O 1.223 -0.299 0 CA-C-O 117.489 -1.243 . . . . 0.0 109.539 171.652 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.51 -35.77 61.02 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 126.758 2.023 . . . . 0.0 112.303 -178.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 71.8 mt -78.11 -37.0 22.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 O-C-N 120.878 -1.139 . . . . 0.0 109.257 -179.133 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -65.47 -36.15 83.01 Favored 'General case' 0 N--CA 1.46 0.07 0 O-C-N 121.363 -0.835 . . . . 0.0 110.406 172.099 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -67.52 -37.65 83.09 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 126.401 1.88 . . . . 0.0 110.051 179.124 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.27 -41.6 80.03 Favored 'General case' 0 C--O 1.236 0.373 0 O-C-N 123.644 0.59 . . . . 0.0 110.769 -178.741 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 109.71 -141.36 16.1 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 124.63 1.11 . . . . 0.0 110.911 171.092 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 85.9 mt -70.4 -40.92 73.62 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 169.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.98 131.75 40.59 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 123.102 0.561 . . . . 0.0 110.083 176.022 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.3 p -133.04 139.85 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 C-N-CA 125.165 1.386 . . . . 0.0 107.559 171.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.73 109.14 19.75 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 177.259 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.464 HD13 HD11 ' A' ' 62' ' ' LEU . 17.9 mt -90.51 145.63 24.74 Favored 'General case' 0 CA--C 1.52 -0.177 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 174.422 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 19.7 ttm180 -114.48 114.17 25.44 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 174.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pp -114.97 160.96 14.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 125.003 1.321 . . . . 0.0 108.913 -179.112 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 89.4 mt -94.62 117.3 66.97 Favored Pre-proline 0 C--O 1.238 0.473 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 167.609 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -87.87 -170.24 0.54 Allowed 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 124.987 3.791 . . . . 0.0 109.472 178.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 4.5 pm0 -145.43 164.54 31.24 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 124.263 1.025 . . . . 0.0 110.049 -173.516 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -139.12 -1.45 1.75 Allowed 'General case' 0 CA--C 1.526 0.056 0 CA-C-N 118.215 0.461 . . . . 0.0 112.132 170.711 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -121.75 -13.73 8.25 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 114.71 1.374 . . . . 0.0 114.71 -165.379 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 8.5 mt -70.51 154.02 42.32 Favored 'General case' 0 C--O 1.24 0.596 0 C-N-CA 123.73 0.812 . . . . 0.0 109.217 166.098 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -161.29 141.01 10.53 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 126.16 1.784 . . . . 0.0 106.727 161.215 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.9 m -133.63 154.32 80.62 Favored Pre-proline 0 CA--C 1.538 0.503 0 CA-C-N 119.42 1.009 . . . . 0.0 110.104 -177.371 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -76.35 161.94 34.22 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 121.967 1.778 . . . . 0.0 111.468 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 77.3 p -72.21 -13.14 61.46 Favored 'General case' 0 N--CA 1.462 0.147 0 C-N-CA 124.427 1.091 . . . . 0.0 113.336 178.277 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 179.06 -179.03 48.97 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 108.341 -1.904 . . . . 0.0 108.341 -175.295 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -63.3 136.79 57.3 Favored 'Trans proline' 0 N--CA 1.451 -1.008 0 C-N-CA 122.597 2.198 . . . . 0.0 110.684 178.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.8 m -72.55 136.04 45.74 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 158.672 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -160.26 -166.85 1.77 Allowed 'General case' 0 C--O 1.237 0.403 0 C-N-CA 124.022 0.929 . . . . 0.0 108.671 167.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.002 0 N-CA-C 103.429 -3.869 . . . . 0.0 103.429 142.031 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.512 0 N-CA-C 108.729 -1.749 . . . . 0.0 108.729 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.5 m -137.05 -91.82 0.24 Allowed 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -178.378 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.8 p -66.74 157.11 33.61 Favored 'General case' 0 C--O 1.238 0.478 0 C-N-CA 124.464 1.106 . . . . 0.0 110.656 173.549 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.53 177.59 21.27 Favored Glycine 0 CA--C 1.526 0.764 0 C-N-CA 126.568 2.033 . . . . 0.0 109.261 -172.395 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.3 t -61.44 143.27 56.14 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 174.288 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.5 m -122.02 108.72 13.71 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 124.23 1.012 . . . . 0.0 109.294 -175.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.59 163.1 35.01 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 174.721 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.36 -53.4 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 125.061 1.344 . . . . 0.0 108.15 174.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.4 mp -49.32 108.61 0.2 Allowed 'General case' 0 C--O 1.234 0.284 0 C-N-CA 127.773 2.429 . . . . 0.0 110.868 178.405 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -63.46 155.15 30.03 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 167.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 32.9 p -132.93 169.07 17.32 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.172 0.589 . . . . 0.0 110.14 171.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.1 t -117.3 158.99 23.42 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 148.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -129.3 94.62 3.83 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 174.073 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 15.2 t -92.58 96.14 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 C-N-CA 125.838 1.655 . . . . 0.0 107.513 -173.181 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.1 p -80.42 135.36 25.47 Favored 'Isoleucine or valine' 0 C--O 1.238 0.451 0 C-N-CA 123.322 0.649 . . . . 0.0 109.792 174.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 46.2 mt -132.28 126.46 55.79 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 C-N-CA 125.155 1.382 . . . . 0.0 107.74 176.272 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -88.76 161.77 16.6 Favored 'General case' 0 C--O 1.233 0.219 0 C-N-CA 125.022 1.329 . . . . 0.0 108.877 171.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 49.3 ptt85 -144.22 -171.11 3.51 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 160.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 168.38 9.59 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 161.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -70.9 -33.68 70.8 Favored 'General case' 0 C--N 1.329 -0.295 0 O-C-N 121.162 -0.962 . . . . 0.0 112.473 -178.464 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -74.1 6.55 3.36 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 124.586 1.154 . . . . 0.0 113.0 -171.575 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -143.81 171.66 13.9 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 126.539 1.936 . . . . 0.0 109.261 -169.626 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.83 176.57 23.01 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 124.434 1.016 . . . . 0.0 111.032 178.503 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -83.44 133.43 34.91 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 163.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -96.89 57.24 1.28 Allowed Glycine 0 CA--C 1.521 0.441 0 C-N-CA 124.599 1.095 . . . . 0.0 112.66 -171.507 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -137.97 167.24 22.17 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 125.522 1.529 . . . . 0.0 108.213 172.098 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.576 HG12 ' H ' ' A' ' 49' ' ' ARG . 0.4 OUTLIER -132.39 157.65 43.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 176.236 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 20.3 mt -117.63 135.82 56.8 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 176.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.7 pt -129.8 156.59 42.19 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 124.104 0.962 . . . . 0.0 109.686 175.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 36.3 t -167.67 -58.97 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 125.383 1.473 . . . . 0.0 109.363 -174.82 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.7 m 63.1 -65.85 0.1 Allowed 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 126.63 1.972 . . . . 0.0 112.582 -170.799 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 79.37 -0.48 2.26 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 128.564 2.746 . . . . 0.0 114.976 173.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 14.4 m120 -63.58 -178.11 0.26 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 127.829 2.452 . . . . 0.0 112.217 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.95 130.85 15.42 Favored Pre-proline 0 N--CA 1.469 0.509 0 CA-C-O 116.458 -1.734 . . . . 0.0 108.446 173.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_exo -58.48 -41.51 64.33 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 121.797 1.665 . . . . 0.0 112.083 178.669 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -157.81 -77.28 0.08 Allowed 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 126.08 1.752 . . . . 0.0 106.504 -179.193 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 92.5 p -142.41 -168.96 2.86 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 127.383 2.273 . . . . 0.0 109.223 175.332 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 65.0 17.46 63.32 Favored Glycine 0 CA--C 1.53 1.018 0 CA-C-O 119.439 -0.645 . . . . 0.0 113.782 168.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.6 m -65.13 147.31 53.68 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 118.33 1.065 . . . . 0.0 110.378 -171.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.2 p -66.84 160.96 24.92 Favored 'General case' 0 C--O 1.24 0.555 0 C-N-CA 124.318 1.047 . . . . 0.0 109.57 166.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ILE . . . . . 0.483 ' H ' HD12 ' A' ' 41' ' ' ILE . 3.2 mp -71.34 105.47 1.74 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.453 0 N-CA-C 104.863 -2.273 . . . . 0.0 104.863 160.035 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.2 t -67.83 -170.95 0.18 Allowed 'General case' 0 CA--C 1.542 0.641 0 CA-C-O 121.768 0.794 . . . . 0.0 109.368 169.36 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 89.7 t -108.47 123.27 37.85 Favored Pre-proline 0 C--O 1.238 0.476 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 174.451 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -66.48 112.51 2.39 Favored 'Trans proline' 0 N--CA 1.449 -1.111 0 N-CA-C 106.692 -2.08 . . . . 0.0 106.692 159.768 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.558 ' NE2' HD13 ' A' ' 84' ' ' ILE . 19.4 m80 68.76 108.19 0.05 Allowed 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 126.531 1.933 . . . . 0.0 113.302 171.145 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 52.1 pttt -143.83 157.59 44.27 Favored 'General case' 0 N--CA 1.467 0.421 0 O-C-N 120.678 -1.264 . . . . 0.0 109.22 167.286 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.1 mm -65.06 123.86 18.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 172.051 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -110.46 -26.49 4.81 Favored Glycine 0 CA--C 1.535 1.285 0 N-CA-C 114.849 0.7 . . . . 0.0 114.849 176.654 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.576 ' H ' HG12 ' A' ' 27' ' ' VAL . 67.5 ttt180 -149.85 147.37 27.88 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 177.461 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.5 mt -121.84 131.76 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.72 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 166.257 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 23.8 mm -65.32 153.89 7.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 -177.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -68.51 118.34 11.43 Favored 'General case' 0 C--N 1.328 -0.351 0 O-C-N 121.474 -0.766 . . . . 0.0 110.634 -169.212 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.41 1.87 24.14 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 115.952 1.141 . . . . 0.0 115.952 169.712 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.49 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 3.5 p -68.77 175.25 2.07 Favored Pre-proline 0 CA--C 1.554 1.108 0 C-N-CA 126.966 2.106 . . . . 0.0 113.067 178.63 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.49 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 3.3 Cg_exo -64.44 -24.43 64.02 Favored 'Trans proline' 0 C--N 1.351 0.704 0 C-N-CA 121.601 1.534 . . . . 0.0 115.154 -168.097 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -69.38 -48.2 61.9 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 118.803 0.729 . . . . 0.0 109.613 172.569 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -54.13 -49.63 68.75 Favored 'General case' 0 N--CA 1.464 0.262 0 C-N-CA 125.294 1.437 . . . . 0.0 110.168 177.553 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.4 mmt-85 -68.88 -15.61 63.54 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 123.694 0.797 . . . . 0.0 112.952 177.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 17.5 t -68.89 -28.2 66.47 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 117.724 -1.131 . . . . 0.0 110.357 177.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 59.38 -28.93 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 128.595 2.758 . . . . 0.0 115.475 -174.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 47.9 mtmt -62.73 -33.17 74.58 Favored 'General case' 0 CA--C 1.521 -0.139 0 C-N-CA 125.55 1.54 . . . . 0.0 112.386 178.043 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -105.87 119.49 39.31 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 -165.081 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 3.0 ptpp? -131.99 167.91 18.84 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 119.665 1.12 . . . . 0.0 110.518 -178.073 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 73.7 t -64.34 137.77 24.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 178.223 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.96 -16.71 57.13 Favored Glycine 0 N--CA 1.447 -0.613 0 CA-C-O 117.475 -1.736 . . . . 0.0 110.725 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -67.45 92.88 0.31 Allowed 'General case' 0 C--N 1.346 0.426 0 CA-C-N 118.909 1.355 . . . . 0.0 108.458 -178.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.587 HH22 HD13 ' A' ' 105' ' ' LEU . 31.3 mtt85 -46.85 128.91 11.41 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 126.543 1.937 . . . . 0.0 110.892 165.173 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 55.0 mt -96.89 155.76 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 C-N-CA 126.417 1.887 . . . . 0.0 107.086 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.13 -54.52 1.7 Allowed 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 125.976 1.71 . . . . 0.0 107.961 -179.343 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.97 158.87 43.33 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 125.629 1.572 . . . . 0.0 108.764 -176.401 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.577 HG22 HD23 ' A' ' 97' ' ' LEU . 39.2 t -136.2 132.96 50.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.067 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 57.75 10.23 1.03 Allowed 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.052 0.941 . . . . 0.0 112.449 -163.359 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 82.04 -2.28 84.42 Favored Glycine 0 CA--C 1.534 1.222 0 C-N-CA 125.0 1.286 . . . . 0.0 113.22 -170.366 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -75.64 141.32 42.82 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 120.537 2.168 . . . . 0.0 107.233 169.727 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 33.1 m -56.58 147.14 23.03 Favored 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 118.71 0.686 . . . . 0.0 109.569 164.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.3 pp -116.56 5.66 7.26 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 C-N-CA 124.361 1.065 . . . . 0.0 111.838 172.525 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 98.0 mt -63.5 143.44 15.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 124.274 1.03 . . . . 0.0 108.282 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 61.62 -18.77 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 128.822 2.849 . . . . 0.0 117.291 172.829 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 4.8 mtp -55.87 145.78 51.21 Favored Pre-proline 0 C--O 1.241 0.611 0 CA-C-N 119.273 0.942 . . . . 0.0 110.034 177.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -69.18 155.21 68.51 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 122.629 2.22 . . . . 0.0 108.027 170.73 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -59.7 -32.16 70.25 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.7 -171.628 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.29 -39.45 72.71 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 126.214 1.806 . . . . 0.0 112.861 175.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 61.8 m-20 -70.98 -46.65 61.95 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -178.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.558 HD13 ' NE2' ' A' ' 45' ' ' HIS . 8.5 mt -64.66 -33.58 64.16 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 C-N-CA 126.018 1.727 . . . . 0.0 111.133 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.5 t -65.07 -51.51 65.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 124.475 1.11 . . . . 0.0 108.888 170.052 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.71 -37.34 81.38 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 116.77 -1.586 . . . . 0.0 110.984 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -51.64 -49.17 62.78 Favored 'General case' 0 N--CA 1.445 -0.697 0 C-N-CA 125.88 1.672 . . . . 0.0 111.301 173.395 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 53.2 mt -70.23 -38.65 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.16 0 O-C-N 121.066 -1.021 . . . . 0.0 108.873 -178.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.1 tttp -65.96 -38.49 88.73 Favored 'General case' 0 N--CA 1.453 -0.291 0 O-C-N 121.728 -0.607 . . . . 0.0 110.925 -179.416 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -66.45 -19.04 65.69 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 129.381 3.072 . . . . 0.0 111.588 174.589 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -64.5 -31.05 72.1 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.722 -0.611 . . . . 0.0 111.938 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 87.65 -149.85 22.03 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -169.19 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.7 mt -83.1 -20.76 34.24 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 118.201 1.001 . . . . 0.0 111.534 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.2 p -94.49 139.52 31.05 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 169.548 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 p -145.02 148.15 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 169.305 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.6 m -125.09 118.39 26.03 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 178.227 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.577 HD23 HG22 ' A' ' 71' ' ' VAL . 71.4 mt -90.78 124.05 34.83 Favored 'General case' 0 CA--C 1.509 -0.597 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 170.405 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 24.5 ttm105 -96.13 121.46 37.93 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 168.182 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -125.56 173.88 10.63 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 C-N-CA 125.559 1.543 . . . . 0.0 109.211 -166.303 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.6 mp -114.58 104.57 54.34 Favored Pre-proline 0 C--O 1.237 0.408 0 C-N-CA 124.057 0.943 . . . . 0.0 108.581 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.34 178.93 5.52 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.564 2.843 . . . . 0.0 110.335 173.583 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.53 162.92 40.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 O-C-N 121.751 -0.593 . . . . 0.0 110.714 -171.244 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -133.64 -13.37 2.59 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 124.294 1.038 . . . . 0.0 113.156 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.69 -8.11 0.74 Allowed 'General case' 0 C--N 1.322 -0.589 0 C-N-CA 124.397 1.079 . . . . 0.0 112.796 -165.723 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.587 HD13 HH22 ' A' ' 67' ' ' ARG . 17.9 mt -90.03 100.06 12.95 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.286 1.434 . . . . 0.0 110.493 -175.675 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 11.0 p-10 -111.46 -157.67 0.62 Allowed 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.08 1.352 . . . . 0.0 110.152 172.402 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.7 p -121.6 143.17 37.36 Favored Pre-proline 0 CA--C 1.533 0.291 0 CA-C-O 117.253 -1.356 . . . . 0.0 107.816 161.502 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.37 -7.85 20.99 Favored 'Trans proline' 0 CA--C 1.533 0.471 0 C-N-CA 122.633 2.222 . . . . 0.0 115.572 -158.379 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.9 m 36.09 85.36 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.658 1.983 . . . . 0.0 115.014 171.551 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -122.54 84.69 0.37 Allowed Glycine 0 CA--C 1.53 0.993 0 C-N-CA 124.317 0.961 . . . . 0.0 111.633 178.799 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -63.42 -52.1 2.18 Favored 'Trans proline' 0 N--CA 1.457 -0.648 0 CA-C-N 119.914 1.857 . . . . 0.0 110.679 167.006 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 14.0 t -66.42 135.24 54.01 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 123.139 0.575 . . . . 0.0 109.628 -177.658 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.0 m 59.77 85.81 0.1 Allowed 'General case' 0 C--O 1.232 0.173 0 C-N-CA 126.964 2.106 . . . . 0.0 109.629 -170.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.084 0 N-CA-C 107.331 -2.308 . . . . 0.0 107.331 173.363 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.771 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.5 m -104.69 149.45 25.56 Favored 'General case' 0 C--O 1.233 0.212 0 C-N-CA 124.481 1.112 . . . . 0.0 110.434 174.508 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.3 m -52.04 121.74 7.26 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 123.853 0.861 . . . . 0.0 108.809 165.698 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 150.14 177.73 24.4 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 106.646 -2.582 . . . . 0.0 106.646 -153.549 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 68.8 m -112.77 175.19 5.54 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -155.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.7 m -132.88 80.31 1.88 Allowed 'General case' 0 C--O 1.234 0.259 0 C-N-CA 125.735 1.614 . . . . 0.0 107.158 -179.787 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.61 91.09 0.09 OUTLIER Glycine 0 C--N 1.334 0.452 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -171.092 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 51.3 m -162.74 158.63 23.17 Favored 'General case' 0 C--O 1.238 0.481 0 C-N-CA 126.716 2.006 . . . . 0.0 107.284 166.251 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 11.0 mp 48.37 51.97 14.28 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 126.27 1.828 . . . . 0.0 111.333 175.445 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.1 tt0 -63.86 134.43 55.18 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 174.43 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 32.8 p -113.92 169.76 8.76 Favored 'General case' 0 C--O 1.238 0.463 0 C-N-CA 124.661 1.184 . . . . 0.0 109.772 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 42.2 m -111.04 153.23 25.91 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 162.225 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -122.89 115.38 21.85 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 105.108 -2.182 . . . . 0.0 105.108 174.114 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -112.31 97.14 5.35 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 C-N-CA 123.703 0.801 . . . . 0.0 109.163 -173.107 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.5 p -76.75 141.36 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 170.253 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 59.7 mt -136.58 140.03 44.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 173.123 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 14.7 m-70 -124.7 113.28 17.78 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.789 2.436 . . . . 0.0 108.117 -170.809 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.2 ptt180 -106.16 -179.41 3.93 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 119.287 0.948 . . . . 0.0 111.238 -176.123 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.93 161.08 13.91 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 119.049 0.84 . . . . 0.0 110.257 170.247 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -64.41 -19.79 65.73 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.501 1.12 . . . . 0.0 112.216 177.76 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -87.68 -16.87 33.13 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 119.537 1.062 . . . . 0.0 113.235 178.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -113.09 -178.53 3.4 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 119.281 0.946 . . . . 0.0 109.877 -171.445 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -105.72 -176.38 23.93 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 169.414 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -78.31 176.79 8.98 Favored 'General case' 0 CA--C 1.533 0.316 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 153.53 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.418 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -135.13 50.79 0.85 Allowed Glycine 0 C--O 1.224 -0.531 0 CA-C-O 118.234 -1.315 . . . . 0.0 113.195 -172.123 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PHE . . . . . 0.52 ' CE2' HD11 ' A' ' 28' ' ' ILE . 11.7 p90 -137.74 135.5 36.44 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 124.756 1.222 . . . . 0.0 110.299 -179.405 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.2 t -102.91 109.25 26.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 -179.108 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.552 HD12 ' H ' ' A' ' 28' ' ' ILE . 4.1 mp -82.26 124.91 39.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 175.21 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.533 HD11 ' HE2' ' A' ' 46' ' ' LYS . 15.5 pt -111.88 153.28 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 C-N-CA 123.852 0.861 . . . . 0.0 109.746 177.743 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 31.3 t -91.75 -63.27 1.27 Allowed 'General case' 0 N--CA 1.447 -0.607 0 C-N-CA 126.113 1.765 . . . . 0.0 106.737 169.669 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 30.1 m 46.92 64.89 1.38 Allowed 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 125.392 1.477 . . . . 0.0 111.647 -173.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 75.71 86.58 0.09 Allowed 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 129.998 3.319 . . . . 0.0 109.691 178.401 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 52.3 t-20 -61.96 136.92 58.17 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 125.381 1.472 . . . . 0.0 109.315 175.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 5.1 mtt180 -132.98 151.99 78.96 Favored Pre-proline 0 C--O 1.236 0.387 0 C-N-CA 124.311 1.044 . . . . 0.0 108.976 167.454 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -70.25 95.93 0.61 Allowed 'Trans proline' 0 N--CA 1.451 -1.008 0 C-N-CA 123.999 3.133 . . . . 0.0 108.642 175.092 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -68.03 110.75 4.07 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 171.381 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.1 t -149.56 103.48 3.27 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 -164.301 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.25 -109.13 2.7 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 108.542 -1.823 . . . . 0.0 108.542 -179.098 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.3 m -65.07 109.97 2.34 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 124.328 1.051 . . . . 0.0 109.754 177.687 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 22.0 p -72.14 148.02 46.08 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.375 1.07 . . . . 0.0 111.843 -174.368 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 84.4 mt -144.39 -51.97 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.399 0 C-N-CA 125.19 1.396 . . . . 0.0 109.1 -174.235 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -146.86 99.34 3.17 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 123.923 0.889 . . . . 0.0 109.623 -159.238 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 15.9 t -65.55 130.95 94.73 Favored Pre-proline 0 CA--C 1.54 0.571 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -174.407 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.97 -19.92 22.66 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 122.456 2.104 . . . . 0.0 113.905 -174.457 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -136.59 140.4 42.83 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 120.815 1.643 . . . . 0.0 108.071 176.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.533 ' HE2' HD11 ' A' ' 29' ' ' ILE . 10.7 pttm -156.5 165.64 35.73 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 170.146 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.438 HD13 HD11 ' A' ' 68' ' ' ILE . 6.9 mm -66.59 148.35 12.14 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.809 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 167.488 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -134.85 -8.45 1.89 Allowed Glycine 0 CA--C 1.529 0.959 0 C-N-CA 125.081 1.324 . . . . 0.0 113.765 173.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.0 ttt180 -165.75 160.95 17.7 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 126.283 1.833 . . . . 0.0 107.13 165.544 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 36.4 mt -132.54 149.95 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 125.654 1.582 . . . . 0.0 107.685 172.698 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 41.5 mm -81.77 118.38 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 C-N-CA 125.529 1.532 . . . . 0.0 108.841 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -62.77 96.31 0.08 Allowed 'General case' 0 C--O 1.235 0.332 0 C-N-CA 125.502 1.521 . . . . 0.0 107.957 168.478 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.23 0.22 6.41 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 125.216 1.388 . . . . 0.0 113.698 -179.166 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.418 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 66.8 p -91.45 166.28 18.7 Favored Pre-proline 0 C--O 1.237 0.415 0 CA-C-N 118.911 1.355 . . . . 0.0 113.333 -179.768 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -62.96 -32.29 76.59 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.55 2.167 . . . . 0.0 111.659 166.079 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.02 -47.24 74.97 Favored 'General case' 0 C--N 1.346 0.414 0 CA-C-N 119.04 0.836 . . . . 0.0 110.806 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -67.97 -52.68 33.1 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.744 0.418 . . . . 0.0 111.043 178.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 15.0 mtp85 -57.7 -34.61 69.63 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 121.589 -0.694 . . . . 0.0 112.285 -173.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 61.1 m -62.81 -16.54 58.62 Favored 'General case' 0 CA--C 1.534 0.345 0 CA-C-O 117.709 -1.138 . . . . 0.0 112.494 -178.754 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 46.21 34.98 2.36 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.105 1.762 . . . . 0.0 113.623 170.686 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 18.9 mtmm -129.65 -6.99 4.61 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 126.908 2.083 . . . . 0.0 111.829 173.623 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.14 101.06 4.06 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 -173.434 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 13.3 pttp -126.75 159.41 33.85 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 126.184 1.794 . . . . 0.0 109.688 -168.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . 0.374 0.4 OUTLIER -65.5 111.69 1.53 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.255 0 O-C-N 121.363 -0.836 . . . . 0.0 109.476 179.814 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 129.95 -18.79 5.3 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 128.285 2.85 . . . . 0.0 111.462 -175.193 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -71.56 97.26 1.66 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.401 1.08 . . . . 0.0 110.333 171.64 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.2 mtm180 -54.34 150.59 8.52 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 127.687 2.395 . . . . 0.0 111.75 173.602 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.484 HG22 ' CD1' ' A' ' 76' ' ' ILE . 87.7 mt -124.86 117.14 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 -165.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 76.5 mt -89.0 -40.19 13.17 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 124.327 1.051 . . . . 0.0 112.179 179.115 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.49 170.65 21.93 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 124.676 1.19 . . . . 0.0 108.764 -170.049 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.4 p -122.48 122.81 67.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 170.641 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 54.32 -73.0 0.01 OUTLIER 'General case' 0 C--O 1.232 0.177 0 C-N-CA 128.191 2.597 . . . . 0.0 111.783 -170.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -155.75 18.93 0.5 Allowed Glycine 0 CA--C 1.529 0.957 0 C-N-CA 126.887 2.184 . . . . 0.0 112.034 -178.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 24.2 mm100 -115.18 135.17 54.46 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 119.661 1.73 . . . . 0.0 108.572 -175.66 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.7 m -72.61 110.23 6.83 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 123.977 0.911 . . . . 0.0 109.759 174.627 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.484 ' CD1' HG22 ' A' ' 68' ' ' ILE . 11.1 pt -75.99 -15.63 15.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 C-N-CA 125.133 1.373 . . . . 0.0 111.962 174.644 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.522 ' H ' HD12 ' A' ' 77' ' ' ILE . 4.1 mp -56.03 -47.0 80.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 C-N-CA 125.121 1.368 . . . . 0.0 113.713 -164.644 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -113.83 -0.93 14.03 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 124.365 1.066 . . . . 0.0 112.237 -169.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . 0.252 11.0 ttt -68.81 146.95 97.82 Favored Pre-proline 0 N--CA 1.434 -1.245 0 C-N-CA 130.62 3.568 . . . . 0.0 109.846 -178.662 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -57.07 141.34 94.17 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.816 2.344 . . . . 0.0 109.792 167.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.517 ' HA ' HD12 ' A' ' 84' ' ' ILE . 41.4 t60 -66.64 -36.34 82.33 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 120.246 1.384 . . . . 0.0 111.055 -178.264 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -57.72 -31.34 66.33 Favored 'General case' 0 CA--C 1.534 0.332 0 O-C-N 121.361 -0.837 . . . . 0.0 112.74 171.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -73.42 -48.52 33.1 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 124.308 1.043 . . . . 0.0 109.144 177.491 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.517 HD12 ' HA ' ' A' ' 81' ' ' HIS . 66.2 mt -56.67 -35.59 45.89 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 C-N-CA 125.505 1.522 . . . . 0.0 110.698 175.151 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 45.9 t -77.07 -39.81 29.57 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 C-N-CA 124.176 0.991 . . . . 0.0 110.313 177.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 21.0 ttmt -60.4 -38.5 84.19 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 120.9 -1.125 . . . . 0.0 110.124 173.786 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -57.61 -38.63 75.28 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 127.464 2.306 . . . . 0.0 112.598 174.718 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 59.9 mt -68.08 -45.98 82.4 Favored 'Isoleucine or valine' 0 C--N 1.341 0.206 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 174.522 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 6.5 tttm -64.16 -40.14 95.49 Favored 'General case' 0 CA--C 1.536 0.416 0 O-C-N 121.739 -0.601 . . . . 0.0 110.263 -176.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -65.69 -11.8 48.22 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 127.099 2.159 . . . . 0.0 112.188 176.323 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -66.67 -13.4 61.18 Favored 'General case' 0 CA--C 1.541 0.633 0 O-C-N 121.34 -0.85 . . . . 0.0 112.155 170.656 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 72.66 -90.04 0.55 Allowed Glycine 0 C--N 1.34 0.796 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.6 mt -125.74 -34.49 2.62 Favored 'General case' 0 CA--C 1.514 -0.423 0 C-N-CA 125.589 1.556 . . . . 0.0 111.526 175.6 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.63 121.85 42.31 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 118.377 0.535 . . . . 0.0 110.131 -179.129 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.7 p -123.96 147.69 28.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 173.589 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.6 m -119.15 135.79 54.49 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 173.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 31.0 mt -125.19 110.57 14.24 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 125.309 1.444 . . . . 0.0 108.317 -176.326 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 33.4 ttm180 -77.74 106.83 9.81 Favored 'General case' 0 C--O 1.238 0.483 0 C-N-CA 123.811 0.844 . . . . 0.0 111.211 177.087 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -111.27 168.73 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 124.161 0.984 . . . . 0.0 110.597 -175.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.1 mp -93.77 118.15 67.35 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-O 118.061 -0.971 . . . . 0.0 108.627 175.172 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -74.65 -169.48 0.62 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 124.095 3.197 . . . . 0.0 112.296 174.691 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 3.0 pm0 -155.71 153.76 30.45 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.372 1.469 . . . . 0.0 108.782 -174.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -145.0 18.22 1.6 Allowed 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.428 1.091 . . . . 0.0 111.017 -175.207 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -150.44 -32.79 0.18 Allowed 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 124.903 1.281 . . . . 0.0 113.137 -164.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 49.0 mt -67.37 109.97 3.38 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 126.804 2.041 . . . . 0.0 106.06 173.136 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -162.51 155.75 20.15 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 127.007 2.123 . . . . 0.0 106.002 -176.239 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -148.03 149.88 33.91 Favored Pre-proline 0 CA--C 1.537 0.453 0 CA-C-N 119.976 1.262 . . . . 0.0 110.238 173.039 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -92.9 -1.73 3.62 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 124.362 3.375 . . . . 0.0 113.872 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 12.8 m -2.83 81.19 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 131.093 3.757 . . . . 0.0 116.087 -172.75 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -96.54 -176.92 35.65 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.012 1.767 . . . . 0.0 110.899 172.138 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -68.24 165.94 26.94 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 122.367 2.045 . . . . 0.0 110.244 173.011 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.4 p -160.54 172.64 16.82 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 123.816 0.846 . . . . 0.0 109.168 175.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . 0.261 71.0 p 55.19 -173.05 0.05 Allowed 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 127.402 2.281 . . . . 0.0 112.587 -173.534 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.932 1 N-CA-C 101.773 -4.531 . . . . 0.0 101.773 -96.221 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.984 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.6 m -63.92 128.59 36.5 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 125.585 1.554 . . . . 0.0 107.333 167.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.8 t -69.2 163.09 25.7 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 119.002 0.819 . . . . 0.0 111.192 -166.611 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.53 103.44 0.34 Allowed Glycine 0 C--N 1.332 0.332 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 -175.009 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.4 m -66.14 -37.76 86.48 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 124.678 1.191 . . . . 0.0 113.135 -172.599 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 65.5 m 43.7 85.3 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 125.224 1.409 . . . . 0.0 112.567 -166.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -86.26 -96.53 0.8 Allowed Glycine 0 CA--C 1.523 0.562 0 N-CA-C 108.582 -1.807 . . . . 0.0 108.582 164.303 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.9 t 67.01 -60.63 0.36 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 126.559 1.944 . . . . 0.0 110.815 -172.526 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 tp -68.93 165.23 20.42 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.263 1.025 . . . . 0.0 110.083 176.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 70.5 mt-30 -123.75 138.56 54.49 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 170.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 44.6 p -131.22 166.09 21.93 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 167.101 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 m -141.74 150.69 42.12 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.706 1.202 . . . . 0.0 108.421 172.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -104.84 97.37 7.26 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 127.722 2.409 . . . . 0.0 105.862 -179.542 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 36.9 t -91.65 95.1 5.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 173.059 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.2 p -74.45 137.7 22.59 Favored 'Isoleucine or valine' 0 C--O 1.238 0.493 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 169.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.5 mt -135.61 134.55 51.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 104.835 -2.283 . . . . 0.0 104.835 174.346 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -108.33 160.43 15.87 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.542 1.137 . . . . 0.0 109.526 177.57 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 43.4 ptt85 -150.95 -179.64 7.46 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 119.424 1.011 . . . . 0.0 109.582 170.347 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.45 162.59 16.39 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 168.14 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.14 -42.52 95.01 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 174.828 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -71.52 -1.49 13.54 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-O 117.963 -1.018 . . . . 0.0 113.254 -167.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -137.1 179.07 6.6 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 121.278 1.854 . . . . 0.0 110.754 170.136 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.45 165.02 12.08 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 126.002 1.763 . . . . 0.0 110.169 170.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -66.94 148.96 51.27 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 124.637 1.175 . . . . 0.0 108.398 178.16 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.88 49.12 3.31 Favored Glycine 0 C--O 1.222 -0.629 0 CA-C-O 117.94 -1.478 . . . . 0.0 113.698 -174.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -136.22 156.27 48.91 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 120.745 2.273 . . . . 0.0 111.926 174.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.9 t -128.16 106.39 14.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 106.687 -1.597 . . . . 0.0 106.687 -175.11 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 23.8 mt -73.68 141.67 15.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 168.066 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.493 HD11 ' HE2' ' A' ' 46' ' ' LYS . 35.7 pt -127.09 170.9 16.3 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 C-N-CA 125.308 1.443 . . . . 0.0 110.826 174.561 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 13.5 m 62.57 95.42 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 128.088 2.555 . . . . 0.0 114.27 173.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.5 p -92.61 96.44 10.2 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 158.343 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 57.3 mt -70.68 151.49 44.86 Favored 'General case' 0 C--O 1.244 0.797 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 155.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 24.3 t30 -168.09 93.69 0.37 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 169.294 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 33.3 mtt85 -117.1 156.4 48.49 Favored Pre-proline 0 N--CA 1.474 0.754 0 O-C-N 120.723 -1.235 . . . . 0.0 111.202 170.637 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -81.82 77.61 3.81 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 123.621 2.881 . . . . 0.0 108.972 172.711 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.0 tm-20 170.91 -42.28 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 129.916 3.286 . . . . 0.0 107.452 173.556 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.3 m 72.4 -70.38 0.16 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 127.699 2.4 . . . . 0.0 111.289 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 59.34 -173.56 4.1 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.153 0.882 . . . . 0.0 113.48 177.612 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 59.1 m -78.6 111.57 14.8 Favored 'General case' 0 C--O 1.233 0.23 0 O-C-N 121.675 -0.897 . . . . 0.0 109.344 172.695 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -103.64 137.83 41.14 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.655 1.582 . . . . 0.0 108.709 -179.097 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 10.9 mm -67.89 -76.96 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 118.79 0.723 . . . . 0.0 109.702 -177.514 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.0 m -56.23 131.11 47.02 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 173.218 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -68.45 156.65 90.02 Favored Pre-proline 0 CA--C 1.541 0.63 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 174.297 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -74.16 -108.75 0.01 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.91 0 C-N-CA 122.58 2.187 . . . . 0.0 109.289 163.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.16 119.79 13.31 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 122.809 1.29 . . . . 0.0 110.973 -167.601 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.493 ' HE2' HD11 ' A' ' 29' ' ' ILE . 15.2 pttm -152.47 160.08 43.29 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 128.523 2.729 . . . . 0.0 106.267 178.433 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.409 HG13 HD22 ' A' ' 62' ' ' LEU . 34.6 mm -64.33 126.76 23.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 164.835 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -109.22 -21.14 7.49 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 125.717 1.627 . . . . 0.0 113.757 174.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 53.7 ttt180 -161.7 162.34 29.74 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 126.438 1.895 . . . . 0.0 108.06 166.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 6.5 mt -127.98 150.38 33.7 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 126.422 1.889 . . . . 0.0 108.094 170.505 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 21.3 mm -85.34 128.67 38.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 126.245 1.818 . . . . 0.0 107.226 178.584 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -62.1 143.02 57.24 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 123.23 0.612 . . . . 0.0 112.047 -172.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.68 -8.11 6.2 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 125.441 1.496 . . . . 0.0 115.47 176.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 84.8 p -67.49 170.25 7.25 Favored Pre-proline 0 C--O 1.239 0.518 0 CA-C-N 118.241 1.02 . . . . 0.0 112.198 -173.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.456 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 6.3 Cg_endo -57.23 -21.61 44.48 Favored 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.028 1.819 . . . . 0.0 112.508 165.843 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.43 -50.18 13.25 Favored 'General case' 0 C--N 1.342 0.242 0 CA-C-N 119.883 1.22 . . . . 0.0 110.699 174.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -63.58 -45.09 92.01 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 118.533 0.606 . . . . 0.0 110.763 -175.467 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -70.55 -13.78 62.24 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 123.565 0.746 . . . . 0.0 112.197 178.578 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 35.6 t -63.16 -49.99 72.15 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 119.127 0.876 . . . . 0.0 109.211 179.254 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.93 -21.41 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 128.439 2.695 . . . . 0.0 115.679 -173.401 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.4 mmmm -63.21 -26.56 68.85 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 125.976 1.71 . . . . 0.0 110.565 165.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.409 HD22 HG13 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -99.39 138.43 36.49 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 161.753 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 21.1 pttm -139.74 171.21 14.55 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 123.641 0.777 . . . . 0.0 110.795 164.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 84.6 t -59.85 137.96 21.52 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.714 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 175.389 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 93.83 -7.31 73.78 Favored Glycine 0 C--N 1.341 0.849 0 O-C-N 121.039 -1.038 . . . . 0.0 110.567 177.057 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 68.9 m-20 -71.84 98.76 2.05 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 171.281 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.9 mtt180 -45.78 158.46 0.09 Allowed 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 127.519 2.328 . . . . 0.0 110.841 162.504 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 19.1 mt -138.47 118.07 14.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -170.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.434 HD22 ' H ' ' A' ' 69' ' ' LEU . 1.9 mm? -78.17 -45.25 23.65 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.567 1.147 . . . . 0.0 111.732 172.21 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -160.3 166.24 29.86 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.181 0.992 . . . . 0.0 112.163 -160.475 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.2 p -128.66 111.83 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 C-N-CA 126.191 1.796 . . . . 0.0 110.138 -178.506 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.5 m-20 56.0 17.48 2.64 Favored 'General case' 0 N--CA 1.465 0.282 0 C-N-CA 125.285 1.434 . . . . 0.0 111.147 -168.545 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.48 -10.33 61.13 Favored Glycine 0 CA--C 1.529 0.944 0 CA-C-O 117.527 -1.707 . . . . 0.0 114.382 -175.684 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -75.92 132.15 40.08 Favored 'General case' 0 C--N 1.341 0.235 0 CA-C-N 120.51 2.155 . . . . 0.0 107.478 177.394 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.3 p -61.68 137.02 58.22 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 124.181 0.992 . . . . 0.0 109.949 175.039 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.7 pt -114.55 -4.37 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 C-N-CA 124.908 1.283 . . . . 0.0 111.331 179.286 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mt -57.9 145.14 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.596 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 162.555 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 18.7 m-80 67.13 -21.92 0.11 Allowed 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 128.117 2.567 . . . . 0.0 116.036 171.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 6.6 mtp -69.45 150.7 96.95 Favored Pre-proline 0 C--O 1.244 0.767 0 C-N-CA 124.658 1.183 . . . . 0.0 109.86 175.737 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -74.68 154.46 44.15 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 123.17 2.58 . . . . 0.0 109.856 173.154 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -54.99 -41.82 71.71 Favored 'General case' 0 N--CA 1.462 0.13 0 C-N-CA 123.42 0.688 . . . . 0.0 111.604 -178.418 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -57.15 -44.58 83.56 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-O 118.822 -0.609 . . . . 0.0 111.332 -174.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.52 -42.44 74.69 Favored 'General case' 0 C--O 1.221 -0.413 0 O-C-N 124.36 1.037 . . . . 0.0 110.011 -175.763 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 68.4 mt -63.33 -41.22 91.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 124.797 1.239 . . . . 0.0 109.679 178.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 41.4 t -62.55 -48.04 90.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 O-C-N 121.161 -0.962 . . . . 0.0 109.456 174.027 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 6.1 tptt -58.44 -43.68 88.86 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 118.614 -0.708 . . . . 0.0 111.279 176.623 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.05 -34.45 73.43 Favored 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 126.154 1.781 . . . . 0.0 111.71 -176.873 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 58.1 mt -73.15 -47.63 46.56 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 173.446 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.3 tttt -58.29 -32.92 68.89 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 122.096 -0.378 . . . . 0.0 111.686 -177.682 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -99.76 2.09 43.81 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 125.173 1.389 . . . . 0.0 112.276 -177.024 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -54.92 -29.57 56.55 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -171.572 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 123.13 27.57 1.49 Allowed Glycine 0 CA--C 1.526 0.768 0 C-N-CA 124.349 0.976 . . . . 0.0 113.285 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 7.8 mt 58.02 -23.11 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 129.023 2.929 . . . . 0.0 114.555 -164.442 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -93.56 148.59 21.95 Favored 'General case' 0 N--CA 1.435 -1.195 0 N-CA-C 105.24 -2.133 . . . . 0.0 105.24 161.316 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.1 p -143.26 140.48 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 0 N-CA-C 105.009 -2.219 . . . . 0.0 105.009 169.639 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.9 m -117.97 102.42 9.04 Favored 'General case' 0 N--CA 1.441 -0.911 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 21.6 mt -90.13 122.1 32.78 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 106.476 -1.676 . . . . 0.0 106.476 -172.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.1 ttt180 -83.73 109.77 17.76 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.011 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -111.94 160.97 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 123.429 0.692 . . . . 0.0 110.83 -177.811 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 28.5 mt -90.6 120.35 68.92 Favored Pre-proline 0 CA--C 1.537 0.459 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 169.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -87.19 -170.83 0.65 Allowed 'Trans proline' 0 N--CA 1.45 -1.046 0 C-N-CA 123.915 3.077 . . . . 0.0 110.978 177.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -145.77 170.41 16.58 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 123.642 0.777 . . . . 0.0 109.293 -178.684 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -146.55 -7.52 0.51 Allowed 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 113.11 0.782 . . . . 0.0 113.11 156.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -102.75 -9.25 20.17 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 123.787 0.835 . . . . 0.0 112.688 -166.52 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 18.1 mt -77.33 163.01 26.84 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 123.416 0.687 . . . . 0.0 109.706 -178.685 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -147.85 179.29 7.83 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 161.553 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.3 t -72.09 126.51 91.19 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 167.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -73.65 -179.56 4.65 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 C-N-CA 123.211 2.608 . . . . 0.0 109.651 171.403 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 5.7 t -145.33 160.78 41.01 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 160.381 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -138.55 167.18 25.11 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 108.652 -1.779 . . . . 0.0 108.652 170.694 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -74.52 -175.93 2.51 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 123.348 2.699 . . . . 0.0 111.673 -175.295 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 10.6 t -129.88 -174.65 3.37 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 127.551 2.34 . . . . 0.0 107.71 165.762 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 24.2 t -67.03 175.84 2.38 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 124.288 1.035 . . . . 0.0 110.316 174.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.42 0 N-CA-C 106.332 -2.707 . . . . 0.0 106.332 144.498 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.391 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.7 t -64.29 112.37 3.03 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 171.656 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.2 m -81.18 98.52 8.1 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 171.559 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.21 -143.57 3.79 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 108.338 -1.905 . . . . 0.0 108.338 -177.693 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.8 m -140.11 -5.59 1.28 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 114.125 1.158 . . . . 0.0 114.125 174.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.3 p -124.84 160.97 27.55 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 120.583 1.538 . . . . 0.0 111.127 -176.509 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 144.58 71.29 0.02 OUTLIER Glycine 0 C--N 1.332 0.308 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 172.448 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 19.7 t -62.91 -53.71 49.8 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 117.815 0.808 . . . . 0.0 108.986 173.598 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -102.33 140.7 36.27 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 177.71 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -156.15 -130.59 0.03 OUTLIER 'General case' 0 C--O 1.232 0.134 0 C-N-CA 125.511 1.525 . . . . 0.0 109.691 173.279 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.7 p -136.47 169.18 18.11 Favored 'General case' 0 C--N 1.319 -0.746 0 C-N-CA 129.232 3.013 . . . . 0.0 110.589 -177.606 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -135.23 163.83 29.07 Favored 'General case' 0 CA--C 1.522 -0.12 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 162.397 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -134.42 94.85 3.27 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 127.185 2.194 . . . . 0.0 107.245 -174.043 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.8 t -96.89 109.73 23.63 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 125.373 1.469 . . . . 0.0 107.86 -165.167 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 1.5 t -84.16 141.89 14.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 173.634 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 69.7 mt -138.22 149.79 24.56 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 105.57 -2.011 . . . . 0.0 105.57 173.815 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 91.3 m-70 -130.82 156.38 45.1 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.928 1.291 . . . . 0.0 109.271 -176.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 35.3 ptt180 -143.08 -176.86 5.08 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 119.779 1.172 . . . . 0.0 110.048 176.633 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.44 163.31 12.54 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 124.047 0.939 . . . . 0.0 108.89 170.199 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -70.57 -19.33 62.88 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -177.554 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.8 m-20 -90.31 5.54 46.81 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 119.745 1.157 . . . . 0.0 112.07 177.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -140.92 176.77 8.53 Favored 'General case' 0 N--CA 1.445 -0.697 0 O-C-N 121.253 -0.905 . . . . 0.0 111.493 -172.832 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.42 170.73 14.61 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 178.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.443 ' CE1' HG12 ' A' ' 95' ' ' VAL . 40.2 m-85 -71.49 171.14 11.86 Favored 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 152.515 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -127.94 55.43 0.75 Allowed Glycine 0 C--O 1.222 -0.646 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 25.7 p90 -131.4 158.61 40.3 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 170.215 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 9.2 t -136.88 127.79 41.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 -174.474 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 4.0 mp -87.07 146.8 5.85 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 175.166 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 31.6 pt -133.68 170.79 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 C-N-CA 126.326 1.85 . . . . 0.0 108.239 160.174 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 t -137.38 -177.7 4.89 Favored 'General case' 0 C--O 1.238 0.478 0 C-N-CA 125.508 1.523 . . . . 0.0 108.847 174.143 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -151.39 99.36 2.63 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 103.743 -2.688 . . . . 0.0 103.743 168.173 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 11.7 tp -163.9 103.32 0.9 Allowed 'General case' 0 C--O 1.233 0.195 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 176.26 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 15.0 m-80 -64.85 -67.47 0.43 Allowed 'General case' 0 C--O 1.234 0.286 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 160.582 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 29.8 ptt-85 -158.71 157.07 28.2 Favored Pre-proline 0 C--O 1.236 0.393 0 CA-C-N 118.705 0.684 . . . . 0.0 111.803 -177.519 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -68.35 175.7 6.53 Favored 'Trans proline' 0 CA--C 1.537 0.629 0 C-N-CA 122.681 2.254 . . . . 0.0 110.68 167.387 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -144.37 -77.19 0.22 Allowed 'General case' 0 C--O 1.235 0.308 0 N-CA-C 107.297 -1.372 . . . . 0.0 107.297 168.173 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -88.93 100.03 12.87 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.392 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 45.42 -111.9 0.66 Allowed Glycine 0 C--N 1.338 0.646 0 C-N-CA 127.398 2.428 . . . . 0.0 113.495 173.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.0 m -125.06 102.79 7.67 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.56 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 p -73.49 154.56 39.86 Favored 'General case' 0 C--O 1.24 0.603 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 165.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 72.2 mt -68.77 112.12 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 176.482 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.6 t -157.08 174.86 14.87 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 125.35 1.46 . . . . 0.0 108.035 174.225 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.659 HG11 ' HD2' ' A' ' 67' ' ' ARG . 10.7 p -126.95 140.18 37.06 Favored Pre-proline 0 C--O 1.237 0.437 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 165.566 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -76.56 -80.36 0.01 OUTLIER 'Trans proline' 0 N--CA 1.446 -1.275 0 C-N-CA 121.884 1.722 . . . . 0.0 109.281 163.264 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.481 ' CE1' HG21 ' A' ' 84' ' ' ILE . 8.2 m-70 -65.37 116.34 6.57 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 124.25 1.02 . . . . 0.0 111.471 -168.505 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 39.5 pttt -135.44 151.86 50.82 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 168.055 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 30.0 mm -60.12 115.92 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 C-N-CA 124.261 1.024 . . . . 0.0 109.208 169.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -90.42 -39.43 5.98 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 124.013 0.816 . . . . 0.0 112.629 172.097 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 41.0 ttt85 -149.02 161.46 41.88 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 118.266 1.033 . . . . 0.0 109.559 178.752 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 15.4 mt -131.99 136.71 56.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 126.298 1.839 . . . . 0.0 106.171 169.455 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.4 mp -79.81 132.55 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 C-N-CA 126.016 1.726 . . . . 0.0 108.089 179.596 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -55.89 133.25 51.25 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 125.942 1.697 . . . . 0.0 109.505 177.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.36 -8.92 75.18 Favored Glycine 0 CA--C 1.528 0.892 0 C-N-CA 123.397 0.522 . . . . 0.0 112.46 169.219 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 76.5 p -71.22 167.1 32.39 Favored Pre-proline 0 N--CA 1.451 -0.385 0 CA-C-N 118.087 0.943 . . . . 0.0 112.836 -169.183 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -54.1 -39.76 84.46 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 C-N-CA 122.35 2.033 . . . . 0.0 111.992 166.414 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.11 -55.78 28.46 Favored 'General case' 0 C--N 1.341 0.216 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -57.13 -30.77 64.69 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.126 1.37 . . . . 0.0 112.447 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 46.6 mtt-85 -83.97 -29.29 27.15 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 114.533 1.309 . . . . 0.0 114.533 175.305 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 77.0 m -69.46 -27.72 65.48 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 120.292 1.405 . . . . 0.0 111.815 179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 51.54 -160.53 0.09 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.914 0.886 . . . . 0.0 110.496 -169.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 60.9 5.33 0.95 Allowed 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 125.544 1.538 . . . . 0.0 113.323 -167.007 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 14.7 tp -146.59 108.58 4.39 Favored 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.613 1.965 . . . . 0.0 107.17 -175.343 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 33.4 mttm -133.95 171.1 14.65 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 125.495 1.518 . . . . 0.0 110.419 -175.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 58.2 t -76.47 101.3 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -174.057 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 139.63 -12.78 3.19 Favored Glycine 0 CA--C 1.522 0.515 0 C-N-CA 127.0 2.238 . . . . 0.0 108.951 -175.433 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 57.7 m-20 -74.6 110.75 9.14 Favored 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 123.219 1.485 . . . . 0.0 107.346 -178.802 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.659 ' HD2' HG11 ' A' ' 43' ' ' VAL . 19.1 mmt-85 -59.9 158.69 10.25 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 113.918 -1.492 . . . . 0.0 110.377 162.687 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 35.0 mt -131.6 132.18 62.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 -175.496 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.7 mt -84.49 -51.25 7.05 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 124.323 1.049 . . . . 0.0 111.172 176.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -151.68 168.91 23.53 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 124.53 1.132 . . . . 0.0 109.609 -164.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.431 HG23 HG21 ' A' ' 76' ' ' ILE . 4.1 t -130.27 118.14 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 179.396 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 39.32 63.12 1.02 Allowed 'General case' 0 N--CA 1.464 0.252 0 C-N-CA 125.53 1.532 . . . . 0.0 110.733 -174.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 69.5 2.09 33.01 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-O 117.672 -1.627 . . . . 0.0 114.461 176.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -111.77 154.03 25.65 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 120.203 2.002 . . . . 0.0 111.676 -171.746 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 26.7 p -65.9 142.27 57.95 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.984 -179.15 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.431 HG21 HG23 ' A' ' 71' ' ' VAL . 5.0 pt -129.8 -5.78 2.87 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 123.318 0.647 . . . . 0.0 112.333 168.213 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 96.5 mt -73.66 -22.56 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.662 0 C-N-CA 125.046 1.338 . . . . 0.0 109.639 173.505 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 -124.84 -42.78 2.03 Favored 'General case' 0 C--N 1.341 0.215 0 C-N-CA 124.186 0.994 . . . . 0.0 111.734 -162.103 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.4 mtp -57.28 151.09 38.89 Favored Pre-proline 0 CA--C 1.533 0.294 0 C-N-CA 123.407 0.683 . . . . 0.0 110.489 176.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -69.34 149.06 69.09 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 121.149 1.233 . . . . 0.0 109.066 171.442 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -55.65 -41.53 73.74 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 124.085 0.954 . . . . 0.0 112.445 -170.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.91 -30.01 70.6 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 118.936 -0.554 . . . . 0.0 111.88 -179.434 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -70.68 -50.97 30.86 Favored 'General case' 0 C--O 1.223 -0.326 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.265 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.481 HG21 ' CE1' ' A' ' 45' ' ' HIS . 14.4 mt -60.18 -40.04 82.37 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 C-N-CA 124.45 1.1 . . . . 0.0 110.19 178.288 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.0 t -60.52 -47.23 93.58 Favored 'Isoleucine or valine' 0 C--O 1.241 0.611 0 O-C-N 120.78 -1.2 . . . . 0.0 109.97 175.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 22.6 ttmt -65.62 -42.13 91.92 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 117.895 -1.05 . . . . 0.0 110.102 178.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -48.53 -44.86 36.69 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 126.22 1.808 . . . . 0.0 111.097 176.483 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 41.4 mt -73.79 -44.24 52.32 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 48.2 tttt -58.87 -39.09 80.32 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 121.774 -0.579 . . . . 0.0 110.826 -178.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.7 -2.18 57.93 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 127.402 2.281 . . . . 0.0 112.436 -179.463 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.57 -13.4 3.77 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 116.058 1.873 . . . . 0.0 116.058 -164.005 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.45 44.3 6.59 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 118.875 0.762 . . . . 0.0 111.761 172.359 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 34.9 mt 66.49 -34.83 0.22 Allowed 'General case' 0 CA--C 1.511 -0.524 0 C-N-CA 129.245 3.018 . . . . 0.0 113.714 -175.189 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -93.47 143.25 26.47 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 178.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.443 HG12 ' CE1' ' A' ' 24' ' ' PHE . 11.5 p -144.88 135.95 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 172.337 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 35.0 m -116.53 106.26 13.38 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 -177.008 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 11.8 mt -91.04 110.48 21.75 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 125.07 1.348 . . . . 0.0 108.362 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 ttt180 -78.74 119.68 22.31 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 166.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -117.99 172.55 5.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 C-N-CA 124.733 1.213 . . . . 0.0 109.19 177.01 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.437 ' HB ' ' HD3' ' A' ' 101' ' ' PRO . 62.4 mt -105.26 -70.8 0.03 OUTLIER Pre-proline 0 CA--C 1.542 0.657 0 C-N-CA 124.647 1.179 . . . . 0.0 108.122 174.707 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.437 ' HD3' ' HB ' ' A' ' 100' ' ' ILE . 72.0 Cg_endo -74.64 106.8 2.32 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.311 2.007 . . . . 0.0 114.51 -171.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -80.41 152.79 28.65 Favored 'General case' 0 N--CA 1.444 -0.751 0 C-N-CA 124.054 0.941 . . . . 0.0 110.482 177.655 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -85.84 -1.79 57.6 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 126.129 1.771 . . . . 0.0 112.112 -176.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -133.15 10.28 4.15 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.553 1.941 . . . . 0.0 110.78 -161.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 13.6 mt -135.85 86.14 2.21 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 126.841 2.056 . . . . 0.0 107.921 -178.731 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 28.2 m120 -62.12 162.8 8.93 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.297 0.639 . . . . 0.0 109.472 176.227 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.5 m -132.05 158.27 75.98 Favored Pre-proline 0 CA--C 1.537 0.447 0 O-C-N 121.766 -0.583 . . . . 0.0 110.961 -173.545 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -71.39 94.5 0.67 Allowed 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 123.81 3.006 . . . . 0.0 111.008 174.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.6 p -158.53 166.57 31.83 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 124.131 0.972 . . . . 0.0 109.305 168.184 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -154.96 161.02 30.1 Favored Glycine 0 CA--C 1.53 0.988 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 171.605 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -78.99 175.79 10.56 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.47 2.78 . . . . 0.0 110.995 175.443 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.9 p -127.0 157.66 38.98 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 156.447 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -147.53 -60.96 0.27 Allowed 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 125.836 1.654 . . . . 0.0 106.902 173.163 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.006 0 N-CA-C 104.229 -3.548 . . . . 0.0 104.229 124.307 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.083 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.7 m 61.13 177.87 0.11 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.267 1.027 . . . . 0.0 111.667 -171.058 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.0 p -69.8 126.69 30.46 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 124.683 1.193 . . . . 0.0 109.284 174.606 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.43 -176.9 49.53 Favored Glycine 0 CA--C 1.53 1.013 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 164.398 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 59.9 m -153.08 126.55 8.7 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 169.111 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.8 m -153.1 167.18 30.12 Favored 'General case' 0 C--O 1.239 0.549 0 C-N-CA 125.726 1.61 . . . . 0.0 108.518 171.757 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 136.29 88.7 0.25 Allowed Glycine 0 C--N 1.334 0.42 0 N-CA-C 106.514 -2.634 . . . . 0.0 106.514 -168.275 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.8 m -87.09 -26.23 23.76 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 123.842 0.857 . . . . 0.0 112.989 -177.059 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 16.1 tp -108.54 97.01 6.74 Favored 'General case' 0 C--O 1.236 0.372 0 C-N-CA 123.161 0.584 . . . . 0.0 110.791 -160.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 6.3 mm-40 -61.89 133.32 55.27 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-O 121.893 0.854 . . . . 0.0 110.126 169.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 51.0 p -140.27 168.88 18.77 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 128.508 2.723 . . . . 0.0 105.769 165.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 m -123.45 151.99 42.11 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 161.685 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -108.67 130.39 55.34 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 128.752 2.821 . . . . 0.0 105.332 176.659 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.8 t -132.99 109.19 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.4 p -100.61 132.32 46.5 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 176.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 46.2 mt -136.05 147.21 28.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.711 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -120.87 159.28 25.84 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 124.36 1.064 . . . . 0.0 109.564 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.1 ptt180 -140.6 -161.95 1.28 Allowed 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 169.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.23 169.24 10.75 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 169.754 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 17.7 mm-40 -64.73 -27.37 68.86 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -80.43 -6.92 58.84 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 114.541 1.311 . . . . 0.0 114.541 -173.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -141.25 176.26 8.99 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 119.547 1.067 . . . . 0.0 110.596 -170.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.6 171.77 16.79 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 123.982 0.801 . . . . 0.0 111.353 -172.071 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -85.04 137.9 32.77 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 163.662 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.447 ' O ' ' HB3' ' A' ' 56' ' ' ALA . . . -97.71 75.3 0.63 Allowed Glycine 0 N--CA 1.442 -0.918 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 -178.093 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -157.77 148.88 21.31 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 164.508 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.2 t -137.59 131.04 43.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -174.196 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 10.3 mt -71.06 154.47 7.92 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.026 0 C-N-CA 124.788 1.235 . . . . 0.0 109.751 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 49.2 pt -134.56 179.12 4.56 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 C-N-CA 127.995 2.518 . . . . 0.0 109.143 149.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.5 t 76.75 173.34 0.22 Allowed 'General case' 0 C--O 1.238 0.468 0 C-N-CA 128.84 2.856 . . . . 0.0 110.033 -171.174 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -165.21 179.82 6.06 Favored 'General case' 0 C--O 1.24 0.554 0 C-N-CA 124.348 1.059 . . . . 0.0 109.175 -178.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 1.8 mp -72.43 106.64 4.62 Favored 'General case' 0 CA--C 1.522 -0.108 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 167.699 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 15.7 t30 -156.47 119.56 4.17 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 127.399 2.28 . . . . 0.0 104.918 179.086 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -162.82 155.54 16.36 Favored Pre-proline 0 CA--C 1.536 0.409 0 C-N-CA 125.161 1.384 . . . . 0.0 108.39 178.708 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -67.8 179.97 2.39 Favored 'Trans proline' 0 CA--C 1.534 0.513 0 C-N-CA 123.581 2.854 . . . . 0.0 112.377 175.189 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -74.31 -71.67 0.32 Allowed 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 172.631 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 80.2 p -78.28 171.08 15.59 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 118.853 0.751 . . . . 0.0 111.249 174.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.93 26.25 60.71 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-O 118.736 -1.036 . . . . 0.0 113.647 167.329 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -64.29 124.55 22.01 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 119.283 1.542 . . . . 0.0 111.264 -172.508 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 28.2 p -124.14 162.99 22.44 Favored 'General case' 0 C--O 1.238 0.457 0 C-N-CA 125.255 1.422 . . . . 0.0 109.185 169.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 24.2 mm -72.57 84.42 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 CA-C-O 123.259 1.504 . . . . 0.0 109.452 178.091 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.7 t -70.92 170.31 12.95 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.848 1.259 . . . . 0.0 109.209 156.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 17.2 t -121.36 113.33 32.36 Favored Pre-proline 0 CA--C 1.532 0.27 0 C-N-CA 126.103 1.761 . . . . 0.0 106.882 -178.393 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -75.03 -20.29 16.94 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 122.389 2.06 . . . . 0.0 113.906 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -138.9 120.78 15.45 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 121.029 1.74 . . . . 0.0 108.913 177.653 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.9 pttt -140.7 162.94 34.2 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 168.572 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 11.4 mm -65.24 130.87 30.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 172.455 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.06 -51.75 0.72 Allowed Glycine 0 CA--C 1.522 0.491 0 C-N-CA 124.619 1.104 . . . . 0.0 111.224 169.112 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 40.0 ttt85 -134.68 151.79 51.28 Favored 'General case' 0 C--O 1.24 0.579 0 CA-C-N 119.142 1.471 . . . . 0.0 111.165 -168.609 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 50.5 mt -137.33 119.24 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 C-N-CA 127.14 2.176 . . . . 0.0 106.134 179.713 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.427 ' H ' HD12 ' A' ' 51' ' ' ILE . 1.9 mp -46.83 126.75 2.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 127.713 2.405 . . . . 0.0 108.418 156.233 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -63.31 128.31 35.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 165.454 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 105.01 4.99 41.51 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 111.514 -0.634 . . . . 0.0 111.514 173.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.5 p -80.88 159.79 67.85 Favored Pre-proline 0 N--CA 1.449 -0.496 0 O-C-N 121.24 -1.153 . . . . 0.0 113.752 -171.693 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -61.71 -35.01 82.25 Favored 'Trans proline' 0 CA--C 1.539 0.737 0 C-N-CA 122.917 2.412 . . . . 0.0 112.404 168.695 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.447 ' HB3' ' O ' ' A' ' 25' ' ' GLY . . . -68.62 -46.35 69.51 Favored 'General case' 0 C--N 1.34 0.188 0 CA-C-O 118.111 -0.947 . . . . 0.0 111.686 -178.069 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.6 t0 -61.95 -47.64 83.95 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 118.912 0.778 . . . . 0.0 109.805 -172.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 -59.89 -27.47 66.74 Favored 'General case' 0 C--N 1.341 0.229 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.671 177.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 6.1 t -60.57 -37.58 81.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-O 118.405 -0.807 . . . . 0.0 109.982 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.04 -14.34 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 130.535 3.534 . . . . 0.0 116.111 177.577 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.08 -19.19 51.89 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 125.187 1.395 . . . . 0.0 111.477 161.892 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -119.83 131.92 55.44 Favored 'General case' 0 C--O 1.235 0.292 0 C-N-CA 125.672 1.589 . . . . 0.0 107.688 176.301 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.09 171.32 14.48 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 124.194 0.998 . . . . 0.0 110.041 172.763 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.4 t -55.89 141.21 12.88 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 O-C-N 121.321 -0.862 . . . . 0.0 109.112 174.333 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.9 -12.92 65.59 Favored Glycine 0 CA--C 1.534 1.231 0 C-N-CA 125.147 1.356 . . . . 0.0 115.688 172.331 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -68.0 7.31 0.56 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 118.262 2.69 . . . . 0.0 118.262 -151.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 30.8 mtm180 51.87 89.56 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 126.438 1.895 . . . . 0.0 113.122 -178.307 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 61.3 mt -71.95 139.71 19.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.694 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -113.52 -53.05 2.72 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 125.632 1.573 . . . . 0.0 108.768 177.737 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -138.25 154.09 49.08 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.589 0.709 . . . . 0.0 112.319 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.446 HG23 HG21 ' A' ' 76' ' ' ILE . 55.6 t -112.15 116.55 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 169.815 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 57.73 5.12 0.31 Allowed 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 126.763 2.025 . . . . 0.0 115.525 177.644 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.91 12.28 26.34 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-O 118.81 -0.994 . . . . 0.0 112.863 -175.125 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 6.0 tp-100 -103.19 140.29 37.56 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 126.405 1.882 . . . . 0.0 108.401 171.034 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 62.9 m -78.68 100.76 7.18 Favored 'General case' 0 C--O 1.233 0.194 0 C-N-CA 124.666 1.186 . . . . 0.0 111.996 -177.062 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.446 HG21 HG23 ' A' ' 71' ' ' VAL . 2.7 pp -77.6 -5.29 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 179.262 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.565 ' H ' HD12 ' A' ' 77' ' ' ILE . 0.6 OUTLIER -70.28 -9.92 13.11 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 124.764 1.226 . . . . 0.0 112.381 -178.811 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -138.61 -24.51 0.94 Allowed 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 114.785 1.402 . . . . 0.0 114.785 -174.34 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.9 mtp -61.06 152.15 72.31 Favored Pre-proline 0 C--O 1.239 0.506 0 CA-C-N 119.856 1.207 . . . . 0.0 110.8 172.205 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -67.12 157.46 61.63 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 121.727 1.618 . . . . 0.0 110.131 171.322 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -63.21 -37.77 88.53 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.732 -0.605 . . . . 0.0 111.164 -172.057 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.49 -32.47 73.93 Favored 'General case' 0 C--N 1.338 0.068 0 CA-C-N 119.352 0.978 . . . . 0.0 111.975 178.019 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.74 -52.23 65.12 Favored 'General case' 0 C--O 1.224 -0.249 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 176.623 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 54.2 mt -65.88 -41.63 90.42 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.492 0 C-N-CA 125.91 1.684 . . . . 0.0 109.764 -175.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 17.1 t -60.14 -45.71 95.49 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 O-C-N 121.101 -0.999 . . . . 0.0 110.096 173.706 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? -59.86 -47.61 85.05 Favored 'General case' 0 C--O 1.219 -0.506 0 CA-C-O 118.692 -0.671 . . . . 0.0 109.376 177.267 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -57.32 -33.75 68.03 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 125.757 1.623 . . . . 0.0 112.676 -177.111 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 63.5 mt -75.1 -45.12 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 175.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.6 ttmp? -60.67 -49.1 78.87 Favored 'General case' 0 CA--C 1.537 0.443 0 O-C-N 121.615 -0.678 . . . . 0.0 110.021 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -76.65 5.93 6.75 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 129.948 3.299 . . . . 0.0 111.842 177.524 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -63.51 -24.01 67.64 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 119.28 0.946 . . . . 0.0 112.386 176.422 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.81 48.16 5.61 Favored Glycine 0 C--N 1.338 0.659 0 CA-C-N 119.201 0.909 . . . . 0.0 111.436 174.111 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.0 mt 69.73 -30.79 0.2 Allowed 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 129.764 3.226 . . . . 0.0 113.455 -178.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.29 131.06 40.29 Favored 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 124.722 1.209 . . . . 0.0 108.651 174.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.3 p -135.74 130.77 49.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 170.222 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.34 125.48 39.99 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 105.96 -1.867 . . . . 0.0 105.96 170.106 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 42.3 mt -116.76 106.85 13.94 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 175.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 -88.82 118.9 28.85 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 177.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.3 pp -119.49 176.66 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 127.216 2.206 . . . . 0.0 108.632 -172.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 5.0 mp -114.48 117.49 42.76 Favored Pre-proline 0 CA--C 1.533 0.327 0 CA-C-N 119.231 0.923 . . . . 0.0 108.903 172.004 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.03 163.2 35.74 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 123.039 2.492 . . . . 0.0 109.712 -178.549 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.51 132.14 51.45 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.254 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -138.24 -9.32 1.5 Allowed 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 113.502 -1.681 . . . . 0.0 110.588 172.305 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.76 37.62 0.36 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 124.493 1.117 . . . . 0.0 110.263 -169.3 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -133.57 121.2 21.76 Favored 'General case' 0 C--O 1.235 0.33 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 163.566 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -151.44 112.7 4.33 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 126.253 1.821 . . . . 0.0 107.077 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 9.0 p -74.66 167.64 34.48 Favored Pre-proline 0 CA--C 1.544 0.723 0 N-CA-C 114.279 1.214 . . . . 0.0 114.279 -166.277 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -73.85 -179.24 4.41 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 124.27 3.314 . . . . 0.0 111.924 167.363 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 46.3 m -100.09 -176.28 3.19 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.49 1.116 . . . . 0.0 109.636 166.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -104.88 167.92 15.55 Favored Glycine 0 CA--C 1.536 1.403 0 N-CA-C 108.961 -1.655 . . . . 0.0 108.961 149.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -71.96 170.02 19.9 Favored 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 123.353 2.702 . . . . 0.0 112.073 -175.615 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.5 p -116.37 167.34 11.12 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 124.672 1.189 . . . . 0.0 109.618 169.371 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.8 t -66.13 166.66 11.39 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.215 1.006 . . . . 0.0 111.114 -178.662 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.338 0 N-CA-C 105.951 -2.859 . . . . 0.0 105.951 153.978 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.226 0 N-CA-C 107.835 -2.106 . . . . 0.0 107.835 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.5 m 70.92 89.44 0.1 Allowed 'General case' 0 CA--C 1.534 0.359 0 O-C-N 124.838 0.964 . . . . 0.0 112.548 153.795 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 58.6 m -58.74 135.27 57.4 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 162.053 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -72.91 -49.96 15.14 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 173.592 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 71.1 m 41.47 59.51 2.39 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 126.301 1.841 . . . . 0.0 111.932 178.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.8 t -128.14 154.72 45.45 Favored 'General case' 0 C--O 1.24 0.587 0 C-N-CA 123.555 0.742 . . . . 0.0 110.155 -174.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.7 91.83 0.11 Allowed Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 107.762 -2.135 . . . . 0.0 107.762 -173.464 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.7 m -139.56 100.63 4.02 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 171.662 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 tp -156.66 164.93 37.59 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 165.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -142.53 127.61 18.51 Favored 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 165.06 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 36.0 p -127.37 167.06 16.71 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 171.528 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 26.0 m -120.22 148.82 43.2 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 171.358 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -96.22 155.52 16.73 Favored 'General case' 0 C--O 1.244 0.789 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 167.721 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.441 HG11 ' HG ' ' A' ' 62' ' ' LEU . 29.3 t -137.54 103.62 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 177.512 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.3 p -98.64 134.81 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 171.616 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 47.6 mt -142.48 134.15 25.49 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 N-CA-C 104.213 -2.514 . . . . 0.0 104.213 -179.659 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 21.1 m-70 -113.93 159.09 20.27 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.762 1.625 . . . . 0.0 110.171 -174.65 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.445 ' HG2' ' CE1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -151.86 175.69 12.21 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 120.334 -1.479 . . . . 0.0 110.863 178.708 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -66.09 161.93 20.69 Favored 'General case' 0 C--O 1.231 0.123 0 C-N-CA 123.426 0.69 . . . . 0.0 109.849 161.458 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -58.11 -50.0 75.0 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 125.863 1.665 . . . . 0.0 111.302 178.27 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 30.5 t30 -76.48 -21.96 55.16 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.247 1.019 . . . . 0.0 112.621 -173.339 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -66.96 174.23 3.16 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.377 1.071 . . . . 0.0 109.162 173.513 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -152.69 46.1 0.58 Allowed Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 124.711 1.148 . . . . 0.0 111.489 -178.404 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.445 ' CE1' ' HG2' ' A' ' 18' ' ' ARG . 22.3 m-85 50.32 -174.02 0.02 OUTLIER 'General case' 0 N--CA 1.432 -1.345 0 C-N-CA 129.767 3.227 . . . . 0.0 110.753 -174.845 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.422 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -132.38 45.49 1.12 Allowed Glycine 0 C--O 1.224 -0.482 0 O-C-N 121.353 -0.842 . . . . 0.0 111.97 -176.617 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -137.96 153.48 49.45 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 124.224 1.01 . . . . 0.0 108.698 -178.75 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.71 123.13 25.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 -176.68 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.21 151.2 3.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 171.218 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 46.2 pt -131.44 163.49 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 125.238 1.415 . . . . 0.0 108.137 168.704 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 75.4 m -78.27 -50.28 12.13 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.103 0.561 . . . . 0.0 110.483 171.806 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.7 t 47.78 100.9 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 127.394 2.278 . . . . 0.0 112.754 -167.124 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -47.13 -36.87 8.98 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 118.001 -1.0 . . . . 0.0 112.665 174.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 47.53 82.54 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 127.599 2.359 . . . . 0.0 113.404 174.546 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 4.5 ptm85 -66.54 150.51 97.28 Favored Pre-proline 0 C--O 1.235 0.313 0 CA-C-O 119.114 -0.47 . . . . 0.0 111.258 -175.801 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -68.62 163.15 38.06 Favored 'Trans proline' 0 N--CA 1.448 -1.18 0 N-CA-C 108.8 -1.269 . . . . 0.0 108.8 164.217 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -148.79 -44.26 0.15 Allowed 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 124.584 1.154 . . . . 0.0 109.08 177.525 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.5 t -160.6 175.3 12.83 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 128.556 2.742 . . . . 0.0 105.346 -171.698 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 54.95 -161.39 4.99 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 124.259 0.933 . . . . 0.0 111.705 -179.483 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 49.4 m -125.56 103.12 7.69 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 105.72 -1.956 . . . . 0.0 105.72 155.481 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -105.51 118.97 37.94 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 176.614 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.5 pp -53.2 145.37 3.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 C-N-CA 124.116 0.967 . . . . 0.0 110.79 -179.465 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.1 m -75.86 142.2 42.22 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 161.277 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.503 HG11 ' HG2' ' A' ' 67' ' ' ARG . 14.0 p -126.56 143.98 48.1 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 104.968 -2.234 . . . . 0.0 104.968 160.632 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -76.91 -95.38 0.01 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.037 0 C-N-CA 121.599 1.532 . . . . 0.0 108.408 172.661 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.0 m170 -61.3 114.24 3.07 Favored 'General case' 0 N--CA 1.446 -0.656 0 C-N-CA 125.595 1.558 . . . . 0.0 111.621 -171.287 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -148.85 154.83 40.05 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 165.491 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.501 HD11 HD11 ' A' ' 68' ' ' ILE . 36.3 mm -60.96 129.16 23.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 123.134 0.574 . . . . 0.0 109.686 -178.29 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -100.22 -36.22 4.21 Favored Glycine 0 CA--C 1.529 0.963 0 C-N-CA 126.278 1.894 . . . . 0.0 112.693 172.53 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 6.9 ttm180 -149.04 151.77 35.07 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 118.437 1.118 . . . . 0.0 108.723 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 11.1 mt -126.86 139.56 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 125.787 1.635 . . . . 0.0 106.709 165.537 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -82.07 121.77 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 C-N-CA 126.653 1.981 . . . . 0.0 107.829 -178.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -51.46 128.29 22.37 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 124.956 1.302 . . . . 0.0 109.655 173.474 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 95.01 -12.32 68.57 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 125.449 1.5 . . . . 0.0 112.945 174.022 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.422 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 59.0 p -69.68 163.07 62.97 Favored Pre-proline 0 CA--C 1.53 0.205 0 CA-C-N 118.98 1.39 . . . . 0.0 113.177 -172.445 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -56.96 -34.81 98.18 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.27 1.98 . . . . 0.0 111.811 165.418 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.44 -49.24 78.34 Favored 'General case' 0 C--N 1.344 0.333 0 CA-C-N 119.526 1.057 . . . . 0.0 110.529 175.133 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -62.17 -49.53 75.46 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 124.265 1.026 . . . . 0.0 111.348 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -53.59 -53.04 57.41 Favored 'General case' 0 C--N 1.343 0.303 0 C-N-CA 124.418 1.087 . . . . 0.0 110.318 178.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 62.5 m -64.73 -13.94 56.73 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 117.536 -1.221 . . . . 0.0 113.592 -170.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 51.89 11.71 0.16 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.577 2.351 . . . . 0.0 116.821 171.167 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.42 ' HB2' HG13 ' A' ' 14' ' ' VAL . 12.4 mtpt -99.37 -6.77 27.22 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 124.864 1.266 . . . . 0.0 112.03 178.524 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.441 ' HG ' HG11 ' A' ' 14' ' ' VAL . 93.7 mt -104.8 142.74 34.18 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 154.804 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 9.4 ptmt -140.81 169.57 17.38 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.492 1.517 . . . . 0.0 110.016 159.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.9 t -73.23 109.32 5.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 O-C-N 121.409 -0.807 . . . . 0.0 109.042 -173.297 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 120.04 -7.71 11.73 Favored Glycine 0 C--N 1.337 0.631 0 O-C-N 121.143 -0.973 . . . . 0.0 110.724 -171.244 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 -74.11 101.67 3.99 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 172.462 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.503 ' HG2' HG11 ' A' ' 43' ' ' VAL . 39.5 mtm-85 -50.76 121.38 5.81 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 128.04 2.536 . . . . 0.0 108.424 164.227 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.501 HD11 HD11 ' A' ' 47' ' ' ILE . 71.5 mt -105.23 106.85 21.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 104.938 -2.245 . . . . 0.0 104.938 174.653 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.658 HD21 HG13 ' A' ' 100' ' ' ILE . 0.3 OUTLIER -80.42 -26.57 38.38 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 122.94 0.496 . . . . 0.0 112.111 -179.117 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.48 155.47 30.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 125.109 1.363 . . . . 0.0 111.305 -166.191 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.6 HG23 HD13 ' A' ' 76' ' ' ILE . 46.8 t -140.24 132.09 32.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 N-CA-C 105.21 -2.145 . . . . 0.0 105.21 176.408 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 46.05 34.86 2.19 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.593 1.157 . . . . 0.0 112.472 175.211 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 55.94 26.23 47.63 Favored Glycine 0 CA--C 1.535 1.318 0 CA-C-O 118.491 -1.172 . . . . 0.0 114.257 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -121.93 104.7 9.72 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 127.341 2.257 . . . . 0.0 107.056 -175.66 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 54.5 p -65.08 103.14 0.71 Allowed 'General case' 0 CA--C 1.538 0.505 0 O-C-N 120.581 -1.324 . . . . 0.0 114.377 -154.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.6 HD13 HG23 ' A' ' 71' ' ' VAL . 11.3 pt -74.1 -5.07 6.25 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 C-N-CA 124.226 1.01 . . . . 0.0 113.385 -174.76 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 50.4 mm -71.4 -21.27 21.57 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 C-N-CA 124.871 1.269 . . . . 0.0 111.336 -178.75 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -118.28 -28.83 5.69 Favored 'General case' 0 N--CA 1.47 0.536 0 C-N-CA 124.888 1.275 . . . . 0.0 112.372 -176.58 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 9.3 mtp -60.02 151.75 64.04 Favored Pre-proline 0 C--O 1.24 0.558 0 CA-C-N 117.925 0.329 . . . . 0.0 111.398 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -67.11 148.69 81.58 Favored 'Trans proline' 0 N--CA 1.448 -1.166 0 C-N-CA 121.992 1.795 . . . . 0.0 110.282 168.403 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -60.51 -30.53 69.78 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -172.394 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -70.03 -35.04 74.02 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 123.692 0.797 . . . . 0.0 112.182 175.932 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -66.88 -45.19 78.86 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 109.225 -0.658 . . . . 0.0 109.225 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 32.5 mt -64.02 -40.75 90.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 125.555 1.542 . . . . 0.0 108.982 179.418 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.2 t -58.63 -51.02 76.87 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 O-C-N 121.169 -0.957 . . . . 0.0 109.611 173.506 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.99 -44.6 74.62 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 118.383 -0.818 . . . . 0.0 111.934 176.338 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.35 -46.67 69.61 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 127.157 2.183 . . . . 0.0 110.909 176.362 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 59.7 mt -70.1 -39.77 77.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -176.603 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.1 mtpp -63.35 -39.65 95.12 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 123.066 0.547 . . . . 0.0 110.799 178.008 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -85.84 7.61 23.3 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.253 1.821 . . . . 0.0 112.184 177.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -61.4 -20.21 62.79 Favored 'General case' 0 CA--C 1.535 0.401 0 O-C-N 120.885 -1.135 . . . . 0.0 113.41 -177.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 81.02 63.81 1.85 Allowed Glycine 0 C--N 1.334 0.447 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 175.468 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 31.4 mt 67.87 -46.96 0.51 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 129.052 2.941 . . . . 0.0 112.699 177.459 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.51 149.18 21.43 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 170.689 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.495 HG22 HD13 ' A' ' 97' ' ' LEU . 14.1 p -131.77 133.1 61.67 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 165.362 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.9 m -106.68 105.02 14.85 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.617 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' LEU . . . . . 0.495 HD13 HG22 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -90.41 160.9 15.82 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 175.856 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 51.7 ttp180 -113.66 133.26 55.42 Favored 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 106.355 -1.721 . . . . 0.0 106.355 166.069 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.4 pp -128.21 161.07 37.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 123.899 0.879 . . . . 0.0 109.605 176.029 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.658 HG13 HD21 ' A' ' 69' ' ' LEU . 51.0 mt -104.13 122.84 42.8 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 169.349 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -89.8 -161.35 0.11 Allowed 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 125.028 3.818 . . . . 0.0 110.199 172.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -157.18 168.19 28.16 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.962 1.305 . . . . 0.0 110.801 -171.578 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -143.23 -4.29 0.91 Allowed 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 124.967 1.307 . . . . 0.0 111.886 163.788 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -136.35 0.86 2.59 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.921 1.689 . . . . 0.0 112.714 -172.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 12.3 mt -97.26 109.03 21.87 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 174.7 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -146.84 155.08 42.06 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 159.113 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.1 m -81.18 124.92 80.54 Favored Pre-proline 0 C--O 1.239 0.51 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 165.598 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -77.13 86.82 1.57 Allowed 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 122.697 2.265 . . . . 0.0 109.718 172.078 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 38.8 t -135.85 116.65 14.07 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 174.371 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -149.65 170.53 29.81 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 108.919 -1.673 . . . . 0.0 108.919 179.504 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -81.12 -2.9 11.97 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 123.195 2.596 . . . . 0.0 114.186 -172.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 32.8 t 147.89 -69.23 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 130.219 3.408 . . . . 0.0 105.854 -171.098 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.0 m -70.66 103.84 2.66 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 170.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.851 0 N-CA-C 104.773 -3.331 . . . . 0.0 104.773 177.252 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.698 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.1 p -158.71 170.91 21.09 Favored 'General case' 0 C--O 1.241 0.619 0 C-N-CA 125.299 1.44 . . . . 0.0 107.914 171.691 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.1 m -142.07 169.15 18.12 Favored 'General case' 0 C--O 1.235 0.322 0 C-N-CA 124.392 1.077 . . . . 0.0 111.355 176.74 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 120.24 144.1 7.05 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 126.328 1.918 . . . . 0.0 108.724 -173.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 28.4 p -139.61 162.93 33.89 Favored 'General case' 0 C--O 1.237 0.432 0 C-N-CA 124.894 1.278 . . . . 0.0 108.282 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.8 t -161.04 -155.76 0.43 Allowed 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -169.328 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 130.22 -77.34 0.4 Allowed Glycine 0 C--O 1.236 0.269 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 174.47 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 77.8 p 48.29 -170.27 0.02 OUTLIER 'General case' 0 C--O 1.238 0.472 0 C-N-CA 127.564 2.345 . . . . 0.0 114.257 177.193 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.7 tp 35.14 81.14 0.02 OUTLIER 'General case' 0 C--O 1.234 0.282 0 C-N-CA 128.844 2.857 . . . . 0.0 112.266 176.214 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -44.62 136.28 4.43 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 125.607 1.563 . . . . 0.0 112.166 -176.734 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 42.4 p -145.24 164.18 32.16 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 125.263 1.425 . . . . 0.0 107.333 168.022 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 57.8 m -126.55 152.83 46.03 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 124.362 1.065 . . . . 0.0 109.112 173.562 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -108.38 103.73 12.94 Favored 'General case' 0 C--O 1.233 0.204 0 C-N-CA 126.235 1.814 . . . . 0.0 106.22 -178.132 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -88.07 95.2 5.04 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.8 p -78.02 138.08 20.98 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 CA-C-O 121.372 0.606 . . . . 0.0 109.423 171.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 41.2 mt -134.38 142.06 41.84 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 N-CA-C 105.796 -1.927 . . . . 0.0 105.796 173.086 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.2 m-70 -115.77 137.16 52.36 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.711 1.204 . . . . 0.0 109.19 177.487 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 16.8 ptt180 -118.4 175.65 5.61 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.118 0.872 . . . . 0.0 109.519 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.33 163.9 12.88 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 169.542 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -71.77 -38.6 70.31 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -173.584 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 54.5 t30 -77.01 18.89 0.33 Allowed 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.785 0.834 . . . . 0.0 112.036 -174.069 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -161.2 -169.84 2.47 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 120.005 -1.684 . . . . 0.0 111.108 -168.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -121.21 -169.71 13.81 Favored Glycine 0 CA--C 1.521 0.429 0 C-N-CA 126.274 1.892 . . . . 0.0 110.867 -174.212 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 84.2 m-85 -85.97 -110.52 0.05 OUTLIER 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 106.117 -1.808 . . . . 0.0 106.117 165.451 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 152.7 59.04 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.392 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 177.058 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -141.69 133.55 27.33 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 178.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.2 t -113.96 113.53 44.13 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 -172.49 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 26.7 mt -74.06 131.0 35.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 173.364 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.409 HD11 ' HE3' ' A' ' 46' ' ' LYS . 14.8 pt -120.75 170.17 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 C-N-CA 125.513 1.525 . . . . 0.0 109.822 172.186 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -129.94 155.18 46.48 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 125.366 1.467 . . . . 0.0 109.735 -177.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -160.3 94.53 1.09 Allowed 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.864 1.666 . . . . 0.0 106.75 163.512 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 4.0 tt -137.9 84.51 2.04 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-O 122.005 0.907 . . . . 0.0 110.837 177.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -69.81 156.76 38.55 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.311 160.094 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 15.3 tpt180 61.28 128.19 0.02 OUTLIER Pre-proline 0 CA--C 1.541 0.596 0 C-N-CA 130.695 3.598 . . . . 0.0 113.484 176.046 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -68.0 100.87 0.65 Allowed 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.08 1.853 . . . . 0.0 107.922 168.22 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 74.8 mm-40 -124.82 166.05 16.92 Favored 'General case' 0 C--O 1.238 0.455 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 171.007 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 38.1 m -159.24 -34.06 0.06 Allowed 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.134 0.974 . . . . 0.0 111.782 -178.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -79.76 -25.51 58.15 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-N 119.463 1.029 . . . . 0.0 112.412 -172.739 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 14.2 t -125.74 133.9 51.94 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 164.359 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.6 p -123.78 108.04 12.07 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.106 1.363 . . . . 0.0 109.796 -163.65 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.6 mt -130.35 -58.61 1.0 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.356 0 C-N-CA 125.029 1.331 . . . . 0.0 109.706 -166.38 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.2 p -65.96 155.06 37.66 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 123.562 0.745 . . . . 0.0 109.202 172.456 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.1 t -126.21 127.37 24.67 Favored Pre-proline 0 CA--C 1.539 0.523 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -78.4 -13.95 14.83 Favored 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 122.825 2.35 . . . . 0.0 113.802 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.485 ' CD2' HD12 ' A' ' 76' ' ' ILE . 0.6 OUTLIER -139.02 119.31 13.67 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 120.831 1.65 . . . . 0.0 110.157 174.75 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.409 ' HE3' HD11 ' A' ' 29' ' ' ILE . 45.4 pttt -143.65 163.99 31.67 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 168.283 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.8 mm -63.1 125.37 19.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 165.548 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.83 -24.05 5.37 Favored Glycine 0 CA--C 1.527 0.799 0 CA-C-O 118.828 -0.985 . . . . 0.0 113.469 172.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -154.09 147.52 25.0 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 176.76 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 5.4 mt -128.37 149.49 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 168.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -78.13 117.38 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 C-N-CA 125.714 1.606 . . . . 0.0 107.105 174.078 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -52.72 105.08 0.11 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.123 2.169 . . . . 0.0 109.256 176.582 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 95.02 7.92 59.37 Favored Glycine 0 CA--C 1.526 0.753 0 C-N-CA 124.569 1.081 . . . . 0.0 114.065 177.361 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 33.9 p -64.38 166.24 11.72 Favored Pre-proline 0 CA--C 1.531 0.242 0 CA-C-N 119.495 1.647 . . . . 0.0 109.802 164.099 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -58.86 -24.3 71.59 Favored 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 121.728 1.618 . . . . 0.0 112.849 170.095 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.03 -60.6 3.52 Favored 'General case' 0 C--N 1.341 0.201 0 CA-C-N 119.277 0.944 . . . . 0.0 108.671 173.103 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -65.69 -42.5 91.14 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.833 0.349 . . . . 0.0 111.048 -176.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -69.96 -22.85 63.13 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 118.442 -0.79 . . . . 0.0 112.501 -174.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 2.0 p -73.84 -16.7 61.13 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 117.618 -1.182 . . . . 0.0 110.976 173.513 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 40.08 66.23 0.63 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.324 1.849 . . . . 0.0 110.633 -173.168 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 33.4 mtmm -139.28 -44.89 0.46 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 124.923 1.289 . . . . 0.0 108.883 170.156 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 22.5 tp -94.02 121.62 35.69 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 -177.179 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.7 mmtt -132.85 162.84 30.48 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 123.394 1.569 . . . . 0.0 110.615 -176.138 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.4 t -62.77 123.77 16.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 172.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 122.11 -24.96 6.86 Favored Glycine 0 N--CA 1.447 -0.585 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -175.277 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -79.22 99.22 6.93 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-O 123.282 1.515 . . . . 0.0 109.416 -167.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 39.4 mtm180 -46.39 137.02 6.81 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 129.119 2.967 . . . . 0.0 110.106 162.737 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 16.0 mt -119.01 144.65 26.72 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 -174.256 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.523 HD11 HG13 ' A' ' 100' ' ' ILE . 6.1 mp -117.54 -47.22 2.64 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 125.246 1.418 . . . . 0.0 111.214 -176.416 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -150.04 169.61 20.83 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.084 0.954 . . . . 0.0 109.368 -175.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.6 p -138.89 123.39 20.88 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.299 0 C-N-CA 125.14 1.376 . . . . 0.0 108.197 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 51.39 31.05 6.74 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 123.616 0.767 . . . . 0.0 112.417 -173.737 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.26 6.75 89.07 Favored Glycine 0 CA--C 1.532 1.117 0 CA-C-O 118.37 -1.239 . . . . 0.0 114.204 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -102.46 135.3 44.32 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 119.963 1.882 . . . . 0.0 109.896 177.651 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -54.43 129.16 34.81 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 123.087 0.555 . . . . 0.0 110.282 168.828 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.485 HD12 ' CD2' ' A' ' 45' ' ' HIS . 25.8 pt -91.16 -17.79 7.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.716 1.206 . . . . 0.0 110.332 164.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 81.2 mt -68.02 136.26 26.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.712 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 82.49 -30.9 0.09 Allowed 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 130.572 3.549 . . . . 0.0 112.847 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 6.3 mtp -64.8 154.07 86.52 Favored Pre-proline 0 CA--C 1.541 0.597 0 CA-C-N 119.298 0.954 . . . . 0.0 111.332 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -76.9 152.1 31.84 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.49 2.127 . . . . 0.0 109.951 173.58 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -51.97 -42.38 62.86 Favored 'General case' 0 C--O 1.222 -0.345 0 C-N-CA 123.742 0.817 . . . . 0.0 111.657 -176.611 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.0 -41.83 75.46 Favored 'General case' 0 C--N 1.338 0.072 0 CA-C-O 118.356 -0.831 . . . . 0.0 112.855 178.825 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.9 -30.38 40.1 Favored 'General case' 0 C--O 1.225 -0.231 0 CA-C-N 118.898 0.772 . . . . 0.0 110.927 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 13.3 mt -69.03 -42.15 81.93 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 C-N-CA 124.455 1.102 . . . . 0.0 108.835 171.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 2.5 t -54.54 -46.4 71.73 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 O-C-N 120.542 -1.349 . . . . 0.0 108.932 170.511 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 9.7 tptt -62.14 -43.51 98.67 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-O 117.033 -1.461 . . . . 0.0 111.903 175.079 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.05 -37.78 80.85 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 121.121 1.782 . . . . 0.0 110.567 -177.361 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 43.0 mt -69.7 -49.58 57.04 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 177.298 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.1 tttp -54.22 -49.14 70.13 Favored 'General case' 0 C--N 1.345 0.371 0 C-N-CA 123.56 0.744 . . . . 0.0 110.234 178.418 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -65.89 -17.42 64.64 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 127.384 2.274 . . . . 0.0 112.362 -177.626 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -67.29 -9.43 40.75 Favored 'General case' 0 CA--C 1.548 0.895 0 CA-C-N 119.384 0.993 . . . . 0.0 112.891 176.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.23 -89.12 0.72 Allowed Glycine 0 C--N 1.34 0.779 0 C-N-CA 125.134 1.35 . . . . 0.0 112.262 167.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 78.4 mt -132.03 -27.3 1.85 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 126.47 1.908 . . . . 0.0 110.28 173.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.55 152.29 19.7 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 105.632 -1.988 . . . . 0.0 105.632 174.091 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.7 p -150.75 147.07 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 N-CA-C 105.126 -2.175 . . . . 0.0 105.126 161.104 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 20.6 m -126.08 103.09 7.53 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -175.254 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 18.8 mt -90.77 123.05 34.03 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 124.762 1.225 . . . . 0.0 108.444 -176.329 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 13.7 ttm180 -83.88 131.42 34.87 Favored 'General case' 0 C--O 1.237 0.431 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 176.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -126.97 159.69 36.6 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 C-N-CA 125.661 1.584 . . . . 0.0 110.581 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.523 HG13 HD11 ' A' ' 69' ' ' LEU . 9.2 mt -69.46 -57.03 7.45 Favored Pre-proline 0 N--CA 1.478 0.94 0 C-N-CA 124.841 1.256 . . . . 0.0 110.842 175.709 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.427 ' HD3' ' HB ' ' A' ' 100' ' ' ILE . 10.9 Cg_endo -67.13 -176.33 0.79 Allowed 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 122.397 2.065 . . . . 0.0 114.051 177.255 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -113.31 169.31 9.04 Favored 'General case' 0 N--CA 1.436 -1.144 0 C-N-CA 128.273 2.629 . . . . 0.0 107.088 171.387 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -121.54 0.95 10.03 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 126.183 1.793 . . . . 0.0 110.8 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -151.17 17.89 0.75 Allowed 'General case' 0 CA--C 1.531 0.242 0 CA-C-O 122.397 1.094 . . . . 0.0 110.31 -165.022 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 12.7 tp -107.53 121.25 44.26 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 126.823 2.049 . . . . 0.0 107.284 -179.005 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -55.54 105.37 0.17 Allowed 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 166.222 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.6 p -154.5 160.0 31.36 Favored Pre-proline 0 C--O 1.237 0.406 0 CA-C-N 120.773 1.624 . . . . 0.0 110.284 163.292 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -84.04 -6.2 10.38 Favored 'Trans proline' 0 CA--C 1.534 0.493 0 C-N-CA 122.617 2.211 . . . . 0.0 114.341 -176.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 26.6 m 4.51 88.01 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 129.014 2.926 . . . . 0.0 114.45 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -64.55 164.41 34.25 Favored Glycine 0 CA--C 1.535 1.311 0 C-N-CA 124.153 0.882 . . . . 0.0 113.517 -166.215 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -66.76 160.5 46.24 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 124.005 3.137 . . . . 0.0 113.061 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.4 p -99.36 -15.17 18.88 Favored 'General case' 0 C--O 1.235 0.326 0 C-N-CA 125.779 1.632 . . . . 0.0 112.402 179.156 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 21.8 p -122.47 68.33 0.95 Allowed 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 124.127 0.971 . . . . 0.0 108.74 -175.657 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.867 0 N-CA-C 106.714 -2.554 . . . . 0.0 106.714 -169.241 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.156 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 31.0 t -136.59 132.69 35.46 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 105.5 -2.037 . . . . 0.0 105.5 174.21 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 m -144.59 126.53 15.41 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -169.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -161.42 76.36 0.18 Allowed Glycine 0 N--CA 1.449 -0.463 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 -175.592 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 44.0 m -145.65 155.57 43.1 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 124.995 1.318 . . . . 0.0 109.522 173.188 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.0 t 61.87 111.35 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 128.54 2.736 . . . . 0.0 113.873 168.14 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.24 152.59 17.33 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 106.335 -2.706 . . . . 0.0 106.335 -178.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.9 m -165.0 -74.91 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 124.98 1.312 . . . . 0.0 109.042 -172.342 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.9 tp -83.14 120.7 26.11 Favored 'General case' 0 C--O 1.238 0.456 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 176.337 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 22.5 mt-30 -70.65 138.03 50.38 Favored 'General case' 0 N--CA 1.453 -0.288 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 169.213 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 33.5 p -138.37 160.48 39.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 178.799 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.9 m -111.23 156.62 21.18 Favored 'General case' 0 C--O 1.235 0.325 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 168.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -120.85 103.54 9.16 Favored 'General case' 0 CA--C 1.511 -0.536 0 N-CA-C 104.029 -2.582 . . . . 0.0 104.029 172.401 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.467 HG11 ' HB2' ' A' ' 62' ' ' LEU . 59.6 t -91.63 95.03 5.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 105.458 -2.053 . . . . 0.0 105.458 -177.713 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.4 p -85.47 124.84 40.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 169.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 13.3 mt -116.97 143.38 27.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 171.269 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.0 m-70 -121.68 143.76 49.16 Favored 'General case' 0 CA--C 1.536 0.404 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 175.445 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.405 ' NH1' ' CE2' ' A' ' 24' ' ' PHE . 3.0 ptt-85 -130.86 -175.48 3.68 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 119.797 1.18 . . . . 0.0 109.008 176.334 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.437 ' N ' ' HE3' ' A' ' 19' ' ' LYS . 0.2 OUTLIER -95.38 168.7 10.56 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 118.814 0.734 . . . . 0.0 109.273 169.836 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -65.94 -20.67 66.29 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.078 0.951 . . . . 0.0 112.544 170.679 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -123.18 65.67 0.99 Allowed 'General case' 0 C--O 1.234 0.265 0 C-N-CA 124.454 1.101 . . . . 0.0 108.133 -177.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -172.6 179.45 2.44 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 128.38 2.672 . . . . 0.0 107.227 163.164 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.67 176.12 23.84 Favored Glycine 0 CA--C 1.526 0.734 0 C-N-CA 124.432 1.015 . . . . 0.0 110.976 173.548 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PHE . . . . . 0.405 ' CE2' ' NH1' ' A' ' 18' ' ' ARG . 40.5 m-85 -84.7 170.68 13.04 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 150.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.45 55.6 0.65 Allowed Glycine 0 C--O 1.224 -0.529 0 O-C-N 120.727 -1.233 . . . . 0.0 111.537 -175.138 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.4 p90 -130.12 121.89 27.21 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 117.981 0.89 . . . . 0.0 108.924 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.6 t -96.25 101.04 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 -175.38 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.567 HD12 ' H ' ' A' ' 28' ' ' ILE . 3.5 mp -74.27 118.87 20.57 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 170.436 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.457 HD11 ' HE3' ' A' ' 46' ' ' LYS . 24.5 pt -103.87 -176.76 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 C-N-CA 124.355 1.062 . . . . 0.0 109.281 176.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.0 m 54.86 53.83 9.91 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.155 0.982 . . . . 0.0 112.325 175.033 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.4 t -60.75 176.05 0.42 Allowed 'General case' 0 CA--C 1.543 0.682 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.726 164.635 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 58.6 tp -25.75 115.49 0.06 Allowed 'General case' 0 N--CA 1.469 0.48 0 C-N-CA 128.681 2.792 . . . . 0.0 111.832 177.489 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 17.4 t30 -136.45 130.62 32.9 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 118.941 -0.552 . . . . 0.0 111.07 -170.696 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 66.17 162.4 0.13 Allowed Pre-proline 0 N--CA 1.471 0.611 0 C-N-CA 128.315 2.646 . . . . 0.0 113.106 -173.476 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -77.86 65.49 8.24 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 123.916 3.078 . . . . 0.0 109.194 168.14 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -130.88 166.44 20.89 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 126.197 1.799 . . . . 0.0 106.703 173.558 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.3 t -123.63 -125.49 0.26 Allowed 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 179.129 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.48 93.52 0.09 OUTLIER Glycine 0 C--N 1.336 0.56 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 173.466 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.4 t -120.74 130.81 54.2 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 -174.489 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 20.4 p -64.86 162.52 16.11 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 124.052 0.941 . . . . 0.0 111.589 177.84 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 12.2 mt 66.24 162.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 C-N-CA 127.023 2.129 . . . . 0.0 109.802 179.182 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.3 m 57.15 171.66 0.04 OUTLIER 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.213 1.405 . . . . 0.0 111.595 -167.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 21.9 t -126.7 123.24 23.79 Favored Pre-proline 0 C--O 1.235 0.332 0 N-CA-C 103.672 -2.714 . . . . 0.0 103.672 161.378 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -58.54 -78.64 0.02 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 121.878 1.719 . . . . 0.0 109.818 175.806 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.2 m80 -63.68 123.71 19.55 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 118.785 0.72 . . . . 0.0 109.869 -177.599 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' LYS . . . . . 0.457 ' HE3' HD11 ' A' ' 29' ' ' ILE . 49.8 pttt -143.67 153.29 42.33 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 107.883 -1.155 . . . . 0.0 107.883 171.086 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ILE . . . . . 0.407 HD13 HD11 ' A' ' 68' ' ' ILE . 32.7 mm -66.69 124.12 21.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 167.57 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -101.97 -30.88 5.59 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 124.246 0.927 . . . . 0.0 112.611 175.199 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 22.7 ttm180 -154.65 158.41 39.63 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 118.847 1.323 . . . . 0.0 107.564 176.014 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 24.5 mt -130.77 135.28 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 170.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.4 mp -68.81 124.96 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.396 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 32.2 t0 -51.96 133.55 32.45 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.375 1.07 . . . . 0.0 109.97 178.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.08 1.0 38.41 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 118.98 -0.9 . . . . 0.0 114.412 174.493 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 61.4 p -64.62 162.7 33.05 Favored Pre-proline 0 CA--C 1.53 0.189 0 CA-C-N 119.483 1.641 . . . . 0.0 109.504 171.394 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -55.76 -18.17 20.42 Favored 'Trans proline' 0 CA--C 1.534 0.488 0 C-N-CA 122.959 2.439 . . . . 0.0 114.028 175.244 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.59 -69.79 0.27 Allowed 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 169.112 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -66.43 -31.88 72.91 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 118.14 0.427 . . . . 0.0 111.655 -173.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.92 -22.92 67.11 Favored 'General case' 0 C--O 1.234 0.247 0 O-C-N 121.351 -0.843 . . . . 0.0 112.508 175.389 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 7.8 t -80.85 -9.51 59.81 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 119.338 0.972 . . . . 0.0 111.475 173.803 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 55.92 5.13 0.14 Allowed 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 128.841 2.856 . . . . 0.0 115.724 173.777 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.9 -49.64 6.96 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 119.796 1.18 . . . . 0.0 110.424 177.39 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' LEU . . . . . 0.467 ' HB2' HG11 ' A' ' 14' ' ' VAL . 14.8 tp -93.85 129.36 40.28 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 123.5 0.72 . . . . 0.0 109.414 -166.044 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.7 mptt -122.99 169.97 10.62 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 125.451 1.5 . . . . 0.0 110.438 170.291 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -58.4 148.47 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 C-N-CA 124.367 1.067 . . . . 0.0 109.798 165.696 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.24 -7.73 80.67 Favored Glycine 0 CA--C 1.524 0.635 0 C-N-CA 125.301 1.429 . . . . 0.0 110.682 -175.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -71.17 88.92 0.83 Allowed 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 172.351 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.1 mtm180 -38.21 121.02 0.94 Allowed 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 128.448 2.699 . . . . 0.0 110.314 159.436 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ILE . . . . . 0.407 HD11 HD13 ' A' ' 47' ' ' ILE . 14.3 mt -101.22 118.83 48.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 -178.697 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 88.1 mt -72.0 -52.52 16.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 124.684 1.194 . . . . 0.0 109.959 168.409 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -150.83 166.24 31.13 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 124.059 0.944 . . . . 0.0 111.951 -162.32 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 37.2 t -126.26 119.84 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 174.45 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.561 HD21 ' HB2' ' A' ' 91' ' ' ALA . 67.7 m-20 54.51 10.01 0.3 Allowed 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 128.918 2.887 . . . . 0.0 114.477 176.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 114.01 -0.26 24.16 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 126.721 2.105 . . . . 0.0 113.909 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 9.8 mm-40 -105.07 145.22 30.8 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 125.422 1.489 . . . . 0.0 109.243 -176.047 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.8 p -84.09 99.26 10.36 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 124.73 1.212 . . . . 0.0 111.63 -167.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 7.1 pt -79.76 -2.84 5.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 C-N-CA 123.904 0.882 . . . . 0.0 112.106 -177.258 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.731 ' H ' HD12 ' A' ' 77' ' ' ILE . 3.3 mp -61.85 -33.29 57.19 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 125.223 1.409 . . . . 0.0 110.383 174.31 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -107.7 -44.12 4.33 Favored 'General case' 0 C--O 1.233 0.215 0 C-N-CA 123.049 0.539 . . . . 0.0 111.217 -166.483 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 5.6 mtp -58.77 153.4 42.54 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 124.329 1.052 . . . . 0.0 111.328 -168.226 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.75 146.27 97.6 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.187 1.258 . . . . 0.0 109.276 167.649 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -52.09 -41.28 62.29 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 124.346 1.058 . . . . 0.0 110.028 -178.064 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -59.93 -35.57 75.19 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 114.24 1.2 . . . . 0.0 114.24 177.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.01 -44.86 79.23 Favored 'General case' 0 N--CA 1.463 0.189 0 C-N-CA 123.727 0.811 . . . . 0.0 108.887 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 24.0 mt -69.37 -37.99 76.47 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 C-N-CA 125.967 1.707 . . . . 0.0 109.261 -178.863 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 4.8 t -56.46 -49.06 78.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 O-C-N 121.127 -0.983 . . . . 0.0 109.427 169.263 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 11.4 ttpt -66.88 -36.48 82.41 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-O 118.742 -0.647 . . . . 0.0 111.258 -177.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -57.09 -44.38 83.11 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 125.4 1.48 . . . . 0.0 111.057 174.29 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 91.1 mt -67.86 -40.99 84.54 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-N 119.371 0.987 . . . . 0.0 108.813 178.22 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.0 tttt -60.08 -48.76 80.38 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 118.819 0.736 . . . . 0.0 109.942 176.146 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -70.31 -12.28 61.48 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 124.642 1.177 . . . . 0.0 111.268 -178.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.561 ' HB2' HD21 ' A' ' 72' ' ' ASN . . . -62.9 -14.99 53.25 Favored 'General case' 0 CA--C 1.545 0.757 0 CA-C-N 119.679 1.127 . . . . 0.0 112.347 168.426 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.28 -132.25 11.16 Favored Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 176.093 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 5.7 mt -90.7 -10.24 43.83 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 118.878 -0.582 . . . . 0.0 110.336 173.682 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 26.7 p -93.42 162.3 14.04 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 168.476 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.6 p -156.68 136.6 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.888 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 159.018 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.1 m -117.34 104.75 11.44 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 -177.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 56.9 mt -90.02 164.55 14.48 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 177.33 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 22.6 ttt180 -127.93 118.74 24.16 Favored 'General case' 0 CA--C 1.513 -0.456 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 173.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pp -129.51 169.2 21.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 C-N-CA 123.952 0.901 . . . . 0.0 109.294 -176.051 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.0 mp -98.45 117.99 63.94 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 124.205 1.002 . . . . 0.0 109.361 -177.251 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -82.97 157.33 15.44 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 123.375 2.717 . . . . 0.0 111.766 172.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -146.12 170.5 16.57 Favored 'General case' 0 C--O 1.242 0.662 0 C-N-CA 129.015 2.926 . . . . 0.0 106.521 -178.102 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -136.72 -19.58 1.35 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 119.094 0.861 . . . . 0.0 113.018 -168.289 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 18.9 pm0 -87.47 -2.93 58.95 Favored 'General case' 0 C--N 1.316 -0.88 0 C-N-CA 127.743 2.417 . . . . 0.0 112.162 -173.121 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 3.1 mt -114.87 108.88 17.33 Favored 'General case' 0 C--O 1.233 0.194 0 C-N-CA 125.578 1.551 . . . . 0.0 109.039 -170.707 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 19.8 t30 -145.87 104.52 3.86 Favored 'General case' 0 C--O 1.232 0.137 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 164.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 72.9 m -65.49 152.32 92.6 Favored Pre-proline 0 CA--C 1.533 0.314 0 CA-C-O 119.395 -0.336 . . . . 0.0 111.638 173.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -79.54 -174.0 2.1 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 124.328 3.352 . . . . 0.0 111.33 171.725 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.2 t -67.17 13.91 0.06 Allowed 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.058 1.743 . . . . 0.0 113.395 175.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 39.32 63.41 1.13 Allowed Glycine 0 CA--C 1.534 1.253 0 C-N-CA 126.565 2.031 . . . . 0.0 112.375 -176.722 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -60.61 118.28 5.13 Favored 'Trans proline' 0 N--CA 1.458 -0.618 0 C-N-CA 123.644 2.896 . . . . 0.0 110.164 -166.701 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.1 t 30.07 63.92 0.16 Allowed 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 127.956 2.503 . . . . 0.0 110.874 -167.125 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 5.6 t -53.83 118.55 4.06 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 170.383 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.006 0 N-CA-C 106.344 -2.702 . . . . 0.0 106.344 -165.754 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.148 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.3 m -54.11 129.41 34.53 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 159.706 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 m -63.8 -45.67 88.61 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.321 0.649 . . . . 0.0 110.383 -173.487 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 140.55 -150.37 21.6 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 -169.543 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 57.4 m -138.07 173.6 11.45 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 107.823 -1.176 . . . . 0.0 107.823 157.517 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -130.44 -175.97 3.81 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 151.797 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 167.58 -145.77 10.06 Favored Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 106.221 -2.752 . . . . 0.0 106.221 -173.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 12.2 m 72.18 159.76 0.22 Allowed 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 126.773 2.029 . . . . 0.0 110.68 -178.244 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 10.1 mp -123.07 125.08 44.51 Favored 'General case' 0 C--O 1.237 0.418 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -168.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -143.89 -154.24 0.52 Allowed 'General case' 0 C--O 1.234 0.283 0 C-N-CA 122.948 0.499 . . . . 0.0 111.185 179.359 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.6 p -138.28 165.54 26.46 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 128.14 2.576 . . . . 0.0 108.735 -171.154 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 37.3 m -126.6 164.41 21.3 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.875 1.67 . . . . 0.0 109.415 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 18.4 p-10 -128.86 95.12 4.0 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 127.15 2.18 . . . . 0.0 108.057 177.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.0 t -89.47 102.9 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 105.798 -1.927 . . . . 0.0 105.798 174.321 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.2 t -106.68 111.47 35.6 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -177.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 12.1 mt -108.83 136.55 44.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 N-CA-C 106.126 -1.805 . . . . 0.0 106.126 -178.72 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -119.87 114.15 21.66 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 126.465 1.906 . . . . 0.0 105.989 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 28.4 ptt180 -95.0 174.99 6.81 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 119.606 1.094 . . . . 0.0 109.116 176.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -82.97 171.13 14.16 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 166.931 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -75.57 -9.85 58.93 Favored 'General case' 0 N--CA 1.469 0.489 0 O-C-N 120.355 -1.466 . . . . 0.0 112.805 175.373 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 40.3 t30 -98.98 -27.38 13.89 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 115.119 1.526 . . . . 0.0 115.119 -160.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -114.37 -122.1 0.29 Allowed 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.235 1.414 . . . . 0.0 108.768 -167.36 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -154.49 -178.34 28.76 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 167.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -72.97 170.82 14.02 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 151.41 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -135.2 62.07 0.62 Allowed Glycine 0 C--O 1.22 -0.749 0 CA-C-O 118.27 -1.294 . . . . 0.0 111.591 -176.185 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.2 p90 -146.12 139.96 26.35 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 119.281 1.541 . . . . 0.0 109.033 178.491 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.848 HG12 ' H ' ' A' ' 49' ' ' ARG . 0.8 OUTLIER -110.08 154.78 11.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 171.798 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -128.79 118.75 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 -178.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 26.1 pt -112.45 156.11 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -179.034 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.5 m -128.05 84.72 2.27 Favored 'General case' 0 C--O 1.239 0.544 0 C-N-CA 124.859 1.263 . . . . 0.0 107.968 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.8 m -73.07 150.91 41.92 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 121.42 -0.8 . . . . 0.0 110.365 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 32.6 mt -70.14 -45.46 66.76 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 124.206 1.002 . . . . 0.0 110.396 -174.522 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.9 m120 37.1 73.04 0.1 Allowed 'General case' 0 C--O 1.238 0.489 0 C-N-CA 127.965 2.506 . . . . 0.0 112.005 178.246 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.45 148.84 63.28 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 122.974 0.51 . . . . 0.0 111.123 -174.223 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -76.7 -24.2 10.44 Favored 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 123.066 2.511 . . . . 0.0 113.922 -174.046 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 37.15 69.52 0.22 Allowed 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 126.863 2.065 . . . . 0.0 112.491 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 66.3 m 57.89 2.64 0.18 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 127.548 2.339 . . . . 0.0 116.287 179.663 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -95.2 -178.72 37.26 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 166.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 8.1 t -126.22 102.16 7.07 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 104.351 -2.463 . . . . 0.0 104.351 132.168 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 65.8 p -101.98 158.45 16.13 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 177.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . 0.26 14.0 tt -60.79 124.52 15.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 C-N-CA 123.862 0.865 . . . . 0.0 111.034 -166.193 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.3 m -144.51 154.94 43.42 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.194 1.398 . . . . 0.0 108.898 -173.019 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 8.6 p -127.51 151.07 74.48 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 117.739 -1.124 . . . . 0.0 109.223 169.064 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -72.08 -84.47 0.0 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.274 1.983 . . . . 0.0 108.475 162.389 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -72.58 120.9 18.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.138 0.975 . . . . 0.0 110.559 -174.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 45.3 pttt -137.31 154.93 49.97 Favored 'General case' 0 C--O 1.236 0.371 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 168.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 5.0 mm -60.79 127.29 20.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 166.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -88.51 -69.75 1.27 Allowed Glycine 0 CA--C 1.527 0.806 0 O-C-N 124.495 1.122 . . . . 0.0 110.627 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ARG . . . . . 0.848 ' H ' HG12 ' A' ' 27' ' ' VAL . 31.4 ttm180 -127.6 153.28 46.6 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 128.751 2.821 . . . . 0.0 107.407 -178.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 12.5 mt -119.27 142.68 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 166.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 50.4 mm -73.05 122.59 26.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.16 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -60.45 137.17 58.19 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 178.443 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.82 -5.23 54.08 Favored Glycine 0 CA--C 1.531 1.058 0 C-N-CA 126.08 1.8 . . . . 0.0 114.495 -178.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' SER . . . . . 0.434 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 83.7 p -68.62 167.65 18.22 Favored Pre-proline 0 C--O 1.234 0.283 0 CA-C-N 119.332 1.566 . . . . 0.0 112.472 -176.224 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 18.0 Cg_endo -58.23 -29.26 87.1 Favored 'Trans proline' 0 N--CA 1.451 -0.994 0 C-N-CA 122.165 1.91 . . . . 0.0 112.458 166.464 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.85 -53.94 46.45 Favored 'General case' 0 C--N 1.345 0.398 0 CA-C-N 119.814 1.188 . . . . 0.0 109.71 177.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -66.21 -45.89 79.14 Favored 'General case' 0 N--CA 1.463 0.187 0 O-C-N 123.135 0.272 . . . . 0.0 110.525 -178.814 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -72.45 -22.58 61.06 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 113.237 0.829 . . . . 0.0 113.237 -173.463 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 24.3 m -61.2 -18.09 56.46 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 119.967 1.258 . . . . 0.0 111.519 165.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 65.16 -25.15 0.09 Allowed 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 130.218 3.407 . . . . 0.0 114.951 171.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 1.9 mtpp -73.54 -8.53 56.31 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 124.955 1.302 . . . . 0.0 112.137 174.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -107.93 125.26 51.28 Favored 'General case' 0 C--N 1.343 0.301 0 CA-C-N 119.645 1.112 . . . . 0.0 108.328 173.262 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 40.5 mttp -135.76 166.41 23.35 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 126.188 1.795 . . . . 0.0 109.115 172.773 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 71.7 t -64.76 152.7 8.52 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 C-N-CA 123.515 0.726 . . . . 0.0 109.118 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 67.43 43.72 86.36 Favored Glycine 0 CA--C 1.528 0.903 0 CA-C-O 122.047 0.804 . . . . 0.0 112.221 174.564 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.8 p-10 -78.46 -20.99 49.76 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 125.782 1.633 . . . . 0.0 115.135 -173.272 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 18.4 mtm180 44.84 90.96 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 128.752 2.821 . . . . 0.0 111.516 -160.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 24.2 mt -68.48 150.21 10.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.343 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -116.56 -50.98 2.61 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.413 2.285 . . . . 0.0 108.898 177.186 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -151.91 169.97 20.99 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 124.179 0.991 . . . . 0.0 111.603 -176.831 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.0 p -128.88 118.89 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 124.371 1.068 . . . . 0.0 109.291 175.628 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 39.05 47.06 1.23 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.413 1.485 . . . . 0.0 110.494 -169.198 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.16 -3.72 51.05 Favored Glycine 0 CA--C 1.53 1.01 0 C-N-CA 125.952 1.739 . . . . 0.0 115.977 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -82.21 141.84 32.66 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 120.829 2.314 . . . . 0.0 108.578 -178.624 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.7 p -90.02 90.66 8.24 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-O 122.675 1.226 . . . . 0.0 110.374 -171.562 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 13.3 pt -65.39 -3.16 1.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.814 0 C-N-CA 126.833 2.053 . . . . 0.0 113.622 -177.224 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 26.1 mm -57.48 -58.13 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 126.799 2.04 . . . . 0.0 109.591 175.274 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -113.8 -22.96 9.91 Favored 'General case' 0 C--O 1.231 0.114 0 O-C-N 123.596 0.56 . . . . 0.0 112.029 -161.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.5 ttt -56.18 142.24 67.29 Favored Pre-proline 0 N--CA 1.437 -1.083 0 C-N-CA 126.292 1.837 . . . . 0.0 109.463 166.47 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -75.35 153.09 39.88 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 121.259 1.306 . . . . 0.0 111.169 -179.134 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 32.9 t60 -58.19 -41.23 83.51 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.255 0.622 . . . . 0.0 112.015 -170.038 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.68 -32.1 73.12 Favored 'General case' 0 C--O 1.227 -0.101 0 CA-C-O 118.879 -0.582 . . . . 0.0 112.41 178.716 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 53.5 m-20 -75.8 -42.04 51.12 Favored 'General case' 0 C--O 1.225 -0.221 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 32.8 mt -60.54 -40.26 83.85 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 124.643 1.177 . . . . 0.0 109.72 173.783 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 19.2 t -68.03 -35.88 73.41 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 O-C-N 120.198 -1.564 . . . . 0.0 110.902 175.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -62.38 -48.67 78.7 Favored 'General case' 0 C--O 1.22 -0.459 0 O-C-N 121.506 -0.746 . . . . 0.0 110.498 171.106 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.88 -35.39 66.45 Favored 'General case' 0 N--CA 1.44 -0.928 0 C-N-CA 126.505 1.922 . . . . 0.0 111.981 -176.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 76.0 mt -69.77 -52.58 30.25 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 176.225 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 6.8 tttp -54.51 -44.33 72.63 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 122.924 0.49 . . . . 0.0 111.172 177.613 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -71.95 -19.43 61.9 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.182 1.793 . . . . 0.0 110.984 -178.112 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.97 -35.38 80.44 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 119.525 1.057 . . . . 0.0 109.447 169.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 86.13 -117.03 4.5 Favored Glycine 0 N--CA 1.449 -0.497 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 172.542 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 39.6 mt -76.48 -49.27 17.0 Favored 'General case' 0 CA--C 1.501 -0.912 0 CA-C-N 118.367 1.083 . . . . 0.0 108.838 -173.636 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.89 145.81 24.36 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 124.229 0.955 . . . . 0.0 108.638 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.9 p -146.39 139.5 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 167.623 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 47.1 m -106.07 105.5 15.56 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 125.584 1.554 . . . . 0.0 107.197 176.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 40.7 mt -90.81 127.12 36.24 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.784 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.418 HH11 ' HB2' ' A' ' 98' ' ' ARG . 6.4 ttm105 -103.53 111.7 24.28 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.2 pp -121.53 174.61 5.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 C-N-CA 126.048 1.739 . . . . 0.0 108.312 -175.224 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 8.5 mt -118.3 121.69 30.94 Favored Pre-proline 0 CA--C 1.54 0.586 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -179.107 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -90.64 134.3 1.89 Allowed 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 123.647 2.898 . . . . 0.0 111.668 -176.792 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 6.4 mt-30 -129.0 -179.92 5.38 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.379 1.872 . . . . 0.0 107.979 -173.38 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -132.1 -25.8 1.98 Allowed 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 118.775 0.716 . . . . 0.0 112.779 173.497 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -81.58 -6.37 58.92 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 124.526 1.131 . . . . 0.0 111.411 -171.453 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -81.58 -11.5 59.11 Favored 'General case' 0 C--O 1.235 0.316 0 C-N-CA 129.298 3.039 . . . . 0.0 114.275 -168.061 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -148.58 -165.29 2.23 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 119.219 0.918 . . . . 0.0 109.401 -169.514 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 56.8 m -79.54 105.16 2.93 Favored Pre-proline 0 N--CA 1.448 -0.526 0 CA-C-O 117.903 -1.046 . . . . 0.0 108.238 156.036 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -70.02 153.18 67.98 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 CA-C-N 120.901 1.357 . . . . 0.0 109.457 168.016 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 14.6 t -162.29 149.65 13.9 Favored 'General case' 0 C--O 1.24 0.603 0 C-N-CA 126.116 1.766 . . . . 0.0 106.646 167.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.24 -165.11 13.1 Favored Glycine 0 CA--C 1.531 1.049 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -67.62 168.96 16.89 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.222 2.615 . . . . 0.0 112.06 -170.124 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.7 t -146.11 -28.56 0.42 Allowed 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 126.458 1.903 . . . . 0.0 110.47 -172.505 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -77.6 96.07 4.71 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 124.158 0.983 . . . . 0.0 110.86 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 171.703 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.2 p . . . . . 0 CA--C 1.535 0.377 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 13.0 m -140.83 164.74 29.41 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.514 1.126 . . . . 0.0 109.071 171.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 25.6 p-10 -128.71 94.45 3.86 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 127.601 2.36 . . . . 0.0 108.901 -173.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.452 HG11 ' HB2' ' A' ' 62' ' ' LEU . 24.3 t -90.64 106.94 17.93 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 176.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.7 t -85.5 142.72 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 166.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.0 mt -137.53 132.01 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.152 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 174.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 -115.04 141.35 48.11 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.715 1.606 . . . . 0.0 109.343 -175.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 30.9 ptt180 -139.88 -169.47 2.73 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 124.426 1.09 . . . . 0.0 110.474 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.67 169.12 10.38 Favored 'General case' 0 N--CA 1.463 0.222 0 C-N-CA 124.567 1.147 . . . . 0.0 109.439 168.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -69.89 -15.98 63.16 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 113.43 0.9 . . . . 0.0 113.43 -177.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -84.5 -7.07 59.4 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-O 118.477 -0.773 . . . . 0.0 112.896 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -136.32 172.34 13.16 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 119.649 1.113 . . . . 0.0 111.479 -166.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.74 166.45 26.36 Favored Glycine 0 C--N 1.333 0.413 0 C-N-CA 123.669 0.652 . . . . 0.0 111.927 -170.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -87.27 115.71 24.86 Favored 'General case' 0 N--CA 1.444 -0.726 0 N-CA-C 104.52 -2.4 . . . . 0.0 104.52 150.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -92.7 48.62 2.55 Favored Glycine 0 C--O 1.224 -0.482 0 CA-C-O 118.518 -1.157 . . . . 0.0 112.643 -168.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.433 ' CE2' HD11 ' A' ' 28' ' ' ILE . 19.9 p90 -126.92 160.08 32.06 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 118.76 1.28 . . . . 0.0 109.873 173.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.4 t -138.39 141.36 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 C-N-CA 126.519 1.927 . . . . 0.0 106.972 -179.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.433 HD11 ' CE2' ' A' ' 26' ' ' PHE . 4.4 mp -105.9 135.85 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.667 0 C-N-CA 125.817 1.647 . . . . 0.0 107.801 178.009 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.473 HD11 ' HE3' ' A' ' 46' ' ' LYS . 13.5 pt . . . . . 0 N--CA 1.45 -0.467 0 C-N-CA 125.459 1.504 . . . . 0.0 110.314 175.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo . . . . . 0 N--CA 1.453 -0.875 0 CA-C-O 118.399 -0.75 . . . . 0.0 111.696 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -138.48 125.35 21.11 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 119.73 1.15 . . . . 0.0 110.746 -170.441 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.473 ' HE3' HD11 ' A' ' 29' ' ' ILE . 48.2 pttt -146.64 162.94 37.38 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 124.407 1.083 . . . . 0.0 108.783 166.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 46.4 mm -65.31 130.61 30.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 170.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.42 -49.66 0.65 Allowed Glycine 0 C--N 1.336 0.56 0 C-N-CA 125.254 1.407 . . . . 0.0 112.492 175.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -129.24 150.63 50.54 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 119.433 1.617 . . . . 0.0 108.373 176.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 11.5 mt -128.93 133.31 66.35 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 167.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -60.14 126.37 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.605 0 C-N-CA 125.191 1.396 . . . . 0.0 108.018 169.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.29 121.13 9.43 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 124.483 1.113 . . . . 0.0 108.059 164.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.51 21.55 40.28 Favored Glycine 0 CA--C 1.526 0.778 0 CA-C-O 118.875 -0.958 . . . . 0.0 112.649 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 29.0 p -90.85 164.76 24.55 Favored Pre-proline 0 C--O 1.236 0.349 0 CA-C-N 119.651 1.725 . . . . 0.0 112.915 177.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -65.65 -21.77 58.66 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 121.695 1.597 . . . . 0.0 112.911 162.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.4 -56.36 16.9 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 119.199 0.909 . . . . 0.0 109.134 172.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -57.95 -48.48 79.83 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.597 0.759 . . . . 0.0 109.923 -177.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.3 mtt85 -71.9 -6.85 44.8 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 113.91 1.078 . . . . 0.0 113.91 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 36.1 t -62.29 -21.58 65.34 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 119.817 1.19 . . . . 0.0 109.646 167.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.69 26.23 11.04 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 125.736 1.614 . . . . 0.0 112.665 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.6 mtmm -126.96 -52.13 1.43 Allowed 'General case' 0 CA--C 1.521 -0.145 0 C-N-CA 126.583 1.953 . . . . 0.0 109.153 175.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.452 ' HB2' HG11 ' A' ' 14' ' ' VAL . 9.9 tp -92.85 118.77 31.48 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -161.441 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 71.4 mmtt -129.97 171.89 12.29 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 123.55 1.643 . . . . 0.0 109.332 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 94.8 t -64.89 122.9 16.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 113.807 -1.542 . . . . 0.0 107.626 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 128.31 -18.89 5.75 Favored Glycine 0 C--N 1.337 0.593 0 C-N-CA 125.02 1.295 . . . . 0.0 109.997 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -77.05 98.25 4.94 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 122.243 1.021 . . . . 0.0 109.196 -165.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 17.8 mtm180 -44.63 120.48 2.28 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 128.653 2.781 . . . . 0.0 110.572 164.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 45.5 mt -101.6 153.31 5.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 126.151 1.78 . . . . 0.0 107.432 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 tp -131.75 -44.89 0.97 Allowed 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.821 1.648 . . . . 0.0 110.589 -172.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -147.98 163.11 37.84 Favored 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 123.267 0.627 . . . . 0.0 110.423 176.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 67.2 t -133.0 118.04 31.54 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 -176.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 42.39 57.11 3.5 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.146 1.778 . . . . 0.0 109.529 -170.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 67.46 -4.12 4.1 Favored Glycine 0 CA--C 1.537 1.435 0 CA-C-O 117.679 -1.623 . . . . 0.0 116.026 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -90.17 130.89 36.26 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 121.398 2.599 . . . . 0.0 110.997 -178.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 70.3 m -73.61 94.33 2.16 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 124.013 0.925 . . . . 0.0 110.509 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.5 pp -60.77 10.96 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.632 0 C-N-CA 128.34 2.656 . . . . 0.0 115.133 177.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 52.5 mt -63.46 -79.41 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 C-N-CA 126.029 1.732 . . . . 0.0 108.729 -178.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 62.9 m-80 -79.95 -11.87 59.76 Favored 'General case' 0 N--CA 1.467 0.4 0 O-C-N 121.453 -0.779 . . . . 0.0 113.079 -174.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 16.6 mtp -60.0 140.39 90.48 Favored Pre-proline 0 C--O 1.237 0.401 0 CA-C-N 118.238 0.472 . . . . 0.0 110.172 -178.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -65.27 156.05 65.21 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 121.962 1.775 . . . . 0.0 109.355 169.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 55.9 t60 -57.31 -34.99 69.3 Favored 'General case' 0 C--O 1.224 -0.261 0 CA-C-O 119.003 -0.522 . . . . 0.0 110.701 173.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.74 -41.66 77.91 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-O 118.591 -0.718 . . . . 0.0 112.362 175.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.88 -45.45 82.03 Favored 'General case' 0 C--O 1.222 -0.388 0 CA-C-N 118.909 0.777 . . . . 0.0 109.415 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 67.9 mt -65.42 -44.26 94.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.481 0 C-N-CA 125.53 1.532 . . . . 0.0 109.21 -175.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 22.5 t -55.18 -47.98 76.84 Favored 'Isoleucine or valine' 0 C--O 1.24 0.585 0 C-N-CA 125.147 1.379 . . . . 0.0 109.629 170.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 24.9 mtpt -70.33 -28.11 64.89 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-O 117.134 -1.412 . . . . 0.0 113.526 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.85 -40.83 79.17 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.932 1.696 . . . . 0.0 110.481 177.07 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 81.8 mt -68.74 -46.81 78.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 178.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.1 tmtm? -63.34 -38.12 89.93 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-O 118.678 -0.677 . . . . 0.0 111.729 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -61.93 -32.02 72.38 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 124.169 0.988 . . . . 0.0 110.282 175.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -67.95 -12.18 60.23 Favored 'General case' 0 CA--C 1.543 0.689 0 CA-C-O 121.636 0.731 . . . . 0.0 112.3 175.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 66.13 -100.31 0.51 Allowed Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 125.674 1.607 . . . . 0.0 110.411 173.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 25.1 mt -105.34 -24.72 12.63 Favored 'General case' 0 CA--C 1.504 -0.792 0 CA-C-O 117.68 -1.153 . . . . 0.0 112.495 -176.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.28 121.06 40.11 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 118.678 0.672 . . . . 0.0 109.495 178.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.3 p -125.68 148.48 30.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -176.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -116.28 117.29 29.58 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 124.656 1.183 . . . . 0.0 108.068 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 57.4 mt -98.99 112.64 24.7 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 171.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.3 ttm180 -81.47 112.56 18.83 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 166.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.9 pp -116.72 166.51 10.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 C-N-CA 124.951 1.301 . . . . 0.0 108.618 -178.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.5 mt . . . . . 0 N--CA 1.464 0.26 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 174.219 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 36.9 p . . . . . 0 CA--C 1.537 0.446 0 CA-C-O 118.292 -0.861 . . . . 0.0 109.212 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.3 t -115.57 173.91 6.29 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.532 1.133 . . . . 0.0 109.592 163.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -134.85 94.68 3.2 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 126.624 1.97 . . . . 0.0 108.376 168.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.6 t -99.22 108.07 21.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 O-C-N 120.68 -1.262 . . . . 0.0 107.94 -170.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.5 p -105.48 121.04 57.15 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 CA-C-N 118.841 0.746 . . . . 0.0 111.315 -170.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.6 mt -134.13 129.21 53.61 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 126.089 1.756 . . . . 0.0 109.363 -169.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 37.8 m-70 -108.54 144.18 36.56 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.214 1.806 . . . . 0.0 111.443 -177.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.414 HH11 ' H ' ' A' ' 24' ' ' PHE . 18.4 ptt180 -126.51 175.59 7.79 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 125.511 1.525 . . . . 0.0 111.018 176.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.436 ' HE3' ' OE2' ' A' ' 22' ' ' GLU . 0.0 OUTLIER -81.05 170.06 16.69 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 160.007 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -68.98 -35.7 77.02 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.609 -0.682 . . . . 0.0 111.709 177.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 68.9 m-20 -71.27 -47.32 57.65 Favored 'General case' 0 C--O 1.232 0.15 0 O-C-N 122.196 -0.315 . . . . 0.0 111.354 -171.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.436 ' OE2' ' HE3' ' A' ' 19' ' ' LYS . 5.3 pt-20 -76.84 166.96 22.64 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.518 0.675 . . . . 0.0 110.456 -176.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.61 -178.07 49.4 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 167.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.483 ' CE1' HG12 ' A' ' 95' ' ' VAL . 73.9 m-85 -70.6 145.28 50.81 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 104.255 -2.498 . . . . 0.0 104.255 149.443 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.419 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -84.81 44.83 3.42 Favored Glycine 0 C--O 1.221 -0.705 0 CA-C-O 117.529 -1.706 . . . . 0.0 112.519 -176.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -131.48 160.64 34.58 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 119.251 1.526 . . . . 0.0 110.519 179.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.9 t -136.88 127.32 40.18 Favored 'Isoleucine or valine' 0 C--O 1.239 0.53 0 C-N-CA 125.004 1.322 . . . . 0.0 108.055 177.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.1 mt -74.39 143.53 13.39 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 170.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.542 HD11 ' HE3' ' A' ' 46' ' ' LYS . 20.4 pt . . . . . 0 C--O 1.243 0.712 0 C-N-CA 124.25 1.02 . . . . 0.0 109.518 162.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_endo . . . . . 0 N--CA 1.454 -0.85 0 CA-C-O 118.27 -0.804 . . . . 0.0 111.292 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.4 m80 -85.42 126.51 33.84 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 120.07 1.305 . . . . 0.0 110.886 -174.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.542 ' HE3' HD11 ' A' ' 29' ' ' ILE . 11.2 pttp -144.32 162.52 36.21 Favored 'General case' 0 N--CA 1.465 0.281 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 166.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 23.0 mm -62.85 120.5 9.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 164.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -98.32 -30.05 7.18 Favored Glycine 0 CA--C 1.524 0.598 0 CA-C-N 118.455 0.571 . . . . 0.0 113.129 170.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 59.3 ttm-85 -151.97 153.98 35.14 Favored 'General case' 0 CA--C 1.514 -0.429 0 CA-C-N 118.635 1.217 . . . . 0.0 108.221 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 13.4 mt -120.15 149.92 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 O-C-N 124.614 1.196 . . . . 0.0 108.184 166.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.2 mp -78.58 127.29 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.825 0 C-N-CA 126.139 1.776 . . . . 0.0 107.25 168.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -59.42 137.51 57.97 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.44 6.1 89.04 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-O 118.461 -1.188 . . . . 0.0 113.331 174.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.419 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 76.6 p -87.3 166.52 25.37 Favored Pre-proline 0 CA--C 1.53 0.208 0 CA-C-N 119.992 1.896 . . . . 0.0 112.705 -175.2 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -58.16 -25.89 73.61 Favored 'Trans proline' 0 N--CA 1.452 -0.931 0 C-N-CA 122.121 1.881 . . . . 0.0 113.394 167.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.95 -60.62 2.85 Favored 'General case' 0 C--N 1.342 0.247 0 CA-C-N 119.283 0.947 . . . . 0.0 108.859 174.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -57.85 -46.38 84.86 Favored 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 122.981 0.512 . . . . 0.0 110.962 -176.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 78.8 mtt-85 -65.78 -18.21 65.17 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 124.885 1.274 . . . . 0.0 112.676 -176.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 9.0 t -63.12 -33.34 75.25 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 119.245 0.93 . . . . 0.0 110.11 175.266 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 58.23 -31.79 0.04 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 129.584 3.154 . . . . 0.0 114.901 -168.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.5 mtpt -61.55 -8.44 4.33 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.999 1.72 . . . . 0.0 112.093 170.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 21.2 tp -134.75 116.32 14.74 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 126.075 1.75 . . . . 0.0 108.981 -176.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 27.4 mmmt -137.4 171.63 14.19 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 123.535 1.636 . . . . 0.0 111.831 176.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 46.5 t -68.64 110.74 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 113.881 -1.509 . . . . 0.0 108.383 -178.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 138.35 -23.5 2.99 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -177.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -64.99 100.14 0.4 Allowed 'General case' 0 C--O 1.233 0.227 0 CA-C-O 122.114 0.959 . . . . 0.0 109.843 -174.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.9 mtm-85 -48.43 137.62 11.19 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 128.048 2.539 . . . . 0.0 109.602 156.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.8 mt -122.86 143.96 33.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.195 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -173.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.7 mt -107.24 -42.34 4.88 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 125.732 1.613 . . . . 0.0 110.379 175.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -154.68 165.99 34.81 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 123.015 0.526 . . . . 0.0 112.04 -170.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 51.4 t -125.71 123.06 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 C-N-CA 128.141 2.577 . . . . 0.0 104.95 174.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 42.78 39.31 1.64 Allowed 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.212 1.805 . . . . 0.0 111.412 -172.511 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 81.26 -9.75 52.74 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-O 117.638 -1.645 . . . . 0.0 115.173 177.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 7.6 mm-40 -75.07 119.59 19.44 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 120.558 2.179 . . . . 0.0 108.557 172.169 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.9 m -55.21 127.76 30.79 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 171.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 15.3 pt -100.79 -5.38 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 C-N-CA 123.331 0.652 . . . . 0.0 112.265 -178.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.1 mt -59.13 142.48 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 167.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 73.2 -20.06 0.3 Allowed 'General case' 0 CA--C 1.533 0.294 0 C-N-CA 126.497 1.919 . . . . 0.0 115.325 167.315 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 14.0 mtp -64.25 148.3 95.97 Favored Pre-proline 0 CA--C 1.539 0.522 0 CA-C-N 119.477 1.035 . . . . 0.0 109.68 167.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -72.57 161.17 44.79 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 122.401 2.067 . . . . 0.0 110.064 169.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -55.28 -47.79 75.0 Favored 'General case' 0 C--O 1.225 -0.209 0 C-N-CA 123.661 0.784 . . . . 0.0 111.016 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -53.76 -40.62 66.37 Favored 'General case' 0 CA--C 1.527 0.092 0 C-N-CA 123.236 0.614 . . . . 0.0 112.174 -176.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -72.19 -42.37 65.9 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 119.259 -0.4 . . . . 0.0 110.478 -175.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 46.9 mt -66.59 -37.28 79.24 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 124.87 1.268 . . . . 0.0 108.846 176.238 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 38.2 t -65.16 -45.63 93.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.484 0 O-C-N 120.274 -1.516 . . . . 0.0 109.841 175.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.3 ttpt -62.41 -42.53 99.51 Favored 'General case' 0 C--O 1.22 -0.482 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.344 175.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.12 -48.01 23.16 Favored 'General case' 0 C--O 1.226 -0.162 0 C-N-CA 126.305 1.842 . . . . 0.0 111.62 171.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 74.4 mt -76.22 -31.89 21.76 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 O-C-N 121.592 -0.692 . . . . 0.0 109.607 -174.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.3 tttp -66.42 -46.08 77.75 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.58 1.082 . . . . 0.0 110.125 170.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -60.87 -18.15 54.47 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 128.134 2.574 . . . . 0.0 111.984 175.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -58.68 -25.91 63.3 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.816 0.446 . . . . 0.0 111.336 169.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 66.86 57.97 8.97 Favored Glycine 0 C--N 1.339 0.71 0 O-C-N 121.338 -0.852 . . . . 0.0 111.063 170.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 48.0 mt 75.48 -38.52 0.36 Allowed 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 128.428 2.691 . . . . 0.0 112.193 -174.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.01 121.43 41.77 Favored 'General case' 0 C--N 1.322 -0.61 0 O-C-N 123.604 0.565 . . . . 0.0 111.062 -173.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.483 HG12 ' CE1' ' A' ' 24' ' ' PHE . 8.5 p -124.77 121.75 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 178.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.2 m -89.49 133.68 34.45 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 164.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 27.7 mt -123.76 139.36 54.06 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 -177.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.8 ttm180 -113.72 115.86 28.5 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -112.52 166.9 6.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 C-N-CA 126.682 1.993 . . . . 0.0 108.083 177.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 70.0 mt . . . . . 0 CA--C 1.54 0.586 0 CA-C-O 117.792 -1.099 . . . . 0.0 109.615 177.529 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 38.4 p . . . . . 0 CA--C 1.537 0.451 0 N-CA-C 107.327 -1.361 . . . . 0.0 107.327 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 23.4 m -137.98 162.3 34.45 Favored 'General case' 0 C--N 1.328 -0.34 0 O-C-N 120.865 -1.147 . . . . 0.0 108.333 164.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -131.72 95.72 3.79 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 127.691 2.396 . . . . 0.0 107.1 -167.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 19.6 t -93.72 94.83 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 -176.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.9 p -80.88 129.25 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 172.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 67.0 mt -135.17 147.15 29.29 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 175.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.6 m-70 -113.4 167.31 10.69 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.008 1.323 . . . . 0.0 109.713 173.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 46.2 ptt85 -145.58 -179.88 6.97 Favored 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 125.996 1.718 . . . . 0.0 107.076 172.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.67 159.29 15.6 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 173.1 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.556 ' HG2' HD21 ' A' ' 93' ' ' LEU . 8.8 mt-10 -70.13 -14.77 62.8 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 120.791 -1.193 . . . . 0.0 112.243 -178.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -80.08 7.63 8.78 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.95 1.3 . . . . 0.0 112.264 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -164.62 170.14 16.1 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 120.249 -1.532 . . . . 0.0 109.863 -167.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.2 -167.81 29.12 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 125.399 1.476 . . . . 0.0 110.909 175.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -85.98 159.44 19.62 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 164.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.88 39.28 2.86 Favored Glycine 0 C--O 1.222 -0.623 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.922 -178.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -118.58 161.35 20.2 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 119.587 1.694 . . . . 0.0 109.387 169.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.8 t -140.81 129.79 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 -178.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 61.5 mt -97.4 145.47 9.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.2 pt . . . . . 0 N--CA 1.441 -0.879 0 C-N-CA 125.249 1.42 . . . . 0.0 109.746 168.781 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo . . . . . 0 N--CA 1.456 -0.688 0 CA-C-O 119.457 -0.309 . . . . 0.0 111.492 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -140.39 132.59 28.1 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 125.206 1.403 . . . . 0.0 108.142 -173.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.0 pttm -156.89 166.93 31.98 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 125.698 1.599 . . . . 0.0 107.734 174.249 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 26.5 mm -72.71 103.69 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 C-N-CA 124.571 1.148 . . . . 0.0 108.87 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -67.91 -42.58 85.47 Favored Glycine 0 N--CA 1.451 -0.33 0 O-C-N 121.284 -0.885 . . . . 0.0 111.366 172.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 23.6 ttm105 -158.1 152.12 24.09 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -165.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 16.1 mt -122.0 150.49 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 168.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 31.9 mm -87.82 136.47 23.08 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.4 t0 -66.66 148.89 51.28 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-O 121.152 0.501 . . . . 0.0 111.185 -176.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.48 7.93 17.12 Favored Glycine 0 CA--C 1.527 0.834 0 C-N-CA 124.519 1.057 . . . . 0.0 114.369 175.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.406 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 79.4 p -76.0 167.98 31.88 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 118.234 1.017 . . . . 0.0 111.144 -176.343 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.406 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 12.5 Cg_endo -57.8 -27.71 79.26 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 122.149 1.899 . . . . 0.0 112.239 165.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -70.83 -51.96 23.38 Favored 'General case' 0 C--N 1.341 0.204 0 CA-C-N 119.996 1.271 . . . . 0.0 110.171 174.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -57.83 -44.68 86.63 Favored 'General case' 0 N--CA 1.465 0.311 0 C-N-CA 123.343 0.657 . . . . 0.0 110.674 -179.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 27.4 mtt-85 -75.86 -5.53 46.46 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 124.634 1.174 . . . . 0.0 112.706 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.9 t -73.21 -35.97 66.43 Favored 'General case' 0 C--O 1.225 -0.2 0 CA-C-O 117.617 -1.182 . . . . 0.0 110.994 178.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 59.49 -24.94 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 127.985 2.514 . . . . 0.0 116.214 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 6.1 mtpt -66.48 -17.29 64.71 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 120.325 1.421 . . . . 0.0 111.975 161.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.78 119.0 34.08 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -178.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.51 171.47 14.21 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-O 122.563 1.173 . . . . 0.0 109.049 -178.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 78.3 t -72.43 108.14 3.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 O-C-N 120.734 -1.229 . . . . 0.0 108.693 -178.399 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 130.39 -3.94 5.87 Favored Glycine 0 CA--C 1.521 0.418 0 C-N-CA 126.261 1.886 . . . . 0.0 111.275 173.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.5 m-20 -71.31 95.86 1.36 Allowed 'General case' 0 C--O 1.234 0.268 0 CA-C-N 118.585 1.192 . . . . 0.0 108.148 172.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 38.5 mtt85 -53.01 143.3 17.61 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 127.382 2.273 . . . . 0.0 109.116 170.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 34.6 mt -116.84 149.53 19.06 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -168.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.86 -46.05 0.87 Allowed 'General case' 0 N--CA 1.463 0.211 0 C-N-CA 126.336 1.854 . . . . 0.0 109.967 -164.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -153.52 168.55 25.77 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.046 0.938 . . . . 0.0 110.012 176.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.453 HG22 HD23 ' A' ' 97' ' ' LEU . 80.6 t -133.6 120.99 39.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 174.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.554 HD21 ' HB2' ' A' ' 91' ' ' ALA . 23.2 m-20 48.73 41.22 17.6 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.308 1.043 . . . . 0.0 110.398 -172.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.13 -11.39 3.82 Favored Glycine 0 CA--C 1.527 0.792 0 C-N-CA 126.907 2.194 . . . . 0.0 116.467 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.5 tp-100 -77.13 121.53 23.73 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 120.146 1.973 . . . . 0.0 107.257 -177.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 p -63.29 112.33 2.65 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.32 1.048 . . . . 0.0 110.992 -174.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 1.7 pp -73.34 14.25 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 125.758 1.623 . . . . 0.0 113.188 175.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 60.6 mt -76.78 -86.16 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 O-C-N 121.199 -0.938 . . . . 0.0 109.353 -158.414 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -77.53 -8.72 58.24 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.416 1.086 . . . . 0.0 111.226 176.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 17.1 ttt -53.65 142.26 42.82 Favored Pre-proline 0 N--CA 1.433 -1.303 0 C-N-CA 128.22 2.608 . . . . 0.0 110.924 -177.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -60.66 139.58 86.47 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 121.873 1.715 . . . . 0.0 110.639 174.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -59.3 -39.87 84.38 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.541 0.736 . . . . 0.0 111.587 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.39 -23.49 63.73 Favored 'General case' 0 CA--C 1.53 0.177 0 O-C-N 122.034 -0.416 . . . . 0.0 111.986 175.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -73.72 -46.54 45.43 Favored 'General case' 0 C--O 1.223 -0.293 0 CA-C-O 118.635 -0.697 . . . . 0.0 109.713 179.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 49.1 mt -56.08 -40.32 63.34 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 126.432 1.893 . . . . 0.0 110.568 172.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 35.0 t -66.57 -43.89 90.36 Favored 'Isoleucine or valine' 0 C--O 1.238 0.451 0 O-C-N 120.109 -1.619 . . . . 0.0 110.75 176.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 6.6 tttt -54.82 -49.11 71.8 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 172.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -48.89 -39.38 25.75 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 129.23 3.012 . . . . 0.0 113.721 177.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.7 mt -75.9 -46.08 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 CA-C-N 118.791 0.723 . . . . 0.0 109.073 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -57.34 -51.21 70.29 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 119.002 0.819 . . . . 0.0 110.137 173.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -57.71 -19.28 26.17 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 128.69 2.796 . . . . 0.0 112.864 177.258 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.554 ' HB2' HD21 ' A' ' 72' ' ' ASN . . . -60.41 -26.87 67.01 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 119.253 0.933 . . . . 0.0 112.596 177.231 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.32 -151.36 18.28 Favored Glycine 0 C--N 1.341 0.822 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -173.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . 0.556 HD21 ' HG2' ' A' ' 20' ' ' GLU . 72.9 mt -71.98 -33.04 67.82 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 117.626 0.713 . . . . 0.0 110.906 168.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.91 145.56 24.54 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 -178.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.6 p -140.98 143.24 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 168.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 23.7 m -114.57 102.69 10.29 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 174.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.453 HD23 HG22 ' A' ' 71' ' ' VAL . 61.3 mt -89.93 115.21 27.06 Favored 'General case' 0 CA--C 1.514 -0.427 0 N-CA-C 106.587 -1.634 . . . . 0.0 106.587 -174.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -86.4 112.14 21.18 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 -178.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -113.51 167.97 6.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 C-N-CA 124.709 1.203 . . . . 0.0 110.356 -174.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.9 mp . . . . . 0 C--O 1.239 0.518 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 172.655 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 74.0 p . . . . . 0 N--CA 1.444 -0.742 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 m -132.18 155.26 48.52 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 144.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -93.21 143.11 26.58 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 105.632 -1.988 . . . . 0.0 105.632 160.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.7 t -129.96 102.06 6.74 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 169.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.6 p -82.95 144.87 9.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 168.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.1 mt -136.81 152.26 28.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 C-N-CA 127.487 2.315 . . . . 0.0 104.933 173.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 83.0 m-70 -129.92 136.56 49.62 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 125.618 1.567 . . . . 0.0 109.122 -168.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.1 ptt180 -131.39 176.6 8.16 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 120.605 1.548 . . . . 0.0 111.195 -178.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.2 161.98 14.04 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.07 0.948 . . . . 0.0 109.289 172.351 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -70.55 -15.78 62.81 Favored 'General case' 0 CA--C 1.538 0.502 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -89.2 -10.64 46.32 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.149 0.886 . . . . 0.0 112.642 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 25.9 pt-20 -127.57 175.38 8.3 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 120.344 1.429 . . . . 0.0 110.974 -166.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.01 176.79 19.44 Favored Glycine 0 CA--C 1.531 1.036 0 C-N-CA 124.899 1.238 . . . . 0.0 111.716 177.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 57.9 m-85 -89.3 137.96 31.86 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.024 -1.473 . . . . 0.0 107.024 163.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.76 66.9 0.32 Allowed Glycine 0 C--O 1.222 -0.603 0 C-N-CA 124.571 1.081 . . . . 0.0 111.101 -176.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -133.85 146.31 50.5 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 124.814 1.246 . . . . 0.0 108.459 167.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.6 t -121.54 144.87 29.25 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 173.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.6 mp -118.43 110.62 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 -173.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.451 HD11 ' HE3' ' A' ' 46' ' ' LYS . 31.1 pt . . . . . 0 C--O 1.234 0.261 0 C-N-CA 123.861 0.864 . . . . 0.0 111.072 -169.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 N--CA 1.461 -0.403 0 CA-C-O 118.212 -0.829 . . . . 0.0 114.026 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -133.55 121.16 21.73 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 119.734 1.152 . . . . 0.0 108.098 -177.324 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.451 ' HE3' HD11 ' A' ' 29' ' ' ILE . 1.9 pttt -145.72 149.46 34.45 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 106.9 -1.519 . . . . 0.0 106.9 170.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.519 HG13 HD22 ' A' ' 62' ' ' LEU . 17.1 mm -63.03 125.84 20.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 174.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -98.41 -37.51 4.27 Favored Glycine 0 C--N 1.333 0.388 0 C-N-CA 123.88 0.753 . . . . 0.0 112.773 178.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 37.6 ttm180 -158.15 149.14 20.85 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 125.198 1.399 . . . . 0.0 107.906 -174.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.2 mt -127.34 124.88 64.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 C-N-CA 126.598 1.959 . . . . 0.0 106.536 172.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.6 mp -55.59 132.91 19.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.339 0 C-N-CA 125.436 1.494 . . . . 0.0 109.828 168.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -57.42 127.5 32.3 Favored 'General case' 0 C--O 1.24 0.572 0 C-N-CA 124.991 1.316 . . . . 0.0 109.309 174.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.04 5.52 89.55 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 124.447 1.023 . . . . 0.0 113.462 174.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.2 p -65.26 162.69 38.08 Favored Pre-proline 0 CA--C 1.532 0.288 0 CA-C-N 119.21 1.505 . . . . 0.0 110.938 173.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -60.5 -28.95 87.62 Favored 'Trans proline' 0 N--CA 1.45 -1.045 0 C-N-CA 121.781 1.654 . . . . 0.0 112.109 168.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.25 -52.84 63.57 Favored 'General case' 0 C--N 1.344 0.33 0 CA-C-N 119.337 0.972 . . . . 0.0 110.282 172.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -61.55 -51.96 66.42 Favored 'General case' 0 N--CA 1.462 0.146 0 O-C-N 123.285 0.366 . . . . 0.0 110.817 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 90.5 mtt-85 -63.93 -28.9 70.15 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 118.409 -0.805 . . . . 0.0 112.059 -173.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 42.3 t -60.94 -19.1 60.26 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.627 1.171 . . . . 0.0 112.573 174.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 55.78 22.4 5.49 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 125.389 1.475 . . . . 0.0 114.197 171.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 44.5 mtmt -130.1 8.24 5.15 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 124.668 1.187 . . . . 0.0 113.273 178.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.519 HD22 HG13 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -141.06 119.27 12.07 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 -179.764 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.13 165.11 24.0 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 119.016 0.826 . . . . 0.0 110.606 176.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . 0.263 0.2 OUTLIER -56.98 141.15 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 O-C-N 121.201 -0.937 . . . . 0.0 109.846 172.684 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.2 -6.97 78.7 Favored Glycine 0 CA--C 1.524 0.655 0 CA-C-O 118.215 -1.325 . . . . 0.0 111.651 -174.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 41.8 m-20 -74.59 96.97 3.06 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 119.244 1.522 . . . . 0.0 107.287 168.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 42.8 mtm180 -45.05 130.87 7.61 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 126.882 2.073 . . . . 0.0 110.061 160.034 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 7.1 mt -111.76 143.99 20.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -177.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 tp -112.81 -44.98 3.24 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 127.343 2.257 . . . . 0.0 108.47 -171.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -155.71 170.88 21.02 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.546 0.739 . . . . 0.0 111.474 -177.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.9 p -131.22 125.39 57.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 C-N-CA 125.154 1.382 . . . . 0.0 107.992 174.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 64.2 m-20 46.64 45.65 14.41 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 124.487 1.115 . . . . 0.0 108.957 -170.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 68.3 -2.51 7.15 Favored Glycine 0 CA--C 1.538 1.477 0 C-N-CA 125.81 1.672 . . . . 0.0 116.772 -175.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -91.13 135.32 33.85 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 121.465 2.632 . . . . 0.0 110.359 -174.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -72.41 109.24 5.97 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 126.109 1.764 . . . . 0.0 112.316 -171.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 7.4 pt -87.74 -5.05 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 O-C-N 121.348 -0.845 . . . . 0.0 112.51 -172.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.521 HD12 ' H ' ' A' ' 77' ' ' ILE . 3.6 mp -65.56 -48.23 83.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 C-N-CA 124.626 1.17 . . . . 0.0 110.207 173.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 63.6 m-80 -93.45 -26.6 17.13 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 118.523 -0.751 . . . . 0.0 112.255 -162.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 3.9 mtp -70.27 160.53 80.62 Favored Pre-proline 0 CA--C 1.534 0.34 0 C-N-CA 124.685 1.194 . . . . 0.0 112.398 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -71.36 146.18 49.95 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 121.822 1.681 . . . . 0.0 109.764 166.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -49.61 -38.6 32.43 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.765 1.226 . . . . 0.0 111.68 178.253 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -65.76 -30.13 70.75 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 124.152 0.981 . . . . 0.0 113.366 -178.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -82.01 -37.91 25.84 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 119.482 1.037 . . . . 0.0 109.908 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.7 mt -60.5 -36.32 68.95 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 C-N-CA 124.047 0.939 . . . . 0.0 109.659 172.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.9 t -63.79 -51.35 70.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 O-C-N 120.542 -1.349 . . . . 0.0 110.24 170.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -51.88 -46.97 64.72 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 118.138 0.426 . . . . 0.0 111.406 178.543 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.45 -36.11 66.2 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 127.686 2.394 . . . . 0.0 113.602 -179.446 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 86.1 mt -76.7 -48.42 26.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.157 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 59.2 tttt -55.7 -44.86 77.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 122.882 0.473 . . . . 0.0 110.879 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -63.68 -26.9 68.87 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 125.251 1.42 . . . . 0.0 112.27 177.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.39 -28.41 69.25 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 118.195 0.452 . . . . 0.0 110.519 176.098 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.16 -106.88 2.93 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 125.385 1.469 . . . . 0.0 109.708 174.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 81.5 mt -100.35 -36.27 9.3 Favored 'General case' 0 CA--C 1.504 -0.812 0 C-N-CA 123.137 0.575 . . . . 0.0 110.758 -170.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -93.73 143.65 26.12 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 170.325 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.2 p -144.21 138.43 24.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 165.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 m -104.79 130.02 52.96 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 179.125 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 26.7 mt -114.4 117.85 32.21 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 124.642 1.177 . . . . 0.0 107.876 177.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -84.93 116.05 23.13 Favored 'General case' 0 C--O 1.232 0.175 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 174.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 pp -114.92 172.71 3.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 C-N-CA 125.867 1.667 . . . . 0.0 109.941 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 6.2 mt . . . . . 0 C--O 1.237 0.447 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 169.627 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 28.9 p . . . . . 0 N--CA 1.447 -0.58 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . 0.401 ' HB2' HG13 ' A' ' 99' ' ' ILE . 5.5 m -97.7 135.91 38.82 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 103.912 -2.625 . . . . 0.0 103.912 -174.217 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -112.92 103.99 11.97 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 18.2 t -87.49 139.29 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 105.532 -2.025 . . . . 0.0 105.532 177.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.4 p -129.11 143.24 41.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 168.037 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 4.0 mt -132.11 152.06 36.07 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 127.12 2.168 . . . . 0.0 105.421 173.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -131.32 130.11 42.31 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 126.646 1.978 . . . . 0.0 107.597 -176.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 34.0 ptt180 -126.11 179.89 5.03 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-N 120.311 1.414 . . . . 0.0 110.492 -175.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.1 164.61 12.09 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.281 1.033 . . . . 0.0 109.073 175.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -75.21 -12.95 60.4 Favored 'General case' 0 N--CA 1.466 0.367 0 O-C-N 120.795 -1.19 . . . . 0.0 111.764 176.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -74.44 -8.25 55.67 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 177.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 26.1 pt-20 -143.0 -175.71 4.62 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 124.082 0.953 . . . . 0.0 110.95 -162.136 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -116.89 -179.39 17.77 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 175.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.404 ' CE1' HG12 ' A' ' 95' ' ' VAL . 69.8 m-85 -75.31 174.53 9.41 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 159.069 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.39 46.43 1.08 Allowed Glycine 0 C--O 1.222 -0.602 0 CA-C-O 118.817 -0.99 . . . . 0.0 111.694 -176.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -133.44 143.95 49.19 Favored 'General case' 0 C--O 1.239 0.506 0 CA-C-N 118.246 1.023 . . . . 0.0 108.29 177.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.6 t -119.21 114.35 44.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 106.009 -1.848 . . . . 0.0 106.009 -171.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 14.5 mt -78.88 136.92 22.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.299 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 174.249 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.0 pt . . . . . 0 N--CA 1.441 -0.883 0 C-N-CA 125.557 1.543 . . . . 0.0 108.236 163.638 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo . . . . . 0 N--CA 1.449 -1.119 0 N-CA-C 108.66 -1.323 . . . . 0.0 108.66 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER 91.74 123.93 0.02 OUTLIER 'General case' 0 C--O 1.233 0.208 0 C-N-CA 130.123 3.369 . . . . 0.0 111.004 167.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -145.44 163.68 33.89 Favored 'General case' 0 C--O 1.233 0.209 0 C-N-CA 124.905 1.282 . . . . 0.0 108.4 163.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.8 mm -65.24 129.73 29.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 165.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -101.97 -49.6 1.24 Allowed Glycine 0 CA--C 1.524 0.628 0 C-N-CA 126.857 2.17 . . . . 0.0 111.774 173.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 49.6 ttt180 -144.38 161.81 38.04 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 125.325 1.45 . . . . 0.0 107.544 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.3 mt -133.46 150.74 32.46 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 C-N-CA 126.453 1.901 . . . . 0.0 107.707 174.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.0 mp -87.03 115.76 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.904 0 C-N-CA 126.57 1.948 . . . . 0.0 106.796 171.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 31.6 m-20 -52.57 142.98 16.74 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.183 0.993 . . . . 0.0 109.048 171.482 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.82 -12.99 26.55 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-O 118.218 -1.323 . . . . 0.0 113.471 175.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 74.3 p -65.85 167.03 12.59 Favored Pre-proline 0 C--O 1.238 0.478 0 CA-C-N 119.639 1.72 . . . . 0.0 111.829 -175.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -59.32 -29.1 89.37 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 121.712 1.608 . . . . 0.0 111.996 166.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.56 -56.74 12.03 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.668 0.667 . . . . 0.0 109.946 177.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -65.29 -51.55 59.97 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 123.039 0.535 . . . . 0.0 110.949 -177.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.0 mtp180 -65.46 -9.37 25.13 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.337 0.865 . . . . 0.0 113.337 -177.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -76.7 -9.27 58.55 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 117.149 -1.405 . . . . 0.0 113.16 171.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 52.11 39.17 26.07 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.905 1.682 . . . . 0.0 113.942 170.377 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 23.6 mtmm -141.11 13.49 2.23 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.784 1.233 . . . . 0.0 113.34 177.197 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.9 mt -144.26 127.41 16.62 Favored 'General case' 0 C--O 1.237 0.437 0 O-C-N 121.09 -1.006 . . . . 0.0 109.743 175.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -116.3 164.83 13.93 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.657 1.218 . . . . 0.0 108.806 175.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 39.3 t -65.75 133.73 30.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 163.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 110.07 -17.32 29.6 Favored Glycine 0 C--N 1.339 0.704 0 C-N-CA 124.918 1.247 . . . . 0.0 110.307 -177.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -71.91 97.12 1.78 Allowed 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 122.667 1.222 . . . . 0.0 109.09 -175.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 49.6 mtt85 -55.17 148.36 14.44 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 126.013 1.725 . . . . 0.0 110.904 166.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 96.3 mt -122.71 148.1 26.62 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 C-N-CA 126.995 2.118 . . . . 0.0 106.788 -166.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 29.1 mt -126.44 -37.29 2.21 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 114.43 1.27 . . . . 0.0 114.43 179.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -148.42 159.54 43.92 Favored 'General case' 0 N--CA 1.465 0.289 0 C-N-CA 124.454 1.101 . . . . 0.0 110.397 178.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 91.8 t -130.9 118.13 40.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 -175.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 63.03 -65.41 0.1 Allowed 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 128.513 2.725 . . . . 0.0 110.002 -165.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.97 -2.09 0.07 OUTLIER Glycine 0 CA--C 1.532 1.109 0 C-N-CA 125.914 1.721 . . . . 0.0 111.922 163.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -74.59 124.54 26.86 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 119.935 1.867 . . . . 0.0 107.142 -175.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.4 p -68.2 103.74 1.64 Allowed 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.8 pp -74.23 9.9 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 C-N-CA 124.079 0.952 . . . . 0.0 112.698 -177.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 83.0 mt -46.61 -55.71 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.275 0 C-N-CA 128.99 2.916 . . . . 0.0 109.697 179.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -108.77 -30.64 8.06 Favored 'General case' 0 N--CA 1.461 0.089 0 C-N-CA 124.802 1.241 . . . . 0.0 110.951 -174.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.462 ' HB3' HD11 ' A' ' 84' ' ' ILE . 15.0 ttt -49.56 132.29 19.32 Favored Pre-proline 0 N--CA 1.443 -0.799 0 C-N-CA 127.252 2.221 . . . . 0.0 110.008 -170.495 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -73.18 144.03 36.68 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 121.357 1.372 . . . . 0.0 108.754 -175.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 37.3 t60 -55.33 -35.86 65.63 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.768 0.827 . . . . 0.0 112.306 -170.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.56 -39.95 74.35 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 118.526 0.603 . . . . 0.0 112.18 174.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -69.24 -48.12 62.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 118.065 -0.969 . . . . 0.0 109.27 -176.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.462 HD11 ' HB3' ' A' ' 79' ' ' MET . 3.1 mp -51.86 -49.75 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 C-N-CA 125.554 1.542 . . . . 0.0 110.785 168.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 3.0 t -58.61 -44.87 90.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 O-C-N 121.362 -0.836 . . . . 0.0 109.768 -176.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 26.7 tttt -64.7 -43.35 93.76 Favored 'General case' 0 C--O 1.223 -0.314 0 CA-C-O 117.966 -1.016 . . . . 0.0 111.759 173.516 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -50.17 -42.71 51.55 Favored 'General case' 0 C--O 1.224 -0.285 0 C-N-CA 126.935 2.094 . . . . 0.0 112.03 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 86.5 mt -75.19 -46.32 39.32 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -177.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -60.18 -35.43 75.35 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 122.483 0.313 . . . . 0.0 111.149 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -83.81 -11.43 57.05 Favored 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 127.499 2.32 . . . . 0.0 112.633 179.26 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -63.84 -11.17 24.99 Favored 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -170.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.86 61.58 2.12 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 166.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 76.5 mt 69.09 -39.78 0.43 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 128.966 2.906 . . . . 0.0 114.335 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.66 158.16 15.82 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 172.56 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.404 HG12 ' CE1' ' A' ' 24' ' ' PHE . 12.1 p -156.32 142.45 10.17 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 166.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.9 m -111.65 101.25 9.65 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 118.521 0.6 . . . . 0.0 111.119 -175.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 46.6 mt -90.44 108.57 19.87 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 125.039 1.336 . . . . 0.0 108.269 -178.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -76.5 122.76 25.02 Favored 'General case' 0 C--O 1.239 0.538 0 C-N-CA 124.074 0.949 . . . . 0.0 110.869 172.388 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.401 HG13 ' HB2' ' A' ' 12' ' ' SER . 2.7 pt -128.59 165.0 29.18 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 124.27 1.028 . . . . 0.0 111.851 -177.061 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 72.6 mt . . . . . 0 CA--C 1.539 0.548 0 C-N-CA 125.304 1.442 . . . . 0.0 109.678 170.586 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 13.8 p . . . . . 0 N--CA 1.451 -0.414 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 m -114.32 164.86 13.35 Favored 'General case' 0 C--O 1.239 0.527 0 N-CA-C 106.113 -1.81 . . . . 0.0 106.113 157.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -103.2 153.73 20.06 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 143.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.658 HG11 ' HB2' ' A' ' 62' ' ' LEU . 62.8 t -129.09 142.0 45.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 103.025 -2.954 . . . . 0.0 103.025 161.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.1 t -123.85 132.44 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 168.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 65.4 mt -130.72 131.45 64.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 105.722 -1.955 . . . . 0.0 105.722 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 76.4 m-70 -117.35 146.87 43.1 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 125.576 1.55 . . . . 0.0 108.271 -176.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 50.0 ptt85 -141.57 177.15 8.34 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 120.178 1.354 . . . . 0.0 112.014 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.63 169.25 11.48 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 167.414 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -73.72 -28.69 61.84 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 119.951 -0.7 . . . . 0.0 111.908 173.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -61.16 -56.91 15.27 Favored 'General case' 0 CA--C 1.521 -0.17 0 C-N-CA 124.348 1.059 . . . . 0.0 110.256 -177.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -75.46 165.43 25.13 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.944 1.297 . . . . 0.0 109.216 178.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.02 176.89 26.17 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 163.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -71.83 167.27 20.34 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 159.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.11 0.11 57.3 Favored Glycine 0 CA--C 1.525 0.715 0 CA-C-O 117.922 -1.488 . . . . 0.0 114.994 -167.337 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -112.18 130.41 55.92 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 120.029 1.915 . . . . 0.0 111.878 -153.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 74.9 t -100.96 135.06 38.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 171.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 23.6 mt -93.23 139.0 18.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 171.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 35.3 pt . . . . . 0 N--CA 1.446 -0.666 0 C-N-CA 126.372 1.869 . . . . 0.0 108.29 168.368 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo . . . . . 0 N--CA 1.452 -0.915 0 N-CA-C 108.404 -1.422 . . . . 0.0 108.404 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 6.2 m80 80.44 107.38 0.07 Allowed 'General case' 0 C--O 1.234 0.267 0 C-N-CA 128.711 2.804 . . . . 0.0 112.138 172.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 55.5 pttt -133.2 161.15 35.21 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 123.824 0.849 . . . . 0.0 108.731 157.511 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 47.6 mm -66.25 135.43 28.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 168.087 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -102.9 -63.05 0.71 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 126.55 2.024 . . . . 0.0 111.223 175.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 8.4 ttm180 -131.14 155.11 47.55 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 125.447 1.499 . . . . 0.0 108.504 -175.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 32.5 mt -133.04 132.61 58.89 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 126.217 1.807 . . . . 0.0 107.117 174.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -55.86 114.18 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.776 1.631 . . . . 0.0 107.018 158.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -56.59 132.49 51.8 Favored 'General case' 0 C--O 1.236 0.383 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 174.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.78 -8.02 67.62 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 125.401 1.477 . . . . 0.0 114.977 175.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 36.2 p -59.91 169.6 1.47 Allowed Pre-proline 0 C--O 1.239 0.53 0 CA-C-N 118.407 1.104 . . . . 0.0 111.971 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -54.91 -31.78 75.05 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 121.242 1.295 . . . . 0.0 112.073 166.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.2 -68.83 0.24 Allowed 'General case' 0 C--N 1.345 0.404 0 C-N-CA 123.793 0.837 . . . . 0.0 110.089 169.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -51.39 -55.23 19.69 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 118.608 0.64 . . . . 0.0 112.559 -171.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -70.11 -7.79 44.3 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 123.349 0.659 . . . . 0.0 111.908 -175.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 10.5 t -62.66 -36.96 84.52 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 119.413 1.006 . . . . 0.0 109.202 166.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 57.69 -22.21 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 129.473 3.109 . . . . 0.0 115.789 -177.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 1.5 mmpp? -68.73 -4.6 16.45 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 127.94 2.496 . . . . 0.0 113.389 174.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.658 ' HB2' HG11 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -147.08 113.13 5.81 Favored 'General case' 0 C--O 1.237 0.421 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 -173.203 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 25.6 mttt -130.66 170.74 13.91 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 122.008 0.908 . . . . 0.0 112.613 -170.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.8 t -60.99 109.85 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.25 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 131.81 -17.16 4.97 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -70.52 106.45 3.46 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-N 118.525 1.163 . . . . 0.0 111.397 -178.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 52.8 mtm-85 -57.5 144.73 35.75 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 127.23 2.212 . . . . 0.0 110.056 161.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 5.4 mt -131.29 149.14 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 C-N-CA 123.295 0.638 . . . . 0.0 109.428 -168.424 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.48 -41.23 2.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.789 1.636 . . . . 0.0 112.663 -171.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -160.91 168.2 25.1 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.316 0.647 . . . . 0.0 111.743 -178.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.6 p -140.21 127.51 23.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 123.532 0.733 . . . . 0.0 110.09 -176.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 40.01 48.24 2.1 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 125.732 1.613 . . . . 0.0 109.774 -158.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 63.21 11.67 40.61 Favored Glycine 0 CA--C 1.528 0.869 0 CA-C-O 116.843 -2.087 . . . . 0.0 114.714 -178.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.84 153.97 20.65 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-N 120.684 2.242 . . . . 0.0 111.844 178.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.2 p -62.41 147.64 47.93 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -171.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 8.5 pt -131.52 -7.13 2.0 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 O-C-N 123.602 0.564 . . . . 0.0 112.05 167.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.1 mm -79.71 -45.84 22.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 O-C-N 120.569 -1.332 . . . . 0.0 109.628 176.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -88.48 -29.47 20.11 Favored 'General case' 0 N--CA 1.465 0.297 0 O-C-N 121.635 -0.666 . . . . 0.0 112.751 -178.252 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.6 mtp -70.61 152.33 95.32 Favored Pre-proline 0 CA--C 1.534 0.352 0 CA-C-N 118.906 0.775 . . . . 0.0 110.984 -177.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_endo -73.64 153.23 48.89 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 122.57 2.18 . . . . 0.0 109.55 171.529 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -62.49 -37.87 87.68 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.516 -0.74 . . . . 0.0 112.724 -167.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.83 -28.2 65.49 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 119.079 0.854 . . . . 0.0 111.611 -176.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -68.47 -45.06 73.44 Favored 'General case' 0 N--CA 1.46 0.072 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 176.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.7 mt -64.4 -38.38 82.42 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 125.299 1.44 . . . . 0.0 109.569 176.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 37.9 t -61.7 -47.6 92.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 O-C-N 120.22 -1.55 . . . . 0.0 109.093 172.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 4.2 tmtt? -63.59 -37.42 87.25 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.016 -177.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.46 -43.93 75.91 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 125.471 1.508 . . . . 0.0 111.446 173.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 60.0 mt -68.56 -43.36 83.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 119.542 1.065 . . . . 0.0 109.287 177.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 21.1 tttm -64.29 -38.64 91.78 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.671 -0.643 . . . . 0.0 110.546 -178.293 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -86.02 -3.44 58.94 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 126.924 2.09 . . . . 0.0 112.051 179.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -54.89 -26.07 33.23 Favored 'General case' 0 C--N 1.345 0.413 0 N-CA-C 113.817 1.043 . . . . 0.0 113.817 -166.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.51 36.02 3.93 Favored Glycine 0 C--N 1.335 0.479 0 N-CA-C 111.266 -0.733 . . . . 0.0 111.266 173.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 44.9 mt 69.29 -30.82 0.2 Allowed 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 128.596 2.759 . . . . 0.0 113.041 -175.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 m -92.66 148.12 22.32 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 167.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.3 p -139.97 124.42 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.002 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 169.224 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 20.9 m -99.04 123.77 43.58 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 177.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 21.9 mt -120.01 122.3 40.85 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.286 1.034 . . . . 0.0 109.835 -172.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 45.9 ttp180 -85.67 111.94 20.55 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 173.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pp -118.78 167.17 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 125.776 1.63 . . . . 0.0 108.76 175.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 7.6 mt . . . . . 0 N--CA 1.468 0.436 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 169.937 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 59.2 p . . . . . 0 C--O 1.237 0.416 0 N-CA-C 108.204 -1.035 . . . . 0.0 108.204 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 13.7 m -120.2 147.17 45.26 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.511 1.125 . . . . 0.0 108.481 163.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -74.37 155.45 38.13 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 125.3 1.44 . . . . 0.0 108.128 152.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 t -137.57 121.16 21.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 105.088 -2.19 . . . . 0.0 105.088 163.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . 0.404 HG22 HG23 ' A' ' 96' ' ' THR . 13.8 t -120.04 97.29 5.0 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -173.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 43.1 mt -99.28 126.32 52.61 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -174.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -103.9 149.62 24.93 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.653 -1.239 . . . . 0.0 107.653 177.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -143.21 -175.54 4.57 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 120.706 1.594 . . . . 0.0 109.899 175.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.525 ' N ' ' HE3' ' A' ' 19' ' ' LYS . 0.1 OUTLIER -92.64 163.71 13.68 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 169.001 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -68.25 -36.62 79.74 Favored 'General case' 0 N--CA 1.465 0.317 0 O-C-N 121.425 -0.797 . . . . 0.0 110.82 173.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -75.96 -4.52 41.56 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.418 1.087 . . . . 0.0 112.499 -166.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -123.41 179.33 4.77 Favored 'General case' 0 C--O 1.238 0.45 0 C-N-CA 126.872 2.069 . . . . 0.0 108.376 -178.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.93 178.71 20.94 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 162.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -72.95 -175.43 1.76 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 164.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -138.81 60.54 0.58 Allowed Glycine 0 C--O 1.223 -0.583 0 CA-C-O 118.774 -1.015 . . . . 0.0 112.582 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.477 ' CE2' HD11 ' A' ' 28' ' ' ILE . 32.8 p90 -140.18 158.16 44.47 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 118.694 1.247 . . . . 0.0 110.651 175.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.9 t -143.45 140.54 26.21 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 105.947 -1.872 . . . . 0.0 105.947 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.477 HD11 ' CE2' ' A' ' 26' ' ' PHE . 1.9 mp -130.47 129.26 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 C-N-CA 124.928 1.291 . . . . 0.0 107.566 -169.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.424 HD11 ' HE3' ' A' ' 46' ' ' LYS . 47.7 pt . . . . . 0 C--O 1.239 0.546 0 C-N-CA 124.32 1.048 . . . . 0.0 110.142 -166.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo . . . . . 0 CA--C 1.531 0.373 0 CA-C-O 120.694 0.206 . . . . 0.0 112.628 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -139.7 115.14 9.91 Favored 'General case' 0 N--CA 1.442 -0.826 0 C-N-CA 125.259 1.423 . . . . 0.0 107.641 -166.654 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.424 ' HE3' HD11 ' A' ' 29' ' ' ILE . 52.1 pttt -127.91 144.09 51.1 Favored 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 167.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.3 mm -55.38 120.98 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 165.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -87.15 -42.59 6.21 Favored Glycine 0 CA--C 1.522 0.494 0 C-N-CA 125.212 1.387 . . . . 0.0 110.85 175.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.6 ttt-85 -148.05 156.36 42.54 Favored 'General case' 0 C--O 1.233 0.225 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 172.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.67 139.6 48.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 164.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 44.1 mm -67.56 118.48 11.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 173.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -53.55 124.4 14.85 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 124.199 1.0 . . . . 0.0 108.448 173.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.94 -0.88 84.68 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 114.535 0.574 . . . . 0.0 114.535 176.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 57.8 p -69.23 169.52 11.58 Favored Pre-proline 0 C--O 1.235 0.336 0 CA-C-N 118.855 1.327 . . . . 0.0 112.019 175.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -57.37 -28.04 78.4 Favored 'Trans proline' 0 N--CA 1.449 -1.128 0 C-N-CA 121.21 1.273 . . . . 0.0 112.809 161.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.04 -54.26 19.64 Favored 'General case' 0 C--N 1.346 0.434 0 CA-C-N 119.967 1.258 . . . . 0.0 110.235 176.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -52.31 -55.07 23.85 Favored 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 124.918 1.287 . . . . 0.0 110.838 178.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 87.9 mtt180 -69.86 -7.35 39.39 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 123.558 0.743 . . . . 0.0 112.622 -175.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 8.9 t -71.24 -31.18 67.23 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 119.586 1.085 . . . . 0.0 110.569 168.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.97 -29.95 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 129.979 3.312 . . . . 0.0 116.364 -174.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.3 mtpt -69.86 -9.06 53.45 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 126.056 1.742 . . . . 0.0 112.32 169.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -106.46 132.31 52.63 Favored 'General case' 0 C--O 1.237 0.424 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 158.158 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 15.6 ptpt -139.56 169.07 18.42 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 124.387 1.075 . . . . 0.0 110.757 169.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 61.7 t -59.21 138.73 19.87 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 174.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 83.35 4.33 89.53 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 115.889 1.116 . . . . 0.0 115.889 174.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -60.89 -6.85 2.0 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 118.528 2.788 . . . . 0.0 118.528 -164.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 84.5 mtm180 49.38 105.59 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 128.658 2.783 . . . . 0.0 114.587 -165.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 57.7 mt -96.79 129.39 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 123.653 0.781 . . . . 0.0 109.241 -179.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 69' ' ' LEU . 2.0 mm? -104.41 -23.88 13.12 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.366 1.066 . . . . 0.0 113.601 176.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -155.58 164.75 38.22 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 118.505 0.593 . . . . 0.0 111.258 -179.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.38 121.19 45.2 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 C-N-CA 126.405 1.882 . . . . 0.0 107.0 178.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 52.59 26.87 4.63 Favored 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 176.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 90.76 -2.77 80.56 Favored Glycine 0 CA--C 1.535 1.326 0 C-N-CA 125.581 1.562 . . . . 0.0 114.514 -177.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -94.37 128.91 41.19 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.751 1.775 . . . . 0.0 108.638 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.07 116.84 4.84 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 123.267 0.627 . . . . 0.0 109.479 171.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.7 pp -80.99 11.64 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.577 0 C-N-CA 124.149 0.979 . . . . 0.0 113.203 178.069 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 79.5 mt -61.04 -70.36 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 C-N-CA 124.961 1.304 . . . . 0.0 109.382 -175.005 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -94.69 -24.66 17.05 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 120.432 -0.507 . . . . 0.0 111.785 -172.325 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.2 mtp -48.6 134.59 13.47 Favored Pre-proline 0 CA--C 1.536 0.442 0 C-N-CA 125.154 1.382 . . . . 0.0 110.512 176.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.25 157.37 61.64 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 122.356 2.038 . . . . 0.0 109.478 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 16.0 m-70 -56.06 -32.96 64.56 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 119.302 -0.38 . . . . 0.0 110.847 174.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.9 -44.1 97.5 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 117.878 -1.058 . . . . 0.0 112.177 178.027 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -64.65 -45.98 84.47 Favored 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 66.3 mt -61.75 -40.46 86.96 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 C-N-CA 123.814 0.846 . . . . 0.0 110.527 -177.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 24.8 t -60.22 -50.25 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.132 0 O-C-N 121.209 -0.932 . . . . 0.0 109.32 171.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -63.2 -34.05 76.8 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 117.479 -1.248 . . . . 0.0 112.746 -177.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -63.78 -41.51 97.94 Favored 'General case' 0 N--CA 1.442 -0.832 0 C-N-CA 128.07 2.548 . . . . 0.0 110.645 174.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 54.4 mt -67.16 -45.61 86.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 O-C-N 120.774 -1.204 . . . . 0.0 108.875 177.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 4.6 tttt -61.77 -38.98 90.03 Favored 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 123.077 0.551 . . . . 0.0 109.597 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -61.65 -43.08 99.53 Favored 'General case' 0 CA--C 1.517 -0.323 0 C-N-CA 125.058 1.343 . . . . 0.0 110.381 175.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -56.01 -34.56 65.92 Favored 'General case' 0 CA--C 1.537 0.473 0 O-C-N 123.339 0.399 . . . . 0.0 110.63 -175.498 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.03 -116.22 5.46 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 124.896 1.236 . . . . 0.0 110.885 157.449 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 8.2 mt -83.53 -20.12 34.44 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-N 117.126 0.463 . . . . 0.0 109.753 167.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 p -94.53 156.32 16.51 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 173.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.8 p -157.39 124.84 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.258 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 160.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . 0.404 HG23 HG22 ' A' ' 15' ' ' VAL . 56.3 m -109.53 101.86 10.77 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.612 1.565 . . . . 0.0 107.514 -172.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 81.8 mt -90.92 165.17 13.73 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 125.014 1.326 . . . . 0.0 110.369 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 26.6 ttm180 -120.57 127.99 52.65 Favored 'General case' 0 CA--C 1.518 -0.282 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 162.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.408 HD12 ' C ' ' A' ' 100' ' ' ILE . 1.7 pp -128.83 178.64 4.77 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 125.318 1.447 . . . . 0.0 109.29 173.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.408 ' C ' HD12 ' A' ' 99' ' ' ILE . 75.8 mt . . . . . 0 N--CA 1.469 0.512 0 CA-C-N 119.334 0.97 . . . . 0.0 109.349 167.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.8 p . . . . . 0 N--CA 1.445 -0.686 0 CA-C-O 121.842 0.83 . . . . 0.0 108.984 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 58.3 m -121.24 146.84 46.39 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 105.406 -2.072 . . . . 0.0 105.406 174.008 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -120.85 131.75 54.59 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 -175.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 24.0 t -129.29 94.86 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 104.431 -2.433 . . . . 0.0 104.431 -172.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.5 p -94.83 104.22 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 36.6 mt -101.84 133.89 43.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 105.307 -2.109 . . . . 0.0 105.307 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 51.8 m-70 -111.53 149.19 31.74 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.924 1.29 . . . . 0.0 108.415 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -138.86 -177.35 4.84 Favored 'General case' 0 N--CA 1.468 0.469 0 O-C-N 120.84 -1.162 . . . . 0.0 110.485 177.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.26 153.17 18.17 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 168.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -61.55 -32.61 72.69 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.294 0.568 . . . . 0.0 111.217 -171.035 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -89.13 3.41 51.94 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 124.744 1.218 . . . . 0.0 112.979 -163.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 25.4 pt-20 -139.78 177.74 7.74 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 119.534 1.061 . . . . 0.0 111.187 -170.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.04 163.66 31.91 Favored Glycine 0 CA--C 1.525 0.718 0 O-C-N 121.634 -0.666 . . . . 0.0 111.653 177.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -75.67 161.2 29.3 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 154.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.56 58.19 0.73 Allowed Glycine 0 C--O 1.218 -0.852 0 CA-C-O 117.432 -1.76 . . . . 0.0 111.351 178.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.421 ' CZ ' HD11 ' A' ' 97' ' ' LEU . 28.7 p90 -142.91 141.53 31.52 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 120.326 2.063 . . . . 0.0 110.586 169.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.0 t -105.22 135.7 42.17 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 170.415 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 25.6 mt -96.63 130.74 44.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 162.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.3 pt . . . . . 0 N--CA 1.447 -0.603 0 C-N-CA 126.585 1.954 . . . . 0.0 108.71 175.042 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo . . . . . 0 N--CA 1.45 -1.081 0 N-CA-C 109.838 -0.87 . . . . 0.0 109.838 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.5 m80 -77.23 103.18 7.01 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.632 1.573 . . . . 0.0 109.614 -172.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.7 ptmt -130.55 153.17 49.14 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 171.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.436 HG13 HD22 ' A' ' 62' ' ' LEU . 39.7 mm -68.54 143.82 14.82 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 175.375 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.89 -59.46 0.53 Allowed Glycine 0 CA--C 1.529 0.926 0 C-N-CA 125.596 1.57 . . . . 0.0 112.508 175.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 37.4 ttm180 -140.05 144.58 36.94 Favored 'General case' 0 C--O 1.235 0.339 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 21.2 mt -122.66 125.43 72.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 105.821 -1.918 . . . . 0.0 105.821 175.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -51.73 131.07 12.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 CA-C-N 119.23 0.923 . . . . 0.0 108.612 172.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.6 123.27 17.43 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 125.553 1.541 . . . . 0.0 108.868 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.28 9.88 84.31 Favored Glycine 0 CA--C 1.535 1.329 0 C-N-CA 123.947 0.784 . . . . 0.0 114.903 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 37.9 p -66.36 171.76 3.8 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 119.662 1.731 . . . . 0.0 112.458 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -56.85 -36.83 99.07 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 121.783 1.655 . . . . 0.0 112.296 166.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.72 -48.95 75.01 Favored 'General case' 0 C--N 1.34 0.177 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -60.34 -52.95 63.09 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 123.44 0.696 . . . . 0.0 111.594 176.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -60.94 -18.59 57.88 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 124.078 0.951 . . . . 0.0 112.31 -176.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 11.5 t -59.36 -26.25 64.91 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-O 117.819 -1.086 . . . . 0.0 111.257 175.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.15 31.49 18.38 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.913 2.085 . . . . 0.0 112.962 -179.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 40.3 mtmt -132.47 -34.11 1.22 Allowed 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.889 0.875 . . . . 0.0 111.977 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.444 HD23 ' HA ' ' A' ' 62' ' ' LEU . 0.3 OUTLIER -93.85 126.46 39.06 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 177.509 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 2.6 ptpp? -117.82 171.58 7.96 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 125.2 1.4 . . . . 0.0 109.139 170.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 82.2 t -66.09 141.66 17.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 O-C-N 120.965 -1.084 . . . . 0.0 108.565 174.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 89.47 -5.02 84.17 Favored Glycine 0 CA--C 1.532 1.095 0 CA-C-O 117.022 -1.988 . . . . 0.0 114.904 176.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -62.9 11.68 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 120.229 3.418 . . . . 0.0 120.229 -150.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.1 mtp180 41.82 86.71 0.02 OUTLIER 'General case' 0 C--O 1.235 0.3 0 C-N-CA 127.178 2.191 . . . . 0.0 113.103 -171.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 44.1 mt -65.32 148.85 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 106.341 -1.725 . . . . 0.0 106.341 170.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.48 HD22 HD11 ' A' ' 100' ' ' ILE . 1.8 tp -118.86 -47.15 2.52 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 125.828 1.651 . . . . 0.0 108.764 177.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -148.54 166.95 26.69 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 125.268 1.427 . . . . 0.0 111.352 -177.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.9 p -134.72 124.36 43.89 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.468 0 C-N-CA 125.493 1.517 . . . . 0.0 107.933 175.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 49.71 38.59 15.72 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.138 0.975 . . . . 0.0 110.009 -178.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 79.21 -10.27 35.88 Favored Glycine 0 CA--C 1.532 1.115 0 CA-C-O 117.822 -1.543 . . . . 0.0 115.415 -176.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.9 mm100 -79.66 122.87 27.08 Favored 'General case' 0 CA--C 1.513 -0.479 0 CA-C-N 121.491 2.646 . . . . 0.0 107.747 -178.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 55.7 m -61.36 110.12 1.34 Allowed 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 167.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.5 pp -80.14 11.49 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 124.604 1.162 . . . . 0.0 112.322 -174.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 25.3 mm -63.01 -77.34 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 C-N-CA 125.24 1.416 . . . . 0.0 108.418 175.268 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 21.8 m-80 -79.7 -26.92 40.76 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.179 -164.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . 0.512 ' CE ' HD13 ' A' ' 87' ' ' LEU . 1.4 mtp -58.29 133.81 84.79 Favored Pre-proline 0 CA--C 1.538 0.488 0 C-N-CA 123.815 0.846 . . . . 0.0 109.513 174.347 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -70.61 155.11 63.8 Favored 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 121.989 1.793 . . . . 0.0 110.665 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -57.09 -39.21 74.56 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.365 0.666 . . . . 0.0 111.938 -174.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -60.38 -42.43 95.86 Favored 'General case' 0 C--N 1.338 0.097 0 CA-C-O 118.421 -0.8 . . . . 0.0 111.368 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . 0.404 ' O ' HD12 ' A' ' 87' ' ' LEU . 1.4 m-20 -62.62 -46.27 89.05 Favored 'General case' 0 C--O 1.218 -0.58 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 177.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.45 ' HA ' ' HB2' ' A' ' 87' ' ' LEU . 29.4 mt -67.71 -33.92 64.74 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 O-C-N 121.212 -0.93 . . . . 0.0 109.925 -175.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.0 t -61.79 -44.47 98.84 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 O-C-N 120.83 -1.169 . . . . 0.0 108.669 171.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 7.0 mmtt -52.45 -53.19 48.74 Favored 'General case' 0 C--O 1.22 -0.462 0 CA-C-O 116.568 -1.682 . . . . 0.0 109.481 166.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.512 HD13 ' CE ' ' A' ' 79' ' ' MET . 0.9 OUTLIER -57.7 -28.34 63.74 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 122.472 2.396 . . . . 0.0 114.514 -174.761 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 66.7 mt -77.44 -48.71 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 176.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 13.6 ttpt -63.36 -37.27 86.64 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 118.164 0.438 . . . . 0.0 110.847 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.03 -10.65 59.67 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 126.98 2.112 . . . . 0.0 111.472 -178.381 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.74 -28.31 63.79 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 113.301 0.852 . . . . 0.0 113.301 -171.509 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 92.22 66.52 1.12 Allowed Glycine 0 C--N 1.339 0.741 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 171.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 56.9 mt 61.81 -44.37 0.15 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 129.605 3.162 . . . . 0.0 114.346 -171.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 6.6 p -93.6 140.66 29.36 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 125.28 1.432 . . . . 0.0 107.79 177.291 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.5 p -134.54 124.34 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 169.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.8 m -93.53 100.57 12.83 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.421 HD11 ' CZ ' ' A' ' 26' ' ' PHE . 19.6 mt -90.18 122.83 33.48 Favored 'General case' 0 CA--C 1.516 -0.334 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 172.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 32.0 ttm105 -99.25 117.75 34.41 Favored 'General case' 0 C--O 1.236 0.347 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 179.039 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.53 ' C ' HD12 ' A' ' 100' ' ' ILE . 1.9 pp -130.6 174.9 12.19 Favored 'Isoleucine or valine' 0 C--O 1.237 0.427 0 C-N-CA 126.669 1.988 . . . . 0.0 110.004 -166.545 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.53 HD12 ' C ' ' A' ' 99' ' ' ILE . 3.4 mp . . . . . 0 CA--C 1.546 0.812 0 C-N-CA 124.483 1.113 . . . . 0.0 108.651 177.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.237 0.423 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.5 m -127.38 150.99 49.37 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.239 1.016 . . . . 0.0 108.291 175.067 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -120.69 93.46 4.04 Favored 'General case' 0 C--O 1.236 0.355 0 N-CA-C 104.442 -2.429 . . . . 0.0 104.442 176.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.5 t -91.43 94.76 5.04 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.332 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 -170.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.0 p -76.2 134.12 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 173.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 82.5 mt -131.12 126.38 59.15 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.197 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 175.269 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -92.55 154.01 18.7 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 167.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.487 ' HD3' ' CZ ' ' A' ' 24' ' ' PHE . 5.7 ptt180 -138.96 -176.95 4.67 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 167.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.461 ' HE3' ' C ' ' A' ' 18' ' ' ARG . 0.1 OUTLIER -109.67 168.19 9.59 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 172.48 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -75.71 -19.3 59.19 Favored 'General case' 0 N--CA 1.463 0.176 0 O-C-N 121.716 -0.615 . . . . 0.0 112.172 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -69.77 -2.98 13.53 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.014 0.926 . . . . 0.0 112.735 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -150.07 177.2 10.11 Favored 'General case' 0 C--O 1.238 0.474 0 C-N-CA 125.485 1.514 . . . . 0.0 109.441 -164.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.98 -173.69 19.94 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 171.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.487 ' CZ ' ' HD3' ' A' ' 18' ' ' ARG . 62.9 m-85 -76.24 166.85 22.86 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 159.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.29 60.26 0.68 Allowed Glycine 0 C--O 1.226 -0.364 0 O-C-N 121.022 -1.049 . . . . 0.0 113.05 -173.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 5.3 p90 -144.56 162.08 37.5 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 124.936 1.294 . . . . 0.0 109.999 175.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.5 t -132.99 124.59 50.41 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.3 mp -84.5 140.86 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 173.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.474 HD11 ' HE3' ' A' ' 46' ' ' LYS . 19.9 pt . . . . . 0 N--CA 1.447 -0.623 0 C-N-CA 127.849 2.46 . . . . 0.0 107.759 172.073 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo . . . . . 0 N--CA 1.46 -0.442 0 CA-C-O 118.977 -0.509 . . . . 0.0 113.072 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.59 ' CD2' HD13 ' A' ' 76' ' ' ILE . 0.6 OUTLIER -135.55 118.82 16.65 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 124.467 1.107 . . . . 0.0 108.367 178.372 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.474 ' HE3' HD11 ' A' ' 29' ' ' ILE . 44.1 pttt -139.88 155.0 47.42 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 123.675 0.79 . . . . 0.0 109.144 167.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.1 mm -64.16 131.02 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 105.409 -2.071 . . . . 0.0 105.409 168.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -113.76 -32.92 1.97 Allowed Glycine 0 CA--C 1.523 0.57 0 C-N-CA 124.233 0.92 . . . . 0.0 113.382 176.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 21.2 ttm-85 -146.21 148.5 32.57 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 7.4 mt -127.43 125.97 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 167.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -57.65 126.99 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 C-N-CA 125.416 1.486 . . . . 0.0 107.1 175.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -60.79 123.09 16.48 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 123.522 0.729 . . . . 0.0 109.145 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.15 24.78 74.96 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.726 0.679 . . . . 0.0 113.284 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 22.5 p -76.94 171.69 11.71 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 118.674 1.237 . . . . 0.0 111.576 168.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -58.16 -22.81 58.4 Favored 'Trans proline' 0 CA--C 1.538 0.696 0 C-N-CA 122.197 1.931 . . . . 0.0 113.259 165.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -72.89 -56.97 4.43 Favored 'General case' 0 C--N 1.343 0.308 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 173.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -57.64 -47.07 83.28 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 123.801 0.841 . . . . 0.0 111.273 -175.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 1.6 ptm180 -54.45 -27.48 37.64 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 113.267 0.839 . . . . 0.0 113.267 174.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 2.7 t -73.17 -12.89 61.04 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 118.29 -0.862 . . . . 0.0 112.858 -162.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 47.33 37.88 6.52 Favored 'General case' 0 C--O 1.239 0.532 0 C-N-CA 126.077 1.751 . . . . 0.0 113.536 178.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.8 mtmt -143.33 -17.47 0.64 Allowed 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 113.92 1.082 . . . . 0.0 113.92 173.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.422 HD23 ' HA ' ' A' ' 62' ' ' LEU . 0.1 OUTLIER -126.54 111.44 14.38 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 124.715 1.206 . . . . 0.0 108.083 -174.583 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 25.8 mtmt -129.35 172.12 11.82 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 126.011 1.724 . . . . 0.0 110.674 172.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 84.4 t -57.43 118.97 2.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.382 0 C-N-CA 125.108 1.363 . . . . 0.0 109.567 -175.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 124.7 -23.25 6.33 Favored Glycine 0 C--N 1.336 0.57 0 CA-C-O 118.699 -1.056 . . . . 0.0 111.063 175.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -70.06 81.44 0.5 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.62 1.568 . . . . 0.0 112.253 -167.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 87.7 mtt180 -48.42 134.02 15.58 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 126.619 1.968 . . . . 0.0 110.998 -162.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 61.3 mt -102.9 130.1 53.53 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -112.02 -32.85 6.45 Favored 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 125.254 1.422 . . . . 0.0 112.095 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -154.97 167.81 29.1 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.995 0.918 . . . . 0.0 109.038 -177.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.7 p -129.57 114.34 30.61 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.324 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 177.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 63.8 m-80 61.42 -37.54 0.11 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 128.937 2.895 . . . . 0.0 113.638 -169.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 169.2 -4.43 0.04 OUTLIER Glycine 0 CA--C 1.531 1.043 0 C-N-CA 128.103 2.763 . . . . 0.0 112.692 -176.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -90.72 136.0 33.35 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 120.569 2.185 . . . . 0.0 108.91 -177.273 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.6 p -73.3 119.5 17.62 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.457 0.571 . . . . 0.0 109.592 179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.59 HD13 ' CD2' ' A' ' 45' ' ' HIS . 2.4 pp -91.31 -24.25 5.63 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.305 0 C-N-CA 122.262 0.225 . . . . 0.0 111.312 -174.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mp -59.73 -32.67 49.98 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 O-C-N 121.389 -0.819 . . . . 0.0 110.903 -179.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -95.2 -7.58 38.68 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 123.801 0.84 . . . . 0.0 112.222 -170.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.7 mtp -105.88 160.0 27.66 Favored Pre-proline 0 N--CA 1.449 -0.487 0 C-N-CA 125.61 1.564 . . . . 0.0 113.348 -169.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -66.96 140.7 55.63 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 123.245 2.63 . . . . 0.0 110.789 169.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -45.93 -52.77 11.02 Favored 'General case' 0 N--CA 1.453 -0.303 0 C-N-CA 126.132 1.773 . . . . 0.0 110.872 173.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.5 -27.23 69.0 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 123.91 0.884 . . . . 0.0 113.261 -177.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.3 t0 -87.29 -34.73 18.79 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-N 118.991 0.814 . . . . 0.0 110.801 -178.236 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.0 mt -63.93 -39.57 85.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 C-N-CA 124.339 1.056 . . . . 0.0 108.43 169.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.1 t -57.13 -50.7 75.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 121.11 -0.994 . . . . 0.0 109.114 168.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.9 -36.61 81.81 Favored 'General case' 0 C--N 1.338 0.093 0 CA-C-N 118.881 0.764 . . . . 0.0 112.822 -178.614 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -61.75 -42.12 98.56 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 128.067 2.547 . . . . 0.0 110.836 175.076 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 62.4 mt -67.42 -42.75 87.6 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.281 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 174.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 46.1 tttt -57.73 -41.66 82.29 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.559 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.7 t0 -65.88 -14.62 61.84 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 127.462 2.305 . . . . 0.0 112.451 178.018 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -75.48 -12.38 60.23 Favored 'General case' 0 CA--C 1.544 0.731 0 O-C-N 121.042 -1.036 . . . . 0.0 111.86 169.18 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 60.45 -116.19 8.82 Favored Glycine 0 CA--C 1.528 0.868 0 O-C-N 120.817 -1.177 . . . . 0.0 110.574 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 93.2 mt -87.1 -36.53 18.07 Favored 'General case' 0 CA--C 1.503 -0.862 0 CA-C-N 117.814 0.807 . . . . 0.0 112.342 -177.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -107.86 120.11 41.33 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.159 0.912 . . . . 0.0 108.628 -175.102 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.7 p -126.99 150.52 32.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.3 m -124.55 138.85 54.3 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 19.0 mt -122.61 128.83 51.18 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 124.583 1.153 . . . . 0.0 109.114 178.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -84.77 107.8 17.13 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 175.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.3 pp -113.92 170.97 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 O-C-N 123.875 0.734 . . . . 0.0 110.763 172.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 20.0 mt . . . . . 0 C--O 1.234 0.263 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 170.984 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 39.1 p . . . . . 0 N--CA 1.448 -0.574 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.2 m -96.09 170.53 9.21 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 -161.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -135.1 94.63 3.17 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 123.505 1.622 . . . . 0.0 107.743 171.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.544 HG11 ' HB3' ' A' ' 62' ' ' LEU . 80.1 t -90.3 93.98 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 104.735 -2.321 . . . . 0.0 104.735 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.7 p -101.93 116.79 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 -175.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 51.1 mt -133.67 136.85 53.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 -172.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 74.4 m-70 -109.27 149.59 29.22 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 125.396 1.478 . . . . 0.0 109.079 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.49 ' HD3' ' CZ ' ' A' ' 24' ' ' PHE . 1.1 ptm180 -138.69 179.29 6.56 Favored 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 124.937 1.295 . . . . 0.0 109.951 -175.353 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.16 157.33 15.99 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 176.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -69.92 -20.71 63.34 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 117.76 0.255 . . . . 0.0 111.239 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 31.0 t30 -78.45 -1.83 35.55 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.451 0.7 . . . . 0.0 112.682 -176.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -159.89 -175.74 5.29 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.573 1.149 . . . . 0.0 110.362 -170.027 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.99 -171.54 29.99 Favored Glycine 0 CA--C 1.522 0.521 0 C-N-CA 125.324 1.44 . . . . 0.0 112.365 177.235 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.49 ' CZ ' ' HD3' ' A' ' 18' ' ' ARG . 29.6 m-85 -73.63 159.68 32.72 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 151.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -105.28 57.52 0.49 Allowed Glycine 0 C--O 1.219 -0.817 0 CA-C-O 118.542 -1.144 . . . . 0.0 110.565 177.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 8.8 p90 -124.02 155.35 38.43 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 118.849 1.324 . . . . 0.0 108.969 171.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -129.63 114.36 30.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 177.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 22.1 mt -78.24 147.38 7.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 171.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 44.0 pt . . . . . 0 N--CA 1.444 -0.77 0 C-N-CA 128.691 2.796 . . . . 0.0 107.662 170.965 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo . . . . . 0 N--CA 1.455 -0.759 0 CA-C-O 116.833 -1.403 . . . . 0.0 113.775 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -141.94 130.02 22.04 Favored 'General case' 0 C--N 1.341 0.22 0 C-N-CA 125.687 1.595 . . . . 0.0 108.948 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 6.8 ptmt -149.66 164.57 34.82 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 125.788 1.635 . . . . 0.0 107.225 176.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.602 HG13 HD23 ' A' ' 62' ' ' LEU . 13.2 mm -84.52 143.7 11.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.506 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -176.612 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.0 -36.62 0.94 Allowed Glycine 0 CA--C 1.522 0.491 0 C-N-CA 126.023 1.773 . . . . 0.0 112.745 -177.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 36.6 ttm105 -150.05 159.81 44.12 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 119.096 1.448 . . . . 0.0 108.585 176.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 7.2 mt -121.05 143.58 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 125.46 1.504 . . . . 0.0 107.012 160.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.4 mm -75.43 136.42 25.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -72.03 119.81 16.74 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.637 0.256 . . . . 0.0 110.462 -159.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.32 12.81 83.92 Favored Glycine 0 CA--C 1.527 0.799 0 CA-C-O 119.362 -0.688 . . . . 0.0 114.432 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.567 ' HB2' ' CD ' ' A' ' 55' ' ' PRO . 81.3 p -71.49 176.55 2.09 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 118.342 1.071 . . . . 0.0 112.004 176.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.567 ' CD ' ' HB2' ' A' ' 54' ' ' SER . 4.7 Cg_exo -64.28 -32.27 62.07 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 C-N-CA 122.767 2.311 . . . . 0.0 110.164 176.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.86 -24.52 66.89 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 118.201 -0.904 . . . . 0.0 112.894 175.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -83.65 -47.06 11.64 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 119.128 0.876 . . . . 0.0 110.543 173.32 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 28.5 mtt-85 -69.11 -41.44 77.41 Favored 'General case' 0 C--O 1.234 0.252 0 C-N-CA 123.247 0.619 . . . . 0.0 111.469 -170.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 62.5 m -81.19 81.38 7.41 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 173.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -62.85 89.78 0.03 OUTLIER 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.22 1.008 . . . . 0.0 109.503 178.2 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.51 ' CB ' HG13 ' A' ' 14' ' ' VAL . 26.4 mmmt -136.85 -33.72 0.76 Allowed 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 126.598 1.959 . . . . 0.0 109.498 -174.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.602 HD23 HG13 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -136.57 154.49 50.68 Favored 'General case' 0 C--O 1.234 0.264 0 C-N-CA 124.576 1.15 . . . . 0.0 109.388 171.055 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 16.3 ptmt -134.9 172.12 13.44 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 124.887 1.275 . . . . 0.0 110.868 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.6 t -59.42 137.66 21.54 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 O-C-N 120.401 -1.437 . . . . 0.0 109.572 -175.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 103.11 -14.05 55.54 Favored Glycine 0 C--N 1.342 0.893 0 C-N-CA 125.119 1.342 . . . . 0.0 114.642 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -67.06 19.46 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 120.368 3.47 . . . . 0.0 120.368 -148.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 4.3 mtt-85 43.61 72.53 0.18 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 126.818 2.047 . . . . 0.0 112.811 168.443 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 31.4 mt -65.33 147.11 12.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -170.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.6 mt -102.69 -52.75 3.01 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 124.606 1.162 . . . . 0.0 109.915 174.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -156.62 171.06 20.99 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.654 0.782 . . . . 0.0 110.524 -172.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 13.0 p -124.54 113.96 38.65 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.257 0 C-N-CA 125.321 1.449 . . . . 0.0 108.1 175.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 45.09 41.75 5.92 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 125.825 1.65 . . . . 0.0 110.095 -169.092 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.31 4.27 78.96 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-O 118.334 -1.259 . . . . 0.0 115.763 179.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -85.99 122.12 29.58 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 120.262 2.031 . . . . 0.0 106.689 174.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 7.7 t -67.52 134.84 52.04 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 -179.036 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 21.8 pt -108.99 0.27 9.65 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 125.508 1.523 . . . . 0.0 111.193 -176.127 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 75.4 mt -65.41 -61.77 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 C-N-CA 125.088 1.355 . . . . 0.0 109.072 -178.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -92.42 -24.22 18.92 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 123.939 0.896 . . . . 0.0 112.33 -174.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.8 ttt -60.91 137.83 93.77 Favored Pre-proline 0 N--CA 1.439 -0.996 0 C-N-CA 125.185 1.394 . . . . 0.0 108.525 178.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -76.07 148.95 31.9 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 121.853 1.702 . . . . 0.0 109.668 -177.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.409 ' HA ' HD12 ' A' ' 84' ' ' ILE . 32.2 t60 -60.76 -31.94 71.26 Favored 'General case' 0 CA--C 1.537 0.476 0 N-CA-C 113.812 1.041 . . . . 0.0 113.812 -165.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -71.18 -27.8 63.78 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 119.217 0.917 . . . . 0.0 113.029 176.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -74.93 -42.09 58.4 Favored 'General case' 0 C--O 1.224 -0.24 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 175.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.409 HD12 ' HA ' ' A' ' 81' ' ' HIS . 28.5 mt -57.82 -37.86 62.46 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 C-N-CA 124.714 1.205 . . . . 0.0 110.476 172.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.3 t -61.4 -52.28 63.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 O-C-N 120.578 -1.326 . . . . 0.0 109.684 172.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.7 ttmt -59.57 -40.39 87.22 Favored 'General case' 0 C--O 1.22 -0.491 0 C-N-CA 119.116 -1.034 . . . . 0.0 111.697 179.299 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.36 -42.98 67.39 Favored 'General case' 0 N--CA 1.443 -0.816 0 C-N-CA 126.633 1.973 . . . . 0.0 112.102 177.006 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.3 mt -69.25 -43.03 81.64 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 50.0 tttm -58.37 -49.83 75.84 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 118.329 0.513 . . . . 0.0 110.575 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -62.69 -18.62 62.76 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 128.773 2.829 . . . . 0.0 111.648 177.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.6 -34.26 76.64 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 119.588 1.085 . . . . 0.0 109.627 171.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.83 -97.88 1.84 Allowed Glycine 0 C--N 1.337 0.596 0 C-N-CA 126.119 1.819 . . . . 0.0 108.924 173.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.6 mt -121.64 -28.91 4.47 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 124.272 1.029 . . . . 0.0 111.819 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 p -93.3 143.61 26.1 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 170.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.3 p -145.51 153.4 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 166.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.98 112.22 15.66 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 -178.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 7.2 mt -90.54 114.7 26.97 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 173.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -71.85 121.14 18.49 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 164.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pt -128.35 -179.96 3.37 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 125.037 1.335 . . . . 0.0 108.359 175.279 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 43.7 mt . . . . . 0 CA--C 1.537 0.464 0 C-N-CA 124.758 1.223 . . . . 0.0 109.202 169.648 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 17.5 p . . . . . 0 C--O 1.238 0.471 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.4 m -122.6 150.71 42.26 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 167.48 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -90.65 147.03 23.56 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 105.734 -1.95 . . . . 0.0 105.734 168.26 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 39.0 t -131.99 101.41 4.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 104.84 -2.282 . . . . 0.0 104.84 161.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.37 141.04 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 165.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.46 HD11 HD12 ' A' ' 62' ' ' LEU . 53.0 mt -134.74 133.19 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 170.383 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 76.7 m-70 -105.84 154.4 20.57 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 125.351 1.46 . . . . 0.0 108.053 173.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.6 ptt180 -136.43 -171.93 3.02 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 170.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.82 170.38 8.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 166.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -80.36 -23.55 40.43 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 113.289 0.848 . . . . 0.0 113.289 -168.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -69.99 -10.05 57.27 Favored 'General case' 0 N--CA 1.472 0.645 0 CA-C-N 119.595 1.089 . . . . 0.0 112.882 176.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -137.15 169.33 17.97 Favored 'General case' 0 C--O 1.241 0.637 0 C-N-CA 124.288 1.035 . . . . 0.0 110.736 -161.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.11 -178.54 45.87 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 179.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -80.1 170.44 16.44 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 142.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.48 52.39 0.83 Allowed Glycine 0 C--O 1.225 -0.437 0 CA-C-O 118.769 -1.017 . . . . 0.0 112.683 -172.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -136.68 142.11 43.16 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 125.764 1.625 . . . . 0.0 110.696 -177.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.4 t -128.08 136.42 60.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 177.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 56.5 mt -108.23 120.1 58.99 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 -171.124 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 27.8 pt . . . . . 0 C--N 1.322 -0.61 0 C-N-CA 126.471 1.909 . . . . 0.0 108.74 -178.099 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo . . . . . 0 N--CA 1.461 -0.403 0 N-CA-C 113.965 0.717 . . . . 0.0 113.965 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -139.73 122.27 16.23 Favored 'General case' 0 CA--C 1.52 -0.199 0 C-N-CA 124.948 1.299 . . . . 0.0 107.801 178.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.3 ptmt -151.55 154.0 35.63 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 124.299 1.04 . . . . 0.0 108.765 168.163 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.429 HG13 HD22 ' A' ' 62' ' ' LEU . 31.1 mm -62.57 144.41 14.38 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 CA-C-N 119.17 0.896 . . . . 0.0 109.6 175.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -128.03 -50.62 0.14 Allowed Glycine 0 CA--C 1.526 0.78 0 C-N-CA 126.39 1.948 . . . . 0.0 113.181 179.334 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 2.0 ttm180 -119.99 139.88 51.81 Favored 'General case' 0 CA--C 1.511 -0.531 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 171.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 12.7 mt -120.06 149.76 22.76 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 N-CA-C 105.568 -2.012 . . . . 0.0 105.568 159.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -87.65 129.54 38.83 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 126.648 1.979 . . . . 0.0 108.097 177.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -61.55 124.51 20.86 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 123.636 0.774 . . . . 0.0 109.194 167.406 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.59 17.61 38.32 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-O 117.771 -1.572 . . . . 0.0 112.767 178.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 87.6 p -106.62 163.76 16.32 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-N 119.006 1.403 . . . . 0.0 113.116 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo -63.85 -25.08 67.76 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 122.902 2.401 . . . . 0.0 112.927 169.217 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.32 -55.88 29.2 Favored 'General case' 0 C--N 1.345 0.404 0 CA-C-N 120.305 1.411 . . . . 0.0 109.883 174.006 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -63.32 -37.53 87.64 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.316 0.647 . . . . 0.0 112.355 -175.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -65.72 -23.02 66.66 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 121.657 -0.652 . . . . 0.0 112.731 172.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 73.9 m -92.96 50.36 1.54 Allowed 'General case' 0 CA--C 1.533 0.321 0 O-C-N 120.568 -1.332 . . . . 0.0 110.824 174.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -59.2 9.16 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 127.036 2.134 . . . . 0.0 116.359 -177.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -61.92 -16.01 47.56 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 120.906 -1.121 . . . . 0.0 111.505 154.194 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.464 HD11 HD13 ' A' ' 97' ' ' LEU . 0.6 OUTLIER -115.51 137.64 51.85 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 127.393 2.277 . . . . 0.0 107.348 174.763 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -136.41 166.35 23.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 119.37 0.986 . . . . 0.0 111.146 172.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.4 t -55.94 112.6 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.251 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 168.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 129.95 -21.23 4.99 Favored Glycine 0 N--CA 1.441 -1.0 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 177.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -70.81 106.05 3.44 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 122.982 1.373 . . . . 0.0 110.772 -174.386 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.4 ' HG3' ' H ' ' A' ' 67' ' ' ARG . 31.1 mtm180 -37.38 143.52 0.1 Allowed 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 129.974 3.31 . . . . 0.0 111.297 156.315 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 23.4 mt -132.41 129.89 59.64 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 -174.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.7 mt -94.28 -40.19 10.11 Favored 'General case' 0 CA--C 1.52 -0.186 0 C-N-CA 123.862 0.865 . . . . 0.0 112.051 179.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.42 168.95 25.84 Favored 'General case' 0 C--O 1.236 0.382 0 C-N-CA 124.189 0.996 . . . . 0.0 109.754 -168.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.5 t -129.2 127.12 65.19 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 169.07 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 43.71 34.94 0.93 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 124.631 1.172 . . . . 0.0 112.193 -165.283 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.93 -3.7 27.02 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-O 118.349 -1.25 . . . . 0.0 113.347 179.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.2 tp60 -74.54 134.69 42.17 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 119.513 1.657 . . . . 0.0 107.057 174.458 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.1 m -72.53 136.89 45.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 -176.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 17.0 pt -115.76 -8.28 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 C-N-CA 125.755 1.622 . . . . 0.0 112.078 -175.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.7 mm -54.14 -52.75 34.62 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 123.813 0.845 . . . . 0.0 110.344 172.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -89.28 -26.44 21.15 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 111.712 0.264 . . . . 0.0 111.712 -173.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 7.0 ttt -66.5 137.87 95.45 Favored Pre-proline 0 N--CA 1.441 -0.884 0 C-N-CA 126.78 2.032 . . . . 0.0 109.645 -170.484 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -75.04 148.03 34.56 Favored 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 121.733 1.622 . . . . 0.0 109.051 178.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -54.24 -35.24 62.25 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -174.647 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -58.66 -43.01 89.71 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 119.937 1.244 . . . . 0.0 112.904 177.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -69.41 -39.68 77.76 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 125.243 1.417 . . . . 0.0 108.957 -178.342 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 36.5 mt -65.89 -40.0 86.28 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.529 1.131 . . . . 0.0 110.872 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 72.6 t -66.03 -41.23 89.26 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 O-C-N 118.998 -2.314 . . . . 0.0 109.607 173.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -52.5 -52.89 52.28 Favored 'General case' 0 C--O 1.223 -0.299 0 CA-C-O 117.489 -1.243 . . . . 0.0 109.539 171.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.51 -35.77 61.02 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 126.758 2.023 . . . . 0.0 112.303 -178.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 71.8 mt -78.11 -37.0 22.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 O-C-N 120.878 -1.139 . . . . 0.0 109.257 -179.133 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -65.47 -36.15 83.01 Favored 'General case' 0 N--CA 1.46 0.07 0 O-C-N 121.363 -0.835 . . . . 0.0 110.406 172.099 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -67.52 -37.65 83.09 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 126.401 1.88 . . . . 0.0 110.051 179.124 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.27 -41.6 80.03 Favored 'General case' 0 C--O 1.236 0.373 0 O-C-N 123.644 0.59 . . . . 0.0 110.769 -178.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 109.71 -141.36 16.1 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 124.63 1.11 . . . . 0.0 110.911 171.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 85.9 mt -70.4 -40.92 73.62 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 169.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.98 131.75 40.59 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 123.102 0.561 . . . . 0.0 110.083 176.022 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.3 p -133.04 139.85 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 C-N-CA 125.165 1.386 . . . . 0.0 107.559 171.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.73 109.14 19.75 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 177.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.464 HD13 HD11 ' A' ' 62' ' ' LEU . 17.9 mt -90.51 145.63 24.74 Favored 'General case' 0 CA--C 1.52 -0.177 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 174.422 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 19.7 ttm180 -114.48 114.17 25.44 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 174.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pp -114.97 160.96 14.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 125.003 1.321 . . . . 0.0 108.913 -179.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 89.4 mt . . . . . 0 C--O 1.238 0.473 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 167.609 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 32.9 p . . . . . 0 CA--C 1.535 0.375 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.1 t -117.3 158.99 23.42 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 148.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -129.3 94.62 3.83 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 174.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 15.2 t -92.58 96.14 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 C-N-CA 125.838 1.655 . . . . 0.0 107.513 -173.181 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.1 p -80.42 135.36 25.47 Favored 'Isoleucine or valine' 0 C--O 1.238 0.451 0 C-N-CA 123.322 0.649 . . . . 0.0 109.792 174.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 46.2 mt -132.28 126.46 55.79 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 C-N-CA 125.155 1.382 . . . . 0.0 107.74 176.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -88.76 161.77 16.6 Favored 'General case' 0 C--O 1.233 0.219 0 C-N-CA 125.022 1.329 . . . . 0.0 108.877 171.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 49.3 ptt85 -144.22 -171.11 3.51 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 160.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 168.38 9.59 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 161.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -70.9 -33.68 70.8 Favored 'General case' 0 C--N 1.329 -0.295 0 O-C-N 121.162 -0.962 . . . . 0.0 112.473 -178.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -74.1 6.55 3.36 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 124.586 1.154 . . . . 0.0 113.0 -171.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -143.81 171.66 13.9 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 126.539 1.936 . . . . 0.0 109.261 -169.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.83 176.57 23.01 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 124.434 1.016 . . . . 0.0 111.032 178.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -83.44 133.43 34.91 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 163.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -96.89 57.24 1.28 Allowed Glycine 0 CA--C 1.521 0.441 0 C-N-CA 124.599 1.095 . . . . 0.0 112.66 -171.507 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -137.97 167.24 22.17 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 125.522 1.529 . . . . 0.0 108.213 172.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.576 HG12 ' H ' ' A' ' 49' ' ' ARG . 0.4 OUTLIER -132.39 157.65 43.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 176.236 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 20.3 mt -117.63 135.82 56.8 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 176.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.7 pt . . . . . 0 C--O 1.241 0.634 0 C-N-CA 124.104 0.962 . . . . 0.0 109.686 175.878 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo . . . . . 0 N--CA 1.449 -1.111 0 N-CA-C 106.692 -2.08 . . . . 0.0 106.692 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.558 ' NE2' HD13 ' A' ' 84' ' ' ILE . 19.4 m80 68.76 108.19 0.05 Allowed 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 126.531 1.933 . . . . 0.0 113.302 171.145 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 52.1 pttt -143.83 157.59 44.27 Favored 'General case' 0 N--CA 1.467 0.421 0 O-C-N 120.678 -1.264 . . . . 0.0 109.22 167.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.1 mm -65.06 123.86 18.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 172.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -110.46 -26.49 4.81 Favored Glycine 0 CA--C 1.535 1.285 0 N-CA-C 114.849 0.7 . . . . 0.0 114.849 176.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.576 ' H ' HG12 ' A' ' 27' ' ' VAL . 67.5 ttt180 -149.85 147.37 27.88 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 177.461 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.5 mt -121.84 131.76 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.72 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 166.257 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 23.8 mm -65.32 153.89 7.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 -177.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -68.51 118.34 11.43 Favored 'General case' 0 C--N 1.328 -0.351 0 O-C-N 121.474 -0.766 . . . . 0.0 110.634 -169.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.41 1.87 24.14 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 115.952 1.141 . . . . 0.0 115.952 169.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.49 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 3.5 p -68.77 175.25 2.07 Favored Pre-proline 0 CA--C 1.554 1.108 0 C-N-CA 126.966 2.106 . . . . 0.0 113.067 178.63 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.49 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 3.3 Cg_exo -64.44 -24.43 64.02 Favored 'Trans proline' 0 C--N 1.351 0.704 0 C-N-CA 121.601 1.534 . . . . 0.0 115.154 -168.097 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -69.38 -48.2 61.9 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 118.803 0.729 . . . . 0.0 109.613 172.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -54.13 -49.63 68.75 Favored 'General case' 0 N--CA 1.464 0.262 0 C-N-CA 125.294 1.437 . . . . 0.0 110.168 177.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.4 mmt-85 -68.88 -15.61 63.54 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 123.694 0.797 . . . . 0.0 112.952 177.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 17.5 t -68.89 -28.2 66.47 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 117.724 -1.131 . . . . 0.0 110.357 177.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 59.38 -28.93 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 128.595 2.758 . . . . 0.0 115.475 -174.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 47.9 mtmt -62.73 -33.17 74.58 Favored 'General case' 0 CA--C 1.521 -0.139 0 C-N-CA 125.55 1.54 . . . . 0.0 112.386 178.043 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -105.87 119.49 39.31 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 -165.081 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 3.0 ptpp? -131.99 167.91 18.84 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 119.665 1.12 . . . . 0.0 110.518 -178.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 73.7 t -64.34 137.77 24.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 178.223 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.96 -16.71 57.13 Favored Glycine 0 N--CA 1.447 -0.613 0 CA-C-O 117.475 -1.736 . . . . 0.0 110.725 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -67.45 92.88 0.31 Allowed 'General case' 0 C--N 1.346 0.426 0 CA-C-N 118.909 1.355 . . . . 0.0 108.458 -178.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 31.3 mtt85 -46.85 128.91 11.41 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 126.543 1.937 . . . . 0.0 110.892 165.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 55.0 mt -96.89 155.76 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 C-N-CA 126.417 1.887 . . . . 0.0 107.086 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.13 -54.52 1.7 Allowed 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 125.976 1.71 . . . . 0.0 107.961 -179.343 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.97 158.87 43.33 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 125.629 1.572 . . . . 0.0 108.764 -176.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.577 HG22 HD23 ' A' ' 97' ' ' LEU . 39.2 t -136.2 132.96 50.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.067 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 57.75 10.23 1.03 Allowed 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.052 0.941 . . . . 0.0 112.449 -163.359 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 82.04 -2.28 84.42 Favored Glycine 0 CA--C 1.534 1.222 0 C-N-CA 125.0 1.286 . . . . 0.0 113.22 -170.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -75.64 141.32 42.82 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 120.537 2.168 . . . . 0.0 107.233 169.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 33.1 m -56.58 147.14 23.03 Favored 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 118.71 0.686 . . . . 0.0 109.569 164.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.3 pp -116.56 5.66 7.26 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 C-N-CA 124.361 1.065 . . . . 0.0 111.838 172.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 98.0 mt -63.5 143.44 15.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 124.274 1.03 . . . . 0.0 108.282 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 61.62 -18.77 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 128.822 2.849 . . . . 0.0 117.291 172.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 4.8 mtp -55.87 145.78 51.21 Favored Pre-proline 0 C--O 1.241 0.611 0 CA-C-N 119.273 0.942 . . . . 0.0 110.034 177.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -69.18 155.21 68.51 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 122.629 2.22 . . . . 0.0 108.027 170.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -59.7 -32.16 70.25 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.7 -171.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.29 -39.45 72.71 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 126.214 1.806 . . . . 0.0 112.861 175.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 61.8 m-20 -70.98 -46.65 61.95 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -178.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.558 HD13 ' NE2' ' A' ' 45' ' ' HIS . 8.5 mt -64.66 -33.58 64.16 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 C-N-CA 126.018 1.727 . . . . 0.0 111.133 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.5 t -65.07 -51.51 65.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 124.475 1.11 . . . . 0.0 108.888 170.052 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.71 -37.34 81.38 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 116.77 -1.586 . . . . 0.0 110.984 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -51.64 -49.17 62.78 Favored 'General case' 0 N--CA 1.445 -0.697 0 C-N-CA 125.88 1.672 . . . . 0.0 111.301 173.395 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 53.2 mt -70.23 -38.65 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.16 0 O-C-N 121.066 -1.021 . . . . 0.0 108.873 -178.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.1 tttp -65.96 -38.49 88.73 Favored 'General case' 0 N--CA 1.453 -0.291 0 O-C-N 121.728 -0.607 . . . . 0.0 110.925 -179.416 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -66.45 -19.04 65.69 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 129.381 3.072 . . . . 0.0 111.588 174.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -64.5 -31.05 72.1 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.722 -0.611 . . . . 0.0 111.938 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 87.65 -149.85 22.03 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -169.19 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.7 mt -83.1 -20.76 34.24 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 118.201 1.001 . . . . 0.0 111.534 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.2 p -94.49 139.52 31.05 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 169.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 p -145.02 148.15 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 169.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.6 m -125.09 118.39 26.03 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 178.227 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.577 HD23 HG22 ' A' ' 71' ' ' VAL . 71.4 mt -90.78 124.05 34.83 Favored 'General case' 0 CA--C 1.509 -0.597 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 170.405 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 24.5 ttm105 -96.13 121.46 37.93 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 168.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -125.56 173.88 10.63 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 C-N-CA 125.559 1.543 . . . . 0.0 109.211 -166.303 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.6 mp . . . . . 0 C--O 1.237 0.408 0 C-N-CA 124.057 0.943 . . . . 0.0 108.581 179.614 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 32.8 p . . . . . 0 C--O 1.238 0.463 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 42.2 m -111.04 153.23 25.91 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 162.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -122.89 115.38 21.85 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 105.108 -2.182 . . . . 0.0 105.108 174.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -112.31 97.14 5.35 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 C-N-CA 123.703 0.801 . . . . 0.0 109.163 -173.107 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.5 p -76.75 141.36 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 170.253 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 59.7 mt -136.58 140.03 44.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 173.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 14.7 m-70 -124.7 113.28 17.78 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.789 2.436 . . . . 0.0 108.117 -170.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.2 ptt180 -106.16 -179.41 3.93 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 119.287 0.948 . . . . 0.0 111.238 -176.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.93 161.08 13.91 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 119.049 0.84 . . . . 0.0 110.257 170.247 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -64.41 -19.79 65.73 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.501 1.12 . . . . 0.0 112.216 177.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -87.68 -16.87 33.13 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 119.537 1.062 . . . . 0.0 113.235 178.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -113.09 -178.53 3.4 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 119.281 0.946 . . . . 0.0 109.877 -171.445 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -105.72 -176.38 23.93 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 169.414 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -78.31 176.79 8.98 Favored 'General case' 0 CA--C 1.533 0.316 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 153.53 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.418 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -135.13 50.79 0.85 Allowed Glycine 0 C--O 1.224 -0.531 0 CA-C-O 118.234 -1.315 . . . . 0.0 113.195 -172.123 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . 0.52 ' CE2' HD11 ' A' ' 28' ' ' ILE . 11.7 p90 -137.74 135.5 36.44 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 124.756 1.222 . . . . 0.0 110.299 -179.405 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.2 t -102.91 109.25 26.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 -179.108 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.552 HD12 ' H ' ' A' ' 28' ' ' ILE . 4.1 mp -82.26 124.91 39.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 175.21 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.533 HD11 ' HE2' ' A' ' 46' ' ' LYS . 15.5 pt . . . . . 0 N--CA 1.448 -0.574 0 C-N-CA 123.852 0.861 . . . . 0.0 109.746 177.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo . . . . . 0 N--CA 1.455 -0.766 0 CA-C-O 117.5 -1.125 . . . . 0.0 113.905 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -136.59 140.4 42.83 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 120.815 1.643 . . . . 0.0 108.071 176.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.533 ' HE2' HD11 ' A' ' 29' ' ' ILE . 10.7 pttm -156.5 165.64 35.73 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 170.146 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.438 HD13 HD11 ' A' ' 68' ' ' ILE . 6.9 mm -66.59 148.35 12.14 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.809 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 167.488 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -134.85 -8.45 1.89 Allowed Glycine 0 CA--C 1.529 0.959 0 C-N-CA 125.081 1.324 . . . . 0.0 113.765 173.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.0 ttt180 -165.75 160.95 17.7 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 126.283 1.833 . . . . 0.0 107.13 165.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 36.4 mt -132.54 149.95 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 125.654 1.582 . . . . 0.0 107.685 172.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 41.5 mm -81.77 118.38 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 C-N-CA 125.529 1.532 . . . . 0.0 108.841 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -62.77 96.31 0.08 Allowed 'General case' 0 C--O 1.235 0.332 0 C-N-CA 125.502 1.521 . . . . 0.0 107.957 168.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.23 0.22 6.41 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 125.216 1.388 . . . . 0.0 113.698 -179.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.418 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 66.8 p -91.45 166.28 18.7 Favored Pre-proline 0 C--O 1.237 0.415 0 CA-C-N 118.911 1.355 . . . . 0.0 113.333 -179.768 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -62.96 -32.29 76.59 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.55 2.167 . . . . 0.0 111.659 166.079 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.02 -47.24 74.97 Favored 'General case' 0 C--N 1.346 0.414 0 CA-C-N 119.04 0.836 . . . . 0.0 110.806 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -67.97 -52.68 33.1 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.744 0.418 . . . . 0.0 111.043 178.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 15.0 mtp85 -57.7 -34.61 69.63 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 121.589 -0.694 . . . . 0.0 112.285 -173.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 61.1 m -62.81 -16.54 58.62 Favored 'General case' 0 CA--C 1.534 0.345 0 CA-C-O 117.709 -1.138 . . . . 0.0 112.494 -178.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 46.21 34.98 2.36 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.105 1.762 . . . . 0.0 113.623 170.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 18.9 mtmm -129.65 -6.99 4.61 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 126.908 2.083 . . . . 0.0 111.829 173.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.14 101.06 4.06 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 -173.434 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 13.3 pttp -126.75 159.41 33.85 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 126.184 1.794 . . . . 0.0 109.688 -168.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . 0.374 0.4 OUTLIER -65.5 111.69 1.53 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.255 0 O-C-N 121.363 -0.836 . . . . 0.0 109.476 179.814 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 129.95 -18.79 5.3 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 128.285 2.85 . . . . 0.0 111.462 -175.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -71.56 97.26 1.66 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.401 1.08 . . . . 0.0 110.333 171.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.2 mtm180 -54.34 150.59 8.52 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 127.687 2.395 . . . . 0.0 111.75 173.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.484 HG22 ' CD1' ' A' ' 76' ' ' ILE . 87.7 mt -124.86 117.14 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 -165.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 76.5 mt -89.0 -40.19 13.17 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 124.327 1.051 . . . . 0.0 112.179 179.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.49 170.65 21.93 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 124.676 1.19 . . . . 0.0 108.764 -170.049 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.4 p -122.48 122.81 67.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 170.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 54.32 -73.0 0.01 OUTLIER 'General case' 0 C--O 1.232 0.177 0 C-N-CA 128.191 2.597 . . . . 0.0 111.783 -170.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -155.75 18.93 0.5 Allowed Glycine 0 CA--C 1.529 0.957 0 C-N-CA 126.887 2.184 . . . . 0.0 112.034 -178.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 24.2 mm100 -115.18 135.17 54.46 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 119.661 1.73 . . . . 0.0 108.572 -175.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.7 m -72.61 110.23 6.83 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 123.977 0.911 . . . . 0.0 109.759 174.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.484 ' CD1' HG22 ' A' ' 68' ' ' ILE . 11.1 pt -75.99 -15.63 15.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 C-N-CA 125.133 1.373 . . . . 0.0 111.962 174.644 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.522 HD12 ' H ' ' A' ' 77' ' ' ILE . 4.1 mp -56.03 -47.0 80.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 C-N-CA 125.121 1.368 . . . . 0.0 113.713 -164.644 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -113.83 -0.93 14.03 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 124.365 1.066 . . . . 0.0 112.237 -169.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . 0.252 11.0 ttt -68.81 146.95 97.82 Favored Pre-proline 0 N--CA 1.434 -1.245 0 C-N-CA 130.62 3.568 . . . . 0.0 109.846 -178.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -57.07 141.34 94.17 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.816 2.344 . . . . 0.0 109.792 167.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.517 ' HA ' HD12 ' A' ' 84' ' ' ILE . 41.4 t60 -66.64 -36.34 82.33 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 120.246 1.384 . . . . 0.0 111.055 -178.264 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -57.72 -31.34 66.33 Favored 'General case' 0 CA--C 1.534 0.332 0 O-C-N 121.361 -0.837 . . . . 0.0 112.74 171.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -73.42 -48.52 33.1 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 124.308 1.043 . . . . 0.0 109.144 177.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.517 HD12 ' HA ' ' A' ' 81' ' ' HIS . 66.2 mt -56.67 -35.59 45.89 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 C-N-CA 125.505 1.522 . . . . 0.0 110.698 175.151 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 45.9 t -77.07 -39.81 29.57 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 C-N-CA 124.176 0.991 . . . . 0.0 110.313 177.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 21.0 ttmt -60.4 -38.5 84.19 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 120.9 -1.125 . . . . 0.0 110.124 173.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -57.61 -38.63 75.28 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 127.464 2.306 . . . . 0.0 112.598 174.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 59.9 mt -68.08 -45.98 82.4 Favored 'Isoleucine or valine' 0 C--N 1.341 0.206 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 174.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 6.5 tttm -64.16 -40.14 95.49 Favored 'General case' 0 CA--C 1.536 0.416 0 O-C-N 121.739 -0.601 . . . . 0.0 110.263 -176.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -65.69 -11.8 48.22 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 127.099 2.159 . . . . 0.0 112.188 176.323 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -66.67 -13.4 61.18 Favored 'General case' 0 CA--C 1.541 0.633 0 O-C-N 121.34 -0.85 . . . . 0.0 112.155 170.656 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 72.66 -90.04 0.55 Allowed Glycine 0 C--N 1.34 0.796 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.6 mt -125.74 -34.49 2.62 Favored 'General case' 0 CA--C 1.514 -0.423 0 C-N-CA 125.589 1.556 . . . . 0.0 111.526 175.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.63 121.85 42.31 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 118.377 0.535 . . . . 0.0 110.131 -179.129 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.7 p -123.96 147.69 28.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 173.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.6 m -119.15 135.79 54.49 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 173.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 31.0 mt -125.19 110.57 14.24 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 125.309 1.444 . . . . 0.0 108.317 -176.326 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 33.4 ttm180 -77.74 106.83 9.81 Favored 'General case' 0 C--O 1.238 0.483 0 C-N-CA 123.811 0.844 . . . . 0.0 111.211 177.087 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -111.27 168.73 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 124.161 0.984 . . . . 0.0 110.597 -175.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.1 mp . . . . . 0 CA--C 1.54 0.583 0 CA-C-O 118.061 -0.971 . . . . 0.0 108.627 175.172 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 44.6 p . . . . . 0 C--O 1.236 0.361 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 m -141.74 150.69 42.12 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.706 1.202 . . . . 0.0 108.421 172.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -104.84 97.37 7.26 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 127.722 2.409 . . . . 0.0 105.862 -179.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 36.9 t -91.65 95.1 5.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 173.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.2 p -74.45 137.7 22.59 Favored 'Isoleucine or valine' 0 C--O 1.238 0.493 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 169.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.5 mt -135.61 134.55 51.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 104.835 -2.283 . . . . 0.0 104.835 174.346 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -108.33 160.43 15.87 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.542 1.137 . . . . 0.0 109.526 177.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 43.4 ptt85 -150.95 -179.64 7.46 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 119.424 1.011 . . . . 0.0 109.582 170.347 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.45 162.59 16.39 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 168.14 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.14 -42.52 95.01 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 174.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -71.52 -1.49 13.54 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-O 117.963 -1.018 . . . . 0.0 113.254 -167.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -137.1 179.07 6.6 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 121.278 1.854 . . . . 0.0 110.754 170.136 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.45 165.02 12.08 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 126.002 1.763 . . . . 0.0 110.169 170.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -66.94 148.96 51.27 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 124.637 1.175 . . . . 0.0 108.398 178.16 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.88 49.12 3.31 Favored Glycine 0 C--O 1.222 -0.629 0 CA-C-O 117.94 -1.478 . . . . 0.0 113.698 -174.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -136.22 156.27 48.91 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 120.745 2.273 . . . . 0.0 111.926 174.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.9 t -128.16 106.39 14.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 106.687 -1.597 . . . . 0.0 106.687 -175.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 23.8 mt -73.68 141.67 15.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 168.066 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.493 HD11 ' HE2' ' A' ' 46' ' ' LYS . 35.7 pt . . . . . 0 CA--C 1.537 0.478 0 C-N-CA 125.308 1.443 . . . . 0.0 110.826 174.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo . . . . . 0 N--CA 1.453 -0.91 0 N-CA-C 109.289 -1.081 . . . . 0.0 109.289 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.16 119.79 13.31 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 122.809 1.29 . . . . 0.0 110.973 -167.601 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.493 ' HE2' HD11 ' A' ' 29' ' ' ILE . 15.2 pttm -152.47 160.08 43.29 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 128.523 2.729 . . . . 0.0 106.267 178.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.409 HG13 HD22 ' A' ' 62' ' ' LEU . 34.6 mm -64.33 126.76 23.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 164.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -109.22 -21.14 7.49 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 125.717 1.627 . . . . 0.0 113.757 174.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 53.7 ttt180 -161.7 162.34 29.74 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 126.438 1.895 . . . . 0.0 108.06 166.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 6.5 mt -127.98 150.38 33.7 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 126.422 1.889 . . . . 0.0 108.094 170.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 21.3 mm -85.34 128.67 38.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 126.245 1.818 . . . . 0.0 107.226 178.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -62.1 143.02 57.24 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 123.23 0.612 . . . . 0.0 112.047 -172.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.68 -8.11 6.2 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 125.441 1.496 . . . . 0.0 115.47 176.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 84.8 p -67.49 170.25 7.25 Favored Pre-proline 0 C--O 1.239 0.518 0 CA-C-N 118.241 1.02 . . . . 0.0 112.198 -173.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.456 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 6.3 Cg_endo -57.23 -21.61 44.48 Favored 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.028 1.819 . . . . 0.0 112.508 165.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.43 -50.18 13.25 Favored 'General case' 0 C--N 1.342 0.242 0 CA-C-N 119.883 1.22 . . . . 0.0 110.699 174.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -63.58 -45.09 92.01 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 118.533 0.606 . . . . 0.0 110.763 -175.467 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -70.55 -13.78 62.24 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 123.565 0.746 . . . . 0.0 112.197 178.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 35.6 t -63.16 -49.99 72.15 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 119.127 0.876 . . . . 0.0 109.211 179.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.93 -21.41 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 128.439 2.695 . . . . 0.0 115.679 -173.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.4 mmmm -63.21 -26.56 68.85 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 125.976 1.71 . . . . 0.0 110.565 165.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.409 HD22 HG13 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -99.39 138.43 36.49 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 161.753 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 21.1 pttm -139.74 171.21 14.55 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 123.641 0.777 . . . . 0.0 110.795 164.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 84.6 t -59.85 137.96 21.52 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.714 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 175.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 93.83 -7.31 73.78 Favored Glycine 0 C--N 1.341 0.849 0 O-C-N 121.039 -1.038 . . . . 0.0 110.567 177.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 68.9 m-20 -71.84 98.76 2.05 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 171.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.9 mtt180 -45.78 158.46 0.09 Allowed 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 127.519 2.328 . . . . 0.0 110.841 162.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 19.1 mt -138.47 118.07 14.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -170.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.434 HD22 ' H ' ' A' ' 69' ' ' LEU . 1.9 mm? -78.17 -45.25 23.65 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.567 1.147 . . . . 0.0 111.732 172.21 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -160.3 166.24 29.86 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.181 0.992 . . . . 0.0 112.163 -160.475 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.2 p -128.66 111.83 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 C-N-CA 126.191 1.796 . . . . 0.0 110.138 -178.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.5 m-20 56.0 17.48 2.64 Favored 'General case' 0 N--CA 1.465 0.282 0 C-N-CA 125.285 1.434 . . . . 0.0 111.147 -168.545 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.48 -10.33 61.13 Favored Glycine 0 CA--C 1.529 0.944 0 CA-C-O 117.527 -1.707 . . . . 0.0 114.382 -175.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -75.92 132.15 40.08 Favored 'General case' 0 C--N 1.341 0.235 0 CA-C-N 120.51 2.155 . . . . 0.0 107.478 177.394 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.3 p -61.68 137.02 58.22 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 124.181 0.992 . . . . 0.0 109.949 175.039 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.7 pt -114.55 -4.37 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 C-N-CA 124.908 1.283 . . . . 0.0 111.331 179.286 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mt -57.9 145.14 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.596 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 162.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 18.7 m-80 67.13 -21.92 0.11 Allowed 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 128.117 2.567 . . . . 0.0 116.036 171.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 6.6 mtp -69.45 150.7 96.95 Favored Pre-proline 0 C--O 1.244 0.767 0 C-N-CA 124.658 1.183 . . . . 0.0 109.86 175.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -74.68 154.46 44.15 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 123.17 2.58 . . . . 0.0 109.856 173.154 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -54.99 -41.82 71.71 Favored 'General case' 0 N--CA 1.462 0.13 0 C-N-CA 123.42 0.688 . . . . 0.0 111.604 -178.418 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -57.15 -44.58 83.56 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-O 118.822 -0.609 . . . . 0.0 111.332 -174.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.52 -42.44 74.69 Favored 'General case' 0 C--O 1.221 -0.413 0 O-C-N 124.36 1.037 . . . . 0.0 110.011 -175.763 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 68.4 mt -63.33 -41.22 91.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 124.797 1.239 . . . . 0.0 109.679 178.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 41.4 t -62.55 -48.04 90.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 O-C-N 121.161 -0.962 . . . . 0.0 109.456 174.027 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 6.1 tptt -58.44 -43.68 88.86 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 118.614 -0.708 . . . . 0.0 111.279 176.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.05 -34.45 73.43 Favored 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 126.154 1.781 . . . . 0.0 111.71 -176.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 58.1 mt -73.15 -47.63 46.56 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 173.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.3 tttt -58.29 -32.92 68.89 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 122.096 -0.378 . . . . 0.0 111.686 -177.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -99.76 2.09 43.81 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 125.173 1.389 . . . . 0.0 112.276 -177.024 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -54.92 -29.57 56.55 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -171.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 123.13 27.57 1.49 Allowed Glycine 0 CA--C 1.526 0.768 0 C-N-CA 124.349 0.976 . . . . 0.0 113.285 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 7.8 mt 58.02 -23.11 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 129.023 2.929 . . . . 0.0 114.555 -164.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -93.56 148.59 21.95 Favored 'General case' 0 N--CA 1.435 -1.195 0 N-CA-C 105.24 -2.133 . . . . 0.0 105.24 161.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.1 p -143.26 140.48 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 0 N-CA-C 105.009 -2.219 . . . . 0.0 105.009 169.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.9 m -117.97 102.42 9.04 Favored 'General case' 0 N--CA 1.441 -0.911 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 21.6 mt -90.13 122.1 32.78 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 106.476 -1.676 . . . . 0.0 106.476 -172.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.1 ttt180 -83.73 109.77 17.76 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.011 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -111.94 160.97 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 123.429 0.692 . . . . 0.0 110.83 -177.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 28.5 mt . . . . . 0 CA--C 1.537 0.459 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 169.703 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.7 p . . . . . 0 CA--C 1.538 0.504 0 N-CA-C 110.589 -0.152 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -135.23 163.83 29.07 Favored 'General case' 0 CA--C 1.522 -0.12 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 162.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -134.42 94.85 3.27 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 127.185 2.194 . . . . 0.0 107.245 -174.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.8 t -96.89 109.73 23.63 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 125.373 1.469 . . . . 0.0 107.86 -165.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 1.5 t -84.16 141.89 14.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 173.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 69.7 mt -138.22 149.79 24.56 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 105.57 -2.011 . . . . 0.0 105.57 173.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 91.3 m-70 -130.82 156.38 45.1 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.928 1.291 . . . . 0.0 109.271 -176.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 35.3 ptt180 -143.08 -176.86 5.08 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 119.779 1.172 . . . . 0.0 110.048 176.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.44 163.31 12.54 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 124.047 0.939 . . . . 0.0 108.89 170.199 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -70.57 -19.33 62.88 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -177.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.8 m-20 -90.31 5.54 46.81 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 119.745 1.157 . . . . 0.0 112.07 177.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -140.92 176.77 8.53 Favored 'General case' 0 N--CA 1.445 -0.697 0 O-C-N 121.253 -0.905 . . . . 0.0 111.493 -172.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.42 170.73 14.61 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 178.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.443 ' CE1' HG12 ' A' ' 95' ' ' VAL . 40.2 m-85 -71.49 171.14 11.86 Favored 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 152.515 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -127.94 55.43 0.75 Allowed Glycine 0 C--O 1.222 -0.646 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 25.7 p90 -131.4 158.61 40.3 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 170.215 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 9.2 t -136.88 127.79 41.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 -174.474 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.468 HG21 ' CD2' ' A' ' 45' ' ' HIS . 4.0 mp -87.07 146.8 5.85 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 175.166 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 31.6 pt . . . . . 0 N--CA 1.442 -0.842 0 C-N-CA 126.326 1.85 . . . . 0.0 108.239 160.174 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo . . . . . 0 N--CA 1.446 -1.275 0 N-CA-C 109.281 -1.084 . . . . 0.0 109.281 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.468 ' CD2' HG21 ' A' ' 28' ' ' ILE . 2.5 m80 -65.37 116.34 6.57 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 124.25 1.02 . . . . 0.0 111.471 -168.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 39.5 pttt -135.44 151.86 50.82 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 168.055 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 30.0 mm -60.12 115.92 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 C-N-CA 124.261 1.024 . . . . 0.0 109.208 169.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -90.42 -39.43 5.98 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 124.013 0.816 . . . . 0.0 112.629 172.097 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 41.0 ttt85 -149.02 161.46 41.88 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 118.266 1.033 . . . . 0.0 109.559 178.752 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 15.4 mt -131.99 136.71 56.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 126.298 1.839 . . . . 0.0 106.171 169.455 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.4 mp -79.81 132.55 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 C-N-CA 126.016 1.726 . . . . 0.0 108.089 179.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -55.89 133.25 51.25 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 125.942 1.697 . . . . 0.0 109.505 177.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.36 -8.92 75.18 Favored Glycine 0 CA--C 1.528 0.892 0 C-N-CA 123.397 0.522 . . . . 0.0 112.46 169.219 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 76.5 p -71.22 167.1 32.39 Favored Pre-proline 0 N--CA 1.451 -0.385 0 CA-C-N 118.087 0.943 . . . . 0.0 112.836 -169.183 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -54.1 -39.76 84.46 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 C-N-CA 122.35 2.033 . . . . 0.0 111.992 166.414 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.11 -55.78 28.46 Favored 'General case' 0 C--N 1.341 0.216 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -57.13 -30.77 64.69 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.126 1.37 . . . . 0.0 112.447 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 46.6 mtt-85 -83.97 -29.29 27.15 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 114.533 1.309 . . . . 0.0 114.533 175.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 77.0 m -69.46 -27.72 65.48 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 120.292 1.405 . . . . 0.0 111.815 179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 51.54 -160.53 0.09 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.914 0.886 . . . . 0.0 110.496 -169.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 60.9 5.33 0.95 Allowed 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 125.544 1.538 . . . . 0.0 113.323 -167.007 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 14.7 tp -146.59 108.58 4.39 Favored 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.613 1.965 . . . . 0.0 107.17 -175.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 33.4 mttm -133.95 171.1 14.65 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 125.495 1.518 . . . . 0.0 110.419 -175.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 58.2 t -76.47 101.3 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -174.057 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 139.63 -12.78 3.19 Favored Glycine 0 CA--C 1.522 0.515 0 C-N-CA 127.0 2.238 . . . . 0.0 108.951 -175.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 57.7 m-20 -74.6 110.75 9.14 Favored 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 123.219 1.485 . . . . 0.0 107.346 -178.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 19.1 mmt-85 -59.9 158.69 10.25 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 113.918 -1.492 . . . . 0.0 110.377 162.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 35.0 mt -131.6 132.18 62.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 -175.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.7 mt -84.49 -51.25 7.05 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 124.323 1.049 . . . . 0.0 111.172 176.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -151.68 168.91 23.53 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 124.53 1.132 . . . . 0.0 109.609 -164.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.431 HG23 HG21 ' A' ' 76' ' ' ILE . 4.1 t -130.27 118.14 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 179.396 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 39.32 63.12 1.02 Allowed 'General case' 0 N--CA 1.464 0.252 0 C-N-CA 125.53 1.532 . . . . 0.0 110.733 -174.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 69.5 2.09 33.01 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-O 117.672 -1.627 . . . . 0.0 114.461 176.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -111.77 154.03 25.65 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 120.203 2.002 . . . . 0.0 111.676 -171.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 26.7 p -65.9 142.27 57.95 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.984 -179.15 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.431 HG21 HG23 ' A' ' 71' ' ' VAL . 5.0 pt -129.8 -5.78 2.87 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 123.318 0.647 . . . . 0.0 112.333 168.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 96.5 mt -73.66 -22.56 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.662 0 C-N-CA 125.046 1.338 . . . . 0.0 109.639 173.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 -124.84 -42.78 2.03 Favored 'General case' 0 C--N 1.341 0.215 0 C-N-CA 124.186 0.994 . . . . 0.0 111.734 -162.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.4 mtp -57.28 151.09 38.89 Favored Pre-proline 0 CA--C 1.533 0.294 0 C-N-CA 123.407 0.683 . . . . 0.0 110.489 176.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -69.34 149.06 69.09 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 121.149 1.233 . . . . 0.0 109.066 171.442 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -55.65 -41.53 73.74 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 124.085 0.954 . . . . 0.0 112.445 -170.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.91 -30.01 70.6 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 118.936 -0.554 . . . . 0.0 111.88 -179.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -70.68 -50.97 30.86 Favored 'General case' 0 C--O 1.223 -0.326 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 14.4 mt -60.18 -40.04 82.37 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 C-N-CA 124.45 1.1 . . . . 0.0 110.19 178.288 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.0 t -60.52 -47.23 93.58 Favored 'Isoleucine or valine' 0 C--O 1.241 0.611 0 O-C-N 120.78 -1.2 . . . . 0.0 109.97 175.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 22.6 ttmt -65.62 -42.13 91.92 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 117.895 -1.05 . . . . 0.0 110.102 178.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -48.53 -44.86 36.69 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 126.22 1.808 . . . . 0.0 111.097 176.483 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 41.4 mt -73.79 -44.24 52.32 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 48.2 tttt -58.87 -39.09 80.32 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 121.774 -0.579 . . . . 0.0 110.826 -178.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.7 -2.18 57.93 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 127.402 2.281 . . . . 0.0 112.436 -179.463 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.57 -13.4 3.77 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 116.058 1.873 . . . . 0.0 116.058 -164.005 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.45 44.3 6.59 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 118.875 0.762 . . . . 0.0 111.761 172.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 34.9 mt 66.49 -34.83 0.22 Allowed 'General case' 0 CA--C 1.511 -0.524 0 C-N-CA 129.245 3.018 . . . . 0.0 113.714 -175.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -93.47 143.25 26.47 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 178.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.443 HG12 ' CE1' ' A' ' 24' ' ' PHE . 11.5 p -144.88 135.95 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 172.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 35.0 m -116.53 106.26 13.38 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 -177.008 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 11.8 mt -91.04 110.48 21.75 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 125.07 1.348 . . . . 0.0 108.362 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 ttt180 -78.74 119.68 22.31 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 166.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -117.99 172.55 5.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 C-N-CA 124.733 1.213 . . . . 0.0 109.19 177.01 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 62.4 mt . . . . . 0 CA--C 1.542 0.657 0 C-N-CA 124.647 1.179 . . . . 0.0 108.122 174.707 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 51.0 p . . . . . 0 C--O 1.234 0.26 0 N-CA-C 105.769 -1.937 . . . . 0.0 105.769 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 m -123.45 151.99 42.11 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 161.685 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -108.67 130.39 55.34 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 128.752 2.821 . . . . 0.0 105.332 176.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.8 t -132.99 109.19 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.4 p -100.61 132.32 46.5 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 176.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 46.2 mt -136.05 147.21 28.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.711 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -120.87 159.28 25.84 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 124.36 1.064 . . . . 0.0 109.564 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.1 ptt180 -140.6 -161.95 1.28 Allowed 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 169.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.23 169.24 10.75 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 169.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 17.7 mm-40 -64.73 -27.37 68.86 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -80.43 -6.92 58.84 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 114.541 1.311 . . . . 0.0 114.541 -173.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -141.25 176.26 8.99 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 119.547 1.067 . . . . 0.0 110.596 -170.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.6 171.77 16.79 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 123.982 0.801 . . . . 0.0 111.353 -172.071 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -85.04 137.9 32.77 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 163.662 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.447 ' O ' ' HB3' ' A' ' 56' ' ' ALA . . . -97.71 75.3 0.63 Allowed Glycine 0 N--CA 1.442 -0.918 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 -178.093 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -157.77 148.88 21.31 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 164.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.2 t -137.59 131.04 43.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -174.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 10.3 mt -71.06 154.47 7.92 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.026 0 C-N-CA 124.788 1.235 . . . . 0.0 109.751 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 49.2 pt . . . . . 0 CA--C 1.54 0.594 0 C-N-CA 127.995 2.518 . . . . 0.0 109.143 149.939 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo . . . . . 0 N--CA 1.457 -0.66 0 CA-C-O 117.542 -1.108 . . . . 0.0 113.906 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -138.9 120.78 15.45 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 121.029 1.74 . . . . 0.0 108.913 177.653 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.9 pttt -140.7 162.94 34.2 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 168.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 11.4 mm -65.24 130.87 30.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 172.455 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.06 -51.75 0.72 Allowed Glycine 0 CA--C 1.522 0.491 0 C-N-CA 124.619 1.104 . . . . 0.0 111.224 169.112 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 40.0 ttt85 -134.68 151.79 51.28 Favored 'General case' 0 C--O 1.24 0.579 0 CA-C-N 119.142 1.471 . . . . 0.0 111.165 -168.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 50.5 mt -137.33 119.24 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 C-N-CA 127.14 2.176 . . . . 0.0 106.134 179.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.427 HD12 ' H ' ' A' ' 51' ' ' ILE . 1.9 mp -46.83 126.75 2.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 127.713 2.405 . . . . 0.0 108.418 156.233 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -63.31 128.31 35.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 165.454 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 105.01 4.99 41.51 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 111.514 -0.634 . . . . 0.0 111.514 173.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.5 p -80.88 159.79 67.85 Favored Pre-proline 0 N--CA 1.449 -0.496 0 O-C-N 121.24 -1.153 . . . . 0.0 113.752 -171.693 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -61.71 -35.01 82.25 Favored 'Trans proline' 0 CA--C 1.539 0.737 0 C-N-CA 122.917 2.412 . . . . 0.0 112.404 168.695 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.447 ' HB3' ' O ' ' A' ' 25' ' ' GLY . . . -68.62 -46.35 69.51 Favored 'General case' 0 C--N 1.34 0.188 0 CA-C-O 118.111 -0.947 . . . . 0.0 111.686 -178.069 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.6 t0 -61.95 -47.64 83.95 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 118.912 0.778 . . . . 0.0 109.805 -172.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 -59.89 -27.47 66.74 Favored 'General case' 0 C--N 1.341 0.229 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.671 177.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 6.1 t -60.57 -37.58 81.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-O 118.405 -0.807 . . . . 0.0 109.982 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.04 -14.34 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 130.535 3.534 . . . . 0.0 116.111 177.577 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.08 -19.19 51.89 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 125.187 1.395 . . . . 0.0 111.477 161.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -119.83 131.92 55.44 Favored 'General case' 0 C--O 1.235 0.292 0 C-N-CA 125.672 1.589 . . . . 0.0 107.688 176.301 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.09 171.32 14.48 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 124.194 0.998 . . . . 0.0 110.041 172.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.4 t -55.89 141.21 12.88 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 O-C-N 121.321 -0.862 . . . . 0.0 109.112 174.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.9 -12.92 65.59 Favored Glycine 0 CA--C 1.534 1.231 0 C-N-CA 125.147 1.356 . . . . 0.0 115.688 172.331 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -68.0 7.31 0.56 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 118.262 2.69 . . . . 0.0 118.262 -151.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 30.8 mtm180 51.87 89.56 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 126.438 1.895 . . . . 0.0 113.122 -178.307 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 61.3 mt -71.95 139.71 19.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -113.52 -53.05 2.72 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 125.632 1.573 . . . . 0.0 108.768 177.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -138.25 154.09 49.08 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.589 0.709 . . . . 0.0 112.319 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.446 HG23 HG21 ' A' ' 76' ' ' ILE . 55.6 t -112.15 116.55 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 169.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 57.73 5.12 0.31 Allowed 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 126.763 2.025 . . . . 0.0 115.525 177.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.91 12.28 26.34 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-O 118.81 -0.994 . . . . 0.0 112.863 -175.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 6.0 tp-100 -103.19 140.29 37.56 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 126.405 1.882 . . . . 0.0 108.401 171.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 62.9 m -78.68 100.76 7.18 Favored 'General case' 0 C--O 1.233 0.194 0 C-N-CA 124.666 1.186 . . . . 0.0 111.996 -177.062 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.446 HG21 HG23 ' A' ' 71' ' ' VAL . 2.7 pp -77.6 -5.29 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 179.262 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.565 HD12 ' H ' ' A' ' 77' ' ' ILE . 0.6 OUTLIER -70.28 -9.92 13.11 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 124.764 1.226 . . . . 0.0 112.381 -178.811 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -138.61 -24.51 0.94 Allowed 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 114.785 1.402 . . . . 0.0 114.785 -174.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.9 mtp -61.06 152.15 72.31 Favored Pre-proline 0 C--O 1.239 0.506 0 CA-C-N 119.856 1.207 . . . . 0.0 110.8 172.205 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -67.12 157.46 61.63 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 121.727 1.618 . . . . 0.0 110.131 171.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -63.21 -37.77 88.53 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.732 -0.605 . . . . 0.0 111.164 -172.057 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.49 -32.47 73.93 Favored 'General case' 0 C--N 1.338 0.068 0 CA-C-N 119.352 0.978 . . . . 0.0 111.975 178.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.74 -52.23 65.12 Favored 'General case' 0 C--O 1.224 -0.249 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 176.623 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 54.2 mt -65.88 -41.63 90.42 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.492 0 C-N-CA 125.91 1.684 . . . . 0.0 109.764 -175.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 17.1 t -60.14 -45.71 95.49 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 O-C-N 121.101 -0.999 . . . . 0.0 110.096 173.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? -59.86 -47.61 85.05 Favored 'General case' 0 C--O 1.219 -0.506 0 CA-C-O 118.692 -0.671 . . . . 0.0 109.376 177.267 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -57.32 -33.75 68.03 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 125.757 1.623 . . . . 0.0 112.676 -177.111 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 63.5 mt -75.1 -45.12 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 175.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.6 ttmp? -60.67 -49.1 78.87 Favored 'General case' 0 CA--C 1.537 0.443 0 O-C-N 121.615 -0.678 . . . . 0.0 110.021 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -76.65 5.93 6.75 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 129.948 3.299 . . . . 0.0 111.842 177.524 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -63.51 -24.01 67.64 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 119.28 0.946 . . . . 0.0 112.386 176.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.81 48.16 5.61 Favored Glycine 0 C--N 1.338 0.659 0 CA-C-N 119.201 0.909 . . . . 0.0 111.436 174.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.0 mt 69.73 -30.79 0.2 Allowed 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 129.764 3.226 . . . . 0.0 113.455 -178.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.29 131.06 40.29 Favored 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 124.722 1.209 . . . . 0.0 108.651 174.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.3 p -135.74 130.77 49.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 170.222 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.34 125.48 39.99 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 105.96 -1.867 . . . . 0.0 105.96 170.106 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 42.3 mt -116.76 106.85 13.94 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 175.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 -88.82 118.9 28.85 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 177.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.3 pp -119.49 176.66 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 127.216 2.206 . . . . 0.0 108.632 -172.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 5.0 mp . . . . . 0 CA--C 1.533 0.327 0 CA-C-N 119.231 0.923 . . . . 0.0 108.903 172.004 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 36.0 p . . . . . 0 C--O 1.238 0.455 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 26.0 m -120.22 148.82 43.2 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 171.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -96.22 155.52 16.73 Favored 'General case' 0 C--O 1.244 0.789 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 167.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.441 HG11 ' HG ' ' A' ' 62' ' ' LEU . 29.3 t -137.54 103.62 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 177.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.3 p -98.64 134.81 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 171.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 47.6 mt -142.48 134.15 25.49 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 N-CA-C 104.213 -2.514 . . . . 0.0 104.213 -179.659 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 21.1 m-70 -113.93 159.09 20.27 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.762 1.625 . . . . 0.0 110.171 -174.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.445 ' HG2' ' CE1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -151.86 175.69 12.21 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 120.334 -1.479 . . . . 0.0 110.863 178.708 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -66.09 161.93 20.69 Favored 'General case' 0 C--O 1.231 0.123 0 C-N-CA 123.426 0.69 . . . . 0.0 109.849 161.458 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -58.11 -50.0 75.0 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 125.863 1.665 . . . . 0.0 111.302 178.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 30.5 t30 -76.48 -21.96 55.16 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.247 1.019 . . . . 0.0 112.621 -173.339 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -66.96 174.23 3.16 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.377 1.071 . . . . 0.0 109.162 173.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -152.69 46.1 0.58 Allowed Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 124.711 1.148 . . . . 0.0 111.489 -178.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.445 ' CE1' ' HG2' ' A' ' 18' ' ' ARG . 22.3 m-85 50.32 -174.02 0.02 OUTLIER 'General case' 0 N--CA 1.432 -1.345 0 C-N-CA 129.767 3.227 . . . . 0.0 110.753 -174.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.422 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -132.38 45.49 1.12 Allowed Glycine 0 C--O 1.224 -0.482 0 O-C-N 121.353 -0.842 . . . . 0.0 111.97 -176.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -137.96 153.48 49.45 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 124.224 1.01 . . . . 0.0 108.698 -178.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.71 123.13 25.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 -176.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.21 151.2 3.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 171.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 46.2 pt . . . . . 0 N--CA 1.45 -0.466 0 C-N-CA 125.238 1.415 . . . . 0.0 108.137 168.704 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo . . . . . 0 N--CA 1.45 -1.037 0 N-CA-C 108.408 -1.42 . . . . 0.0 108.408 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.492 ' CD2' HD12 ' A' ' 76' ' ' ILE . 1.2 m80 -61.3 114.24 3.07 Favored 'General case' 0 N--CA 1.446 -0.656 0 C-N-CA 125.595 1.558 . . . . 0.0 111.621 -171.287 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -148.85 154.83 40.05 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 165.491 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.501 HD11 HD11 ' A' ' 68' ' ' ILE . 36.3 mm -60.96 129.16 23.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 123.134 0.574 . . . . 0.0 109.686 -178.29 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -100.22 -36.22 4.21 Favored Glycine 0 CA--C 1.529 0.963 0 C-N-CA 126.278 1.894 . . . . 0.0 112.693 172.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 6.9 ttm180 -149.04 151.77 35.07 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 118.437 1.118 . . . . 0.0 108.723 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 11.1 mt -126.86 139.56 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 125.787 1.635 . . . . 0.0 106.709 165.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -82.07 121.77 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 C-N-CA 126.653 1.981 . . . . 0.0 107.829 -178.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -51.46 128.29 22.37 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 124.956 1.302 . . . . 0.0 109.655 173.474 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 95.01 -12.32 68.57 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 125.449 1.5 . . . . 0.0 112.945 174.022 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.422 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 59.0 p -69.68 163.07 62.97 Favored Pre-proline 0 CA--C 1.53 0.205 0 CA-C-N 118.98 1.39 . . . . 0.0 113.177 -172.445 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -56.96 -34.81 98.18 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.27 1.98 . . . . 0.0 111.811 165.418 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.44 -49.24 78.34 Favored 'General case' 0 C--N 1.344 0.333 0 CA-C-N 119.526 1.057 . . . . 0.0 110.529 175.133 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -62.17 -49.53 75.46 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 124.265 1.026 . . . . 0.0 111.348 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -53.59 -53.04 57.41 Favored 'General case' 0 C--N 1.343 0.303 0 C-N-CA 124.418 1.087 . . . . 0.0 110.318 178.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 62.5 m -64.73 -13.94 56.73 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 117.536 -1.221 . . . . 0.0 113.592 -170.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 51.89 11.71 0.16 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.577 2.351 . . . . 0.0 116.821 171.167 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.42 ' HB2' HG13 ' A' ' 14' ' ' VAL . 12.4 mtpt -99.37 -6.77 27.22 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 124.864 1.266 . . . . 0.0 112.03 178.524 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.441 ' HG ' HG11 ' A' ' 14' ' ' VAL . 93.7 mt -104.8 142.74 34.18 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 154.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 9.4 ptmt -140.81 169.57 17.38 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.492 1.517 . . . . 0.0 110.016 159.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.9 t -73.23 109.32 5.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 O-C-N 121.409 -0.807 . . . . 0.0 109.042 -173.297 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 120.04 -7.71 11.73 Favored Glycine 0 C--N 1.337 0.631 0 O-C-N 121.143 -0.973 . . . . 0.0 110.724 -171.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 -74.11 101.67 3.99 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 172.462 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 39.5 mtm-85 -50.76 121.38 5.81 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 128.04 2.536 . . . . 0.0 108.424 164.227 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.501 HD11 HD11 ' A' ' 47' ' ' ILE . 71.5 mt -105.23 106.85 21.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 104.938 -2.245 . . . . 0.0 104.938 174.653 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.658 HD21 HG13 ' A' ' 100' ' ' ILE . 0.3 OUTLIER -80.42 -26.57 38.38 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 122.94 0.496 . . . . 0.0 112.111 -179.117 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.48 155.47 30.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 125.109 1.363 . . . . 0.0 111.305 -166.191 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.6 HG23 HD13 ' A' ' 76' ' ' ILE . 46.8 t -140.24 132.09 32.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 N-CA-C 105.21 -2.145 . . . . 0.0 105.21 176.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 46.05 34.86 2.19 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.593 1.157 . . . . 0.0 112.472 175.211 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 55.94 26.23 47.63 Favored Glycine 0 CA--C 1.535 1.318 0 CA-C-O 118.491 -1.172 . . . . 0.0 114.257 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -121.93 104.7 9.72 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 127.341 2.257 . . . . 0.0 107.056 -175.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 54.5 p -65.08 103.14 0.71 Allowed 'General case' 0 CA--C 1.538 0.505 0 O-C-N 120.581 -1.324 . . . . 0.0 114.377 -154.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.6 HD13 HG23 ' A' ' 71' ' ' VAL . 11.3 pt -74.1 -5.07 6.25 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 C-N-CA 124.226 1.01 . . . . 0.0 113.385 -174.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 50.4 mm -71.4 -21.27 21.57 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 C-N-CA 124.871 1.269 . . . . 0.0 111.336 -178.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -118.28 -28.83 5.69 Favored 'General case' 0 N--CA 1.47 0.536 0 C-N-CA 124.888 1.275 . . . . 0.0 112.372 -176.58 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 9.3 mtp -60.02 151.75 64.04 Favored Pre-proline 0 C--O 1.24 0.558 0 CA-C-N 117.925 0.329 . . . . 0.0 111.398 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -67.11 148.69 81.58 Favored 'Trans proline' 0 N--CA 1.448 -1.166 0 C-N-CA 121.992 1.795 . . . . 0.0 110.282 168.403 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -60.51 -30.53 69.78 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -172.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -70.03 -35.04 74.02 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 123.692 0.797 . . . . 0.0 112.182 175.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -66.88 -45.19 78.86 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 109.225 -0.658 . . . . 0.0 109.225 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 32.5 mt -64.02 -40.75 90.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 125.555 1.542 . . . . 0.0 108.982 179.418 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.2 t -58.63 -51.02 76.87 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 O-C-N 121.169 -0.957 . . . . 0.0 109.611 173.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.99 -44.6 74.62 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 118.383 -0.818 . . . . 0.0 111.934 176.338 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.35 -46.67 69.61 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 127.157 2.183 . . . . 0.0 110.909 176.362 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 59.7 mt -70.1 -39.77 77.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -176.603 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.1 mtpp -63.35 -39.65 95.12 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 123.066 0.547 . . . . 0.0 110.799 178.008 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -85.84 7.61 23.3 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.253 1.821 . . . . 0.0 112.184 177.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -61.4 -20.21 62.79 Favored 'General case' 0 CA--C 1.535 0.401 0 O-C-N 120.885 -1.135 . . . . 0.0 113.41 -177.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 81.02 63.81 1.85 Allowed Glycine 0 C--N 1.334 0.447 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 175.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 31.4 mt 67.87 -46.96 0.51 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 129.052 2.941 . . . . 0.0 112.699 177.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.51 149.18 21.43 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 170.689 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.495 HG22 HD13 ' A' ' 97' ' ' LEU . 14.1 p -131.77 133.1 61.67 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 165.362 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.9 m -106.68 105.02 14.85 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . 0.495 HD13 HG22 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -90.41 160.9 15.82 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 175.856 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 51.7 ttp180 -113.66 133.26 55.42 Favored 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 106.355 -1.721 . . . . 0.0 106.355 166.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.4 pp -128.21 161.07 37.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 123.899 0.879 . . . . 0.0 109.605 176.029 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.658 HG13 HD21 ' A' ' 69' ' ' LEU . 51.0 mt . . . . . 0 CA--C 1.544 0.748 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 169.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 42.4 p . . . . . 0 N--CA 1.447 -0.616 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 57.8 m -126.55 152.83 46.03 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 124.362 1.065 . . . . 0.0 109.112 173.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -108.38 103.73 12.94 Favored 'General case' 0 C--O 1.233 0.204 0 C-N-CA 126.235 1.814 . . . . 0.0 106.22 -178.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -88.07 95.2 5.04 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.8 p -78.02 138.08 20.98 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 CA-C-O 121.372 0.606 . . . . 0.0 109.423 171.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 41.2 mt -134.38 142.06 41.84 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 N-CA-C 105.796 -1.927 . . . . 0.0 105.796 173.086 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.2 m-70 -115.77 137.16 52.36 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.711 1.204 . . . . 0.0 109.19 177.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 16.8 ptt180 -118.4 175.65 5.61 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.118 0.872 . . . . 0.0 109.519 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.33 163.9 12.88 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 169.542 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -71.77 -38.6 70.31 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -173.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 54.5 t30 -77.01 18.89 0.33 Allowed 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.785 0.834 . . . . 0.0 112.036 -174.069 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -161.2 -169.84 2.47 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 120.005 -1.684 . . . . 0.0 111.108 -168.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -121.21 -169.71 13.81 Favored Glycine 0 CA--C 1.521 0.429 0 C-N-CA 126.274 1.892 . . . . 0.0 110.867 -174.212 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 84.2 m-85 -85.97 -110.52 0.05 OUTLIER 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 106.117 -1.808 . . . . 0.0 106.117 165.451 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 152.7 59.04 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.392 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 177.058 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -141.69 133.55 27.33 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 178.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.2 t -113.96 113.53 44.13 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 -172.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 26.7 mt -74.06 131.0 35.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 173.364 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.409 HD11 ' HE3' ' A' ' 46' ' ' LYS . 14.8 pt . . . . . 0 N--CA 1.451 -0.386 0 C-N-CA 125.513 1.525 . . . . 0.0 109.822 172.186 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo . . . . . 0 N--CA 1.456 -0.723 0 CA-C-O 117.661 -1.058 . . . . 0.0 113.802 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.485 ' CD2' HD12 ' A' ' 76' ' ' ILE . 0.6 OUTLIER -139.02 119.31 13.67 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 120.831 1.65 . . . . 0.0 110.157 174.75 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.409 ' HE3' HD11 ' A' ' 29' ' ' ILE . 45.4 pttt -143.65 163.99 31.67 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 168.283 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.8 mm -63.1 125.37 19.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 165.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.83 -24.05 5.37 Favored Glycine 0 CA--C 1.527 0.799 0 CA-C-O 118.828 -0.985 . . . . 0.0 113.469 172.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -154.09 147.52 25.0 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 176.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 5.4 mt -128.37 149.49 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 168.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -78.13 117.38 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 C-N-CA 125.714 1.606 . . . . 0.0 107.105 174.078 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -52.72 105.08 0.11 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.123 2.169 . . . . 0.0 109.256 176.582 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 95.02 7.92 59.37 Favored Glycine 0 CA--C 1.526 0.753 0 C-N-CA 124.569 1.081 . . . . 0.0 114.065 177.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 33.9 p -64.38 166.24 11.72 Favored Pre-proline 0 CA--C 1.531 0.242 0 CA-C-N 119.495 1.647 . . . . 0.0 109.802 164.099 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -58.86 -24.3 71.59 Favored 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 121.728 1.618 . . . . 0.0 112.849 170.095 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.03 -60.6 3.52 Favored 'General case' 0 C--N 1.341 0.201 0 CA-C-N 119.277 0.944 . . . . 0.0 108.671 173.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -65.69 -42.5 91.14 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.833 0.349 . . . . 0.0 111.048 -176.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -69.96 -22.85 63.13 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 118.442 -0.79 . . . . 0.0 112.501 -174.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 2.0 p -73.84 -16.7 61.13 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 117.618 -1.182 . . . . 0.0 110.976 173.513 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 40.08 66.23 0.63 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.324 1.849 . . . . 0.0 110.633 -173.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 33.4 mtmm -139.28 -44.89 0.46 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 124.923 1.289 . . . . 0.0 108.883 170.156 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 22.5 tp -94.02 121.62 35.69 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 -177.179 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.7 mmtt -132.85 162.84 30.48 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 123.394 1.569 . . . . 0.0 110.615 -176.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.4 t -62.77 123.77 16.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 172.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 122.11 -24.96 6.86 Favored Glycine 0 N--CA 1.447 -0.585 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -175.277 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -79.22 99.22 6.93 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-O 123.282 1.515 . . . . 0.0 109.416 -167.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 39.4 mtm180 -46.39 137.02 6.81 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 129.119 2.967 . . . . 0.0 110.106 162.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 16.0 mt -119.01 144.65 26.72 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 -174.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.523 HD11 HG13 ' A' ' 100' ' ' ILE . 6.1 mp -117.54 -47.22 2.64 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 125.246 1.418 . . . . 0.0 111.214 -176.416 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -150.04 169.61 20.83 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.084 0.954 . . . . 0.0 109.368 -175.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.6 p -138.89 123.39 20.88 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.299 0 C-N-CA 125.14 1.376 . . . . 0.0 108.197 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 51.39 31.05 6.74 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 123.616 0.767 . . . . 0.0 112.417 -173.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.26 6.75 89.07 Favored Glycine 0 CA--C 1.532 1.117 0 CA-C-O 118.37 -1.239 . . . . 0.0 114.204 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -102.46 135.3 44.32 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 119.963 1.882 . . . . 0.0 109.896 177.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -54.43 129.16 34.81 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 123.087 0.555 . . . . 0.0 110.282 168.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.485 HD12 ' CD2' ' A' ' 45' ' ' HIS . 25.8 pt -91.16 -17.79 7.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.716 1.206 . . . . 0.0 110.332 164.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 81.2 mt -68.02 136.26 26.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.712 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 82.49 -30.9 0.09 Allowed 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 130.572 3.549 . . . . 0.0 112.847 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 6.3 mtp -64.8 154.07 86.52 Favored Pre-proline 0 CA--C 1.541 0.597 0 CA-C-N 119.298 0.954 . . . . 0.0 111.332 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -76.9 152.1 31.84 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.49 2.127 . . . . 0.0 109.951 173.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -51.97 -42.38 62.86 Favored 'General case' 0 C--O 1.222 -0.345 0 C-N-CA 123.742 0.817 . . . . 0.0 111.657 -176.611 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.0 -41.83 75.46 Favored 'General case' 0 C--N 1.338 0.072 0 CA-C-O 118.356 -0.831 . . . . 0.0 112.855 178.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.9 -30.38 40.1 Favored 'General case' 0 C--O 1.225 -0.231 0 CA-C-N 118.898 0.772 . . . . 0.0 110.927 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 13.3 mt -69.03 -42.15 81.93 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 C-N-CA 124.455 1.102 . . . . 0.0 108.835 171.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 2.5 t -54.54 -46.4 71.73 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 O-C-N 120.542 -1.349 . . . . 0.0 108.932 170.511 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 9.7 tptt -62.14 -43.51 98.67 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-O 117.033 -1.461 . . . . 0.0 111.903 175.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.05 -37.78 80.85 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 121.121 1.782 . . . . 0.0 110.567 -177.361 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 43.0 mt -69.7 -49.58 57.04 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 177.298 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.1 tttp -54.22 -49.14 70.13 Favored 'General case' 0 C--N 1.345 0.371 0 C-N-CA 123.56 0.744 . . . . 0.0 110.234 178.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -65.89 -17.42 64.64 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 127.384 2.274 . . . . 0.0 112.362 -177.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -67.29 -9.43 40.75 Favored 'General case' 0 CA--C 1.548 0.895 0 CA-C-N 119.384 0.993 . . . . 0.0 112.891 176.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.23 -89.12 0.72 Allowed Glycine 0 C--N 1.34 0.779 0 C-N-CA 125.134 1.35 . . . . 0.0 112.262 167.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 78.4 mt -132.03 -27.3 1.85 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 126.47 1.908 . . . . 0.0 110.28 173.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.55 152.29 19.7 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 105.632 -1.988 . . . . 0.0 105.632 174.091 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.7 p -150.75 147.07 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 N-CA-C 105.126 -2.175 . . . . 0.0 105.126 161.104 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 20.6 m -126.08 103.09 7.53 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -175.254 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 18.8 mt -90.77 123.05 34.03 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 124.762 1.225 . . . . 0.0 108.444 -176.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 13.7 ttm180 -83.88 131.42 34.87 Favored 'General case' 0 C--O 1.237 0.431 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 176.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -126.97 159.69 36.6 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 C-N-CA 125.661 1.584 . . . . 0.0 110.581 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.523 HG13 HD11 ' A' ' 69' ' ' LEU . 9.2 mt . . . . . 0 N--CA 1.478 0.94 0 C-N-CA 124.841 1.256 . . . . 0.0 110.842 175.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 33.5 p . . . . . 0 N--CA 1.448 -0.536 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.9 m -111.23 156.62 21.18 Favored 'General case' 0 C--O 1.235 0.325 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 168.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -120.85 103.54 9.16 Favored 'General case' 0 CA--C 1.511 -0.536 0 N-CA-C 104.029 -2.582 . . . . 0.0 104.029 172.401 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.467 HG11 ' HB2' ' A' ' 62' ' ' LEU . 59.6 t -91.63 95.03 5.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 105.458 -2.053 . . . . 0.0 105.458 -177.713 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.4 p -85.47 124.84 40.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 169.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 13.3 mt -116.97 143.38 27.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 171.269 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.0 m-70 -121.68 143.76 49.16 Favored 'General case' 0 CA--C 1.536 0.404 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 175.445 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.405 ' NH1' ' CE2' ' A' ' 24' ' ' PHE . 3.0 ptt-85 -130.86 -175.48 3.68 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 119.797 1.18 . . . . 0.0 109.008 176.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.437 ' N ' ' HE3' ' A' ' 19' ' ' LYS . 0.2 OUTLIER -95.38 168.7 10.56 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 118.814 0.734 . . . . 0.0 109.273 169.836 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -65.94 -20.67 66.29 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.078 0.951 . . . . 0.0 112.544 170.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -123.18 65.67 0.99 Allowed 'General case' 0 C--O 1.234 0.265 0 C-N-CA 124.454 1.101 . . . . 0.0 108.133 -177.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -172.6 179.45 2.44 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 128.38 2.672 . . . . 0.0 107.227 163.164 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.67 176.12 23.84 Favored Glycine 0 CA--C 1.526 0.734 0 C-N-CA 124.432 1.015 . . . . 0.0 110.976 173.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . 0.405 ' CE2' ' NH1' ' A' ' 18' ' ' ARG . 40.5 m-85 -84.7 170.68 13.04 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 150.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.45 55.6 0.65 Allowed Glycine 0 C--O 1.224 -0.529 0 O-C-N 120.727 -1.233 . . . . 0.0 111.537 -175.138 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.4 p90 -130.12 121.89 27.21 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 117.981 0.89 . . . . 0.0 108.924 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.6 t -96.25 101.04 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 -175.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.567 HD12 ' H ' ' A' ' 28' ' ' ILE . 3.5 mp -74.27 118.87 20.57 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 170.436 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.457 HD11 ' HE3' ' A' ' 46' ' ' LYS . 24.5 pt . . . . . 0 CA--C 1.536 0.438 0 C-N-CA 124.355 1.062 . . . . 0.0 109.281 176.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo . . . . . 0 N--CA 1.456 -0.728 0 N-CA-C 109.818 -0.878 . . . . 0.0 109.818 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.2 m80 -63.68 123.71 19.55 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 118.785 0.72 . . . . 0.0 109.869 -177.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . 0.457 ' HE3' HD11 ' A' ' 29' ' ' ILE . 49.8 pttt -143.67 153.29 42.33 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 107.883 -1.155 . . . . 0.0 107.883 171.086 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . 0.407 HD13 HD11 ' A' ' 68' ' ' ILE . 32.7 mm -66.69 124.12 21.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 167.57 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -101.97 -30.88 5.59 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 124.246 0.927 . . . . 0.0 112.611 175.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 22.7 ttm180 -154.65 158.41 39.63 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 118.847 1.323 . . . . 0.0 107.564 176.014 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 24.5 mt -130.77 135.28 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 170.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.4 mp -68.81 124.96 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 32.2 t0 -51.96 133.55 32.45 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.375 1.07 . . . . 0.0 109.97 178.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.08 1.0 38.41 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 118.98 -0.9 . . . . 0.0 114.412 174.493 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 61.4 p -64.62 162.7 33.05 Favored Pre-proline 0 CA--C 1.53 0.189 0 CA-C-N 119.483 1.641 . . . . 0.0 109.504 171.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -55.76 -18.17 20.42 Favored 'Trans proline' 0 CA--C 1.534 0.488 0 C-N-CA 122.959 2.439 . . . . 0.0 114.028 175.244 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.59 -69.79 0.27 Allowed 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 169.112 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -66.43 -31.88 72.91 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 118.14 0.427 . . . . 0.0 111.655 -173.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.92 -22.92 67.11 Favored 'General case' 0 C--O 1.234 0.247 0 O-C-N 121.351 -0.843 . . . . 0.0 112.508 175.389 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 7.8 t -80.85 -9.51 59.81 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 119.338 0.972 . . . . 0.0 111.475 173.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 55.92 5.13 0.14 Allowed 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 128.841 2.856 . . . . 0.0 115.724 173.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.9 -49.64 6.96 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 119.796 1.18 . . . . 0.0 110.424 177.39 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . 0.467 ' HB2' HG11 ' A' ' 14' ' ' VAL . 14.8 tp -93.85 129.36 40.28 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 123.5 0.72 . . . . 0.0 109.414 -166.044 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.7 mptt -122.99 169.97 10.62 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 125.451 1.5 . . . . 0.0 110.438 170.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -58.4 148.47 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 C-N-CA 124.367 1.067 . . . . 0.0 109.798 165.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.24 -7.73 80.67 Favored Glycine 0 CA--C 1.524 0.635 0 C-N-CA 125.301 1.429 . . . . 0.0 110.682 -175.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -71.17 88.92 0.83 Allowed 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 172.351 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.1 mtm180 -38.21 121.02 0.94 Allowed 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 128.448 2.699 . . . . 0.0 110.314 159.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . 0.407 HD11 HD13 ' A' ' 47' ' ' ILE . 14.3 mt -101.22 118.83 48.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 -178.697 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 88.1 mt -72.0 -52.52 16.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 124.684 1.194 . . . . 0.0 109.959 168.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -150.83 166.24 31.13 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 124.059 0.944 . . . . 0.0 111.951 -162.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 37.2 t -126.26 119.84 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 174.45 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.561 HD21 ' HB2' ' A' ' 91' ' ' ALA . 67.7 m-20 54.51 10.01 0.3 Allowed 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 128.918 2.887 . . . . 0.0 114.477 176.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 114.01 -0.26 24.16 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 126.721 2.105 . . . . 0.0 113.909 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 9.8 mm-40 -105.07 145.22 30.8 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 125.422 1.489 . . . . 0.0 109.243 -176.047 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.8 p -84.09 99.26 10.36 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 124.73 1.212 . . . . 0.0 111.63 -167.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 7.1 pt -79.76 -2.84 5.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 C-N-CA 123.904 0.882 . . . . 0.0 112.106 -177.258 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.731 HD12 ' H ' ' A' ' 77' ' ' ILE . 3.3 mp -61.85 -33.29 57.19 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 125.223 1.409 . . . . 0.0 110.383 174.31 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -107.7 -44.12 4.33 Favored 'General case' 0 C--O 1.233 0.215 0 C-N-CA 123.049 0.539 . . . . 0.0 111.217 -166.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 5.6 mtp -58.77 153.4 42.54 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 124.329 1.052 . . . . 0.0 111.328 -168.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.75 146.27 97.6 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.187 1.258 . . . . 0.0 109.276 167.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -52.09 -41.28 62.29 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 124.346 1.058 . . . . 0.0 110.028 -178.064 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -59.93 -35.57 75.19 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 114.24 1.2 . . . . 0.0 114.24 177.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.01 -44.86 79.23 Favored 'General case' 0 N--CA 1.463 0.189 0 C-N-CA 123.727 0.811 . . . . 0.0 108.887 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 24.0 mt -69.37 -37.99 76.47 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 C-N-CA 125.967 1.707 . . . . 0.0 109.261 -178.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 4.8 t -56.46 -49.06 78.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 O-C-N 121.127 -0.983 . . . . 0.0 109.427 169.263 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 11.4 ttpt -66.88 -36.48 82.41 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-O 118.742 -0.647 . . . . 0.0 111.258 -177.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -57.09 -44.38 83.11 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 125.4 1.48 . . . . 0.0 111.057 174.29 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 91.1 mt -67.86 -40.99 84.54 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-N 119.371 0.987 . . . . 0.0 108.813 178.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.0 tttt -60.08 -48.76 80.38 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 118.819 0.736 . . . . 0.0 109.942 176.146 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -70.31 -12.28 61.48 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 124.642 1.177 . . . . 0.0 111.268 -178.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.561 ' HB2' HD21 ' A' ' 72' ' ' ASN . . . -62.9 -14.99 53.25 Favored 'General case' 0 CA--C 1.545 0.757 0 CA-C-N 119.679 1.127 . . . . 0.0 112.347 168.426 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.28 -132.25 11.16 Favored Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 176.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 5.7 mt -90.7 -10.24 43.83 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 118.878 -0.582 . . . . 0.0 110.336 173.682 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 26.7 p -93.42 162.3 14.04 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 168.476 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.6 p -156.68 136.6 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.888 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 159.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.1 m -117.34 104.75 11.44 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 -177.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 56.9 mt -90.02 164.55 14.48 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 177.33 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 22.6 ttt180 -127.93 118.74 24.16 Favored 'General case' 0 CA--C 1.513 -0.456 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 173.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pp -129.51 169.2 21.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 C-N-CA 123.952 0.901 . . . . 0.0 109.294 -176.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.0 mp . . . . . 0 CA--C 1.54 0.585 0 C-N-CA 124.205 1.002 . . . . 0.0 109.361 -177.251 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.6 p . . . . . 0 CA--C 1.54 0.581 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 37.3 m -126.6 164.41 21.3 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.875 1.67 . . . . 0.0 109.415 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 18.4 p-10 -128.86 95.12 4.0 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 127.15 2.18 . . . . 0.0 108.057 177.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.0 t -89.47 102.9 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 105.798 -1.927 . . . . 0.0 105.798 174.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.2 t -106.68 111.47 35.6 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -177.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 12.1 mt -108.83 136.55 44.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 N-CA-C 106.126 -1.805 . . . . 0.0 106.126 -178.72 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -119.87 114.15 21.66 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 126.465 1.906 . . . . 0.0 105.989 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 28.4 ptt180 -95.0 174.99 6.81 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 119.606 1.094 . . . . 0.0 109.116 176.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -82.97 171.13 14.16 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 166.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -75.57 -9.85 58.93 Favored 'General case' 0 N--CA 1.469 0.489 0 O-C-N 120.355 -1.466 . . . . 0.0 112.805 175.373 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 40.3 t30 -98.98 -27.38 13.89 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 115.119 1.526 . . . . 0.0 115.119 -160.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -114.37 -122.1 0.29 Allowed 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.235 1.414 . . . . 0.0 108.768 -167.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -154.49 -178.34 28.76 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 167.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -72.97 170.82 14.02 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 151.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -135.2 62.07 0.62 Allowed Glycine 0 C--O 1.22 -0.749 0 CA-C-O 118.27 -1.294 . . . . 0.0 111.591 -176.185 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.2 p90 -146.12 139.96 26.35 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 119.281 1.541 . . . . 0.0 109.033 178.491 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.848 HG12 ' H ' ' A' ' 49' ' ' ARG . 0.8 OUTLIER -110.08 154.78 11.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 171.798 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -128.79 118.75 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 -178.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 26.1 pt . . . . . 0 N--CA 1.45 -0.445 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -179.034 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo . . . . . 0 N--CA 1.453 -0.865 0 N-CA-C 108.475 -1.394 . . . . 0.0 108.475 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -72.58 120.9 18.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.138 0.975 . . . . 0.0 110.559 -174.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 45.3 pttt -137.31 154.93 49.97 Favored 'General case' 0 C--O 1.236 0.371 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 168.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 5.0 mm -60.79 127.29 20.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 166.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -88.51 -69.75 1.27 Allowed Glycine 0 CA--C 1.527 0.806 0 O-C-N 124.495 1.122 . . . . 0.0 110.627 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ARG . . . . . 0.848 ' H ' HG12 ' A' ' 27' ' ' VAL . 31.4 ttm180 -127.6 153.28 46.6 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 128.751 2.821 . . . . 0.0 107.407 -178.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 12.5 mt -119.27 142.68 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 166.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 50.4 mm -73.05 122.59 26.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -60.45 137.17 58.19 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 178.443 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.82 -5.23 54.08 Favored Glycine 0 CA--C 1.531 1.058 0 C-N-CA 126.08 1.8 . . . . 0.0 114.495 -178.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . 0.434 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 83.7 p -68.62 167.65 18.22 Favored Pre-proline 0 C--O 1.234 0.283 0 CA-C-N 119.332 1.566 . . . . 0.0 112.472 -176.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 18.0 Cg_endo -58.23 -29.26 87.1 Favored 'Trans proline' 0 N--CA 1.451 -0.994 0 C-N-CA 122.165 1.91 . . . . 0.0 112.458 166.464 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.85 -53.94 46.45 Favored 'General case' 0 C--N 1.345 0.398 0 CA-C-N 119.814 1.188 . . . . 0.0 109.71 177.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -66.21 -45.89 79.14 Favored 'General case' 0 N--CA 1.463 0.187 0 O-C-N 123.135 0.272 . . . . 0.0 110.525 -178.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -72.45 -22.58 61.06 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 113.237 0.829 . . . . 0.0 113.237 -173.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 24.3 m -61.2 -18.09 56.46 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 119.967 1.258 . . . . 0.0 111.519 165.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 65.16 -25.15 0.09 Allowed 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 130.218 3.407 . . . . 0.0 114.951 171.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 1.9 mtpp -73.54 -8.53 56.31 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 124.955 1.302 . . . . 0.0 112.137 174.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -107.93 125.26 51.28 Favored 'General case' 0 C--N 1.343 0.301 0 CA-C-N 119.645 1.112 . . . . 0.0 108.328 173.262 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 40.5 mttp -135.76 166.41 23.35 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 126.188 1.795 . . . . 0.0 109.115 172.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 71.7 t -64.76 152.7 8.52 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 C-N-CA 123.515 0.726 . . . . 0.0 109.118 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 67.43 43.72 86.36 Favored Glycine 0 CA--C 1.528 0.903 0 CA-C-O 122.047 0.804 . . . . 0.0 112.221 174.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.8 p-10 -78.46 -20.99 49.76 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 125.782 1.633 . . . . 0.0 115.135 -173.272 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 18.4 mtm180 44.84 90.96 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 128.752 2.821 . . . . 0.0 111.516 -160.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 24.2 mt -68.48 150.21 10.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -116.56 -50.98 2.61 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.413 2.285 . . . . 0.0 108.898 177.186 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -151.91 169.97 20.99 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 124.179 0.991 . . . . 0.0 111.603 -176.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.0 p -128.88 118.89 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 124.371 1.068 . . . . 0.0 109.291 175.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 39.05 47.06 1.23 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.413 1.485 . . . . 0.0 110.494 -169.198 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.16 -3.72 51.05 Favored Glycine 0 CA--C 1.53 1.01 0 C-N-CA 125.952 1.739 . . . . 0.0 115.977 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -82.21 141.84 32.66 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 120.829 2.314 . . . . 0.0 108.578 -178.624 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.7 p -90.02 90.66 8.24 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-O 122.675 1.226 . . . . 0.0 110.374 -171.562 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 13.3 pt -65.39 -3.16 1.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.814 0 C-N-CA 126.833 2.053 . . . . 0.0 113.622 -177.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 26.1 mm -57.48 -58.13 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 126.799 2.04 . . . . 0.0 109.591 175.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -113.8 -22.96 9.91 Favored 'General case' 0 C--O 1.231 0.114 0 O-C-N 123.596 0.56 . . . . 0.0 112.029 -161.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.5 ttt -56.18 142.24 67.29 Favored Pre-proline 0 N--CA 1.437 -1.083 0 C-N-CA 126.292 1.837 . . . . 0.0 109.463 166.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -75.35 153.09 39.88 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 121.259 1.306 . . . . 0.0 111.169 -179.134 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 32.9 t60 -58.19 -41.23 83.51 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.255 0.622 . . . . 0.0 112.015 -170.038 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.68 -32.1 73.12 Favored 'General case' 0 C--O 1.227 -0.101 0 CA-C-O 118.879 -0.582 . . . . 0.0 112.41 178.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 53.5 m-20 -75.8 -42.04 51.12 Favored 'General case' 0 C--O 1.225 -0.221 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 32.8 mt -60.54 -40.26 83.85 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 124.643 1.177 . . . . 0.0 109.72 173.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 19.2 t -68.03 -35.88 73.41 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 O-C-N 120.198 -1.564 . . . . 0.0 110.902 175.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -62.38 -48.67 78.7 Favored 'General case' 0 C--O 1.22 -0.459 0 O-C-N 121.506 -0.746 . . . . 0.0 110.498 171.106 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.88 -35.39 66.45 Favored 'General case' 0 N--CA 1.44 -0.928 0 C-N-CA 126.505 1.922 . . . . 0.0 111.981 -176.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 76.0 mt -69.77 -52.58 30.25 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 176.225 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 6.8 tttp -54.51 -44.33 72.63 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 122.924 0.49 . . . . 0.0 111.172 177.613 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -71.95 -19.43 61.9 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.182 1.793 . . . . 0.0 110.984 -178.112 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.97 -35.38 80.44 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 119.525 1.057 . . . . 0.0 109.447 169.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 86.13 -117.03 4.5 Favored Glycine 0 N--CA 1.449 -0.497 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 172.542 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 39.6 mt -76.48 -49.27 17.0 Favored 'General case' 0 CA--C 1.501 -0.912 0 CA-C-N 118.367 1.083 . . . . 0.0 108.838 -173.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.89 145.81 24.36 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 124.229 0.955 . . . . 0.0 108.638 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.9 p -146.39 139.5 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 167.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 47.1 m -106.07 105.5 15.56 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 125.584 1.554 . . . . 0.0 107.197 176.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 40.7 mt -90.81 127.12 36.24 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.418 HH11 ' HB2' ' A' ' 98' ' ' ARG . 6.4 ttm105 -103.53 111.7 24.28 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.2 pp -121.53 174.61 5.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 C-N-CA 126.048 1.739 . . . . 0.0 108.312 -175.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 8.5 mt . . . . . 0 CA--C 1.54 0.586 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -179.107 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.53 0 N-CA-C 111.311 -0.716 . . . . 0.0 111.311 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 67.3 m -50.11 134.2 22.39 Favored 'General case' 0 C--O 1.237 0.419 0 C-N-CA 124.553 1.141 . . . . 0.0 113.157 -178.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.0 p -62.79 148.47 46.8 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 149.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 125.31 -171.78 17.28 Favored Glycine 0 CA--C 1.522 0.476 0 C-N-CA 124.049 0.833 . . . . 0.0 111.626 178.024 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 83.2 p -144.42 -164.46 1.91 Allowed 'General case' 0 N--CA 1.453 -0.324 0 C-N-CA 124.943 1.297 . . . . 0.0 109.287 177.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 4.1 m -84.75 -6.06 59.34 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.391 0.677 . . . . 0.0 112.466 -176.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 78.9 79.57 0.79 Allowed Glycine 0 C--N 1.335 0.484 0 N-CA-C 109.959 -1.257 . . . . 0.0 109.959 -179.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 18.7 m -130.33 167.52 18.38 Favored 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 126.392 1.877 . . . . 0.0 108.038 177.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.5 mp -61.48 146.56 48.13 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.17 164.42 16.24 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 124.32 1.048 . . . . 0.0 108.953 -174.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 3.2 p -141.75 163.84 31.83 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.787 1.235 . . . . 0.0 109.613 -172.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 13.0 m -140.83 164.74 29.41 Favored 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.514 1.126 . . . . 0.0 109.071 171.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 25.6 p-10 -128.71 94.45 3.86 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 127.601 2.36 . . . . 0.0 108.901 -173.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.452 HG11 ' HB2' ' A' ' 62' ' ' LEU . 24.3 t -90.64 106.94 17.93 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 176.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.7 t -85.5 142.72 12.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 166.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 34.0 mt -137.53 132.01 44.65 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.152 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 174.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 65.5 m-70 -115.04 141.35 48.11 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.715 1.606 . . . . 0.0 109.343 -175.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 30.9 ptt180 -139.88 -169.47 2.73 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 124.426 1.09 . . . . 0.0 110.474 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.67 169.12 10.38 Favored 'General case' 0 N--CA 1.463 0.222 0 C-N-CA 124.567 1.147 . . . . 0.0 109.439 168.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.7 mm-40 -69.89 -15.98 63.16 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 113.43 0.9 . . . . 0.0 113.43 -177.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.3 m-20 -84.5 -7.07 59.4 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-O 118.477 -0.773 . . . . 0.0 112.896 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -136.32 172.34 13.16 Favored 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 119.649 1.113 . . . . 0.0 111.479 -166.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -94.74 166.45 26.36 Favored Glycine 0 C--N 1.333 0.413 0 C-N-CA 123.669 0.652 . . . . 0.0 111.927 -170.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -87.27 115.71 24.86 Favored 'General case' 0 N--CA 1.444 -0.726 0 N-CA-C 104.52 -2.4 . . . . 0.0 104.52 150.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -92.7 48.62 2.55 Favored Glycine 0 C--O 1.224 -0.482 0 CA-C-O 118.518 -1.157 . . . . 0.0 112.643 -168.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.433 ' CE2' HD11 ' A' ' 28' ' ' ILE . 19.9 p90 -126.92 160.08 32.06 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 118.76 1.28 . . . . 0.0 109.873 173.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.4 t -138.39 141.36 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.326 0 C-N-CA 126.519 1.927 . . . . 0.0 106.972 -179.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.433 HD11 ' CE2' ' A' ' 26' ' ' PHE . 4.4 mp -105.9 135.85 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.667 0 C-N-CA 125.817 1.647 . . . . 0.0 107.801 178.009 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.473 HD11 ' HE3' ' A' ' 46' ' ' LYS . 13.5 pt -125.96 -178.73 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 C-N-CA 125.459 1.504 . . . . 0.0 110.314 175.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.3 t 67.35 178.71 0.23 Allowed 'General case' 0 C--O 1.239 0.542 0 C-N-CA 126.552 1.941 . . . . 0.0 109.926 -163.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.9 p -174.29 -57.01 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 127.643 2.377 . . . . 0.0 106.239 169.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.8 tp 34.3 62.72 0.46 Allowed 'General case' 0 C--N 1.342 0.254 0 C-N-CA 126.309 1.844 . . . . 0.0 110.304 -172.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -80.73 41.65 0.58 Allowed 'General case' 0 CA--C 1.538 0.493 0 CA-C-O 121.425 0.631 . . . . 0.0 109.59 -175.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 8.2 tpt180 -122.23 104.99 37.28 Favored Pre-proline 0 N--CA 1.455 -0.212 0 C-N-CA 127.548 2.339 . . . . 0.0 105.498 -173.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -58.01 116.31 3.15 Favored 'Trans proline' 0 N--CA 1.449 -1.113 0 C-N-CA 123.344 2.696 . . . . 0.0 110.079 -177.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -93.04 128.69 39.02 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 124.625 1.17 . . . . 0.0 108.808 175.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 2.0 t -61.56 -41.51 97.48 Favored 'General case' 0 CA--C 1.543 0.7 0 C-N-CA 124.458 1.103 . . . . 0.0 111.498 178.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.86 156.42 19.27 Favored Glycine 0 CA--C 1.525 0.677 0 CA-C-N 119.034 0.834 . . . . 0.0 111.486 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 69.9 m -70.18 102.83 2.18 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 109.673 -0.492 . . . . 0.0 109.673 172.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -85.85 162.71 18.51 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 125.308 1.443 . . . . 0.0 107.463 158.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 3.6 pt -93.51 86.29 2.08 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 170.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 2.0 t -133.33 151.79 51.89 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 124.792 1.237 . . . . 0.0 107.702 -174.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.7 p -127.51 142.49 44.23 Favored Pre-proline 0 C--O 1.238 0.465 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 173.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.3 -29.73 9.21 Favored 'Trans proline' 0 N--CA 1.453 -0.875 0 C-N-CA 121.275 1.316 . . . . 0.0 111.696 169.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -138.48 125.35 21.11 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-N 119.73 1.15 . . . . 0.0 110.746 -170.441 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.473 ' HE3' HD11 ' A' ' 29' ' ' ILE . 48.2 pttt -146.64 162.94 37.38 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 124.407 1.083 . . . . 0.0 108.783 166.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 46.4 mm -65.31 130.61 30.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 170.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.42 -49.66 0.65 Allowed Glycine 0 C--N 1.336 0.56 0 C-N-CA 125.254 1.407 . . . . 0.0 112.492 175.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -129.24 150.63 50.54 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-N 119.433 1.617 . . . . 0.0 108.373 176.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 11.5 mt -128.93 133.31 66.35 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.588 0 N-CA-C 105.754 -1.943 . . . . 0.0 105.754 167.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -60.14 126.37 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.605 0 C-N-CA 125.191 1.396 . . . . 0.0 108.018 169.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -57.29 121.13 9.43 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 124.483 1.113 . . . . 0.0 108.059 164.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 89.51 21.55 40.28 Favored Glycine 0 CA--C 1.526 0.778 0 CA-C-O 118.875 -0.958 . . . . 0.0 112.649 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 29.0 p -90.85 164.76 24.55 Favored Pre-proline 0 C--O 1.236 0.349 0 CA-C-N 119.651 1.725 . . . . 0.0 112.915 177.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -65.65 -21.77 58.66 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 121.695 1.597 . . . . 0.0 112.911 162.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.4 -56.36 16.9 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 119.199 0.909 . . . . 0.0 109.134 172.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -57.95 -48.48 79.83 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 123.597 0.759 . . . . 0.0 109.923 -177.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 61.3 mtt85 -71.9 -6.85 44.8 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 113.91 1.078 . . . . 0.0 113.91 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 36.1 t -62.29 -21.58 65.34 Favored 'General case' 0 CA--C 1.538 0.518 0 CA-C-N 119.817 1.19 . . . . 0.0 109.646 167.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.69 26.23 11.04 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 125.736 1.614 . . . . 0.0 112.665 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.6 mtmm -126.96 -52.13 1.43 Allowed 'General case' 0 CA--C 1.521 -0.145 0 C-N-CA 126.583 1.953 . . . . 0.0 109.153 175.758 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.452 ' HB2' HG11 ' A' ' 14' ' ' VAL . 9.9 tp -92.85 118.77 31.48 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 -161.441 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 71.4 mmtt -129.97 171.89 12.29 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 123.55 1.643 . . . . 0.0 109.332 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 94.8 t -64.89 122.9 16.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-N 113.807 -1.542 . . . . 0.0 107.626 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 128.31 -18.89 5.75 Favored Glycine 0 C--N 1.337 0.593 0 C-N-CA 125.02 1.295 . . . . 0.0 109.997 -178.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 49.7 m-20 -77.05 98.25 4.94 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 122.243 1.021 . . . . 0.0 109.196 -165.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 17.8 mtm180 -44.63 120.48 2.28 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 128.653 2.781 . . . . 0.0 110.572 164.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 45.5 mt -101.6 153.31 5.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 126.151 1.78 . . . . 0.0 107.432 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.9 tp -131.75 -44.89 0.97 Allowed 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 125.821 1.648 . . . . 0.0 110.589 -172.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -147.98 163.11 37.84 Favored 'General case' 0 CA--C 1.533 0.307 0 C-N-CA 123.267 0.627 . . . . 0.0 110.423 176.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 67.2 t -133.0 118.04 31.54 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 -176.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 8.4 m-20 42.39 57.11 3.5 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 126.146 1.778 . . . . 0.0 109.529 -170.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 67.46 -4.12 4.1 Favored Glycine 0 CA--C 1.537 1.435 0 CA-C-O 117.679 -1.623 . . . . 0.0 116.026 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -90.17 130.89 36.26 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 121.398 2.599 . . . . 0.0 110.997 -178.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 70.3 m -73.61 94.33 2.16 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 124.013 0.925 . . . . 0.0 110.509 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.5 pp -60.77 10.96 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.632 0 C-N-CA 128.34 2.656 . . . . 0.0 115.133 177.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 52.5 mt -63.46 -79.41 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 C-N-CA 126.029 1.732 . . . . 0.0 108.729 -178.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 62.9 m-80 -79.95 -11.87 59.76 Favored 'General case' 0 N--CA 1.467 0.4 0 O-C-N 121.453 -0.779 . . . . 0.0 113.079 -174.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 16.6 mtp -60.0 140.39 90.48 Favored Pre-proline 0 C--O 1.237 0.401 0 CA-C-N 118.238 0.472 . . . . 0.0 110.172 -178.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -65.27 156.05 65.21 Favored 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 121.962 1.775 . . . . 0.0 109.355 169.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 55.9 t60 -57.31 -34.99 69.3 Favored 'General case' 0 C--O 1.224 -0.261 0 CA-C-O 119.003 -0.522 . . . . 0.0 110.701 173.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.74 -41.66 77.91 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-O 118.591 -0.718 . . . . 0.0 112.362 175.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -65.88 -45.45 82.03 Favored 'General case' 0 C--O 1.222 -0.388 0 CA-C-N 118.909 0.777 . . . . 0.0 109.415 177.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 67.9 mt -65.42 -44.26 94.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.481 0 C-N-CA 125.53 1.532 . . . . 0.0 109.21 -175.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 22.5 t -55.18 -47.98 76.84 Favored 'Isoleucine or valine' 0 C--O 1.24 0.585 0 C-N-CA 125.147 1.379 . . . . 0.0 109.629 170.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 24.9 mtpt -70.33 -28.11 64.89 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-O 117.134 -1.412 . . . . 0.0 113.526 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -68.85 -40.83 79.17 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-N 120.932 1.696 . . . . 0.0 110.481 177.07 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 81.8 mt -68.74 -46.81 78.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 178.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.1 tmtm? -63.34 -38.12 89.93 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-O 118.678 -0.677 . . . . 0.0 111.729 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 26.4 t70 -61.93 -32.02 72.38 Favored 'General case' 0 C--N 1.329 -0.304 0 C-N-CA 124.169 0.988 . . . . 0.0 110.282 175.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -67.95 -12.18 60.23 Favored 'General case' 0 CA--C 1.543 0.689 0 CA-C-O 121.636 0.731 . . . . 0.0 112.3 175.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 66.13 -100.31 0.51 Allowed Glycine 0 N--CA 1.444 -0.793 0 C-N-CA 125.674 1.607 . . . . 0.0 110.411 173.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 25.1 mt -105.34 -24.72 12.63 Favored 'General case' 0 CA--C 1.504 -0.792 0 CA-C-O 117.68 -1.153 . . . . 0.0 112.495 -176.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -117.28 121.06 40.11 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 118.678 0.672 . . . . 0.0 109.495 178.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.3 p -125.68 148.48 30.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -176.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -116.28 117.29 29.58 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 124.656 1.183 . . . . 0.0 108.068 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 57.4 mt -98.99 112.64 24.7 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 171.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.3 ttm180 -81.47 112.56 18.83 Favored 'General case' 0 C--O 1.235 0.342 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 166.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.9 pp -116.72 166.51 10.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 C-N-CA 124.951 1.301 . . . . 0.0 108.618 -178.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.5 mt -105.07 117.15 59.29 Favored Pre-proline 0 N--CA 1.464 0.26 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 174.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -77.39 -172.85 1.57 Allowed 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.988 3.125 . . . . 0.0 109.22 174.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -154.28 162.28 41.27 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.529 -0.732 . . . . 0.0 109.707 179.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 4.3 pt-20 -127.9 -1.18 5.95 Favored 'General case' 0 CA--C 1.537 0.447 0 N-CA-C 112.876 0.695 . . . . 0.0 112.876 165.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -106.89 5.56 28.49 Favored 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 125.949 1.699 . . . . 0.0 111.917 -163.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.5 mm? -75.09 143.48 43.38 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 124.756 1.222 . . . . 0.0 108.131 172.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 51.4 t30 -149.58 170.95 17.47 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 127.943 2.497 . . . . 0.0 105.567 165.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -50.55 108.16 0.97 Allowed Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 119.817 1.19 . . . . 0.0 113.076 -171.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -67.18 -50.74 0.93 Allowed 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 121.77 1.646 . . . . 0.0 110.429 179.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 8.6 m 53.1 176.47 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 125.265 1.426 . . . . 0.0 113.003 -167.407 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 159.85 173.32 28.18 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 107.936 -2.066 . . . . 0.0 107.936 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -78.39 56.81 5.98 Favored 'Trans proline' 0 CA--C 1.542 0.917 0 C-N-CA 123.223 2.615 . . . . 0.0 110.002 175.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.1 t -156.76 -178.86 7.67 Favored 'General case' 0 C--O 1.238 0.486 0 C-N-CA 123.768 0.827 . . . . 0.0 111.234 -177.554 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 2.4 p -139.72 31.82 2.04 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 127.028 2.131 . . . . 0.0 111.566 -168.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.185 0 N-CA-C 108.488 -1.845 . . . . 0.0 108.488 165.642 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.886 0 N-CA-C 108.295 -1.922 . . . . 0.0 108.295 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 11.7 t -131.04 158.17 41.06 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 124.846 1.258 . . . . 0.0 107.784 177.194 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 32.2 t -61.72 -60.02 4.3 Favored 'General case' 0 CA--C 1.536 0.434 0 C-N-CA 123.488 0.715 . . . . 0.0 110.494 -177.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 74.78 -171.34 53.61 Favored Glycine 0 CA--C 1.53 1.016 0 N-CA-C 110.492 -1.043 . . . . 0.0 110.492 -169.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.6 t 55.52 -167.54 0.1 Allowed 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.782 1.633 . . . . 0.0 113.444 175.036 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -165.04 157.0 15.4 Favored 'General case' 0 C--O 1.239 0.52 0 C-N-CA 127.168 2.187 . . . . 0.0 106.226 160.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -176.82 33.64 0.08 OUTLIER Glycine 0 C--N 1.335 0.509 0 O-C-N 120.496 -1.378 . . . . 0.0 113.617 -178.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -76.71 -47.93 20.42 Favored 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 118.506 1.153 . . . . 0.0 111.915 -168.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 88.2 mt -100.56 110.59 22.76 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.939 1.296 . . . . 0.0 110.715 -168.217 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 25.8 mp0 -63.59 147.9 50.25 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.712 1.205 . . . . 0.0 110.602 173.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 36.9 p -145.49 154.0 41.75 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.214 1.406 . . . . 0.0 109.212 171.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 12.3 t -115.57 173.91 6.29 Favored 'General case' 0 CA--C 1.537 0.454 0 C-N-CA 124.532 1.133 . . . . 0.0 109.592 163.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -134.85 94.68 3.2 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 126.624 1.97 . . . . 0.0 108.376 168.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.6 t -99.22 108.07 21.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 O-C-N 120.68 -1.262 . . . . 0.0 107.94 -170.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.5 p -105.48 121.04 57.15 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 CA-C-N 118.841 0.746 . . . . 0.0 111.315 -170.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.6 mt -134.13 129.21 53.61 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 126.089 1.756 . . . . 0.0 109.363 -169.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 37.8 m-70 -108.54 144.18 36.56 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 126.214 1.806 . . . . 0.0 111.443 -177.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.414 HH11 ' H ' ' A' ' 24' ' ' PHE . 18.4 ptt180 -126.51 175.59 7.79 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 125.511 1.525 . . . . 0.0 111.018 176.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.436 ' HE3' ' OE2' ' A' ' 22' ' ' GLU . 0.0 OUTLIER -81.05 170.06 16.69 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 107.672 -1.233 . . . . 0.0 107.672 160.007 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -68.98 -35.7 77.02 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 121.609 -0.682 . . . . 0.0 111.709 177.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 68.9 m-20 -71.27 -47.32 57.65 Favored 'General case' 0 C--O 1.232 0.15 0 O-C-N 122.196 -0.315 . . . . 0.0 111.354 -171.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.436 ' OE2' ' HE3' ' A' ' 19' ' ' LYS . 5.3 pt-20 -76.84 166.96 22.64 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-O 121.518 0.675 . . . . 0.0 110.456 -176.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -86.61 -178.07 49.4 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 167.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.483 ' CE1' HG12 ' A' ' 95' ' ' VAL . 73.9 m-85 -70.6 145.28 50.81 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 104.255 -2.498 . . . . 0.0 104.255 149.443 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.419 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -84.81 44.83 3.42 Favored Glycine 0 C--O 1.221 -0.705 0 CA-C-O 117.529 -1.706 . . . . 0.0 112.519 -176.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -131.48 160.64 34.58 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 119.251 1.526 . . . . 0.0 110.519 179.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.9 t -136.88 127.32 40.18 Favored 'Isoleucine or valine' 0 C--O 1.239 0.53 0 C-N-CA 125.004 1.322 . . . . 0.0 108.055 177.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 35.1 mt -74.39 143.53 13.39 Favored 'Isoleucine or valine' 0 C--O 1.236 0.391 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 170.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.542 HD11 ' HE3' ' A' ' 46' ' ' LYS . 20.4 pt -127.32 176.66 6.88 Favored 'Isoleucine or valine' 0 C--O 1.243 0.712 0 C-N-CA 124.25 1.02 . . . . 0.0 109.518 162.539 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -128.14 114.32 16.86 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 124.376 1.07 . . . . 0.0 108.747 164.092 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -141.92 120.16 12.24 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 -179.404 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.2 mp -98.44 -78.82 0.48 Allowed 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 107.221 -1.399 . . . . 0.0 107.221 176.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 43.9 t-20 44.77 92.73 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 127.842 2.457 . . . . 0.0 112.123 -168.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -62.86 135.6 96.07 Favored Pre-proline 0 C--N 1.342 0.266 0 O-C-N 121.796 -0.565 . . . . 0.0 109.688 -163.571 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -79.44 31.12 0.47 Allowed 'Trans proline' 0 CA--C 1.539 0.759 0 C-N-CA 124.023 3.149 . . . . 0.0 111.542 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 9.2 mt-10 47.9 -157.49 0.05 Allowed 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 123.646 0.778 . . . . 0.0 111.276 -152.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 41.6 t 58.31 165.24 0.04 OUTLIER 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.977 1.711 . . . . 0.0 110.504 -147.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -96.47 -34.0 5.98 Favored Glycine 0 CA--C 1.523 0.532 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 171.249 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 70.8 m -77.13 110.07 11.49 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 106.481 -1.674 . . . . 0.0 106.481 160.045 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 66.6 p -116.17 101.87 9.09 Favored 'General case' 0 C--O 1.239 0.507 0 CA-C-N 119.229 0.922 . . . . 0.0 110.357 -171.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 12.8 pt -67.99 110.62 2.08 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 177.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.21 156.53 43.03 Favored 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.936 2.095 . . . . 0.0 107.035 177.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 77.9 t -126.42 146.73 57.5 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-O 117.685 -1.15 . . . . 0.0 108.748 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 15.4 Cg_endo -62.61 -74.87 0.02 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.85 0 C-N-CA 122.463 2.109 . . . . 0.0 111.292 168.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.4 m80 -85.42 126.51 33.84 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 120.07 1.305 . . . . 0.0 110.886 -174.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.542 ' HE3' HD11 ' A' ' 29' ' ' ILE . 11.2 pttp -144.32 162.52 36.21 Favored 'General case' 0 N--CA 1.465 0.281 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 166.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 23.0 mm -62.85 120.5 9.56 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 164.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -98.32 -30.05 7.18 Favored Glycine 0 CA--C 1.524 0.598 0 CA-C-N 118.455 0.571 . . . . 0.0 113.129 170.187 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 59.3 ttm-85 -151.97 153.98 35.14 Favored 'General case' 0 CA--C 1.514 -0.429 0 CA-C-N 118.635 1.217 . . . . 0.0 108.221 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 13.4 mt -120.15 149.92 22.86 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.711 0 O-C-N 124.614 1.196 . . . . 0.0 108.184 166.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.2 mp -78.58 127.29 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.825 0 C-N-CA 126.139 1.776 . . . . 0.0 107.25 168.516 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -59.42 137.51 57.97 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.44 6.1 89.04 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-O 118.461 -1.188 . . . . 0.0 113.331 174.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.419 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 76.6 p -87.3 166.52 25.37 Favored Pre-proline 0 CA--C 1.53 0.208 0 CA-C-N 119.992 1.896 . . . . 0.0 112.705 -175.2 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -58.16 -25.89 73.61 Favored 'Trans proline' 0 N--CA 1.452 -0.931 0 C-N-CA 122.121 1.881 . . . . 0.0 113.394 167.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.95 -60.62 2.85 Favored 'General case' 0 C--N 1.342 0.247 0 CA-C-N 119.283 0.947 . . . . 0.0 108.859 174.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -57.85 -46.38 84.86 Favored 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 122.981 0.512 . . . . 0.0 110.962 -176.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 78.8 mtt-85 -65.78 -18.21 65.17 Favored 'General case' 0 CA--C 1.518 -0.28 0 C-N-CA 124.885 1.274 . . . . 0.0 112.676 -176.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 9.0 t -63.12 -33.34 75.25 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-N 119.245 0.93 . . . . 0.0 110.11 175.266 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 58.23 -31.79 0.04 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 129.584 3.154 . . . . 0.0 114.901 -168.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.5 mtpt -61.55 -8.44 4.33 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 125.999 1.72 . . . . 0.0 112.093 170.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 21.2 tp -134.75 116.32 14.74 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 126.075 1.75 . . . . 0.0 108.981 -176.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 27.4 mmmt -137.4 171.63 14.19 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 123.535 1.636 . . . . 0.0 111.831 176.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 46.5 t -68.64 110.74 2.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 113.881 -1.509 . . . . 0.0 108.383 -178.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 138.35 -23.5 2.99 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -177.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -64.99 100.14 0.4 Allowed 'General case' 0 C--O 1.233 0.227 0 CA-C-O 122.114 0.959 . . . . 0.0 109.843 -174.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.9 mtm-85 -48.43 137.62 11.19 Favored 'General case' 0 C--N 1.332 -0.19 0 C-N-CA 128.048 2.539 . . . . 0.0 109.602 156.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 10.8 mt -122.86 143.96 33.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.195 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 -173.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 86.7 mt -107.24 -42.34 4.88 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 125.732 1.613 . . . . 0.0 110.379 175.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -154.68 165.99 34.81 Favored 'General case' 0 CA--C 1.534 0.338 0 C-N-CA 123.015 0.526 . . . . 0.0 112.04 -170.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 51.4 t -125.71 123.06 63.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 C-N-CA 128.141 2.577 . . . . 0.0 104.95 174.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 42.78 39.31 1.64 Allowed 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 126.212 1.805 . . . . 0.0 111.412 -172.511 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 81.26 -9.75 52.74 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-O 117.638 -1.645 . . . . 0.0 115.173 177.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 7.6 mm-40 -75.07 119.59 19.44 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 120.558 2.179 . . . . 0.0 108.557 172.169 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 16.9 m -55.21 127.76 30.79 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 171.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 15.3 pt -100.79 -5.38 9.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 C-N-CA 123.331 0.652 . . . . 0.0 112.265 -178.138 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.1 mt -59.13 142.48 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 167.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 73.2 -20.06 0.3 Allowed 'General case' 0 CA--C 1.533 0.294 0 C-N-CA 126.497 1.919 . . . . 0.0 115.325 167.315 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 14.0 mtp -64.25 148.3 95.97 Favored Pre-proline 0 CA--C 1.539 0.522 0 CA-C-N 119.477 1.035 . . . . 0.0 109.68 167.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -72.57 161.17 44.79 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 122.401 2.067 . . . . 0.0 110.064 169.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.8 m-70 -55.28 -47.79 75.0 Favored 'General case' 0 C--O 1.225 -0.209 0 C-N-CA 123.661 0.784 . . . . 0.0 111.016 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -53.76 -40.62 66.37 Favored 'General case' 0 CA--C 1.527 0.092 0 C-N-CA 123.236 0.614 . . . . 0.0 112.174 -176.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -72.19 -42.37 65.9 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 119.259 -0.4 . . . . 0.0 110.478 -175.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 46.9 mt -66.59 -37.28 79.24 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.786 0 C-N-CA 124.87 1.268 . . . . 0.0 108.846 176.238 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 38.2 t -65.16 -45.63 93.43 Favored 'Isoleucine or valine' 0 C--O 1.238 0.484 0 O-C-N 120.274 -1.516 . . . . 0.0 109.841 175.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.3 ttpt -62.41 -42.53 99.51 Favored 'General case' 0 C--O 1.22 -0.482 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.344 175.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -47.12 -48.01 23.16 Favored 'General case' 0 C--O 1.226 -0.162 0 C-N-CA 126.305 1.842 . . . . 0.0 111.62 171.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 74.4 mt -76.22 -31.89 21.76 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 O-C-N 121.592 -0.692 . . . . 0.0 109.607 -174.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.3 tttp -66.42 -46.08 77.75 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 119.58 1.082 . . . . 0.0 110.125 170.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -60.87 -18.15 54.47 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 128.134 2.574 . . . . 0.0 111.984 175.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -58.68 -25.91 63.3 Favored 'General case' 0 CA--C 1.546 0.808 0 C-N-CA 122.816 0.446 . . . . 0.0 111.336 169.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 66.86 57.97 8.97 Favored Glycine 0 C--N 1.339 0.71 0 O-C-N 121.338 -0.852 . . . . 0.0 111.063 170.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 48.0 mt 75.48 -38.52 0.36 Allowed 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 128.428 2.691 . . . . 0.0 112.193 -174.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -101.01 121.43 41.77 Favored 'General case' 0 C--N 1.322 -0.61 0 O-C-N 123.604 0.565 . . . . 0.0 111.062 -173.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.483 HG12 ' CE1' ' A' ' 24' ' ' PHE . 8.5 p -124.77 121.75 61.97 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 178.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.2 m -89.49 133.68 34.45 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 105.095 -2.187 . . . . 0.0 105.095 164.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 27.7 mt -123.76 139.36 54.06 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 -177.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 29.8 ttm180 -113.72 115.86 28.5 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -112.52 166.9 6.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 C-N-CA 126.682 1.993 . . . . 0.0 108.083 177.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 70.0 mt -72.2 -59.85 2.51 Favored Pre-proline 0 CA--C 1.54 0.586 0 CA-C-O 117.792 -1.099 . . . . 0.0 109.615 177.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -59.79 167.49 6.85 Favored 'Trans proline' 0 N--CA 1.455 -0.762 0 C-N-CA 121.682 1.588 . . . . 0.0 115.827 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 7.4 mt-30 -146.65 126.81 13.8 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 127.146 2.179 . . . . 0.0 105.55 -175.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -86.79 -24.7 24.95 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.91 0.862 . . . . 0.0 111.34 172.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -84.77 -5.34 59.32 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 125.48 1.512 . . . . 0.0 112.791 -161.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.3 mt -123.62 69.4 1.03 Allowed 'General case' 0 N--CA 1.454 -0.254 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 -175.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 44.5 t30 -64.54 -54.04 38.5 Favored 'General case' 0 CA--C 1.529 0.148 0 C-N-CA 123.77 0.828 . . . . 0.0 110.509 -175.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.6 m -164.28 151.2 9.98 Favored Pre-proline 0 CA--C 1.542 0.673 0 C-N-CA 126.275 1.83 . . . . 0.0 109.141 170.073 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -79.46 72.55 6.46 Favored 'Trans proline' 0 CA--C 1.539 0.75 0 C-N-CA 124.458 3.439 . . . . 0.0 111.21 173.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 6.9 m 61.34 14.77 5.96 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 114.596 1.332 . . . . 0.0 114.596 165.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -68.25 146.13 45.49 Favored Glycine 0 CA--C 1.533 1.186 0 N-CA-C 110.192 -1.163 . . . . 0.0 110.192 177.342 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -62.38 159.26 36.5 Favored 'Trans proline' 0 C--O 1.238 0.524 0 C-N-CA 124.038 3.158 . . . . 0.0 113.61 -174.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 7.8 m -141.31 -19.0 0.78 Allowed 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 114.691 1.367 . . . . 0.0 114.691 -174.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 60.1 m -165.41 -177.28 4.39 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 127.187 2.195 . . . . 0.0 106.939 178.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.243 0.682 0 N-CA-C 107.401 -2.279 . . . . 0.0 107.401 159.887 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.896 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 49.7 m -94.86 162.57 13.7 Favored 'General case' 0 C--O 1.234 0.25 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 156.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 21.2 p -157.74 -176.91 6.2 Favored 'General case' 0 C--O 1.237 0.447 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 171.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 175.18 -138.98 4.55 Favored Glycine 0 N--CA 1.446 -0.666 0 N-CA-C 106.691 -2.563 . . . . 0.0 106.691 -177.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 77.8 p -152.26 168.43 25.4 Favored 'General case' 0 N--CA 1.447 -0.613 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 167.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.3 m -160.85 130.73 5.01 Favored 'General case' 0 CA--C 1.519 -0.217 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 164.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 142.07 105.77 0.57 Allowed Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 58.6 m -150.01 -88.32 0.07 Allowed 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 161.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 14.2 tp -61.19 150.1 35.45 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 124.005 0.922 . . . . 0.0 111.277 -173.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -67.39 151.64 47.08 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-O 122.403 1.096 . . . . 0.0 110.861 172.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 38.4 p -144.68 170.03 16.87 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 126.491 1.917 . . . . 0.0 107.327 -173.29 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 23.4 m -137.98 162.3 34.45 Favored 'General case' 0 C--N 1.328 -0.34 0 O-C-N 120.865 -1.147 . . . . 0.0 108.333 164.632 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -131.72 95.72 3.79 Favored 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 127.691 2.396 . . . . 0.0 107.1 -167.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 19.6 t -93.72 94.83 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.379 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 -176.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.9 p -80.88 129.25 37.84 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 172.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 67.0 mt -135.17 147.15 29.29 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 N-CA-C 106.151 -1.796 . . . . 0.0 106.151 175.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.6 m-70 -113.4 167.31 10.69 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 125.008 1.323 . . . . 0.0 109.713 173.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 46.2 ptt85 -145.58 -179.88 6.97 Favored 'General case' 0 N--CA 1.465 0.29 0 C-N-CA 125.996 1.718 . . . . 0.0 107.076 172.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -102.67 159.29 15.6 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 173.1 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.556 ' HG2' HD21 ' A' ' 93' ' ' LEU . 8.8 mt-10 -70.13 -14.77 62.8 Favored 'General case' 0 N--CA 1.473 0.721 0 O-C-N 120.791 -1.193 . . . . 0.0 112.243 -178.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 -80.08 7.63 8.78 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.95 1.3 . . . . 0.0 112.264 179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -164.62 170.14 16.1 Favored 'General case' 0 CA--C 1.539 0.543 0 O-C-N 120.249 -1.532 . . . . 0.0 109.863 -167.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -100.2 -167.81 29.12 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 125.399 1.476 . . . . 0.0 110.909 175.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 72.9 m-85 -85.98 159.44 19.62 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 164.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.88 39.28 2.86 Favored Glycine 0 C--O 1.222 -0.623 0 CA-C-O 118.445 -1.197 . . . . 0.0 112.922 -178.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -118.58 161.35 20.2 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 119.587 1.694 . . . . 0.0 109.387 169.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 44.8 t -140.81 129.79 25.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.442 0 N-CA-C 106.033 -1.84 . . . . 0.0 106.033 -178.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 61.5 mt -97.4 145.47 9.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 -180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.2 pt -136.51 166.54 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.879 0 C-N-CA 125.249 1.42 . . . . 0.0 109.746 168.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 2.0 t -102.23 177.35 4.91 Favored 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 126.944 2.098 . . . . 0.0 108.67 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.1 m -134.21 10.47 3.83 Favored 'General case' 0 N--CA 1.466 0.333 0 C-N-CA 125.101 1.36 . . . . 0.0 112.274 164.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 25.5 tp -75.69 63.53 1.61 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.039 0.936 . . . . 0.0 109.493 173.63 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -169.89 139.59 1.93 Allowed 'General case' 0 C--O 1.234 0.241 0 C-N-CA 128.344 2.658 . . . . 0.0 106.676 166.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 6.0 mtt-85 179.2 141.22 0.29 Allowed Pre-proline 0 N--CA 1.466 0.356 0 C-N-CA 127.675 2.39 . . . . 0.0 106.57 154.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -73.68 94.33 0.86 Allowed 'Trans proline' 0 N--CA 1.455 -0.756 0 C-N-CA 122.988 2.458 . . . . 0.0 107.677 176.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 4.2 tt0 158.34 -60.49 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 128.717 2.807 . . . . 0.0 107.108 -166.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 69.6 m 53.72 71.33 0.51 Allowed 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 125.078 1.351 . . . . 0.0 112.358 -163.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.55 11.73 0.99 Allowed Glycine 0 CA--C 1.531 1.077 0 C-N-CA 125.223 1.392 . . . . 0.0 113.842 -176.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 67.8 m -66.84 130.46 43.24 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 118.502 1.151 . . . . 0.0 108.335 170.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 12.7 p -85.09 163.07 19.02 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 125.223 1.409 . . . . 0.0 108.398 161.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 13.3 mm 52.09 35.02 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.909 0 C-N-CA 124.498 1.119 . . . . 0.0 110.173 178.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.4 m -63.74 135.14 56.45 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 120.116 -1.615 . . . . 0.0 106.882 169.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 13.9 m -126.98 157.88 70.55 Favored Pre-proline 0 N--CA 1.446 -0.658 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 173.195 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -75.66 -37.48 1.7 Allowed 'Trans proline' 0 N--CA 1.456 -0.688 0 C-N-CA 123.275 2.65 . . . . 0.0 111.492 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -140.39 132.59 28.1 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 125.206 1.403 . . . . 0.0 108.142 -173.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 10.0 pttm -156.89 166.93 31.98 Favored 'General case' 0 C--N 1.326 -0.449 0 C-N-CA 125.698 1.599 . . . . 0.0 107.734 174.249 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 26.5 mm -72.71 103.69 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 C-N-CA 124.571 1.148 . . . . 0.0 108.87 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -67.91 -42.58 85.47 Favored Glycine 0 N--CA 1.451 -0.33 0 O-C-N 121.284 -0.885 . . . . 0.0 111.366 172.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 23.6 ttm105 -158.1 152.12 24.09 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -165.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 16.1 mt -122.0 150.49 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 168.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 31.9 mm -87.82 136.47 23.08 Favored 'Isoleucine or valine' 0 C--O 1.235 0.337 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 175.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.4 t0 -66.66 148.89 51.28 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-O 121.152 0.501 . . . . 0.0 111.185 -176.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 62.48 7.93 17.12 Favored Glycine 0 CA--C 1.527 0.834 0 C-N-CA 124.519 1.057 . . . . 0.0 114.369 175.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.406 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 79.4 p -76.0 167.98 31.88 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 118.234 1.017 . . . . 0.0 111.144 -176.343 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.406 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 12.5 Cg_endo -57.8 -27.71 79.26 Favored 'Trans proline' 0 N--CA 1.451 -1.019 0 C-N-CA 122.149 1.899 . . . . 0.0 112.239 165.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -70.83 -51.96 23.38 Favored 'General case' 0 C--N 1.341 0.204 0 CA-C-N 119.996 1.271 . . . . 0.0 110.171 174.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -57.83 -44.68 86.63 Favored 'General case' 0 N--CA 1.465 0.311 0 C-N-CA 123.343 0.657 . . . . 0.0 110.674 -179.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 27.4 mtt-85 -75.86 -5.53 46.46 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 124.634 1.174 . . . . 0.0 112.706 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.9 t -73.21 -35.97 66.43 Favored 'General case' 0 C--O 1.225 -0.2 0 CA-C-O 117.617 -1.182 . . . . 0.0 110.994 178.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 59.49 -24.94 0.03 OUTLIER 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 127.985 2.514 . . . . 0.0 116.214 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 6.1 mtpt -66.48 -17.29 64.71 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 120.325 1.421 . . . . 0.0 111.975 161.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.78 119.0 34.08 Favored 'General case' 0 CA--C 1.518 -0.256 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 -178.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.51 171.47 14.21 Favored 'General case' 0 CA--C 1.535 0.374 0 CA-C-O 122.563 1.173 . . . . 0.0 109.049 -178.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 78.3 t -72.43 108.14 3.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 O-C-N 120.734 -1.229 . . . . 0.0 108.693 -178.399 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 130.39 -3.94 5.87 Favored Glycine 0 CA--C 1.521 0.418 0 C-N-CA 126.261 1.886 . . . . 0.0 111.275 173.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 31.5 m-20 -71.31 95.86 1.36 Allowed 'General case' 0 C--O 1.234 0.268 0 CA-C-N 118.585 1.192 . . . . 0.0 108.148 172.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 38.5 mtt85 -53.01 143.3 17.61 Favored 'General case' 0 C--N 1.33 -0.254 0 C-N-CA 127.382 2.273 . . . . 0.0 109.116 170.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 34.6 mt -116.84 149.53 19.06 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.291 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 -168.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -132.86 -46.05 0.87 Allowed 'General case' 0 N--CA 1.463 0.211 0 C-N-CA 126.336 1.854 . . . . 0.0 109.967 -164.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -153.52 168.55 25.77 Favored 'General case' 0 N--CA 1.453 -0.311 0 C-N-CA 124.046 0.938 . . . . 0.0 110.012 176.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.453 HG22 HD23 ' A' ' 97' ' ' LEU . 80.6 t -133.6 120.99 39.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 105.187 -2.153 . . . . 0.0 105.187 174.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.554 HD21 ' HB2' ' A' ' 91' ' ' ALA . 23.2 m-20 48.73 41.22 17.6 Favored 'General case' 0 CA--C 1.537 0.451 0 C-N-CA 124.308 1.043 . . . . 0.0 110.398 -172.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.13 -11.39 3.82 Favored Glycine 0 CA--C 1.527 0.792 0 C-N-CA 126.907 2.194 . . . . 0.0 116.467 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.5 tp-100 -77.13 121.53 23.73 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 120.146 1.973 . . . . 0.0 107.257 -177.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 4.5 p -63.29 112.33 2.65 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.32 1.048 . . . . 0.0 110.992 -174.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 1.7 pp -73.34 14.25 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.617 0 C-N-CA 125.758 1.623 . . . . 0.0 113.188 175.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 60.6 mt -76.78 -86.16 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 O-C-N 121.199 -0.938 . . . . 0.0 109.353 -158.414 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.0 m120 -77.53 -8.72 58.24 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.416 1.086 . . . . 0.0 111.226 176.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 17.1 ttt -53.65 142.26 42.82 Favored Pre-proline 0 N--CA 1.433 -1.303 0 C-N-CA 128.22 2.608 . . . . 0.0 110.924 -177.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -60.66 139.58 86.47 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 121.873 1.715 . . . . 0.0 110.639 174.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.7 t-80 -59.3 -39.87 84.38 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 123.541 0.736 . . . . 0.0 111.587 -178.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.39 -23.49 63.73 Favored 'General case' 0 CA--C 1.53 0.177 0 O-C-N 122.034 -0.416 . . . . 0.0 111.986 175.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -73.72 -46.54 45.43 Favored 'General case' 0 C--O 1.223 -0.293 0 CA-C-O 118.635 -0.697 . . . . 0.0 109.713 179.089 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 49.1 mt -56.08 -40.32 63.34 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 126.432 1.893 . . . . 0.0 110.568 172.059 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 35.0 t -66.57 -43.89 90.36 Favored 'Isoleucine or valine' 0 C--O 1.238 0.451 0 O-C-N 120.109 -1.619 . . . . 0.0 110.75 176.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 6.6 tttt -54.82 -49.11 71.8 Favored 'General case' 0 C--O 1.223 -0.315 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 172.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -48.89 -39.38 25.75 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 129.23 3.012 . . . . 0.0 113.721 177.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.7 mt -75.9 -46.08 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.233 0 CA-C-N 118.791 0.723 . . . . 0.0 109.073 -178.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.2 tttp -57.34 -51.21 70.29 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 119.002 0.819 . . . . 0.0 110.137 173.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 18.7 t70 -57.71 -19.28 26.17 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 128.69 2.796 . . . . 0.0 112.864 177.258 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.554 ' HB2' HD21 ' A' ' 72' ' ' ASN . . . -60.41 -26.87 67.01 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 119.253 0.933 . . . . 0.0 112.596 177.231 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.32 -151.36 18.28 Favored Glycine 0 C--N 1.341 0.822 0 N-CA-C 110.024 -1.23 . . . . 0.0 110.024 -173.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . 0.556 HD21 ' HG2' ' A' ' 20' ' ' GLU . 72.9 mt -71.98 -33.04 67.82 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 117.626 0.713 . . . . 0.0 110.906 168.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -93.91 145.56 24.54 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 -178.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.6 p -140.98 143.24 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 168.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 23.7 m -114.57 102.69 10.29 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 174.428 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.453 HD23 HG22 ' A' ' 71' ' ' VAL . 61.3 mt -89.93 115.21 27.06 Favored 'General case' 0 CA--C 1.514 -0.427 0 N-CA-C 106.587 -1.634 . . . . 0.0 106.587 -174.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.3 ttm180 -86.4 112.14 21.18 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 -178.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -113.51 167.97 6.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 C-N-CA 124.709 1.203 . . . . 0.0 110.356 -174.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.9 mp -97.4 121.67 57.83 Favored Pre-proline 0 C--O 1.239 0.518 0 N-CA-C 108.118 -1.067 . . . . 0.0 108.118 172.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -88.98 168.44 5.47 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 124.635 3.556 . . . . 0.0 111.431 169.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -133.8 157.22 46.44 Favored 'General case' 0 N--CA 1.447 -0.613 0 C-N-CA 126.148 1.779 . . . . 0.0 107.904 178.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -136.04 -0.05 2.57 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 126.384 1.874 . . . . 0.0 110.438 -179.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -156.09 50.26 0.52 Allowed 'General case' 0 N--CA 1.453 -0.3 0 CA-C-O 123.877 1.799 . . . . 0.0 106.691 -167.323 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 2.4 tp -122.89 127.08 48.5 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 104.699 -2.334 . . . . 0.0 104.699 177.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 1.1 t-20 53.35 56.23 7.67 Favored 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 127.608 2.363 . . . . 0.0 113.117 -177.184 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -53.27 126.26 44.96 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-O 117.657 -1.163 . . . . 0.0 108.815 170.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -64.24 97.1 0.24 Allowed 'Trans proline' 0 C--N 1.346 0.405 0 C-N-CA 123.393 2.729 . . . . 0.0 111.188 -172.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 3.2 p -159.75 170.78 20.79 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.728 1.611 . . . . 0.0 108.006 -176.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 134.45 85.66 0.23 Allowed Glycine 0 CA--C 1.528 0.865 0 CA-C-O 118.583 -1.12 . . . . 0.0 111.511 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -69.64 -21.99 33.28 Favored 'Trans proline' 0 CA--C 1.534 0.509 0 C-N-CA 122.517 2.145 . . . . 0.0 113.292 -176.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 14.7 m 58.39 -179.8 0.07 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.811 1.645 . . . . 0.0 112.556 -170.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 73.6 m -155.65 -50.24 0.08 Allowed 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 126.149 1.78 . . . . 0.0 106.393 160.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.254 1.372 0 N-CA-C 106.432 -2.667 . . . . 0.0 106.432 139.772 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.24 0.506 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 17.3 p -121.53 175.5 6.17 Favored 'General case' 0 C--O 1.24 0.572 0 C-N-CA 126.64 1.976 . . . . 0.0 107.708 173.745 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 15.7 m -65.52 164.74 13.46 Favored 'General case' 0 CA--C 1.535 0.369 0 O-C-N 121.238 -0.914 . . . . 0.0 109.757 166.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 155.18 -115.51 0.67 Allowed Glycine 0 N--CA 1.447 -0.594 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 -177.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.6 m -65.47 142.95 57.98 Favored 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 123.751 0.82 . . . . 0.0 110.205 -179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 45.09 68.91 0.49 Allowed 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 125.727 1.611 . . . . 0.0 112.903 -172.319 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -142.74 -88.53 0.11 Allowed Glycine 0 N--CA 1.452 -0.289 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 165.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 38.4 m 56.35 -178.63 0.05 OUTLIER 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 124.998 1.319 . . . . 0.0 112.344 -170.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 6.2 mp 39.1 76.66 0.06 Allowed 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.743 2.417 . . . . 0.0 111.422 179.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 45.4 mt-30 -51.16 157.09 0.96 Allowed 'General case' 0 C--O 1.239 0.546 0 CA-C-O 122.731 1.253 . . . . 0.0 113.212 -174.092 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 74.0 p -142.59 169.84 16.82 Favored 'General case' 0 N--CA 1.444 -0.742 0 C-N-CA 127.286 2.235 . . . . 0.0 108.558 -175.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.3 m -132.18 155.26 48.52 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 144.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -93.21 143.11 26.58 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 105.632 -1.988 . . . . 0.0 105.632 160.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.7 t -129.96 102.06 6.74 Favored 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 169.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.6 p -82.95 144.87 9.34 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 168.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 18.1 mt -136.81 152.26 28.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 C-N-CA 127.487 2.315 . . . . 0.0 104.933 173.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 83.0 m-70 -129.92 136.56 49.62 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 125.618 1.567 . . . . 0.0 109.122 -168.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.1 ptt180 -131.39 176.6 8.16 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 120.605 1.548 . . . . 0.0 111.195 -178.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.2 161.98 14.04 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 124.07 0.948 . . . . 0.0 109.289 172.351 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -70.55 -15.78 62.81 Favored 'General case' 0 CA--C 1.538 0.502 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -89.2 -10.64 46.32 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 119.149 0.886 . . . . 0.0 112.642 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 25.9 pt-20 -127.57 175.38 8.3 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 120.344 1.429 . . . . 0.0 110.974 -166.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.01 176.79 19.44 Favored Glycine 0 CA--C 1.531 1.036 0 C-N-CA 124.899 1.238 . . . . 0.0 111.716 177.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 57.9 m-85 -89.3 137.96 31.86 Favored 'General case' 0 C--O 1.24 0.597 0 N-CA-C 107.024 -1.473 . . . . 0.0 107.024 163.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.76 66.9 0.32 Allowed Glycine 0 C--O 1.222 -0.603 0 C-N-CA 124.571 1.081 . . . . 0.0 111.101 -176.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -133.85 146.31 50.5 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 124.814 1.246 . . . . 0.0 108.459 167.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.6 t -121.54 144.87 29.25 Favored 'Isoleucine or valine' 0 C--O 1.238 0.452 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 173.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.6 mp -118.43 110.62 30.87 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 107.124 -1.435 . . . . 0.0 107.124 -173.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.451 HD11 ' HE3' ' A' ' 46' ' ' LYS . 31.1 pt -107.64 169.37 2.93 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 C-N-CA 123.861 0.864 . . . . 0.0 111.072 -169.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.8 t 75.85 -177.83 0.14 Allowed 'General case' 0 C--O 1.238 0.464 0 C-N-CA 127.168 2.187 . . . . 0.0 109.452 -167.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 3.1 p -158.23 177.44 11.28 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 128.858 2.863 . . . . 0.0 106.033 160.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.3 tt -146.85 112.49 5.64 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 120.324 1.42 . . . . 0.0 107.578 161.317 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -74.36 145.56 43.72 Favored 'General case' 0 C--O 1.233 0.23 0 C-N-CA 123.523 0.729 . . . . 0.0 110.182 -175.624 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 94.5 mtt-85 62.74 162.15 0.12 Allowed Pre-proline 0 CA--C 1.542 0.648 0 C-N-CA 126.978 2.111 . . . . 0.0 111.378 -177.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -69.43 -34.19 16.19 Favored 'Trans proline' 0 N--CA 1.459 -0.511 0 CA-C-O 117.56 -1.1 . . . . 0.0 113.625 -168.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 60.04 108.86 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.368 0 C-N-CA 126.25 1.82 . . . . 0.0 110.997 -168.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 7.3 t -79.05 91.55 4.89 Favored 'General case' 0 N--CA 1.45 -0.444 0 O-C-N 121.275 -0.891 . . . . 0.0 109.576 177.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 150.27 -152.39 24.28 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 111.891 -0.483 . . . . 0.0 111.891 177.153 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 66.7 m -75.62 149.95 38.11 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 125.789 1.635 . . . . 0.0 108.394 168.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 15.4 p -124.05 110.12 14.35 Favored 'General case' 0 C--N 1.332 -0.168 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -176.241 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 48.2 mm -62.7 -72.03 0.1 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -174.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 20.5 m -80.94 114.77 20.05 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 107.869 -1.159 . . . . 0.0 107.869 -178.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 11.9 p -65.21 152.25 92.1 Favored Pre-proline 0 CA--C 1.552 1.02 0 C-N-CA 123.716 0.807 . . . . 0.0 109.765 -174.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -78.8 -31.88 2.24 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.614 2.21 . . . . 0.0 114.026 176.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -133.55 121.16 21.73 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 119.734 1.152 . . . . 0.0 108.098 -177.324 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.451 ' HE3' HD11 ' A' ' 29' ' ' ILE . 1.9 pttt -145.72 149.46 34.45 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 106.9 -1.519 . . . . 0.0 106.9 170.654 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.519 HG13 HD22 ' A' ' 62' ' ' LEU . 17.1 mm -63.03 125.84 20.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 174.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -98.41 -37.51 4.27 Favored Glycine 0 C--N 1.333 0.388 0 C-N-CA 123.88 0.753 . . . . 0.0 112.773 178.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 37.6 ttm180 -158.15 149.14 20.85 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 125.198 1.399 . . . . 0.0 107.906 -174.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.2 mt -127.34 124.88 64.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 C-N-CA 126.598 1.959 . . . . 0.0 106.536 172.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.6 mp -55.59 132.91 19.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.339 0 C-N-CA 125.436 1.494 . . . . 0.0 109.828 168.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -57.42 127.5 32.3 Favored 'General case' 0 C--O 1.24 0.572 0 C-N-CA 124.991 1.316 . . . . 0.0 109.309 174.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 80.04 5.52 89.55 Favored Glycine 0 CA--C 1.523 0.562 0 C-N-CA 124.447 1.023 . . . . 0.0 113.462 174.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 35.2 p -65.26 162.69 38.08 Favored Pre-proline 0 CA--C 1.532 0.288 0 CA-C-N 119.21 1.505 . . . . 0.0 110.938 173.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -60.5 -28.95 87.62 Favored 'Trans proline' 0 N--CA 1.45 -1.045 0 C-N-CA 121.781 1.654 . . . . 0.0 112.109 168.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.25 -52.84 63.57 Favored 'General case' 0 C--N 1.344 0.33 0 CA-C-N 119.337 0.972 . . . . 0.0 110.282 172.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -61.55 -51.96 66.42 Favored 'General case' 0 N--CA 1.462 0.146 0 O-C-N 123.285 0.366 . . . . 0.0 110.817 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 90.5 mtt-85 -63.93 -28.9 70.15 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 118.409 -0.805 . . . . 0.0 112.059 -173.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 42.3 t -60.94 -19.1 60.26 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.627 1.171 . . . . 0.0 112.573 174.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 55.78 22.4 5.49 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 125.389 1.475 . . . . 0.0 114.197 171.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 44.5 mtmt -130.1 8.24 5.15 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 124.668 1.187 . . . . 0.0 113.273 178.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.519 HD22 HG13 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -141.06 119.27 12.07 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 -179.764 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.13 165.11 24.0 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 119.016 0.826 . . . . 0.0 110.606 176.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . 0.263 0.2 OUTLIER -56.98 141.15 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 O-C-N 121.201 -0.937 . . . . 0.0 109.846 172.684 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 92.2 -6.97 78.7 Favored Glycine 0 CA--C 1.524 0.655 0 CA-C-O 118.215 -1.325 . . . . 0.0 111.651 -174.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 41.8 m-20 -74.59 96.97 3.06 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 119.244 1.522 . . . . 0.0 107.287 168.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 42.8 mtm180 -45.05 130.87 7.61 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 126.882 2.073 . . . . 0.0 110.061 160.034 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 7.1 mt -111.76 143.99 20.47 Favored 'Isoleucine or valine' 0 C--O 1.234 0.263 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 -177.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 tp -112.81 -44.98 3.24 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 127.343 2.257 . . . . 0.0 108.47 -171.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -155.71 170.88 21.02 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.546 0.739 . . . . 0.0 111.474 -177.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.9 p -131.22 125.39 57.16 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 C-N-CA 125.154 1.382 . . . . 0.0 107.992 174.285 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 64.2 m-20 46.64 45.65 14.41 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 124.487 1.115 . . . . 0.0 108.957 -170.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 68.3 -2.51 7.15 Favored Glycine 0 CA--C 1.538 1.477 0 C-N-CA 125.81 1.672 . . . . 0.0 116.772 -175.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.7 tp60 -91.13 135.32 33.85 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 121.465 2.632 . . . . 0.0 110.359 -174.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.4 p -72.41 109.24 5.97 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 126.109 1.764 . . . . 0.0 112.316 -171.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 7.4 pt -87.74 -5.05 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 O-C-N 121.348 -0.845 . . . . 0.0 112.51 -172.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.521 HD12 ' H ' ' A' ' 77' ' ' ILE . 3.6 mp -65.56 -48.23 83.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 C-N-CA 124.626 1.17 . . . . 0.0 110.207 173.097 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 63.6 m-80 -93.45 -26.6 17.13 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 118.523 -0.751 . . . . 0.0 112.255 -162.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 3.9 mtp -70.27 160.53 80.62 Favored Pre-proline 0 CA--C 1.534 0.34 0 C-N-CA 124.685 1.194 . . . . 0.0 112.398 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -71.36 146.18 49.95 Favored 'Trans proline' 0 N--CA 1.449 -1.134 0 C-N-CA 121.822 1.681 . . . . 0.0 109.764 166.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -49.61 -38.6 32.43 Favored 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.765 1.226 . . . . 0.0 111.68 178.253 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -65.76 -30.13 70.75 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 124.152 0.981 . . . . 0.0 113.366 -178.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -82.01 -37.91 25.84 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 119.482 1.037 . . . . 0.0 109.908 178.048 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.7 mt -60.5 -36.32 68.95 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.724 0 C-N-CA 124.047 0.939 . . . . 0.0 109.659 172.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.9 t -63.79 -51.35 70.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 O-C-N 120.542 -1.349 . . . . 0.0 110.24 170.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 28.6 ttmt -51.88 -46.97 64.72 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 118.138 0.426 . . . . 0.0 111.406 178.543 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.45 -36.11 66.2 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 127.686 2.394 . . . . 0.0 113.602 -179.446 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 86.1 mt -76.7 -48.42 26.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.157 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 59.2 tttt -55.7 -44.86 77.79 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 122.882 0.473 . . . . 0.0 110.879 178.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -63.68 -26.9 68.87 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 125.251 1.42 . . . . 0.0 112.27 177.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.39 -28.41 69.25 Favored 'General case' 0 CA--C 1.538 0.516 0 CA-C-N 118.195 0.452 . . . . 0.0 110.519 176.098 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.16 -106.88 2.93 Favored Glycine 0 N--CA 1.447 -0.598 0 C-N-CA 125.385 1.469 . . . . 0.0 109.708 174.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 81.5 mt -100.35 -36.27 9.3 Favored 'General case' 0 CA--C 1.504 -0.812 0 C-N-CA 123.137 0.575 . . . . 0.0 110.758 -170.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -93.73 143.65 26.12 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 170.325 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.2 p -144.21 138.43 24.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 106.506 -1.664 . . . . 0.0 106.506 165.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 m -104.79 130.02 52.96 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 179.125 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 26.7 mt -114.4 117.85 32.21 Favored 'General case' 0 CA--C 1.516 -0.328 0 C-N-CA 124.642 1.177 . . . . 0.0 107.876 177.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -84.93 116.05 23.13 Favored 'General case' 0 C--O 1.232 0.175 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 174.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.7 pp -114.92 172.71 3.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 C-N-CA 125.867 1.667 . . . . 0.0 109.941 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 6.2 mt -113.21 123.06 34.17 Favored Pre-proline 0 C--O 1.237 0.447 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 169.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -83.84 -175.5 2.29 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 123.797 2.998 . . . . 0.0 110.446 178.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.83 151.51 47.08 Favored 'General case' 0 N--CA 1.451 -0.382 0 C-N-CA 122.749 0.419 . . . . 0.0 109.979 177.52 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -137.73 -3.53 1.85 Allowed 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 123.449 0.699 . . . . 0.0 112.111 -178.526 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -158.0 12.57 0.2 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 124.075 0.95 . . . . 0.0 109.857 -165.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.6 tp -103.63 109.39 21.05 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 103.994 -2.595 . . . . 0.0 103.994 169.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -153.52 -153.42 0.47 Allowed 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 158.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.6 p -146.09 142.23 17.47 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 156.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -67.71 -55.88 0.25 Allowed 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.964 2.443 . . . . 0.0 110.85 -172.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 16.4 m 59.43 27.48 16.61 Favored 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 166.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -65.63 172.23 24.08 Favored Glycine 0 CA--C 1.534 1.252 0 O-C-N 121.572 -0.705 . . . . 0.0 111.637 167.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -65.99 162.49 35.07 Favored 'Trans proline' 0 N--CA 1.455 -0.753 0 C-N-CA 123.207 2.605 . . . . 0.0 110.792 177.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -156.7 -174.75 5.08 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.08 1.752 . . . . 0.0 107.105 179.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.0 p -66.16 150.3 48.98 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 162.079 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.159 0 N-CA-C 107.428 -2.269 . . . . 0.0 107.428 175.738 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.344 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 68.5 m -141.61 131.28 24.1 Favored 'General case' 0 C--O 1.234 0.286 0 N-CA-C 105.368 -2.086 . . . . 0.0 105.368 169.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.2 t -171.92 160.45 5.46 Favored 'General case' 0 C--N 1.33 -0.256 0 C-N-CA 125.492 1.517 . . . . 0.0 107.596 -157.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -91.68 128.49 9.38 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 171.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.9 m -130.1 120.43 24.62 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 178.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 31.5 m -54.09 121.67 8.59 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 123.526 0.73 . . . . 0.0 110.223 -175.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -168.94 150.06 14.96 Favored Glycine 0 N--CA 1.449 -0.494 0 N-CA-C 108.577 -1.809 . . . . 0.0 108.577 176.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.1 p -153.56 0.11 0.23 Allowed 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 124.553 1.141 . . . . 0.0 111.505 -165.542 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.8 tp -141.69 95.68 2.86 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 -170.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -103.37 -164.38 1.07 Allowed 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 125.311 1.445 . . . . 0.0 108.72 174.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 28.9 p -132.18 140.09 48.61 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 169.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . 0.401 ' HB2' HG13 ' A' ' 99' ' ' ILE . 5.5 m -97.7 135.91 38.82 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 103.912 -2.625 . . . . 0.0 103.912 -174.217 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -112.92 103.99 11.97 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 107.361 -1.348 . . . . 0.0 107.361 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 18.2 t -87.49 139.29 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.475 0 N-CA-C 105.532 -2.025 . . . . 0.0 105.532 177.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.4 p -129.11 143.24 41.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.338 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 168.037 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 4.0 mt -132.11 152.06 36.07 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.166 0 C-N-CA 127.12 2.168 . . . . 0.0 105.421 173.528 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -131.32 130.11 42.31 Favored 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 126.646 1.978 . . . . 0.0 107.597 -176.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 34.0 ptt180 -126.11 179.89 5.03 Favored 'General case' 0 N--CA 1.477 0.916 0 CA-C-N 120.311 1.414 . . . . 0.0 110.492 -175.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.1 164.61 12.09 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.281 1.033 . . . . 0.0 109.073 175.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -75.21 -12.95 60.4 Favored 'General case' 0 N--CA 1.466 0.367 0 O-C-N 120.795 -1.19 . . . . 0.0 111.764 176.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -74.44 -8.25 55.67 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 113.023 0.749 . . . . 0.0 113.023 177.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 26.1 pt-20 -143.0 -175.71 4.62 Favored 'General case' 0 C--O 1.236 0.355 0 C-N-CA 124.082 0.953 . . . . 0.0 110.95 -162.136 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -116.89 -179.39 17.77 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 175.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.404 ' CE1' HG12 ' A' ' 95' ' ' VAL . 69.8 m-85 -75.31 174.53 9.41 Favored 'General case' 0 C--O 1.237 0.415 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 159.069 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.39 46.43 1.08 Allowed Glycine 0 C--O 1.222 -0.602 0 CA-C-O 118.817 -0.99 . . . . 0.0 111.694 -176.491 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -133.44 143.95 49.19 Favored 'General case' 0 C--O 1.239 0.506 0 CA-C-N 118.246 1.023 . . . . 0.0 108.29 177.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.6 t -119.21 114.35 44.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 106.009 -1.848 . . . . 0.0 106.009 -171.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 14.5 mt -78.88 136.92 22.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.299 0 N-CA-C 106.611 -1.626 . . . . 0.0 106.611 174.249 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.0 pt -132.21 171.95 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.883 0 C-N-CA 125.557 1.543 . . . . 0.0 108.236 163.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 74.62 119.21 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 126.073 1.749 . . . . 0.0 108.62 178.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.9 p -149.98 162.66 39.93 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 125.177 1.391 . . . . 0.0 107.731 178.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 21.0 tp -123.53 172.1 9.0 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -123.18 93.23 3.89 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 124.697 1.199 . . . . 0.0 108.261 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 66.64 142.99 0.08 OUTLIER Pre-proline 0 CA--C 1.537 0.477 0 C-N-CA 128.648 2.779 . . . . 0.0 110.927 -166.359 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -81.16 78.0 3.8 Favored 'Trans proline' 0 N--CA 1.452 -0.959 0 C-N-CA 122.2 1.933 . . . . 0.0 109.924 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -68.18 98.71 0.82 Allowed 'General case' 0 CA--C 1.536 0.428 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 170.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 8.3 t -69.29 108.03 3.51 Favored 'General case' 0 CA--C 1.537 0.447 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -174.03 -82.22 0.05 OUTLIER Glycine 0 C--N 1.336 0.541 0 CA-C-N 119.292 0.951 . . . . 0.0 111.842 -179.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 40.6 m -117.73 143.23 46.41 Favored 'General case' 0 CA--C 1.518 -0.282 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 172.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 36.1 p -123.48 105.97 10.23 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 -175.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 32.0 mm -92.76 -20.35 6.52 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 C-N-CA 123.546 0.738 . . . . 0.0 109.598 -177.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 26.4 p -133.7 -170.31 2.47 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 126.42 1.888 . . . . 0.0 109.345 -167.541 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 2.7 p -127.25 144.29 50.15 Favored Pre-proline 0 CA--C 1.534 0.362 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 163.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -72.2 89.69 0.79 Allowed 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 122.346 2.03 . . . . 0.0 108.66 160.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER 91.74 123.93 0.02 OUTLIER 'General case' 0 C--O 1.233 0.208 0 C-N-CA 130.123 3.369 . . . . 0.0 111.004 167.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 55.4 pttt -145.44 163.68 33.89 Favored 'General case' 0 C--O 1.233 0.209 0 C-N-CA 124.905 1.282 . . . . 0.0 108.4 163.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 35.8 mm -65.24 129.73 29.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 165.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -101.97 -49.6 1.24 Allowed Glycine 0 CA--C 1.524 0.628 0 C-N-CA 126.857 2.17 . . . . 0.0 111.774 173.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 49.6 ttt180 -144.38 161.81 38.04 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 125.325 1.45 . . . . 0.0 107.544 -179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 27.3 mt -133.46 150.74 32.46 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 C-N-CA 126.453 1.901 . . . . 0.0 107.707 174.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.0 mp -87.03 115.76 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.904 0 C-N-CA 126.57 1.948 . . . . 0.0 106.796 171.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 31.6 m-20 -52.57 142.98 16.74 Favored 'General case' 0 N--CA 1.464 0.255 0 C-N-CA 124.183 0.993 . . . . 0.0 109.048 171.482 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.82 -12.99 26.55 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-O 118.218 -1.323 . . . . 0.0 113.471 175.413 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 74.3 p -65.85 167.03 12.59 Favored Pre-proline 0 C--O 1.238 0.478 0 CA-C-N 119.639 1.72 . . . . 0.0 111.829 -175.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -59.32 -29.1 89.37 Favored 'Trans proline' 0 N--CA 1.456 -0.726 0 C-N-CA 121.712 1.608 . . . . 0.0 111.996 166.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.56 -56.74 12.03 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-N 118.668 0.667 . . . . 0.0 109.946 177.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.5 t70 -65.29 -51.55 59.97 Favored 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 123.039 0.535 . . . . 0.0 110.949 -177.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 9.0 mtp180 -65.46 -9.37 25.13 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.337 0.865 . . . . 0.0 113.337 -177.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -76.7 -9.27 58.55 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 117.149 -1.405 . . . . 0.0 113.16 171.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 52.11 39.17 26.07 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 125.905 1.682 . . . . 0.0 113.942 170.377 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 23.6 mtmm -141.11 13.49 2.23 Favored 'General case' 0 CA--C 1.536 0.436 0 C-N-CA 124.784 1.233 . . . . 0.0 113.34 177.197 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 7.9 mt -144.26 127.41 16.62 Favored 'General case' 0 C--O 1.237 0.437 0 O-C-N 121.09 -1.006 . . . . 0.0 109.743 175.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.4 mmpt? -116.3 164.83 13.93 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.657 1.218 . . . . 0.0 108.806 175.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 39.3 t -65.75 133.73 30.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 163.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 110.07 -17.32 29.6 Favored Glycine 0 C--N 1.339 0.704 0 C-N-CA 124.918 1.247 . . . . 0.0 110.307 -177.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -71.91 97.12 1.78 Allowed 'General case' 0 N--CA 1.451 -0.403 0 CA-C-O 122.667 1.222 . . . . 0.0 109.09 -175.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 49.6 mtt85 -55.17 148.36 14.44 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 126.013 1.725 . . . . 0.0 110.904 166.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 96.3 mt -122.71 148.1 26.62 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.846 0 C-N-CA 126.995 2.118 . . . . 0.0 106.788 -166.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 29.1 mt -126.44 -37.29 2.21 Favored 'General case' 0 N--CA 1.477 0.88 0 N-CA-C 114.43 1.27 . . . . 0.0 114.43 179.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -148.42 159.54 43.92 Favored 'General case' 0 N--CA 1.465 0.289 0 C-N-CA 124.454 1.101 . . . . 0.0 110.397 178.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 91.8 t -130.9 118.13 40.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 -175.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 81.1 m-20 63.03 -65.41 0.1 Allowed 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 128.513 2.725 . . . . 0.0 110.002 -165.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -158.97 -2.09 0.07 OUTLIER Glycine 0 CA--C 1.532 1.109 0 C-N-CA 125.914 1.721 . . . . 0.0 111.922 163.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.5 mm100 -74.59 124.54 26.86 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 119.935 1.867 . . . . 0.0 107.142 -175.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 59.4 p -68.2 103.74 1.64 Allowed 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.293 -1.002 . . . . 0.0 108.293 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.8 pp -74.23 9.9 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.656 0 C-N-CA 124.079 0.952 . . . . 0.0 112.698 -177.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 83.0 mt -46.61 -55.71 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.275 0 C-N-CA 128.99 2.916 . . . . 0.0 109.697 179.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -108.77 -30.64 8.06 Favored 'General case' 0 N--CA 1.461 0.089 0 C-N-CA 124.802 1.241 . . . . 0.0 110.951 -174.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.462 ' HB3' HD11 ' A' ' 84' ' ' ILE . 15.0 ttt -49.56 132.29 19.32 Favored Pre-proline 0 N--CA 1.443 -0.799 0 C-N-CA 127.252 2.221 . . . . 0.0 110.008 -170.495 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -73.18 144.03 36.68 Favored 'Trans proline' 0 N--CA 1.451 -1.017 0 C-N-CA 121.357 1.372 . . . . 0.0 108.754 -175.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 37.3 t60 -55.33 -35.86 65.63 Favored 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 123.768 0.827 . . . . 0.0 112.306 -170.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.56 -39.95 74.35 Favored 'General case' 0 C--O 1.234 0.269 0 CA-C-N 118.526 0.603 . . . . 0.0 112.18 174.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -69.24 -48.12 62.81 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 118.065 -0.969 . . . . 0.0 109.27 -176.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.462 HD11 ' HB3' ' A' ' 79' ' ' MET . 3.1 mp -51.86 -49.75 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 C-N-CA 125.554 1.542 . . . . 0.0 110.785 168.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 3.0 t -58.61 -44.87 90.5 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 O-C-N 121.362 -0.836 . . . . 0.0 109.768 -176.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 26.7 tttt -64.7 -43.35 93.76 Favored 'General case' 0 C--O 1.223 -0.314 0 CA-C-O 117.966 -1.016 . . . . 0.0 111.759 173.516 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -50.17 -42.71 51.55 Favored 'General case' 0 C--O 1.224 -0.285 0 C-N-CA 126.935 2.094 . . . . 0.0 112.03 178.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 86.5 mt -75.19 -46.32 39.32 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.107 0 N-CA-C 108.412 -0.958 . . . . 0.0 108.412 -177.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.7 tttt -60.18 -35.43 75.35 Favored 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 122.483 0.313 . . . . 0.0 111.149 179.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -83.81 -11.43 57.05 Favored 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 127.499 2.32 . . . . 0.0 112.633 179.26 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -63.84 -11.17 24.99 Favored 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 114.294 1.22 . . . . 0.0 114.294 -170.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.86 61.58 2.12 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 166.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 76.5 mt 69.09 -39.78 0.43 Allowed 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 128.966 2.906 . . . . 0.0 114.335 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.66 158.16 15.82 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 172.56 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.404 HG12 ' CE1' ' A' ' 24' ' ' PHE . 12.1 p -156.32 142.45 10.17 Favored 'Isoleucine or valine' 0 C--O 1.238 0.471 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 166.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.9 m -111.65 101.25 9.65 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 118.521 0.6 . . . . 0.0 111.119 -175.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 46.6 mt -90.44 108.57 19.87 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 125.039 1.336 . . . . 0.0 108.269 -178.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -76.5 122.76 25.02 Favored 'General case' 0 C--O 1.239 0.538 0 C-N-CA 124.074 0.949 . . . . 0.0 110.869 172.388 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.401 HG13 ' HB2' ' A' ' 12' ' ' SER . 2.7 pt -128.59 165.0 29.18 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 C-N-CA 124.27 1.028 . . . . 0.0 111.851 -177.061 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.423 ' HB ' ' HD3' ' A' ' 101' ' ' PRO . 72.6 mt -82.03 -54.21 0.65 Allowed Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 125.304 1.442 . . . . 0.0 109.678 170.586 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.423 ' HD3' ' HB ' ' A' ' 100' ' ' ILE . 20.9 Cg_endo -66.4 -171.49 0.25 Allowed 'Trans proline' 0 N--CA 1.456 -0.695 0 C-N-CA 122.308 2.005 . . . . 0.0 114.799 178.342 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -160.07 150.65 18.78 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 131.031 3.732 . . . . 0.0 103.681 172.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 4.2 pt-20 -103.8 -3.99 24.19 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 119.943 1.247 . . . . 0.0 111.304 174.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 -114.58 -2.64 13.07 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.511 1.525 . . . . 0.0 112.808 -163.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -79.99 176.76 9.45 Favored 'General case' 0 C--O 1.234 0.263 0 C-N-CA 125.306 1.442 . . . . 0.0 112.106 -173.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.8 m-20 -97.3 96.83 8.66 Favored 'General case' 0 C--O 1.232 0.166 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 -171.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 36.4 m -107.85 113.58 61.02 Favored Pre-proline 0 C--O 1.237 0.421 0 C-N-CA 123.737 0.815 . . . . 0.0 109.28 176.037 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -73.28 163.46 37.85 Favored 'Trans proline' 0 CA--C 1.535 0.571 0 C-N-CA 122.885 2.39 . . . . 0.0 109.896 175.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 20.8 m -53.68 -51.15 64.12 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 123.827 0.851 . . . . 0.0 112.746 -169.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 69.41 162.96 3.37 Favored Glycine 0 CA--C 1.539 1.535 0 C-N-CA 123.267 0.461 . . . . 0.0 112.401 -173.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -78.08 -19.65 12.04 Favored 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 123.334 2.689 . . . . 0.0 113.948 -179.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.2 t 34.61 64.99 0.37 Allowed 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 127.989 2.516 . . . . 0.0 114.76 174.196 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . 0.266 87.0 p 69.59 59.9 0.3 Allowed 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 127.555 2.342 . . . . 0.0 114.077 170.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.052 0 N-CA-C 108.786 -1.725 . . . . 0.0 108.786 166.262 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.561 0 N-CA-C 108.041 -2.024 . . . . 0.0 108.041 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.6 t -145.43 -157.11 0.76 Allowed 'General case' 0 C--O 1.237 0.418 0 N-CA-C 106.36 -1.718 . . . . 0.0 106.36 162.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 4.3 t -99.3 160.38 14.32 Favored 'General case' 0 C--O 1.236 0.389 0 C-N-CA 123.627 0.771 . . . . 0.0 110.548 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -82.32 122.4 5.72 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -175.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 1.3 p -56.31 146.33 24.26 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 126.094 1.757 . . . . 0.0 110.569 172.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.2 t -165.34 159.75 17.49 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 124.913 1.285 . . . . 0.0 108.277 175.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.3 9.06 0.08 OUTLIER Glycine 0 CA--C 1.53 0.982 0 CA-C-O 118.011 -1.438 . . . . 0.0 115.145 -177.499 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 46.3 m -83.76 -78.46 0.23 Allowed 'General case' 0 C--O 1.232 0.156 0 CA-C-N 120.453 2.127 . . . . 0.0 110.699 176.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 84.5 mt -71.15 148.77 47.05 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 118.023 0.374 . . . . 0.0 111.16 -161.154 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 5.1 mm-40 -55.86 147.51 19.07 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 124.216 1.006 . . . . 0.0 110.098 171.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 13.8 p -145.08 169.41 18.19 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 127.172 2.189 . . . . 0.0 107.264 177.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.1 m -114.32 164.86 13.35 Favored 'General case' 0 C--O 1.239 0.527 0 N-CA-C 106.113 -1.81 . . . . 0.0 106.113 157.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -103.2 153.73 20.06 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 106.426 -1.694 . . . . 0.0 106.426 143.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.658 HG11 ' HB2' ' A' ' 62' ' ' LEU . 62.8 t -129.09 142.0 45.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 103.025 -2.954 . . . . 0.0 103.025 161.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.1 t -123.85 132.44 71.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 168.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 65.4 mt -130.72 131.45 64.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 105.722 -1.955 . . . . 0.0 105.722 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 76.4 m-70 -117.35 146.87 43.1 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 125.576 1.55 . . . . 0.0 108.271 -176.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 50.0 ptt85 -141.57 177.15 8.34 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 120.178 1.354 . . . . 0.0 112.014 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.63 169.25 11.48 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 167.414 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -73.72 -28.69 61.84 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 119.951 -0.7 . . . . 0.0 111.908 173.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.1 m120 -61.16 -56.91 15.27 Favored 'General case' 0 CA--C 1.521 -0.17 0 C-N-CA 124.348 1.059 . . . . 0.0 110.256 -177.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -75.46 165.43 25.13 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 124.944 1.297 . . . . 0.0 109.216 178.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -102.02 176.89 26.17 Favored Glycine 0 CA--C 1.523 0.556 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 163.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -71.83 167.27 20.34 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 159.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.11 0.11 57.3 Favored Glycine 0 CA--C 1.525 0.715 0 CA-C-O 117.922 -1.488 . . . . 0.0 114.994 -167.337 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -112.18 130.41 55.92 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 120.029 1.915 . . . . 0.0 111.878 -153.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 74.9 t -100.96 135.06 38.94 Favored 'Isoleucine or valine' 0 C--O 1.234 0.273 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 171.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 23.6 mt -93.23 139.0 18.92 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.381 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 171.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 35.3 pt -132.3 179.32 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 C-N-CA 126.372 1.869 . . . . 0.0 108.29 168.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 66.04 101.46 0.04 OUTLIER 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 125.731 1.612 . . . . 0.0 108.935 -172.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.8 t -166.2 -72.13 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 107.081 -1.451 . . . . 0.0 107.081 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.6 tt -122.07 108.05 12.92 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 -176.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 14.9 t-20 -133.81 97.41 3.89 Favored 'General case' 0 CA--C 1.522 -0.115 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 176.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 29.5 mtm105 81.46 145.3 0.09 OUTLIER Pre-proline 0 N--CA 1.468 0.455 1 C-N-CA 131.873 4.069 . . . . 0.0 111.427 -170.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -77.18 25.28 0.47 Allowed 'Trans proline' 0 CA--C 1.54 0.815 0 C-N-CA 124.613 3.542 . . . . 0.0 111.349 171.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -130.49 105.74 8.06 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 105.469 -2.048 . . . . 0.0 105.469 -163.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.1 p -61.23 118.74 7.25 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 -177.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 126.46 73.45 0.2 Allowed Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 107.622 -2.191 . . . . 0.0 107.622 -172.083 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 19.8 m -125.68 147.19 49.43 Favored 'General case' 0 C--O 1.237 0.414 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 165.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.4 m -124.25 162.94 22.66 Favored 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 123.677 0.791 . . . . 0.0 109.555 -175.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.9 mp 53.17 57.54 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.358 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 -172.127 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 15.1 t -142.59 151.19 41.26 Favored 'General case' 0 N--CA 1.448 -0.572 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 175.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 7.5 p -127.97 155.35 77.84 Favored Pre-proline 0 C--N 1.324 -0.5 0 C-N-CA 127.637 2.375 . . . . 0.0 105.856 169.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -72.97 106.13 2.09 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 CA-C-N 121.757 1.663 . . . . 0.0 108.404 156.021 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 6.2 m80 80.44 107.38 0.07 Allowed 'General case' 0 C--O 1.234 0.267 0 C-N-CA 128.711 2.804 . . . . 0.0 112.138 172.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 55.5 pttt -133.2 161.15 35.21 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 123.824 0.849 . . . . 0.0 108.731 157.511 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 47.6 mm -66.25 135.43 28.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 168.087 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -102.9 -63.05 0.71 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 126.55 2.024 . . . . 0.0 111.223 175.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 8.4 ttm180 -131.14 155.11 47.55 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 125.447 1.499 . . . . 0.0 108.504 -175.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 32.5 mt -133.04 132.61 58.89 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 126.217 1.807 . . . . 0.0 107.117 174.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -55.86 114.18 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.776 1.631 . . . . 0.0 107.018 158.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -56.59 132.49 51.8 Favored 'General case' 0 C--O 1.236 0.383 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 174.216 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.78 -8.02 67.62 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 125.401 1.477 . . . . 0.0 114.977 175.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 36.2 p -59.91 169.6 1.47 Allowed Pre-proline 0 C--O 1.239 0.53 0 CA-C-N 118.407 1.104 . . . . 0.0 111.971 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -54.91 -31.78 75.05 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 121.242 1.295 . . . . 0.0 112.073 166.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.2 -68.83 0.24 Allowed 'General case' 0 C--N 1.345 0.404 0 C-N-CA 123.793 0.837 . . . . 0.0 110.089 169.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -51.39 -55.23 19.69 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 118.608 0.64 . . . . 0.0 112.559 -171.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 16.3 mmt180 -70.11 -7.79 44.3 Favored 'General case' 0 C--O 1.235 0.293 0 C-N-CA 123.349 0.659 . . . . 0.0 111.908 -175.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 10.5 t -62.66 -36.96 84.52 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 119.413 1.006 . . . . 0.0 109.202 166.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 57.69 -22.21 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.42 0 C-N-CA 129.473 3.109 . . . . 0.0 115.789 -177.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 1.5 mmpp? -68.73 -4.6 16.45 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 127.94 2.496 . . . . 0.0 113.389 174.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.658 ' HB2' HG11 ' A' ' 14' ' ' VAL . 0.0 OUTLIER -147.08 113.13 5.81 Favored 'General case' 0 C--O 1.237 0.421 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 -173.203 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 25.6 mttt -130.66 170.74 13.91 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 122.008 0.908 . . . . 0.0 112.613 -170.527 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.8 t -60.99 109.85 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.25 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 174.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 131.81 -17.16 4.97 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -70.52 106.45 3.46 Favored 'General case' 0 N--CA 1.45 -0.428 0 CA-C-N 118.525 1.163 . . . . 0.0 111.397 -178.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 52.8 mtm-85 -57.5 144.73 35.75 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 127.23 2.212 . . . . 0.0 110.056 161.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 5.4 mt -131.29 149.14 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 C-N-CA 123.295 0.638 . . . . 0.0 109.428 -168.424 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.48 -41.23 2.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.789 1.636 . . . . 0.0 112.663 -171.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -160.91 168.2 25.1 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 123.316 0.647 . . . . 0.0 111.743 -178.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.6 p -140.21 127.51 23.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 123.532 0.733 . . . . 0.0 110.09 -176.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 9.1 m-80 40.01 48.24 2.1 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 125.732 1.613 . . . . 0.0 109.774 -158.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 63.21 11.67 40.61 Favored Glycine 0 CA--C 1.528 0.869 0 CA-C-O 116.843 -2.087 . . . . 0.0 114.714 -178.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -104.84 153.97 20.65 Favored 'General case' 0 CA--C 1.515 -0.388 0 CA-C-N 120.684 2.242 . . . . 0.0 111.844 178.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.2 p -62.41 147.64 47.93 Favored 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -171.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 8.5 pt -131.52 -7.13 2.0 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.831 0 O-C-N 123.602 0.564 . . . . 0.0 112.05 167.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 12.1 mm -79.71 -45.84 22.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 O-C-N 120.569 -1.332 . . . . 0.0 109.628 176.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 13.5 m120 -88.48 -29.47 20.11 Favored 'General case' 0 N--CA 1.465 0.297 0 O-C-N 121.635 -0.666 . . . . 0.0 112.751 -178.252 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.6 mtp -70.61 152.33 95.32 Favored Pre-proline 0 CA--C 1.534 0.352 0 CA-C-N 118.906 0.775 . . . . 0.0 110.984 -177.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 82.3 Cg_endo -73.64 153.23 48.89 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 122.57 2.18 . . . . 0.0 109.55 171.529 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.9 t-80 -62.49 -37.87 87.68 Favored 'General case' 0 CA--C 1.53 0.187 0 O-C-N 121.516 -0.74 . . . . 0.0 112.724 -167.652 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -69.83 -28.2 65.49 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 119.079 0.854 . . . . 0.0 111.611 -176.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -68.47 -45.06 73.44 Favored 'General case' 0 N--CA 1.46 0.072 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 176.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.7 mt -64.4 -38.38 82.42 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.589 0 C-N-CA 125.299 1.44 . . . . 0.0 109.569 176.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 37.9 t -61.7 -47.6 92.55 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 O-C-N 120.22 -1.55 . . . . 0.0 109.093 172.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 4.2 tmtt? -63.59 -37.42 87.25 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.016 -177.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.46 -43.93 75.91 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 125.471 1.508 . . . . 0.0 111.446 173.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 60.0 mt -68.56 -43.36 83.62 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.311 0 CA-C-N 119.542 1.065 . . . . 0.0 109.287 177.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 21.1 tttm -64.29 -38.64 91.78 Favored 'General case' 0 CA--C 1.53 0.178 0 O-C-N 121.671 -0.643 . . . . 0.0 110.546 -178.293 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -86.02 -3.44 58.94 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 126.924 2.09 . . . . 0.0 112.051 179.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -54.89 -26.07 33.23 Favored 'General case' 0 C--N 1.345 0.413 0 N-CA-C 113.817 1.043 . . . . 0.0 113.817 -166.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 101.51 36.02 3.93 Favored Glycine 0 C--N 1.335 0.479 0 N-CA-C 111.266 -0.733 . . . . 0.0 111.266 173.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 44.9 mt 69.29 -30.82 0.2 Allowed 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 128.596 2.759 . . . . 0.0 113.041 -175.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 m -92.66 148.12 22.32 Favored 'General case' 0 N--CA 1.438 -1.073 0 N-CA-C 106.395 -1.706 . . . . 0.0 106.395 167.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.3 p -139.97 124.42 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.002 0 N-CA-C 106.784 -1.561 . . . . 0.0 106.784 169.224 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 20.9 m -99.04 123.77 43.58 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 106.697 -1.594 . . . . 0.0 106.697 177.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 21.9 mt -120.01 122.3 40.85 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 124.286 1.034 . . . . 0.0 109.835 -172.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 45.9 ttp180 -85.67 111.94 20.55 Favored 'General case' 0 C--O 1.234 0.27 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 173.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pp -118.78 167.17 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 C-N-CA 125.776 1.63 . . . . 0.0 108.76 175.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 7.6 mt -100.8 119.96 56.96 Favored Pre-proline 0 N--CA 1.468 0.436 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 169.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -86.2 -175.58 1.83 Allowed 'Trans proline' 0 N--CA 1.449 -1.092 0 C-N-CA 124.266 3.311 . . . . 0.0 110.137 174.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . 0.437 ' HG3' HD23 ' A' ' 105' ' ' LEU . 0.1 OUTLIER -144.29 171.98 13.56 Favored 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 123.83 0.852 . . . . 0.0 109.43 177.634 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -130.02 -2.8 4.58 Favored 'General case' 0 N--CA 1.463 0.221 0 C-N-CA 123.895 0.878 . . . . 0.0 112.885 170.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -108.62 -6.65 15.91 Favored 'General case' 0 N--CA 1.464 0.252 0 C-N-CA 123.895 0.878 . . . . 0.0 113.125 -164.293 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.437 HD23 ' HG3' ' A' ' 102' ' ' GLN . 0.4 OUTLIER -70.8 102.48 2.35 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 125.531 1.532 . . . . 0.0 112.007 -163.719 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 22.5 t-20 -156.54 102.5 2.07 Favored 'General case' 0 N--CA 1.452 -0.345 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 3.3 m -156.89 159.42 31.29 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 118.804 0.729 . . . . 0.0 110.473 178.7 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -71.78 178.94 5.21 Favored 'Trans proline' 0 N--CA 1.458 -0.56 0 C-N-CA 123.904 3.069 . . . . 0.0 111.385 173.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 14.4 m -126.68 41.36 3.54 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 124.691 1.196 . . . . 0.0 111.26 -164.151 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -73.49 -141.84 0.56 Allowed Glycine 0 CA--C 1.536 1.406 0 C-N-CA 125.392 1.472 . . . . 0.0 112.712 -177.806 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -57.06 143.05 94.06 Favored 'Trans proline' 0 N--CA 1.457 -0.646 0 C-N-CA 122.956 2.437 . . . . 0.0 112.446 -163.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.76 148.34 17.48 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 114.654 -1.157 . . . . 0.0 110.344 -156.357 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.3 m -145.61 -115.39 0.09 Allowed 'General case' 0 C--O 1.236 0.349 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 171.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.929 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 176.855 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.899 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.8 m 47.95 65.67 1.24 Allowed 'General case' 0 CA--C 1.538 0.488 0 C-N-CA 126.143 1.777 . . . . 0.0 113.644 168.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.5 p -79.55 -31.39 41.99 Favored 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 123.976 0.91 . . . . 0.0 112.212 174.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 50.33 -114.49 2.6 Favored Glycine 0 C--N 1.338 0.666 0 C-N-CA 126.116 1.817 . . . . 0.0 111.812 177.206 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 40.0 m -115.09 83.9 1.99 Allowed 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 124.977 1.311 . . . . 0.0 109.079 -175.319 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 1.3 m 47.47 49.2 16.15 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 126.688 1.995 . . . . 0.0 115.512 157.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -173.62 48.39 0.15 Allowed Glycine 0 C--N 1.336 0.546 0 N-CA-C 108.651 -1.78 . . . . 0.0 108.651 -172.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.9 m -54.77 -34.23 62.32 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 124.846 1.258 . . . . 0.0 114.191 -154.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.3 tp -147.16 85.58 1.61 Allowed 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 174.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 35.0 mm-40 53.75 -169.38 0.06 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 124.996 1.319 . . . . 0.0 112.624 -175.146 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 59.2 p -130.59 169.65 15.31 Favored 'General case' 0 C--O 1.237 0.416 0 C-N-CA 125.255 1.422 . . . . 0.0 108.204 164.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 13.7 m -120.2 147.17 45.26 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.511 1.125 . . . . 0.0 108.481 163.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -74.37 155.45 38.13 Favored 'General case' 0 C--N 1.323 -0.569 0 C-N-CA 125.3 1.44 . . . . 0.0 108.128 152.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 t -137.57 121.16 21.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 105.088 -2.19 . . . . 0.0 105.088 163.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . 0.404 HG22 HG23 ' A' ' 96' ' ' THR . 13.8 t -120.04 97.29 5.0 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -173.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 43.1 mt -99.28 126.32 52.61 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.371 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -174.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 88.5 m-70 -103.9 149.62 24.93 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 107.653 -1.239 . . . . 0.0 107.653 177.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -143.21 -175.54 4.57 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 120.706 1.594 . . . . 0.0 109.899 175.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.525 ' N ' ' HE3' ' A' ' 19' ' ' LYS . 0.1 OUTLIER -92.64 163.71 13.68 Favored 'General case' 0 C--O 1.238 0.449 0 N-CA-C 107.441 -1.318 . . . . 0.0 107.441 169.001 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -68.25 -36.62 79.74 Favored 'General case' 0 N--CA 1.465 0.317 0 O-C-N 121.425 -0.797 . . . . 0.0 110.82 173.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -75.96 -4.52 41.56 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 124.418 1.087 . . . . 0.0 112.499 -166.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -123.41 179.33 4.77 Favored 'General case' 0 C--O 1.238 0.45 0 C-N-CA 126.872 2.069 . . . . 0.0 108.376 -178.731 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -108.93 178.71 20.94 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 162.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -72.95 -175.43 1.76 Allowed 'General case' 0 N--CA 1.449 -0.483 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 164.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -138.81 60.54 0.58 Allowed Glycine 0 C--O 1.223 -0.583 0 CA-C-O 118.774 -1.015 . . . . 0.0 112.582 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.477 ' CE2' HD11 ' A' ' 28' ' ' ILE . 32.8 p90 -140.18 158.16 44.47 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-N 118.694 1.247 . . . . 0.0 110.651 175.847 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.9 t -143.45 140.54 26.21 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.27 0 N-CA-C 105.947 -1.872 . . . . 0.0 105.947 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.477 HD11 ' CE2' ' A' ' 26' ' ' PHE . 1.9 mp -130.47 129.26 64.52 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.452 0 C-N-CA 124.928 1.291 . . . . 0.0 107.566 -169.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.424 HD11 ' HE3' ' A' ' 46' ' ' LYS . 47.7 pt -126.44 159.61 35.32 Favored 'Isoleucine or valine' 0 C--O 1.239 0.546 0 C-N-CA 124.32 1.048 . . . . 0.0 110.142 -166.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 29.2 t -128.08 118.17 22.98 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 126.16 1.784 . . . . 0.0 109.275 -173.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 57.7 m -126.79 68.05 1.25 Allowed 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.825 1.65 . . . . 0.0 107.016 170.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -154.11 117.04 4.46 Favored 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 166.383 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 -151.01 168.01 25.9 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 162.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 69.2 mtt180 56.32 161.09 0.07 OUTLIER Pre-proline 0 CA--C 1.533 0.301 0 C-N-CA 128.699 2.8 . . . . 0.0 113.472 -166.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -81.56 107.11 1.76 Allowed 'Trans proline' 0 N--CA 1.448 -1.193 0 C-N-CA 123.075 2.517 . . . . 0.0 109.713 172.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -78.88 105.1 9.97 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 106.079 -1.823 . . . . 0.0 106.079 156.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 67.7 m 16.33 77.01 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 128.95 2.9 . . . . 0.0 115.06 179.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.14 -150.6 18.16 Favored Glycine 0 N--CA 1.45 -0.429 0 C-N-CA 124.663 1.125 . . . . 0.0 111.052 177.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -112.8 113.68 25.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 104.979 -2.23 . . . . 0.0 104.979 166.156 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 25.5 p -79.81 143.68 34.18 Favored 'General case' 0 N--CA 1.452 -0.367 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 -179.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.503 ' H ' HD12 ' A' ' 41' ' ' ILE . 0.9 OUTLIER -77.85 20.91 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 C-N-CA 126.082 1.753 . . . . 0.0 111.167 -177.168 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 1.6 p -59.19 171.25 0.77 Allowed 'General case' 0 N--CA 1.447 -0.608 0 C-N-CA 127.354 2.262 . . . . 0.0 111.105 173.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 48.1 t -118.13 138.34 25.44 Favored Pre-proline 0 CA--C 1.532 0.283 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 -178.196 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -79.82 -16.44 11.48 Favored 'Trans proline' 0 CA--C 1.531 0.373 0 C-N-CA 122.767 2.311 . . . . 0.0 112.628 -175.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -139.7 115.14 9.91 Favored 'General case' 0 N--CA 1.442 -0.826 0 C-N-CA 125.259 1.423 . . . . 0.0 107.641 -166.654 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.424 ' HE3' HD11 ' A' ' 29' ' ' ILE . 52.1 pttt -127.91 144.09 51.1 Favored 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 167.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.3 mm -55.38 120.98 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 107.02 -1.474 . . . . 0.0 107.02 165.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -87.15 -42.59 6.21 Favored Glycine 0 CA--C 1.522 0.494 0 C-N-CA 125.212 1.387 . . . . 0.0 110.85 175.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.6 ttt-85 -148.05 156.36 42.54 Favored 'General case' 0 C--O 1.233 0.225 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 172.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 3.5 mt -121.67 139.6 48.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 164.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 44.1 mm -67.56 118.48 11.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 106.124 -1.806 . . . . 0.0 106.124 173.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -53.55 124.4 14.85 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 124.199 1.0 . . . . 0.0 108.448 173.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.94 -0.88 84.68 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 114.535 0.574 . . . . 0.0 114.535 176.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 57.8 p -69.23 169.52 11.58 Favored Pre-proline 0 C--O 1.235 0.336 0 CA-C-N 118.855 1.327 . . . . 0.0 112.019 175.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -57.37 -28.04 78.4 Favored 'Trans proline' 0 N--CA 1.449 -1.128 0 C-N-CA 121.21 1.273 . . . . 0.0 112.809 161.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.04 -54.26 19.64 Favored 'General case' 0 C--N 1.346 0.434 0 CA-C-N 119.967 1.258 . . . . 0.0 110.235 176.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -52.31 -55.07 23.85 Favored 'General case' 0 N--CA 1.466 0.346 0 C-N-CA 124.918 1.287 . . . . 0.0 110.838 178.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 87.9 mtt180 -69.86 -7.35 39.39 Favored 'General case' 0 C--N 1.333 -0.129 0 C-N-CA 123.558 0.743 . . . . 0.0 112.622 -175.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 8.9 t -71.24 -31.18 67.23 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 119.586 1.085 . . . . 0.0 110.569 168.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.97 -29.95 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 129.979 3.312 . . . . 0.0 116.364 -174.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 5.3 mtpt -69.86 -9.06 53.45 Favored 'General case' 0 C--N 1.331 -0.233 0 C-N-CA 126.056 1.742 . . . . 0.0 112.32 169.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -106.46 132.31 52.63 Favored 'General case' 0 C--O 1.237 0.424 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 158.158 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 15.6 ptpt -139.56 169.07 18.42 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 124.387 1.075 . . . . 0.0 110.757 169.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 61.7 t -59.21 138.73 19.87 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 174.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 83.35 4.33 89.53 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 115.889 1.116 . . . . 0.0 115.889 174.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -60.89 -6.85 2.0 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 118.528 2.788 . . . . 0.0 118.528 -164.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 84.5 mtm180 49.38 105.59 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 128.658 2.783 . . . . 0.0 114.587 -165.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 57.7 mt -96.79 129.39 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 C-N-CA 123.653 0.781 . . . . 0.0 109.241 -179.198 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 69' ' ' LEU . 2.0 mm? -104.41 -23.88 13.12 Favored 'General case' 0 C--O 1.236 0.365 0 C-N-CA 124.366 1.066 . . . . 0.0 113.601 176.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -155.58 164.75 38.22 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 118.505 0.593 . . . . 0.0 111.258 -179.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.38 121.19 45.2 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 C-N-CA 126.405 1.882 . . . . 0.0 107.0 178.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 52.59 26.87 4.63 Favored 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 113.627 0.973 . . . . 0.0 113.627 176.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 90.76 -2.77 80.56 Favored Glycine 0 CA--C 1.535 1.326 0 C-N-CA 125.581 1.562 . . . . 0.0 114.514 -177.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 6.2 mm-40 -94.37 128.91 41.19 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 119.751 1.775 . . . . 0.0 108.638 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.07 116.84 4.84 Favored 'General case' 0 N--CA 1.454 -0.239 0 C-N-CA 123.267 0.627 . . . . 0.0 109.479 171.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.7 pp -80.99 11.64 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.577 0 C-N-CA 124.149 0.979 . . . . 0.0 113.203 178.069 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 79.5 mt -61.04 -70.36 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.106 0 C-N-CA 124.961 1.304 . . . . 0.0 109.382 -175.005 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.7 t-20 -94.69 -24.66 17.05 Favored 'General case' 0 N--CA 1.454 -0.241 0 C-N-CA 120.432 -0.507 . . . . 0.0 111.785 -172.325 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.2 mtp -48.6 134.59 13.47 Favored Pre-proline 0 CA--C 1.536 0.442 0 C-N-CA 125.154 1.382 . . . . 0.0 110.512 176.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -69.25 157.37 61.64 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 122.356 2.038 . . . . 0.0 109.478 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 16.0 m-70 -56.06 -32.96 64.56 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 119.302 -0.38 . . . . 0.0 110.847 174.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.9 -44.1 97.5 Favored 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 117.878 -1.058 . . . . 0.0 112.177 178.027 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -64.65 -45.98 84.47 Favored 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 66.3 mt -61.75 -40.46 86.96 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 C-N-CA 123.814 0.846 . . . . 0.0 110.527 -177.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 24.8 t -60.22 -50.25 80.98 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.132 0 O-C-N 121.209 -0.932 . . . . 0.0 109.32 171.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 4.2 mttm -63.2 -34.05 76.8 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 117.479 -1.248 . . . . 0.0 112.746 -177.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -63.78 -41.51 97.94 Favored 'General case' 0 N--CA 1.442 -0.832 0 C-N-CA 128.07 2.548 . . . . 0.0 110.645 174.226 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 54.4 mt -67.16 -45.61 86.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 O-C-N 120.774 -1.204 . . . . 0.0 108.875 177.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 4.6 tttt -61.77 -38.98 90.03 Favored 'General case' 0 CA--C 1.53 0.182 0 C-N-CA 123.077 0.551 . . . . 0.0 109.597 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -61.65 -43.08 99.53 Favored 'General case' 0 CA--C 1.517 -0.323 0 C-N-CA 125.058 1.343 . . . . 0.0 110.381 175.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -56.01 -34.56 65.92 Favored 'General case' 0 CA--C 1.537 0.473 0 O-C-N 123.339 0.399 . . . . 0.0 110.63 -175.498 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.03 -116.22 5.46 Favored Glycine 0 N--CA 1.447 -0.57 0 C-N-CA 124.896 1.236 . . . . 0.0 110.885 157.449 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 8.2 mt -83.53 -20.12 34.44 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-N 117.126 0.463 . . . . 0.0 109.753 167.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 p -94.53 156.32 16.51 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 173.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.8 p -157.39 124.84 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.258 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 160.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . 0.404 HG23 HG22 ' A' ' 15' ' ' VAL . 56.3 m -109.53 101.86 10.77 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.612 1.565 . . . . 0.0 107.514 -172.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 81.8 mt -90.92 165.17 13.73 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 125.014 1.326 . . . . 0.0 110.369 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 26.6 ttm180 -120.57 127.99 52.65 Favored 'General case' 0 CA--C 1.518 -0.282 0 N-CA-C 107.837 -1.171 . . . . 0.0 107.837 162.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.408 HD12 ' C ' ' A' ' 100' ' ' ILE . 1.7 pp -128.83 178.64 4.77 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 C-N-CA 125.318 1.447 . . . . 0.0 109.29 173.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.408 ' C ' HD12 ' A' ' 99' ' ' ILE . 75.8 mt -115.68 125.32 28.85 Favored Pre-proline 0 N--CA 1.469 0.512 0 CA-C-N 119.334 0.97 . . . . 0.0 109.349 167.578 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -78.64 167.38 22.64 Favored 'Trans proline' 0 N--CA 1.453 -0.886 0 C-N-CA 122.3 2.0 . . . . 0.0 111.252 176.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 4.2 pt20 -149.52 151.36 33.78 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.466 -0.938 . . . . 0.0 108.466 -177.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -146.62 1.6 0.81 Allowed 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 123.763 0.825 . . . . 0.0 112.24 177.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 16.9 tt0 -126.07 1.29 7.22 Favored 'General case' 0 CA--C 1.541 0.634 0 C-N-CA 126.398 1.879 . . . . 0.0 110.649 -178.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 12.7 mt -104.63 102.05 11.67 Favored 'General case' 0 CA--C 1.515 -0.382 0 C-N-CA 125.782 1.633 . . . . 0.0 106.99 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 6.3 p-10 -139.13 167.57 21.76 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 126.522 1.929 . . . . 0.0 107.42 174.276 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 3.3 p -147.35 78.53 10.14 Favored Pre-proline 0 CA--C 1.536 0.415 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -163.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -66.95 -57.89 0.17 Allowed 'Trans proline' 0 N--CA 1.453 -0.868 0 C-N-CA 123.486 2.791 . . . . 0.0 109.818 -176.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 13.7 m -147.93 -100.78 0.08 Allowed 'General case' 0 CA--C 1.536 0.438 0 C-N-CA 125.403 1.481 . . . . 0.0 108.25 167.766 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 161.77 -178.38 37.66 Favored Glycine 0 CA--C 1.529 0.931 0 CA-C-N 119.683 1.129 . . . . 0.0 111.14 -174.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 67.2 Cg_endo -72.83 102.02 1.38 Allowed 'Trans proline' 0 N--CA 1.457 -0.629 0 C-N-CA 124.438 3.426 . . . . 0.0 109.822 174.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -68.23 91.74 0.38 Allowed 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 125.224 1.41 . . . . 0.0 111.279 -178.233 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 22.3 t -72.72 136.82 45.62 Favored 'General case' 0 C--O 1.236 0.374 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 164.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.989 0 CA-C-O 117.66 -1.633 . . . . 0.0 109.814 -178.864 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.325 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.2 m 65.83 97.29 0.05 OUTLIER 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 125.796 1.638 . . . . 0.0 112.361 169.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 66.4 m -76.43 169.03 19.0 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.883 0.873 . . . . 0.0 111.206 178.174 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 67.14 -179.82 13.59 Favored Glycine 0 CA--C 1.53 1.0 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -172.17 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.5 m 58.05 171.21 0.05 Allowed 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 124.991 1.316 . . . . 0.0 113.995 -175.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 32.9 t -162.05 173.15 14.79 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 126.883 2.073 . . . . 0.0 106.725 159.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 140.12 -39.49 1.49 Allowed Glycine 0 CA--C 1.523 0.566 0 C-N-CA 126.134 1.826 . . . . 0.0 109.832 172.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 17.3 m -75.4 85.86 2.54 Favored 'General case' 0 N--CA 1.448 -0.573 0 O-C-N 122.127 -0.631 . . . . 0.0 110.015 164.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 39.8 mt -130.18 80.9 1.98 Allowed 'General case' 0 CA--C 1.52 -0.187 0 C-N-CA 125.126 1.37 . . . . 0.0 108.695 173.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 4.6 tt0 60.93 172.17 0.1 Allowed 'General case' 0 C--O 1.236 0.352 0 C-N-CA 126.591 1.956 . . . . 0.0 112.714 178.594 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 24.8 p -116.07 161.84 18.3 Favored 'General case' 0 N--CA 1.445 -0.686 0 C-N-CA 123.884 0.874 . . . . 0.0 108.984 -169.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 58.3 m -121.24 146.84 46.39 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 105.406 -2.072 . . . . 0.0 105.406 174.008 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -120.85 131.75 54.59 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 -175.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 24.0 t -129.29 94.86 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 104.431 -2.433 . . . . 0.0 104.431 -172.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.5 p -94.83 104.22 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 36.6 mt -101.84 133.89 43.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 105.307 -2.109 . . . . 0.0 105.307 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 51.8 m-70 -111.53 149.19 31.74 Favored 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 124.924 1.29 . . . . 0.0 108.415 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 30.4 ptt180 -138.86 -177.35 4.84 Favored 'General case' 0 N--CA 1.468 0.469 0 O-C-N 120.84 -1.162 . . . . 0.0 110.485 177.272 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.26 153.17 18.17 Favored 'General case' 0 N--CA 1.451 -0.424 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 168.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -61.55 -32.61 72.69 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 121.294 0.568 . . . . 0.0 111.217 -171.035 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -89.13 3.41 51.94 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 124.744 1.218 . . . . 0.0 112.979 -163.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 25.4 pt-20 -139.78 177.74 7.74 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 119.534 1.061 . . . . 0.0 111.187 -170.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.04 163.66 31.91 Favored Glycine 0 CA--C 1.525 0.718 0 O-C-N 121.634 -0.666 . . . . 0.0 111.653 177.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -75.67 161.2 29.3 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 106.323 -1.732 . . . . 0.0 106.323 154.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.56 58.19 0.73 Allowed Glycine 0 C--O 1.218 -0.852 0 CA-C-O 117.432 -1.76 . . . . 0.0 111.351 178.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.421 ' CZ ' HD11 ' A' ' 97' ' ' LEU . 28.7 p90 -142.91 141.53 31.52 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-N 120.326 2.063 . . . . 0.0 110.586 169.862 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.0 t -105.22 135.7 42.17 Favored 'Isoleucine or valine' 0 C--O 1.234 0.266 0 N-CA-C 106.95 -1.5 . . . . 0.0 106.95 170.415 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 25.6 mt -96.63 130.74 44.83 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 162.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 28.3 pt -122.53 178.69 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.603 0 C-N-CA 126.585 1.954 . . . . 0.0 108.71 175.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 22.5 p -121.12 170.02 9.96 Favored 'General case' 0 C--O 1.237 0.41 0 C-N-CA 126.197 1.799 . . . . 0.0 109.434 170.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 66.4 m -121.19 -173.08 2.53 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 126.172 1.789 . . . . 0.0 107.597 160.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 7.9 mp -63.71 128.36 35.46 Favored 'General case' 0 C--O 1.236 0.384 0 O-C-N 121.541 -0.724 . . . . 0.0 109.555 177.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -66.52 171.37 5.08 Favored 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 125.366 1.466 . . . . 0.0 110.296 170.028 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . 0.537 ' H ' HG21 ' A' ' 42' ' ' THR . 0.6 OUTLIER -133.22 148.11 67.81 Favored Pre-proline 0 C--O 1.238 0.449 0 C-N-CA 124.606 1.162 . . . . 0.0 108.038 173.137 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -81.03 80.95 2.86 Favored 'Trans proline' 0 N--CA 1.45 -1.03 0 C-N-CA 123.928 3.086 . . . . 0.0 108.298 175.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 34.3 mm-40 -136.16 160.58 38.24 Favored 'General case' 0 C--O 1.237 0.402 0 C-N-CA 126.768 2.027 . . . . 0.0 106.796 176.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 12.0 p -144.04 170.04 16.69 Favored 'General case' 0 C--O 1.237 0.397 0 C-N-CA 123.356 0.662 . . . . 0.0 110.674 -175.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.19 -80.47 0.85 Allowed Glycine 0 C--N 1.335 0.491 0 C-N-CA 124.21 0.91 . . . . 0.0 110.96 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.5 m -65.88 164.18 15.46 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 122.117 0.96 . . . . 0.0 110.544 170.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 12.8 p -123.37 102.34 7.85 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 106.546 -1.649 . . . . 0.0 106.546 -176.537 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 41.5 mm -108.73 -63.3 1.91 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 C-N-CA 124.933 1.293 . . . . 0.0 107.917 -169.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.537 HG21 ' H ' ' A' ' 34' ' ' ARG . 2.7 t -75.03 96.21 3.16 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -177.167 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 12.6 p -65.6 123.66 85.18 Favored Pre-proline 0 CA--C 1.539 0.528 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -74.72 -65.72 0.03 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 121.851 1.701 . . . . 0.0 109.838 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.5 m80 -77.23 103.18 7.01 Favored 'General case' 0 N--CA 1.447 -0.589 0 C-N-CA 125.632 1.573 . . . . 0.0 109.614 -172.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.7 ptmt -130.55 153.17 49.14 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 171.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.436 HG13 HD22 ' A' ' 62' ' ' LEU . 39.7 mm -68.54 143.82 14.82 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 175.375 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.89 -59.46 0.53 Allowed Glycine 0 CA--C 1.529 0.926 0 C-N-CA 125.596 1.57 . . . . 0.0 112.508 175.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 37.4 ttm180 -140.05 144.58 36.94 Favored 'General case' 0 C--O 1.235 0.339 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 21.2 mt -122.66 125.43 72.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 105.821 -1.918 . . . . 0.0 105.821 175.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.8 mp -51.73 131.07 12.85 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 CA-C-N 119.23 0.923 . . . . 0.0 108.612 172.506 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -61.6 123.27 17.43 Favored 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 125.553 1.541 . . . . 0.0 108.868 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.28 9.88 84.31 Favored Glycine 0 CA--C 1.535 1.329 0 C-N-CA 123.947 0.784 . . . . 0.0 114.903 -179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 37.9 p -66.36 171.76 3.8 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 119.662 1.731 . . . . 0.0 112.458 179.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -56.85 -36.83 99.07 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 121.783 1.655 . . . . 0.0 112.296 166.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.72 -48.95 75.01 Favored 'General case' 0 C--N 1.34 0.177 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 178.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.0 t70 -60.34 -52.95 63.09 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 123.44 0.696 . . . . 0.0 111.594 176.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -60.94 -18.59 57.88 Favored 'General case' 0 N--CA 1.463 0.188 0 C-N-CA 124.078 0.951 . . . . 0.0 112.31 -176.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 11.5 t -59.36 -26.25 64.91 Favored 'General case' 0 CA--C 1.54 0.579 0 CA-C-O 117.819 -1.086 . . . . 0.0 111.257 175.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.15 31.49 18.38 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.913 2.085 . . . . 0.0 112.962 -179.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 40.3 mtmt -132.47 -34.11 1.22 Allowed 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 123.889 0.875 . . . . 0.0 111.977 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.444 HD23 ' HA ' ' A' ' 62' ' ' LEU . 0.3 OUTLIER -93.85 126.46 39.06 Favored 'General case' 0 C--O 1.236 0.358 0 N-CA-C 107.046 -1.465 . . . . 0.0 107.046 177.509 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 2.6 ptpp? -117.82 171.58 7.96 Favored 'General case' 0 C--N 1.33 -0.273 0 C-N-CA 125.2 1.4 . . . . 0.0 109.139 170.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 82.2 t -66.09 141.66 17.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 O-C-N 120.965 -1.084 . . . . 0.0 108.565 174.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 89.47 -5.02 84.17 Favored Glycine 0 CA--C 1.532 1.095 0 CA-C-O 117.022 -1.988 . . . . 0.0 114.904 176.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -62.9 11.68 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 120.229 3.418 . . . . 0.0 120.229 -150.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.1 mtp180 41.82 86.71 0.02 OUTLIER 'General case' 0 C--O 1.235 0.3 0 C-N-CA 127.178 2.191 . . . . 0.0 113.103 -171.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 44.1 mt -65.32 148.85 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 106.341 -1.725 . . . . 0.0 106.341 170.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.48 HD22 HD11 ' A' ' 100' ' ' ILE . 1.8 tp -118.86 -47.15 2.52 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 125.828 1.651 . . . . 0.0 108.764 177.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -148.54 166.95 26.69 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 125.268 1.427 . . . . 0.0 111.352 -177.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 4.9 p -134.72 124.36 43.89 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.468 0 C-N-CA 125.493 1.517 . . . . 0.0 107.933 175.012 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 49.71 38.59 15.72 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.138 0.975 . . . . 0.0 110.009 -178.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 79.21 -10.27 35.88 Favored Glycine 0 CA--C 1.532 1.115 0 CA-C-O 117.822 -1.543 . . . . 0.0 115.415 -176.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 14.9 mm100 -79.66 122.87 27.08 Favored 'General case' 0 CA--C 1.513 -0.479 0 CA-C-N 121.491 2.646 . . . . 0.0 107.747 -178.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 55.7 m -61.36 110.12 1.34 Allowed 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 167.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.5 pp -80.14 11.49 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.65 0 C-N-CA 124.604 1.162 . . . . 0.0 112.322 -174.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 25.3 mm -63.01 -77.34 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 C-N-CA 125.24 1.416 . . . . 0.0 108.418 175.268 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 21.8 m-80 -79.7 -26.92 40.76 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.179 -164.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . 0.512 ' CE ' HD13 ' A' ' 87' ' ' LEU . 1.4 mtp -58.29 133.81 84.79 Favored Pre-proline 0 CA--C 1.538 0.488 0 C-N-CA 123.815 0.846 . . . . 0.0 109.513 174.347 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 70.7 Cg_endo -70.61 155.11 63.8 Favored 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 121.989 1.793 . . . . 0.0 110.665 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.4 t-80 -57.09 -39.21 74.56 Favored 'General case' 0 CA--C 1.53 0.197 0 C-N-CA 123.365 0.666 . . . . 0.0 111.938 -174.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -60.38 -42.43 95.86 Favored 'General case' 0 C--N 1.338 0.097 0 CA-C-O 118.421 -0.8 . . . . 0.0 111.368 178.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.404 ' O ' HD12 ' A' ' 87' ' ' LEU . 1.4 m-20 -62.62 -46.27 89.05 Favored 'General case' 0 C--O 1.218 -0.58 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 177.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.45 ' HA ' ' HB2' ' A' ' 87' ' ' LEU . 29.4 mt -67.71 -33.92 64.74 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 O-C-N 121.212 -0.93 . . . . 0.0 109.925 -175.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 9.0 t -61.79 -44.47 98.84 Favored 'Isoleucine or valine' 0 C--O 1.237 0.442 0 O-C-N 120.83 -1.169 . . . . 0.0 108.669 171.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 7.0 mmtt -52.45 -53.19 48.74 Favored 'General case' 0 C--O 1.22 -0.462 0 CA-C-O 116.568 -1.682 . . . . 0.0 109.481 166.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.512 HD13 ' CE ' ' A' ' 79' ' ' MET . 0.9 OUTLIER -57.7 -28.34 63.74 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 122.472 2.396 . . . . 0.0 114.514 -174.761 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 66.7 mt -77.44 -48.71 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 176.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 13.6 ttpt -63.36 -37.27 86.64 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 118.164 0.438 . . . . 0.0 110.847 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.03 -10.65 59.67 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 126.98 2.112 . . . . 0.0 111.472 -178.381 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.74 -28.31 63.79 Favored 'General case' 0 CA--C 1.539 0.52 0 N-CA-C 113.301 0.852 . . . . 0.0 113.301 -171.509 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 92.22 66.52 1.12 Allowed Glycine 0 C--N 1.339 0.741 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 171.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 56.9 mt 61.81 -44.37 0.15 Allowed 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 129.605 3.162 . . . . 0.0 114.346 -171.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 6.6 p -93.6 140.66 29.36 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 125.28 1.432 . . . . 0.0 107.79 177.291 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 12.5 p -134.54 124.34 44.49 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 169.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.8 m -93.53 100.57 12.83 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 177.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.421 HD11 ' CZ ' ' A' ' 26' ' ' PHE . 19.6 mt -90.18 122.83 33.48 Favored 'General case' 0 CA--C 1.516 -0.334 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 172.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 32.0 ttm105 -99.25 117.75 34.41 Favored 'General case' 0 C--O 1.236 0.347 0 N-CA-C 106.264 -1.754 . . . . 0.0 106.264 179.039 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.53 ' C ' HD12 ' A' ' 100' ' ' ILE . 1.9 pp -130.6 174.9 12.19 Favored 'Isoleucine or valine' 0 C--O 1.237 0.427 0 C-N-CA 126.669 1.988 . . . . 0.0 110.004 -166.545 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.53 HD12 ' C ' ' A' ' 99' ' ' ILE . 3.4 mp -129.88 115.21 17.84 Favored Pre-proline 0 CA--C 1.546 0.812 0 C-N-CA 124.483 1.113 . . . . 0.0 108.651 177.158 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -79.76 -179.07 5.01 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 125.294 3.996 . . . . 0.0 109.169 169.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -158.64 163.78 36.59 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 121.224 -0.923 . . . . 0.0 108.568 177.581 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -102.94 7.05 39.28 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 125.478 1.511 . . . . 0.0 111.957 -171.163 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -130.77 10.03 5.05 Favored 'General case' 0 CA--C 1.537 0.476 0 C-N-CA 125.204 1.402 . . . . 0.0 111.223 -173.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 11.2 mt -121.66 64.55 0.9 Allowed 'General case' 0 C--O 1.235 0.321 0 C-N-CA 125.729 1.612 . . . . 0.0 108.789 -169.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 37.0 t30 -148.39 89.49 1.72 Allowed 'General case' 0 C--O 1.234 0.273 0 C-N-CA 125.757 1.623 . . . . 0.0 107.767 172.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.1 m -67.02 149.29 98.6 Favored Pre-proline 0 CA--C 1.543 0.692 0 CA-C-O 119.013 -0.518 . . . . 0.0 111.319 -171.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -79.5 179.55 6.26 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.699 2.932 . . . . 0.0 112.145 -172.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 14.4 t -128.6 -171.98 2.6 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.66 1.584 . . . . 0.0 107.413 163.393 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 67.38 62.24 4.53 Favored Glycine 0 CA--C 1.534 1.265 0 C-N-CA 124.944 1.259 . . . . 0.0 112.949 178.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -67.05 -26.3 43.28 Favored 'Trans proline' 0 C--N 1.347 0.496 0 C-N-CA 122.636 2.224 . . . . 0.0 113.649 -177.432 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 42.9 t -155.33 98.28 1.97 Allowed 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 104.961 -2.237 . . . . 0.0 104.961 175.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 73.4 m -152.06 73.62 1.06 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 174.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.975 0 N-CA-C 103.662 -3.775 . . . . 0.0 103.662 -146.307 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.648 0 N-CA-C 111.589 -0.605 . . . . 0.0 111.589 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 64.2 p -70.44 93.95 0.92 Allowed 'General case' 0 C--O 1.232 0.148 0 C-N-CA 123.834 0.854 . . . . 0.0 109.238 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 9.5 m -146.55 162.76 37.68 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 106.188 -1.782 . . . . 0.0 106.188 169.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 159.8 107.08 0.23 Allowed Glycine 0 N--CA 1.448 -0.544 0 N-CA-C 109.012 -1.635 . . . . 0.0 109.012 -174.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 11.5 t -123.82 -71.79 0.7 Allowed 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 106.293 -1.743 . . . . 0.0 106.293 174.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 15.5 m -68.79 -57.57 5.41 Favored 'General case' 0 N--CA 1.451 -0.387 0 C-N-CA 124.641 1.176 . . . . 0.0 112.888 -174.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 130.84 51.18 0.1 Allowed Glycine 0 C--N 1.342 0.902 0 CA-C-N 119.672 1.124 . . . . 0.0 113.979 174.033 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 27.8 m -70.44 33.77 0.04 OUTLIER 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.094 1.758 . . . . 0.0 113.184 173.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.2 tp -155.94 119.44 4.36 Favored 'General case' 0 N--CA 1.454 -0.241 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 161.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.3 tp60 -112.13 114.62 27.56 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 106.279 -1.749 . . . . 0.0 106.279 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.2 p -132.51 167.58 19.74 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 123.842 0.857 . . . . 0.0 109.74 -174.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 22.5 m -127.38 150.99 49.37 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.239 1.016 . . . . 0.0 108.291 175.067 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -120.69 93.46 4.04 Favored 'General case' 0 C--O 1.236 0.355 0 N-CA-C 104.442 -2.429 . . . . 0.0 104.442 176.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.5 t -91.43 94.76 5.04 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.332 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 -170.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.0 p -76.2 134.12 29.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 108.134 -1.062 . . . . 0.0 108.134 173.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 82.5 mt -131.12 126.38 59.15 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.197 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 175.269 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 90.8 m-70 -92.55 154.01 18.7 Favored 'General case' 0 C--N 1.327 -0.38 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 167.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.487 ' HD3' ' CZ ' ' A' ' 24' ' ' PHE . 5.7 ptt180 -138.96 -176.95 4.67 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 167.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.461 ' HE3' ' C ' ' A' ' 18' ' ' ARG . 0.1 OUTLIER -109.67 168.19 9.59 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 172.48 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 23.3 mt-10 -75.71 -19.3 59.19 Favored 'General case' 0 N--CA 1.463 0.176 0 O-C-N 121.716 -0.615 . . . . 0.0 112.172 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 69.6 m-80 -69.77 -2.98 13.53 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.014 0.926 . . . . 0.0 112.735 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -150.07 177.2 10.11 Favored 'General case' 0 C--O 1.238 0.474 0 C-N-CA 125.485 1.514 . . . . 0.0 109.441 -164.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -110.98 -173.69 19.94 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 171.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.487 ' CZ ' ' HD3' ' A' ' 18' ' ' ARG . 62.9 m-85 -76.24 166.85 22.86 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 159.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -131.29 60.26 0.68 Allowed Glycine 0 C--O 1.226 -0.364 0 O-C-N 121.022 -1.049 . . . . 0.0 113.05 -173.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 5.3 p90 -144.56 162.08 37.5 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 124.936 1.294 . . . . 0.0 109.999 175.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 38.5 t -132.99 124.59 50.41 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 -176.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 5.3 mp -84.5 140.86 15.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 107.216 -1.402 . . . . 0.0 107.216 173.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.474 HD11 ' HE3' ' A' ' 46' ' ' LYS . 19.9 pt -131.73 -176.15 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 C-N-CA 127.849 2.46 . . . . 0.0 107.759 172.073 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.6 p -116.39 -58.55 2.08 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 165.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 60.16 88.35 0.08 Allowed 'General case' 0 C--O 1.235 0.301 0 C-N-CA 125.69 1.596 . . . . 0.0 108.743 -159.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 1.4 mt -140.46 159.34 42.41 Favored 'General case' 0 C--O 1.239 0.552 0 C-N-CA 126.017 1.727 . . . . 0.0 107.467 178.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -174.35 137.4 0.51 Allowed 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.249 1.42 . . . . 0.0 108.417 -175.445 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 63.5 mtt85 60.99 156.55 0.11 Allowed Pre-proline 0 CA--C 1.543 0.678 0 C-N-CA 127.464 2.306 . . . . 0.0 112.355 -175.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 94.6 Cg_endo -77.08 -22.06 11.64 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 122.093 1.862 . . . . 0.0 111.667 -178.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 58.95 177.99 0.07 Allowed 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 126.213 1.805 . . . . 0.0 113.848 -175.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.0 m -130.73 119.67 22.69 Favored 'General case' 0 C--O 1.238 0.451 0 C-N-CA 126.928 2.091 . . . . 0.0 106.618 175.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 128.75 -174.28 19.07 Favored Glycine 0 N--CA 1.446 -0.646 0 C-N-CA 125.507 1.527 . . . . 0.0 111.768 169.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 12.6 t -70.22 103.35 2.33 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 160.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 19.6 p -67.57 152.63 45.32 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 124.071 0.948 . . . . 0.0 109.564 179.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 5.0 mp -127.21 80.83 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.52 -0.183 0 N-CA-C 104.601 -2.37 . . . . 0.0 104.601 169.353 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.61 164.52 29.69 Favored 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 128.212 2.605 . . . . 0.0 105.459 171.393 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.2 p -127.85 138.02 32.01 Favored Pre-proline 0 CA--C 1.541 0.604 0 CA-C-N 120.259 1.39 . . . . 0.0 111.015 -178.151 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -74.32 -20.01 19.02 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 122.593 2.196 . . . . 0.0 113.072 178.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.59 ' CD2' HD13 ' A' ' 76' ' ' ILE . 0.6 OUTLIER -135.55 118.82 16.65 Favored 'General case' 0 C--O 1.235 0.329 0 C-N-CA 124.467 1.107 . . . . 0.0 108.367 178.372 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.474 ' HE3' HD11 ' A' ' 29' ' ' ILE . 44.1 pttt -139.88 155.0 47.42 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 123.675 0.79 . . . . 0.0 109.144 167.573 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 19.1 mm -64.16 131.02 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 105.409 -2.071 . . . . 0.0 105.409 168.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -113.76 -32.92 1.97 Allowed Glycine 0 CA--C 1.523 0.57 0 C-N-CA 124.233 0.92 . . . . 0.0 113.382 176.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 21.2 ttm-85 -146.21 148.5 32.57 Favored 'General case' 0 CA--C 1.517 -0.322 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 7.4 mt -127.43 125.97 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 167.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -57.65 126.99 16.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 C-N-CA 125.416 1.486 . . . . 0.0 107.1 175.609 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -60.79 123.09 16.48 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 123.522 0.729 . . . . 0.0 109.145 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.15 24.78 74.96 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.726 0.679 . . . . 0.0 113.284 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 22.5 p -76.94 171.69 11.71 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 118.674 1.237 . . . . 0.0 111.576 168.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -58.16 -22.81 58.4 Favored 'Trans proline' 0 CA--C 1.538 0.696 0 C-N-CA 122.197 1.931 . . . . 0.0 113.259 165.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -72.89 -56.97 4.43 Favored 'General case' 0 C--N 1.343 0.308 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 173.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 23.6 t0 -57.64 -47.07 83.28 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 123.801 0.841 . . . . 0.0 111.273 -175.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 1.6 ptm180 -54.45 -27.48 37.64 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 113.267 0.839 . . . . 0.0 113.267 174.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 2.7 t -73.17 -12.89 61.04 Favored 'General case' 0 CA--C 1.536 0.429 0 CA-C-O 118.29 -0.862 . . . . 0.0 112.858 -162.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 47.33 37.88 6.52 Favored 'General case' 0 C--O 1.239 0.532 0 C-N-CA 126.077 1.751 . . . . 0.0 113.536 178.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 31.8 mtmt -143.33 -17.47 0.64 Allowed 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 113.92 1.082 . . . . 0.0 113.92 173.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.422 HD23 ' HA ' ' A' ' 62' ' ' LEU . 0.1 OUTLIER -126.54 111.44 14.38 Favored 'General case' 0 C--N 1.328 -0.347 0 C-N-CA 124.715 1.206 . . . . 0.0 108.083 -174.583 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 25.8 mtmt -129.35 172.12 11.82 Favored 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 126.011 1.724 . . . . 0.0 110.674 172.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 84.4 t -57.43 118.97 2.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.382 0 C-N-CA 125.108 1.363 . . . . 0.0 109.567 -175.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 124.7 -23.25 6.33 Favored Glycine 0 C--N 1.336 0.57 0 CA-C-O 118.699 -1.056 . . . . 0.0 111.063 175.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 70.2 m-20 -70.06 81.44 0.5 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.62 1.568 . . . . 0.0 112.253 -167.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 87.7 mtt180 -48.42 134.02 15.58 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 126.619 1.968 . . . . 0.0 110.998 -162.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 61.3 mt -102.9 130.1 53.53 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 -174.389 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -112.02 -32.85 6.45 Favored 'General case' 0 N--CA 1.447 -0.617 0 C-N-CA 125.254 1.422 . . . . 0.0 112.095 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -154.97 167.81 29.1 Favored 'General case' 0 N--CA 1.452 -0.351 0 C-N-CA 123.995 0.918 . . . . 0.0 109.038 -177.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.7 p -129.57 114.34 30.61 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.324 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 177.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 63.8 m-80 61.42 -37.54 0.11 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 128.937 2.895 . . . . 0.0 113.638 -169.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 169.2 -4.43 0.04 OUTLIER Glycine 0 CA--C 1.531 1.043 0 C-N-CA 128.103 2.763 . . . . 0.0 112.692 -176.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -90.72 136.0 33.35 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 120.569 2.185 . . . . 0.0 108.91 -177.273 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.6 p -73.3 119.5 17.62 Favored 'General case' 0 CA--C 1.53 0.193 0 CA-C-N 118.457 0.571 . . . . 0.0 109.592 179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.59 HD13 ' CD2' ' A' ' 45' ' ' HIS . 2.4 pp -91.31 -24.25 5.63 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.305 0 C-N-CA 122.262 0.225 . . . . 0.0 111.312 -174.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mp -59.73 -32.67 49.98 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 O-C-N 121.389 -0.819 . . . . 0.0 110.903 -179.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -95.2 -7.58 38.68 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 123.801 0.84 . . . . 0.0 112.222 -170.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 10.7 mtp -105.88 160.0 27.66 Favored Pre-proline 0 N--CA 1.449 -0.487 0 C-N-CA 125.61 1.564 . . . . 0.0 113.348 -169.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -66.96 140.7 55.63 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 123.245 2.63 . . . . 0.0 110.789 169.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -45.93 -52.77 11.02 Favored 'General case' 0 N--CA 1.453 -0.303 0 C-N-CA 126.132 1.773 . . . . 0.0 110.872 173.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.5 -27.23 69.0 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 123.91 0.884 . . . . 0.0 113.261 -177.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 24.3 t0 -87.29 -34.73 18.79 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-N 118.991 0.814 . . . . 0.0 110.801 -178.236 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.0 mt -63.93 -39.57 85.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 C-N-CA 124.339 1.056 . . . . 0.0 108.43 169.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.1 t -57.13 -50.7 75.67 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.195 0 O-C-N 121.11 -0.994 . . . . 0.0 109.114 168.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.9 -36.61 81.81 Favored 'General case' 0 C--N 1.338 0.093 0 CA-C-N 118.881 0.764 . . . . 0.0 112.822 -178.614 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -61.75 -42.12 98.56 Favored 'General case' 0 N--CA 1.449 -0.478 0 C-N-CA 128.067 2.547 . . . . 0.0 110.836 175.076 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 62.4 mt -67.42 -42.75 87.6 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.281 0 N-CA-C 108.053 -1.092 . . . . 0.0 108.053 174.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 46.1 tttt -57.73 -41.66 82.29 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 120.267 -0.573 . . . . 0.0 109.559 178.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 36.7 t0 -65.88 -14.62 61.84 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 127.462 2.305 . . . . 0.0 112.451 178.018 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -75.48 -12.38 60.23 Favored 'General case' 0 CA--C 1.544 0.731 0 O-C-N 121.042 -1.036 . . . . 0.0 111.86 169.18 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 60.45 -116.19 8.82 Favored Glycine 0 CA--C 1.528 0.868 0 O-C-N 120.817 -1.177 . . . . 0.0 110.574 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 93.2 mt -87.1 -36.53 18.07 Favored 'General case' 0 CA--C 1.503 -0.862 0 CA-C-N 117.814 0.807 . . . . 0.0 112.342 -177.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -107.86 120.11 41.33 Favored 'General case' 0 C--N 1.325 -0.479 0 O-C-N 124.159 0.912 . . . . 0.0 108.628 -175.102 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.7 p -126.99 150.52 32.96 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.398 0 N-CA-C 106.627 -1.62 . . . . 0.0 106.627 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.3 m -124.55 138.85 54.3 Favored 'General case' 0 N--CA 1.435 -1.181 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 173.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 19.0 mt -122.61 128.83 51.18 Favored 'General case' 0 CA--C 1.515 -0.376 0 C-N-CA 124.583 1.153 . . . . 0.0 109.114 178.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -84.77 107.8 17.13 Favored 'General case' 0 C--O 1.237 0.401 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 175.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.3 pp -113.92 170.97 4.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 O-C-N 123.875 0.734 . . . . 0.0 110.763 172.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 20.0 mt -121.29 125.74 26.8 Favored Pre-proline 0 C--O 1.234 0.263 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 170.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -85.1 178.84 4.46 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 124.867 3.711 . . . . 0.0 110.715 172.51 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 20.1 mp0 -146.86 135.49 22.07 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 125.9 1.68 . . . . 0.0 107.202 -176.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -123.94 -6.22 7.9 Favored 'General case' 0 C--N 1.325 -0.461 0 C-N-CA 123.764 0.826 . . . . 0.0 111.702 170.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -143.42 0.04 1.12 Allowed 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.758 1.223 . . . . 0.0 113.881 -170.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 18.4 mt -119.95 90.03 3.25 Favored 'General case' 0 C--N 1.339 0.137 0 C-N-CA 124.005 0.922 . . . . 0.0 108.954 -168.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 61.8 t-20 -140.43 -96.75 0.15 Allowed 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 164.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.4 t -163.56 136.31 4.11 Favored Pre-proline 0 C--O 1.241 0.612 0 C-N-CA 126.339 1.856 . . . . 0.0 107.044 179.018 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -77.19 -24.16 9.73 Favored 'Trans proline' 0 N--CA 1.458 -0.589 0 C-N-CA 122.325 2.016 . . . . 0.0 112.658 -174.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 5.3 m -145.09 99.09 3.27 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.12 1.368 . . . . 0.0 108.267 -169.095 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -116.37 87.33 0.43 Allowed Glycine 0 CA--C 1.526 0.735 0 N-CA-C 108.516 -1.834 . . . . 0.0 108.516 176.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -73.43 136.5 24.02 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.294 1.996 . . . . 0.0 109.558 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 16.3 t -127.89 157.04 41.58 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 125.26 1.424 . . . . 0.0 107.772 178.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -160.01 176.66 11.58 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.629 0.771 . . . . 0.0 110.304 -178.071 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.329 0 C-N-CA 129.086 3.231 . . . . 0.0 106.109 174.389 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.158 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.9 p -66.71 144.91 56.08 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-N 117.882 0.841 . . . . 0.0 109.017 167.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 7.4 t -179.99 142.43 0.15 Allowed 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 128.811 2.844 . . . . 0.0 104.898 165.156 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -163.42 67.19 0.23 Allowed Glycine 0 N--CA 1.453 -0.232 0 O-C-N 121.683 -0.636 . . . . 0.0 111.519 -170.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 54.4 m -70.37 156.23 39.59 Favored 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 117.36 0.58 . . . . 0.0 111.652 171.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 16.9 t -151.8 174.71 13.22 Favored 'General case' 0 C--O 1.24 0.564 0 C-N-CA 126.776 2.03 . . . . 0.0 108.226 175.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 147.81 157.38 7.44 Favored Glycine 0 C--O 1.236 0.252 0 C-N-CA 125.206 1.384 . . . . 0.0 110.883 173.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 40.0 t -152.29 51.35 0.78 Allowed 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 124.252 1.021 . . . . 0.0 109.176 176.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 2.5 tp -139.33 170.72 15.43 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 118.392 0.542 . . . . 0.0 110.536 173.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -177.21 148.54 0.62 Allowed 'General case' 0 C--O 1.239 0.515 0 C-N-CA 127.919 2.488 . . . . 0.0 104.714 167.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 39.1 p -145.11 153.05 41.0 Favored 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 172.237 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 2.2 m -96.09 170.53 9.21 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 -161.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -135.1 94.63 3.17 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-O 123.505 1.622 . . . . 0.0 107.743 171.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.544 HG11 ' HB3' ' A' ' 62' ' ' LEU . 80.1 t -90.3 93.98 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.491 0 N-CA-C 104.735 -2.321 . . . . 0.0 104.735 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 11.7 p -101.93 116.79 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.513 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 -175.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 51.1 mt -133.67 136.85 53.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 -172.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 74.4 m-70 -109.27 149.59 29.22 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 125.396 1.478 . . . . 0.0 109.079 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.49 ' HD3' ' CZ ' ' A' ' 24' ' ' PHE . 1.1 ptm180 -138.69 179.29 6.56 Favored 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 124.937 1.295 . . . . 0.0 109.951 -175.353 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.16 157.33 15.99 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 176.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.2 mm-40 -69.92 -20.71 63.34 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 117.76 0.255 . . . . 0.0 111.239 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 31.0 t30 -78.45 -1.83 35.55 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 123.451 0.7 . . . . 0.0 112.682 -176.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -159.89 -175.74 5.29 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.573 1.149 . . . . 0.0 110.362 -170.027 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -99.99 -171.54 29.99 Favored Glycine 0 CA--C 1.522 0.521 0 C-N-CA 125.324 1.44 . . . . 0.0 112.365 177.235 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.49 ' CZ ' ' HD3' ' A' ' 18' ' ' ARG . 29.6 m-85 -73.63 159.68 32.72 Favored 'General case' 0 N--CA 1.443 -0.81 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 151.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -105.28 57.52 0.49 Allowed Glycine 0 C--O 1.219 -0.817 0 CA-C-O 118.542 -1.144 . . . . 0.0 110.565 177.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 8.8 p90 -124.02 155.35 38.43 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 118.849 1.324 . . . . 0.0 108.969 171.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -129.63 114.36 30.51 Favored 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 177.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 22.1 mt -78.24 147.38 7.07 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.628 -1.249 . . . . 0.0 107.628 171.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 44.0 pt -141.2 174.67 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.77 0 C-N-CA 128.691 2.796 . . . . 0.0 107.662 170.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 35.9 p -113.09 177.22 4.7 Favored 'General case' 0 C--O 1.237 0.42 0 C-N-CA 124.182 0.993 . . . . 0.0 108.926 164.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.1 t -144.58 139.62 28.26 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 169.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 14.7 tp -148.04 76.65 1.38 Allowed 'General case' 0 C--O 1.236 0.351 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 6.0 t30 -131.72 -78.86 0.51 Allowed 'General case' 0 N--CA 1.457 -0.119 0 CA-C-O 117.903 -1.046 . . . . 0.0 108.825 174.242 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -137.52 157.83 73.11 Favored Pre-proline 0 N--CA 1.472 0.647 0 CA-C-N 120.682 1.583 . . . . 0.0 112.214 -179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.568 ' HB3' ' H ' ' A' ' 41' ' ' ILE . 97.7 Cg_endo -75.23 160.23 39.64 Favored 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 123.072 2.514 . . . . 0.0 110.197 165.269 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -94.72 73.88 3.65 Favored 'General case' 0 CA--C 1.532 0.268 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 175.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 49.2 m 57.3 171.3 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 128.441 2.696 . . . . 0.0 115.11 178.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.36 -142.93 39.97 Favored Glycine 0 CA--C 1.525 0.711 0 O-C-N 121.302 -0.874 . . . . 0.0 111.435 -175.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 78.9 p -65.5 163.81 15.23 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-O 122.407 1.099 . . . . 0.0 111.171 -178.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 12.5 p -84.61 109.77 18.22 Favored 'General case' 0 N--CA 1.447 -0.61 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -172.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.568 ' H ' ' HB3' ' A' ' 35' ' ' PRO . 37.5 mt -126.53 137.12 58.8 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 C-N-CA 127.916 2.487 . . . . 0.0 106.788 -166.437 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 10.6 t -160.48 123.56 3.39 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 -178.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 14.0 p -103.59 139.81 20.46 Favored Pre-proline 0 N--CA 1.469 0.514 0 C-N-CA 124.258 1.023 . . . . 0.0 110.335 -173.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -72.96 -27.64 14.01 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 121.75 1.633 . . . . 0.0 113.775 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -141.94 130.02 22.04 Favored 'General case' 0 C--N 1.341 0.22 0 C-N-CA 125.687 1.595 . . . . 0.0 108.948 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 6.8 ptmt -149.66 164.57 34.82 Favored 'General case' 0 C--N 1.328 -0.348 0 C-N-CA 125.788 1.635 . . . . 0.0 107.225 176.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.602 HG13 HD23 ' A' ' 62' ' ' LEU . 13.2 mm -84.52 143.7 11.23 Favored 'Isoleucine or valine' 0 C--O 1.239 0.506 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 -176.612 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -118.0 -36.62 0.94 Allowed Glycine 0 CA--C 1.522 0.491 0 C-N-CA 126.023 1.773 . . . . 0.0 112.745 -177.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 36.6 ttm105 -150.05 159.81 44.12 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 119.096 1.448 . . . . 0.0 108.585 176.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 7.2 mt -121.05 143.58 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.543 0 C-N-CA 125.46 1.504 . . . . 0.0 107.012 160.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.4 mm -75.43 136.42 25.02 Favored 'Isoleucine or valine' 0 C--O 1.234 0.274 0 N-CA-C 106.01 -1.848 . . . . 0.0 106.01 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -72.03 119.81 16.74 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.637 0.256 . . . . 0.0 110.462 -159.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 76.32 12.81 83.92 Favored Glycine 0 CA--C 1.527 0.799 0 CA-C-O 119.362 -0.688 . . . . 0.0 114.432 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.567 ' HB2' ' CD ' ' A' ' 55' ' ' PRO . 81.3 p -71.49 176.55 2.09 Favored Pre-proline 0 CA--C 1.541 0.618 0 CA-C-N 118.342 1.071 . . . . 0.0 112.004 176.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.567 ' CD ' ' HB2' ' A' ' 54' ' ' SER . 4.7 Cg_exo -64.28 -32.27 62.07 Favored 'Trans proline' 0 N--CA 1.453 -0.87 0 C-N-CA 122.767 2.311 . . . . 0.0 110.164 176.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -65.86 -24.52 66.89 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-O 118.201 -0.904 . . . . 0.0 112.894 175.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -83.65 -47.06 11.64 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 119.128 0.876 . . . . 0.0 110.543 173.32 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 28.5 mtt-85 -69.11 -41.44 77.41 Favored 'General case' 0 C--O 1.234 0.252 0 C-N-CA 123.247 0.619 . . . . 0.0 111.469 -170.627 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 62.5 m -81.19 81.38 7.41 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 173.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -62.85 89.78 0.03 OUTLIER 'General case' 0 C--O 1.236 0.346 0 C-N-CA 124.22 1.008 . . . . 0.0 109.503 178.2 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.51 ' CB ' HG13 ' A' ' 14' ' ' VAL . 26.4 mmmt -136.85 -33.72 0.76 Allowed 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 126.598 1.959 . . . . 0.0 109.498 -174.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.602 HD23 HG13 ' A' ' 47' ' ' ILE . 0.0 OUTLIER -136.57 154.49 50.68 Favored 'General case' 0 C--O 1.234 0.264 0 C-N-CA 124.576 1.15 . . . . 0.0 109.388 171.055 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 16.3 ptmt -134.9 172.12 13.44 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 124.887 1.275 . . . . 0.0 110.868 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 14.6 t -59.42 137.66 21.54 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 O-C-N 120.401 -1.437 . . . . 0.0 109.572 -175.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 103.11 -14.05 55.54 Favored Glycine 0 C--N 1.342 0.893 0 C-N-CA 125.119 1.342 . . . . 0.0 114.642 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -67.06 19.46 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 120.368 3.47 . . . . 0.0 120.368 -148.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 4.3 mtt-85 43.61 72.53 0.18 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 126.818 2.047 . . . . 0.0 112.811 168.443 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 31.4 mt -65.33 147.11 12.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -170.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.6 mt -102.69 -52.75 3.01 Favored 'General case' 0 C--O 1.233 0.213 0 C-N-CA 124.606 1.162 . . . . 0.0 109.915 174.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -156.62 171.06 20.99 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.654 0.782 . . . . 0.0 110.524 -172.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 13.0 p -124.54 113.96 38.65 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.257 0 C-N-CA 125.321 1.449 . . . . 0.0 108.1 175.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 45.09 41.75 5.92 Favored 'General case' 0 CA--C 1.534 0.341 0 C-N-CA 125.825 1.65 . . . . 0.0 110.095 -169.092 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.31 4.27 78.96 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-O 118.334 -1.259 . . . . 0.0 115.763 179.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -85.99 122.12 29.58 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 120.262 2.031 . . . . 0.0 106.689 174.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 7.7 t -67.52 134.84 52.04 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 -179.036 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 21.8 pt -108.99 0.27 9.65 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 125.508 1.523 . . . . 0.0 111.193 -176.127 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 75.4 mt -65.41 -61.77 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 C-N-CA 125.088 1.355 . . . . 0.0 109.072 -178.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -92.42 -24.22 18.92 Favored 'General case' 0 N--CA 1.463 0.198 0 C-N-CA 123.939 0.896 . . . . 0.0 112.33 -174.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.8 ttt -60.91 137.83 93.77 Favored Pre-proline 0 N--CA 1.439 -0.996 0 C-N-CA 125.185 1.394 . . . . 0.0 108.525 178.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -76.07 148.95 31.9 Favored 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 121.853 1.702 . . . . 0.0 109.668 -177.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.409 ' HA ' HD12 ' A' ' 84' ' ' ILE . 32.2 t60 -60.76 -31.94 71.26 Favored 'General case' 0 CA--C 1.537 0.476 0 N-CA-C 113.812 1.041 . . . . 0.0 113.812 -165.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -71.18 -27.8 63.78 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-N 119.217 0.917 . . . . 0.0 113.029 176.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -74.93 -42.09 58.4 Favored 'General case' 0 C--O 1.224 -0.24 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 175.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.409 HD12 ' HA ' ' A' ' 81' ' ' HIS . 28.5 mt -57.82 -37.86 62.46 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 C-N-CA 124.714 1.205 . . . . 0.0 110.476 172.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.3 t -61.4 -52.28 63.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.39 0 O-C-N 120.578 -1.326 . . . . 0.0 109.684 172.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 20.7 ttmt -59.57 -40.39 87.22 Favored 'General case' 0 C--O 1.22 -0.491 0 C-N-CA 119.116 -1.034 . . . . 0.0 111.697 179.299 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -53.36 -42.98 67.39 Favored 'General case' 0 N--CA 1.443 -0.816 0 C-N-CA 126.633 1.973 . . . . 0.0 112.102 177.006 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.3 mt -69.25 -43.03 81.64 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.127 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 176.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 50.0 tttm -58.37 -49.83 75.84 Favored 'General case' 0 N--CA 1.456 -0.167 0 CA-C-N 118.329 0.513 . . . . 0.0 110.575 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -62.69 -18.62 62.76 Favored 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 128.773 2.829 . . . . 0.0 111.648 177.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -62.6 -34.26 76.64 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 119.588 1.085 . . . . 0.0 109.627 171.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 99.83 -97.88 1.84 Allowed Glycine 0 C--N 1.337 0.596 0 C-N-CA 126.119 1.819 . . . . 0.0 108.924 173.07 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.6 mt -121.64 -28.91 4.47 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 124.272 1.029 . . . . 0.0 111.819 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 p -93.3 143.61 26.1 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 170.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.3 p -145.51 153.4 13.88 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.944 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 166.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -125.98 112.22 15.66 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 -178.755 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 7.2 mt -90.54 114.7 26.97 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 173.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -71.85 121.14 18.49 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 164.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pt -128.35 -179.96 3.37 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 125.037 1.335 . . . . 0.0 108.359 175.279 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.435 ' H ' ' HD2' ' A' ' 101' ' ' PRO . 43.7 mt -99.86 -55.05 0.16 Allowed Pre-proline 0 CA--C 1.537 0.464 0 C-N-CA 124.758 1.223 . . . . 0.0 109.202 169.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.435 ' HD2' ' H ' ' A' ' 100' ' ' ILE 0.257 10.7 Cg_endo -61.29 -178.11 0.24 Allowed 'Trans proline' 0 C--N 1.351 0.665 0 C-N-CA 121.708 1.605 . . . . 0.0 114.39 175.331 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -166.94 175.8 7.42 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 128.736 2.814 . . . . 0.0 105.573 171.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 18.2 pt-20 -136.75 5.98 2.91 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 124.455 1.102 . . . . 0.0 111.914 174.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -124.68 -17.83 5.82 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 121.642 0.735 . . . . 0.0 111.708 -172.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -74.64 -18.21 60.58 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 124.37 1.068 . . . . 0.0 111.936 -170.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 17.9 m-80 -136.28 111.84 9.3 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 104.344 -2.465 . . . . 0.0 104.344 162.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 1.3 m -52.81 -51.69 71.69 Favored Pre-proline 0 CA--C 1.538 0.494 0 C-N-CA 125.506 1.523 . . . . 0.0 110.996 172.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -69.55 149.03 67.74 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 CA-C-N 121.223 1.473 . . . . 0.0 109.385 171.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 96.7 p -132.05 178.81 6.5 Favored 'General case' 0 C--O 1.237 0.426 0 C-N-CA 124.06 0.944 . . . . 0.0 109.495 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -86.74 164.31 35.75 Favored Glycine 0 CA--C 1.531 1.086 0 O-C-N 121.328 -0.857 . . . . 0.0 111.856 -174.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -66.9 177.43 3.56 Favored 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.519 2.812 . . . . 0.0 110.506 166.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 6.9 t -147.37 161.56 40.77 Favored 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 122.134 0.968 . . . . 0.0 109.681 160.299 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -165.2 -167.68 1.23 Allowed 'General case' 0 C--O 1.239 0.529 0 C-N-CA 127.166 2.187 . . . . 0.0 106.782 171.202 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.14 0 N-CA-C 107.79 -2.124 . . . . 0.0 107.79 -165.51 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.991 0 N-CA-C 112.165 -0.374 . . . . 0.0 112.165 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.4 m -73.09 136.68 44.95 Favored 'General case' 0 C--O 1.236 0.356 0 C-N-CA 123.602 0.761 . . . . 0.0 111.279 174.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.6 t -137.26 -170.65 2.78 Favored 'General case' 0 C--O 1.239 0.51 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 150.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.55 -97.97 0.91 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 -174.018 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.2 m 59.52 103.8 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 126.603 1.961 . . . . 0.0 110.882 -170.439 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 6.9 t -122.65 113.7 19.59 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 124.41 1.084 . . . . 0.0 108.816 177.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -163.72 143.71 8.84 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 104.513 -3.435 . . . . 0.0 104.513 167.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 37.3 m 69.78 -67.79 0.22 Allowed 'General case' 0 C--N 1.328 -0.339 0 C-N-CA 126.77 2.028 . . . . 0.0 112.759 -175.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.0 tp -86.31 70.2 10.5 Favored 'General case' 0 C--O 1.237 0.402 0 CA-C-O 122.186 0.993 . . . . 0.0 110.527 -165.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.401 ' HG2' ' H ' ' A' ' 11' ' ' THR . 22.9 tt0 -103.88 -172.44 2.11 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 125.534 1.533 . . . . 0.0 108.716 175.456 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . 0.401 ' H ' ' HG2' ' A' ' 10' ' ' GLN . 17.5 p -136.49 168.46 19.42 Favored 'General case' 0 C--O 1.238 0.471 0 C-N-CA 125.937 1.695 . . . . 0.0 108.486 167.113 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.4 m -122.6 150.71 42.26 Favored 'General case' 0 CA--C 1.514 -0.442 0 N-CA-C 107.109 -1.441 . . . . 0.0 107.109 167.48 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -90.65 147.03 23.56 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 105.734 -1.95 . . . . 0.0 105.734 168.26 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 39.0 t -131.99 101.41 4.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 N-CA-C 104.84 -2.282 . . . . 0.0 104.84 161.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.7 p -72.37 141.04 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 165.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.46 HD11 HD12 ' A' ' 62' ' ' LEU . 53.0 mt -134.74 133.19 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.36 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 170.383 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 76.7 m-70 -105.84 154.4 20.57 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 125.351 1.46 . . . . 0.0 108.053 173.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 32.6 ptt180 -136.43 -171.93 3.02 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 170.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.82 170.38 8.51 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 166.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -80.36 -23.55 40.43 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 113.289 0.848 . . . . 0.0 113.289 -168.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -69.99 -10.05 57.27 Favored 'General case' 0 N--CA 1.472 0.645 0 CA-C-N 119.595 1.089 . . . . 0.0 112.882 176.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -137.15 169.33 17.97 Favored 'General case' 0 C--O 1.241 0.637 0 C-N-CA 124.288 1.035 . . . . 0.0 110.736 -161.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -89.11 -178.54 45.87 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 179.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -80.1 170.44 16.44 Favored 'General case' 0 CA--C 1.538 0.483 0 N-CA-C 105.963 -1.866 . . . . 0.0 105.963 142.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -129.48 52.39 0.83 Allowed Glycine 0 C--O 1.225 -0.437 0 CA-C-O 118.769 -1.017 . . . . 0.0 112.683 -172.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 4.6 p90 -136.68 142.11 43.16 Favored 'General case' 0 C--O 1.233 0.222 0 C-N-CA 125.764 1.625 . . . . 0.0 110.696 -177.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.4 t -128.08 136.42 60.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 177.642 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 56.5 mt -108.23 120.1 58.99 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 -171.124 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 27.8 pt -110.89 -169.6 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 C-N-CA 126.471 1.909 . . . . 0.0 108.74 -178.099 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 67.83 -177.92 0.21 Allowed 'General case' 0 CA--C 1.54 0.585 0 C-N-CA 124.868 1.267 . . . . 0.0 108.319 -159.813 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -161.61 165.64 28.04 Favored 'General case' 0 C--O 1.237 0.443 0 C-N-CA 125.839 1.656 . . . . 0.0 107.164 170.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.583 HD22 ' C ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -57.22 145.35 31.98 Favored 'General case' 0 CA--C 1.536 0.432 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 160.309 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -163.81 157.25 18.69 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 125.001 1.32 . . . . 0.0 109.723 176.256 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 16.4 ptt-85 -51.66 130.76 36.56 Favored Pre-proline 0 CA--C 1.539 0.55 0 C-N-CA 124.34 1.056 . . . . 0.0 109.511 170.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -80.82 -26.36 3.73 Favored 'Trans proline' 0 N--CA 1.459 -0.526 0 C-N-CA 121.97 1.78 . . . . 0.0 112.5 -171.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 63.43 -54.1 0.2 Allowed 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 127.769 2.428 . . . . 0.0 113.645 -172.658 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 3.4 t -79.23 174.84 11.15 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 119.441 1.019 . . . . 0.0 109.549 171.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -64.99 -54.49 27.52 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 177.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 3.7 p -125.4 146.76 49.46 Favored 'General case' 0 C--O 1.243 0.714 0 C-N-CA 124.386 1.075 . . . . 0.0 108.753 171.086 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 40.8 p -124.05 151.79 43.4 Favored 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 171.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 42.0 pt -82.27 5.12 1.9 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 C-N-CA 123.776 0.83 . . . . 0.0 110.96 175.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.5 m -62.21 146.98 49.27 Favored 'General case' 0 N--CA 1.446 -0.64 0 C-N-CA 126.122 1.769 . . . . 0.0 109.105 174.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.5 t -125.15 136.47 28.21 Favored Pre-proline 0 CA--C 1.533 0.306 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 165.697 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -75.15 -9.43 20.56 Favored 'Trans proline' 0 N--CA 1.461 -0.403 0 C-N-CA 122.904 2.403 . . . . 0.0 113.965 -178.293 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -139.73 122.27 16.23 Favored 'General case' 0 CA--C 1.52 -0.199 0 C-N-CA 124.948 1.299 . . . . 0.0 107.801 178.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 9.3 ptmt -151.55 154.0 35.63 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 124.299 1.04 . . . . 0.0 108.765 168.163 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.429 HG13 HD22 ' A' ' 62' ' ' LEU . 31.1 mm -62.57 144.41 14.38 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 CA-C-N 119.17 0.896 . . . . 0.0 109.6 175.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -128.03 -50.62 0.14 Allowed Glycine 0 CA--C 1.526 0.78 0 C-N-CA 126.39 1.948 . . . . 0.0 113.181 179.334 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 2.0 ttm180 -119.99 139.88 51.81 Favored 'General case' 0 CA--C 1.511 -0.531 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 171.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 12.7 mt -120.06 149.76 22.76 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 N-CA-C 105.568 -2.012 . . . . 0.0 105.568 159.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -87.65 129.54 38.83 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.803 0 C-N-CA 126.648 1.979 . . . . 0.0 108.097 177.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -61.55 124.51 20.86 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 123.636 0.774 . . . . 0.0 109.194 167.406 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 94.59 17.61 38.32 Favored Glycine 0 CA--C 1.524 0.614 0 CA-C-O 117.771 -1.572 . . . . 0.0 112.767 178.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 87.6 p -106.62 163.76 16.32 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-N 119.006 1.403 . . . . 0.0 113.116 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo -63.85 -25.08 67.76 Favored 'Trans proline' 0 N--CA 1.449 -1.106 0 C-N-CA 122.902 2.401 . . . . 0.0 112.927 169.217 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.32 -55.88 29.2 Favored 'General case' 0 C--N 1.345 0.404 0 CA-C-N 120.305 1.411 . . . . 0.0 109.883 174.006 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -63.32 -37.53 87.64 Favored 'General case' 0 CA--C 1.532 0.277 0 C-N-CA 123.316 0.647 . . . . 0.0 112.355 -175.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 12.6 mtt180 -65.72 -23.02 66.66 Favored 'General case' 0 N--CA 1.469 0.498 0 O-C-N 121.657 -0.652 . . . . 0.0 112.731 172.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 73.9 m -92.96 50.36 1.54 Allowed 'General case' 0 CA--C 1.533 0.321 0 O-C-N 120.568 -1.332 . . . . 0.0 110.824 174.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -59.2 9.16 0.01 OUTLIER 'General case' 0 CA--C 1.547 0.833 0 C-N-CA 127.036 2.134 . . . . 0.0 116.359 -177.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -61.92 -16.01 47.56 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 120.906 -1.121 . . . . 0.0 111.505 154.194 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.464 HD11 HD13 ' A' ' 97' ' ' LEU . 0.6 OUTLIER -115.51 137.64 51.85 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 127.393 2.277 . . . . 0.0 107.348 174.763 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 82.3 mttt -136.41 166.35 23.69 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 119.37 0.986 . . . . 0.0 111.146 172.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.4 t -55.94 112.6 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.251 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 168.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 129.95 -21.23 4.99 Favored Glycine 0 N--CA 1.441 -1.0 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 177.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -70.81 106.05 3.44 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 122.982 1.373 . . . . 0.0 110.772 -174.386 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.4 ' HG3' ' H ' ' A' ' 67' ' ' ARG . 31.1 mtm180 -37.38 143.52 0.1 Allowed 'General case' 0 C--N 1.321 -0.648 0 C-N-CA 129.974 3.31 . . . . 0.0 111.297 156.315 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 23.4 mt -132.41 129.89 59.64 Favored 'Isoleucine or valine' 0 C--O 1.233 0.228 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 -174.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.7 mt -94.28 -40.19 10.11 Favored 'General case' 0 CA--C 1.52 -0.186 0 C-N-CA 123.862 0.865 . . . . 0.0 112.051 179.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.42 168.95 25.84 Favored 'General case' 0 C--O 1.236 0.382 0 C-N-CA 124.189 0.996 . . . . 0.0 109.754 -168.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.5 t -129.2 127.12 65.19 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 N-CA-C 106.073 -1.825 . . . . 0.0 106.073 169.07 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 27.8 m-80 43.71 34.94 0.93 Allowed 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 124.631 1.172 . . . . 0.0 112.193 -165.283 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 72.93 -3.7 27.02 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-O 118.349 -1.25 . . . . 0.0 113.347 179.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.2 tp60 -74.54 134.69 42.17 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 119.513 1.657 . . . . 0.0 107.057 174.458 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.1 m -72.53 136.89 45.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 110.45 -0.204 . . . . 0.0 110.45 -176.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 17.0 pt -115.76 -8.28 12.2 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 C-N-CA 125.755 1.622 . . . . 0.0 112.078 -175.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.7 mm -54.14 -52.75 34.62 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.453 0 C-N-CA 123.813 0.845 . . . . 0.0 110.344 172.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -89.28 -26.44 21.15 Favored 'General case' 0 C--O 1.234 0.267 0 N-CA-C 111.712 0.264 . . . . 0.0 111.712 -173.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 7.0 ttt -66.5 137.87 95.45 Favored Pre-proline 0 N--CA 1.441 -0.884 0 C-N-CA 126.78 2.032 . . . . 0.0 109.645 -170.484 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 72.9 Cg_endo -75.04 148.03 34.56 Favored 'Trans proline' 0 N--CA 1.454 -0.832 0 C-N-CA 121.733 1.622 . . . . 0.0 109.051 178.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 5.5 m-70 -54.24 -35.24 62.25 Favored 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -174.647 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -58.66 -43.01 89.71 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-N 119.937 1.244 . . . . 0.0 112.904 177.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -69.41 -39.68 77.76 Favored 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 125.243 1.417 . . . . 0.0 108.957 -178.342 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 36.5 mt -65.89 -40.0 86.28 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.961 0 C-N-CA 124.529 1.131 . . . . 0.0 110.872 175.032 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 72.6 t -66.03 -41.23 89.26 Favored 'Isoleucine or valine' 0 C--O 1.239 0.542 0 O-C-N 118.998 -2.314 . . . . 0.0 109.607 173.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -52.5 -52.89 52.28 Favored 'General case' 0 C--O 1.223 -0.299 0 CA-C-O 117.489 -1.243 . . . . 0.0 109.539 171.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.51 -35.77 61.02 Favored 'General case' 0 N--CA 1.444 -0.748 0 C-N-CA 126.758 2.023 . . . . 0.0 112.303 -178.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 71.8 mt -78.11 -37.0 22.12 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 O-C-N 120.878 -1.139 . . . . 0.0 109.257 -179.133 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 41.4 tttp -65.47 -36.15 83.01 Favored 'General case' 0 N--CA 1.46 0.07 0 O-C-N 121.363 -0.835 . . . . 0.0 110.406 172.099 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -67.52 -37.65 83.09 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 126.401 1.88 . . . . 0.0 110.051 179.124 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.27 -41.6 80.03 Favored 'General case' 0 C--O 1.236 0.373 0 O-C-N 123.644 0.59 . . . . 0.0 110.769 -178.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 109.71 -141.36 16.1 Favored Glycine 0 C--N 1.336 0.562 0 C-N-CA 124.63 1.11 . . . . 0.0 110.911 171.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 85.9 mt -70.4 -40.92 73.62 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 169.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.98 131.75 40.59 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 123.102 0.561 . . . . 0.0 110.083 176.022 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.3 p -133.04 139.85 48.56 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 C-N-CA 125.165 1.386 . . . . 0.0 107.559 171.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.73 109.14 19.75 Favored 'General case' 0 N--CA 1.45 -0.426 0 N-CA-C 107.881 -1.155 . . . . 0.0 107.881 177.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.464 HD13 HD11 ' A' ' 62' ' ' LEU . 17.9 mt -90.51 145.63 24.74 Favored 'General case' 0 CA--C 1.52 -0.177 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 174.422 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 19.7 ttm180 -114.48 114.17 25.44 Favored 'General case' 0 C--O 1.236 0.368 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 174.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pp -114.97 160.96 14.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 125.003 1.321 . . . . 0.0 108.913 -179.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 89.4 mt -94.62 117.3 66.97 Favored Pre-proline 0 C--O 1.238 0.473 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 167.609 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 17.6 Cg_endo -87.87 -170.24 0.54 Allowed 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 124.987 3.791 . . . . 0.0 109.472 178.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 4.5 pm0 -145.43 164.54 31.24 Favored 'General case' 0 N--CA 1.449 -0.525 0 C-N-CA 124.263 1.025 . . . . 0.0 110.049 -173.516 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.2 pm0 -139.12 -1.45 1.75 Allowed 'General case' 0 CA--C 1.526 0.056 0 CA-C-N 118.215 0.461 . . . . 0.0 112.132 170.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -121.75 -13.73 8.25 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 114.71 1.374 . . . . 0.0 114.71 -165.379 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 8.5 mt -70.51 154.02 42.32 Favored 'General case' 0 C--O 1.24 0.596 0 C-N-CA 123.73 0.812 . . . . 0.0 109.217 166.098 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -161.29 141.01 10.53 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 126.16 1.784 . . . . 0.0 106.727 161.215 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 19.9 m -133.63 154.32 80.62 Favored Pre-proline 0 CA--C 1.538 0.503 0 CA-C-N 119.42 1.009 . . . . 0.0 110.104 -177.371 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -76.35 161.94 34.22 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 121.967 1.778 . . . . 0.0 111.468 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 77.3 p -72.21 -13.14 61.46 Favored 'General case' 0 N--CA 1.462 0.147 0 C-N-CA 124.427 1.091 . . . . 0.0 113.336 178.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 179.06 -179.03 48.97 Favored Glycine 0 N--CA 1.444 -0.826 0 N-CA-C 108.341 -1.904 . . . . 0.0 108.341 -175.295 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -63.3 136.79 57.3 Favored 'Trans proline' 0 N--CA 1.451 -1.008 0 C-N-CA 122.597 2.198 . . . . 0.0 110.684 178.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 2.8 m -72.55 136.04 45.74 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 107.183 -1.414 . . . . 0.0 107.183 158.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -160.26 -166.85 1.77 Allowed 'General case' 0 C--O 1.237 0.403 0 C-N-CA 124.022 0.929 . . . . 0.0 108.671 167.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.002 0 N-CA-C 103.429 -3.869 . . . . 0.0 103.429 142.031 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.512 0 N-CA-C 108.729 -1.749 . . . . 0.0 108.729 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 16.5 m -137.05 -91.82 0.24 Allowed 'General case' 0 CA--C 1.53 0.19 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -178.378 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 3.8 p -66.74 157.11 33.61 Favored 'General case' 0 C--O 1.238 0.478 0 C-N-CA 124.464 1.106 . . . . 0.0 110.656 173.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 146.53 177.59 21.27 Favored Glycine 0 CA--C 1.526 0.764 0 C-N-CA 126.568 2.033 . . . . 0.0 109.261 -172.395 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 12.3 t -61.44 143.27 56.14 Favored 'General case' 0 C--O 1.235 0.323 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 174.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.5 m -122.02 108.72 13.71 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 124.23 1.012 . . . . 0.0 109.294 -175.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.59 163.1 35.01 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 108.837 -1.705 . . . . 0.0 108.837 174.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.36 -53.4 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.23 0 C-N-CA 125.061 1.344 . . . . 0.0 108.15 174.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.4 mp -49.32 108.61 0.2 Allowed 'General case' 0 C--O 1.234 0.284 0 C-N-CA 127.773 2.429 . . . . 0.0 110.868 178.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -63.46 155.15 30.03 Favored 'General case' 0 C--O 1.233 0.232 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 167.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 32.9 p -132.93 169.07 17.32 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.172 0.589 . . . . 0.0 110.14 171.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.1 t -117.3 158.99 23.42 Favored 'General case' 0 C--O 1.234 0.276 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 148.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -129.3 94.62 3.83 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 105.783 -1.932 . . . . 0.0 105.783 174.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 15.2 t -92.58 96.14 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 C-N-CA 125.838 1.655 . . . . 0.0 107.513 -173.181 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.1 p -80.42 135.36 25.47 Favored 'Isoleucine or valine' 0 C--O 1.238 0.451 0 C-N-CA 123.322 0.649 . . . . 0.0 109.792 174.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 46.2 mt -132.28 126.46 55.79 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 C-N-CA 125.155 1.382 . . . . 0.0 107.74 176.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.9 m-70 -88.76 161.77 16.6 Favored 'General case' 0 C--O 1.233 0.219 0 C-N-CA 125.022 1.329 . . . . 0.0 108.877 171.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 49.3 ptt85 -144.22 -171.11 3.51 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 160.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -101.29 168.38 9.59 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 161.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -70.9 -33.68 70.8 Favored 'General case' 0 C--N 1.329 -0.295 0 O-C-N 121.162 -0.962 . . . . 0.0 112.473 -178.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -74.1 6.55 3.36 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 124.586 1.154 . . . . 0.0 113.0 -171.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -143.81 171.66 13.9 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 126.539 1.936 . . . . 0.0 109.261 -169.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -104.83 176.57 23.01 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 124.434 1.016 . . . . 0.0 111.032 178.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -83.44 133.43 34.91 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 107.006 -1.479 . . . . 0.0 107.006 163.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -96.89 57.24 1.28 Allowed Glycine 0 CA--C 1.521 0.441 0 C-N-CA 124.599 1.095 . . . . 0.0 112.66 -171.507 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 14.0 p90 -137.97 167.24 22.17 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 125.522 1.529 . . . . 0.0 108.213 172.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.576 HG12 ' H ' ' A' ' 49' ' ' ARG . 0.4 OUTLIER -132.39 157.65 43.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 107.23 -1.396 . . . . 0.0 107.23 176.236 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 20.3 mt -117.63 135.82 56.8 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 176.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 2.7 pt -129.8 156.59 42.19 Favored 'Isoleucine or valine' 0 C--O 1.241 0.634 0 C-N-CA 124.104 0.962 . . . . 0.0 109.686 175.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 36.3 t -167.67 -58.97 0.03 OUTLIER 'General case' 0 CA--C 1.53 0.181 0 C-N-CA 125.383 1.473 . . . . 0.0 109.363 -174.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 21.7 m 63.1 -65.85 0.1 Allowed 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 126.63 1.972 . . . . 0.0 112.582 -170.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 79.37 -0.48 2.26 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 128.564 2.746 . . . . 0.0 114.976 173.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 14.4 m120 -63.58 -178.11 0.26 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 127.829 2.452 . . . . 0.0 112.217 179.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.95 130.85 15.42 Favored Pre-proline 0 N--CA 1.469 0.509 0 CA-C-O 116.458 -1.734 . . . . 0.0 108.446 173.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.9 Cg_exo -58.48 -41.51 64.33 Favored 'Trans proline' 0 N--CA 1.461 -0.402 0 C-N-CA 121.797 1.665 . . . . 0.0 112.083 178.669 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 1.6 tm-20 -157.81 -77.28 0.08 Allowed 'General case' 0 CA--C 1.537 0.443 0 C-N-CA 126.08 1.752 . . . . 0.0 106.504 -179.193 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 92.5 p -142.41 -168.96 2.86 Favored 'General case' 0 CA--C 1.535 0.399 0 C-N-CA 127.383 2.273 . . . . 0.0 109.223 175.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 65.0 17.46 63.32 Favored Glycine 0 CA--C 1.53 1.018 0 CA-C-O 119.439 -0.645 . . . . 0.0 113.782 168.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 4.6 m -65.13 147.31 53.68 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 118.33 1.065 . . . . 0.0 110.378 -171.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.2 p -66.84 160.96 24.92 Favored 'General case' 0 C--O 1.24 0.555 0 C-N-CA 124.318 1.047 . . . . 0.0 109.57 166.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . 0.483 ' H ' HD12 ' A' ' 41' ' ' ILE . 3.2 mp -71.34 105.47 1.74 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.453 0 N-CA-C 104.863 -2.273 . . . . 0.0 104.863 160.035 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.2 t -67.83 -170.95 0.18 Allowed 'General case' 0 CA--C 1.542 0.641 0 CA-C-O 121.768 0.794 . . . . 0.0 109.368 169.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 89.7 t -108.47 123.27 37.85 Favored Pre-proline 0 C--O 1.238 0.476 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 174.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -66.48 112.51 2.39 Favored 'Trans proline' 0 N--CA 1.449 -1.111 0 N-CA-C 106.692 -2.08 . . . . 0.0 106.692 159.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.558 ' NE2' HD13 ' A' ' 84' ' ' ILE . 19.4 m80 68.76 108.19 0.05 Allowed 'General case' 0 CA--C 1.536 0.415 0 C-N-CA 126.531 1.933 . . . . 0.0 113.302 171.145 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 52.1 pttt -143.83 157.59 44.27 Favored 'General case' 0 N--CA 1.467 0.421 0 O-C-N 120.678 -1.264 . . . . 0.0 109.22 167.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 42.1 mm -65.06 123.86 18.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 172.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -110.46 -26.49 4.81 Favored Glycine 0 CA--C 1.535 1.285 0 N-CA-C 114.849 0.7 . . . . 0.0 114.849 176.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.576 ' H ' HG12 ' A' ' 27' ' ' VAL . 67.5 ttt180 -149.85 147.37 27.88 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 177.461 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.5 mt -121.84 131.76 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.72 0 N-CA-C 105.314 -2.106 . . . . 0.0 105.314 166.257 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 23.8 mm -65.32 153.89 7.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 -177.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -68.51 118.34 11.43 Favored 'General case' 0 C--N 1.328 -0.351 0 O-C-N 121.474 -0.766 . . . . 0.0 110.634 -169.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 68.41 1.87 24.14 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 115.952 1.141 . . . . 0.0 115.952 169.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.49 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 3.5 p -68.77 175.25 2.07 Favored Pre-proline 0 CA--C 1.554 1.108 0 C-N-CA 126.966 2.106 . . . . 0.0 113.067 178.63 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.49 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 3.3 Cg_exo -64.44 -24.43 64.02 Favored 'Trans proline' 0 C--N 1.351 0.704 0 C-N-CA 121.601 1.534 . . . . 0.0 115.154 -168.097 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -69.38 -48.2 61.9 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 118.803 0.729 . . . . 0.0 109.613 172.569 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -54.13 -49.63 68.75 Favored 'General case' 0 N--CA 1.464 0.262 0 C-N-CA 125.294 1.437 . . . . 0.0 110.168 177.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 55.4 mmt-85 -68.88 -15.61 63.54 Favored 'General case' 0 C--O 1.234 0.286 0 C-N-CA 123.694 0.797 . . . . 0.0 112.952 177.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 17.5 t -68.89 -28.2 66.47 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-O 117.724 -1.131 . . . . 0.0 110.357 177.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 59.38 -28.93 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.405 0 C-N-CA 128.595 2.758 . . . . 0.0 115.475 -174.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 47.9 mtmt -62.73 -33.17 74.58 Favored 'General case' 0 CA--C 1.521 -0.139 0 C-N-CA 125.55 1.54 . . . . 0.0 112.386 178.043 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -105.87 119.49 39.31 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 -165.081 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 3.0 ptpp? -131.99 167.91 18.84 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 119.665 1.12 . . . . 0.0 110.518 -178.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 73.7 t -64.34 137.77 24.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 178.223 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.96 -16.71 57.13 Favored Glycine 0 N--CA 1.447 -0.613 0 CA-C-O 117.475 -1.736 . . . . 0.0 110.725 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -67.45 92.88 0.31 Allowed 'General case' 0 C--N 1.346 0.426 0 CA-C-N 118.909 1.355 . . . . 0.0 108.458 -178.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.587 HH22 HD13 ' A' ' 105' ' ' LEU . 31.3 mtt85 -46.85 128.91 11.41 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 126.543 1.937 . . . . 0.0 110.892 165.173 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 55.0 mt -96.89 155.76 3.49 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.42 0 C-N-CA 126.417 1.887 . . . . 0.0 107.086 -178.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -124.13 -54.52 1.7 Allowed 'General case' 0 C--N 1.332 -0.177 0 C-N-CA 125.976 1.71 . . . . 0.0 107.961 -179.343 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -140.97 158.87 43.33 Favored 'General case' 0 N--CA 1.453 -0.325 0 C-N-CA 125.629 1.572 . . . . 0.0 108.764 -176.401 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.577 HG22 HD23 ' A' ' 97' ' ' LEU . 39.2 t -136.2 132.96 50.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 107.019 -1.474 . . . . 0.0 107.019 177.067 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 57.75 10.23 1.03 Allowed 'General case' 0 N--CA 1.472 0.653 0 C-N-CA 124.052 0.941 . . . . 0.0 112.449 -163.359 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 82.04 -2.28 84.42 Favored Glycine 0 CA--C 1.534 1.222 0 C-N-CA 125.0 1.286 . . . . 0.0 113.22 -170.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -75.64 141.32 42.82 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 120.537 2.168 . . . . 0.0 107.233 169.727 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 33.1 m -56.58 147.14 23.03 Favored 'General case' 0 CA--C 1.535 0.381 0 CA-C-N 118.71 0.686 . . . . 0.0 109.569 164.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 2.3 pp -116.56 5.66 7.26 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 C-N-CA 124.361 1.065 . . . . 0.0 111.838 172.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 98.0 mt -63.5 143.44 15.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.278 0 C-N-CA 124.274 1.03 . . . . 0.0 108.282 -179.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 61.62 -18.77 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 128.822 2.849 . . . . 0.0 117.291 172.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 4.8 mtp -55.87 145.78 51.21 Favored Pre-proline 0 C--O 1.241 0.611 0 CA-C-N 119.273 0.942 . . . . 0.0 110.034 177.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -69.18 155.21 68.51 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 122.629 2.22 . . . . 0.0 108.027 170.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -59.7 -32.16 70.25 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.7 -171.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.29 -39.45 72.71 Favored 'General case' 0 N--CA 1.452 -0.329 0 C-N-CA 126.214 1.806 . . . . 0.0 112.861 175.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 61.8 m-20 -70.98 -46.65 61.95 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -178.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.558 HD13 ' NE2' ' A' ' 45' ' ' HIS . 8.5 mt -64.66 -33.58 64.16 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 C-N-CA 126.018 1.727 . . . . 0.0 111.133 -179.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 10.5 t -65.07 -51.51 65.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.32 0 C-N-CA 124.475 1.11 . . . . 0.0 108.888 170.052 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.71 -37.34 81.38 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 116.77 -1.586 . . . . 0.0 110.984 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -51.64 -49.17 62.78 Favored 'General case' 0 N--CA 1.445 -0.697 0 C-N-CA 125.88 1.672 . . . . 0.0 111.301 173.395 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 53.2 mt -70.23 -38.65 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.16 0 O-C-N 121.066 -1.021 . . . . 0.0 108.873 -178.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.1 tttp -65.96 -38.49 88.73 Favored 'General case' 0 N--CA 1.453 -0.291 0 O-C-N 121.728 -0.607 . . . . 0.0 110.925 -179.416 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -66.45 -19.04 65.69 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 129.381 3.072 . . . . 0.0 111.588 174.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -64.5 -31.05 72.1 Favored 'General case' 0 CA--C 1.537 0.453 0 O-C-N 121.722 -0.611 . . . . 0.0 111.938 -178.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 87.65 -149.85 22.03 Favored Glycine 0 CA--C 1.527 0.816 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -169.19 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.7 mt -83.1 -20.76 34.24 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 118.201 1.001 . . . . 0.0 111.534 178.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.2 p -94.49 139.52 31.05 Favored 'General case' 0 N--CA 1.452 -0.354 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 169.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.2 p -145.02 148.15 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 169.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.6 m -125.09 118.39 26.03 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 178.227 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.577 HD23 HG22 ' A' ' 71' ' ' VAL . 71.4 mt -90.78 124.05 34.83 Favored 'General case' 0 CA--C 1.509 -0.597 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 170.405 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 24.5 ttm105 -96.13 121.46 37.93 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 168.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -125.56 173.88 10.63 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 C-N-CA 125.559 1.543 . . . . 0.0 109.211 -166.303 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.6 mp -114.58 104.57 54.34 Favored Pre-proline 0 C--O 1.237 0.408 0 C-N-CA 124.057 0.943 . . . . 0.0 108.581 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.34 178.93 5.52 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 123.564 2.843 . . . . 0.0 110.335 173.583 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -151.53 162.92 40.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 O-C-N 121.751 -0.593 . . . . 0.0 110.714 -171.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -133.64 -13.37 2.59 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 124.294 1.038 . . . . 0.0 113.156 179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.69 -8.11 0.74 Allowed 'General case' 0 C--N 1.322 -0.589 0 C-N-CA 124.397 1.079 . . . . 0.0 112.796 -165.723 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.587 HD13 HH22 ' A' ' 67' ' ' ARG . 17.9 mt -90.03 100.06 12.95 Favored 'General case' 0 CA--C 1.534 0.334 0 C-N-CA 125.286 1.434 . . . . 0.0 110.493 -175.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 11.0 p-10 -111.46 -157.67 0.62 Allowed 'General case' 0 N--CA 1.471 0.613 0 C-N-CA 125.08 1.352 . . . . 0.0 110.152 172.402 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.7 p -121.6 143.17 37.36 Favored Pre-proline 0 CA--C 1.533 0.291 0 CA-C-O 117.253 -1.356 . . . . 0.0 107.816 161.502 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -73.37 -7.85 20.99 Favored 'Trans proline' 0 CA--C 1.533 0.471 0 C-N-CA 122.633 2.222 . . . . 0.0 115.572 -158.379 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.9 m 36.09 85.36 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 126.658 1.983 . . . . 0.0 115.014 171.551 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -122.54 84.69 0.37 Allowed Glycine 0 CA--C 1.53 0.993 0 C-N-CA 124.317 0.961 . . . . 0.0 111.633 178.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -63.42 -52.1 2.18 Favored 'Trans proline' 0 N--CA 1.457 -0.648 0 CA-C-N 119.914 1.857 . . . . 0.0 110.679 167.006 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 14.0 t -66.42 135.24 54.01 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 123.139 0.575 . . . . 0.0 109.628 -177.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.0 m 59.77 85.81 0.1 Allowed 'General case' 0 C--O 1.232 0.173 0 C-N-CA 126.964 2.106 . . . . 0.0 109.629 -170.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.084 0 N-CA-C 107.331 -2.308 . . . . 0.0 107.331 173.363 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.771 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.5 m -104.69 149.45 25.56 Favored 'General case' 0 C--O 1.233 0.212 0 C-N-CA 124.481 1.112 . . . . 0.0 110.434 174.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 49.3 m -52.04 121.74 7.26 Favored 'General case' 0 C--O 1.236 0.375 0 C-N-CA 123.853 0.861 . . . . 0.0 108.809 165.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 150.14 177.73 24.4 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 106.646 -2.582 . . . . 0.0 106.646 -153.549 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 68.8 m -112.77 175.19 5.54 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -155.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 33.7 m -132.88 80.31 1.88 Allowed 'General case' 0 C--O 1.234 0.259 0 C-N-CA 125.735 1.614 . . . . 0.0 107.158 -179.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.61 91.09 0.09 OUTLIER Glycine 0 C--N 1.334 0.452 0 N-CA-C 111.341 -0.704 . . . . 0.0 111.341 -171.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 51.3 m -162.74 158.63 23.17 Favored 'General case' 0 C--O 1.238 0.481 0 C-N-CA 126.716 2.006 . . . . 0.0 107.284 166.251 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 11.0 mp 48.37 51.97 14.28 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 126.27 1.828 . . . . 0.0 111.333 175.445 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 28.1 tt0 -63.86 134.43 55.18 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 174.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 32.8 p -113.92 169.76 8.76 Favored 'General case' 0 C--O 1.238 0.463 0 C-N-CA 124.661 1.184 . . . . 0.0 109.772 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 42.2 m -111.04 153.23 25.91 Favored 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 106.335 -1.728 . . . . 0.0 106.335 162.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -122.89 115.38 21.85 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 105.108 -2.182 . . . . 0.0 105.108 174.114 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -112.31 97.14 5.35 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 C-N-CA 123.703 0.801 . . . . 0.0 109.163 -173.107 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 4.5 p -76.75 141.36 15.77 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 170.253 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 59.7 mt -136.58 140.03 44.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.344 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 173.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 14.7 m-70 -124.7 113.28 17.78 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 127.789 2.436 . . . . 0.0 108.117 -170.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.2 ptt180 -106.16 -179.41 3.93 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 119.287 0.948 . . . . 0.0 111.238 -176.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.93 161.08 13.91 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 119.049 0.84 . . . . 0.0 110.257 170.247 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -64.41 -19.79 65.73 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 124.501 1.12 . . . . 0.0 112.216 177.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.8 m120 -87.68 -16.87 33.13 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 119.537 1.062 . . . . 0.0 113.235 178.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -113.09 -178.53 3.4 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 119.281 0.946 . . . . 0.0 109.877 -171.445 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -105.72 -176.38 23.93 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 169.414 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -78.31 176.79 8.98 Favored 'General case' 0 CA--C 1.533 0.316 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 153.53 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.418 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -135.13 50.79 0.85 Allowed Glycine 0 C--O 1.224 -0.531 0 CA-C-O 118.234 -1.315 . . . . 0.0 113.195 -172.123 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . 0.52 ' CE2' HD11 ' A' ' 28' ' ' ILE . 11.7 p90 -137.74 135.5 36.44 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 124.756 1.222 . . . . 0.0 110.299 -179.405 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 39.2 t -102.91 109.25 26.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 -179.108 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.552 HD12 ' H ' ' A' ' 28' ' ' ILE . 4.1 mp -82.26 124.91 39.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 175.21 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.533 HD11 ' HE2' ' A' ' 46' ' ' LYS . 15.5 pt -111.88 153.28 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 C-N-CA 123.852 0.861 . . . . 0.0 109.746 177.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 31.3 t -91.75 -63.27 1.27 Allowed 'General case' 0 N--CA 1.447 -0.607 0 C-N-CA 126.113 1.765 . . . . 0.0 106.737 169.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 30.1 m 46.92 64.89 1.38 Allowed 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 125.392 1.477 . . . . 0.0 111.647 -173.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER 75.71 86.58 0.09 Allowed 'General case' 0 CA--C 1.529 0.162 0 C-N-CA 129.998 3.319 . . . . 0.0 109.691 178.401 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 52.3 t-20 -61.96 136.92 58.17 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 125.381 1.472 . . . . 0.0 109.315 175.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 5.1 mtt180 -132.98 151.99 78.96 Favored Pre-proline 0 C--O 1.236 0.387 0 C-N-CA 124.311 1.044 . . . . 0.0 108.976 167.454 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -70.25 95.93 0.61 Allowed 'Trans proline' 0 N--CA 1.451 -1.008 0 C-N-CA 123.999 3.133 . . . . 0.0 108.642 175.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -68.03 110.75 4.07 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 171.381 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.1 t -149.56 103.48 3.27 Favored 'General case' 0 N--CA 1.453 -0.279 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 -164.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 75.25 -109.13 2.7 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 108.542 -1.823 . . . . 0.0 108.542 -179.098 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.3 m -65.07 109.97 2.34 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 124.328 1.051 . . . . 0.0 109.754 177.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 22.0 p -72.14 148.02 46.08 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.375 1.07 . . . . 0.0 111.843 -174.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 84.4 mt -144.39 -51.97 0.15 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.399 0 C-N-CA 125.19 1.396 . . . . 0.0 109.1 -174.235 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -146.86 99.34 3.17 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 123.923 0.889 . . . . 0.0 109.623 -159.238 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 15.9 t -65.55 130.95 94.73 Favored Pre-proline 0 CA--C 1.54 0.571 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -174.407 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -72.97 -19.92 22.66 Favored 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 122.456 2.104 . . . . 0.0 113.905 -174.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -136.59 140.4 42.83 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 120.815 1.643 . . . . 0.0 108.071 176.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.533 ' HE2' HD11 ' A' ' 29' ' ' ILE . 10.7 pttm -156.5 165.64 35.73 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 170.146 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.438 HD13 HD11 ' A' ' 68' ' ' ILE . 6.9 mm -66.59 148.35 12.14 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.809 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 167.488 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -134.85 -8.45 1.89 Allowed Glycine 0 CA--C 1.529 0.959 0 C-N-CA 125.081 1.324 . . . . 0.0 113.765 173.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 38.0 ttt180 -165.75 160.95 17.7 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 126.283 1.833 . . . . 0.0 107.13 165.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 36.4 mt -132.54 149.95 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.482 0 C-N-CA 125.654 1.582 . . . . 0.0 107.685 172.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 41.5 mm -81.77 118.38 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 C-N-CA 125.529 1.532 . . . . 0.0 108.841 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -62.77 96.31 0.08 Allowed 'General case' 0 C--O 1.235 0.332 0 C-N-CA 125.502 1.521 . . . . 0.0 107.957 168.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.23 0.22 6.41 Favored Glycine 0 CA--C 1.525 0.706 0 C-N-CA 125.216 1.388 . . . . 0.0 113.698 -179.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.418 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 66.8 p -91.45 166.28 18.7 Favored Pre-proline 0 C--O 1.237 0.415 0 CA-C-N 118.911 1.355 . . . . 0.0 113.333 -179.768 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -62.96 -32.29 76.59 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.55 2.167 . . . . 0.0 111.659 166.079 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.02 -47.24 74.97 Favored 'General case' 0 C--N 1.346 0.414 0 CA-C-N 119.04 0.836 . . . . 0.0 110.806 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.4 t0 -67.97 -52.68 33.1 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.744 0.418 . . . . 0.0 111.043 178.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 15.0 mtp85 -57.7 -34.61 69.63 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 121.589 -0.694 . . . . 0.0 112.285 -173.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 61.1 m -62.81 -16.54 58.62 Favored 'General case' 0 CA--C 1.534 0.345 0 CA-C-O 117.709 -1.138 . . . . 0.0 112.494 -178.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 46.21 34.98 2.36 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 126.105 1.762 . . . . 0.0 113.623 170.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 18.9 mtmm -129.65 -6.99 4.61 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 126.908 2.083 . . . . 0.0 111.829 173.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -140.14 101.06 4.06 Favored 'General case' 0 N--CA 1.454 -0.273 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 -173.434 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 13.3 pttp -126.75 159.41 33.85 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 126.184 1.794 . . . . 0.0 109.688 -168.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . 0.374 0.4 OUTLIER -65.5 111.69 1.53 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.255 0 O-C-N 121.363 -0.836 . . . . 0.0 109.476 179.814 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 129.95 -18.79 5.3 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 128.285 2.85 . . . . 0.0 111.462 -175.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -71.56 97.26 1.66 Allowed 'General case' 0 CA--C 1.531 0.216 0 C-N-CA 124.401 1.08 . . . . 0.0 110.333 171.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.2 mtm180 -54.34 150.59 8.52 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 127.687 2.395 . . . . 0.0 111.75 173.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.484 HG22 ' CD1' ' A' ' 76' ' ' ILE . 87.7 mt -124.86 117.14 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 -165.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 76.5 mt -89.0 -40.19 13.17 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 124.327 1.051 . . . . 0.0 112.179 179.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.49 170.65 21.93 Favored 'General case' 0 C--O 1.237 0.434 0 C-N-CA 124.676 1.19 . . . . 0.0 108.764 -170.049 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 7.4 p -122.48 122.81 67.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 170.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 54.32 -73.0 0.01 OUTLIER 'General case' 0 C--O 1.232 0.177 0 C-N-CA 128.191 2.597 . . . . 0.0 111.783 -170.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -155.75 18.93 0.5 Allowed Glycine 0 CA--C 1.529 0.957 0 C-N-CA 126.887 2.184 . . . . 0.0 112.034 -178.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 24.2 mm100 -115.18 135.17 54.46 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-N 119.661 1.73 . . . . 0.0 108.572 -175.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 1.7 m -72.61 110.23 6.83 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 123.977 0.911 . . . . 0.0 109.759 174.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.484 ' CD1' HG22 ' A' ' 68' ' ' ILE . 11.1 pt -75.99 -15.63 15.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.688 0 C-N-CA 125.133 1.373 . . . . 0.0 111.962 174.644 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.522 HD12 ' H ' ' A' ' 77' ' ' ILE . 4.1 mp -56.03 -47.0 80.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 C-N-CA 125.121 1.368 . . . . 0.0 113.713 -164.644 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 68.0 m-80 -113.83 -0.93 14.03 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 124.365 1.066 . . . . 0.0 112.237 -169.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . 0.252 11.0 ttt -68.81 146.95 97.82 Favored Pre-proline 0 N--CA 1.434 -1.245 0 C-N-CA 130.62 3.568 . . . . 0.0 109.846 -178.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -57.07 141.34 94.17 Favored 'Trans proline' 0 CA--C 1.532 0.396 0 C-N-CA 122.816 2.344 . . . . 0.0 109.792 167.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.517 ' HA ' HD12 ' A' ' 84' ' ' ILE . 41.4 t60 -66.64 -36.34 82.33 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 120.246 1.384 . . . . 0.0 111.055 -178.264 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -57.72 -31.34 66.33 Favored 'General case' 0 CA--C 1.534 0.332 0 O-C-N 121.361 -0.837 . . . . 0.0 112.74 171.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 49.8 t0 -73.42 -48.52 33.1 Favored 'General case' 0 N--CA 1.464 0.266 0 C-N-CA 124.308 1.043 . . . . 0.0 109.144 177.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.517 HD12 ' HA ' ' A' ' 81' ' ' HIS . 66.2 mt -56.67 -35.59 45.89 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 C-N-CA 125.505 1.522 . . . . 0.0 110.698 175.151 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 45.9 t -77.07 -39.81 29.57 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.369 0 C-N-CA 124.176 0.991 . . . . 0.0 110.313 177.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 21.0 ttmt -60.4 -38.5 84.19 Favored 'General case' 0 N--CA 1.465 0.277 0 O-C-N 120.9 -1.125 . . . . 0.0 110.124 173.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -57.61 -38.63 75.28 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 127.464 2.306 . . . . 0.0 112.598 174.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 59.9 mt -68.08 -45.98 82.4 Favored 'Isoleucine or valine' 0 C--N 1.341 0.206 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 174.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 6.5 tttm -64.16 -40.14 95.49 Favored 'General case' 0 CA--C 1.536 0.416 0 O-C-N 121.739 -0.601 . . . . 0.0 110.263 -176.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -65.69 -11.8 48.22 Favored 'General case' 0 C--N 1.33 -0.259 0 C-N-CA 127.099 2.159 . . . . 0.0 112.188 176.323 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -66.67 -13.4 61.18 Favored 'General case' 0 CA--C 1.541 0.633 0 O-C-N 121.34 -0.85 . . . . 0.0 112.155 170.656 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 72.66 -90.04 0.55 Allowed Glycine 0 C--N 1.34 0.796 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 66.6 mt -125.74 -34.49 2.62 Favored 'General case' 0 CA--C 1.514 -0.423 0 C-N-CA 125.589 1.556 . . . . 0.0 111.526 175.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -100.63 121.85 42.31 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 118.377 0.535 . . . . 0.0 110.131 -179.129 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 11.7 p -123.96 147.69 28.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 173.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.6 m -119.15 135.79 54.49 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 173.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 31.0 mt -125.19 110.57 14.24 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 125.309 1.444 . . . . 0.0 108.317 -176.326 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 33.4 ttm180 -77.74 106.83 9.81 Favored 'General case' 0 C--O 1.238 0.483 0 C-N-CA 123.811 0.844 . . . . 0.0 111.211 177.087 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -111.27 168.73 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 124.161 0.984 . . . . 0.0 110.597 -175.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.1 mp -93.77 118.15 67.35 Favored Pre-proline 0 CA--C 1.54 0.583 0 CA-C-O 118.061 -0.971 . . . . 0.0 108.627 175.172 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -74.65 -169.48 0.62 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 124.095 3.197 . . . . 0.0 112.296 174.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 3.0 pm0 -155.71 153.76 30.45 Favored 'General case' 0 N--CA 1.443 -0.785 0 C-N-CA 125.372 1.469 . . . . 0.0 108.782 -174.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -145.0 18.22 1.6 Allowed 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.428 1.091 . . . . 0.0 111.017 -175.207 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -150.44 -32.79 0.18 Allowed 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 124.903 1.281 . . . . 0.0 113.137 -164.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 49.0 mt -67.37 109.97 3.38 Favored 'General case' 0 C--N 1.323 -0.578 0 C-N-CA 126.804 2.041 . . . . 0.0 106.06 173.136 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -162.51 155.75 20.15 Favored 'General case' 0 C--N 1.327 -0.383 0 C-N-CA 127.007 2.123 . . . . 0.0 106.002 -176.239 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -148.03 149.88 33.91 Favored Pre-proline 0 CA--C 1.537 0.453 0 CA-C-N 119.976 1.262 . . . . 0.0 110.238 173.039 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -92.9 -1.73 3.62 Favored 'Trans proline' 0 CA--C 1.544 0.992 0 C-N-CA 124.362 3.375 . . . . 0.0 113.872 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 12.8 m -2.83 81.19 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 131.093 3.757 . . . . 0.0 116.087 -172.75 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -96.54 -176.92 35.65 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 126.012 1.767 . . . . 0.0 110.899 172.138 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -68.24 165.94 26.94 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 122.367 2.045 . . . . 0.0 110.244 173.011 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.4 p -160.54 172.64 16.82 Favored 'General case' 0 C--O 1.239 0.527 0 C-N-CA 123.816 0.846 . . . . 0.0 109.168 175.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . 0.261 71.0 p 55.19 -173.05 0.05 Allowed 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 127.402 2.281 . . . . 0.0 112.587 -173.534 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.932 1 N-CA-C 101.773 -4.531 . . . . 0.0 101.773 -96.221 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.471 0.984 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.6 m -63.92 128.59 36.5 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 125.585 1.554 . . . . 0.0 107.333 167.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.8 t -69.2 163.09 25.7 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 119.002 0.819 . . . . 0.0 111.192 -166.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -141.53 103.44 0.34 Allowed Glycine 0 C--N 1.332 0.332 0 N-CA-C 109.025 -1.63 . . . . 0.0 109.025 -175.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.4 m -66.14 -37.76 86.48 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 124.678 1.191 . . . . 0.0 113.135 -172.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 65.5 m 43.7 85.3 0.02 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 125.224 1.409 . . . . 0.0 112.567 -166.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -86.26 -96.53 0.8 Allowed Glycine 0 CA--C 1.523 0.562 0 N-CA-C 108.582 -1.807 . . . . 0.0 108.582 164.303 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.9 t 67.01 -60.63 0.36 Allowed 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 126.559 1.944 . . . . 0.0 110.815 -172.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 tp -68.93 165.23 20.42 Favored 'General case' 0 C--O 1.238 0.46 0 C-N-CA 124.263 1.025 . . . . 0.0 110.083 176.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 70.5 mt-30 -123.75 138.56 54.49 Favored 'General case' 0 N--CA 1.451 -0.393 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 170.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 44.6 p -131.22 166.09 21.93 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 167.101 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 m -141.74 150.69 42.12 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 124.706 1.202 . . . . 0.0 108.421 172.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -104.84 97.37 7.26 Favored 'General case' 0 C--O 1.238 0.497 0 C-N-CA 127.722 2.409 . . . . 0.0 105.862 -179.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 36.9 t -91.65 95.1 5.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 173.059 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 8.2 p -74.45 137.7 22.59 Favored 'Isoleucine or valine' 0 C--O 1.238 0.493 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 169.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.5 mt -135.61 134.55 51.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 N-CA-C 104.835 -2.283 . . . . 0.0 104.835 174.346 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -108.33 160.43 15.87 Favored 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 124.542 1.137 . . . . 0.0 109.526 177.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 43.4 ptt85 -150.95 -179.64 7.46 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 119.424 1.011 . . . . 0.0 109.582 170.347 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.45 162.59 16.39 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 168.14 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -60.14 -42.52 95.01 Favored 'General case' 0 N--CA 1.455 -0.177 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 174.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -71.52 -1.49 13.54 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-O 117.963 -1.018 . . . . 0.0 113.254 -167.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 5.1 pt-20 -137.1 179.07 6.6 Favored 'General case' 0 CA--C 1.541 0.601 0 CA-C-N 121.278 1.854 . . . . 0.0 110.754 170.136 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -111.45 165.02 12.08 Favored Glycine 0 CA--C 1.532 1.106 0 C-N-CA 126.002 1.763 . . . . 0.0 110.169 170.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -66.94 148.96 51.27 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 124.637 1.175 . . . . 0.0 108.398 178.16 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.88 49.12 3.31 Favored Glycine 0 C--O 1.222 -0.629 0 CA-C-O 117.94 -1.478 . . . . 0.0 113.698 -174.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -136.22 156.27 48.91 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 120.745 2.273 . . . . 0.0 111.926 174.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.9 t -128.16 106.39 14.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.3 0 N-CA-C 106.687 -1.597 . . . . 0.0 106.687 -175.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 23.8 mt -73.68 141.67 15.92 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 N-CA-C 107.353 -1.351 . . . . 0.0 107.353 168.066 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.493 HD11 ' HE2' ' A' ' 46' ' ' LYS . 35.7 pt -127.09 170.9 16.3 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 C-N-CA 125.308 1.443 . . . . 0.0 110.826 174.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 13.5 m 62.57 95.42 0.04 OUTLIER 'General case' 0 CA--C 1.531 0.222 0 C-N-CA 128.088 2.555 . . . . 0.0 114.27 173.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 11.5 p -92.61 96.44 10.2 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 158.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 57.3 mt -70.68 151.49 44.86 Favored 'General case' 0 C--O 1.244 0.797 0 N-CA-C 106.777 -1.564 . . . . 0.0 106.777 155.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 24.3 t30 -168.09 93.69 0.37 Allowed 'General case' 0 CA--C 1.534 0.345 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 169.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 33.3 mtt85 -117.1 156.4 48.49 Favored Pre-proline 0 N--CA 1.474 0.754 0 O-C-N 120.723 -1.235 . . . . 0.0 111.202 170.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -81.82 77.61 3.81 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 123.621 2.881 . . . . 0.0 108.972 172.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.0 tm-20 170.91 -42.28 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.684 0 C-N-CA 129.916 3.286 . . . . 0.0 107.452 173.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 5.3 m 72.4 -70.38 0.16 Allowed 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 127.699 2.4 . . . . 0.0 111.289 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 59.34 -173.56 4.1 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 124.153 0.882 . . . . 0.0 113.48 177.612 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 59.1 m -78.6 111.57 14.8 Favored 'General case' 0 C--O 1.233 0.23 0 O-C-N 121.675 -0.897 . . . . 0.0 109.344 172.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -103.64 137.83 41.14 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 125.655 1.582 . . . . 0.0 108.709 -179.097 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 10.9 mm -67.89 -76.96 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 118.79 0.723 . . . . 0.0 109.702 -177.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 8.0 m -56.23 131.11 47.02 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 173.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -68.45 156.65 90.02 Favored Pre-proline 0 CA--C 1.541 0.63 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 174.297 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -74.16 -108.75 0.01 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.91 0 C-N-CA 122.58 2.187 . . . . 0.0 109.289 163.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.16 119.79 13.31 Favored 'General case' 0 N--CA 1.45 -0.474 0 CA-C-O 122.809 1.29 . . . . 0.0 110.973 -167.601 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.493 ' HE2' HD11 ' A' ' 29' ' ' ILE . 15.2 pttm -152.47 160.08 43.29 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 128.523 2.729 . . . . 0.0 106.267 178.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.409 HG13 HD22 ' A' ' 62' ' ' LEU . 34.6 mm -64.33 126.76 23.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 164.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -109.22 -21.14 7.49 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 125.717 1.627 . . . . 0.0 113.757 174.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 53.7 ttt180 -161.7 162.34 29.74 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 126.438 1.895 . . . . 0.0 108.06 166.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 6.5 mt -127.98 150.38 33.7 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 126.422 1.889 . . . . 0.0 108.094 170.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 21.3 mm -85.34 128.67 38.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 C-N-CA 126.245 1.818 . . . . 0.0 107.226 178.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -62.1 143.02 57.24 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 123.23 0.612 . . . . 0.0 112.047 -172.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.68 -8.11 6.2 Favored Glycine 0 CA--C 1.533 1.169 0 C-N-CA 125.441 1.496 . . . . 0.0 115.47 176.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.456 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 84.8 p -67.49 170.25 7.25 Favored Pre-proline 0 C--O 1.239 0.518 0 CA-C-N 118.241 1.02 . . . . 0.0 112.198 -173.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.456 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 6.3 Cg_endo -57.23 -21.61 44.48 Favored 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.028 1.819 . . . . 0.0 112.508 165.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.43 -50.18 13.25 Favored 'General case' 0 C--N 1.342 0.242 0 CA-C-N 119.883 1.22 . . . . 0.0 110.699 174.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -63.58 -45.09 92.01 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 118.533 0.606 . . . . 0.0 110.763 -175.467 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 70.8 mtp180 -70.55 -13.78 62.24 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 123.565 0.746 . . . . 0.0 112.197 178.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 35.6 t -63.16 -49.99 72.15 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 119.127 0.876 . . . . 0.0 109.211 179.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.93 -21.41 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.673 0 C-N-CA 128.439 2.695 . . . . 0.0 115.679 -173.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 11.4 mmmm -63.21 -26.56 68.85 Favored 'General case' 0 C--O 1.231 0.104 0 C-N-CA 125.976 1.71 . . . . 0.0 110.565 165.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.409 HD22 HG13 ' A' ' 47' ' ' ILE . 0.2 OUTLIER -99.39 138.43 36.49 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 161.753 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 21.1 pttm -139.74 171.21 14.55 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 123.641 0.777 . . . . 0.0 110.795 164.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 84.6 t -59.85 137.96 21.52 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.714 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 175.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 93.83 -7.31 73.78 Favored Glycine 0 C--N 1.341 0.849 0 O-C-N 121.039 -1.038 . . . . 0.0 110.567 177.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 68.9 m-20 -71.84 98.76 2.05 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 106.768 -1.567 . . . . 0.0 106.768 171.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.9 mtt180 -45.78 158.46 0.09 Allowed 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 127.519 2.328 . . . . 0.0 110.841 162.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 19.1 mt -138.47 118.07 14.66 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -170.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.434 HD22 ' H ' ' A' ' 69' ' ' LEU . 1.9 mm? -78.17 -45.25 23.65 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 124.567 1.147 . . . . 0.0 111.732 172.21 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -160.3 166.24 29.86 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 124.181 0.992 . . . . 0.0 112.163 -160.475 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 14.2 p -128.66 111.83 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 C-N-CA 126.191 1.796 . . . . 0.0 110.138 -178.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.5 m-20 56.0 17.48 2.64 Favored 'General case' 0 N--CA 1.465 0.282 0 C-N-CA 125.285 1.434 . . . . 0.0 111.147 -168.545 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 99.48 -10.33 61.13 Favored Glycine 0 CA--C 1.529 0.944 0 CA-C-O 117.527 -1.707 . . . . 0.0 114.382 -175.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 3.3 tp60 -75.92 132.15 40.08 Favored 'General case' 0 C--N 1.341 0.235 0 CA-C-N 120.51 2.155 . . . . 0.0 107.478 177.394 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 24.3 p -61.68 137.02 58.22 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 124.181 0.992 . . . . 0.0 109.949 175.039 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.7 pt -114.55 -4.37 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 C-N-CA 124.908 1.283 . . . . 0.0 111.331 179.286 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 2.5 mt -57.9 145.14 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.596 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 162.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 18.7 m-80 67.13 -21.92 0.11 Allowed 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 128.117 2.567 . . . . 0.0 116.036 171.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 6.6 mtp -69.45 150.7 96.95 Favored Pre-proline 0 C--O 1.244 0.767 0 C-N-CA 124.658 1.183 . . . . 0.0 109.86 175.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -74.68 154.46 44.15 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 123.17 2.58 . . . . 0.0 109.856 173.154 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -54.99 -41.82 71.71 Favored 'General case' 0 N--CA 1.462 0.13 0 C-N-CA 123.42 0.688 . . . . 0.0 111.604 -178.418 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -57.15 -44.58 83.56 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-O 118.822 -0.609 . . . . 0.0 111.332 -174.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -69.52 -42.44 74.69 Favored 'General case' 0 C--O 1.221 -0.413 0 O-C-N 124.36 1.037 . . . . 0.0 110.011 -175.763 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 68.4 mt -63.33 -41.22 91.94 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 124.797 1.239 . . . . 0.0 109.679 178.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 41.4 t -62.55 -48.04 90.1 Favored 'Isoleucine or valine' 0 C--O 1.239 0.524 0 O-C-N 121.161 -0.962 . . . . 0.0 109.456 174.027 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 6.1 tptt -58.44 -43.68 88.86 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 118.614 -0.708 . . . . 0.0 111.279 176.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.05 -34.45 73.43 Favored 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 126.154 1.781 . . . . 0.0 111.71 -176.873 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 58.1 mt -73.15 -47.63 46.56 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.317 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 173.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 29.3 tttt -58.29 -32.92 68.89 Favored 'General case' 0 CA--C 1.53 0.204 0 O-C-N 122.096 -0.378 . . . . 0.0 111.686 -177.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -99.76 2.09 43.81 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 125.173 1.389 . . . . 0.0 112.276 -177.024 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -54.92 -29.57 56.55 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -171.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 123.13 27.57 1.49 Allowed Glycine 0 CA--C 1.526 0.768 0 C-N-CA 124.349 0.976 . . . . 0.0 113.285 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 7.8 mt 58.02 -23.11 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.931 0 C-N-CA 129.023 2.929 . . . . 0.0 114.555 -164.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -93.56 148.59 21.95 Favored 'General case' 0 N--CA 1.435 -1.195 0 N-CA-C 105.24 -2.133 . . . . 0.0 105.24 161.316 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 13.1 p -143.26 140.48 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.044 0 N-CA-C 105.009 -2.219 . . . . 0.0 105.009 169.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.9 m -117.97 102.42 9.04 Favored 'General case' 0 N--CA 1.441 -0.911 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 -179.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 21.6 mt -90.13 122.1 32.78 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 106.476 -1.676 . . . . 0.0 106.476 -172.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.1 ttt180 -83.73 109.77 17.76 Favored 'General case' 0 N--CA 1.453 -0.318 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 178.011 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.4 pp -111.94 160.97 11.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 C-N-CA 123.429 0.692 . . . . 0.0 110.83 -177.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 28.5 mt -90.6 120.35 68.92 Favored Pre-proline 0 CA--C 1.537 0.459 0 N-CA-C 106.731 -1.581 . . . . 0.0 106.731 169.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -87.19 -170.83 0.65 Allowed 'Trans proline' 0 N--CA 1.45 -1.046 0 C-N-CA 123.915 3.077 . . . . 0.0 110.978 177.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -145.77 170.41 16.58 Favored 'General case' 0 N--CA 1.443 -0.808 0 C-N-CA 123.642 0.777 . . . . 0.0 109.293 -178.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -146.55 -7.52 0.51 Allowed 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 113.11 0.782 . . . . 0.0 113.11 156.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 24.5 pt-20 -102.75 -9.25 20.17 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 123.787 0.835 . . . . 0.0 112.688 -166.52 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 18.1 mt -77.33 163.01 26.84 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 123.416 0.687 . . . . 0.0 109.706 -178.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -147.85 179.29 7.83 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 161.553 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 2.3 t -72.09 126.51 91.19 Favored Pre-proline 0 N--CA 1.449 -0.515 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 167.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -73.65 -179.56 4.65 Favored 'Trans proline' 0 N--CA 1.451 -1.024 0 C-N-CA 123.211 2.608 . . . . 0.0 109.651 171.403 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 5.7 t -145.33 160.78 41.01 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 160.381 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -138.55 167.18 25.11 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 108.652 -1.779 . . . . 0.0 108.652 170.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -74.52 -175.93 2.51 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 123.348 2.699 . . . . 0.0 111.673 -175.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 10.6 t -129.88 -174.65 3.37 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 127.551 2.34 . . . . 0.0 107.71 165.762 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 24.2 t -67.03 175.84 2.38 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 124.288 1.035 . . . . 0.0 110.316 174.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.42 0 N-CA-C 106.332 -2.707 . . . . 0.0 106.332 144.498 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.391 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 15.7 t -64.29 112.37 3.03 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 171.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.2 m -81.18 98.52 8.1 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 171.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.21 -143.57 3.79 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 108.338 -1.905 . . . . 0.0 108.338 -177.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 14.8 m -140.11 -5.59 1.28 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 114.125 1.158 . . . . 0.0 114.125 174.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 36.3 p -124.84 160.97 27.55 Favored 'General case' 0 C--O 1.238 0.49 0 CA-C-N 120.583 1.538 . . . . 0.0 111.127 -176.509 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 144.58 71.29 0.02 OUTLIER Glycine 0 C--N 1.332 0.308 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 172.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 19.7 t -62.91 -53.71 49.8 Favored 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 117.815 0.808 . . . . 0.0 108.986 173.598 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -102.33 140.7 36.27 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 177.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -156.15 -130.59 0.03 OUTLIER 'General case' 0 C--O 1.232 0.134 0 C-N-CA 125.511 1.525 . . . . 0.0 109.691 173.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 16.7 p -136.47 169.18 18.11 Favored 'General case' 0 C--N 1.319 -0.746 0 C-N-CA 129.232 3.013 . . . . 0.0 110.589 -177.606 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -135.23 163.83 29.07 Favored 'General case' 0 CA--C 1.522 -0.12 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 162.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -134.42 94.85 3.27 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 127.185 2.194 . . . . 0.0 107.245 -174.043 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.8 t -96.89 109.73 23.63 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 C-N-CA 125.373 1.469 . . . . 0.0 107.86 -165.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 1.5 t -84.16 141.89 14.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.286 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 173.634 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 69.7 mt -138.22 149.79 24.56 Favored 'Isoleucine or valine' 0 C--O 1.235 0.302 0 N-CA-C 105.57 -2.011 . . . . 0.0 105.57 173.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 91.3 m-70 -130.82 156.38 45.1 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.928 1.291 . . . . 0.0 109.271 -176.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 35.3 ptt180 -143.08 -176.86 5.08 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 119.779 1.172 . . . . 0.0 110.048 176.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.44 163.31 12.54 Favored 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 124.047 0.939 . . . . 0.0 108.89 170.199 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 15.2 mt-10 -70.57 -19.33 62.88 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -177.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.8 m-20 -90.31 5.54 46.81 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 119.745 1.157 . . . . 0.0 112.07 177.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 19.6 pt-20 -140.92 176.77 8.53 Favored 'General case' 0 N--CA 1.445 -0.697 0 O-C-N 121.253 -0.905 . . . . 0.0 111.493 -172.832 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -109.42 170.73 14.61 Favored Glycine 0 N--CA 1.444 -0.815 0 N-CA-C 109.461 -1.455 . . . . 0.0 109.461 178.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.443 ' CE1' HG12 ' A' ' 95' ' ' VAL . 40.2 m-85 -71.49 171.14 11.86 Favored 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 152.515 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -127.94 55.43 0.75 Allowed Glycine 0 C--O 1.222 -0.646 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.425 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 25.7 p90 -131.4 158.61 40.3 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 170.215 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 9.2 t -136.88 127.79 41.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 -174.474 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.468 HG21 ' CD2' ' A' ' 45' ' ' HIS . 4.0 mp -87.07 146.8 5.85 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.415 0 N-CA-C 107.227 -1.397 . . . . 0.0 107.227 175.166 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 31.6 pt -133.68 170.79 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 C-N-CA 126.326 1.85 . . . . 0.0 108.239 160.174 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 42.3 t -137.38 -177.7 4.89 Favored 'General case' 0 C--O 1.238 0.478 0 C-N-CA 125.508 1.523 . . . . 0.0 108.847 174.143 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -151.39 99.36 2.63 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 103.743 -2.688 . . . . 0.0 103.743 168.173 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 11.7 tp -163.9 103.32 0.9 Allowed 'General case' 0 C--O 1.233 0.195 0 N-CA-C 107.934 -1.135 . . . . 0.0 107.934 176.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 15.0 m-80 -64.85 -67.47 0.43 Allowed 'General case' 0 C--O 1.234 0.286 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 160.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 29.8 ptt-85 -158.71 157.07 28.2 Favored Pre-proline 0 C--O 1.236 0.393 0 CA-C-N 118.705 0.684 . . . . 0.0 111.803 -177.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 95.0 Cg_endo -68.35 175.7 6.53 Favored 'Trans proline' 0 CA--C 1.537 0.629 0 C-N-CA 122.681 2.254 . . . . 0.0 110.68 167.387 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -144.37 -77.19 0.22 Allowed 'General case' 0 C--O 1.235 0.308 0 N-CA-C 107.297 -1.372 . . . . 0.0 107.297 168.173 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -88.93 100.03 12.87 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.392 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 45.42 -111.9 0.66 Allowed Glycine 0 C--N 1.338 0.646 0 C-N-CA 127.398 2.428 . . . . 0.0 113.495 173.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 58.0 m -125.06 102.79 7.67 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.1 p -73.49 154.56 39.86 Favored 'General case' 0 C--O 1.24 0.603 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 165.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 72.2 mt -68.77 112.12 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 176.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.6 t -157.08 174.86 14.87 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 125.35 1.46 . . . . 0.0 108.035 174.225 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.659 HG11 ' HD2' ' A' ' 67' ' ' ARG . 10.7 p -126.95 140.18 37.06 Favored Pre-proline 0 C--O 1.237 0.437 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 165.566 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -76.56 -80.36 0.01 OUTLIER 'Trans proline' 0 N--CA 1.446 -1.275 0 C-N-CA 121.884 1.722 . . . . 0.0 109.281 163.264 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.468 ' CD2' HG21 ' A' ' 28' ' ' ILE . 2.5 m80 -65.37 116.34 6.57 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 124.25 1.02 . . . . 0.0 111.471 -168.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 39.5 pttt -135.44 151.86 50.82 Favored 'General case' 0 CA--C 1.531 0.246 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 168.055 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 30.0 mm -60.12 115.92 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 C-N-CA 124.261 1.024 . . . . 0.0 109.208 169.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -90.42 -39.43 5.98 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 124.013 0.816 . . . . 0.0 112.629 172.097 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 41.0 ttt85 -149.02 161.46 41.88 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 118.266 1.033 . . . . 0.0 109.559 178.752 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 15.4 mt -131.99 136.71 56.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.309 0 C-N-CA 126.298 1.839 . . . . 0.0 106.171 169.455 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.4 mp -79.81 132.55 31.68 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 C-N-CA 126.016 1.726 . . . . 0.0 108.089 179.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 72.5 m-20 -55.89 133.25 51.25 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 125.942 1.697 . . . . 0.0 109.505 177.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.36 -8.92 75.18 Favored Glycine 0 CA--C 1.528 0.892 0 C-N-CA 123.397 0.522 . . . . 0.0 112.46 169.219 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 76.5 p -71.22 167.1 32.39 Favored Pre-proline 0 N--CA 1.451 -0.385 0 CA-C-N 118.087 0.943 . . . . 0.0 112.836 -169.183 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -54.1 -39.76 84.46 Favored 'Trans proline' 0 N--CA 1.451 -0.996 0 C-N-CA 122.35 2.033 . . . . 0.0 111.992 166.414 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.11 -55.78 28.46 Favored 'General case' 0 C--N 1.341 0.216 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 178.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -57.13 -30.77 64.69 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.126 1.37 . . . . 0.0 112.447 179.405 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 46.6 mtt-85 -83.97 -29.29 27.15 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 114.533 1.309 . . . . 0.0 114.533 175.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 77.0 m -69.46 -27.72 65.48 Favored 'General case' 0 C--O 1.237 0.427 0 CA-C-N 120.292 1.405 . . . . 0.0 111.815 179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 51.54 -160.53 0.09 Allowed 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.914 0.886 . . . . 0.0 110.496 -169.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 60.9 5.33 0.95 Allowed 'General case' 0 N--CA 1.465 0.301 0 C-N-CA 125.544 1.538 . . . . 0.0 113.323 -167.007 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 14.7 tp -146.59 108.58 4.39 Favored 'General case' 0 N--CA 1.445 -0.711 0 C-N-CA 126.613 1.965 . . . . 0.0 107.17 -175.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 33.4 mttm -133.95 171.1 14.65 Favored 'General case' 0 C--O 1.237 0.423 0 C-N-CA 125.495 1.518 . . . . 0.0 110.419 -175.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 58.2 t -76.47 101.3 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 -174.057 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 139.63 -12.78 3.19 Favored Glycine 0 CA--C 1.522 0.515 0 C-N-CA 127.0 2.238 . . . . 0.0 108.951 -175.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 57.7 m-20 -74.6 110.75 9.14 Favored 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 123.219 1.485 . . . . 0.0 107.346 -178.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.659 ' HD2' HG11 ' A' ' 43' ' ' VAL . 19.1 mmt-85 -59.9 158.69 10.25 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 113.918 -1.492 . . . . 0.0 110.377 162.687 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 35.0 mt -131.6 132.18 62.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 N-CA-C 106.751 -1.574 . . . . 0.0 106.751 -175.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 10.7 mt -84.49 -51.25 7.05 Favored 'General case' 0 C--N 1.332 -0.188 0 C-N-CA 124.323 1.049 . . . . 0.0 111.172 176.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -151.68 168.91 23.53 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 124.53 1.132 . . . . 0.0 109.609 -164.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.431 HG23 HG21 ' A' ' 76' ' ' ILE . 4.1 t -130.27 118.14 42.43 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.698 0 N-CA-C 106.612 -1.625 . . . . 0.0 106.612 179.396 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 39.32 63.12 1.02 Allowed 'General case' 0 N--CA 1.464 0.252 0 C-N-CA 125.53 1.532 . . . . 0.0 110.733 -174.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 69.5 2.09 33.01 Favored Glycine 0 CA--C 1.527 0.803 0 CA-C-O 117.672 -1.627 . . . . 0.0 114.461 176.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -111.77 154.03 25.65 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 120.203 2.002 . . . . 0.0 111.676 -171.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 26.7 p -65.9 142.27 57.95 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.984 -179.15 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.431 HG21 HG23 ' A' ' 71' ' ' VAL . 5.0 pt -129.8 -5.78 2.87 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 123.318 0.647 . . . . 0.0 112.333 168.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 96.5 mt -73.66 -22.56 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.662 0 C-N-CA 125.046 1.338 . . . . 0.0 109.639 173.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 -124.84 -42.78 2.03 Favored 'General case' 0 C--N 1.341 0.215 0 C-N-CA 124.186 0.994 . . . . 0.0 111.734 -162.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.4 mtp -57.28 151.09 38.89 Favored Pre-proline 0 CA--C 1.533 0.294 0 C-N-CA 123.407 0.683 . . . . 0.0 110.489 176.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -69.34 149.06 69.09 Favored 'Trans proline' 0 N--CA 1.449 -1.119 0 C-N-CA 121.149 1.233 . . . . 0.0 109.066 171.442 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 3.5 t-80 -55.65 -41.53 73.74 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 124.085 0.954 . . . . 0.0 112.445 -170.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.91 -30.01 70.6 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 118.936 -0.554 . . . . 0.0 111.88 -179.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -70.68 -50.97 30.86 Favored 'General case' 0 C--O 1.223 -0.326 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 14.4 mt -60.18 -40.04 82.37 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 C-N-CA 124.45 1.1 . . . . 0.0 110.19 178.288 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.0 t -60.52 -47.23 93.58 Favored 'Isoleucine or valine' 0 C--O 1.241 0.611 0 O-C-N 120.78 -1.2 . . . . 0.0 109.97 175.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 22.6 ttmt -65.62 -42.13 91.92 Favored 'General case' 0 N--CA 1.448 -0.572 0 CA-C-O 117.895 -1.05 . . . . 0.0 110.102 178.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -48.53 -44.86 36.69 Favored 'General case' 0 N--CA 1.453 -0.283 0 C-N-CA 126.22 1.808 . . . . 0.0 111.097 176.483 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 41.4 mt -73.79 -44.24 52.32 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 48.2 tttt -58.87 -39.09 80.32 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 121.774 -0.579 . . . . 0.0 110.826 -178.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -85.7 -2.18 57.93 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 127.402 2.281 . . . . 0.0 112.436 -179.463 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -57.57 -13.4 3.77 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 116.058 1.873 . . . . 0.0 116.058 -164.005 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.45 44.3 6.59 Favored Glycine 0 C--N 1.335 0.476 0 CA-C-N 118.875 0.762 . . . . 0.0 111.761 172.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 34.9 mt 66.49 -34.83 0.22 Allowed 'General case' 0 CA--C 1.511 -0.524 0 C-N-CA 129.245 3.018 . . . . 0.0 113.714 -175.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -93.47 143.25 26.47 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 178.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.443 HG12 ' CE1' ' A' ' 24' ' ' PHE . 11.5 p -144.88 135.95 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.595 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 172.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 35.0 m -116.53 106.26 13.38 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 -177.008 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 11.8 mt -91.04 110.48 21.75 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 125.07 1.348 . . . . 0.0 108.362 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 3.8 ttt180 -78.74 119.68 22.31 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 166.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -117.99 172.55 5.39 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 C-N-CA 124.733 1.213 . . . . 0.0 109.19 177.01 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.437 ' HB ' ' HD3' ' A' ' 101' ' ' PRO . 62.4 mt -105.26 -70.8 0.03 OUTLIER Pre-proline 0 CA--C 1.542 0.657 0 C-N-CA 124.647 1.179 . . . . 0.0 108.122 174.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.437 ' HD3' ' HB ' ' A' ' 100' ' ' ILE . 72.0 Cg_endo -74.64 106.8 2.32 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.311 2.007 . . . . 0.0 114.51 -171.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -80.41 152.79 28.65 Favored 'General case' 0 N--CA 1.444 -0.751 0 C-N-CA 124.054 0.941 . . . . 0.0 110.482 177.655 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -85.84 -1.79 57.6 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 126.129 1.771 . . . . 0.0 112.112 -176.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 3.4 mm-40 -133.15 10.28 4.15 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 126.553 1.941 . . . . 0.0 110.78 -161.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 13.6 mt -135.85 86.14 2.21 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 126.841 2.056 . . . . 0.0 107.921 -178.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 28.2 m120 -62.12 162.8 8.93 Favored 'General case' 0 N--CA 1.465 0.31 0 C-N-CA 123.297 0.639 . . . . 0.0 109.472 176.227 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.5 m -132.05 158.27 75.98 Favored Pre-proline 0 CA--C 1.537 0.447 0 O-C-N 121.766 -0.583 . . . . 0.0 110.961 -173.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -71.39 94.5 0.67 Allowed 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 123.81 3.006 . . . . 0.0 111.008 174.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.6 p -158.53 166.57 31.83 Favored 'General case' 0 C--O 1.236 0.377 0 C-N-CA 124.131 0.972 . . . . 0.0 109.305 168.184 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -154.96 161.02 30.1 Favored Glycine 0 CA--C 1.53 0.988 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 171.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -78.99 175.79 10.56 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.47 2.78 . . . . 0.0 110.995 175.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 19.9 p -127.0 157.66 38.98 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 156.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -147.53 -60.96 0.27 Allowed 'General case' 0 C--N 1.329 -0.293 0 C-N-CA 125.836 1.654 . . . . 0.0 106.902 173.163 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.006 0 N-CA-C 104.229 -3.548 . . . . 0.0 104.229 124.307 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.472 1.083 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.7 m 61.13 177.87 0.11 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 124.267 1.027 . . . . 0.0 111.667 -171.058 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 6.0 p -69.8 126.69 30.46 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 124.683 1.193 . . . . 0.0 109.284 174.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -79.43 -176.9 49.53 Favored Glycine 0 CA--C 1.53 1.013 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 164.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 59.9 m -153.08 126.55 8.7 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 169.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 63.8 m -153.1 167.18 30.12 Favored 'General case' 0 C--O 1.239 0.549 0 C-N-CA 125.726 1.61 . . . . 0.0 108.518 171.757 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 136.29 88.7 0.25 Allowed Glycine 0 C--N 1.334 0.42 0 N-CA-C 106.514 -2.634 . . . . 0.0 106.514 -168.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 42.8 m -87.09 -26.23 23.76 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 123.842 0.857 . . . . 0.0 112.989 -177.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 16.1 tp -108.54 97.01 6.74 Favored 'General case' 0 C--O 1.236 0.372 0 C-N-CA 123.161 0.584 . . . . 0.0 110.791 -160.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 6.3 mm-40 -61.89 133.32 55.27 Favored 'General case' 0 C--O 1.238 0.462 0 CA-C-O 121.893 0.854 . . . . 0.0 110.126 169.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 51.0 p -140.27 168.88 18.77 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 128.508 2.723 . . . . 0.0 105.769 165.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 5.3 m -123.45 151.99 42.11 Favored 'General case' 0 N--CA 1.448 -0.549 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 161.685 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -108.67 130.39 55.34 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 128.752 2.821 . . . . 0.0 105.332 176.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.8 t -132.99 109.19 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.499 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 14.4 p -100.61 132.32 46.5 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 176.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 46.2 mt -136.05 147.21 28.27 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 178.711 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -120.87 159.28 25.84 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 124.36 1.064 . . . . 0.0 109.564 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 11.1 ptt180 -140.6 -161.95 1.28 Allowed 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 169.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -121.23 169.24 10.75 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 106.911 -1.514 . . . . 0.0 106.911 169.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 17.7 mm-40 -64.73 -27.37 68.86 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -80.43 -6.92 58.84 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 114.541 1.311 . . . . 0.0 114.541 -173.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -141.25 176.26 8.99 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 119.547 1.067 . . . . 0.0 110.596 -170.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -107.6 171.77 16.79 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 123.982 0.801 . . . . 0.0 111.353 -172.071 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -85.04 137.9 32.77 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 163.662 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.447 ' O ' ' HB3' ' A' ' 56' ' ' ALA . . . -97.71 75.3 0.63 Allowed Glycine 0 N--CA 1.442 -0.918 0 N-CA-C 108.77 -1.732 . . . . 0.0 108.77 -178.093 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 22.2 p90 -157.77 148.88 21.31 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 107.21 -1.404 . . . . 0.0 107.21 164.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.2 t -137.59 131.04 43.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.319 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -174.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 10.3 mt -71.06 154.47 7.92 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.026 0 C-N-CA 124.788 1.235 . . . . 0.0 109.751 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 49.2 pt -134.56 179.12 4.56 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 C-N-CA 127.995 2.518 . . . . 0.0 109.143 149.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 1.5 t 76.75 173.34 0.22 Allowed 'General case' 0 C--O 1.238 0.468 0 C-N-CA 128.84 2.856 . . . . 0.0 110.033 -171.174 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -165.21 179.82 6.06 Favored 'General case' 0 C--O 1.24 0.554 0 C-N-CA 124.348 1.059 . . . . 0.0 109.175 -178.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 1.8 mp -72.43 106.64 4.62 Favored 'General case' 0 CA--C 1.522 -0.108 0 N-CA-C 107.013 -1.477 . . . . 0.0 107.013 167.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 15.7 t30 -156.47 119.56 4.17 Favored 'General case' 0 C--N 1.323 -0.558 0 C-N-CA 127.399 2.28 . . . . 0.0 104.918 179.086 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -162.82 155.54 16.36 Favored Pre-proline 0 CA--C 1.536 0.409 0 C-N-CA 125.161 1.384 . . . . 0.0 108.39 178.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -67.8 179.97 2.39 Favored 'Trans proline' 0 CA--C 1.534 0.513 0 C-N-CA 123.581 2.854 . . . . 0.0 112.377 175.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -74.31 -71.67 0.32 Allowed 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 172.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 80.2 p -78.28 171.08 15.59 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 118.853 0.751 . . . . 0.0 111.249 174.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.93 26.25 60.71 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-O 118.736 -1.036 . . . . 0.0 113.647 167.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -64.29 124.55 22.01 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 119.283 1.542 . . . . 0.0 111.264 -172.508 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 28.2 p -124.14 162.99 22.44 Favored 'General case' 0 C--O 1.238 0.457 0 C-N-CA 125.255 1.422 . . . . 0.0 109.185 169.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 24.2 mm -72.57 84.42 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 CA-C-O 123.259 1.504 . . . . 0.0 109.452 178.091 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 13.7 t -70.92 170.31 12.95 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 124.848 1.259 . . . . 0.0 109.209 156.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 17.2 t -121.36 113.33 32.36 Favored Pre-proline 0 CA--C 1.532 0.27 0 C-N-CA 126.103 1.761 . . . . 0.0 106.882 -178.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -75.03 -20.29 16.94 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 122.389 2.06 . . . . 0.0 113.906 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -138.9 120.78 15.45 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 121.029 1.74 . . . . 0.0 108.913 177.653 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.9 pttt -140.7 162.94 34.2 Favored 'General case' 0 CA--C 1.516 -0.346 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 168.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 11.4 mm -65.24 130.87 30.9 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 172.455 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -108.06 -51.75 0.72 Allowed Glycine 0 CA--C 1.522 0.491 0 C-N-CA 124.619 1.104 . . . . 0.0 111.224 169.112 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 40.0 ttt85 -134.68 151.79 51.28 Favored 'General case' 0 C--O 1.24 0.579 0 CA-C-N 119.142 1.471 . . . . 0.0 111.165 -168.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 50.5 mt -137.33 119.24 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 C-N-CA 127.14 2.176 . . . . 0.0 106.134 179.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.427 HD12 ' H ' ' A' ' 51' ' ' ILE . 1.9 mp -46.83 126.75 2.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.505 0 C-N-CA 127.713 2.405 . . . . 0.0 108.418 156.233 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -63.31 128.31 35.26 Favored 'General case' 0 N--CA 1.455 -0.209 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 165.454 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 105.01 4.99 41.51 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 111.514 -0.634 . . . . 0.0 111.514 173.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.5 p -80.88 159.79 67.85 Favored Pre-proline 0 N--CA 1.449 -0.496 0 O-C-N 121.24 -1.153 . . . . 0.0 113.752 -171.693 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -61.71 -35.01 82.25 Favored 'Trans proline' 0 CA--C 1.539 0.737 0 C-N-CA 122.917 2.412 . . . . 0.0 112.404 168.695 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.447 ' HB3' ' O ' ' A' ' 25' ' ' GLY . . . -68.62 -46.35 69.51 Favored 'General case' 0 C--N 1.34 0.188 0 CA-C-O 118.111 -0.947 . . . . 0.0 111.686 -178.069 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.6 t0 -61.95 -47.64 83.95 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 118.912 0.778 . . . . 0.0 109.805 -172.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 76.2 mtt180 -59.89 -27.47 66.74 Favored 'General case' 0 C--N 1.341 0.229 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.671 177.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 6.1 t -60.57 -37.58 81.77 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-O 118.405 -0.807 . . . . 0.0 109.982 176.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 56.04 -14.34 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 130.535 3.534 . . . . 0.0 116.111 177.577 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.08 -19.19 51.89 Favored 'General case' 0 N--CA 1.451 -0.417 0 C-N-CA 125.187 1.395 . . . . 0.0 111.477 161.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -119.83 131.92 55.44 Favored 'General case' 0 C--O 1.235 0.292 0 C-N-CA 125.672 1.589 . . . . 0.0 107.688 176.301 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.09 171.32 14.48 Favored 'General case' 0 C--O 1.235 0.291 0 C-N-CA 124.194 0.998 . . . . 0.0 110.041 172.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 25.4 t -55.89 141.21 12.88 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 O-C-N 121.321 -0.862 . . . . 0.0 109.112 174.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.9 -12.92 65.59 Favored Glycine 0 CA--C 1.534 1.231 0 C-N-CA 125.147 1.356 . . . . 0.0 115.688 172.331 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -68.0 7.31 0.56 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 118.262 2.69 . . . . 0.0 118.262 -151.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 30.8 mtm180 51.87 89.56 0.03 OUTLIER 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 126.438 1.895 . . . . 0.0 113.122 -178.307 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 61.3 mt -71.95 139.71 19.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 179.694 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -113.52 -53.05 2.72 Favored 'General case' 0 N--CA 1.454 -0.268 0 C-N-CA 125.632 1.573 . . . . 0.0 108.768 177.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -138.25 154.09 49.08 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.589 0.709 . . . . 0.0 112.319 -178.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.446 HG23 HG21 ' A' ' 76' ' ' ILE . 55.6 t -112.15 116.55 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 169.815 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 57.73 5.12 0.31 Allowed 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 126.763 2.025 . . . . 0.0 115.525 177.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 105.91 12.28 26.34 Favored Glycine 0 CA--C 1.528 0.877 0 CA-C-O 118.81 -0.994 . . . . 0.0 112.863 -175.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 6.0 tp-100 -103.19 140.29 37.56 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 126.405 1.882 . . . . 0.0 108.401 171.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 62.9 m -78.68 100.76 7.18 Favored 'General case' 0 C--O 1.233 0.194 0 C-N-CA 124.666 1.186 . . . . 0.0 111.996 -177.062 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.446 HG21 HG23 ' A' ' 71' ' ' VAL . 2.7 pp -77.6 -5.29 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 179.262 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.565 HD12 ' H ' ' A' ' 77' ' ' ILE . 0.6 OUTLIER -70.28 -9.92 13.11 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 124.764 1.226 . . . . 0.0 112.381 -178.811 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 62.6 m-80 -138.61 -24.51 0.94 Allowed 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 114.785 1.402 . . . . 0.0 114.785 -174.34 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 2.9 mtp -61.06 152.15 72.31 Favored Pre-proline 0 C--O 1.239 0.506 0 CA-C-N 119.856 1.207 . . . . 0.0 110.8 172.205 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -67.12 157.46 61.63 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 121.727 1.618 . . . . 0.0 110.131 171.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -63.21 -37.77 88.53 Favored 'General case' 0 CA--C 1.533 0.308 0 O-C-N 121.732 -0.605 . . . . 0.0 111.164 -172.057 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.49 -32.47 73.93 Favored 'General case' 0 C--N 1.338 0.068 0 CA-C-N 119.352 0.978 . . . . 0.0 111.975 178.019 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.74 -52.23 65.12 Favored 'General case' 0 C--O 1.224 -0.249 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 176.623 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 54.2 mt -65.88 -41.63 90.42 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.492 0 C-N-CA 125.91 1.684 . . . . 0.0 109.764 -175.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 17.1 t -60.14 -45.71 95.49 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 O-C-N 121.101 -0.999 . . . . 0.0 110.096 173.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? -59.86 -47.61 85.05 Favored 'General case' 0 C--O 1.219 -0.506 0 CA-C-O 118.692 -0.671 . . . . 0.0 109.376 177.267 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -57.32 -33.75 68.03 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 125.757 1.623 . . . . 0.0 112.676 -177.111 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 63.5 mt -75.1 -45.12 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 175.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.6 ttmp? -60.67 -49.1 78.87 Favored 'General case' 0 CA--C 1.537 0.443 0 O-C-N 121.615 -0.678 . . . . 0.0 110.021 179.898 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 76.0 m-20 -76.65 5.93 6.75 Favored 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 129.948 3.299 . . . . 0.0 111.842 177.524 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -63.51 -24.01 67.64 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 119.28 0.946 . . . . 0.0 112.386 176.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.81 48.16 5.61 Favored Glycine 0 C--N 1.338 0.659 0 CA-C-N 119.201 0.909 . . . . 0.0 111.436 174.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 9.0 mt 69.73 -30.79 0.2 Allowed 'General case' 0 CA--C 1.513 -0.449 0 C-N-CA 129.764 3.226 . . . . 0.0 113.455 -178.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.29 131.06 40.29 Favored 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 124.722 1.209 . . . . 0.0 108.651 174.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 9.3 p -135.74 130.77 49.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.593 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 170.222 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -95.34 125.48 39.99 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 105.96 -1.867 . . . . 0.0 105.96 170.106 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 42.3 mt -116.76 106.85 13.94 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 175.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.8 ttm180 -88.82 118.9 28.85 Favored 'General case' 0 C--O 1.235 0.315 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 177.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.3 pp -119.49 176.66 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 127.216 2.206 . . . . 0.0 108.632 -172.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 5.0 mp -114.48 117.49 42.76 Favored Pre-proline 0 CA--C 1.533 0.327 0 CA-C-N 119.231 0.923 . . . . 0.0 108.903 172.004 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.03 163.2 35.74 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 123.039 2.492 . . . . 0.0 109.712 -178.549 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.51 132.14 51.45 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 108.258 -1.015 . . . . 0.0 108.258 179.254 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -138.24 -9.32 1.5 Allowed 'General case' 0 N--CA 1.448 -0.532 0 CA-C-N 113.502 -1.681 . . . . 0.0 110.588 172.305 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -155.76 37.62 0.36 Allowed 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 124.493 1.117 . . . . 0.0 110.263 -169.3 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -133.57 121.2 21.76 Favored 'General case' 0 C--O 1.235 0.33 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 163.566 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -151.44 112.7 4.33 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 126.253 1.821 . . . . 0.0 107.077 -179.216 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 9.0 p -74.66 167.64 34.48 Favored Pre-proline 0 CA--C 1.544 0.723 0 N-CA-C 114.279 1.214 . . . . 0.0 114.279 -166.277 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 92.6 Cg_endo -73.85 -179.24 4.41 Favored 'Trans proline' 0 CA--C 1.538 0.71 0 C-N-CA 124.27 3.314 . . . . 0.0 111.924 167.363 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 46.3 m -100.09 -176.28 3.19 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.49 1.116 . . . . 0.0 109.636 166.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -104.88 167.92 15.55 Favored Glycine 0 CA--C 1.536 1.403 0 N-CA-C 108.961 -1.655 . . . . 0.0 108.961 149.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -71.96 170.02 19.9 Favored 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 123.353 2.702 . . . . 0.0 112.073 -175.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.5 p -116.37 167.34 11.12 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 124.672 1.189 . . . . 0.0 109.618 169.371 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.8 t -66.13 166.66 11.39 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.215 1.006 . . . . 0.0 111.114 -178.662 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.338 0 N-CA-C 105.951 -2.859 . . . . 0.0 105.951 153.978 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.226 0 N-CA-C 107.835 -2.106 . . . . 0.0 107.835 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.5 m 70.92 89.44 0.1 Allowed 'General case' 0 CA--C 1.534 0.359 0 O-C-N 124.838 0.964 . . . . 0.0 112.548 153.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 58.6 m -58.74 135.27 57.4 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 162.053 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -72.91 -49.96 15.14 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 173.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 71.1 m 41.47 59.51 2.39 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 126.301 1.841 . . . . 0.0 111.932 178.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 47.8 t -128.14 154.72 45.45 Favored 'General case' 0 C--O 1.24 0.587 0 C-N-CA 123.555 0.742 . . . . 0.0 110.155 -174.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -162.7 91.83 0.11 Allowed Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 107.762 -2.135 . . . . 0.0 107.762 -173.464 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.7 m -139.56 100.63 4.02 Favored 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 105.738 -1.949 . . . . 0.0 105.738 171.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 tp -156.66 164.93 37.59 Favored 'General case' 0 N--CA 1.447 -0.602 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 165.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 8.7 tt0 -142.53 127.61 18.51 Favored 'General case' 0 N--CA 1.453 -0.325 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 165.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 36.0 p -127.37 167.06 16.71 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 171.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 26.0 m -120.22 148.82 43.2 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 171.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -96.22 155.52 16.73 Favored 'General case' 0 C--O 1.244 0.789 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 167.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.441 HG11 ' HG ' ' A' ' 62' ' ' LEU . 29.3 t -137.54 103.62 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 106.193 -1.78 . . . . 0.0 106.193 177.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.3 p -98.64 134.81 35.95 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.314 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 171.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 47.6 mt -142.48 134.15 25.49 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.176 0 N-CA-C 104.213 -2.514 . . . . 0.0 104.213 -179.659 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 21.1 m-70 -113.93 159.09 20.27 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.762 1.625 . . . . 0.0 110.171 -174.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.445 ' HG2' ' CE1' ' A' ' 24' ' ' PHE . 0.0 OUTLIER -151.86 175.69 12.21 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 120.334 -1.479 . . . . 0.0 110.863 178.708 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -66.09 161.93 20.69 Favored 'General case' 0 C--O 1.231 0.123 0 C-N-CA 123.426 0.69 . . . . 0.0 109.849 161.458 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -58.11 -50.0 75.0 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 125.863 1.665 . . . . 0.0 111.302 178.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 30.5 t30 -76.48 -21.96 55.16 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.247 1.019 . . . . 0.0 112.621 -173.339 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -66.96 174.23 3.16 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.377 1.071 . . . . 0.0 109.162 173.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -152.69 46.1 0.58 Allowed Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 124.711 1.148 . . . . 0.0 111.489 -178.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.445 ' CE1' ' HG2' ' A' ' 18' ' ' ARG . 22.3 m-85 50.32 -174.02 0.02 OUTLIER 'General case' 0 N--CA 1.432 -1.345 0 C-N-CA 129.767 3.227 . . . . 0.0 110.753 -174.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.422 ' HA3' ' CB ' ' A' ' 54' ' ' SER . . . -132.38 45.49 1.12 Allowed Glycine 0 C--O 1.224 -0.482 0 O-C-N 121.353 -0.842 . . . . 0.0 111.97 -176.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 7.7 p90 -137.96 153.48 49.45 Favored 'General case' 0 N--CA 1.444 -0.731 0 C-N-CA 124.224 1.01 . . . . 0.0 108.698 -178.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.71 123.13 25.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 106.071 -1.825 . . . . 0.0 106.071 -176.68 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -85.21 151.2 3.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 171.218 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 46.2 pt -131.44 163.49 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 125.238 1.415 . . . . 0.0 108.137 168.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 75.4 m -78.27 -50.28 12.13 Favored 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 123.103 0.561 . . . . 0.0 110.483 171.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.7 t 47.78 100.9 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 127.394 2.278 . . . . 0.0 112.754 -167.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -47.13 -36.87 8.98 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 118.001 -1.0 . . . . 0.0 112.665 174.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 47.53 82.54 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 127.599 2.359 . . . . 0.0 113.404 174.546 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 4.5 ptm85 -66.54 150.51 97.28 Favored Pre-proline 0 C--O 1.235 0.313 0 CA-C-O 119.114 -0.47 . . . . 0.0 111.258 -175.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -68.62 163.15 38.06 Favored 'Trans proline' 0 N--CA 1.448 -1.18 0 N-CA-C 108.8 -1.269 . . . . 0.0 108.8 164.217 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 7.0 pt-20 -148.79 -44.26 0.15 Allowed 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 124.584 1.154 . . . . 0.0 109.08 177.525 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 46.5 t -160.6 175.3 12.83 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 128.556 2.742 . . . . 0.0 105.346 -171.698 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 54.95 -161.39 4.99 Favored Glycine 0 CA--C 1.53 1.019 0 C-N-CA 124.259 0.933 . . . . 0.0 111.705 -179.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 49.4 m -125.56 103.12 7.69 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 105.72 -1.956 . . . . 0.0 105.72 155.481 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -105.51 118.97 37.94 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 176.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 2.5 pp -53.2 145.37 3.33 Favored 'Isoleucine or valine' 0 C--O 1.236 0.359 0 C-N-CA 124.116 0.967 . . . . 0.0 110.79 -179.465 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 4.1 m -75.86 142.2 42.22 Favored 'General case' 0 C--O 1.234 0.274 0 N-CA-C 106.219 -1.771 . . . . 0.0 106.219 161.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.503 HG11 ' HG2' ' A' ' 67' ' ' ARG . 14.0 p -126.56 143.98 48.1 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 104.968 -2.234 . . . . 0.0 104.968 160.632 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_endo -76.91 -95.38 0.01 OUTLIER 'Trans proline' 0 N--CA 1.45 -1.037 0 C-N-CA 121.599 1.532 . . . . 0.0 108.408 172.661 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.492 ' CD2' HD12 ' A' ' 76' ' ' ILE . 1.2 m80 -61.3 114.24 3.07 Favored 'General case' 0 N--CA 1.446 -0.656 0 C-N-CA 125.595 1.558 . . . . 0.0 111.621 -171.287 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -148.85 154.83 40.05 Favored 'General case' 0 C--O 1.235 0.301 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 165.491 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.501 HD11 HD11 ' A' ' 68' ' ' ILE . 36.3 mm -60.96 129.16 23.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 C-N-CA 123.134 0.574 . . . . 0.0 109.686 -178.29 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -100.22 -36.22 4.21 Favored Glycine 0 CA--C 1.529 0.963 0 C-N-CA 126.278 1.894 . . . . 0.0 112.693 172.53 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 6.9 ttm180 -149.04 151.77 35.07 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 118.437 1.118 . . . . 0.0 108.723 178.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 11.1 mt -126.86 139.56 51.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.431 0 C-N-CA 125.787 1.635 . . . . 0.0 106.709 165.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -82.07 121.77 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.681 0 C-N-CA 126.653 1.981 . . . . 0.0 107.829 -178.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -51.46 128.29 22.37 Favored 'General case' 0 C--O 1.239 0.519 0 C-N-CA 124.956 1.302 . . . . 0.0 109.655 173.474 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 95.01 -12.32 68.57 Favored Glycine 0 CA--C 1.526 0.779 0 C-N-CA 125.449 1.5 . . . . 0.0 112.945 174.022 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.422 ' CB ' ' HA3' ' A' ' 25' ' ' GLY . 59.0 p -69.68 163.07 62.97 Favored Pre-proline 0 CA--C 1.53 0.205 0 CA-C-N 118.98 1.39 . . . . 0.0 113.177 -172.445 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -56.96 -34.81 98.18 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 122.27 1.98 . . . . 0.0 111.811 165.418 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.44 -49.24 78.34 Favored 'General case' 0 C--N 1.344 0.333 0 CA-C-N 119.526 1.057 . . . . 0.0 110.529 175.133 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -62.17 -49.53 75.46 Favored 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 124.265 1.026 . . . . 0.0 111.348 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -53.59 -53.04 57.41 Favored 'General case' 0 C--N 1.343 0.303 0 C-N-CA 124.418 1.087 . . . . 0.0 110.318 178.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 62.5 m -64.73 -13.94 56.73 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 117.536 -1.221 . . . . 0.0 113.592 -170.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 51.89 11.71 0.16 Allowed 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 127.577 2.351 . . . . 0.0 116.821 171.167 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.42 ' HB2' HG13 ' A' ' 14' ' ' VAL . 12.4 mtpt -99.37 -6.77 27.22 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 124.864 1.266 . . . . 0.0 112.03 178.524 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.441 ' HG ' HG11 ' A' ' 14' ' ' VAL . 93.7 mt -104.8 142.74 34.18 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 107.031 -1.47 . . . . 0.0 107.031 154.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 9.4 ptmt -140.81 169.57 17.38 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.492 1.517 . . . . 0.0 110.016 159.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.9 t -73.23 109.32 5.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 O-C-N 121.409 -0.807 . . . . 0.0 109.042 -173.297 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 120.04 -7.71 11.73 Favored Glycine 0 C--N 1.337 0.631 0 O-C-N 121.143 -0.973 . . . . 0.0 110.724 -171.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 -74.11 101.67 3.99 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 172.462 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.503 ' HG2' HG11 ' A' ' 43' ' ' VAL . 39.5 mtm-85 -50.76 121.38 5.81 Favored 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 128.04 2.536 . . . . 0.0 108.424 164.227 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.501 HD11 HD11 ' A' ' 47' ' ' ILE . 71.5 mt -105.23 106.85 21.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 104.938 -2.245 . . . . 0.0 104.938 174.653 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.658 HD21 HG13 ' A' ' 100' ' ' ILE . 0.3 OUTLIER -80.42 -26.57 38.38 Favored 'General case' 0 N--CA 1.453 -0.293 0 C-N-CA 122.94 0.496 . . . . 0.0 112.111 -179.117 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -157.48 155.47 30.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 125.109 1.363 . . . . 0.0 111.305 -166.191 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.6 HG23 HD13 ' A' ' 76' ' ' ILE . 46.8 t -140.24 132.09 32.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 N-CA-C 105.21 -2.145 . . . . 0.0 105.21 176.408 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 8.9 m-80 46.05 34.86 2.19 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 124.593 1.157 . . . . 0.0 112.472 175.211 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 55.94 26.23 47.63 Favored Glycine 0 CA--C 1.535 1.318 0 CA-C-O 118.491 -1.172 . . . . 0.0 114.257 -179.321 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 40.7 tp60 -121.93 104.7 9.72 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 127.341 2.257 . . . . 0.0 107.056 -175.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 54.5 p -65.08 103.14 0.71 Allowed 'General case' 0 CA--C 1.538 0.505 0 O-C-N 120.581 -1.324 . . . . 0.0 114.377 -154.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.6 HD13 HG23 ' A' ' 71' ' ' VAL . 11.3 pt -74.1 -5.07 6.25 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.569 0 C-N-CA 124.226 1.01 . . . . 0.0 113.385 -174.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 50.4 mm -71.4 -21.27 21.57 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 C-N-CA 124.871 1.269 . . . . 0.0 111.336 -178.75 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -118.28 -28.83 5.69 Favored 'General case' 0 N--CA 1.47 0.536 0 C-N-CA 124.888 1.275 . . . . 0.0 112.372 -176.58 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 9.3 mtp -60.02 151.75 64.04 Favored Pre-proline 0 C--O 1.24 0.558 0 CA-C-N 117.925 0.329 . . . . 0.0 111.398 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -67.11 148.69 81.58 Favored 'Trans proline' 0 N--CA 1.448 -1.166 0 C-N-CA 121.992 1.795 . . . . 0.0 110.282 168.403 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -60.51 -30.53 69.78 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 112.451 0.537 . . . . 0.0 112.451 -172.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -70.03 -35.04 74.02 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 123.692 0.797 . . . . 0.0 112.182 175.932 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -66.88 -45.19 78.86 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 109.225 -0.658 . . . . 0.0 109.225 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 32.5 mt -64.02 -40.75 90.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 125.555 1.542 . . . . 0.0 108.982 179.418 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 8.2 t -58.63 -51.02 76.87 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 O-C-N 121.169 -0.957 . . . . 0.0 109.611 173.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -54.99 -44.6 74.62 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-O 118.383 -0.818 . . . . 0.0 111.934 176.338 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -53.35 -46.67 69.61 Favored 'General case' 0 N--CA 1.451 -0.416 0 C-N-CA 127.157 2.183 . . . . 0.0 110.909 176.362 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 59.7 mt -70.1 -39.77 77.54 Favored 'Isoleucine or valine' 0 C--O 1.232 0.14 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 -176.603 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 1.1 mtpp -63.35 -39.65 95.12 Favored 'General case' 0 N--CA 1.44 -0.963 0 C-N-CA 123.066 0.547 . . . . 0.0 110.799 178.008 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -85.84 7.61 23.3 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.253 1.821 . . . . 0.0 112.184 177.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -61.4 -20.21 62.79 Favored 'General case' 0 CA--C 1.535 0.401 0 O-C-N 120.885 -1.135 . . . . 0.0 113.41 -177.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 81.02 63.81 1.85 Allowed Glycine 0 C--N 1.334 0.447 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 175.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 31.4 mt 67.87 -46.96 0.51 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 129.052 2.941 . . . . 0.0 112.699 177.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -93.51 149.18 21.43 Favored 'General case' 0 C--N 1.322 -0.603 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 170.689 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.495 HG22 HD13 ' A' ' 97' ' ' LEU . 14.1 p -131.77 133.1 61.67 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.732 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 165.362 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.9 m -106.68 105.02 14.85 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . 0.495 HD13 HG22 ' A' ' 95' ' ' VAL . 0.5 OUTLIER -90.41 160.9 15.82 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 175.856 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 51.7 ttp180 -113.66 133.26 55.42 Favored 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 106.355 -1.721 . . . . 0.0 106.355 166.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.4 pp -128.21 161.07 37.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 123.899 0.879 . . . . 0.0 109.605 176.029 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.658 HG13 HD21 ' A' ' 69' ' ' LEU . 51.0 mt -104.13 122.84 42.8 Favored Pre-proline 0 CA--C 1.544 0.748 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 169.349 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo -89.8 -161.35 0.11 Allowed 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 125.028 3.818 . . . . 0.0 110.199 172.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -157.18 168.19 28.16 Favored 'General case' 0 N--CA 1.452 -0.33 0 C-N-CA 124.962 1.305 . . . . 0.0 110.801 -171.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -143.23 -4.29 0.91 Allowed 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 124.967 1.307 . . . . 0.0 111.886 163.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -136.35 0.86 2.59 Favored 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 125.921 1.689 . . . . 0.0 112.714 -172.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 12.3 mt -97.26 109.03 21.87 Favored 'General case' 0 CA--C 1.512 -0.504 0 N-CA-C 108.384 -0.969 . . . . 0.0 108.384 174.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -146.84 155.08 42.06 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 106.96 -1.496 . . . . 0.0 106.96 159.113 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 16.1 m -81.18 124.92 80.54 Favored Pre-proline 0 C--O 1.239 0.51 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 165.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -77.13 86.82 1.57 Allowed 'Trans proline' 0 N--CA 1.451 -1.015 0 C-N-CA 122.697 2.265 . . . . 0.0 109.718 172.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 38.8 t -135.85 116.65 14.07 Favored 'General case' 0 N--CA 1.453 -0.309 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 174.371 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -149.65 170.53 29.81 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 108.919 -1.673 . . . . 0.0 108.919 179.504 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -81.12 -2.9 11.97 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 123.195 2.596 . . . . 0.0 114.186 -172.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 32.8 t 147.89 -69.23 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.441 0 C-N-CA 130.219 3.408 . . . . 0.0 105.854 -171.098 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.0 m -70.66 103.84 2.66 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 170.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.851 0 N-CA-C 104.773 -3.331 . . . . 0.0 104.773 177.252 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.698 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 12.1 p -158.71 170.91 21.09 Favored 'General case' 0 C--O 1.241 0.619 0 C-N-CA 125.299 1.44 . . . . 0.0 107.914 171.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.1 m -142.07 169.15 18.12 Favored 'General case' 0 C--O 1.235 0.322 0 C-N-CA 124.392 1.077 . . . . 0.0 111.355 176.74 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 120.24 144.1 7.05 Favored Glycine 0 N--CA 1.449 -0.474 0 C-N-CA 126.328 1.918 . . . . 0.0 108.724 -173.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 28.4 p -139.61 162.93 33.89 Favored 'General case' 0 C--O 1.237 0.432 0 C-N-CA 124.894 1.278 . . . . 0.0 108.282 179.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.8 t -161.04 -155.76 0.43 Allowed 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -169.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 130.22 -77.34 0.4 Allowed Glycine 0 C--O 1.236 0.269 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 174.47 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 77.8 p 48.29 -170.27 0.02 OUTLIER 'General case' 0 C--O 1.238 0.472 0 C-N-CA 127.564 2.345 . . . . 0.0 114.257 177.193 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.7 tp 35.14 81.14 0.02 OUTLIER 'General case' 0 C--O 1.234 0.282 0 C-N-CA 128.844 2.857 . . . . 0.0 112.266 176.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.516 ' NE2' HE22 ' A' ' 102' ' ' GLN . 15.9 pt20 -44.62 136.28 4.43 Favored 'General case' 0 C--O 1.236 0.348 0 C-N-CA 125.607 1.563 . . . . 0.0 112.166 -176.734 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 42.4 p -145.24 164.18 32.16 Favored 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 125.263 1.425 . . . . 0.0 107.333 168.022 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 57.8 m -126.55 152.83 46.03 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 124.362 1.065 . . . . 0.0 109.112 173.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -108.38 103.73 12.94 Favored 'General case' 0 C--O 1.233 0.204 0 C-N-CA 126.235 1.814 . . . . 0.0 106.22 -178.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 t -88.07 95.2 5.04 Favored 'Isoleucine or valine' 0 C--O 1.236 0.388 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 9.8 p -78.02 138.08 20.98 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 CA-C-O 121.372 0.606 . . . . 0.0 109.423 171.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 41.2 mt -134.38 142.06 41.84 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 N-CA-C 105.796 -1.927 . . . . 0.0 105.796 173.086 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 80.2 m-70 -115.77 137.16 52.36 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 124.711 1.204 . . . . 0.0 109.19 177.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 16.8 ptt180 -118.4 175.65 5.61 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 119.118 0.872 . . . . 0.0 109.519 174.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.33 163.9 12.88 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 169.542 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -71.77 -38.6 70.31 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 112.672 0.619 . . . . 0.0 112.672 -173.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 54.5 t30 -77.01 18.89 0.33 Allowed 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 123.785 0.834 . . . . 0.0 112.036 -174.069 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -161.2 -169.84 2.47 Favored 'General case' 0 C--O 1.235 0.317 0 O-C-N 120.005 -1.684 . . . . 0.0 111.108 -168.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -121.21 -169.71 13.81 Favored Glycine 0 CA--C 1.521 0.429 0 C-N-CA 126.274 1.892 . . . . 0.0 110.867 -174.212 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 84.2 m-85 -85.97 -110.52 0.05 OUTLIER 'General case' 0 N--CA 1.451 -0.392 0 N-CA-C 106.117 -1.808 . . . . 0.0 106.117 165.451 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 152.7 59.04 0.01 OUTLIER Glycine 0 N--CA 1.45 -0.392 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 177.058 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 50.4 p90 -141.69 133.55 27.33 Favored 'General case' 0 N--CA 1.454 -0.239 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 178.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 13.2 t -113.96 113.53 44.13 Favored 'Isoleucine or valine' 0 C--O 1.238 0.474 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 -172.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 26.7 mt -74.06 131.0 35.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.388 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 173.364 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.409 HD11 ' HE3' ' A' ' 46' ' ' LYS . 14.8 pt -120.75 170.17 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.386 0 C-N-CA 125.513 1.525 . . . . 0.0 109.822 172.186 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -129.94 155.18 46.48 Favored 'General case' 0 C--O 1.236 0.369 0 C-N-CA 125.366 1.467 . . . . 0.0 109.735 -177.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -160.3 94.53 1.09 Allowed 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 125.864 1.666 . . . . 0.0 106.75 163.512 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 4.0 tt -137.9 84.51 2.04 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-O 122.005 0.907 . . . . 0.0 110.837 177.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 7.8 p-10 -69.81 156.76 38.55 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.311 160.094 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 15.3 tpt180 61.28 128.19 0.02 OUTLIER Pre-proline 0 CA--C 1.541 0.596 0 C-N-CA 130.695 3.598 . . . . 0.0 113.484 176.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 79.5 Cg_endo -68.0 100.87 0.65 Allowed 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.08 1.853 . . . . 0.0 107.922 168.22 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 74.8 mm-40 -124.82 166.05 16.92 Favored 'General case' 0 C--O 1.238 0.455 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 171.007 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 38.1 m -159.24 -34.06 0.06 Allowed 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 124.134 0.974 . . . . 0.0 111.782 -178.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -79.76 -25.51 58.15 Favored Glycine 0 CA--C 1.529 0.94 0 CA-C-N 119.463 1.029 . . . . 0.0 112.412 -172.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 14.2 t -125.74 133.9 51.94 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 164.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.6 p -123.78 108.04 12.07 Favored 'General case' 0 C--N 1.328 -0.344 0 C-N-CA 125.106 1.363 . . . . 0.0 109.796 -163.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 96.6 mt -130.35 -58.61 1.0 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.356 0 C-N-CA 125.029 1.331 . . . . 0.0 109.706 -166.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.2 p -65.96 155.06 37.66 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 123.562 0.745 . . . . 0.0 109.202 172.456 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 29.1 t -126.21 127.37 24.67 Favored Pre-proline 0 CA--C 1.539 0.523 0 N-CA-C 107.802 -1.185 . . . . 0.0 107.802 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -78.4 -13.95 14.83 Favored 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 122.825 2.35 . . . . 0.0 113.802 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.485 ' CD2' HD12 ' A' ' 76' ' ' ILE . 0.6 OUTLIER -139.02 119.31 13.67 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 120.831 1.65 . . . . 0.0 110.157 174.75 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.409 ' HE3' HD11 ' A' ' 29' ' ' ILE . 45.4 pttt -143.65 163.99 31.67 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 168.283 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 40.8 mm -63.1 125.37 19.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 165.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -111.83 -24.05 5.37 Favored Glycine 0 CA--C 1.527 0.799 0 CA-C-O 118.828 -0.985 . . . . 0.0 113.469 172.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 40.0 ttm180 -154.09 147.52 25.0 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 176.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 5.4 mt -128.37 149.49 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 N-CA-C 106.504 -1.665 . . . . 0.0 106.504 168.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 1.9 mp -78.13 117.38 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.789 0 C-N-CA 125.714 1.606 . . . . 0.0 107.105 174.078 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -52.72 105.08 0.11 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.123 2.169 . . . . 0.0 109.256 176.582 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 95.02 7.92 59.37 Favored Glycine 0 CA--C 1.526 0.753 0 C-N-CA 124.569 1.081 . . . . 0.0 114.065 177.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 33.9 p -64.38 166.24 11.72 Favored Pre-proline 0 CA--C 1.531 0.242 0 CA-C-N 119.495 1.647 . . . . 0.0 109.802 164.099 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -58.86 -24.3 71.59 Favored 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 121.728 1.618 . . . . 0.0 112.849 170.095 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.03 -60.6 3.52 Favored 'General case' 0 C--N 1.341 0.201 0 CA-C-N 119.277 0.944 . . . . 0.0 108.671 173.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -65.69 -42.5 91.14 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.833 0.349 . . . . 0.0 111.048 -176.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 2.3 mtm180 -69.96 -22.85 63.13 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 118.442 -0.79 . . . . 0.0 112.501 -174.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 2.0 p -73.84 -16.7 61.13 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 117.618 -1.182 . . . . 0.0 110.976 173.513 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 40.08 66.23 0.63 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.324 1.849 . . . . 0.0 110.633 -173.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 33.4 mtmm -139.28 -44.89 0.46 Allowed 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 124.923 1.289 . . . . 0.0 108.883 170.156 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 22.5 tp -94.02 121.62 35.69 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 -177.179 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 22.7 mmtt -132.85 162.84 30.48 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 123.394 1.569 . . . . 0.0 110.615 -176.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 42.4 t -62.77 123.77 16.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 172.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 122.11 -24.96 6.86 Favored Glycine 0 N--CA 1.447 -0.585 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 -175.277 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 69.1 m-20 -79.22 99.22 6.93 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-O 123.282 1.515 . . . . 0.0 109.416 -167.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 39.4 mtm180 -46.39 137.02 6.81 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 129.119 2.967 . . . . 0.0 110.106 162.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 16.0 mt -119.01 144.65 26.72 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 -174.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.523 HD11 HG13 ' A' ' 100' ' ' ILE . 6.1 mp -117.54 -47.22 2.64 Favored 'General case' 0 N--CA 1.451 -0.423 0 C-N-CA 125.246 1.418 . . . . 0.0 111.214 -176.416 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -150.04 169.61 20.83 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.084 0.954 . . . . 0.0 109.368 -175.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 9.6 p -138.89 123.39 20.88 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.299 0 C-N-CA 125.14 1.376 . . . . 0.0 108.197 178.701 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 51.39 31.05 6.74 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 123.616 0.767 . . . . 0.0 112.417 -173.737 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 80.26 6.75 89.07 Favored Glycine 0 CA--C 1.532 1.117 0 CA-C-O 118.37 -1.239 . . . . 0.0 114.204 -177.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 10.9 mm100 -102.46 135.3 44.32 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 119.963 1.882 . . . . 0.0 109.896 177.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -54.43 129.16 34.81 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 123.087 0.555 . . . . 0.0 110.282 168.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.485 HD12 ' CD2' ' A' ' 45' ' ' HIS . 25.8 pt -91.16 -17.79 7.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.467 0 C-N-CA 124.716 1.206 . . . . 0.0 110.332 164.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 81.2 mt -68.02 136.26 26.86 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.194 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.712 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 74.5 m-20 82.49 -30.9 0.09 Allowed 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 130.572 3.549 . . . . 0.0 112.847 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 6.3 mtp -64.8 154.07 86.52 Favored Pre-proline 0 CA--C 1.541 0.597 0 CA-C-N 119.298 0.954 . . . . 0.0 111.332 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -76.9 152.1 31.84 Favored 'Trans proline' 0 N--CA 1.455 -0.775 0 C-N-CA 122.49 2.127 . . . . 0.0 109.951 173.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -51.97 -42.38 62.86 Favored 'General case' 0 C--O 1.222 -0.345 0 C-N-CA 123.742 0.817 . . . . 0.0 111.657 -176.611 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -56.0 -41.83 75.46 Favored 'General case' 0 C--N 1.338 0.072 0 CA-C-O 118.356 -0.831 . . . . 0.0 112.855 178.825 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -79.9 -30.38 40.1 Favored 'General case' 0 C--O 1.225 -0.231 0 CA-C-N 118.898 0.772 . . . . 0.0 110.927 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 13.3 mt -69.03 -42.15 81.93 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.657 0 C-N-CA 124.455 1.102 . . . . 0.0 108.835 171.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 2.5 t -54.54 -46.4 71.73 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 O-C-N 120.542 -1.349 . . . . 0.0 108.932 170.511 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 9.7 tptt -62.14 -43.51 98.67 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-O 117.033 -1.461 . . . . 0.0 111.903 175.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.05 -37.78 80.85 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 121.121 1.782 . . . . 0.0 110.567 -177.361 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 43.0 mt -69.7 -49.58 57.04 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 177.298 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 51.1 tttp -54.22 -49.14 70.13 Favored 'General case' 0 C--N 1.345 0.371 0 C-N-CA 123.56 0.744 . . . . 0.0 110.234 178.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -65.89 -17.42 64.64 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 127.384 2.274 . . . . 0.0 112.362 -177.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -67.29 -9.43 40.75 Favored 'General case' 0 CA--C 1.548 0.895 0 CA-C-N 119.384 0.993 . . . . 0.0 112.891 176.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 102.23 -89.12 0.72 Allowed Glycine 0 C--N 1.34 0.779 0 C-N-CA 125.134 1.35 . . . . 0.0 112.262 167.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 78.4 mt -132.03 -27.3 1.85 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 126.47 1.908 . . . . 0.0 110.28 173.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -92.55 152.29 19.7 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 105.632 -1.988 . . . . 0.0 105.632 174.091 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 10.7 p -150.75 147.07 16.05 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.925 0 N-CA-C 105.126 -2.175 . . . . 0.0 105.126 161.104 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 20.6 m -126.08 103.09 7.53 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 -175.254 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 18.8 mt -90.77 123.05 34.03 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 124.762 1.225 . . . . 0.0 108.444 -176.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 13.7 ttm180 -83.88 131.42 34.87 Favored 'General case' 0 C--O 1.237 0.431 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 176.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -126.97 159.69 36.6 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.43 0 C-N-CA 125.661 1.584 . . . . 0.0 110.581 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.523 HG13 HD11 ' A' ' 69' ' ' LEU . 9.2 mt -69.46 -57.03 7.45 Favored Pre-proline 0 N--CA 1.478 0.94 0 C-N-CA 124.841 1.256 . . . . 0.0 110.842 175.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.427 ' HD3' ' HB ' ' A' ' 100' ' ' ILE . 10.9 Cg_endo -67.13 -176.33 0.79 Allowed 'Trans proline' 0 N--CA 1.451 -0.99 0 C-N-CA 122.397 2.065 . . . . 0.0 114.051 177.255 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . 0.516 HE22 ' NE2' ' A' ' 10' ' ' GLN . 2.1 mp0 -113.31 169.31 9.04 Favored 'General case' 0 N--CA 1.436 -1.144 0 C-N-CA 128.273 2.629 . . . . 0.0 107.088 171.387 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 2.7 pp20? -121.54 0.95 10.03 Favored 'General case' 0 C--N 1.325 -0.498 0 C-N-CA 126.183 1.793 . . . . 0.0 110.8 179.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -151.17 17.89 0.75 Allowed 'General case' 0 CA--C 1.531 0.242 0 CA-C-O 122.397 1.094 . . . . 0.0 110.31 -165.022 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 12.7 tp -107.53 121.25 44.26 Favored 'General case' 0 N--CA 1.44 -0.96 0 C-N-CA 126.823 2.049 . . . . 0.0 107.284 -179.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -55.54 105.37 0.17 Allowed 'General case' 0 CA--C 1.535 0.388 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 166.222 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 7.6 p -154.5 160.0 31.36 Favored Pre-proline 0 C--O 1.237 0.406 0 CA-C-N 120.773 1.624 . . . . 0.0 110.284 163.292 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -84.04 -6.2 10.38 Favored 'Trans proline' 0 CA--C 1.534 0.493 0 C-N-CA 122.617 2.211 . . . . 0.0 114.341 -176.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 26.6 m 4.51 88.01 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 129.014 2.926 . . . . 0.0 114.45 179.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -64.55 164.41 34.25 Favored Glycine 0 CA--C 1.535 1.311 0 C-N-CA 124.153 0.882 . . . . 0.0 113.517 -166.215 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -66.76 160.5 46.24 Favored 'Trans proline' 0 CA--C 1.538 0.687 0 C-N-CA 124.005 3.137 . . . . 0.0 113.061 -179.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.4 p -99.36 -15.17 18.88 Favored 'General case' 0 C--O 1.235 0.326 0 C-N-CA 125.779 1.632 . . . . 0.0 112.402 179.156 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 21.8 p -122.47 68.33 0.95 Allowed 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 124.127 0.971 . . . . 0.0 108.74 -175.657 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.867 0 N-CA-C 106.714 -2.554 . . . . 0.0 106.714 -169.241 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.156 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 31.0 t -136.59 132.69 35.46 Favored 'General case' 0 C--O 1.235 0.327 0 N-CA-C 105.5 -2.037 . . . . 0.0 105.5 174.21 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 1.4 m -144.59 126.53 15.41 Favored 'General case' 0 C--O 1.238 0.499 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -169.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -161.42 76.36 0.18 Allowed Glycine 0 N--CA 1.449 -0.463 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 -175.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 44.0 m -145.65 155.57 43.1 Favored 'General case' 0 C--O 1.235 0.298 0 C-N-CA 124.995 1.318 . . . . 0.0 109.522 173.188 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.0 t 61.87 111.35 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 128.54 2.736 . . . . 0.0 113.873 168.14 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.24 152.59 17.33 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 106.335 -2.706 . . . . 0.0 106.335 -178.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 3.9 m -165.0 -74.91 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 124.98 1.312 . . . . 0.0 109.042 -172.342 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 5.9 tp -83.14 120.7 26.11 Favored 'General case' 0 C--O 1.238 0.456 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 176.337 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 22.5 mt-30 -70.65 138.03 50.38 Favored 'General case' 0 N--CA 1.453 -0.288 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 169.213 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 33.5 p -138.37 160.48 39.39 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 178.799 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.9 m -111.23 156.62 21.18 Favored 'General case' 0 C--O 1.235 0.325 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 168.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -120.85 103.54 9.16 Favored 'General case' 0 CA--C 1.511 -0.536 0 N-CA-C 104.029 -2.582 . . . . 0.0 104.029 172.401 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.467 HG11 ' HB2' ' A' ' 62' ' ' LEU . 59.6 t -91.63 95.03 5.17 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 105.458 -2.053 . . . . 0.0 105.458 -177.713 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 10.4 p -85.47 124.84 40.37 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 169.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 13.3 mt -116.97 143.38 27.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 105.508 -2.034 . . . . 0.0 105.508 171.269 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 52.0 m-70 -121.68 143.76 49.16 Favored 'General case' 0 CA--C 1.536 0.404 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 175.445 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.405 ' NH1' ' CE2' ' A' ' 24' ' ' PHE . 3.0 ptt-85 -130.86 -175.48 3.68 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 119.797 1.18 . . . . 0.0 109.008 176.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.437 ' N ' ' HE3' ' A' ' 19' ' ' LYS . 0.2 OUTLIER -95.38 168.7 10.56 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 118.814 0.734 . . . . 0.0 109.273 169.836 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -65.94 -20.67 66.29 Favored 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 124.078 0.951 . . . . 0.0 112.544 170.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 33.6 m120 -123.18 65.67 0.99 Allowed 'General case' 0 C--O 1.234 0.265 0 C-N-CA 124.454 1.101 . . . . 0.0 108.133 -177.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 22.0 pt-20 -172.6 179.45 2.44 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 128.38 2.672 . . . . 0.0 107.227 163.164 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -103.67 176.12 23.84 Favored Glycine 0 CA--C 1.526 0.734 0 C-N-CA 124.432 1.015 . . . . 0.0 110.976 173.548 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . 0.405 ' CE2' ' NH1' ' A' ' 18' ' ' ARG . 40.5 m-85 -84.7 170.68 13.04 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 150.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -139.45 55.6 0.65 Allowed Glycine 0 C--O 1.224 -0.529 0 O-C-N 120.727 -1.233 . . . . 0.0 111.537 -175.138 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.4 p90 -130.12 121.89 27.21 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 117.981 0.89 . . . . 0.0 108.924 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 12.6 t -96.25 101.04 11.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 -175.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.567 HD12 ' H ' ' A' ' 28' ' ' ILE . 3.5 mp -74.27 118.87 20.57 Favored 'Isoleucine or valine' 0 C--O 1.237 0.414 0 N-CA-C 106.564 -1.643 . . . . 0.0 106.564 170.436 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.457 HD11 ' HE3' ' A' ' 46' ' ' LYS . 24.5 pt -103.87 -176.76 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 C-N-CA 124.355 1.062 . . . . 0.0 109.281 176.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 55.0 m 54.86 53.83 9.91 Favored 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 124.155 0.982 . . . . 0.0 112.325 175.033 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.4 t -60.75 176.05 0.42 Allowed 'General case' 0 CA--C 1.543 0.682 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.726 164.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 58.6 tp -25.75 115.49 0.06 Allowed 'General case' 0 N--CA 1.469 0.48 0 C-N-CA 128.681 2.792 . . . . 0.0 111.832 177.489 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 17.4 t30 -136.45 130.62 32.9 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-O 118.941 -0.552 . . . . 0.0 111.07 -170.696 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 66.17 162.4 0.13 Allowed Pre-proline 0 N--CA 1.471 0.611 0 C-N-CA 128.315 2.646 . . . . 0.0 113.106 -173.476 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -77.86 65.49 8.24 Favored 'Trans proline' 0 N--CA 1.458 -0.591 0 C-N-CA 123.916 3.078 . . . . 0.0 109.194 168.14 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -130.88 166.44 20.89 Favored 'General case' 0 N--CA 1.452 -0.37 0 C-N-CA 126.197 1.799 . . . . 0.0 106.703 173.558 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 23.3 t -123.63 -125.49 0.26 Allowed 'General case' 0 C--N 1.327 -0.388 0 N-CA-C 106.197 -1.779 . . . . 0.0 106.197 179.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -62.48 93.52 0.09 OUTLIER Glycine 0 C--N 1.336 0.56 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 173.466 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.4 t -120.74 130.81 54.2 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 -174.489 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 20.4 p -64.86 162.52 16.11 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 124.052 0.941 . . . . 0.0 111.589 177.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 12.2 mt 66.24 162.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 C-N-CA 127.023 2.129 . . . . 0.0 109.802 179.182 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 3.3 m 57.15 171.66 0.04 OUTLIER 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 125.213 1.405 . . . . 0.0 111.595 -167.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 21.9 t -126.7 123.24 23.79 Favored Pre-proline 0 C--O 1.235 0.332 0 N-CA-C 103.672 -2.714 . . . . 0.0 103.672 161.378 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -58.54 -78.64 0.02 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 121.878 1.719 . . . . 0.0 109.818 175.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 1.2 m80 -63.68 123.71 19.55 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-N 118.785 0.72 . . . . 0.0 109.869 -177.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . 0.457 ' HE3' HD11 ' A' ' 29' ' ' ILE . 49.8 pttt -143.67 153.29 42.33 Favored 'General case' 0 CA--C 1.516 -0.339 0 N-CA-C 107.883 -1.155 . . . . 0.0 107.883 171.086 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . 0.407 HD13 HD11 ' A' ' 68' ' ' ILE . 32.7 mm -66.69 124.12 21.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 167.57 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -101.97 -30.88 5.59 Favored Glycine 0 CA--C 1.525 0.683 0 C-N-CA 124.246 0.927 . . . . 0.0 112.611 175.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . . . . . . . . . 22.7 ttm180 -154.65 158.41 39.63 Favored 'General case' 0 C--O 1.235 0.315 0 CA-C-N 118.847 1.323 . . . . 0.0 107.564 176.014 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 24.5 mt -130.77 135.28 60.55 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.537 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 170.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.4 mp -68.81 124.96 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 174.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 32.2 t0 -51.96 133.55 32.45 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.375 1.07 . . . . 0.0 109.97 178.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.08 1.0 38.41 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-O 118.98 -0.9 . . . . 0.0 114.412 174.493 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 61.4 p -64.62 162.7 33.05 Favored Pre-proline 0 CA--C 1.53 0.189 0 CA-C-N 119.483 1.641 . . . . 0.0 109.504 171.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -55.76 -18.17 20.42 Favored 'Trans proline' 0 CA--C 1.534 0.488 0 C-N-CA 122.959 2.439 . . . . 0.0 114.028 175.244 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.59 -69.79 0.27 Allowed 'General case' 0 CA--C 1.533 0.323 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 169.112 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -66.43 -31.88 72.91 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 118.14 0.427 . . . . 0.0 111.655 -173.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.92 -22.92 67.11 Favored 'General case' 0 C--O 1.234 0.247 0 O-C-N 121.351 -0.843 . . . . 0.0 112.508 175.389 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 7.8 t -80.85 -9.51 59.81 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 119.338 0.972 . . . . 0.0 111.475 173.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 55.92 5.13 0.14 Allowed 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 128.841 2.856 . . . . 0.0 115.724 173.777 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -87.9 -49.64 6.96 Favored 'General case' 0 CA--C 1.517 -0.289 0 CA-C-N 119.796 1.18 . . . . 0.0 110.424 177.39 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . 0.467 ' HB2' HG11 ' A' ' 14' ' ' VAL . 14.8 tp -93.85 129.36 40.28 Favored 'General case' 0 C--N 1.331 -0.21 0 C-N-CA 123.5 0.72 . . . . 0.0 109.414 -166.044 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 8.7 mptt -122.99 169.97 10.62 Favored 'General case' 0 N--CA 1.45 -0.427 0 C-N-CA 125.451 1.5 . . . . 0.0 110.438 170.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -58.4 148.47 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 C-N-CA 124.367 1.067 . . . . 0.0 109.798 165.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.24 -7.73 80.67 Favored Glycine 0 CA--C 1.524 0.635 0 C-N-CA 125.301 1.429 . . . . 0.0 110.682 -175.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -71.17 88.92 0.83 Allowed 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 172.351 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 7.1 mtm180 -38.21 121.02 0.94 Allowed 'General case' 0 C--N 1.329 -0.318 0 C-N-CA 128.448 2.699 . . . . 0.0 110.314 159.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . 0.407 HD11 HD13 ' A' ' 47' ' ' ILE . 14.3 mt -101.22 118.83 48.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 107.103 -1.443 . . . . 0.0 107.103 -178.697 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 88.1 mt -72.0 -52.52 16.65 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 124.684 1.194 . . . . 0.0 109.959 168.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -150.83 166.24 31.13 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 124.059 0.944 . . . . 0.0 111.951 -162.32 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 37.2 t -126.26 119.84 55.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 174.45 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.561 HD21 ' HB2' ' A' ' 91' ' ' ALA . 67.7 m-20 54.51 10.01 0.3 Allowed 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 128.918 2.887 . . . . 0.0 114.477 176.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 114.01 -0.26 24.16 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 126.721 2.105 . . . . 0.0 113.909 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 9.8 mm-40 -105.07 145.22 30.8 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 125.422 1.489 . . . . 0.0 109.243 -176.047 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 2.8 p -84.09 99.26 10.36 Favored 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 124.73 1.212 . . . . 0.0 111.63 -167.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 7.1 pt -79.76 -2.84 5.64 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 C-N-CA 123.904 0.882 . . . . 0.0 112.106 -177.258 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.731 HD12 ' H ' ' A' ' 77' ' ' ILE . 3.3 mp -61.85 -33.29 57.19 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 125.223 1.409 . . . . 0.0 110.383 174.31 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 17.7 m120 -107.7 -44.12 4.33 Favored 'General case' 0 C--O 1.233 0.215 0 C-N-CA 123.049 0.539 . . . . 0.0 111.217 -166.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 5.6 mtp -58.77 153.4 42.54 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 124.329 1.052 . . . . 0.0 111.328 -168.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -60.75 146.27 97.6 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.187 1.258 . . . . 0.0 109.276 167.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -52.09 -41.28 62.29 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 124.346 1.058 . . . . 0.0 110.028 -178.064 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -59.93 -35.57 75.19 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 114.24 1.2 . . . . 0.0 114.24 177.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.01 -44.86 79.23 Favored 'General case' 0 N--CA 1.463 0.189 0 C-N-CA 123.727 0.811 . . . . 0.0 108.887 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 24.0 mt -69.37 -37.99 76.47 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 C-N-CA 125.967 1.707 . . . . 0.0 109.261 -178.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 4.8 t -56.46 -49.06 78.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 O-C-N 121.127 -0.983 . . . . 0.0 109.427 169.263 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 11.4 ttpt -66.88 -36.48 82.41 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-O 118.742 -0.647 . . . . 0.0 111.258 -177.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -57.09 -44.38 83.11 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 125.4 1.48 . . . . 0.0 111.057 174.29 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 91.1 mt -67.86 -40.99 84.54 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.152 0 CA-C-N 119.371 0.987 . . . . 0.0 108.813 178.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.0 tttt -60.08 -48.76 80.38 Favored 'General case' 0 N--CA 1.451 -0.419 0 CA-C-N 118.819 0.736 . . . . 0.0 109.942 176.146 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -70.31 -12.28 61.48 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 124.642 1.177 . . . . 0.0 111.268 -178.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.561 ' HB2' HD21 ' A' ' 72' ' ' ASN . . . -62.9 -14.99 53.25 Favored 'General case' 0 CA--C 1.545 0.757 0 CA-C-N 119.679 1.127 . . . . 0.0 112.347 168.426 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 80.28 -132.25 11.16 Favored Glycine 0 N--CA 1.444 -0.773 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 176.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 5.7 mt -90.7 -10.24 43.83 Favored 'General case' 0 CA--C 1.515 -0.387 0 CA-C-O 118.878 -0.582 . . . . 0.0 110.336 173.682 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 26.7 p -93.42 162.3 14.04 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 168.476 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 8.6 p -156.68 136.6 4.07 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.888 0 N-CA-C 105.483 -2.043 . . . . 0.0 105.483 159.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.1 m -117.34 104.75 11.44 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 -177.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 56.9 mt -90.02 164.55 14.48 Favored 'General case' 0 C--N 1.325 -0.459 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 177.33 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 22.6 ttt180 -127.93 118.74 24.16 Favored 'General case' 0 CA--C 1.513 -0.456 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 173.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.1 pp -129.51 169.2 21.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.508 0 C-N-CA 123.952 0.901 . . . . 0.0 109.294 -176.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 4.0 mp -98.45 117.99 63.94 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 124.205 1.002 . . . . 0.0 109.361 -177.251 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -82.97 157.33 15.44 Favored 'Trans proline' 0 N--CA 1.455 -0.792 0 C-N-CA 123.375 2.717 . . . . 0.0 111.766 172.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 9.2 mt-30 -146.12 170.5 16.57 Favored 'General case' 0 C--O 1.242 0.662 0 C-N-CA 129.015 2.926 . . . . 0.0 106.521 -178.102 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -136.72 -19.58 1.35 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 119.094 0.861 . . . . 0.0 113.018 -168.289 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 18.9 pm0 -87.47 -2.93 58.95 Favored 'General case' 0 C--N 1.316 -0.88 0 C-N-CA 127.743 2.417 . . . . 0.0 112.162 -173.121 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 3.1 mt -114.87 108.88 17.33 Favored 'General case' 0 C--O 1.233 0.194 0 C-N-CA 125.578 1.551 . . . . 0.0 109.039 -170.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 19.8 t30 -145.87 104.52 3.86 Favored 'General case' 0 C--O 1.232 0.137 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 164.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 72.9 m -65.49 152.32 92.6 Favored Pre-proline 0 CA--C 1.533 0.314 0 CA-C-O 119.395 -0.336 . . . . 0.0 111.638 173.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -79.54 -174.0 2.1 Favored 'Trans proline' 0 N--CA 1.455 -0.757 0 C-N-CA 124.328 3.352 . . . . 0.0 111.33 171.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 2.2 t -67.17 13.91 0.06 Allowed 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 126.058 1.743 . . . . 0.0 113.395 175.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 39.32 63.41 1.13 Allowed Glycine 0 CA--C 1.534 1.253 0 C-N-CA 126.565 2.031 . . . . 0.0 112.375 -176.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -60.61 118.28 5.13 Favored 'Trans proline' 0 N--CA 1.458 -0.618 0 C-N-CA 123.644 2.896 . . . . 0.0 110.164 -166.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 3.1 t 30.07 63.92 0.16 Allowed 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 127.956 2.503 . . . . 0.0 110.874 -167.125 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 5.6 t -53.83 118.55 4.06 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 170.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.006 0 N-CA-C 106.344 -2.702 . . . . 0.0 106.344 -165.754 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.148 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.3 m -54.11 129.41 34.53 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 159.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 2.9 m -63.8 -45.67 88.61 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 123.321 0.649 . . . . 0.0 110.383 -173.487 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 140.55 -150.37 21.6 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 -169.543 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 57.4 m -138.07 173.6 11.45 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 107.823 -1.176 . . . . 0.0 107.823 157.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -130.44 -175.97 3.81 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 151.797 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 167.58 -145.77 10.06 Favored Glycine 0 N--CA 1.446 -0.676 0 N-CA-C 106.221 -2.752 . . . . 0.0 106.221 -173.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 12.2 m 72.18 159.76 0.22 Allowed 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 126.773 2.029 . . . . 0.0 110.68 -178.244 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 10.1 mp -123.07 125.08 44.51 Favored 'General case' 0 C--O 1.237 0.418 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 -168.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -143.89 -154.24 0.52 Allowed 'General case' 0 C--O 1.234 0.283 0 C-N-CA 122.948 0.499 . . . . 0.0 111.185 179.359 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' THR . . . . . . . . . . . . . 7.6 p -138.28 165.54 26.46 Favored 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 128.14 2.576 . . . . 0.0 108.735 -171.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 37.3 m -126.6 164.41 21.3 Favored 'General case' 0 C--O 1.235 0.29 0 C-N-CA 125.875 1.67 . . . . 0.0 109.415 -179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 18.4 p-10 -128.86 95.12 4.0 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 127.15 2.18 . . . . 0.0 108.057 177.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.0 t -89.47 102.9 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 105.798 -1.927 . . . . 0.0 105.798 174.321 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' VAL . . . . . . . . . . . . . 2.2 t -106.68 111.47 35.6 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 -177.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 12.1 mt -108.83 136.55 44.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 N-CA-C 106.126 -1.805 . . . . 0.0 106.126 -178.72 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 38.7 m-70 -119.87 114.15 21.66 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 126.465 1.906 . . . . 0.0 105.989 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 28.4 ptt180 -95.0 174.99 6.81 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 119.606 1.094 . . . . 0.0 109.116 176.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -82.97 171.13 14.16 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 166.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -75.57 -9.85 58.93 Favored 'General case' 0 N--CA 1.469 0.489 0 O-C-N 120.355 -1.466 . . . . 0.0 112.805 175.373 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 40.3 t30 -98.98 -27.38 13.89 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 115.119 1.526 . . . . 0.0 115.119 -160.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -114.37 -122.1 0.29 Allowed 'General case' 0 C--N 1.326 -0.429 0 C-N-CA 125.235 1.414 . . . . 0.0 108.768 -167.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -154.49 -178.34 28.76 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 167.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PHE . . . . . . . . . . . . . 58.3 m-85 -72.97 170.82 14.02 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 106.954 -1.498 . . . . 0.0 106.954 151.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -135.2 62.07 0.62 Allowed Glycine 0 C--O 1.22 -0.749 0 CA-C-O 118.27 -1.294 . . . . 0.0 111.591 -176.185 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PHE . . . . . . . . . . . . . 21.2 p90 -146.12 139.96 26.35 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-N 119.281 1.541 . . . . 0.0 109.033 178.491 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.848 HG12 ' H ' ' A' ' 49' ' ' ARG . 0.8 OUTLIER -110.08 154.78 11.52 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 171.798 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . 3.5 mp -128.79 118.75 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.822 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 -178.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 26.1 pt -112.45 156.11 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.445 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -179.034 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 68.5 m -128.05 84.72 2.27 Favored 'General case' 0 C--O 1.239 0.544 0 C-N-CA 124.859 1.263 . . . . 0.0 107.968 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.8 m -73.07 150.91 41.92 Favored 'General case' 0 CA--C 1.539 0.527 0 O-C-N 121.42 -0.8 . . . . 0.0 110.365 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 32.6 mt -70.14 -45.46 66.76 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 124.206 1.002 . . . . 0.0 110.396 -174.522 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.9 m120 37.1 73.04 0.1 Allowed 'General case' 0 C--O 1.238 0.489 0 C-N-CA 127.965 2.506 . . . . 0.0 112.005 178.246 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.45 148.84 63.28 Favored Pre-proline 0 CA--C 1.54 0.568 0 C-N-CA 122.974 0.51 . . . . 0.0 111.123 -174.223 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -76.7 -24.2 10.44 Favored 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 123.066 2.511 . . . . 0.0 113.922 -174.046 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 37.15 69.52 0.22 Allowed 'General case' 0 CA--C 1.536 0.417 0 C-N-CA 126.863 2.065 . . . . 0.0 112.491 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 66.3 m 57.89 2.64 0.18 Allowed 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 127.548 2.339 . . . . 0.0 116.287 179.663 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -95.2 -178.72 37.26 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 166.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 8.1 t -126.22 102.16 7.07 Favored 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 104.351 -2.463 . . . . 0.0 104.351 132.168 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 65.8 p -101.98 158.45 16.13 Favored 'General case' 0 C--O 1.24 0.567 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 177.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . 0.26 14.0 tt -60.79 124.52 15.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 C-N-CA 123.862 0.865 . . . . 0.0 111.034 -166.193 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 11.3 m -144.51 154.94 43.42 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.194 1.398 . . . . 0.0 108.898 -173.019 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 8.6 p -127.51 151.07 74.48 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 117.739 -1.124 . . . . 0.0 109.223 169.064 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -72.08 -84.47 0.0 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.274 1.983 . . . . 0.0 108.475 162.389 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -72.58 120.9 18.84 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 124.138 0.975 . . . . 0.0 110.559 -174.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 45.3 pttt -137.31 154.93 49.97 Favored 'General case' 0 C--O 1.236 0.371 0 N-CA-C 107.715 -1.217 . . . . 0.0 107.715 168.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 5.0 mm -60.79 127.29 20.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 166.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -88.51 -69.75 1.27 Allowed Glycine 0 CA--C 1.527 0.806 0 O-C-N 124.495 1.122 . . . . 0.0 110.627 173.373 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ARG . . . . . 0.848 ' H ' HG12 ' A' ' 27' ' ' VAL . 31.4 ttm180 -127.6 153.28 46.6 Favored 'General case' 0 CA--C 1.516 -0.344 0 C-N-CA 128.751 2.821 . . . . 0.0 107.407 -178.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 12.5 mt -119.27 142.68 33.33 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.601 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 166.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 50.4 mm -73.05 122.59 26.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.325 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -60.45 137.17 58.19 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 178.443 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 77.82 -5.23 54.08 Favored Glycine 0 CA--C 1.531 1.058 0 C-N-CA 126.08 1.8 . . . . 0.0 114.495 -178.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . 0.434 ' HB2' ' HD2' ' A' ' 55' ' ' PRO . 83.7 p -68.62 167.65 18.22 Favored Pre-proline 0 C--O 1.234 0.283 0 CA-C-N 119.332 1.566 . . . . 0.0 112.472 -176.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 54' ' ' SER . 18.0 Cg_endo -58.23 -29.26 87.1 Favored 'Trans proline' 0 N--CA 1.451 -0.994 0 C-N-CA 122.165 1.91 . . . . 0.0 112.458 166.464 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.85 -53.94 46.45 Favored 'General case' 0 C--N 1.345 0.398 0 CA-C-N 119.814 1.188 . . . . 0.0 109.71 177.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 27.2 t0 -66.21 -45.89 79.14 Favored 'General case' 0 N--CA 1.463 0.187 0 O-C-N 123.135 0.272 . . . . 0.0 110.525 -178.814 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ARG . . . . . . . . . . . . . 5.4 mtt180 -72.45 -22.58 61.06 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 113.237 0.829 . . . . 0.0 113.237 -173.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 24.3 m -61.2 -18.09 56.46 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 119.967 1.258 . . . . 0.0 111.519 165.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . 65.16 -25.15 0.09 Allowed 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 130.218 3.407 . . . . 0.0 114.951 171.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 1.9 mtpp -73.54 -8.53 56.31 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 124.955 1.302 . . . . 0.0 112.137 174.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -107.93 125.26 51.28 Favored 'General case' 0 C--N 1.343 0.301 0 CA-C-N 119.645 1.112 . . . . 0.0 108.328 173.262 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' LYS . . . . . . . . . . . . . 40.5 mttp -135.76 166.41 23.35 Favored 'General case' 0 C--O 1.235 0.314 0 C-N-CA 126.188 1.795 . . . . 0.0 109.115 172.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 71.7 t -64.76 152.7 8.52 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 C-N-CA 123.515 0.726 . . . . 0.0 109.118 -178.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 67.43 43.72 86.36 Favored Glycine 0 CA--C 1.528 0.903 0 CA-C-O 122.047 0.804 . . . . 0.0 112.221 174.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 24.8 p-10 -78.46 -20.99 49.76 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 125.782 1.633 . . . . 0.0 115.135 -173.272 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 18.4 mtm180 44.84 90.96 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 128.752 2.821 . . . . 0.0 111.516 -160.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ILE . . . . . . . . . . . . . 24.2 mt -68.48 150.21 10.91 Favored 'Isoleucine or valine' 0 C--O 1.236 0.354 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -116.56 -50.98 2.61 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 127.413 2.285 . . . . 0.0 108.898 177.186 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -151.91 169.97 20.99 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 124.179 0.991 . . . . 0.0 111.603 -176.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 8.0 p -128.88 118.89 48.18 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 124.371 1.068 . . . . 0.0 109.291 175.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 39.05 47.06 1.23 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.413 1.485 . . . . 0.0 110.494 -169.198 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 76.16 -3.72 51.05 Favored Glycine 0 CA--C 1.53 1.01 0 C-N-CA 125.952 1.739 . . . . 0.0 115.977 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -82.21 141.84 32.66 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 120.829 2.314 . . . . 0.0 108.578 -178.624 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' SER . . . . . . . . . . . . . 3.7 p -90.02 90.66 8.24 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-O 122.675 1.226 . . . . 0.0 110.374 -171.562 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 13.3 pt -65.39 -3.16 1.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.814 0 C-N-CA 126.833 2.053 . . . . 0.0 113.622 -177.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 26.1 mm -57.48 -58.13 7.36 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.245 0 C-N-CA 126.799 2.04 . . . . 0.0 109.591 175.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 7.5 t-20 -113.8 -22.96 9.91 Favored 'General case' 0 C--O 1.231 0.114 0 O-C-N 123.596 0.56 . . . . 0.0 112.029 -161.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 12.5 ttt -56.18 142.24 67.29 Favored Pre-proline 0 N--CA 1.437 -1.083 0 C-N-CA 126.292 1.837 . . . . 0.0 109.463 166.47 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -75.35 153.09 39.88 Favored 'Trans proline' 0 N--CA 1.452 -0.928 0 C-N-CA 121.259 1.306 . . . . 0.0 111.169 -179.134 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . . . . . . . . . 32.9 t60 -58.19 -41.23 83.51 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.255 0.622 . . . . 0.0 112.015 -170.038 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.68 -32.1 73.12 Favored 'General case' 0 C--O 1.227 -0.101 0 CA-C-O 118.879 -0.582 . . . . 0.0 112.41 178.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 53.5 m-20 -75.8 -42.04 51.12 Favored 'General case' 0 C--O 1.225 -0.221 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 -178.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 32.8 mt -60.54 -40.26 83.85 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 124.643 1.177 . . . . 0.0 109.72 173.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 19.2 t -68.03 -35.88 73.41 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 O-C-N 120.198 -1.564 . . . . 0.0 110.902 175.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -62.38 -48.67 78.7 Favored 'General case' 0 C--O 1.22 -0.459 0 O-C-N 121.506 -0.746 . . . . 0.0 110.498 171.106 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -55.88 -35.39 66.45 Favored 'General case' 0 N--CA 1.44 -0.928 0 C-N-CA 126.505 1.922 . . . . 0.0 111.981 -176.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 76.0 mt -69.77 -52.58 30.25 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.124 0 N-CA-C 108.736 -0.838 . . . . 0.0 108.736 176.225 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 6.8 tttp -54.51 -44.33 72.63 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 122.924 0.49 . . . . 0.0 111.172 177.613 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 -71.95 -19.43 61.9 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 126.182 1.793 . . . . 0.0 110.984 -178.112 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -65.97 -35.38 80.44 Favored 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 119.525 1.057 . . . . 0.0 109.447 169.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 86.13 -117.03 4.5 Favored Glycine 0 N--CA 1.449 -0.497 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 172.542 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 39.6 mt -76.48 -49.27 17.0 Favored 'General case' 0 CA--C 1.501 -0.912 0 CA-C-N 118.367 1.083 . . . . 0.0 108.838 -173.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.89 145.81 24.36 Favored 'General case' 0 C--N 1.324 -0.521 0 O-C-N 124.229 0.955 . . . . 0.0 108.638 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 14.9 p -146.39 139.5 20.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 106.45 -1.685 . . . . 0.0 106.45 167.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 47.1 m -106.07 105.5 15.56 Favored 'General case' 0 N--CA 1.453 -0.313 0 C-N-CA 125.584 1.554 . . . . 0.0 107.197 176.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' LEU . . . . . . . . . . . . . 40.7 mt -90.81 127.12 36.24 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.418 HH11 ' HB2' ' A' ' 98' ' ' ARG . 6.4 ttm105 -103.53 111.7 24.28 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 2.2 pp -121.53 174.61 5.88 Favored 'Isoleucine or valine' 0 C--O 1.238 0.462 0 C-N-CA 126.048 1.739 . . . . 0.0 108.312 -175.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 8.5 mt -118.3 121.69 30.94 Favored Pre-proline 0 CA--C 1.54 0.586 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -179.107 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -90.64 134.3 1.89 Allowed 'Trans proline' 0 N--CA 1.453 -0.889 0 C-N-CA 123.647 2.898 . . . . 0.0 111.668 -176.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' GLN . . . . . . . . . . . . . 6.4 mt-30 -129.0 -179.92 5.38 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 126.379 1.872 . . . . 0.0 107.979 -173.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -132.1 -25.8 1.98 Allowed 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 118.775 0.716 . . . . 0.0 112.779 173.497 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -81.58 -6.37 58.92 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 124.526 1.131 . . . . 0.0 111.411 -171.453 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -81.58 -11.5 59.11 Favored 'General case' 0 C--O 1.235 0.316 0 C-N-CA 129.298 3.039 . . . . 0.0 114.275 -168.061 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -148.58 -165.29 2.23 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 119.219 0.918 . . . . 0.0 109.401 -169.514 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 56.8 m -79.54 105.16 2.93 Favored Pre-proline 0 N--CA 1.448 -0.526 0 CA-C-O 117.903 -1.046 . . . . 0.0 108.238 156.036 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -70.02 153.18 67.98 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 CA-C-N 120.901 1.357 . . . . 0.0 109.457 168.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' SER . . . . . . . . . . . . . 14.6 t -162.29 149.65 13.9 Favored 'General case' 0 C--O 1.24 0.603 0 C-N-CA 126.116 1.766 . . . . 0.0 106.646 167.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . 107.24 -165.11 13.1 Favored Glycine 0 CA--C 1.531 1.049 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -67.62 168.96 16.89 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.222 2.615 . . . . 0.0 112.06 -170.124 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 5.7 t -146.11 -28.56 0.42 Allowed 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 126.458 1.903 . . . . 0.0 110.47 -172.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -77.6 96.07 4.71 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 124.158 0.983 . . . . 0.0 110.86 179.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.045 0 N-CA-C 108.579 -1.808 . . . . 0.0 108.579 171.703 . . . . . . . . 0 0 . 1 stop_ save_